Express Mail Label No. EL951597410US Attorney Docket No.: 018501-000840US EOS Docket No.: COCA-011-3

## PATENT APPLICATION

# NOVEL METHODS OF DIAGNOSIS OF METASTATIC COLORECTAL CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF METASTATIC COLORECTAL CANCER

Inventor(s):

David H. Mack, a citizen of the United States, residing at 2076 Monterey Avenue, Menlo Park, California 94025

Sanford David Markowitz, a citizen of the United States, residing at

28950 Bolingbrook Rd., Pepper Pike, Ohio 44124

Assignee:

Eos Biotechnology, Inc.

Case Western Reserve University

Entity:

Small

10

15

25

30

## NOVEL METHODS OF DIAGNOSIS OF METASTATIC COLORECTAL CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF METASTATIC COLORECTAL CANCER

CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is related to USSN 60/272,206, filed February 27, 2001, USSN 60/281,149, filed April 2, 2001, and USSN 60/284,555, filed April 17, 2001, all of which are herein incorporated by referenced in their entirety.

FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in metastatic colorectal cancer; and to the use of such expression profiles and compositions in diagnosis and therapy of metastatic colorectal cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit metastatic colorectal cancer.

BACKGROUND OF THE INVENTION

Cancer of the colon and/or rectum (referred to as "colorectal cancer") are 20 significant in Western populations and particularly in the United States. Cancers of the colon

and rectum occur in both men and women most commonly after the age of 50. These develop as the result of a pathologic transformation of normal colon epithelium to an invasive cancer. There have been a number of recently characterized genetic alterations that have

been implicated in colorectal cancer, including mutations in two classes of genes, tumorsuppressor genes and proto-oncogenes, with recent work suggesting that mutations in DNA

repair genes may also be involved in tumorigenesis. For example, inactivating mutations of both alleles of the adenomatous polyposis coli (APC) gene, a tumor suppressor gene, appears

to be one of the earliest events in colorectal cancer, and may even be the initiating event.

Other genes implicated in colorectal cancer include the MCC gene, the p53 gene, the DCC (deleted in colorectal carcinoma) gene and other chromosome 18q genes, and genes in the TGF-β signaling pathway. For a review, see Molecular Biology of Colorectal Cancer, pp.

238-299, in Curr. Probl. Cancer, Sept/Oct 1997; see also Willams, Colorectal Cancer

10

15

20

25

30

(1996); Kinsella & Schofield, Colorectal Cancer: A Scientific Perspective (1993); Colorectal Cancer: Molecular Mechanisms, Premalignant State and its Prevention (Schmiegel & Scholmerich eds., 2000); Colorectal Cancer: New Aspects of Molecular Biology and Their Clinical Applications (Hanski et al., eds 2000); McArdle et al., Colorectal Cancer (2000); Wanebo, Colorectal Cancer (1993); Levin, The American Cancer Society: Colorectal Cancer (1999); Treatment of Hepatic Metastases of Colorectal Cancer (Nordlinger & Jaeck eds., 1993); Management of Colorectal Cancer (Dunitz et al., eds. 1998); Cancer: Principles and Practice of Oncology (Devita et al., eds. 2001); Surgical Oncology: Contemporary Principles and Practice (Kirby et al., eds. 2001); Offit, Clinical Cancer Genetics: Risk Counseling and Management (1997); Radioimmunotherapy of Cancer (Abrams & Fritzberg eds. 2000); Fleming, AJCC Cancer Staging Handbook (1998); Textbook of Radiation Oncology (Leibel & Phillips eds. 2000); and Clinical Oncology (Abeloff et al., eds. 2000).

Imaging of colorectal cancer for diagnosis has been problematic and limited. In addition, metastasis of the tumor to the lumen, and metastasis of tumor cells to regional lymph nodes are important prognostic factors (see, e.g., PET in Oncology: Basics and Clinical Application (Ruhlmann et al. eds. 1999). For example, five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of colorectal cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998). In addition, colorectal cancers often metastasize to the liver. However, the lack of information about the gene expression exhibited by these cancers limits the ability to effectively diagnose and treat the disease.

Thus, methods for diagnosis and prognosis of metastatic colorectal cancer and effective treatment of colorectal cancer would be desirable. Accordingly, provided herein are methods that can be used in diagnosis and prognosis of metastatic colorectal cancer. Further provided are methods that can be used to screen candidate therapeutic agents for the ability to modulate, e.g., treat, colorectal cancer. Additionally, provided herein are molecular targets and compositions for therapeutic intervention in metastatic colorectal disease and other metastatic cancers.

## SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in metastatic colorectal cancer cells. Such genes and the proteins they

10

15

20

25

30

encode are useful for diagnostic and prognostic purposes, and also as targets for screening for therapeutic compounds that modulate metastatic colorectal cancer, such as antibodies. The methods of detecting nucleic acids of the invention or their encoded proteins can be used for a number of purposes. Examples include, early detection of colon cancers, monitoring and early detection of relapse following treatment of colon cancers, monitoring response to therapy of colon cancers, determining prognosis of colon cancers, directing therapy of colon cancers, selecting patients for postoperative chemotherapy or radiation therapy, selecting therapy, determining tumor prognosis, treatment, or response to treatment, and early detection of precancerous colon adenomas. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

In one aspect, the present invention provides a method of detecting a metastatic colorectal cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-26. In another embodiment, the polynucleotide comprises a sequence as shown in Tables 1-26.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat metastatic colorectal cancer. In another embodiment, the patient is suspected of having metastatic colorectal cancer.

In one embodiment, the patient is a human.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides methods of detecting polypeptide encoded by a metastatic colorectal cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with an antibody that specifically binds a polypeptide encoded by a sequence at least 80% identical to a sequence as shown in Tables 1-26.

10

15

20

25

30

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of metastatic colorectal cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a metastatic colorectal cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26., thereby monitoring the efficacy of the therapy.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the metastatic colorectal cancer-associated transcript to a level of the metastatic colorectal cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of metastatic colorectal cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a metastatic colorectal cancer-associated antibody in the biological sample by contacting the biological sample with a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26, wherein the polypeptide specifically binds to the metastatic colorectal cancer-associated antibody, thereby monitoring the efficacy of the therapy.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the metastatic colorectal cancer-associated antibody to a level of the metastatic colorectal cancer-associated antibody in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of metastatic colorectal cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a metastatic colorectal cancer-associated polypeptide in the biological sample by contacting the biological sample with an antibody, wherein the antibody specifically binds to a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26, thereby monitoring the efficacy of the therapy.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the metastatic colorectal cancer-associated polypeptide to a level of the metastatic

10

15

20

25

30

colorectal cancer-associated polypeptide in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-26.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

In one aspect, the present invention provides a method of detecting a metastatic colorectal cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to metastatic colorectal cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprises a sequence from Tables 1-26.

In another aspect, the present invention provides a method for identifying a compound that modulates a metastatic colorectal cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a metastatic colorectal cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

10

15

20

25

30

In another aspect, the present invention provides a method of inhibiting proliferation of a metastatic colorectal cancer-associated cell to treat colorectal cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having colorectal cancer or a cell isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26. in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of colorectal cancer.

In one embodiment, the control is a mammal with colorectal cancer or a cell therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

In another aspect, the present invention provides a method for treating a mammal having colorectal cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having colorectal cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

# DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and treatment of colon and/or rectal cancer (e.g., colorectal cancer), including metastatic colorectal cancers, as well as methods for screening for compositions which modulate colorectal cancer. By "metastatic colorectal cancer" herein is meant a colon and/or rectal tumor or cancer that is classified as Dukes stage C or D (see, e.g., Cohen et al., Cancer of the Colon, in Cancer: Principles and Practice of Oncology, pp. 1144-1197 (Devita et al., eds., 5<sup>th</sup> ed. 1997); see also Harrison's Principles of Internal Medicine, pp. 1289-129 (Wilson et al., eds., 12<sup>th</sup> ed., 1991). "Treatment, monitoring, detection or modulation of metastatic colorectal cancer" includes treatment, monitoring, detection, or modulation of metastatic colorectal disease in those patients who have metastatic colorectal

10

15

20

25

30

disease (Dukes stage C or D). In Dukes stage A, the tumor has penetrated into, but not through, the bowel wall. In Dukes stage B, the tumor has penetrated through the bowel wall but there is not yet any lymph involvement. In Dukes stage C, the cancer involves regional lymph nodes. In Dukes stage D, there is distant metastasis, e.g., liver, lung, etc.

Tables 1-26 provide UniGene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in metastasizing colorectal cancer samples. Tables 1-26 also provide an exemplar accession number that provides a nucleotide sequence that is part of the UniGene cluster. In Tables 1-26, the ratio provided represents primary tumor samples from known Dukes B stage survivors vs. liver metastasis samples from patients with metastatic colorectal cancer. In these samples, the identified genes are underexpressed in the metastatic samples, as the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater. In Tables 1-26, the ratio provided represents liver metastasis samples from patients with known metastatic colorectal cancer vs. known primary tumor samples from Dukes B stage survivors. In these samples, the identified genes are overexpressed in the metastatic samples, as the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater. In Tables 1-26, the ratio provided represents primary tumor samples from known Dukes B stage survivors vs. liver metastasis samples from patients with metastatic colorectal cancer. In these samples, the identified genes are overexpressed in the metastatic samples, as the ratio is less than one, preferably 0.5 or less, more preferably 0.25 or less. Survivors are subjects who have been disease free for five years or longer.

In Tables 1-26, the ratio provided represents liver metastasis samples from patients with known metastatic disease vs. tissue samples from normal colon tissue. In these samples, the identified genes are overexpressed in the metastatic samples, as the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater. In Tables 1-26, the ratio represents liver metastasis samples from patients with known metastatic disease vs. tissue samples from normal colon tissue. In these samples, the identified genes are underexpressed in the metastatic samples, as the ratio is less than one, preferably 0.5 or less, more preferably 0.25 or less.

One of skill will recognize that although the sequences identified in Tables 1-26 exhibited increased or decreased expression in metastasizing colorectal cancer samples, the sequences of the invention, and their encoded proteins, can be used to diagnose, treat or prevent cancers in patients with Dukes stage A or B colorectal cancers. Alteration of gene expression for a gene in Tables 1-26 may be more likely or less likely to indicate that the subject will progress to metastatic disease. The sequences can also be used to diagnose, treat or prevent precancerous or benign conditions such as precancerous colon adenomas. Alteration of gene expression for a gene in Tables 1-26 may or may not indicate that the subject is more likely to progress to cancer or to metastatic disease. Thus, although the specification focuses primarily on metastasizing colorectal cancer, the methods described below can also be applied to non- metastasizing colorectal cancers (e.g., Dukes stages A and B) and precancerous or benign conditions (e.g., precancerous adenomas) as well.

#### Definitions

5

10

15

20

25

30

The term "metastatic colorectal cancer protein" or "metastatic colorectal cancer polynucleotide" or "metastatic colorectal cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a UniGene cluster of Tables 1-26; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a UniGene cluster of Tables 1-26, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-26 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a UniGene cluster of Tables 1-26. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "metastatic colorectal cancer polypeptide" and a "metastatic colorectal cancer polynucleotide," include both naturally occurring or recombinant.

10

15

20

25

30

A "full length" metastatic colorectal cancer protein or nucleic acid refers to a metastatic colorectal cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type metastatic colorectal cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a metastatic colorectal cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate, e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or other mammal; or a bird; reptile; fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention *in vivo*. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions

10

15

20

25

30

and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* 25:3389-3402 (1977) and Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short

10

15

20

25

30

words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules

10

15

20

25

30

or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (*see, e.g.*, the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,  $\gamma$ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an  $\alpha$  carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine,

norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

10

15

20

5

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

25

30

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

The following eight groups each contain amino acids that are typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3<sup>rd</sup> ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of  $\beta$ -sheet and  $\alpha$ -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together.

Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui &

10

15

20

25

30

Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T<sub>m</sub>) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T<sub>m</sub> for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include <sup>32</sup>P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins

10

15

20

25

30

or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g.,

recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence,

10

15

20

25

30

wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to essentially no other sequences. Stringent conditions are sequencedependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions are often: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification,

10

15

20

25

30

although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a metastatic colorectal cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the metastatic colorectal cancer protein or nucleic acid, e.g., an enzymatic, functional, physical, or chemical effect, such as the ability to decrease metastatic colorectal cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of metastatic colorectal cancer cells. "Functional effects" include in vitro, in vivo, and ex vivo activities.

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a metastatic colorectal cancer protein sequence, e.g., functional, enzymatic, physical and

10

15

20

25

30

chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the metastatic colorectal cancer protein; measuring binding activity or binding assays, e.g., binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on metastatic colorectal cancer can also be performed using metastatic colorectal cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of metastatic colorectal cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for metastatic colorectal cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase,  $\beta$ gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of metastatic colorectal cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using *in vitro* and *in vivo* assays of metastatic colorectal cancer polynucleotide and polypeptide sequences of the invention. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of metastatic colorectal cancer proteins of the invention, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate metastatic colorectal cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of metastatic colorectal cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the metastatic colorectal cancer protein *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then

10

15

20

25

30

determining the functional effects on activity, as described above. Activators and inhibitors of metastatic colorectal cancer can also be identified by incubating metastatic colorectal cancer cells with the test compound and determining increases or decreases in the expression of 1 or more metastatic colorectal cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more metastatic colorectal cancer proteins, such as colorectal cancer proteins encoded by the sequences set out in Tables 1-26.

Samples or assays comprising metastatic colorectal cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a metastatic colorectal cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics *in vitro* or *in vivo*, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. *See, e.g.*, Freshney, *Culture of Animal Cells a Manual of Basic Technique* pp. 231-241 (3<sup>rd</sup> ed. 1994).

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3<sup>rd</sup> ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen.

10

15

20

25

30

The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain  $(V_L)$  and variable heavy chain  $(V_H)$  refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab')2, a dimer of Fab which itself is a light chain joined to V<sub>H</sub>-C<sub>H</sub>1 by a disulfide bond. The F(ab')2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab')2 dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce

. 10

15

20

25

30

antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which, e.g, (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

# Identification of metastatic colorectal cancer-associated sequences

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue may be distinguished from cancerous or metastatic cancerous tissue, or metastatic cancerous tissue can be compared with tissue from surviving cancer patients. By comparing expression profiles of tissue in known different metastatic colorectal cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in metastatic colorectal cancer versus non-metastatic colorectal cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate metastatic colorectal cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of metastatic colorectal cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a

10

15

20

25

30

particular expression profile; e.g., screening can be done for drugs that suppress the metastatic colorectal cancer expression profile. This may be done by making biochips comprising sets of the important metastatic colorectal cancer genes, which can then be used in these screens. PCR methods may be applied with selected primer pairs, and analysis may be of RNA or of genomic sequences. These methods can also be done on the protein basis; that is, protein expression levels of the metastatic colorectal cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the metastatic colorectal cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the metastatic colorectal cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs or as protein or DNA vaccines.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in metastatic colorectal cancer, herein termed "metastatic colorectal cancer sequences." As outlined below, metastatic colorectal cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in metastatic colorectal cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the metastatic colorectal cancer sequences are from humans; however, as will be appreciated by those in the art, metastatic colorectal cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other metastatic colorectal cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets (dogs, cats, etc.). Metastatic colorectal cancer sequences from other organisms may be obtained using the techniques outlined below.

Metastatic colorectal cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, metastatic colorectal cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the metastatic colorectal cancer sequences can be generated.

A metastatic colorectal cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the metastatic colorectal cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid

10

15

20

25

30

or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying metastatic colorectal cancer-associated sequences, the metastatic colorectal cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue, or tumor tissue samples from patients who have been diagnosed with Dukes stage A or B cancer but have survived vs. metastatic tissue. Other suitable tissue comparisons include comparing metastatic colorectal cancer samples with metastatic cancer samples from other cancers, such as lung, breast, other gastrointestinal cancers, prostate, ovarian, etc. Samples of, e.g., Dukes stage B survivor tissue and tissue undergoing metastasis are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art for the preparation of mRNA. Suitable biochips are commercially available, e.g., from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal colon, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, prostate, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the metastatic colorectal cancer screen that are expressed in significant amounts in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, metastatic colorectal cancer sequences are those that are up-regulated in metastatic colorectal cancer; that is, the expression of these genes is higher in the metastatic tissue as compared to non-metastatic cancerous tissue or normal colon tissue (see, e.g., Tables 1-26). "Up-regulation" as used herein means, when the ratio is presented as a number greater than one, that the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater. All UniGene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ).

In another preferred embodiment, metastatic colorectal cancer sequences are those that are down-regulated in the metastatic colorectal cancer; that is, the expression of these genes is lower in metastatic tissue as compared to non-metastatic cancerous tissue or normal colon tissue (see, e.g., Tables 1-26). "Down-regulation" as used herein means, when the ratio is presented as a number greater than one, that the ratio is greater than one, preferably 1.5 or greater, more preferably 2.0 or greater, or, when the ratio is presented as a number less than one, that the ratio is less than one, preferably 0.5 or less, more preferably 0.25 or less.

#### Informatics

5

10

15

20

25

30

The ability to identify genes that are over or under expressed in metastatic colorectal cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with metastatic colorectal cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for assay data acquired using an assay of the invention.

10

15

20

25

30

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing metastatic colorectal cancer, i.e., the identification of metastatic colorectal cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized.

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis:

Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999);

Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological

10

15

20

25

30

Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for metastatic colorectal cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The

10

15

20

25

30

comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example,

10

15

20

25

30

a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

### Characteristics of metastatic colorectal cancer-associated proteins

Metastatic colorectal cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the metastatic colorectal cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus and/or in the organelles. Proteins containing one or more transmembrane domains that exclusively reside in organelles are also considered intracellular proteins. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein

10

15

20

25

30

(1998)).

interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et

In another embodiment, the metastatic colorectal cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels, pumps, and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive

10

15

20

25

30

hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/).

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, hormones, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Metastatic colorectal cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for extracellular immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins *in situ* or in histological analysis. Alternatively, antibodies can also label intracellular proteins, in which case analytical samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the metastatic colorectal cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they often serve to transmit signals to various other cell types. The secreted protein may

10

15

20

25

30

function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Metastatic colorectal cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests.

## Use of metastatic colorectal cancer nucleic acids

As described above, metastatic colorectal cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the metastatic colorectal cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

The metastatic colorectal cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-26, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the metastatic colorectal cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/unigene/).

Once the metastatic colorectal cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire metastatic colorectal cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant metastatic colorectal cancer nucleic acid can be further-used as a probe to identify and isolate other metastatic colorectal cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant metastatic colorectal cancer nucleic acids and proteins.

The metastatic colorectal cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the metastatic colorectal

10

15

20

25

30

cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications. Alternatively, the metastatic colorectal cancer nucleic acids that include coding regions of metastatic colorectal cancer proteins can be put into expression vectors for the expression of metastatic colorectal cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to metastatic colorectal cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the metastatic colorectal cancer nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under appropriate reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally complements of ORFs or whole genes are not used. In some embodiments, nucleic acids of lengths up to hundreds of bases can be used.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical

10

15

20

25

30

equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is typically meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

In general, the probes are attached to a biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, Teflon, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize

10

15

20

25

30

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g., using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized *in situ*, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip<sup>TM</sup> technology.

Often, amplification-based assays are performed to measure the expression level of metastatic colorectal cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a metastatic colorectal cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of metastatic colorectal

10

15

20

25

30

cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

## Expression of metastatic colorectal cancer proteins from nucleic acids

In a preferred embodiment, metastatic colorectal cancer nucleic acids, e.g., encoding metastatic colorectal cancer proteins, are used to make a variety of expression vectors to express metastatic colorectal cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the metastatic colorectal cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

10

15

20

25

30

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the metastatic colorectal cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g., in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, *supra*).

10

15

20

25

30

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The metastatic colorectal cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a metastatic colorectal cancer protein, under the appropriate conditions to induce or cause expression of the metastatic colorectal cancer protein. Conditions appropriate for metastatic colorectal cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the metastatic colorectal cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenylation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation,

rooeroeo.cerroe

5

10

15

20

25

30

polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, metastatic colorectal cancer proteins are expressed in bacterial systems. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the metastatic colorectal cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others (e.g., Fernandez & Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, metastatic colorectal cancer proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, metastatic colorectal cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The metastatic colorectal cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies,

10

15

20

25

30

if the desired epitope is small, the metastatic colorectal cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the metastatic colorectal cancer protein may be made as a fusion protein to increase expression for affinity purification purposes, or for other reasons. For example, when the metastatic colorectal cancer protein is a metastatic colorectal cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the metastatic colorectal cancer protein is purified or isolated after expression. Metastatic colorectal cancer proteins may be isolated or purified in a variety of appropriate ways. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the metastatic colorectal cancer protein may be purified using a standard antimetastatic colorectal cancer protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, *Protein Purification* (1982). The degree of purification necessary will vary depending on the use of the metastatic colorectal cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the metastatic colorectal cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

#### Variants of metastatic colorectal cancer proteins

In one embodiment, the metastatic colorectal cancer proteins are derivative or variant metastatic colorectal cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative metastatic colorectal cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at a particular residue within the metastatic colorectal cancer peptide.

Also included within one embodiment of metastatic colorectal cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the metastatic colorectal cancer protein, using cassette or PCR mutagenesis or other techniques, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell

10

15

20

25

30

culture as outlined above. However, variant metastatic colorectal cancer protein fragments having up to about 100-150 residues may be prepared by *in vitro* synthesis. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the metastatic colorectal cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is often predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed metastatic colorectal cancer variants screened for the optimal combination of desired activity. Techniques exist for making substitution mutations at predetermined sites in DNA having a known sequence, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of metastatic colorectal cancer protein activities.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be occasionally tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. Larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of a metastatic colorectal cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution chart provided in the definition section.

Variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the metastatic colorectal cancer proteins as needed. Alternatively, the variant may be designed or reorganized such that the biological activity of the metastatic colorectal cancer protein is altered. For example, glycosylation sites may be altered or removed.

Covalent modifications of metastatic colorectal cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a metastatic colorectal cancer polypeptide with an

10

15

20

25

30

organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a metastatic colorectal cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking metastatic colorectal cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-metastatic colorectal cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the  $\gamma$ -amino groups of lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the metastatic colorectal cancer polypeptide encompassed by this invention is an altered native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended herein to mean adding to or deleting one or more carbohydrate moieties of a native sequence metastatic colorectal cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express metastatic colorectal cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to metastatic colorectal cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence metastatic colorectal cancer polypeptide (for O-linked glycosylation sites). The metastatic colorectal cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the metastatic colorectal cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the metastatic colorectal cancer polypeptide is by chemical or enzymatic coupling of glycosides

10

15

20

25

30

to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the metastatic colorectal cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of metastatic colorectal cancer comprises linking the metastatic colorectal cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Metastatic colorectal cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a metastatic colorectal cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a metastatic colorectal cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the metastatic colorectal cancer polypeptide. The presence of such epitope-tagged forms of a metastatic colorectal cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the metastatic colorectal cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a metastatic colorectal cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known and examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field *et al.*, *Mol. Cell. Biol.* 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan *et al.*, *Molecular and Cellular Biology* 5:3610-3616 (1985));

10

15

20

25

30

and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (*Paborsky et al.*, *Protein Engineering* 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (*Hopp et al.*, *BioTechnology* 6:1204-1210 (1988)); the KT3 epitope peptide (Martin *et al.*, *Science* 255:192-194 (1992)); tubulin epitope peptide (Skinner *et al.*, *J. Biol. Chem.* 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth *et al.*, *Proc. Natl. Acad. Sci. USA* 87:6393-6397 (1990)).

Also included are other metastatic colorectal cancer proteins of the metastatic colorectal cancer family, and metastatic colorectal cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related metastatic colorectal cancer proteins from primates or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include unique areas of the metastatic colorectal cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. PCR reaction conditions are well known in the art (e.g., Innis, PCR Protocols, *supra*).

#### Antibodies to metastatic colorectal cancer proteins

In a preferred embodiment, when a metastatic colorectal cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the metastatic colorectal cancer protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller metastatic colorectal cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are well known (e.g., Coligan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of Tables 1-26 or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal

10

15

20

25

30

being immunized. Immunogenic proteins include, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Adjuvants include, e.g., Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-26, or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and primate origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are typically monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid of Tables 1-26 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

10

15

20

25

30

In a preferred embodiment, the antibodies to metastatic colorectal cancer protein are capable of reducing or eliminating a biological function of a metastatic colorectal cancer protein, as is described below. That is, the addition of anti-metastatic colorectal cancer protein antibodies (either polyclonal or preferably monoclonal) to metastatic colorectal cancer tissue (or cells containing metastatic colorectal cancer) may reduce or eliminate the metastatic colorectal cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the metastatic colorectal cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact

10

15

20

25

30

human variable domain has been substituted by the corresponding sequence from a non-human species.

Human-like antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner et al., J. Immunol. 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in virtually all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

By immunotherapy is meant treatment of metastatic colorectal cancer with an antibody raised against a metastatic colorectal cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. The antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the metastatic colorectal cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted metastatic colorectal cancer protein.

In another preferred embodiment, the metastatic colorectal cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory,

10

15

20

25

30

antibodies used for this treatment typically bind the extracellular domain of the metastatic colorectal cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane metastatic colorectal cancer protein. The antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the metastatic colorectal cancer protein. The antibody may be an antagonist of the metastatic colorectal cancer protein or may prevent activation of the transmembrane metastatic colorectal cancer protein. In some embodiments, when the antibody prevents the binding of other molecules to the metastatic colorectal cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigendependent cytotoxicity (ADCC). Thus, metastatic colorectal cancer is treated by administering to a patient antibodies directed against the transmembrane metastatic colorectal cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the metastatic colorectal cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the metastatic colorectal cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase activity associated with metastatic colorectal cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to metastatic colorectal cancer tissue or cells results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with metastatic colorectal cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like.

10

15

20

25

30

Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against metastatic colorectal cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane metastatic colorectal cancer proteins not only serves to increase the local concentration of therapeutic moiety in the metastatic colorectal cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the metastatic colorectal cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein or other entity which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the metastatic colorectal cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

The metastatic colorectal cancer antibodies of the invention specifically bind to metastatic colorectal cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a  $K_d$  of at least about 0.1 mM, more usually at least about 1  $\mu$ M, preferably at least about 0.1  $\mu$ M or better, and most preferably, 0.01  $\mu$ M or better. Selectivity of binding is also important.

# Detection of metastatic colorectal cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the metastatic colorectal cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing metastatic colorectal cancer) and in metastatic colorectal cancer tissue (and in some cases, for varying severities of metastatic colorectal cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may

10

15

20

25

30

be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus metastatic colorectal cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is typically at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the metastatic colorectal cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to metastatic colorectal cancer genes, i.e., those identified as being important in a metastatic colorectal cancer phenotype, can be evaluated in a metastatic colorectal cancer diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes.

10

15

20

25

30

The metastatic colorectal cancer nucleic acid probes may be attached to biochips as outlined herein for the detection and quantification of metastatic colorectal cancer sequences in a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In a preferred embodiment nucleic acids encoding the metastatic colorectal cancer protein are detected. Although DNA or RNA encoding the metastatic colorectal cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a metastatic colorectal cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the nonspecifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a metastatic colorectal cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The metastatic colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing metastatic colorectal cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, metastatic colorectal cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of metastatic colorectal cancer. Detection of these proteins in putative metastatic colorectal cancer tissue

10

15

20

25

30

allows for detection or diagnosis of metastatic colorectal cancer. In one embodiment, antibodies are used to detect metastatic colorectal cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the metastatic colorectal cancer protein is detected, e.g., by immunoblotting with antibodies raised against the metastatic colorectal cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

In another preferred method, antibodies to the metastatic colorectal cancer protein find use in *in situ* imaging techniques, e.g., in histology (e.g., *Methods in Cell Biology: Antibodies in Cell Biology*, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the metastatic colorectal cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label, e.g., multicolor fluorescence or confocal imaging. In another method the primary antibody to the metastatic colorectal cancer protein(s) contains a detectable label, e.g., an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of metastatic colorectal cancer proteins. Many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing metastatic colorectal cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of metastatic colorectal cancer proteins. Antibodies can be used to detect a metastatic colorectal cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous metastatic colorectal cancer protein or vaccine.

In a preferred embodiment, in situ hybridization of labeled metastatic colorectal cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue

10

15

20

25

30

samples, including metastatic colorectal cancer tissue and/or normal tissue, are made. *In situ* hybridization (*see*, *e.g.*, Ausubel, *supra*) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the metastatic colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing metastatic colorectal cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to metastatic colorectal cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, metastatic colorectal cancer probes may be attached to biochips for the detection and quantification of metastatic colorectal cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

# Assays for therapeutic compounds

In a preferred embodiment members of the three classes of proteins as described herein are used in drug screening assays. The metastatic colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing metastatic colorectal cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996).

In a preferred embodiment, the metastatic colorectal cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified metastatic colorectal cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the metastatic colorectal cancer phenotype or an identified physiological function of a metastatic colorectal cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput

10

15

20

25

30

screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

Having identified the differentially expressed genes herein, a variety of assays may be applied. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene with altered regulation in metastatic colorectal cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the metastatic colorectal cancer protein. "Modulation" thus includes an increase or a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing metastatic colorectal cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in metastatic colorectal cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in metastatic colorectal cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the metastatic colorectal cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene or protein expression monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.

In this embodiment, the metastatic colorectal cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of metastatic colorectal cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more metastatic colorectal cancer-associated sequences, e.g., a polynucleotide sequence set out in Tables 1-26. Generally, in a preferred embodiment, a test compound is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate metastatic colorectal cancer, modulate metastatic colorectal

10

15

20

25

30

cancer proteins, bind to a metastatic colorectal cancer protein, or interfere with the binding of a metastatic colorectal cancer protein and an antibody, substrate, or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the metastatic colorectal cancer phenotype or the expression of a metastatic colorectal cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles of nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a metastatic colorectal cancer phenotype, e.g., to a normal tissue fingerprint. In another embodiment, a modulator induces a metastatic colorectal cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

In one aspect, a modulator will neutralize the effect of a metastatic colorectal cancer protein. By "neutralize" is meant that activity of a protein and the consequent effect on the cell is inhibited or blocked.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a metastatic colorectal cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of

10

15

20

25

30

chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop et al., J. Med. Chem. 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual

10

15

20

25

30

synthetic operations performed by a chemist. The above devices, with appropriate modification, are suitable for use with the present invention. In addition, numerous combinatorial libraries are themselves commercially available (*see, e.g.,* ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect modulation of metastatic colorectal cancer gene transcription, polypeptide expression, and polypeptide activity.

High throughput assays for evaluating the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate procedures, including sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

10

15

20

25

30

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that the nucleic acid or peptide consists of essentially random sequences of nucleotides and amino acids, respectively. Since these random peptides (or nucleic acids, discussed below) are often chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. In a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc.

Modulators of metastatic colorectal cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. Digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After a candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence is analyzed. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

10

15

20

25

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

Nucleic acid assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allow formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration, pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

The reactions outlined herein may be accomplished in a variety of ways.

Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g., albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the

10

15

20

25

30

assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the metastatic colorectal cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product, or evaluate genetic polymorphisms.

Genes can be screened for those that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a metastatic colorectal cancer expression pattern leading to a normal expression pattern, or to modulate a single metastatic colorectal cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated metastatic colorectal cancer tissue reveals genes that are not expressed in normal tissue or metastatic colorectal cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for metastatic colorectal cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated metastatic colorectal cancer tissue sample.

Thus, in one embodiment, a test compound is administered to a population of metastatic colorectal cancer cells, that have an associated metastatic colorectal cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral

10

15

20

25

30

construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., metastatic colorectal cancer tissue may be screened for agents that modulate, e.g., induce or suppress the metastatic colorectal cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on metastatic colorectal cancer activity. By defining such a signature for the metastatic colorectal cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

Measure of metastatic colorectal cancer polypeptide activity, or of metastatic colorectal cancer or the metastatic colorectal cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the metastatic polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of metastatic colorectal cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian metastatic colorectal cancer polypeptide is typically used, e.g., mouse, preferably human.

Assays to identify compounds with modulating activity can be performed *in vitro*. For example, a colorectal cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the metastatic colorectal cancer polypeptide levels are determined *in vitro* by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively

5

10

15

20

25

30

binds to the metastatic colorectal cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the metastatic colorectal cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or  $\beta$ -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "metastatic colorectal cancer proteins." The metastatic colorectal cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the metastatic colorectal cancer proteins can be used in the assays.

Thus, in a preferred embodiment, the methods comprise combining a metastatic colorectal cancer protein and a candidate compound, and determining the binding of the compound to the metastatic colorectal cancer protein. Preferred embodiments utilize

10

15

20

25

30

the human metastatic colorectal cancer protein, although other mammalian proteins may also be used, e.g., for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative metastatic colorectal cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the metastatic colorectal cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the metastatic colorectal cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the metastatic colorectal cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the test modulating compound to the metastatic colorectal cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all

10

15

20

25

30

or a portion of the metastatic colorectal cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., <sup>125</sup>I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a metastatic colorectal cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present.

Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the metastatic colorectal cancer protein and thus is capable of binding to, and potentially modulating, the activity of the metastatic colorectal cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the metastatic colorectal cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the metastatic colorectal cancer protein.

10

15

20

25

30

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the metastatic colorectal cancer proteins. In this embodiment, the methods comprise combining a metastatic colorectal cancer protein and a competitor in a first sample. A second sample comprises a test compound, a metastatic colorectal cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the metastatic colorectal cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the metastatic colorectal cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native metastatic colorectal cancer protein, but cannot bind to modified metastatic colorectal cancer proteins. The structure of the metastatic colorectal cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a metastatic colorectal cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a metastatic colorectal cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising metastatic colorectal cancer proteins. Preferred cell types include almost any cell. The cells contain a

10

15

20

25

30

recombinant nucleic acid that encodes a metastatic colorectal cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g., hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate metastatic colorectal cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the metastatic colorectal cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting metastatic colorectal cancer cell division is provided. The method comprises administration of a metastatic colorectal cancer inhibitor. In another embodiment, a method of inhibiting metastatic colorectal cancer is provided. The method comprises administration of a metastatic colorectal cancer inhibitor. In a further embodiment, methods of treating cells or individuals with metastatic colorectal cancer are provided. The method comprises administration of a metastatic colorectal cancer inhibitor.

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

# Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of metastatic colorectal cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, Culture of Animal Cells a Manual of Basic Technique (3<sup>rd</sup> ed., 1994),

10

15

20

25

30

herein incorporated by reference. See also, the methods section of Garkavtsev et al. (1996), supra, herein incorporated by reference.

## Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (<sup>3</sup>H)-thymidine at saturation density can be used to measure density limitation of growth. *See* Freshney (1994), *supra*. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (<sup>3</sup>H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a metastatic colorectal cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (<sup>3</sup>H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

#### Growth factor or serum dependence

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

# Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor

10

15

20

angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305-312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

#### Invasiveness into Matrigel

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate metastatic colorectal cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with <sup>125</sup>I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

#### Tumor growth in vivo

cancer gene, e.g., by exposure to carcinogens.

Effects of metastatic colorectal cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the metastatic colorectal cancer gene is disrupted or in which a metastatic colorectal cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous metastatic colorectal cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous metastatic colorectal cancer gene with a mutated version of the metastatic colorectal cancer gene, or by mutating the endogenous metastatic colorectal

10

15

20

25

30

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10<sup>6</sup> cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a metastatic colorectal cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth. Additionally, human tumor cells expressing the genes of the invention may be injected into immune compromised animals. Growth of these tumors, or xenografts, is compared to growth of similar human tumor cell that do not express the genes of the invention. These animals may also be used to binding assays and efficacy studies for therapeutic compounds that modulate metastatic colorectal cancer, such as antibodies or small molecules.

# Polynucleotide modulators of metastatic colorectal cancer

Antisense Polynucleotides

In certain embodiments, the activity of a metastatic colorectal cancerassociated protein is downregulated, or entirely inhibited, by the use of antisense polynucleotide, i.e., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a metastatic colorectal cancer

10

15

20

25

30

protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the metastatic colorectal cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for metastatic colorectal cancer molecules. A preferred antisense molecule is for a metastatic colorectal cancer sequence in Tables 1-26, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).

#### Ribozymes

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of metastatic colorectal cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al.,

10

15

20

25

30

Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al., Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g., WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

Polynucleotide modulators of metastatic colorectal cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of metastatic colorectal cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating metastatic colorectal cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-metastatic colorectal cancer antibody that reduces or eliminates the biological activity of an endogenous metastatic colorectal cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a metastatic colorectal cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g., when the metastatic colorectal cancer sequence is down-regulated in metastatic colorectal cancer, such state may be reversed by increasing the amount of metastatic colorectal cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous metastatic colorectal cancer gene or administering a gene encoding the metastatic colorectal cancer sequence, using known gene-therapy techniques. In a preferred embodiment, the gene therapy techniques include the

10

15

20

25

30

incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g., as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g., when the metastatic colorectal cancer sequence is up-regulated in metastatic colorectal cancer, the activity of the endogenous metastatic colorectal cancer gene is decreased, e.g., by the administration of a metastatic colorectal cancer antisense nucleic acid.

In one embodiment, the metastatic colorectal cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to metastatic colorectal cancer proteins. Similarly, the metastatic colorectal cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify metastatic colorectal cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a metastatic colorectal cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The metastatic colorectal cancer antibodies may be coupled to standard affinity chromatography columns and used to purify metastatic colorectal cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the metastatic colorectal cancer protein.

### Methods of identifying variant metastatic colorectal cancer-associated sequences

Without being bound by theory, expression of various metastatic colorectal cancer sequences is correlated with metastatic colorectal cancer. Accordingly, disorders based on mutant or variant metastatic colorectal cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant metastatic colorectal cancer genes, e.g., determining all or part of the sequence of at least one endogenous metastatic colorectal cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the metastatic colorectal cancer genotype of an individual, e.g., determining all or part of the sequence of at least one metastatic colorectal cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced metastatic colorectal cancer gene to a known metastatic colorectal cancer gene, i.e., a wild-type gene.

The sequence of all or part of the metastatic colorectal cancer gene can then be compared to the sequence of a known metastatic colorectal cancer gene to determine if any

10

15

20

25

30

differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the metastatic colorectal cancer gene of the patient and the known metastatic colorectal cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the metastatic colorectal cancer genes are used as probes to determine the number of copies of the metastatic colorectal cancer gene in the genome.

In another preferred embodiment, the metastatic colorectal cancer genes are used as probes to determine the chromosomal localization of the metastatic colorectal cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the metastatic colorectal cancer gene locus.

#### Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a metastatic colorectal cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for metastatic colorectal cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the metastatic colorectal cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above,

10

15

20

25

30

including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the metastatic colorectal cancer proteins and modulators may be directly applied as a solution or spray.

The pharmaceutical compositions of the present invention comprise a metastatic colorectal cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that metastatic colorectal cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. It is also recognized that, after delivery to other

10

15

20

25

30

sites in the body (e.g., circulatory system, lymphatic system, or the tumor site) the metastatic colorectal cancer modulators of the invention may need to be protected from excretion, hydrolisis, proteolytic digestion or modification, or detoxification by the liver. In all these cases, protection is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier or by modifying the molecular size, weight, and/or charge of the modulator. Means of protecting agents from digestion degradation, and excretion are well known in the art.

The compositions for administration will commonly comprise a metastatic colorectal cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacologial Basis of Therapeutics (Hardman et al., eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of metastatic colorectal cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its

10

15

20

25

30

complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

It will be appreciated that the present metastatic colorectal cancer protein-modulating compounds can be administered alone or in combination with additional metastatic colorectal cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-26, such as antisense polynucleotides or ribozymes, will be introduced into cells, *in vitro* or *in vivo*. The present invention provides methods, reagents, vectors, and cells useful for expression of metastatic colorectal cancer-associated polypeptides and nucleic acids using *in vitro* (cell-free), *ex vivo* or *in vivo* (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

In a preferred embodiment, metastatic colorectal cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above.

10

15

20

25

30

Similarly, metastatic colorectal cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the metastatic colorectal cancer coding regions) can be administered in a gene therapy application. These metastatic colorectal cancer genes can include antisense applications, either as gene therapy (i.e., for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

Metastatic colorectal cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986); Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit,

25

30

5

10

MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff *et. al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (*see, e.g.*, U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode metastatic colorectal cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g., adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

Methods for the use of genes as DNA vaccines are well known, and include placing a metastatic colorectal cancer gene or portion of a metastatic colorectal cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a metastatic colorectal cancer patient. The metastatic colorectal cancer gene used for DNA vaccines can encode full-length metastatic colorectal cancer proteins, but more preferably

10

15

20

25

30

encodes portions of the metastatic colorectal cancer proteins including peptides derived from the metastatic colorectal cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a metastatic colorectal cancer gene. For example, metastatic colorectal cancer-associated genes or sequence encoding subfragments of a metastatic colorectal cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the metastatic colorectal cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment metastatic colorectal cancer genes find use in generating animal models of metastatic colorectal cancer. When the metastatic colorectal cancer gene identified is repressed or diminished in metastatic tissue, gene therapy technology, e.g., wherein antisense RNA directed to the metastatic colorectal cancer gene will also diminish or repress expression of the gene. Animal models of metastatic colorectal cancer find use in screening for modulators of a metastatic colorectal cancer-associated sequence or modulators of metastatic colorectal cancer. Similarly, transgenic animal technology including gene knockout technology, e.g., as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the metastatic colorectal cancer protein. When desired, tissue-specific expression or knockout of the metastatic colorectal cancer protein may be necessary.

It is also possible that the metastatic colorectal cancer protein is overexpressed in metastatic colorectal cancer. As such, transgenic animals can be generated that overexpress the metastatic colorectal cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of metastatic colorectal cancer and are additionally useful in screening for modulators to treat metastatic colorectal cancer.

10

15

20

25

## Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, metastatic colorectal cancerspecific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative metastatic colorectal cancer polypeptides or polynucleotides, small molecules inhibitors of metastatic colorectal cancer-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of metastatic colorectal cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a metastatic colorectal cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing metastatic colorectal cancer-associated activity. Optionally, the kit contains biologically active metastatic colorectal cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

# Table 1

		5	Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigeneID: Unigene number Unigene Title: Unigene gene title						
		10	Pkey	ExAccn	UnigenelD	Unigene Title	Ratio BS_Mets	Top 3 expressing cell lines	
		10	103989 A		Hs.423	ESTs; Weakly similar to LITHOSTATHINE 1 pancreatitis-associated protein	15.77 11.98	EB_cells, HT29_cells, HMEC HMEC (total RNA), Fibroblasts 2, Fibroblasts 2	
		1.5	101880 129462	M97925 D84239	Hs.111732	defensin; alpha 5; Paneth cell-specific lgG Fc binding protein	9.24 8.57 7.43	Fibroblasts 2, MB231_cells, MB-MDA-453 EB_cells, OVCAR_cells, HS578T_cells HMEC (total RNA), HMEC, Fibroblasts 2	
		15	131676 131861 118823	D11925	Hs.30514 Hs.184245 Hs.50813	KIAA0929 protein Msx2 interacting nuclea ESTs; Weakly similar to long chain fatty	7.15 6.72	HMEC, HMEC (total RNA), Fibroblasts 2 HMEC, HMEC (total RNA), Lu_AD_H23	
		20	101107 103466	L08010 Y00339	Hs.155097	regenerating islet-derived 1 beta (pancr carbonic anhydrase II defensin; alpha 6; Paneth cell-specific	6.33 6.18 5.67	BT474_cells, Fibroblasts 2, MB231_cells OVCAR_cells, MCF7, 293T_cells Fibroblasts 2, HMEC, HT29_cells	
		20	102306 126419 101198	AA451775	Hs.129064 Hs.315	H sapiens chromosome 19; cosmid F22162 mucin 2; intestinal/tracheal	5.14 5.1	HS578T_cells, HMEC (total RNA), HMEC EB_cells, HT29_cells, MB231_cells	
		25	107652	AA010195 Al498467	Hs.52642 Hs.166669 Hs.28043	ESTs; Weakly similar to !!!! ALU CLASS F ESTs; Weakly similar to sodium bicarbona	4.94 4.77 4.54	HMEC (total RNA), HMEC, EB_cells HS578T_cells, HMEC, Lu_SQ_H520 HMEC, HS578T_cells, BT474_cells	
,	H	23	111669 124867	R19305 R68971	Hs.110347 Hs.168500	H sapiens mRNA for alpha integrin bindin ESTs	4.52 4.5	HMEC, HS578T_cells, Caco2 HMEC, HMEC (total RNA), HS578T_cells HMEC, HMEC (total RNA), MB-MDA-435s	
		30	130736	T99385	Hs.189105 Hs.18646		4.41 4.29 4.18	HMEC, EB_cells, HMEC (total RNA) HMEC (total RNA), HMEC, Fibroblasts 2	
		30	108092 133373	AA045961 S72487	Hs.169355	ESTs; Weakly similar to TRANSCRIPTION F endothelial cell growth factor 1 (platel		4.04 HMEC (total RNA), HMEC, Fibroblasts 2 EB_cells, HMEC, HMEC (total RNA) HMEC (total RNA), HMEC, Fibroblasts 2	
		35	100572 115775 120811	HG2271 AA424030 AA346854	Hs.46627 Hs.52788	Profilaggrin ESTs fragile X mental retardation; autosomal	4.02 4.01	HMEC, HMEC (total RNA), EB_cells HMEC (total RNA), HMEC, Fibroblasts 2	
	₽		111919 117009	R39926 H85422	Hs.21031 Hs.108556	ESTs	3.98 3.97 3.89	EB_cells, HMEC (total RNA), HMEC HMEC (total RNA), HMEC, Fibroblasts 2 PC3_cells, RPWE_2, Cacc2	
		40	134733	AA424958 U03644	Hs.33735 Hs.89421	ESTs CBF1 interacting corepressor	3.88 3.88	EB_cells, HMEC, HMEC (total RNA) EB_cells, HMEC, HMEC (total RNA) HS578T_cells, MB-MDA-435s, HT29_cells	
	F-7			AA490469	Hs.31386 Hs.48752 Hs.79630	ESTs; Highly similar to secreted apoptos ESTs CD79A antigen (immunoglobulin-associated	3.87 3.84 3.83	HS578T_cells, HMEC, LNCaP_cells DU145_cells, Lu_AD_H23, MB231_cells	
		45	106753 104842	AA476944 AA039854	Hs.7331 Hs.8065	ESTs H sapiens mRNA full length insert cDNA c	3.82 3.78 3.75	LNCaP_cells, Lu_SC_H345, DU145_cells HS578T_cells, A549_cells, CALU6_cells HMEC (total RNA), HMEC, BT474_cells	
			105675	N27334 AA284767 HG2149	Hs.181780 Hs.252808	ESTs; Highly similar to pulmonary surfac Mucin (Gb:M57417)	3.75 3.75	293T_cells, PRSC_con, HT29_cells HMEC (total RNA), HMEC, Fibroblasts 2	
		50	116857 113222	H65841 T59670	Hs.186550 Hs.10615	ESTs ESTs	3.73 3.7 3.68	HS578T_cells, 293T_cells, HMEC HMEC, HS578T_cells, Cacc2 HMEC, HS578T_cells, OVCAR_cells	
			114542	N74467 AA055768 M58459	Hs.94304 Hs.122576 Hs.180911	ESTs ribosomal protein S4; Y-linked	3.66 3.62	EB_cells, MCF7, LNCaP_cells DU145_cells, RPWE_2, A549_cells	
		55	107754 104668	AA017462 AA007312	Hs.187571		3.6 3.58 from	HMEC (total RNA), Fibroblasts 2, Fibroblasts 2 HMEC (total RNA), HMEC, Fibroblasts 2 3.56 HMEC, HMEC (total RNA), EB_cells	
			127083	C21382 Z44079 U35407	Hs.91608 Hs.158084	otoferlin peroxisome receptor 1	3.53 3.51	HMEC (total RNA), HMEC, Fibroblasts 2 HMEC, HMEC (total RNA), EB_cells	
		60	126405	N50101 U46278 AA463886	Hs.122489	ESTs; Weakly similar to coded for by C. ESTs small glutamine-rich tetratricopeptide r	3.47 3.46 3.45	HMEC (total RNA), HMEC, EB_cells LNCaP_cells, MCF7, DU145_cells EB_cells, HMEC, HMEC (total RNA)	
			111418 135398	R01084 AA194075	Hs.19081 Hs.99908	ESTs nuclear receptor coactivator 4	3.43 3.4	HS578T_cells, EB_cells, Lu_AD_H23 HS578T_cells, EB_cells, HMEC	
		65		AA121960 AA252191		zm24g9.s1 Stratagene pancreas (#93728) I mRNA seq ESTs; Highly similar to match to ESTs AA	3.4 3.38	EB_cells, HMEC, HMEC (total RNA) EB_cells, LNCaP_cells, RPWE_2	
			103448 130436	X99133 M84526	Hs.204238	lipocalin 2 (oncogene 24p3)  D component of complement (adipsin)  yj76d5.s1 Soares breast 2NbHBst H sapien	3.38 3.37 3.36	PC3_cells, EB_cells, HT29_cells PRSC_con, EB_cells, Lu_AD_H23 EB_cells, HMEC, HMEC (total RNA)	
		70	103211	R55021 X73079 AA156576	3 Hs.191466	polymeric immunoglobulin receptor ESTs	3.35 3.21	MB231_cells, HT29_cells, Lu_SC_H69 EB cells, HMEC, HMEC (total RNA)	
			129989 113466	AF005887 T86945 X54489		activating transcription factor 6	3.19 3.18 ati 3.16	HMEC (total RNA), HMEC, Lu_AD_H23 HMEC, MB231_cells, Caco2 Lu_LC_H460, PC3_cells, Fibroblasts 2	
			103029	COPPECA	113.700	Server and an analysis of the server			

	109374	AA218727	Hs.210785	ESTs; Highly similar to Ibd1 [H.sapiens]	3.13	Caco2, A549_cells, MB231_cells
	131403	R55750	Hs.26455	ESTs	3.13	HS578T_cells, HMEC, MB231_cells
	113420	T83964	Hs.15400	ESTs	3.11	HMEC (total RNA), HMEC, EB_cells
_	112532	R69824	Hs.28313	ESTs	3.11	HMEC, HMEC (total RNA), EB_cells
5	117905	N50782	Hs.231713	EST	3.11	HMEC, HS578T_cells, Cacc2
	125349		Hs.164480		3.1	HS578T_cells, EB_cells, MB-MDA-435s
	107072	AA609113	Hs.177533	H sapiens mRNA; cDNA DKFZp586N0318 (fro		3.1 Lu_SC_H69, MB-MDA-453, MB231_cells
	118389	N64583	Hs.182385	ESTs	3.05	HMEC, HMEC, LNCaP_cells
	117653	N38970	Hs.194214	ESTs	3.04	HMEC, HMEC (total RNA), Fibroblasts 2
10	101082	L05072		interferon regulatory factor 1	3.04	EB_cells, PRSC_con, DU145_cells
		H75323	Hs.167614	ESTs	3.03	HS578T_cells, HMEC (total RNA), HMEC
	120006	W90108	Hs.10848	KIAA0187 gene product	3.03	HMEC, HMEC (total RNA), EB_cells
		AA297581		EST113160 Gall bladder I H sapiens cDNA	3.02	HMEC, Lu_AD_H23, Lu_SQ_H520
	106899	AA490107	Hs.21753	JM5 protein	3.02	EB_cells, HMEC (total RNA), HMEC
15		R96306	Hs.191290		3.02	EB_cells, HMEC, Lu_AD_358
	113613		Hs.17167	ESTs; Highly similar to LRR FLI-I intera	3.02	HMEC (total RNA), EB_cells, HMEC
		AA007230	Hs.95026	ESTs	3.02	Lu_SC_H345, HS578T_cells, Lu_LC_H460
	101923	S75256		HNL=neutrophil lipocalin [human, ovanan	3.01	PC3_cells, EB_cells, HT29_cells
••		HG315T		Beta-1-Glycoprotein 11, Pregnancy-Specif	3.01	Fibroblasts 2, Lu_AD_H23, MB-MDA-435s
20		U53445	Hs.15432	downregulated in ovarian cancer 1	2.98	PRSC_con, Fibroblasts 2, HMEC
		AA416615			2.94	HMEC, HS578T_cells, BT474_cells
		AA047055			2.94	HS578T_ceils, EB_ceils, HMEC
		AA056588			2.93	HMEC (total RNA), Fibroblasts 2, HMEC
~ -		H05961	Hs.26331		2.92	HMEC, MB231_cells, HS578T_cells
25		R78309	Hs.20787	ESTs	2.92	Cacc2, Lu_AD_358, Lu_AD_358
		L29433	Hs.47913	coagulation factor X	2.91	HMEC, HS578T_cells, Cacc2
	134749		Hs.89485		2.9	BT474_cells, MCF7, HMEC (total RNA)
		R07294		solute carrier family 22 (organic cation	2.9	HMEC, HMEC (total RNA), MB-MDA-435s
• •		Z38431	Hs.27038	ESTs; Moderately similar to X-linked ret	2.89	HMEC, HMEC (total RNA), EB_cells
30		AA024687		ESTs	2.88	HS578T_cells, MB231_cells, HMEC
		R10759	Hs.15177	ESTS	2.88	HS578T_cells, Lu_LC_H460, PRSC_con
	127553	AA282433		H sapiens p60 katanin mRNA; complete cds	2.87	EB_cells, MB-MDA-435s, RPWE_2
				ESTs; Weakly similar to ZINC FINGER PROT	2.86	EB_cells, PC3_cells, HMEC
26		H65459	Hs.38323	ESTs	2.85	HMEC, Caco2, HS578T_cells
35		X03068	Hs.73931	major histocompatibility complex; class	2.82	MB-MDA-435s, BT474_cells, HT29_cells
		C00810	Hs.21970		2.82	LNCaP_cells, Lu_SC_H345, EB_cells
		H05741	Hs.101643		2.82	HMEC, HS578T_cells, HT29_cells
		A1247422	Hs.129966	ESTS	2.82	HS578T_cells, Lu_LC_H460, Lu_SC_H69
40		R15413	Hs.164919	ESTs; Highly similar to PROTEIN KINASE C		MB231_cells, Lu_AD_H23, RPWE_2
40	126619	Z28861		HSBA7E032 STRATAGENE Human skeletal		HATCO I AD U22 HATCO (total BNA)
				cDNA clone A7E03, mRNA seq.	2.77	HMEC, Lu_AD_H23, HMEC (total RNA)
		AA011383			2.77	HS578T_cells, EB_cells, MCF7
		AA228030			2.77	EB_cells, Fibroblasts 2, HMEC (total RNA) Fibroblasts 2, PRSC_con, DU145_cells
45	126535	H73017	Hs.250723	ESTs; Weakly similar to atrophin-1 relat	2.76	
45		T64349	11- 444400	yc10d08.s1 Stratagene lung (#937210) H s	2.76	EB_cells, Lu_AD_H23, Lu_SC_H69 Lu_AD_H23, HMEC (total RNA), MB-MDA-435s
		N36368		ESTs; Moderately similar to similar to C	2.76 =	2.75 HMEC, HMEC (total RNA), Lu_SC_H69
		R43963		ESTs; Weakly similar to TRANSCRIPTION RI		HS578T_cells, HMEC, MB-MDA-453
		X52008	Hs.2700	glycine receptor, alpha 2	2.74 2.74	Fibroblasts 2, HMEC (total RNA), MB-MDA-435s
50		AA180352	HS.1914/2	ESIS		Lu_LC_H460, 293T_cells, EB_cells
50		L10373		transmembrane 4 superfamily member 2	2.73 2.73	HMEC (total RNA), HMEC, Fibroblasts 2
		Z20481		KIAA0699 protein	2.72	HMEC, EB_cells, HMEC (total RNA)
		AA476728		ESTs; Weakly similar to PHOSPHOLEMMAN		2.71 Lu_SC_H345, Lu_SC_H69, 293T_cells
		AA055978	HS.3007	EST: Medantely similar to Phospholewivery	2.71	EB_cells, HMEC, HMEC (total RNA)
55		R16539		EST; Moderately similar to Cd-7 Metallo	2.71	Caco2, Fibroblasts 2, MB-MDA-435s
33		AA033790		apolipoprotein D	2.7	HMEC, HS578T_cells, HMEC (total RNA)
		AA582324			2.69	HMEC (total RNA), Fibroblasts 2, PRSC_con
		T70580	Hs.13759		2.68	MB-MDA-435s, HS578T_cells, Lu_SC_H69
		AA210719			2.68	HS578T_cells, EB_cells, PRSC_con
60		H42527	Hs.92832	H.sapiens mRNA for 5'UTR for unknown pro		HMEC, HS578T_cells, PRSC_con
60		Z70220	Un 101219		2.67	HMEC (total RNA), HMEC, EB_cells
		R07728	Hs.191218		2.67	HS578T_cells, HMEC, MB231_cells
	11/004	H93081	Hs.41829	ESTs ESTs; Moderately similar to !!!! ALU SUB	2.67	DU145_cells, HS578T_cells, MB-MDA-435s
				ESTs; Moderately similar to motekin [M.	2.66	HS578T_cells, EB_cells, 293T_cells
65	132000	R89741	Hs.58215		2.61	HMEC (total RNA), HMEC, EB_cells
03		AA416770		EST	2.6	HMEC (total RNA), HMEC, Fibroblasts 2
		H63111 Z39055	Hs.6655 Hs.27264	ESTs ESTs; Moderately similar to !!!! ALU SUB	2.58	Ca∞2, MB-MDA-453, A549_œlls
					2.57	Lu_LC_H460, Lu_SC_H69, MB-MDA-435s
		T23724	Hs.258677		2.57	HMEC, HMEC (total RNA), EB_cells
70		N26480	Hs.43805		2.57	HS578T_cells, EB_cells, HT29_cells
70				ESTs; Weakly similar to EG:87B1.6 [D.mel	2.57	HMEC, HMEC (total RNA), Lu_SC_H69
	11901/	W74257	Hs.159690	ESTs; Weakly similar to KIAA0390 [H.sapi	2.56	HMEC, HT29_cells, Lu_LC_H460
		AAU19594 AA287286			2.55	HMEC, HMEC (total RNA), Fibroblasts 2
		WYTO 1 500	113.3300/	E013		
		AA201012	He 37617	FSTs: Weakly similar to KIAA0727 nmtain	2.55	HMEC (total RNA), EB_CEIIS, B14/4_CEIIS
75	105707	AA291012 T58588		ESTs; Weakly similar to KIAA0727 protein	2.55 2.54	HMEC (total RNA), EB_cells, BT474_cells HMEC, HS578T_cells, MB231_cells
75	105707 128483	T58588	Hs.5148	ESTs; Weakly similar to KIAA0727 protein FLN29 gene product ESTs; Weakly similar to HYPOTHETICAL PR	2.54	HMEC (total RNA), EB_ceils, B14/4_ceils HMEC, HS578T_ceils, MB231_ceils 2.54 HMEC (total RNA), HMEC, OVCAR_ceils


	134764	M74715	Hs.89560	iduronidase; alpha-L-	2.54	BT474_cells, PRSC_con, HT29_cells
		T82323	Hs.70337	immunoglobulin superfamily; member 4	2.54	Caco2, HS578T_cells, HMEC
		AA423854			2.54	BT474_cells, MB-MDA-435s, HMEC
		M19684		protease inhibitor 1 (alpha-1-antitrypsi	2.54	HMEC, HT29_cells, HMEC (total RNA)
5		X72755	Hs.77367	monokine induced by gamma interferon	2.53	Fibroblasts 2, MB231_cells, HMEC (total RNA)
•		AA489716		DKFZP586L151 protein	2.53	EB_cells, HMEC, HMEC (total RNA)
		AA075124		zm86a1.s1 Stratagene ovarian cancer (#93		
				IMAGE:544776 3', mRNA seq	2.52	HMEC (total RNA), HMEC, HS578T_cells
	119508	W37895	Hs.45519	ESTs	2.52	Lu_SC_H69, CALU6_cells, 293T_cells
10		F13763	Hs.19827	ESTs	2.52	PRSC_log, PRSC_con, HS578T_cells
		N89775	Hs.132390	zinc finger protein 36 (KOX 18)	2.51	HMEC, HS578T_cells, HT29_cells
	130860	U66061		protease; serine; 1 (trypsin 1)	2.51	OVCAR_cells, MB231_cells, PC3_cells
	105725	AA292228	Hs.199791	STAT induced STAT inhibitor 3	2.51	HS578T_cells, HT29_cells, HMEC
	110427	H48579	Hs.36275	EST	2.51	HS578T_cells, Cacc2, Lu_LC_H460
15	123762	AA610013	Hs.244553	EST	2.51	HMEC (total RNA), HMEC, Fibroblasts 2
	126406	AA034096		zi06f05.r1 Soares_fetal_liver_spleen_1NF		
				IMAGE:430017 5', mRNA seq.	2.5	Lu_AD_H23, HS578T_cells, Lu_AD_358
	129751	AA346065	Hs.111286	KIAA0714 protein	2.5	HMEC, HS578T_cells, Fibroblasts 2
•		AA418743		ESTs	2.5	EB_cells, HMEC (total RNA), HMEC
20		R77783	Hs.22404	protease; serine; 12 (neurotrypsin; moto	2.5	Fibroblasts 2, EB_cells, PRSC_con
	108499	AA083103		zn1b12.s1 Stratagene hNT neuron (#937233		LNO-D II- MD MDA 452 UMEC
				IMAGE:5477 3', mRNA seq	2.5	LNCaP_cells, MB-MDA-453, HMEC
		AA151333			2.5	Fibroblasts 2, A549_cells, 293T_cells
25		R85661	Hs.221447		2.48	Lu_AD_H23, HMEC, Lu_LC_H460
25		AA421562		anterior gradient 2 (Xenepus laevis) hom	2.48	EB_cells, Caco2, MCF7 OVCAR_cells, BT474_cells, Caco2
		AA405540		ESTs	2.48 2.48	HMEC (total RNA), EB_cells, HMEC
		R79519	Hs.16899	ESTs	2.46	HS578T_cells, HMEC, OVCAR_cells
		H16681		guanine nucleotide binding protein (G pr	2.46	HMEC, HS578T_cells, Cacc2
30		AA009809		ESTs	2.45	OVCAR_cells, 293T_cells, HMEC (total RNA)
30		D80030	Hs.45127	chondroitin sulfate proteoglycan 5 (neur ESTs; Weakly similar to !!!! ALU SUBFAMI	2.45	Lu_SQ_H520, Lu_AD_H23, Lu_SC_H69
		M96843		inhibitor of DNA binding 2; dominant neg	2.44	MB-MDA-453, 293T_cells, Cacc2
				neuropeptide FF-amide peptide precursor	2.43	HMEC, HMEC (total RNA), EB_cells
	106670	AA461174	He 50/3	ESTs	2.43	EB_cells, HS578T_cells, Lu_SC_H69
35		T26914		EAP30 subunit of ELL complex	2.43	EB_cells, HMEC (total RNA), HMEC
33		X74295	Hs.74369	integrin; alpha 7	2.42	Fibroblasts 2, Caco2, EB_cells
		AA367905		transferrin receptor (p90; CD71)	2.41	HS578T_cells, Fibroblasts 2, Lu_AD_H23
		W27841	Hs.17118	ESTs; Weakly similar to B0025.2 [C.elega	2.41	HMEC, HS578T_cells, MB231_cells
		M83186		cytochrome c oxidase subunit VIIa polype	2.41	Fibroblasts 2, PRSC_con, PRSC_log
40				endonuclease G	2.4	EB_cells, HMEC, Lu_AD_H23
		T95642	Hs.189759		2.4	EB_cells, A549_cells, HS578T_cells
		AA380418		SHP2 interacting transmembrane adaptor	2.4	HMEC, HMEC (total RNA), EB_cells
		T47906	Hs.220512	ESTs	2.39	MB-MDA-435s, HS578T_ceils, HMEC
		AA029046	Hs.30377	ESTs; Moderately similar to cAMP inducib	2.39	LNCaP_cells, OVCAR_cells, PC3_cells
45	115833	AA428269	Hs.125035	ESTs	2.38	Caco2, LNCaP_cells, CALU6_cells
	132223	R77451	Hs.4245	ESTs; Weakly similar to similar to S. ce	2.38	HMEC, HMEC (total RNA), EB_cells
	115836	AA428863	Hs.89388	ESTs	2.38	HS578T_cells, HMEC, PRSC_con
		S45630	Hs.1940	crystallin; alpha B	2.38	HS578T_cells, OVCAR_cells, Lu_LC_H460
••		D82422	Hs.5944	ESTs	2.37	Caco2, MB-MDA-453, HT29_cells
50		AA496048		ESTs	2.35	LNCaP_cells, 293T_cells, EB_cells
		W27770	Hs.258721		2.35	HMEC (total RNA), HMEC, HT29_cells
			Hs.189324		2.34	HMEC (total RNA), HMEC, EB_cells
	119343	T62873		yc3d2.s1 Stratagene lung (#93721) H sapi	2.34	HS578T_cells, Lu_SC_H69, HT29_cells
55	445440	4 400 4700	11- 00404	to contains Alu repetitive element;, mR	2.33	Lu_AD_H23, HMEC (total RNA), BT474_cells
55		AA284722 T69384	Hs.68398	H sapiens mRNA; chromosome 1 specific tr period (Drosophila) homolog 1	2.33	HMEC, HMEC (total RNA), MB231_cells
		Al375276			2.33	HMEC (total RNA), EB_cells, HMEC
		AI421866	Hs.158732	ribophorin II	2.33	Lu_AD_H23, HMEC (total RNA), HMEC
		H23927	Hs.222381		2.33	HS578T_cells, HMEC, Lu_LC_H460
60		W86471		hypocretin (orexin) receptor 2	2.32	HMEC, HMEC (total RNA), EB_cells
00		AI073357		H sapiens clone 23570 mRNA seq	2.32	MB231_cells, HMEC (total RNA), HMEC
		W70279		ESTs; Weakly similar to 15-HYDROXYPROS		2.32 HMEC, HS578T_cells, MB231_cells
				H sapiens DNA seq from cosmid ICK0721Q o		
	100074	701101112	110.101	L12 LIKE protein in an intron of the HS	2.32	Caco2, PRSC_con, LNCaP_cells
65	127368	AA434362	Hs.193326		2.32	HMEC (total RNA), HS578T_cells, HMEC
00		AA243427	Hs.104311		2.32	HMEC (total RNA), HMEC, MB-MDA-435s
		W80852		KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	2.32	Fibroblasts 2, HS578T_cells, MB-MDA-435s
		J02947	Hs.2420	superoxide dismutase 3; extracellular	2.32	PRSC_con, EB_cells, Lu_AD_358
		X76057	Hs.75694	mannose phosphate isomerase	2.31	293T_cells, LNCaP_cells, RPWE_2
70		AA039331	Hs.16323		2.31	Caco2, HS578T_cells, HMEC
-		T56048	Hs.189674	- · · · · · · · · · · · · · · · · · · ·	2.31	HMEC, Fibroblasts 2, HMEC (total RNA)
		T86826	Hs.142528		2.31	PC3_cells, HS578T_cells, HMEC
		AA021157	Hs.33619		2.3	HMEC (total RNA), HMEC, OVCAR_cells
		Y00097		annexin A6	2.3	PRSC_log, PRSC_con, HS578T_cells
75	111573	R10305	Hs.185683		2.3	HMEC, HMEC (total RNA), EB_cells
		N32626	Hs.145532	ESTs; Weakly similar to Gag polyprotein	2.29	EB_cells, Fibroblasts 2, HS578T_cells

						5th-shipsto 2 STA74 colle MP221 colle
				ESTs; Weakly similar to ASB-1 protein [H	2.29	Fibroblasts 2, BT474_cells, MB231_cells
		M55621		mannosyl (alpha-1;3-)-glycoprotein beta-	2.29	PRSC_con, RPWE_2, PRSC_log Lu SC_H69, Lu_AD_358, Lu_AD_H23
	103535			B-cell CLL/lymphoma 9	2.28	
-		Al337294	Hs.155014		2.28	HS578T_cells, 293T_cells, CALU6_cells
5	104297			ESTs; Highly similar to NY-REN-50 antige	2.27	EB_cells, DU145_cells, HT29_cells MB-MDA-453, LNCaP_cells, OVCAR_cells
	112318		_	ESTs	2.27	HT29_cells, BT474_cells, Cacc2
		M97496	Hs.778	guanylate cyclase activator 1B (retina)	2.27	MD MDA 4250 MD224 colle RT474 colle
		HG3576		Major Histocompatibility Complex, Class	2.26	MB-MDA-435s, MB231_cells, BT474_cells
		U39412	Hs.75932	N-ethylmaleimide-sensitive factor attach	2.26	LNCaP_cells, MB-MDA-453, Cacc2
10		AA424590		Golgi transport complex protein (90 kDa)	2.26	HMEC, HS578T_cells, Caco2
		M22430		phospholipase A2; group IIA (platelets;	2.26	LNCaP_cells, BT474_cells, Cacc2
	119336		Hs.208238		2.26	HS578T_cells, EB_cells, HMEC
		AA627122	Hs.163787	ESTs	2.25	Lu_SQ_H520, Lu_LC_H460, Lu_SC_H69
			Hs.181202	ESTs; Weakly similar to Wiscott-Aldrich	2.25	MB-MDA-435s, Fibroblasts 2, HMEC (total RNA)
15		C00476		small inducible cytokine subfamily B (Cy	2.25	Lu_SQ_H520, BT474_cells, Fibroblasts 2
		N91481	Hs.54713	ESTs	2.25	HMEC (total RNA), HMEC, MCF7
		AA679831	Hs.190228		2.24	HS578T_cells, EB_cells, HMEC
		U59286		small inducible cytokine subfamily B (Cy	2.24	HMEC, HS578T_cells, Fibroblasts 2
	113674	T96374	Hs.5753	inositol(myo)-1(or 4)-monophosphatase 2	2.24	A549_cells, DU145_cells, Lu_AD_358
20	133085	M73720	Hs.646	carboxypeptidase A3 (mast cell)	2.24	HS578T_cells, Fibroblasts 2, HT29_cells
	106017	AA411882	Hs.26268	ESTs	2.24	MB-MDA-453, OVCAR_cells, 293T_cells
		HG2348		Peptide Yy	2.24	HMEC, HS578T_ceils, HMEC (total RNA)
	134811	N66357	Hs.89761	ATP synthase; H+ transporting; mitochond	2.23	Lu_SQ_H520, LNCaP_cells, Lu_AD_H23
		U57627	Hs.234776	oculocerebrorenal syndrome of Lowe	2.23	293T_cells, EB_cells, LNCaP_cells
25	127357	AA452788		zx39g11.r1 Soares_total_fetus_Nb2HF8_9w		
				IMAGE:788900 5', mRNA seq.	2.23	HS578T_cells, RPWE_2, HMEC (total RNA)
	135288	AA402930	Hs.97876	ESTs	2.23	HS578T_cells, 293T_cells, OVCAR_cells
	105581	AA278850	Hs.28891	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.23	BT474_cells, BT474_cells, MB231_cells
	103812	AA137107	Hs.124094	ESTs; Weakly similar to NFAT1-A [M.muscu	2.23	Lu_SC_H345, Lu_AD_H23, PRSC_con
30	117016	H87171	Hs.52170	ESTs	2.22	Fibroblasts 2, Lu_LC_H460, HMEC (total RNA)
	114607	AA079342	Hs.129057	breast carcinoma amplified seq 1	2.22	BT474_cells, HT29_cells, HT29_cells
		U29091	Hs.7833	selenium binding protein 1	2.22	LNCaP_cells, MB-MDA-453, BT474_cells
		N58461	Hs.22036	ESTs	2.22	HMEC, Lu_SC_H345, HS578T_cells
	129048	L27670	Hs.108287	intercellular adhesion molecule 4; Lands	2.21	Lu_AD_H23, HS578T_cells, Lu_SQ_H520
35		T52700	Hs.110044	ESTs	2.2	Caco2, MB-MDA-453, HT29_cells
		F05063	Hs.251736	ESTs	2.2	HS578T_cells, BT474_cells, 293T_cells
		N62263	Hs.48501		2.2	HS578T_cells, BT474_cells, MB231_cells
		AI149662	Hs.143590	ESTs	2.19	BT474_cells, CALU6_cells, MB231_cells
		W33178	Hs.26912	ESTs	2.19	HMEC, HMEC (total RNA), Fibroblasts 2
40		AF002224		H sapiens Angelman Syndrome Gene, E6-AF	)	
				from promoter P1, 5'UTR	2.19	HS578T_cells, CALU6_cells, 293T_cells
	109151	AA176800	Hs.73452	ESTs	2.19	CALU6_cells, Lu_AD_H23, Lu_SC_H69
		AA086057		ribosomal protein; mitochondrial; S12	2.19	OVCAR_cells, A549_cells, Lu_AD_H23
		AA156936		ESTs; Highly similar to type II cAMP-dep	2.19	HS578T_cells, BT474_cells, A549_cells
45		H92575		ESTs; Weakly similar to !!!! ALU SUBFAMI	2.18	Lu_AD_358, Lu_SC_H69, Lu_SC_H345
	123450	AA598913	Hs.111207	ESTs	2.18	HMEC (total RNA), HMEC, MB-MDA-435s
		N27628		yw50b08.s1 Weizmann Olfactory Epithelium	2.18	LNCaP_cells, DU145_cells, Lu_SQ_H520
		W80709	Hs.58485	ESTs	2.18	HS578T_cells, MB231_cells, Cacc2
			Hs.112889	ESTs	2.18	Lu_AD_H23, Lu_SQ_H520, Lu_AD_358
50			Hs.53115		2.17	Caco2, 293T_cells, 293T_cells
20		T83659	Hs.184407		2.16	Lu_AD_H23, Lu_AD_358, PRSC_∞n
		Z38152	Hs.26920	ESTs	2.15	HMEC (total RNA), HMEC, EB_cells
		T59001	Hs.10475		2.15	HMEC, HT29_cells, MB231_cells
		M21121	Hs.241392	small inducible cytokine A5 (RANTES)	2.15	HS578T_cells, PC3_cells, A549_cells
55	123490	AA599723		TAP binding protein (tapasin)	2.15	HS578T_cells, EB_cells, Lu_SC_H69
55		R77302	Hs.20226		2.14	HMEC (total RNA), HMEC, Fibroblasts 2
		H58715	Hs.14706		2.14	HMEC, HMEC (total RNA), HT29_cells
		M34996	Hs 198253	major histocompatibility complex; class	2.14	MB-MDA-435s, HMEC, HMEC
	115248	AA278887	Hs 194530	ESTs; Weakly similar to unknown [H.sapie	2.14	HT29_cells, BT474_cells, CALU6_cells
60	105610	AA280810	Hs 24003	ESTs; Moderately similar to LEYDIG CELL	2.14	Lu_SQ_H520, MB-MDA-435s, LNCaP_cells
00		Al126617	Hs.132449		2.14	HS578T_cells, EB_cells, HMEC (total RNA)
	124573	AA442125	Hs 171873	ESTs; Weakly similar to PUTATIVE STERO!	D2.14	EB_cells, MB231_cells, Cacc2
	134863	AA353903	Hs 183373	ATX1 (antioxidant protein 1; yeast) homo	2.14	Lu_SC_H345, HT29_cells, BT474_cells
		H17317		ESTs; Weakly similar to HPBRII-7 protein	2.13	Caco2, Lu_SC_H345, EB_cells
65		R59371	Hs.26653		2.13	HMEC, HMEC (total RNA), Lu_SQ_H520
05		AA075144		zm86f6.s1 Stratagene ovarian cancer (#93		
	100333	77075177		gb:X1664 TRANSLATIONALLY CONTROLL	ED TUM	2.13 HMEC (total RNA), HMEC, OVCAR_cells
	120611	D45680	Hs.11614		2.13	HMEC, HS578T_cells, Cacc2
		L34355	Hs.99931	sarcoglycan; alpha (50kD dystrophin-asso	2.12	HS578T_cells, OVCAR_cells, CALU6_cells
70	101200	MAS45242	口3.3333 I He 202500	ESTs; Weakly similar to mucin glycoprote	2.12	EB_cells, Lu_AD_H23, Lu_AD_H23
70			Hs.4014	KIAA0946 protein; Huntingtin interacting	2.12	A549_cells, BT474_cells, MB-MDA-435s
		R15825			2.12	Lu_AD_H23, MB-MDA-453, PRSC_∞n
			Hs.61816	DKFZP564O0823 protein	2.12	EB_cells, Lu_SC_H69, Lu_SC_H69
•		Z44658			2.12	HMEC, HS578T_cells, HMEC (total RNA)
75		F02465	Hs.27281 Hs.242890		2.12	Lu_AD_H23, Caco2, BT474_cells
13		D12124 R45402	Hs.23789	FSTs	2.12	EB_cells, Lu_AD_H23, Lu_SQ_H520
	11211/	1/40402	1 13.23/ 03	20.0		

128357 AA477289 h 128358   128							
19765 NASS91 https://doi.org/10.1004/j.cs.2017 Haspins done 2377 putative transmemb 211 https://doi.org/10.1004/j.cs.2017 Haspins done 2377 putative transmemb 211 https://doi.org/10.1004/j.cs.2017 https://doi.o		126367	AA477929	Hs.25584	ESTs	2.12	Lu_SC_H69, Lu_AD_H23, Lu_AD_358
129453 AA359801 H. 197877 H. sapins done 2777 putsible transmanch 2.11 HSV871 Cells, L. L. J. J. S. S. McA-MAN-4555 120359 AA459801 H. 197877 Branchates of PREPZ 1 (1051) (1) 2.11 HSV871 Cells (L. J. J. J. S. S. McA-MAN-4555 120359 AA45924 H. 197877 Branchates 2.11 HSV871 Cells (May 1) 2.11 HSV871 Cells		135252	U62966	Hs.97207	solute carrier family 28 (sodium-coupled		
5 12/256 AA (56898) 1. 11748 of the transport of the tran		117565	N34301	Hs.248426	EST	2.11	
120256 AA165801   147637   1		129430	AA258842	Hs.197877	H sapiens clone 23777 putative transmemb	2.11	HS578T_cells, Lu_AD_358, MB-MDA-435s
13496 D20332 Hs.178137 manufactor of ERBEZ,*1 (TOB1) 2.11 hs. 211 ls. 2357 cells. QVCAR_cells 132559 D20522 hs. 3842 Ls. 211 ls. 2358 D20522 hs. 3842 Ls. 211 ls. 2358 D20522 hs. 3842 ls. 211 ls. 2359 AAB25437 ls. 2857 ls. 215 ls. 211 ls. 2359 AAB25437 ls. 2857 ls. 215 ls. 211 ls. 2359 AAB25437 ls. 2857 ls. 2857 ls. 211 ls. 2359 AAB25437 ls. 2857 ls. 28	5	120256	AA169801		sema domain; immunoglobulin domain (lg);	2.11	HMEC, HMEC (total RNA), EB_cells
130937 AAASTA2 14.155340 IN Argamentation factor, 45 IO, alpha s 2.11 17633 N35404 In 14407 EST5 2.11 INC. Caroz, LAD. 172 INC. Caroz,	_			Hs.178137		2.11	HMEC (total RNA), 293T_cells, OVCAR_cells
172539 NS6404 Hs. 4407 ESTs 2.11 Hs. 2004 ESTs 2.10 Hs. 2004 Hs. 2004 ESTs 2.10 Hs. 2004 Hs. 2004 ESTs 2.10 Hs. 2004 Hs. 2004 ESTs 2.10 Hs. 2004 Hs. 2004 ESTs 2.10 H							293T_cells, Caco2, Lu_AD_H23
17533 75842 Hs. 44407 ESTs 2.11 17539 75842 Hs. 58875 ESTs 2.11 17539 75852 Hs. 58875 ESTs 2.11 17539 75852 Hs. 58875 ESTs 2.11 17539 75852 Hs. 75875 ESTs 2.11 17539 75875 ESTS 2.11							
10 125003 T59442 Hs. 100445 ESTs 2.11 MSANDA-4535, HMEC (botal RNA), HT29, cells 14055 Z38149 Hs. 134015 urray 72-suirotransferanse 2.11 MSANDA-4535, 287 Colors, PRSC. Lon, PRSC. Long, PRSC. Long, PRSC. Long, PRSC. Long, PRSC. Long, PRSC. Long, PRSC. Lon, PRSC. Long, PRSC.							
125323 AAB2537 Hs.5875 E5T3	10						
14065 238149 Hs.130105 urroyl 2-sulchransferase 2.11 17276 A202274 hs.2726 EST 2.11 17278 A202274 hs.2726	10						
12719 A422747 Hs.97266 EST5				HS.300/3			
13888 749444							
15333 AA39179 Hs 9933 publishe A-cible transposoon 121 HS576T_cells, EB_cells, HMEC 131878 AA017161 Hs.33792 ESTs 2.99 HMEC (total RNA), MEG 122 HME							
110973 N51529 Hs.118047 ESTS 2.09 HEC. (bits IRNA), 133792 ESTS 2.09 HMEC (bits IRNA), 18237 cells BT474_cells 11666 F03835 Hs.241606 EST 2.09 HMEC (bits IRNA), 18237 cells BT474_cells HS576T_cells, LLL_CAMO, LLL_CAM							
131879 AA017161 Hs.33792 ESTs 2.09 HSRC (total RNA), MB231_cells, B1474_cells 119666 F09335 hs.241640 EST 2.09 HSRC (total RNA), HMBC (tot	15	135351	AA430179		·		
19856 F09395 Hs_241640 EST 2.09		110973	N51529	Hs.118047	ESTs		
120311 AA194074   Hs. 193401   ESTs   2.09   OVCAR_cells, HMEC (botal RNA), HMEC   12036   A4040433   Hs. 19160   ESTs   2.09   Hr. 19474_cells, HM-BADA-435, EB_cells   120206   A204066   Hs. 19507   ESTs   2.09   Hr. 19474_cells, HM-BADA-435, EB_cells   12036   A204067   Hs. 194707   ESTs   2.09   Hr. 19474_cells, HM-BADA-435, EB_cells   Lu, AD H23, Fibroblasts 2, Lu, LC, H460   Lu, AD H23, Fibroblasts 2, Lu, SD, H461		131879	AA017161	Hs.33792	ESTs		
109072   AAAQUA33   Hs.51898   DKFZPSSRN2124 protein   2.09   Floriblasts 2, A459   SKS76T_cells   SKS76T_cel		116656	F03935	Hs.241640	EST	2.09	HS578T_cells, Lu_LC_H460, Lu_SC_H69
108074 AA040433 Hs.161898 DK7ZP5SRN2124 protein 108074 AA040433 Hs.161898 DK7ZP5SRN2124 protein 108074 AA096033 Hs.391668 ESTs 120206 20005 Hs.391668 ESTs 12030 308005 Hs.391668 ESTs 12030 308005 Hs.391668 ESTs 12030 308005 Hs.391668 ESTs 12050 AA041225 Hs.39172 ESTs 10550 AA041227 Hs.39172 ESTs 10550 AA040237 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA073331 Hs.180549 ESTs, Highly similar to R26660_1; partia 108052 AA080214 Hs.192 108052 AA080214 Hs.1		120311	AA194074	Hs.193401	ESTs	2.09	OVCAR_cells, HMEC (total RNA), HMEC
109871 AJ99633 1s.24872 ESTS	20					2.09	HMEC (total RNA), BT474_cells, HT29_cells
120206 240605   169166   16916   169						2.09	Fibroblasts 2, A549_cells, HS578T_cells
117233 R5222   112678 HO8811   117281						2.09	BT474 cells, MB-MDA-453, EB_cells
116746 H04811 Hs.79027 ESTs 2.08 MB-MDA-435s, HMEC (btal RNA), Lu.SC.1435 H0592 AA27937 Hs.180549 ESTs, Highly similar to R26660.1; partia 2.08 LNCaP_colls, PRSC_0g, Lu_CL_H450, PRSC_0g, Lu_LCR_Pcsl_Ng, PRSC_0g, PRSC_0g, Lu_CL_H450, PRSC_0g, Lu_LCR_Pcsl_Ng, PRSC_0g, PRSC_0g, PRSC_0g, Lu_CL_H450, PRSC_0g, Lu_LCR_Pcsl_Ng, PRSC_0g, PRSC_0g, PRSC_0g, PRSC_0g, Lu_CL_H450, PRSC_0g, Lu_LCR_Pcsl_Ng, PRSC_0g, Lu_LC_H450, Lu_CR_0g, PRSC_0g, Lu_LC_H450, Lu_CR_0g, PRSC_0g, Lu_LC_H450, Lu_CR_0g, PRSC_0g, Lu_LC_H450, Lu_SC_1H50, P							
121529   AA412257   Hs. 180494   ESTs   Highly similar to R26660_1; partia   2.08   MISCR_CHMEC (total RNA), HSS76T_cells   106852   AA088231   Hs. 191732   ESTs   2.08   HSS76T_cells   Lu, SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345, Lu_,SC_H345   Lu, SC_H345, Lu_,SC_H345, Lu_,S							
105822 AA279337 Hs.180549 ESTS; Highly similar to R26660_1; partial 2.08 105828 AA08231 Hs.91732 ESTS serine palmitoythransferase; subunit II 2.08 ESC, 208 123197 AA488250 Hs.9403 Serine palmitoythransferase; subunit II 2.08 ESC, 208 123856 AA52014 Hs.144999 ESTS 2.08 ESTS 2.08 ESC, 208 123256 AA251737 Hs.172818 App12 (autophagy 12: 5. cerevisiae)-like 2.07 128467 R94668 Hs.195155 ESTS; Weakly similar to transporter prot 2.07 PRSC_log, Lu_LC_LH60, Lu_SC_LH35 123036 AA251737 Hs.21111 ESTS 2.07 Elements he shaded to transporter prot 2.07 PRSC_log, Lu_LC_LH60, RPWE_2 2.07 PRSC_log, Lu_LC_LH60, Lu_AD_LH23 PRSC_log, Lu_AD_H23 PRSC_log, PRSC_log, Lu_AD_H23 PRSC_log, PRSC_log, Lu_AD_H23 PRSC_log, Lu_AD_H23 PRSC_log, PRSC_log, Lu_AD_H23 PRSC_log, Lu_AD_H23 PRSC_log, Lu_AD_H23 PRSC_log, PRSC_log, Lu_AD_H23 PRSC_log, PRSC_log, Lu_AD_H23 PRSC	25						
103882 AA08231 Hs. 591732 ESTs 2.08 HS.7571 Cells, Lu. SC. H345, Lu. SC. H347, La. Sc. H345, Lu. Sc.	23	121029	AA412237	HS.90121			
123197 AA48276 H.5.9403   Serine palmithythransferase; subunit II   2.08   EB_colls, Lu_SC_H945   Lu_SC_H94							
134985   J05490   Hs 9.2   protein phosphatase 3 (formerly 2B); cat 2.08   LHCGP_cells, MB-MDA-435s, HMEC   HS787_cells MFS787_cells							
13256 AASD814 Hs.14495 ESTs 208 HS578T_cells BT474_cells BT474_cells B17474_cells P1745 P18578T_cells T1747_cells B1747_cells P1747_cells							
132058 AA251737 Hs. 172818 Agg12 (autophagy 12; S. cerevisiae)-like 2.07 Hs. 172816 R94868 166087 AA418740 Hs. 195155 ESTs; Weakly similar to transporter pro 2.07 OVCAR_cells, A.549_cells, Lu_AD_t23 Hs. 19517 R94841 Hs. 195187 ESTs; Weakly similar to transporter pro 2.07 OVCAR_cells, A.549_cells, Lu_AD_t23 Hs. 195283 AA908225 Hs. 128841 ESTs 2.07 Hs. 145841 ESTs 2.07 Hs. 145842 ESTs; Weakly similar to Closely related 2.07 Hs. 145842 ESTs; Weakly similar to Closely related 2.07 Hs. 145843 Hs. 145843 ESTs 2.07 Hs. 145845 ESTs 2.08 Hs. 145845 Hs. 14		134965	J05480	Hs.92	protein phosphatase 3 (formerly 2B); cat		
126476 R94666	30	123856	AA620814	Hs.144959			HS578T_cells, BT474_cells, BT474_cells
106087 AA/18740 Hs.21111 ESTS 2.07 OVCAR_cells, AS49_cells, Lu_AD_H23 Hs.2634 Interfits, heavy polypeptide 1 2.07 HMCE, ChMEC (total RNA), HSS78T_cells EB, cells, Fibroblasts 2, Lu_SC_H69 Hs.12837 Ns.2634 Hs.14584 ESTs 2.07 HMCE (total RNA), HSS78T_cells EB, cells, Fibroblasts 2, Lu_SC_H69 Hs.14584 Hs.14584 ESTs 2.07 HMCE (total RNA), HSS78T_cells EB, cells, Fibroblasts 2, Lu_SC_H69 Hs.12837 Ns.2634 Hs.12836 Hs.12839 Hs.12839 Hs.12839 Hs.12839 Hs.12839 ESTs 2.07 HMCE (total RNA), HMEC, EB_cells Logis Problems 1, 12834 Hs.12839 Hs.12839 Hs.12839 ESTs 2.06 Hs.12836 Hs.12839		132058	AA251737	Hs.172818	Apg 12 (autophagy 12; S. cerevisiae)-like	2.07	HS578T_cells, MCF7, HMEC
106087 AA418740 Hs.21111 ESTS 2.07 OVCAR_cells, A549_cells, Lu_AD_H23 10802 AA122030 sh.5c2954 ferrith; heavy polypeptide 1 2.07 HMCE_C MHCE (total RNA), HSS78T_cells ESTS 2.07 HMCE_C MHCE (total RNA), HSS78T_cells EB_cells, Fibroblasts 2, Lu_SC_H69 HMCE (total RNA), HSS78T_cells EB_cells, Fibroblasts 2, Lu_SC_H69 HMCE (total RNA), HSS78T_cells EB_cells, Cells, Cells HMCE (total RNA), HSS78T_cells EB_cells, Cells HMCE (total RNA), HMSCE EB_cells HMCE (total RNA), HMCE (EB_cells LMCAP_cells LMC		126476	R94666	Hs.195155	ESTs: Weakly similar to transporter prot	2.07	PRSC_log, Lu_LC_H460, RPWE_2
103802 AN122003 Hs. 62354 ferrifith; heavy polypeptide 1 2.07 HMEC, (India RNA), HSS78T_cells ESTs 2.07 HMEC, HMEC (India RNA), HSS78T_cells 112817 R98491 Hs. 14584 ESTs 2.07 HMEC, HMEC (India RNA), Fibroblasts 2 HMEC, HMEC (India RNA), HMEC, EB, cells 12037 US6922 HMEC (India RNA), HMEC EB, cells 12037 US6922 HMEC (India RNA), HMEC, HEC cells 12037 US6922 HMEC (India RNA), HMEC HMEC HMEC HMEC HMEC HMEC HMEC HMEC						2.07	OVCAR_cells, A549_cells, Lu_AD_H23
125533 A-9036225   Hs. 126841 EST5							HMEC, HMEC (total RNA), HS578T_cells
112817 R98491 113070 N56984 113070 N56984 113070 N56984 118270 N56288 118270 N562888 118270 N56288 118270 N562888 118270 N5628888 118270 N5628888 118270 N56288888 118270 N56288888 118270 N5628888888 118270 N562888888888888888888888888888888888888	35						
111050   156984   Hs. 47335   heat shock 90kD protein 1; beta   2.07   LICaP_cells, DIJ145_cells, 293T_cells   LICaP_cells, DIJ145_cells, 293T_cells   LICaP_cells, DIJ145_cells, 293T_cells   LICaP_cells, DIJ145_cells   LICaP_cells   LICaP	33						
133072 AA425294 Hs. A4322							
118270 Nic2888							
105335 AA129486   Hs.8859   ESTs   2.07   LNCaP_cells, PC3_cells, EB_cells							
102337   136922   Human fork head domain protein (FKHR) mR   2.07   293T_cells, HMEC, HT29_cells   Hs. 182859   lifeguard   2.06   109802   F10789   Hs. 12439   ESTs   2.06   HS. 22439   ESTs   2.06   HT29_cells, LL_AD_H23   EB_cells, Caco2   128103   AA905960   Hs. 48516   ESTs   2.06   HT29_cells, HMEC (total RNA), HMEC   131873   H39997   Hs. 33716   ESTs   2.06   HMEC (total RNA), HMEC, EB_cells   128066   AA848438   Hs. 189171   ESTs   2.05   LN_CAP_cells, LL_AD_H23, HS578T_cells   HMEC, HT29_cells,	40						
109687 F09380	40			Hs.8859			
109802 F10789					Human fork head domain protein (FKHR) mR		
128103 AA905960 Hs.48516 ESTs 2.06 H729_cells, HMEC (total RNA), HMEC 128278 A0108243 Hs.131275 ESTs 2.06 HMEC (total RNA), HMEC 128281 Hs.131275 ESTs 2.06 HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HS578T_cells HMEC, HMEC (total RNA), HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HS578T_cells HMEC, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HMEC, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HMEC, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HMEC, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HMEC, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, HMEC, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, LU_AD_H23, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, LU_AD_H23, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, LU_AD_H23, HMEC (total RNA), HMEC ESTs 2.05 LMCaP_cells, LU_AD_H23, LU_AD		109687	F09380	Hs.182859	lifeguard		
128278 AIO18343 Hs.131275 ESTs   2.06   PRSC_con, Lu_SC_H345, HSS78T_cells   131873 H39997   Hs.33716   ESTs   2.05   LNCaP_cells   LNCaP_ce							
128278 AIO18343 Hs.131275 ESTs   2.06   PRSC_con, Lu_SC_H345, HSS78T_cells   131873 H39997   Hs.33716   ESTs   2.05   LNCaP_cells   LNCaP_ce		128103	AA905960	Hs.48516	ESTs		
131873 H39997   Hs.33716   ESTs   2.06   HMEC (total RNA), HMEC, EB_cells   122683 AA455528   Hs.96772   ESTs   2.05   LNCAP_cells, LU_AD_L/32, HSS78T_cells   HSS78T_cells   HSS78T_cells   HSS78T_cells   HMEC, HMEC (total RNA), Fibroblasts 2   HMEC, HMEC (total RNA), Fibroblasts 2   HMEC, HMEC (total RNA), EB_cells   HMEC, HMEC (total RNA), EB_cells   HMEC, HMEC (total RNA), LNCAP_cells, LU_LC_H460, LU_SQ_H520   HSS78T_cells, PRSC_con, HMEC   HMEC (total RNA), LNCAP_cells, LU_LC_H460, LU_SQ_H520   HSS78T_cells, PRSC_con, HMEC   HMEC (total RNA), LNCAP_cells, LU_LC_H460, LU_SQ_H520   HSS78T_cells, PRSC_con, HMEC   HMEC (total RNA), LNCAP_cells, LU_CL_H460, LU_SQ_H520   HSS78T_cells, LMEC, LU_SQ_H520   HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, LU_LC_H460, LU_SQ_H520   HSS78T_cells, HMEC, LU_SQ_H520   HSS78T_cells, HMEC, LU_SQ_H520   HSS78T_cells, HMEC, LU_SQ_H520   HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HSS78T_cells, HSS78T_cells, HSS78T_cells, HSS78T_cells, HSS78T_cells, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HSS78T_cells, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HMEC, HSS78T_cells, HMEC, H	45	128278	AI018343	Hs.131275	ESTs	2.06	PRSC_con, Lu_SC_H345, HS578T_cells
122683				Hs.33716	ESTs	2.06	HMEC (total RNA), HMEC, EB_cells
12806   AA884838   Hs. 189171   ESTs   2.05   HMEC, HMEC (total RNA), Fibroblasts 2						2.05	
131451   N28028   Hs.26368   Hs.prot3   Hs.27270   ESTs   2.05   MB-MDA 435s, Lu_LC_H460, Lu_SQ_H520						2.05	HMEC, HMEC (total RNA), Fibroblasts 2
120887   AA365644   Hs.97043   ESTs   2.05   HS.78T_cells, PRSC_con, HMEC     103966   AA303166   Hs.127270   ESTs   2.05   HMEC (total RNA), LNCaP_cells, PC3_cells     104627   AA001976   Hs.19603   ESTs   2.05   HS.78T_cells, HMEC, BT474_cells     108794   AA129468   Hs.203392   ESTs   2.04   HS.78T_cells, HMEC, BT474_cells     101849   M94167   Hs.172816   Hs.172816   Hs.172816   Hs.58785     130785   AA242826   Hs.7745   Hs.58785   ESTs   2.04   HMEC, HS.78T_cells, HMEC (total RNA)     124702   R06984   Hs.7745   Hs.22593   Hs.7745     132219   N48682   Hs.27931   ESTs   2.04   HMEC, HS.78T_cells, HMEC (total RNA)     132219   N48682   Hs.172971   ESTs   2.04   HMEC, HS.78T_cells, HMEC (total RNA)     132219   N48682   Hs.172971   ESTs   2.03   Hs.172971     123378   D78947   Hs.18538     101950   S79219   Hs.37131     103459   X99894   Hs.3718   Hs.32938     101950   S79219   Hs.3718   Hs.32938   Hs.30741     103459   X99894   Hs.32938   Hs.32938   Hs.32938     101950   X99894   Hs.32938   Hs.32938   Hs.32938     101950   X99894   Hs.32938   Hs.32938   Hs.32938   Hs.32938     101950   X99894   Hs.32938   Hs.32938   Hs.32938     101950   X99894   Hs.32938   Hs.32938   Hs.32893     101950   X99894   Hs.32893   Hs.32893   Hs.32893     101950   X99894   Hs.32893   Hs.32893   Hs.32893     101950   X99894   Hs.32893   Hs.32893   Hs.32893   Hs.32893     101950   X99894   Hs.32893   Hs.					H saniens mRNA from chromosome 5g21-22:		
103966   AA303166   Hs. 127270   ESTs   2.05   HMEC (total RNA), LNCaP_cells, PC3_cells   105861   AA399260   Hs. 28454   ESTs   2.05   HS578T_cells, HMEC, BT474_cells   108794   AA129468   Hs. 203392   ESTs   2.04   HS578T_cells, HMEC, A549_cells   Hs. 24894   Hs. 203392   Hs. 24894   Hs. 24894   Hs. 57858   Hs. 57745   ESTs   2.04   HMEC, HS578T_cells, HMEC (total RNA)   HMEC, HS578T_cells, HMEC (total RNA)   HMEC, HS578T_cells, PC3_cells, PC3_cells   HMEC, HS578T_cells, HMEC, HS578T_cells, HMEC (total RNA)   HMEC, HS578T_cells, HS578T_cells, HMEC, HS578T_cells, HS578T_cells, HMEC, HS578T_cells, HS578T_cells, HMEC, HS578T_cells, HMEC, HS578T_cells, HS578T_cells, HMEC, HS578T_cells,	50						·
105861	50						HMEC (total RNA), LNCaP cells, PC3 cells
104627 AA001976 Hs. 19603 ESTs 2.05 HS578T_cells, HMEC, BT474_cells 108794 AA129468 Hs. 203392 ESTs 2.04 HS578T_cells, HMEC, A549_cells 11896 R38936 Hs. 24894 H sapiens clone 25248 mRNA seq 2.04 HS578T_cells, HMEC, A549_cells Hs. 172816 neuregulin 1 2.04 HMEC, HS578T_cells, HMEC (total RNA) Hs. 5787_cells, HMEC (total RNA) Hs. 5787_cells, HMEC (total RNA) Hs. 5785 Ls. 130785 AA242826 Hs. 19405 Caspase recruitment domain 4 2.04 HMEC, HS578T_cells, HMEC (total RNA) HMEC, BT474_cells HS578T_cells, HMEC (total RNA) HMEC, HS578T_cells, HMEC,							Fibroblasts 2 HMFC (total RNA) FB cells
108794 AA129468 Hs.203392 ESTs 2.04 HS578T_cells, HMEC, A549_cells 11896 R38936 Hs.24894 H sapiens clone 25248 mRNA seq 2.04 HS578T_cells, PC3_cells, 293T_cells 101849 M94167 Hs.172816 neuregulin 1 2.04 HMEC, HS578T_cells, HMEC (total RNA) 119913 W85931 Hs.58785 ESTs 2.04 HMEC, BT474_cells, MB231_cells 130785 AA242826 Hs.19405 caspase recruitment domain 4 2.04 HMEC, BT474_cells, MB231_cells 124702 R06984 Hs.7745 ESTs; Weakly similar to TESTIS-SPECIFIC 2.03 Fibroblasts 2, PRSC_con, HMEC (total RNA) Hs.172971 ESTs 2.03 HMEC, HS578T_cells, BT474_cells Fibroblasts 2, PRSC_con, HMEC (total RNA) HMEC, BT474_cells HMEC, HS578T_cells, BT474_cells Fibroblasts 2, PRSC_con, HMEC (total RNA) HMEC, BT474_cells Fibroblasts 2, PRSC_con, HMEC (total RNA) HMEC, HS578T_cells, BT474_cells Fibroblasts 2, PRSC_con, HMEC (total RNA) HMEC, HS578T_cells, BT474_cells Fibroblasts 2, PRSC_con, HMEC (total RNA) HMEC, HS578T_cells, BT474_cells Fibroblasts 2, PRSC_con, HMEC (total RNA) HMEC, HS578T_cells, EB_cells, HS578T_cells, EB_cells, HS578T_cells, EB_cells, HS578T_cells, EB_cells, FC3_cells, FC3_cells, FC3_cells, FC3_cells, FC3_cells, FC3_cells, FC3_cells, FC3_cells, FC4_cells FC4_cells FC4_cells FC4_cells FC4_cells FC4_cells,							
11896 R38936							
101849   M94167   Hs.172816   neuregulin 1   2.04   HMEC, HS578T_cells, HMEC (total RNA)	55			ris.203392	Harriage date 05040 mDNA		
119913 W85931 Hs.58785 ESTs 2.04 HMEC, BT474_cells, MB231_cells 130785 AA242826 Hs.19405 caspase recruitment domain 4 2.04 HMEC, HS578T_cells, BT474_cells 124702 R06984 Hs.7745 ESTs; Weakly similar to TESTIS-SPECIFIC 2.03 Fibroblasts 2, PRSC_con, HMEC 106769 AA478001 Hs.225935 idacylglycerol O-acyltransferase (mouse) 2.03 PC3_cells, EB_cells, HS578T_cells 132219 N48682 Hs.172971 ESTs 2.03 OVCAR_cells, PC3_cells, A549_cells 122033 AA431334 Hs.109297 ESTs 2.03 OVCAR_cells, A549_cells 1220461 AA251301 zs10b02.s1 NCI_CGAP_GCB1 H sapiens cDNA contains Alu repetitive element;, mRNA 2.03 HS578T_cells, EB_cells, EB_cells 104909 AA055892 Hs.14543 ESTs 2.03 HMEC, Fibroblasts 2, EB_cells 101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 2.03 Lu_SC_H345, PC3_cells, DU145_cells 133878 D78947 Hs.7718 ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells 103459 X99894 Hs.32938 Hs.32938 insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_SQ_H520, Lu_AD_H23, Lu_AD_358 1126762 AA064671 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358	22						
130785							HIMEC, HSS/81_COIIS, HIMEC (LUIZI KINA)
124702 R06984 Hs.7745 ESTs; Weakly similar to TESTIS-SPECIFIC 2.03 Fibroblasts 2, PRSC_con, HMEC 106769 AA478001 Hs.225935 diacylglycerol O-acyltransferase (mouse) 2.03 PC3_cells, EB_cells, HS578T_cells 132219 N48682 Hs.172971 ESTs 2.03 OVCAR_cells, A549_cells 122033 AA431334 Hs.109297 ESTs 2.03 OVCAR_cells, A549_cells, Cacc2 2310b02.s1 NCI_CGAP_GCB1 H sapiens cDNA contains Alu repetitive element;, mRNA 2.03 HS578T_cells, EB_cells, EB_cells 104909 AA055892 Hs.14543 ESTs 2.03 HMEC, Fibroblasts 2, EB_cells 101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 133878 D78947 Hs.7718 ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells 103459 X99894 Hs.32938 insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358 105507 Al436377 Hs.258590 ESTs 2.01 HS578T_cells, EB_cells, HMEC, MB231_cells 112920 T10234 Hs.65996 ESTs 2.01 HS578T_cells, Lu_SQ_H520, Lu_AD_H23 1126762 AA064671 Zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358							
60 106769 AA478001 Hs.225935 diacylglycerol O-acyltransferase (mouse) 2.03 PC3_cells, EB_cells, HS578T_cells 132219 N48682 Hs.172971 ESTs 2.03 HT29_cells, PC3_cells, A549_cells OVCAR_cells, A549_cells OVCAR_cells, A549_cells, Caco2 PC3_cells, A549_cells OVCAR_cells, A549_cells, Caco2 PC4_cells, A549_cells OVCAR_cells, A549_cells, Caco2 PC4_cells, A549_cells, Caco2 PC4_cells, A549_cells, Caco2 PC4_cells, A549_cells, Caco2 PC5_cells, A549_cells, A540_cells, A549_cells, A549_cells, A549_cells, A549_cells, A549_cel		130785	AA242826	Hs.19405			
132219 N48682 Hs.172971 ESTs 2.03 HT29_cells, PC3_cells, A549_cells 122033 AA431334 Hs.109297 ESTs 2.03 OVCAR_cells, A549_cells, Caco2  120461 AA251301		124702	R06984			2.03	
132219 N48682 Hs.172971 ESTs 2.03 OVCAR_cells, PC3_cells, A549_cells 122033 AA431334 Hs.109297 ESTs 2.03 OVCAR_cells, A549_cells, Caco2 2310b02.s1 NCI_CGAP_GCB1 H sapiens cDNA contains Alu repetitive element;, mRNA 2.03 HS578T_cells, EB_cells 134959 U90550 Hs.91813 butyrophilin; subfamily 2; member A2 2.03 HMEC, Fibroblasts 2, EB_cells 104909 AA055892 Hs.14543 ESTs 2.03 Lu_SC_H345, PC3_cells, A549_cells 101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 2.03 Lu_SC_H345, PC3_cells, CALU6_cells 133878 D78947 Hs.7718 ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells 103459 X99894 Hs.32938 Hs.32938 insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358 116657 F04014 Hs.65996 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con 105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells 126762 AA064671 Zm13842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358	60	106769	AA478001	Hs.225935	diacylglycerol O-acyltransferase (mouse)	2.03	PC3_cells, EB_cells, HS578T_cells
122033 AA431334 Hs.109297 ESTs 2.03 OVCAR_cells, A549_cells, Caco2  120461 AA251301						2.03	HT29_cells, PC3_cells, A549_cells
120461 AA251301						2.03	OVCAR_cells, A549_cells, Cacc2
contains Alu repetitive element;, mRNA 2.03 HS578T_cells, EB_cells EB_cells   134959 U90550 Hs.91813 butyrophilin; subfamily 2; member A2 2.03 HMEC, Fibroblasts 2, EB_cells   104909 AA055892 Hs.14543 ESTs 2.03 Lu_SC_H345, PC3_cells, DU145_cells   101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 2.03 Lu_SC_H69, EB_cells, CALU6_cells   133878 D78947 Hs.7718 ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells   103459 X99894 Hs.32938 Hs.32938 insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358   125507 AI436377 Hs.258590 ESTs 2.01 HS578T_cells, HMEC, MB231_cells   112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, HMEC, MB231_cells   112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con   105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells   126762 AA064671 RPWE_2, Lu_AD_H23, Lu_AD_358							
134959 U90550 Hs.91813 butyrophilin; subfamily 2; member A2 2.03 HMEC, Fibroblasts 2, EB_cells 104909 AA055892 Hs.14543 ESTs 2.03 Lu_SC_H345, PC3_cells, DU145_cells 101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 2.03 Lu_SC_H69, EB_cells, CALU6_cells ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358 Hs.258590 tetraspanin TM4-B 2.02 A549_cells, Lu_SQ_H520, Lu_AD_H23 Hs.65996 ESTs 2.01 HS578T_cells, HMEC, MB231_cells HS578T_cells, HMEC, MB231_cells ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells, PRSC_con HS578T_cells, EB_cells HMEC, EB_cells SCALU6_cells ESTs SCALU6_cells ESTs SCALU6_cells HS578T_cells, Lu_SQ_H520, Lu_AD_H23 Hs.65996 ESTs SCALU6_cells HS578T_cells, HMEC, MB231_cells HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells, EB_cells PRSC_con HS578T_cells, EB_cells PRSC_con HS578T_cells, HMEC, EB_cells SCALU6_cells ESTs SCALU6_cells HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells, HMEC, EB_cells SCALU6_cells ESTs SCALU6_cells HS578T_cells, HMEC, EB_cells SCALU6_cells ESTs SCALU6_cells HS578T_cells, HMEC, EB_cells SCALU6_cells ESTs SCALU6_cells ESTs SCALU6_cells ESTs SCALU6_cells ESTs SCALU6_cells ESTs SCALU6_cells EB_cells, MCF7, MB231_cells HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells, HMEC, EB_cells PRSC_con SCALU6_cells PRSC_con HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells, HMCC, EB_cells PRSC_con HS578T_cells, HMCC, EB_cells PRSC_con HS578T_cells, HMCC, EB_cells PRSC		120101	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				HS578T cells, EB cells, EB cells
104909 AA055892 Hs.14543 ESTs 2.03 Lu_SC_H345, PC3_cells, DU145_cells 101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 133878 D78947 Hs.7718 ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells 103459 X99894 Hs.32938 insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358  70 125507 Al436377 Hs.258590 tetraspanin TM4-B 2.02 A549_cells, Lu_SQ_H520, Lu_AD_H23 116657 F04014 Hs.65996 ESTs 2.01 HS578T_cells, HMEC, MB231_cells 112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con 105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells 126762 AA064671 zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358	65	134050	1190550	He 91817			
101950 S79219 Hs.80741 propionyl Coenzyme A carboxylase; alpha 2.03 Lu_SC_H69, EB_cells, CALU6_cells ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358 Hs.258590 tetraspanin TM4-B 2.02 A549_cells, Lu_SQ_H520, Lu_AD_H23 Hs.65996 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con 105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells, PRSC_con HS578T_cells, EB_cells	05				• •		
133878 D78947 Hs.7718 ESTs; Weakly similar to weak similarity 2.02 EB_cells, MCF7, MB231_cells insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358 Hs.258590 Hs.258590 ESTs 2.01 HS578T_cells, Lu_EQ_H520, Lu_AD_H23 Hs.6596 ESTs 2.01 HS578T_cells, HMEC, MB231_cells ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells, PRSC_con HS578T_cells, PRSC_con HS578T_cells, Lu_AD_H23, Lu_AD_358 HS.6418 ESTs; Moderately similar to Seven transm 2.01 HS578T_cells, HMEC, EB_cells PRSC_con HS578T_cells,							
103459 X99894 Hs.32938 insulin promoter factor 1; homeodomain t 2.02 EB_cells, Lu_AD_H23, Lu_AD_358  70 125507 Al436377 Hs.258590 tetraspanin TM4-B 2.02 A549_cells, Lu_AD_H23, Lu_AD_H23 116657 F04014 Hs.65996 ESTs 2.01 HS578T_cells, HMEC, MB231_cells 112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con 105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, HMEC, EB_cells 126762 AA064671 zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358							
70 125507 Al436377 Hs.258590 tetraspanin TM4-B 2.02 A549_cells, Lu_SQ_H520, Lu_AD_H23 116657 F04014 Hs.65996 ESTs 2.01 HS578T_cells, HMEC, MB231_cells 112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, HMEC, MB231_cells Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells, PRSC_con HS578T_cells, HMEC, EB_cells EST8 T126762 AA064671 Zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358							
116657 F04014 Hs.65996 ESTs 2.01 HS578T_cells, HMEC, MB231_cells 112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con 105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells, PRSC_con 126762 AA064671 Zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358	70				*		
112920 T10234 Hs.4275 ESTs 2.01 HS578T_cells, EB_cells, PRSC_con 105533 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, EB_cells, PRSC_con 126762 AA064671 zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358	/U				•		
10553 AA258572 Hs.6418 ESTs; Moderately similar to seven transm 2.01 HS578T_cells, HMEC, EB_cells 126762 AA064671 zm13b04.r1 Stratagene pancreas (#937208) similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358							
126762 AA064671 zm13b04.r1 Stratagene pancreas (#937208) 75 similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358							
75 similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358		105533	AA258572	Hs.6418	ESTs; Moderately similar to seven transm	2.01	HS578T_cells, HMEC, EB_cells
75 similar to TR:G413842 G413842 NONCLASSI 2.01 RPWE_2, Lu_AD_H23, Lu_AD_358		126762	AA064671		zm13b04.r1 Stratagene pancreas (#937208)		
	75				similar to TR:G413842 G413842 NONCLASS	31	2.01 RPWE_2, Lu_AD_H23, Lu_AD_358
	_	128999	R37808	Hs.107765			HS578T_cells, OVCAR_cells, EB_cells
			-	_			

# Table 2

5			Pkey: ExAccn: Unigene Unigene	ID: Unigene number	ession number	
10	Pkey	Ex Accn	UniG_ID	Complete_Title	Ratio Mets/BS	Top 3 expressing cell lines
10	101447	M21305	Hs 247946	Human alpha satellite and satellite 3 ju	110.98	EB_cells, Fibroblasts 2, A549_cells
		AA130349		ESTs	9.13	EB_cells, OVCAR_cells, Lu_SC_H345
	106094	AA419461	Hs.18127	ESTs	8.51	HT29_cells, MB-MDA-453, HS578T_cells
		AA348412		ESTs	8.4	293T_cells, OVCAR_cells, EB_cells
15		N54841	Hs.172572	ESTs	7.2	Lu_SC_H69, EB_cells, Lu_SC_H345
	118475	N66845	Hs.165411	ESTs; Weakly similar to !!!! ALU CLASS B	7	DU145_ceils, EB_ceils, Cacc2
	112170	R48744	Hs.192878	ESTs	6.91	293T_cells, DU145_cells, HT29_cells
			Hs.72324		6.6	EB_cells, 293T_cells, DU145_cells
••		R79750	Hs.83623	nuclear receptor subfamily 1; group I; m	6.58	293T_cells, OVCAR_cells, HMEC
20			Hs.107168		6.55	CALU6_cells, OVCAR_cells, EB_cells
			Hs.47094		6.43	EB_cells, LNCaP_cells, Lu_SC_H345
		N67086	Hs.102000		6.35	PC3_cells, A549_cells, DU145_cells
		R81509		splicing factor, arginine/serine-rich 11	6.32	293T_cells, Lu_SC_H345, HMEC Cacc2, MB-MDA-435s, PRSC_log
25			Hs.103822		6.13 6	OVCAR_cells, EB_cells, 293T_cells
25		AA424791 AA081079	NS.37 34	KIAA0679 protein zn32h9.s1 Stratagene endothelial cell 93	·	0 V O A ( _ colo, _ colo, _ colo _ colo
	114010	AA001013		IMAGE:549185 3', mRNA seq	5.97	PRSC_con, DU145_cells, HS578T_cells
	130281	R12777	Hs.15395	ESTs; Weakly similar to ARGINYL-TRNA SY		5.94 PRSC_con, HT29_cells, EB_cells
		R05818	Hs.173830		5.92	LNCaP_cells, EB_cells, OVCAR_cells
30		T88700	Hs.173374		5.81	DU145_cells, PC3_cells, HMEC (total RNA)
		H88496	Hs.40583		5.77	OVCAR_cells, HS578T_cells, A549_cells
		N79496	Hs.50824	EST	5.45	LNCaP_ceils, OVCAR_ceils, DU145_ceils
	129076	AA262179	Hs.169343	ESTs	5.35	293T_cells, BT474_cells, MCF7
25		F09317		ESTs; Weakly similar to LINE-1 REVERSE T		Fibroblasts 2, Lu_SC_H69, DU145_cells
35	104558	R56678	Hs.88959	Human DNA seq from clone 967N21 on chr 2		ED salle DOS salle Lu CO HSAF
	400000	4.450004	11- 70000	part of KIAA0172; the gene for a novel	5.32	EB_cells, PC3_cells, Lu_SC_H345
			Hs.72222	Human BRCA2 region; mRNA seq CG006	5.23 5.2	HT29_cells, PC3_cells, Lu_AD_358 293T_cells, EB_cells, DU145_cells
		U50535 R85436	Hs.193150	<u> </u>	5.2	MB-MDA-435s, PRSC_con, MB-MDA-453
40			Hs.168147		5.18	PC3_cells, LNCaP_cells, CALU6_cells
40		AA136653	113.100147	ESTs	5.04	EB_cells, Fibroblasts 2, A549_cells
			Hs.250992		5.04	Lu_SC_H345, PRSC_con, LNCaP_cells
		U20758	Hs.313	secreted phosphoprotein 1 (osteopontin;	5.02	Lu_LC_H460, A549_cells, MB-MDA-435s
	121332	AA404384	Hs.97921	ESTs	5.01	EB_cells, Lu_SC_H69, DU145_cells
45			Hs.79572		4.96	EB_cells, MCF7, DU145_cells
			Hs.193380		4.86	DU145_cells, PC3_cells, PRSC_log
		AA082041		ESTS	4.83	EB_cells, Lu_SC_H345, HS578T_cells
		R70506		ESTs; Weakly similar to !!!! ALU SUBFAMI	4.75 4.71	DU145_cells, OVCAR_cells, LNCaP_cells OVCAR_cells, Lu_AD_H23, RPWE_2
50		U40434	Hs.194013	mesothelin ESTe	4.69	EB_cells, HS578T_cells, DU145_cells
50		T78089	Hs.168887		4.58	OVCAR_ceils, 293T_ceils, DU145_ceils
		U52696	115.100001	Humn adrenal Creb-rp hmlg (Creb-rp), com	4.57	Lu_SC_H345, Lu_SC_H69, HT29_cells
			Hs.238380	Human endogenous retroviral protease mRN		PC3_cells, EB_cells, Lu_SQ_H520
			Hs.175319		4.57	OVCAR_ceils, 293T_ceils, PC3_ceils
55	123470	AA599106	Hs.194208	ESTs	4.55	LNCaP_cells, Lu_SC_H69, 293T_cells
		T59257	Hs.194407		4.55	A549_cells, 293T_cells, 293T_cells
	123433	AA598661	Hs.112478	ESTs	4.55	EB_cells, OVCAR_cells, HT29_cells
		M28170		CD19 antigen	4.53	OVCAR_cells, DU145_cells, EB_cells
60			Hs.199961		4.51	DU145_cells, LNCaP_cells, EB_cells
60		H88486	Hs.108806		4.45 4.43	LNCaP_cells, Cacc2, EB_cells LNCaP_cells, DU145_cells, OVCAR_cells
		R60044		ESTs; Moderately similar to !!!! ALU SUB ESTs; Highly similar to BETA-CATENIN [H.	4.42	OVCAR_cells, CALU6_cells, CALU6_cells
		H40988	ns.100700	ESTs; Weakly similar to !!!! ALU SUBFAMI	4.39	DU145_cells, OVCAR_cells, LNCaP_cells
		U25165	Hs.82712		4.38	HS578T_cells, OVCAR_cells, DU145_cells
65			Hs.256517		4.36	Lu_SC_H345, OVCAR_cells, PC3_cells
		R71234		yi54c08.s1 Soares placenta Nb2HP H sapie		
				transcript, (rRNA); gb:S41458 ROD CGMP-	.0.	
				BETA-SUBUNIT (HUMAN);contain	4.33	DU145_cells, OVCAR_cells, LNCaP_cells
70			Hs.126759		4.3	EB_cells, HT29_cells, Lu_SC_H69
70		N33063	rts.23291	ESTs; Weakly similar to S164 [H.sapiens]	4.28 4.28	OVCAR_cells, EB_cells, Lu_SC_H69 DU145_cells, LNCaP_cells, OVCAR_cells
		U49973	He 112400	Human Tigger1 transposable element, comp	4.28 4.27	A549_cells, A549_cells, BT474_cells
				KIAA0612 protein	4.27 4.22	Caco2, HS578T_cells, MB-MDA-435s
		N62371	Hs.64193	ESTs; Weakly similar to Similar to cutic	4.22	PC3_cells, DU145_cells, Lu_SC_H345
75			Hs.251119		4.22	Lu_SC_H345, Lu_SC_H69, OVCAR_cells



	130641 A	A182001	Hs.17155	ESTs	3.36	DU145_cells, MB-MDA-435s, HS578T_cells
			Hs.194348		3.33	HT29_cells, Fibroblasts 2, BT474_cells
				ESTs; Moderately similar to !!!! ALU SUB	3.33	EB_cells, Fibroblasts 2, BT474_cells
5				H sapiens mRNA; cDNA DKFZp564J2116 (fro	m 3.32	3.32 LNCaP_cells, DU145_cells, EB_cells DU145_cells, EB_cells, Cacc2
3	133339 No 113260 Te		Hs.71252 Hs.237992		3.32	Lu_SC_H345, LNCaP_cells, Lu_SC_H69
	133349 N		Hs.7153	L-3-hydroxyacyl-Coenzyme A dehydrogenase		Caco2, EB_cells, OVCAR_cells
	107149 A			ESTs	3.29	HS578T_cells, DU145_cells, PRSC_con
	133195 A	A350744	Hs.181409	KIAA1007 protein	3.29	EB_cells, Lu_AD_H23, Lu_AD_358
10	111302 N		Hs.15049		3.29	DU145_cells, EB_cells, HS578T_cells
			Hs.28827		3.28 3.28	A549_cells, OVCAR_cells, PC3_cells Cacc2, PRSC_con, PRSC_log
	121768 AV			insulin-like growth factor 2 (somatomedi ESTs; Weakly similar to hypothetical pro	3.28	PRSC_log, CALU6_cells, OVCAR_cells
				splicing factor (CC1.3)	3.28	EB_cells, LNCaP_cells, DU145_cells
15	100700 H		113.140000	Guanine Nucleotide-Binding Protein Hsr1	3.27	EB_cells, RPWE_2, Lu_AD_H23
	134275 A			acid-inducible phosphoprotein	3.26	EB_cells, DU145_cells, LNCaP_cells
	117667 N	39214	Hs.44708	Ser-Thr protein kinase related to the my	3.26	LNCaP_ceils, DU145_cells, MB-MDA-453
	124889 R		Hs.101570		3.25	Lu_AD_H23, Lu_SC_H69, Lu_SC_H345
20	126631 W		Hs.193337		3.25 3.24	Lu_SC_H345, OVCAR_cells, Lu_SC_H69 Cacc2, EB_cells, 293T_cells
20				KIAA0603 gene product Sjogren syndrome antigen A2 (60kD; ribon	3.24	CALU6_cells, OVCAR_cells, A549_cells
	132718 A			ESTs; Weakly similar to !!!! ALU SUBFAMI	3.24	A549_cells, CALU6_cells, 293T_cells
	108039 A		Hs.46670		3.24	293T_cells, EB_cells, Caco2
	114116 Z			KIAA0594 protein	3.23	DU145_œils, OVCAR_œils, EB_œils
25	124514 N		Hs.142737		3.22	EB_cells, Caco2, Lu_SQ_H520
	110802 N		Hs.252748		3.22	LNCaP_cells, MB-MDA-435s, MB-MDA-453 DU145_cells, EB_cells, OVCAR_cells
			Hs.24462		3.22 3.21	DU145_ceils, LNCaP_ceils, OVCAR_ceils
	123523 A		Hs.193634 Hs.28792		3.2	HS578T_cells, HMEC (total RNA), HMEC
30	119423 TS		Hs 173734	ESTs; Weakly similar to !!!! ALU CLASS B	3.2	EB_cells, DU145_cells, Cacc2
50	128736 F		Hs.104607		3.19	PC3_cells, Lu_SQ_H520, Lu_SC_H69
	101511 M	127826	Hs.238380	Human endogenous retroviral protease mRN	3.18	PC3_cells, DU145_cells, Lu_SQ_H520
			Hs.95249		3.18	EB_cells, Lu_SC_H345, DU145_cells
25	124196 H		Hs.144167		3.17 3.17	BT474_cells, MB231_cells, HMEC Fibroblasts 2, PRSC_con, PRSC_log
35	129095 L1			thrombospondin 2	3.17	293T_cells, Lu_SC_H345, CALU6_cells
	116457 A 117040 H		Hs.119683	yw25e5.s1 Morton Fetal Cochlea H sapiens	3.16	OVCAR_cells, 293T_cells, EB_cells
	129112 N		Hs.108738		3.16	EB_cells, Fibroblasts 2, MB231_cells
	130418 JO			insulin-like growth factor 2 (somatomedi	3.16	Caco2, PRSC_con, PRSC_log
40	131199 R	80048		ESTs; Weakly similar to transporter prot	3.15	PC3_cells, EB_cells, OVCAR_cells
	110357 H			ESTs; Highly similar to sulfonylurea rec	3.15	Lu_SC_H345, PRSC_con, Lu_AD_H23
	130068 A			KIAA0336 gene product	3.15 3.15	OVCAR_œils, CALU6_œils, HS578T_œils EB_œils, PRSC_con, LNCaP_ceils
	127423 T		Hs.119252 Hs.25282	tumor protein; translationally-controlle	3.14	LNCaP_cells, PC3_cells, EB_cells
45	102349 U		Hs.75263	apoptosis inhibitor 1	3.14	DU145_cells, HS578T_cells, LNCaP_cells
73	105126 A			ESTs	3.13	EB_cells, HS578T_cells, LNCaP_cells
	115465 A			ESTs	3.12	EB_cells, DU145_cells, 293T_cells
	133246 A			triadin	3.12	Lu_SQ_H520, Lu_AD_H23, PRSC_log
50	122698 A			ESTS	3.12	DU145_cells, OVCAR_cells, A549_cells EB_cells, Caco2, DU145_cells
50			Hs.111977		3.12 3.11	HS578T_cells, 293T_cells, Cacc2
	133437 R 104956 A	13/4 19 407/880	Hs.7370	ESTs ESTs; Weakly similar to hypothetical pro	3.11	OVCAR_cells, Fibroblasts 2, Caco2
			Hs.43118		3.11	EB_cells, MB-MDA-435s, HT29_cells
				eukaryotic translation initiation factor	3.11	LNCaP_cells, DU145_cells, EB_cells
55			Hs.71027		3.11	Lu_LC_H460, Lu_SC_H345, Lu_AD_358
	129791 F	02778		KIAA0876 protein	3.1	Lu_SC_H345, Lu_SC_H69, PRSC_log
	115783 A			ESTs; Weakly similar to LIV-1 protein [H	3.09 3.07	Lu_AD_358, EB_œlls, PC3_œlls Lu_SC_H345, CALU6_œlls, Lu_SC_H69
	107630 A 124339 H	AUU/218	Hs.60178 Hs.6179	ESTs H sapiens mRNA; cDNA DKFZp586K2322 (fr		3.07 293T_cells, MB-MDA-453, Cacc2
60			Hs.192076		3.07	293T_cells, LNCaP_cells, PC3_cells
00	104589 R		Hs.241160	ESTs; Moderately similar to !!!! ALU SUB	3.07	293T_cells, DU145_cells, EB_cells
			Hs.183765	ESTs; Moderately smlr to ORF derived frm	3.06	Caco2, EB_cells, MB231_cells
	123796 A	A620390	Hs.247444	ESTs	3.06	Lu_SC_H345, LNCaP_cells, DU145_cells
~			Hs.30299	IGF-II mRNA-binding protein 2	3.06	OVCAR_cells, HMEC (total RNA), HMEC OVCAR_cells, LNCaP_cells, 293T_cells
65	133318 A			ESTS	3.05	OVCAR_Cells, LNCaP_Cells, 2931_Cells
	117244 N	1209/9	Hs.1757	L1 cell adhesion molecule (hydrocephalus thumbs) syndrome; spastic paraplegia 1)	3.05	MB231_cells, MCF7, CALU6_cells
	130797 A	A430050	Hs 180948	KIAA0729 protein	3.05	EB_cells, DU145_cells, DU145_cells
	128959 D			ESTs; Weakly similar to F38A5.1 [C.elega	3.05	LNCaP_cells, HS578T_cells, Lu_SQ_H520
70	120481 A	A252703	Hs.191754		3.04	EB_cells, Fibroblasts 2, PRSC_con
	126649 A	A856990	Hs.125058	ESTs	3.03	OVCAR_cells, LNCaP_cells, 293T_cells
			Hs.24252	ESTs	3.03	EB_cells, OVCAR_cells, 293T_cells
	126488 N	134935	Hs.25633	ESTs; Highly similar to ARF GTPase-activ	3.03	Lu_AD_358, MCF7, MB231_cells 293T_cells, HS578T_cells, CALU6_cells
75	119498 W		Hs.55573		3.01 3.01	Lu_SC_H345, Lu_SC_H69, PRSC_log
75	129967 H		Hs.138618 Hs.188212		3.01	OVCAR_cells, LNCaP_cells, DU145_cells
	150050 7	J.1007.007	10.100212			

	111018	N54067	Hs.3628	mitogen-activated protein kinase kinase	3.01	PC3_cells, Caco2, Fibroblasts 2
		AA489250	Hs.59403	serine palmitoyltransferase; subunit II	3	Lu_SC_H345, BT474_cells, Lu_SC_H69
		AA203433	Hs.6834	KIAA1014 protein	3	OVCAR_cells, 293T_cells, EB_cells
	130405	H88359	Hs.155396	nuclear factor (erythroid-derived 2)-lik	3	PRSC_con, EB_cells, DU145_cells
5	107881	AA025567		H sapiens chromosome 19; cosmid R32611	3	Lu_SQ_H520, MCF7, Lu_AD_358
		D59570		ESTs	3	EB_cells, A549_cells, HS578T_cells
		AA255546		ESTs	2.99	Lu_SC_H345, PC3_cells, OVCAR_cells
	115560	AA393812	Hs.50575	ESTs; Moderately similar to !!!! ALU SUB	2.99	EB_cells, Lu_SC_H69, Fibroblasts 2
				KIAA0916 protein	2.98	LNCaP_cells, EB_cells, 293T_cells
10		AA504773			2.98	PRSC_con, PRSC_log, PRSC_log Lu SC H345, HT29_cells, BT474_cells
		F01449	Hs.26954		2.97 2.97	EB_cells, Lu_AD_H23, Lu_AD_358
			H\$.10/812	ESTs; Weakly similar to proline-rich pro	2.97	EB_cells, MB231_cells, OVCAR_cells
		U28369		sema domain; immunoglobulin domain (lg);	2.96	EB_cells, DU145_cells, 293T_cells
15		AA278907	Hs.3337	ESTs transmembrane 4 superfamily member 1	2.96	A549_cells, PC3_cells, DU145_cells
15		M90657 AA053401			2.96	293T_cells, Lu_LC_H460, PC3_cells
		H23543	Hs.27090	ESTS	2.95	PRSC_log, Lu_SC_H345, MB231_cells
		R91241	Hs.75470	hypothetical protein; expressed in osteo	2.95	Lu_SC_H345, Lu_SC_H69, PRSC_log
		AA805726			2.94	HS578T_cells, 293T_cells, 293T_cells
20		N73762	Hs.90638		2.94	EB_cells, MB-MDA-453, Fibroblasts 2
20	121788	AA423968		ESTs; Moderately similar to kinesin like	2.94	HT29_cells, CALU6_cells, HMEC
	128530	AA504343	Hs.183475	H sapiens clone 25061 mRNA seq	2.94	DU145_cells, Lu_SC_H345, Cacc2
		Al301201			2.93	EB_cells, Lu_SQ_H520, PRSC_con
		W15580	Hs.15342		2.93	EB_cells, Lu_AD_H23, PRSC_log
25		AA588536		ESTs	2.93	EB_cells, HS578T_cells, Lu_AD_358
	109642	F04465	Hs.22394	ESTs; Weakly similar to weak similarity		
				protein US)1 [C.elegans]	2.92	PC3_cells, EB_cells, OVCAR_cells
	114615	AA083812	Hs.159456	DKFZP566F123 protein	2.92	A549_cells, HS578T_cells, PRSC_con
		AA086320		zn52d12.s1 Stratagene muscle 937209 H sa	2.92	Lu_SC_H69, Lu_SC_H345, EB_cells
30		W84768	Hs.141742		2.92	DU145_cells, Fibroblasts 2, MCF7
	129455	W27301		DKFZP564A122 protein	2.91	OVCAR_cells, DU145_cells, CALU6_cells
	107772	AA018587	Hs.40515	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.91	OVCAR_cells, EB_cells, PC3_cells
			Hs.237955	RAB7; member RAS oncogene family	2.91	293T_cells, OVCAR_cells, PC3_cells DU145_cells, DU145_cells, CALU6_cells
25	124792	R44357		ESTs; Weakly similar to cDNA EST EMBL:T0		2.91 EB_cells, Lu_SC_H69, 293T_cells
35	109751	F10210	Hs.6679	H sapiens mRNA; cDNA DKFZp586A0424 (fr		CALU6_œlls, EB_œlls, OVCAR_œlls
	128926	AA481403	HS.10/213	ESTs; Highly similar to NY-REN-6 antigen	2.9 2.9	EB_cells, Cacc2, MB-MDA-435s
		AA459961		procollagen-lysine; 2-oxoglutarate 5-dio	2.9	DU145_œlis, HS578T_œlis, A549_œlis
		U84573	Hs.41270	ESTs	2.9	MCF7, HMEC (total RNA), 293T_cells
40		AA905327 AA034947	He 2/831	ESTS	2.9	EB_cells, Lu_LC_H460, 293T_cells
40		H27267	Hs.75860	hydroxyacyl-Coenzyme A dehydrogenase/3-k		
	120030	1127 207	113.75000	-Coenzyme A hydratase (trifunctional pro	2.89	LNCaP_cells, DU145_cells, OVCAR_cells
	116696	F09780	Hs.66124	EST	2.89	CALU6_cells, 293T_cells, 293T_cells
				cell division cycle 2-like 1 (PITSLRE pr	2.89	PC3_cells, EB_cells, LNCaP_cells
45	134946	AA406534	Hs.193053	ESTs; Weakly similar to hiwi [H.sapiens]	2.88	EB_cells, LNCaP_cells, Caco2
		AA250850			2.88	EB_cells, EB_cells, EB_cells
		W35212	Hs.17691	ESTs; Weakly similar to env protein [H.s	2.88	MB-MDA-435s, Lu_SC_H69, CALU6_cells
		U34962	Hs.54473	cardiac-specific homeo box	2.88	293T_cells, HT29_cells, Lu_AD_H23
		AI096849	Hs.25274	ESTs; Moderately similar to putative sev	2.88	PC3_cells, CALU6_cells, 293T_cells
50	100288	D43951	Hs.153834	Human mRNA for KIAA0099 gene; complete	c2.88	293T_cells, LNCaP_cells, EB_cells
			Hs.24656	KIAA0907 protein	2.88	OVCAR_cells, DU145_cells, 293T_cells DU145_cells, HS578T_cells, MB231_cells
	125262	W88755	Hs.108514	ESTs; Highly similar to Trio [H.sapiens]	2.88	EB_cells, Lu_AD_H23, Fibroblasts 2
				ESTs; Weakly similar to transposon LRE2	2.88	EB_celis, A549_cells, OVCAR_cells
55	130639	D59711	Hs.17132	LI agrico mana appla prezentate for	2.87	2.87 293T_œlis, A549_œlis, Lu_LC_H460
55				H sapiens mRNA; cDNA DKFZp586I1518 (fro ESTs; Highly similar to CALCIUM-BINDING	2.87	Lu_SC_H345, Lu_SC_H69, LNCaP_cells
	120900	H66949	Hs. 100009	H sapiens Mut S homolog 5 gene; partial	2.07	E0_00_1010, 20_00_100, C11000 _0000
	121007	AA424507	N3.24/4/0	1C7; LST-1; lymphotoxin beta; tumor necr	2.87	Lu_SC_H69, HT29_ceils, RPWE_2
	105474	ΔΔ255440	He 219614	F-box protein FBL11	2.87	Lu_AD_H23, Caco2, EB_cells
60		AA443695			2.87	HT29_cells, Lu_SC_H69, BT474_cells
00		AA521186			2.86	MB-MDA-453, OVCAR_cells, Lu_SC_H69
				KIAA1096 protein	2.86	PC3_cells, EB_cells, 293T_cells
	106711	AA464741	Hs.143187	Human DNA from chromosome 19-specific of	2.86	EB_cells, Lu_AD_H23, Lu_LC_H460
		L32832	Hs.101842	AT-binding transcription factor 1	2.85	LNCaP_cells, Cacc2, EB_cells
65	132139	AA213410	Hs.111554	ADP-ribosylation factor-like 7	2.85	A549_cells, HS578T_cells, Cacc2
	114484	AA034378	Hs.252351	HERV-H LTR-associating 2	2.85	PC3_cells, Lu_SQ_H520, MB231_cells
		N74051	Hs.194092	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.85	Lu_SC_H345, MB231_cells, Fibroblasts 2
	100403	D85527		H sapiens mRNA for LIM domain, partial c	2.84	Lu_AD_358, Lu_AD_358, MB231_cells
~~			Hs.125163	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.84	Lu_SC_H345, OVCAR_cells, PC3_cells
70		T70214	Hs.183548	ESTS	2.84	DU145_cells, DU145_cells, OVCAR_cells EB_cells, Lu_AD_H23, Fibroblasts 2
		U70321		tumor necrosis factor receptor superfami	2.84	EB_cells, CVCAR_cells, Lu_SC_H345
		AA252030			2.84	EB_cells, Lu_LC_H460, OVCAR_cells
		AA421638		ESTs	2.83 2.83	DU145_cells, LNCaP_cells, Lu_SC_H345
75	123963	C13961	Hs.210115	COT.	2.83	EB_cells, MCF7, Lu_SC_H69
75	1/2/83	AA459895 R96586	Hs. 163630		2.82	DU145_cells, Lu_SC_H345, EB_cells
	112/00	V20200	1 13. 103030			

			405700	FOT-	2.82	HT29_cells, HMEC (total RNA), BT474_cells
			Hs.185780		2.82	Caco2, PC3_cells, OVCAR_cells
	100378			KIAA0187 gene product	2.81	DU145_cells, MCF7, EB_cells
		AA045602	Hs.188877	ESTs; Moderately similar to serine/threo	2.81	EB_cells, Lu_AD_H23, HT29_cells
5		AA064627		ESTs; Highly similar to CGI-72 protein [	2.81	PC3_cells, HS578T_cells, OVCAR_cells
,		AA237013	Hs 2730	heterogeneous nuclear ribonucleoprotein	2.8	OVCAR_cells, LNCaP_cells, Cacc2
	124314			GTP-binding protein	2.8	LNCaP_cells, DU145_cells, Cacc2
	134227		Hs.80338	KIAA0164 gene product	2.8	LNCaP_cells, A549_cells, EB_cells
		AA476268		zw44h1.s1 Soares_total_fetus_Nb2HF8_9w H	1	
10				contains Alu repetitive element;contain	2.79	Lu_SC_H345, OVCAR_cells, Lu_SC_H69
	126096	H42968	Hs.155606	paired mesoderm homeo box 1	2.78	Lu_AD_H23, Lu_SC_H69, Lu_LC_H460
		AA424782	Hs.110121	SEC7 homolog	2.78	Lu_AD_H23, EB_cells, Lu_SC_H345
				DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.78	EB_cells, OVCAR_cells, 293T_cells
			Hs.189910		2.77	293T_cells, HS578T_cells, DU145_cells EB_cells, Lu_AD_H23, Lu_AD_358
15	119232		Hs.258624		2.77 2.77	EB cells, Lu_LC_H460, MCF7
				ESTs; Weakly similar to homology with is	2.76	OVCAR_cells, Lu_SC_H345, 293T_cells
		AA416697	Hs.15330		2.76	MCF7, MB-MDA-453, CALU6_cells
		N21626	Hs.102406	KIAA0220 protein	2.76	DU145_cells, HT29_cells, Lu_SC_H69
20	129349			RNA helicase-related protein	2.76	OVCAR_cells, EB_cells, 293T_cells
20		AA423808 HG2755-H	HS.0705	T-Plastin	2.75	293T_cells, PC3_cells, HS578T_cells
	128500		Hs 100641	caspase 9; apoptosis-related cysteine pr	2.75	Lu_AD_358, Lu_SC_H69, Lu_SC_H345
	126090		Hs.119486	ESTs; Weakly similar to rostral cerebell	2.75	Lu_SC_H69, Lu_SC_H345, BT474_cells
	127064	743709		HSC1JA091 normalized infant brain cDNA H	2.75	Caco2, A549_cells, HT29_cells
25	132989	AA480074	Hs.394	adrenomedullin	2.75	EB_cells, OVCAR_cells, DU145_cells
23	108888	AA135606	Hs.189384	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.75	OVCAR_cells, LNCaP_cells, DU145_cells
		W42429	Hs.150607		2.74	293T_cells, DU145_cells, PC3_cells
	100387	D83777	Hs.75137	KIAA0193 gene product	2.74	CALU6_cells, DU145_cells, Caco2
	114744	AA135407	Hs.252351	HERV-H LTR-associating 2	2.74	PC3_cells, Lu_SQ_H520, RPWE_2
30	129092	AA011243	Hs.63525	poly(rC)-binding protein 2	2.74	EB_cells, MCF7, DU145_cells
	125360	AA677978	Hs.189741	ESTs	2.74	Lu_AD_358, Lu_AD_358, PRSC_log
	107874	AA025305	Hs.25218	ESTs; Weakly similar to reverse transcri	2.74	Lu_SC_H345, Lu_LC_H460, HT29_cells
	114086	Z38266	Hs.12770	H sapiens PAC clone DJ0777O23 from 7p14-	2.74	EB_cells, LNCaP_cells, BT474_cells Lu_SC_H69, PRSC_con, Lu_AD_H23
0.5			Hs.94964		2.73	LNCaP_cells, DU145_cells, A549_cells
35		M61982		ESTS	2.73	EB_cells, DU145_cells, OVCAR_cells
	116339	AA496257	Hs.72165	ESTs; Weakly similar to R26984_1 [H.sapi	2.73	PC3_cells, EB_cells, Cacc2
				chromosome 1 open reading frame 9	2.72 2.72	EB_cells, LNCaP_cells, 293T_cells
		N91273	Hs.27179		2.72	PC3_cells, Lu_SC_H345, Cacc2
40		AA461458		ESTs	2.72	MB-MDA-453, 293T_cells, BT474_cells
40		N69136	Hs.214343	ESTS; Highly similar to G1 TO S PHASE TR	2.71	EB_cells, MCF7, Lu_SC_H345
	10/913	AAU2/101	Hs.59523	ESTs; Weakly similar to S164 [H.sapiens]	2.71	EB_cells, DU145_cells, HMEC
	134315	AA136269	HS.01040	protein-kinase; interferon-inducible dou	2.71	EB_cells, OVCAR_cells, Caco2
		AA127463	Hs.189810	•	2.7	293T_cells, Lu_AD_H23, PC3_cells
45	112932	T15470 R11501	ns. 1030 IV	yf28f1.s1 Soares fetal liver spleen 1NFL		
73	113033	KIISOI		contains Alu repetitive element, mRNA	2.7	Lu_SC_H345, Lu_SC_H69, DU145_cells
	131206	AA044078	Hs.24210	ESTs	2.7	Caco2, Lu_SC_H345, HS578T_cells
		AA063642		ESTs; Highly similar to (defline not ava	2.7	LNCaP_cells, Lu_SC_H345, Lu_SC_H69
		AA160890	Hs.22564	myosin VI	2.7	LNCaP_cells, MCF7, HT29_cells
50		N69101	Hs.40730	EŠTs	2.7	EB_cells, 293T_cells, OVCAR_cells
		AA348446	Hs.96906	ESTs	2.7	Fibroblasts 2, CALU6_cells, RPWE_2
	113815	W45311	Hs.14756	ESTs	2.7	EB_cells, PC3_cells, DU145_cells
	133234	T90092	Hs.6853	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.69	Lu_SC_H345, OVCAR_cells, DU145_cells
		AA305536			2.69	EB_cells, DU145_cells, Caco2 Lu_SC_H345, Lu_AD_H23, Lu_AD_H23
55	125198	W69474	Hs.225550	ESTs (#02	2.69	LU_SC_N345, LU_AD_1125, LU_AD_1125
	108394	AA075144		zm86f6.s1 Stratagene ovarian cancer (#93	ED TIIM	2.69 HMEC, HMEC (total RNA), Fibroblasts 2
				gb:X1664 TRANSLATIONALLY CONTROLL	2.69	EB_cells, LNCaP_cells, DU145_cells
		X59405	Hs.83532	membrane cofactor protein (CD46; trophob	2.68	PC3_cells, HMEC (total RNA), OVCAR_cells
60	111720	R23739	Hs.23585	KIAA1078 protein	2.68	DU145_cells, LNCaP_cells, OVCAR_cells
60			Hs.110659	ESTs; Weakly similar to !!!! ALU CLASS C	2.68	HT29_cells, Lu_SC_H345, MB231_cells
		AA731764	Hs.7594	solute carrier family 2 (facilitated glu	2.68	Caco2, Lu_LC_H460, Fibroblasts 2
		M20681	Hs.75922	brain protein I3	2.68	EB_cells, Lu_AD_H23, Lu_SC_H345
	105701	AA399574	Hs.19086	ESTs	2.68	PC3_cells, MCF7, MB231_cells
65	125191	W67257	Hs.138871	ESTs; Weakly similar to !!!! ALU CLASS B	2.68	OVCAR_ceils, DU145_ceils, LNCaP_cells
05			Hs.47144		2.67	OVCAR_cells, DU145_cells, LNCaP_cells
		R40555	Hs.120429		2.67	Lu_AD_H23, Lu_SC_H69, PRSC_con
		M80563	Hs.81256	S100 calcium-binding protein A4 (calcium		
				murine placental homolog)	2.67	A549_cells, MB231_cells, OVCAR_cells
70	130897	AA063428	Hs.21022	adaptor-related protein complex 3; beta	2.67	EB_cells, Lu_AD_H23, HMEC
		H61046	Hs.237352	EST	2.66	Lu_SC_H345, Lu_SC_H69, PRSC_con
	124724	R12405	Hs.112423	H sapiens mRNA; cDNA DKFZp586I1420 (fr	mom	2.66 Lu_SC_H345, BT474_cells, OVCAR_cells
	123697	AA609601	Hs.221224		2.66	OVCAR_cells, 293T_cells, Lu_SC_H69 293T_cells, CALU6_cells, A549_cells
	111548	R09170	Hs.258707		2.66	Lu_SC_H345, OVCAR_cells, Lu_AD_H23
75	107005	AA598679	Hs.194215	ESIS	2.66	MCF7, HT29_cells, BT474_cells
	105569	AA278399	Hs.20596	ESIS	2.65	HO 1, 11125_0010, 0137 (_0010

	132687	AB002301	Hs.54985	KIAA0303 protein	2.65	HMEC (total RNA), HMEC, LNCaP_cells
	104105	AA422123	Hs.42457	ESTs	2.65	Lu_SC_H345, Lu_SC_H69, DU145_cells
	121335	AA404418	Hs.144953	ESTs	2.65	EB_cells, Fibroblasts 2, DU145_cells
		R61693		ESTs; Weakly similar to Wiskott-Aldrich	2.64	Lu_SC_H69, 293T_cells, EB_cells
5		H69742	Hs.102201		2.64	DU145_œlls, OVCAR_œlls, Lu_SC_H345
	123044	AA481549	Hs.165694	ESTs	2.64	EB_cells, Lu_SC_H69, Lu_SC_H345
			Hs.112603		2.64	EB_cells, Lu_AD_H23, Fibroblasts 2
				erythrocyte membrane protein band 4.1-li	2.64	EB_cells, DU145_cells, Cacc2
10		X75593		RAB13; member RAS oncogene family	2.64	Fibroblasts 2, PRSC_con, HS578T_cells
10		AI188445			2.63	EB_cells, Lu_AD_H23, Lu_LC_H460
			Hs.24371		2.63	Caco2, EB_cells, CALU6_cells
				ESTs; Weakly similar to !!!! ALU SUBFAMI	2.63	EB_cells, DU145_cells, Cacc2
		W19983	Hs.75761		2.63	EB_cells, Lu_AD_H23, Lu_SC_H69
15	132300	H68018		yr76h05.r1 Soares fetal liver spleen 1NF IMAGE:211257 5', mRNA seq.	2.62	ED colle Lu AD H22 Lu SC H60
15	127086	AI370418	He 102050	ESTs; Weakly similar to !!!! ALU CLASS A	2.62	EB_cells, Lu_AD_H23, Lu_SC_H69 DU145_cells, OVCAR_cells, LNCaP_cells
			Hs.42532		2.61	DU145_cells, PRSC_con, Fibroblasts 2
				KIAA0438 gene product	2.6	LNCaP_cells, DU145_cells, HS578T_cells
				KIAA0792 gene product	2.59	EB_œils, MB-MDA-453, Ca∞2
20		M31606		phosphorylase kinase; gamma 2 (testis)	2.59	LNCaP_cells, EB_cells, MB-MDA-453
			Hs.124841	ESTs; Moderately similar to transformati	2.59	DU145_œils, Ca∞2, OVCAR_œils
		R37495	Hs.23578		2.59	HT29_cells, MB231_cells, Lu_SQ_H520
				small membrane protein 1	2.59	A549_cells, EB_cells, HS578T_cells
	107058	AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	2.58	DU145_cells, Lu_SC_H345, EB_cells
25				DKFZP434N161 protein	2.58	Lu_SC_H345, DU145_cells, LNCaP_cells
	131979	D52154	Hs.172458	iduronate 2-sulfatase (Hunter syndrome)	2.58	DU145_cells, PC3_cells, A549_cells
		H80181		ESTs	2.58	DU145_cells, OVCAR_cells, LNCaP_cells
			Hs.18063		2.58	HMEC, DU145_cells, DU145_cells
20				ESTs; Weakly similar to The KIAA0138 gen	2.58	DU145_cells, LNCaP_cells, MCF7
30		N24020	Hs.132913		2.58	HS578T_cells, DU145_cells, LNCaP_cells
			Hs.29692		2.57	PRSC_con, PRSC_log, HS578T_cells
				ESTs; Moderately similar to !!!! ALU SUB	2.57	Lu_SC_H345, Lu_SC_H69, BT474_cells
		N24848		ESTs; Weakly similar to T15B7.2 [C.elega	2.57	HS578T_cells, PRSC_con, EB_cells
35			ns.100/40	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.57	Lu_SC_H69, Cacc2, PRSC_con
33	125324	KU//00		yf15c06.r1 Soares fetal liver spleen 1NF	2.57	ER colle Lu AD H23 Eihmhlasts 2
	129813	T33/62	Hs.12600	contains Alu repetitive element;contain ESTs	2.57 2.57	EB_cells, Lu_AD_H23, Fibroblasts 2 Lu_SC_H345, 293T_cells, Lu_SC_H69
	100265			KIAA0077 protein	2.57	EB_cells, LNCaP_cells, PC3_cells
	134890			ATP-binding cassette; sub-family C (CFTR	2.57	A549_cells, DU145_cells, EB_cells
40		AA421874		Fas-activated serine/threonine kinase	2.56	EB_cells, Lu_AD_H23, Lu_AD_358
	135011		Hs.92991	ESTs; Weakly similar to C13F10.4 [C.eleg	2.56	EB_cells, LNCaP_cells, MB-MDA-453
	107226			ESTs	2.56	Lu_SC_H345, Lu_SC_H69, HMEC (total RNA)
	126042			H sapiens PAC clone DJ0988G15 from 7q33-		HMEC (total RNA), HMEC, RPWE_2
	114472	AA028924	Hs.177407	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.56	Lu_SC_H345, Lu_SC_H69, DU145_cells
45	126291	N42090		yy05b07.r1 Soares melanocyte 2NbHM H sap	2.56	HMEC, HMEC (total RNA), PC3_cells
	113349			ESTs; Moderately similar to histamine N-	2.56	HT29_cells, PRSC_log, Lu_SC_H345
		AA347485	Hs.25477	ESTs; Moderately similar to rig-1 protei	2.56	Lu_AD_H23, RPWE_2, Lu_SQ_H520
	110918		Hs.24283	ESTs	2.56	EB_cells, CALU6_cells, DU145_cells
50	117170			ADP-ribosylation factor-like 5	2.56	OVCAR_cells, EB_cells, LNCaP_cells
50		AA173981		CD2-associated protein	2.55	LNCaP_cells, EB_cells, DU145_cells
		AA292328		activating transcription factor 5	2.55	MCF7, EB_cells, MB-MDA-453
	132079		Hs.38694	ESTS	2.55	EB_cells, DU145_cells, HS578T_cells
	131813 133538		Hs.3268	heat shock 70kD protein 6 (HSP70B')	2.55 2.54	Lu_AD_H23, MB231_cells, Fibroblasts 2
55	124981		Hs.74614 Hs.114034	tight junction protein 1 (zona occludens maternal G10 transcript	2.54	DU145_cells, Caco2, A549_cells EB_cells, Caco2, LNCaP_cells
33		AA431306		ESTs	2.54	Fibroblasts 2, BT474_cells, HMEC (total RNA)
		AA448332		transcription elongation factor A (SII);	2.54	Lu_SC_H345, MCF7, MB-MDA-453
	119315			ESTs	2.54	Lu_SC_H345, MB-MDA-435s, PRSC_con
		AA031948			2.54	A549_cells, RPWE_2, DU145_cells
60					2.54	DU145_cells, EB_cells, A549_cells
	103572	Z25749			2.54	EB_cells, CALU6_cells, DU145_cells
	124395		Hs.193977		2.54	HMEC (total RNA), HMEC, RPWE_2
	116024	AA451748	Hs.83883	Human DNA seq from clone 718J7 on chromo		
				phosphoenolpyruvate carboxykinase 1; ES	2.53	LNCaP_cells, RPWE_2, MB-MDA-453
65	134361				2.53	LNCaP_œlis, CALU6_œlis, DU145_œlis
	130420			Human hybrid receptor gp25 precursor mRN		EB_cells, HMEC (total RNA), Cacc2
	100336				2.53	BT474_cells, HT29_cells, Lu_AD_358
					2.53	EB_cells, Cacc2, MB-MDA-435s
70	124684		Hs.221078		2.53	Lu_SC_H345, OVCAR_cells, Lu_SC_H69
70					2.52	LNCaP_cells, DU145_cells, EB_cells
	100012				2.52	CALU6_œlis, Cacc2, DU145_celis
	126534	447315 <u>0</u>		Human DNA seq from clone 8B1 on chromoso -CELL MEMBRANE GLYCOPROTEIN PC-1; 1		2.52 BT474_cells, LNCaP_cells, Lu_AD_H23
	135334	AA053134			ле де 2.52	293T_cells, CALU6_cells, DU145_cells
75	128538		Hs.101189		2.52 2.52	EB_cells, Lu_AD_H23, Lu_SC_H345
, 5	109865			H sapiens mRNA; cDNA DKFZp434N174 (fror		2.52 DU145_cells, LNCaP_cells, OVCAR_cells

	118579	N68905		small inducible cytokine A5 (RANTES)	2.51	Lu_SC_H345, LNCaP_cells, Lu_SC_H69
		N34904		ESTs; Moderately similar to !!!! ALU SUB	2.51	Lu_SC_H345, DU145_cells, Lu_SC_H69
	104340	F15201		ESTs	2.51	Lu_SC_H345, PRSC_con, PRSC_log
_		AA447744		EST	2.51	Caco2, Lu_SC_H69, 293T_cells EB_cells, DU145_cells, CALU6_cells
5		AA211901		ESTS	2.51 2.51	EB_cells, Lu_AD_H23, Lu_SC_H69
		AA490929 N66763	Hs.43080		2.51	CALU6_œils, HS578T_œils, OVCAR_œils
	106044	AA416546		kinesin family member 5B	2.51	EB_cells, Caco2, DU145_cells
		W58057	Hs.74304		2.5	Caco2, OVCAR_cells, HMEC (total RNA)
10		R26892	Hs.221434	ESTs	2.5	Lu_AD_H23, EB_cells, Lu_AD_358
		N68018	Hs.180930	TBP-associated factor 172	2.5	LNCaP_cells, EB_cells, DU145_cells
	103423	X97249	Hs.123122	FSH primary response (LRPR1; rat) homolo	2.5	HS578T_cells, Lu_SC_H345, PC3_cells OVCAR_cells, Lu_SC_H345, DU145_cells
				ESTs; Weakly similar to !!!! ALU SUBFAMI carcinoembryonic antigen-related cell ad	2.49 2.49	MB-MDA-453, 293T_cells, CALU6_cells
15		D90276 R42547	Hs.12 Hs.172551		2.49	EB_cells, Lu_AD_H23, Lu_SC_H345
13		Z41027	Hs.26297	ESTs	2.49	Lu_SC_H69, OVCAR_cells, Lu_AD_H23
		AA233311		ESTs	2.49	EB_cells, CALU6_cells, DU145_cells
		AA188934		ESTs	2.49	MB-MDA-453, Lu_SC_H69, 293T_cells
••		X78262		H.sapiens mRNA for TRE5	2.49	Lu_SC_H345, Lu_SC_H69, PRSC_con
20	108373	AA074393	Hs.61950	ESTs; Weakly similar to nuclear protein	2.49	MCF7, MB-MDA-453, Lu_SC_H345 DU145_cells, Lu_SC_H345, Lu_SC_H345
				ESTs; Weakly similar to ubiquitous TPR m	2.48 2.48	PC3_cells, OVCAR_cells, Lu_SQ_H520
		H45516 M22348	Hs.33268	ESTs ubiquinol-cytochrome c reductase binding	2.48	LNCaP_cells, CALU6_cells, PC3_cells
		H12661	Hs.8107	H sapiens mRNA; cDNA DKFZp586B0918 (fro		2.48 HMEC (total RNA), HS578T_cells, HMEC
25		M93425	Hs.62	protein tyrosine phosphatase; non-recept	2.48	DU145_ceils, EB_ceils, CALU6_ceils
		M33318	Hs.183584	cytochrome P450; subfamily IIA (phenobar	2.48	EB_cells, Lu_AD_H23, Lu_AD_358
		Z14000	Hs.35384	ring finger protein 1	2.47	HT29_cells, Lu_SQ_H520, BT474_cells
		N76763		ESTs	2.47	EB_cells, Lu_AD_H23, Lu_AD_358 Lu_SC_H345, CALU6_cells, Lu_SC_H69
20		H05625	Hs.92414	ESTs: Highly similar to partial CDS: hum	2.47 2.47	MB-MDA-453, 293T_cells, MB-MDA-435s
30		AA489016 AA598675	Hs.239475	ESTs; Highly similar to partial CDS; hum	2.47	LNCaP_ceils, Cacc2, OVCAR_cells
		AA282312		CTD (carboxy-terminal domain; RNA polyme		Lu_SC_H69, HMEC, EB_cells
		W28286		tetraspan 3	2.46	EB_cells, DU145_cells, LNCaP_cells
		T26366	Hs.22711	EST; Weakly similar to 60S RIBOSOMAL PRO		2.46 Lu_LC_H460, EB_cells, Lu_AD_358
35		M60858	Hs.79110	nucleolin	2.46	PC3_cells, 293T_cells, A549_cells
	108569	AA085398		zn7e3.s1 Stratagene hNT neuron (#937233)	2.45	HT29_cells, BT474_cells, Lu_SQ_H520
	447406	HOOOGO	Hs.42612	IMAGE:546748 3', mRNA seq ESTs	2.45	EB_cells, Lu_AD_H23, Lu_AD_358
	120001	H98988	Hs 183755	Human Chromosome 16 BAC clone CIT987S		2.45 EB_cells, Lu_AD_H23, Lu_AD_H23
40		T23625	Hs.258674		2.45	Lu_AD_H23, EB_cells, Lu_SC_H69
		N31726	Hs.44268	ESTs; Highly similar to myelin gene expr	2.45	Lu_SC_H69, DU145_cells, OVCAR_cells
	105407	AA243478	Hs.5206	ESTs	2.45	EB_cells, 293T_cells, PC3_cells
		R55763	Hs.107287		2.44	EB_cells, LNCaP_cells, A549_cells MB-MDA-435s, HS578T_cells, 293T_cells
15		C14128	Hs.251980		2.44 2.44	EB_cells, Lu_AD_H23, Lu_AD_358
45		T35288 R09049	Hs.90421 Hs.17625	ESTs; Moderately stirillar to IIII ACO 308	2.44	PC3_cells, EB_cells, A549_cells
		AA035638	Hs.71968	H sapiens mRNA; cDNA DKFZp564F053 (fro		2.44 PRSC_con, PRSC_log, Caco2
		H37820	Hs.124147		2.44	MB-MDA-453, Cacc2, OVCAR_cells
		T87174	Hs.16341	ESTs; Moderately similar to !!!! ALU SUB	2.44	Caco2, OVCAR_cells, LNCaP_cells
50	131474	U28749	Hs.2726	high-mobility group (nonhistone chromoso	2.44	CALU6_cells, OVCAR_cells, 293T_cells
		AA342802			2.44	Lu_AD_H23, Lu_SQ_H520, PRSC_con
	133733	AA416973	HS./5/98	Human DNA seq from clone 1183121 on chro to predicted fly and worm proteins. Con	2.43	EB_cells, Caco2, DU145_cells
	110077	W88579	Hs.124744		2.43	HT29_cells, HMEC (total RNA), HMEC
55		W60186		Kreisler (mouse) maf-related leucine zip	2.43	LNCaP_cells, HS578T_cells, MB-MDA-453
55		H66351		Dmx-like 1	2.43	Lu_SC_H69, BT474_cells, Lu_SQ_H520
	133395	AA491296	Hs.72805	ESTs	2.43	EB_cells, LNCaP_cells, OVCAR_cells
	106728	AA465355	Hs.153768	U3 snoRNP-associated 55-kDa protein	2.43	EB_cells, Lu_AD_H23, PC3_cells
<i>c</i> 0			Hs.236204	ESTs; Moderately similar to NUCLEAR PORE	2.43	EB_cells, A549_cells, 293T_cells 293T_cells, OVCAR_cells, Fibroblasts 2
60		W81552		nuclear receptor subfamily 1; group I; m	2.43 2.43	EB_cells, DU145_cells, DU145_cells
		R61297 R12581	Hs.191146	eukaryotic translation initiation factor	2.43	HMEC (total RNA), Fibroblasts 2, MB-MDA-435s
		R42241	Hs.106359		2.43	A549_cells, DU145_cells, CALU6_cells
	131554	AA100026	Hs.28669	ESTs; Weakly similar to PROTEIN-TYROSIN	E	2.43 EB_cells, LNCaP_cells, Cacc2
65		N71215	Hs.21862	NCK-associated protein 1	2.42	EB_cells, Caco2, A549_cells
		AA497050			2.42	MCF7, MB-MDA-435s, Lu_SC_H345
	105014	AA121123	Hs.191374	ESTs	2.42	EB_ceils, Lu_AD_H23, Lu_LC_H460 EB_ceils, Lu_SC_H345, A549_ceils
				high-mobility group (nonhistone chromoso	2.42	OVCAR_cells, EB_cells, DU145_cells
70	102386	U40998	Hs.81728		2.42 2.42	Cacc2, MCF7, DU145_cells
70		R68589 H72971	Hs.23721	KIAA0277 gene product	2.42	Lu_SC_H345, OVCAR_cells, Lu_SC_H69
	1233/3	AA620552	Hs.25682	ESTs; Weakly similar to PHOSPHATIDYLET		2.42 EB_cells, Lu_AD_H23, Lu_SC_H69
	114950	AA243503	Hs.11801	adenosine A2b receptor pseudogene	2.42	MB-MDA-453, HT29_cells, Lu_LC_H460
		H39216	Hs.239970	ESTs; Weakly similar to ZNF91L [H.sapien	2.41	Lu_SC_H345, .Fibroblasts 2, DU145_cells
75		X95876	Hs.198252	G protein-coupled receptor 9	2.41	RPWE_2, PRSC_log, Lu_SC_H345
	129703	AA401348	Hs.179999	ESTS	2.41	EB_cells, 293T_cells, DU145_cells

				(5		COOT II- OALLIC II- AE40 II-
				U5 snRNP-specific protein (220 kD); orth	2.41	293T_cells, CALU6_cells, A549_cells
	106532	AA453628	Hs.37443	ESTs	2.41	EB_œils, OVCAR_œils, Ca∞2
	132132	AA010933	Hs.4055	core promoter element binding protein	2.41	HMEC, HMEC (total RNA), EB_cells
		R00311	Hs.18798	EST: Weakly similar to !!!! ALU SUBFAMIL	2.41	Lu_SC_H345, Lu_SC_H69, PRSC_con
5		M26657	Hs.250711	dipeptidyl carboxypeptidase 1 (angiotens	2.41	HT29_cells, BT474_cells, MB231_cells
,				ESTs; Moderately similar to !!!! ALU SUB	2.41	Lu_SC_H345, DU145_cells, LNCaP_cells
		AA086071		chromosome-associated polypeptide C	2.41	OVCAR_cells, DU145_cells, PC3_cells
	118078	N54321	Hs.47790	EST	2.41	EB_cells, Fibroblasts 2, HMEC (total RNA)
	115840	AA429253	Hs.58103	A kinase (PRKA) anchor protein 9	2.41	OVCAR_cells, EB_cells, PC3_cells
10	101186	L20298	Hs.179881	core-binding factor; beta subunit	2.4	EB_cells, DU145_cells, CALU6_cells
		T40936	Hs.8349	ESTs	2.4	Caco2, HT29_cells, EB_cells
		AA259140		ESTs	2.4	Lu_SC_H69, EB_cells, Cacc2
					2.4	Caco2, MB-MDA-435s, LNCaP_cells
		W15263	Hs.5422	ESTS		
1.5			Hs.13179	ESTs; Moderately similar to !!!! ALU SUB	2.4	DU145_cells, LNCaP_cells, OVCAR_cells
15		AA235013		A kinase (PRKA) anchor protein 2	2.4	Caco2, DU145_cells, PRSC_log
	112561	R72427	Hs.129873	ESTs; Weakly similar to CYTOCHROME P45	0	2.4 Lu_SQ_H520, Lu_AD_H23, EB_œlls
	127598	AA610677	Hs.168851	ESTs	2.4	LNCaP_cells, DU145_cells, OVCAR_cells
		AA460969		mitogen-activated protein kinase kinase	2.4	OVCAR_cells, 293T_cells, A549_cells
		AA456687		ESTs	2.4	EB_cells, MB-MDA-453, 293T_cells
20		X67683	110.20007	H.sapiens mRNA for keratin 4	2.39	EB_cells, Lu_AD_H23, Lu_AD_358
20			11- 0047		2.39	EB_cells, Lu_SC_H345, Lu_SC_H69
		F04444	Hs.6217	ESTs; Weakly similar to !!!! ALU SUBFAMI		
		R42671	Hs.140853	EST; Weakly similar to !!!! ALU SUBFAMIL	2.39	MB-MDA-435s, Lu_SC_H345, Lu_AD_H23
	100023			AFFX control: BioC-3	2.39	Caco2, Lu_AD_358, LNCaP_cells
	119923	W86214	Hs.184642	ESTs	2.39	EB_cells, HS578T_cells, DU145_cells
25		AJ003307		AJ003307 Selected chr 21 cDNA library H	2.39	Lu_AD_H23, Lu_SC_H345, Lu_LC_H460
			He 170817	DKFZP586F0222 protein	2.39	EB_cells, DU145_cells, PC3_cells
			Hs.394	adrenomedullin	2.39	Fibroblasts 2, Caco2, HS578T_cells
		D14874			2.03	1 1510516355 2, 06002, 1100701_5015
	134261	AA227678	MS.8084	Human DNA seq from clone 465N24 on chr 1	0.00	DDCC MD MDA 452 I MCaD calls
••				Contains two novel genes; ESTs; GSSs an	2.39	PRSC_con, MB-MDA-453, LNCaP_cells
30	103392	X94563		H.sapiens dbi/acbp gene exon 1 & 2	2.38	EB_cells, Lu_AD_H23, Lu_SC_H69
	129888	U81001	Hs.131891	Human SNRPN mRNA; 3' UTR; partial seq	2.38	LNCaP_cells, Lu_SC_H69, Lu_LC_H460
	130119			tubulin; beta; 2	2.38	Lu_AD_H23, Lu_LC_H460, Lu_LC_H460
		N57710		proteasome (prosome; macropain) subunit;	2.38	293T_cells, OVCAR_cells, HS578T_cells
				• •	2.38	Lu_AD_H23, Lu_SC_H69, Lu_SC_H345
25	131163		Hs.23754	ESTs		
35				ESTs	2.38	EB_cells, LNCaP_cells, DU145_cells
	135026	H59730	Hs.93231	ESTs	2.37	EB_cells, 293T_cells, Lu_SC_H69
	133300	D51401	Hs.70333	ESTs	2.37	OVCAR_cells, Cacc2, CALU6_cells
	129948	H69281	Hs.13643	ESTs	2.37	EB_cells, Lu_AD_H23, Lu_SC_H345
	112505		Hs.23368		2.37	DU145_cells, OVCAR_cells, 293T_cells
40		T98227	Hs.171952		2.37	Caco2, LNCaP_cells, DU145_cells
40		AA192163			2.37	Lu_AD_H23, EB_cells, PRSC_con
		AA379500			2.37	EB_cells, LNCaP_cells, DU145_cells
				ESTs; Weakly similar to !!!! ALU SUBFAMI	2.37	HS578T_cells, MCF7, Lu_SC_H69
	102814	U90716	Hs.79187	coxsackie virus and adenovirus receptor	2.37	OVCAR_cells, DU145_cells, Lu_SC_H345
45	120239	Z41691	Hs.65919	ESTs	2.37	EB_cells, DU145_cells, LNCaP_cells
		AA481883	Hs.31236	ESTs; Weakly similar to Unknown [H.sapie	2.37	EB_cells, DU145_cells, OVCAR_cells
		AA435762		ESTs; Highly similar to unknown [H.sapie	2.37	EB_cells, LNCaP_cells, PRSC_con
		AA132946		ESTs	2.36	Lu_AD_H23, Lu_AD_358, Lu_SQ_H520
					2.36	Caco2, MB-MDA-453, MCF7
50	133226		Hs.169552			
50				ESTs; Moderately similar to !!!! ALU SUB	2.36	MB-MDA-453, Caco2, OVCAR_cells
	119236	T10166	Hs.237297	ESTs		EB_cells, 293T_cells, LNCaP_cells
	106619	AA459255	Hs.23956	ESTs	2.36	LNCaP_cells, A549_cells, Cacc2
		AA181600			2.36	Lu_SC_H345, LNCaP_œils, EB_œils
		R91753	Hs.17757		2.36	Caco2, EB cells, DU145_cells
55		R85069	Hs.141139		2.36	Fibroblasts 2, Lu_AD_H23, Lu_LC_H460
55		AA454988		ESTs	2.36	EB_œlls, OVCAR_œlls, HS578T_œlls
					2.36	OVCAR_cells, Lu_SC_H345, MB-MDA-453
		AA425309		nuclear factor I/B		
				ESTs; Weakly similar to !!!! ALU SUBFAMI	2.35	Lu_SC_H345, Lu_LC_H460, Lu_AD_H23
	134776		Hs.89603	mucin 1; transmembrane	2.35	DU145_œlls, Lu_AD_H23, Lu_AD_358
60	101192	L20859	Hs.78452	solute carrier family 20 (phosphate tran	2.35	PC3_cells, CALU6_cells, MB-MDA-435s
		W16686	Hs.171825	basic helix-loop-helix domain containing	2.35	A549_cells, DU145_cells, HT29_cells
		AA446949		ESTs	2.35	LNCaP_cells, PC3_cells, DU145_cells
			Hs.23131		2.35	MB-MDA-435s, A549_cells, Lu_LC_H460
	109637			kinesin family member C3		PC3_cells, HS578T_cells, EB_cells
		M24486		procollagen-proline; 2-oxoglutarate 4-di	2.35	
65		H18335	Hs.31562		2.35	DU145_cells, MB231_cells, HMEC
	131050	X13967	Hs.2250	leukemia inhibitory factor (cholinergic	2.35	Lu_AD_H23, PC3_cells, PRSC_log
	130097	N21159		forkhead box O3A	2.34	EB_cells, LNCaP_cells, LNCaP_cells
	134533	AA013468		natural killer-tumor recognition seq	2.34	EB_cells, HT29_cells, HMEC
		D63479		diacylglycerol kinase; delta (130kD)	2.34	Lu_LC_H460, Caco2, DU145_cells
70					2.34	PC3_cells, EB_cells, OVCAR_cells
70		AA410894				
	129079		Hs.108502		2.34	Lu_AD_H23, Lu_SC_H69, Lu_AD_358
		AA608525			2.34	Lu_SC_H345, PC3_cells, MB-MDA-435s
			Hs.75879	ribosomal protein L19	2.34	BT474_cells, Lu_LC_H460, Lu_AD_H23
		N46435		ESTs	2.34	Lu_SC_H69, HT29_cells, MB-MDA-435s
75		R05809	Hs.205481		2.34	Lu_AD_H23, PRSC_log, Lu_SQ_H520
		H18428		ESTs; Moderately similar to !!!! ALU SUB	2.34	Lu_SC_H69, Lu_SC_H345, LNCaP_cells
	. 20000					

	104857	AA043219	Hs.19058	ESTs	2.34	Lu_AD_H23, Lu_SC_H345, Lu_SC_H345
	109647	F04587	Hs.28241	ESTs	2.34	HS578T_cells, A549_cells, CALU6_cells
		H97817	Hs.183302		2.34	EB_cells, Fibroblasts 2, Lu_SC_H69
		R58974	Hs.167343		2.34	EB_ceils, Lu_SC_H345, HT29_ceils
5		T95745	Hs.187433	_ `	2.34	
,						MB-MDA-435s, MB-MDA-453, Lu_SC_H345
		W56804		AFG3 (ATPase family gene 3; yeast)-like	2.34	OVCAR_cells, Fibroblasts 2, MB-MDA-435s
		M29536	Hs.12163	eukaryotic translation initiation factor	2.34	EB_cells, Cacc2, DU145_cells
	125921	AA775029	Hs.122591	ESTs	2.33	293T_cells, PRSC_log, Lu_SC_H345
	125775	AA213555	Hs.29205	alpha integrin binding protein 63	2.33	EB_cells, DU145_cells, LNCaP_cells
10		AA126917		ESTs	2.33	Lu_AD_H23, Lu_AD_358, Lu_LC_H460
				nuclear pore complex interacting protein	2.33	LNCaP_cells, Lu_SC_H69, DU145_cells
		AA234916			2.33	MB231_cells, Lu_SC_H345, Lu_SC_H69
		R02207	Hs.92679	ESTs; Weakly similar to microtubule-base	2.33	LNCaP_cells, BT474_cells, MCF7
	108456	AA079326			2.33	HT29_cells, Lu_AD_H23, RPWE_2
15	130552	M86667	Hs.179662	nucleosome assembly protein 1-like 1	2.33	EB_cells, A549_cells, DU145_cells
	111114	N63391	Hs.9238	ESTs	2.33	Cacc2, EB_cells, MB-MDA-453
		AI269498		ESTs; Moderately similar to TADA1 protei	2.33	CALU6_cells, 293T_cells, PC3_cells
				H sapiens mRNA from chromosome 5q21-22;		OVCAR_cells, Cacc2, LNCaP_cells
20		AA446110			2.33	BT474_cells, Fibroblasts 2, MB-MDA-435s
20		D84294		tetratricopeptide repeat domain 3	2.33	Lu_SC_H345, EB_cells, EB_cells
		AA449099		ESTs; Weakly similar to atopy related au	2.33	EB_cells, LNCaP_cells, Cacc2
	105297	AA233451	Hs.183858	transcriptional intermediary factor 1	2.33	EB_cells, LNCaP_cells, Cacc2
		AA447442		ESTs	2.33	EB_cells, 293T_cells, Lu_SC_H69
		AA351031		solute carrier family 22 (organic anion	2.33	EB_cells, Lu_AD_H23, Lu_SC_H345
25		W04550	Hs.9927	H sapiens mRNA; cDNA DKFZp564D156 (fro		2.32 OVCAR_cells, EB_cells, Lu_SC_H69
23						
		H68772	Hs.35820	ESTs; Weakly similar to b34l8.1 [H.sapie	2.32	Lu_SC_H345, Lu_AD_H23, PRSC_con
		U26312	Hs.8123	chromobox homolog 3 (Drosophila HP1 gamn		CALU6_cells, LNCaP_cells, A549_cells
	114777	AA151699	Hs.184519	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.32	HT29_cells, Fibroblasts 2, Lu_SC_H345
	125518	R20148	Hs.193851	ESTs	2.32	HT29_cells, HMEC (total RNA), MB231_cells
30	130814	AA256695			2.32	MB-MDA-435s, Lu_SC_H69, PRSC_log
-		AA599143		ESTs; Moderately similar to !!!! ALU SUB	2.32	LNCaP_cells, DU145_cells, Lu_SC_H345
		AA313414	Ho 0140	H sapiens clone 24856 mRNA seq; complete		
						PC3_cells, LNCaP_cells, OVCAR_cells
		R85375	Hs.237262		2.32	Lu_SC_H69, PRSC_log, PRSC_con
2.5	114391	AA004876	Hs.133100	ESTs	2.32	PC3_cells, 293T_cells, 293T_cells
35	119133	R49144	Hs.119756	ESTs	2.32	PRSC_log, 293T_cells, 293T_cells
	109710	F09792	Hs.12929	ESTs	2.32	Lu_AD_H23, Lu_SC_H69, Lu_SC_H345
		F13681	Hs.42309	ESTs	2.32	MCF7, BT474_cells, MB-MDA-453
		R32993	Hs.6762	ESTs; Weakly similar to similar to leucy	2.31	DU145_cells, 293T_cells, EB_cells
		AA125988			2.31	Lu_SC_H345, LNCaP_cells, DU145_cells
40						
40		N68836	Hs.19247	ESTs	2.31	OVCAR_cells, LNCaP_cells, 293T_cells
		H29565	Hs.12271	ESTs	2.31	BT474_cells, MB231_cells, MB-MDA-453
	103772	AA092473	Hs.8123	chromobox homolog 3 (Drosophila HP1 gamm	12.31	CALU6_celis, MCF7, DU145_cells
	122766	AA459386	Hs.194058	ESTs; Weakly similar to atypical PKC spe	2.31	HT29_cells, BT474_cells, HMEC
	120886	AA365566	Hs.132736	ESTs; Weakly similar to allograft inflam	2.31	DU145_cells, A549_cells, Lu_LC_H460
45				HERV-H LTR-associating 3	2.31	PC3_cells, 293T_cells, DU145_cells
		AA460239			2.31	
			ris. 12000	_		HS578T_cells, MB231_cells, Lu_SQ_H520
	127359			KIAA0277 gene product	2.31	Lu_SC_H345, DU145_cells, OVCAR_cells
		AA402494	Hs.3990	ESTs	2.31	HS578T_cells, DU145_cells, LNCaP_cells
	125241	W86291	Hs.121593	ESTs	2.3	HMEC, HMEC (total RNA), EB_cells
50	104624	AA001936	Hs.184721	ESTs	2.3	DU145_œlls, PC3_œlls, PRSC_log
	128765	AA101767	Hs.10494	ESTs	2.3	EB_cells, HMEC (total RNA), Lu_LC_H460
		AA071539		zm74b6.s1 Stratagene neuroepithelium (#9		
	100000	701071000		HYDROXYSTEROID DEHYDROGENASE/DE	TA E DEI	2.3 HT29_cells, RPWE_2, Lu_AD_H23
	445000	A A 440200	Un 44C40			
55		AA410300		ESTS	2.3	HT29_cells, Lu_SQ_H520, Lu_AD_H23
33					2.3	EB_cells, CALU6_cells, A549_cells
	111091			H sapiens mRNA; cDNA DKFZp434N185 (fror	n	2.3 LNCaP_cells, DU145_cells, PRSC_log
	134044	AA262475	Hs.78746	phosphodiesterase 8A	2.29	DU145_cells, A549_cells, MCF7
	118229	N62339	Hs.180532	heat shock 90kD protein 1; alpha	2.29	MCF7, DU145_cells, EB_cells
•	110188		Hs.20969		2.29	Fibroblasts 2, MB-MDA-435s, Lu_LC_H460
60	125073				2.29	EB_cells, Lu_SC_H345, Lu_SC_H69
00			Hs.19913		2.29	
						CALU6_cells, EB_cells, MCF7
	124024		Hs.106672		2.29	HS578T_cells, RPWE_2, Lu_AD_358
		AA984074			2.29	LNCaP_cells, DU145_cells, OVCAR_cells
	125471	AA477571	Hs.152601	UDP-glucose ceramide glucosyltransferase	2.29	DU145_cells, PRSC_con, PRSC_log
65	120734	AA299949		EST12545 Uterus tumor I H sapiens cDNA 3	2.28	Lu_AD_H23, Lu_SC_H345, Lu_SC_H69
		AA406373	Hs.8208		2.28	DU145_cells, PC3_cells, LNCaP_cells
		AA521443			2.28	BT474_cells, BT474_cells, Lu_SC_H69
		AA489042			2.28	EB_cells, 293T_cells, MB-MDA-453
70	104476				2.28	LNCaP_cells, MCF7, PC3_cells
70	101004				2.28	HT29_cells, MB-MDA-435s, HMEC (total RNA)
	109991				2.28	EB_cells, CALU6_cells, 293T_cells
	118934	N92571	Hs.54808	ESTs	2.28	HS578T_cells, 293T_cells, A549_cells
	125096		Hs.194533		2.28	Lu_SC_H345, Lu_SC_H69, 293T_cells
	117514		Hs.124058		2.28	CALU6_cells, HMEC, Lu_AD_H23
75					2.28	OVCAR_cells, Lu_SC_H69, MCF7
, ,						
	123003	AA131421	⊓S. IU/884	E018	2.28	HS578T_cells, CALU6_cells, Cacc2

	111658	R16981	Hs.15276	ESTs	2.28	MB-MDA-435s, 293T_cells, A549_cells
		R55757	Hs.26457	EST	2.28	Lu_SC_H345, Lu_SC_H69, Lu_AD_358
		W69310	Hs.740	PTK2 protein tyrosine kinase 2	2.28	EB_cells, PC3_cells, DU145_cells
		T10822	Hs.4095	ESTs	2.28	LNCaP_cells, EB_cells, PC3_cells
5		AA256524		Human DNA seq from clone 30M3 on chromo		
				yeast and archaea bacterial genes; and	2.27	A549_cells, EB_cells, LNCaP_cells
	102130	U15009	Hs.1575	small nuclear ribonucleoprotein D3 polyp	2.27	LNCaP_cells, Cacc2, EB_cells
		Z41424	Hs.21259	ESTs	2.27	HT29_cells, OVCAR_cells, Fibroblasts 2
10		AA476436		ESTs	2.27	Lu_AD_358, RPWE_2, Lu_AD_H23
10		T71021	Hs.93334		2.27	Lu_SC_H69, 293T_cells, DU145_cells
				kinesin family member 3B	2.27	OVCAR_cells, LNCaP_cells, EB_cells
		L13738 W69468		activated p21cdc42Hs kinase	2.27 2.27	MB-MDA-453, DU145_cells, DU145_cells PC3_cells, HT29_cells, A549_cells
		AA150199	Hs.47622	ESTs DKFZP586D0919 protein	2.27	EB_cells, HS578T_cells, Lu_AD_358
15		Y08614	Hs.79090	exportin 1 (CRM1; yeast; homolog)	2.26	EB_cells, CALU6_cells, DU145_cells
10			Hs.220687		2.26	EB_cells, Lu_AD_H23, Lu_AD_358
		W84704	Hs.35380		2.26	HS578T_cells, OVCAR_cells, MB-MDA-435s
	107093	AA609600	Hs.10018		2.26	LNCaP_cells, OVCAR_cells, DU145_cells
		T95641	Hs.16400	ESTs; Weakly similar to Hrs [H.sapiens]	2.26	Lu_AD_H23, Lu_SC_H69, PRSC_log
20		AA227498		ESTs	2.26	HS578T_cells, 293T_cells, Lu_SC_H345
		H43286		gamma-aminobutyric acid (GABA) B recepto	2.26	Fibroblasts 2, MB231_cells, 293T_cells
		R37959	Hs.13358	ESTS	2.26	CALU6_cells, Lu_SQ_H520, 293T_cells
				ESTs; Weakly similar to CALPAIN 2; LARGE		HT29_cells, MB-MDA-453, PC3_cells
25		N74702 W67569	Hs.102834 Hs.44143		2.26 2.26	293T_cells, CALU6_cells, CALU6_cells 293T_cells, OVCAR_cells, Lu_SC_H345
25		AA470080		ESTs; Moderately similar to CGI-34 prote	2.26	LNCaP_cells, DU145_cells, MB-MDA-435s
		N22798	Hs.43248	EST Similar to octor prote	2.26	HT29_cells, BT474_cells, Fibroblasts 2
		X54942	Hs.83758	CDC28 protein kinase 2	2.26	DU145_cells, CALU6_cells, LNCaP_cells
		T99337	Hs.18624	KIAA1052 protein	2.26	Lu_AD_H23, Lu_SC_H345, Lu_SC_H69
30	128561	R69227	Hs.101489		2.26	Lu_SC_H345, DU145_cells, OVCAR_cells
	100670	HG2992-H		Beta-Hexosaminidase, Alpha Polypeptide,	2.26	HT29_cells, BT474_cells, Lu_SC_H345
		AA443958	Hs.90960	ESTs	2.26	Caco2, 293T_cells, DU145_cells
		H17476	Hs.11615	ESTs; Highly similar to map kinase phosp	2.25	CALU6_cells, LNCaP_cells, PC3_cells
25		N91973	Hs.23595	deoxyribonuclease III; dnaQ/mutD (E. col	2.25	Lu_SQ_H520, Lu_AD_H23, RPWE_2
35				interleukin 13 receptor; alpha 1	2.25	OVCAR_cells, 293T_cells, DU145_cells
			Hs.126705 Hs.79013		2.25 2.25	EB_cells, Lu_AD_H23, Lu_AD_H23 293T_cells, EB_cells, OVCAR_cells
		Z24724	Hs.4934	H.sapiens polyA site DNA	2.25	EB_cells, HS578T_cells, Caco2
		AA131328	113.7307	zo8d1.s1 Stratagene neuroepithelium NT2R	2.20	25_0015, 1100701_0015, 04002
40		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		SW:COX2_MOUSE P45 CYTOCHROME C C	XIDASE P	2.25 MB-MDA-435s, HT29_cells, Lu_SC_H69
	129499	R40395	Hs.242908	lecithin-cholesterol acyttransferase	2.25	HMEC (total RNA), Fibroblasts 2, HMEC
	124758	R38422	Hs.169168	ESTs	2.25	293T_cells, RPWE_2, Lu_LC_H460
	130301		Hs.172471	potassium voltage-gated channel; shaker-	2.25	EB_cells, OVCAR_cells, A549_cells
4.5		R38334	Hs.24950	regulator of G-protein signalling 5	2.25	Lu_AD_H23, EB_cells, Lu_SC_H69
45			Hs.10600		2.25	LNCaP_cells, HMEC, EB_cells
		N72009	Hs.206710		2.24	Lu_SC_H345, DU145_cells, LNCaP_cells
	114172		Hs.02113	KIAA0717 protein ESTs; Weakly similar to cysteine desulfu	2.24 2.24	EB_cells, Lu_AD_H23, Lu_AD_358 293T_cells, CALU6_cells, Lu_SQ_H520
			Hs.126717		2.24	LNCaP_cells, DU145_cells, Lu_SC_H69
50			Hs.16727		2.24	Lu_SC_H345, MB-MDA-453, Lu_SC_H69
	105095	AA150088	Hs.27023	KIAA0917 protein	2.24	DU145_cells, LNCaP_cells, CALU6_cells
			Hs.191453		2.24	EB_cells, Lu_SC_H345, Lu_AD_H23
	121971	AA429667	Hs.120405	ESTs	2.24	Lu_AD_H23, 293T_cells, CALU6_cells
	114334		Hs.22941		2.24	DU145_cells, PC3_cells, EB_cells
55				SH2 domain protein 2A	2.24	Lu_LC_H460, MCF7, HMEC (total RNA)
		AA421761		ESTs	2.24	Fibroblasts 2, MB-MDA-435s, MB231_cells
		AA608546		ESTS	2.24	PC3_cells, LNCaP_cells, DU145_cells
	111154	AA489461	Hs.29169	H sapiens mRNA for KIAA0540 protein; par ESTs	2.24 2.24	BT474_cells, EB_cells, LNCaP_cells OVCAR_cells, MB-MDA-435s, HMEC
60		AA262881		ESTs; Weakly similar to alternatively sp	2.23	HS578T_cells, A549_cells, HMEC
00		AA404421		ESTs	2.23	EB_cells, LNCaP_cells, DU145_cells
				Homer; neuronal immediate early gene; 3	2.23	HS578T_cells, PC3_cells, RPWE_2
		AA458882		ESTs; Moderately similar to Lasp-1 prote	2.23	DU145_cells, MCF7, Lu_SC_H345
	132786	AA424545	Hs.56851	H sapiens mRNA expressed in placenta	2.23	EB_cells, Lu_AD_H23, Fibroblasts 2
65	107206		Hs.30767	ESTs	2.23	BT474_cells, Fibroblasts 2, MB-MDA-435s
	133708	R42172	Hs.75667	synaptophysin	2.23	Lu_SC_H345, CALU6_cells, Lu_SC_H69
		AA227567		target of myb1 (chicken) homolog	2.23	BT474_cells, MB231_cells, EB_cells
		AA157401		S-adenosylhomocysteine hydrolase-like 1	2.23	DU145_ceils, 293T_ceils, LNCaP_ceils
70	116934		Hs.39662	ESTS	2.23	CALU6_cells, Lu_SC_H345, Lu_LC_H460
70	133660	10/3/3		ym88e05.r1 Soares adult brain N2b4HB55Y IMAGE:166016 5', mRNA seq.	2.23	DU145_cells, A549_cells, PC3_cells
	119468	W23633	Hs.125043		2.23	293T_cells, MB-MDA-453, OVCAR_cells
	101247		Hs.78802	glycogen synthase kinase 3 beta	2.23	LNCaP_cells, EB_cells, MB-MDA-435s
		AA253460		zs06f04.s1 NCI_CGAP_GCB1 H sapiens cDN		2.23 HT29_cells, PRSC_log, Fibroblasts 2
75		AA477119		zu37c7.s1 Soares ovary tumor NbHOT H sap		
				TR:G288289 G288289 MITOCHONDRIAL D-	LOOP	2.23 PC3_cells, MCF7, MB-MDA-435s

	114148	Z38804	Hs.184777	ESTs; Moderately similar to OPIOID BINDI	2.23	HS578T_cells, Fibroblasts 2, Lu_SC_H345
	103433	V09004	Hs.78948	MOLECULE PRECURSOR [H.sapiens] Rab geranylgeranyltransferase; beta subu	2.22	LNCaP_cells, EB_cells, 293T_cells
			Hs.216194		2.22	EB_cells, Lu_AD_H23, Fibroblasts 2
5	133228		Hs.6831	H sapiens clone 1400 unknown protein mRN		293T_cells, PC3_cells, DU145_cells
,			Hs.124186	ring finger protein 2	2.22	EB_cells, Lu_SC_H69, Lu_SC_H345
	124883	R75630	Hs.177242		2.22	EB_cells, Lu_AD_H23, Lu_SC_H345
	109921		Hs.30559		2.22	Lu_SQ_H520, 293T_cells, RPWE_2
	127306	Al305162	Hs.193687	ESTs	2.22	MCF7, HT29_cells, MB-MDA-453
10		U77456	Hs.78103	nucleosome assembly protein 1-like 4	2.22	Caco2, EB_cells, CALU6_cells
			Hs.23272	ESTS	2.22	293T_cells, EB_cells, A549_cells Lu_SC_H345, Lu_SC_H69, DU145_cells
	118819		Hs.50800	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.22 2.22	HS578T_cells, PRSC_log, CALU6_cells
	112241	U16306	Hs.81800 Hs.16027	chondroitin sulfate proteoglycan 2 (vers	2.22	293T_cells, HMEC (total RNA), HMEC (total RNA)
15			Hs.112728		2.22	HT29_cells, HMEC (total RNA), BT474_cells
13				ribosomal protein S11	2.22	EB_cells, Lu_AD_H23, Lu_AD_358
	122481	AA448271	Hs.99126	ESTs	2.21	Lu_AD_H23, HT29_cells, Lu_AD_358
		R37753	Hs.106985	ESTs	2.21	EB_cells, Lu_AD_H23, Lu_SC_H345
••		R05835		ESTs; Weakly similar to B-CELL GROWTH F	A	2.21 EB_cells, Lu_AD_H23, Lu_AD_358
20		AA442853		cyclin-dependent kinase 5; regulatory su	2.21	HT29_cells, Lu_LC_H460, Lu_SC_H69 EB_cells, Lu_AD_H23, Lu_SC_H69
	128869	AA424570	Hs.106736	ESIS	2.21 2.21	MCF7, Lu_SC_H345, DU145_cells
				U4/U6-associated RNA splicing factor	2.21	EB_cells, Cacc2, DU145_cells
			Hs.161489 Hs.179680		2.2	EB_cells, Lu_AD_H23, Lu_SC_H69
25		AA255874		ESTs	2.2	LNCaP_cells, DU145_cells, PC3_cells
23		N93503	Hs.54961	stoned B/TFIIA-alpha/beta-like factor	2.2	293T_cells, HS578T_cells, OVCAR_cells
		AA346041		ESTs	2.2	HT29_cells, HS578T_cells, 293T_cells
		AA425382		ESTs	2.2	CALU6_œils, PC3_œils, EB_œils
		U14391	Hs.82251	myosin IC	2.2	A549_cells, EB_cells, Cacc2
30			Hs.87062		2.2	HT29_cells, Lu_LC_H460, CALU6_cells Lu_SC_H345, BT474_cells, Caco2
			Hs.112227		2.2 2.2	Lu_SQ_H520, Lu_AD_H23, Lu_AD_358
		T49325 AI041014	Hs.8977 Hs.220752	ESTS ESTe	2.2	EB_cells, Lu_AD_H23, Lu_AD_H23
	1203	ΔΔΩ47344	Hs 107213	ESTs; Highly similar to NY-REN-6 antigen	2.2	CALU6_œlis, A549_œlis, EB_œlis
35		AA411685		ESTs	2.2	OVCAR_cells, EB_cells, Cacc2
		AA431873		H sapiens clone 24711 mRNA seq	2.2	Lu_SQ_H520, EB_cells, PC3_cells
		T03593	Hs.182814	ESTs	2.19	A549_cells, OVCAR_cells, 293T_cells
	116902	H70739		yu69f11.s1 Weizmann Olfactory Epithelium	2.19	LNCaP_cells, DU145_cells, PC3_cells
40	405004	*****	U- C275	IMAGE:239085 3' similar to contains LTR		2.19 HMEC, Caco2, HMEC (total RNA)
40	100021	AA280865 R31652	Hs.821	H sapiens mRNA; cDNA DKFZp564K0222 (fi biglycan	2.19	Fibroblasts 2, Lu_SC_H69, HS578T_cells
	120991	R08234	Hs.180461	_ = = =	2.19	Lu_AD_358, Lu_AD_H23, Lu_SQ_H520
		AA082973	113.100401	zn7g1.s1 Stratagene hNT neuron (#937233)		
				to gb:M3672 6S RIBOSOMAL PROTEIN L7/	A (H	2.19 Lu_AD_358, RPWE_2, Lu_LC_H460
45		H09356	Hs.22528	ESTs	2.19	PRSC_log, Lu_SC_H345, Lu_SC_H69
		AA521354		ESTs	2.19	EB_cells, LNCaP_cells, OVCAR_cells EB_cells, Lu_AD_358, PRSC_con
		AA443919		ESTs	2.19 2.19	HT29_cells, Lu_SC_H69, Lu_AD_H23
		AI016490	Hs.81964 Hs.35096	SEC24 (S. cerevisiae) related gene famil ESTs	2.19	DU145_cells, Fibroblasts 2, PRSC_con
50		H97188 R11267	Hs 180570	H sapiens chromosome 19; cosmid F22329	2.19	293T_cells, MB-MDA-435s, A549_cells
50	104992	AA102652	Hs.22753	ESTs; Weakly similar to coded for by C.	2.18	MCF7, MB-MDA-453, Lu_SQ_H520
	119896	W84738	Hs.137319		2.18	293T_cells, 293T_cells, OVCAR_cells
		N69022	Hs.49599	ESTs	2.18	Lu_SC_H69, Lu_AD_H23, Lu_SC_H345
		H98977	Hs.246109	ESTs	2.18	293T_cells, 293T_cells, 293T_cells
55		D81608	Hs.150675	polymerase (RNA) II (DNA directed) polyp	2.18	PC3_cells, Lu_SC_H345, LNCaP_cells
	123022	AA480909		aa28f10.s1 NCI_CGAP_GCB1 H sapiens cD Alu repetitive element; contains element	2.18	OVCAR cells, DU145_cells, LNCaP_cells
	422572	W94333	Hs.7499	translocase of inner mitochondrial membr	2.18	Caco2, LNCaP_cells, Lu_SQ_H520
		AA479713		ESTs	2.18	EB_cells, Lu_AD_H23, Fibroblasts 2
60	135361	AA053319	Hs.167700		2.18	EB_cells, 293T_cells, Cacc2
	128319	AA808904	Hs.115095	ESTs; Weakly similar to RHO-RELATED GT	P-	2.18 Lu_SC_H345, OVCAR_cells,
	DU145_	cells			0.40	ER colle L., AD H22 L., CO H520
	128660	AA011597	Hs.177398	ESTS	2.18 2.18	EB_cells, Lu_AD_H23, Lu_SQ_H520 DU145_cells, 293T_cells, OVCAR_cells
65			Hs.205125	ESTs; Moderately similar to !!!! ALU SUB	2.18	Lu SC H69, Lu_SC_H345, HS578T_cells
05		H28737 T85105	Hs.15471	ESTs	2.18	EB_cells, Lu_AD_H23, Lu_SC_H69
		N31909	Hs.44278	ESTs	2.18	PRSC_con, Lu_SC_H345, PRSC_log
		F13608	Hs.26226	ESTs	2.18	293T_cells, LNCaP_cells, OVCAR_cells
	134499	U70370	Hs.84136	paired-like homeodomain transcription fa	2.18	Cacc2, BT474_cells, MB231_cells
70	128154	AA922969	Hs.127100	ESTs	2.17	MB-MDA-453, MB-MDA-453, Lu_SC_H345
		T48154		H sapiens mRNA for H-2K binding factor-2	2.17	LNCaP_cells, 293T_cells, PRSC_log EB_cells, MCF7, DU145_cells
		AA101723		ESTS	2.17 2.17	Caco2, LNCaP_cells, DU145_cells
		AA091017		ESTs X-ray repair complementing defective rep	2.17 2.17	HMEC (total RNA), Fibroblasts 2, HMEC
75	133311	M36089 T54613	Hs.98493 Hs.9761	EST	2.17	HT29_cells, PRSC_con, Lu_SQ_H520
, 5		N46999	Hs.46648	ESTs	2.16	PRSC_log, OVCAR_cells, A549_cells

					0.46	LNCaP cells, DU145_cells, 293T_cells
		W58461	Hs.12396	20.0	2.16	LNCaP_cells, MB-MDA-453, HMEC (total RNA)
	120187	Z40251			2.16	
	100308	D50532	Hs.54403	macrophage lectin 2 (calcium dependent)	2.16	HT29_cells, Lu_AD_H23, Lu_AD_H23
	110960	N50887	Hs.26549	ESTs; Weakly similar to KIAA0449 protein	2.16	Caco2, A549_cells, LNCaP_cells
5	113608	T93113		ESTs; Moderately similar to !!!! ALU SUB	2.16	Lu_SC_H69, CALU6_cells, 293T_cells
-	107538		Hs.50094	ESTs; Weakly similar to KALIRIN [R.norve	2.16	HS578T_cells, 293T_cells, DU145_cells
	128703			vav 2 oncogene	2.16	RPWE_2, Lu_SC_H69, HT29_cells
		AI366484		ESTs	2.16	293T_cells, CALU6_cells, A549_cells
	120000	A A A 65727	He 124084	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.16	DU145_cells, LNCaP_cells, OVCAR_cells
10			Hs.107283		2.16	EB_cells, 293T_cells, A549_cells
10			Hs.97792		2.16	Lu_AD_358, Lu_AD_H23, A549_cells
	121199	AA4003/1	Ha 4020EE	ECTA	2.16	DU145_cells, PRSC_con, LNCaP_cells
			Hs.193055	high-mobility group (nonhistone chromoso	2.15	CALU6_cells, MB-MDA-453, Cacc2
		D63874	MS. 189009	nigh-mobility group (nothinstone chronicso	2.15	Lu_AD_H23, Lu_SC_H69, Lu_SC_H345
1.5		T88822		yd32f5.s1 Soares fetal liver spleen 1NFL		293T_cells, Lu_SC_H345, Lu_SC_H69
15	117286	N22181		yw36d12.s1 Morton Fetal Cochlea H sapien	2.15	EB_cells, LNCaP_cells, HS578T_cells
	132876	AA130603	Hs.169683	ESTs; Moderately similar to !!!! ALU SUB	2.15	
			Hs.154737	serine protease; umbilical endothelium	2.15	DU145_cells, EB_cells, Cacc2
		AA169866		ESTs; Weakly similar to !!!! ALU SUBFAM!	2.15	DU145_cells, LNCaP_cells, OVCAR_cells
	106900	AA490142	Hs.6193	ESTs	2.15	Fibroblasts 2, Lu_AD_H23, PRSC_con
20	129398	AA437374	Hs.234573	H sapiens mRNA for TL132	2.15	MCF7, DU145_cells, LNCaP_cells
			Hs.165215	ESTs	2.15	Lu_AD_358, MB-MDA-453, HS578T_cells
		U56637	Hs.184270	capping protein (actin filament) muscle	2.15	LNCaP_cells, EB_cells, PC3_cells
		N80671	Hs.220255		2.14	EB_cells, DU145_cells, MCF7
			Hs.69606		2.14	293T_cells, Cacc2, Lu_SC_H69
25			Hs.251122		2.14	Lu_SC_H345, DU145_cells, MCF7
23		W73951	Hs.58348	ESTs; Weakly similar to CORNIFIN A [H.sa	2.14	293T_cells, HS578T_cells, CALU6_cells
				ESTs	2.14	A549_cells, HMEC (total RNA), EB_cells
		AA227926		ribosomal protein S17	2.14	293T_cells, CALU6_cells, HMEC (total RNA)
	129242	W81679	Hs.5174		2.14	A549_cells, HT29_cells, Lu_SQ_H520
20	132348	AAU3/285	HS.1/U311	heterogeneous nuclear ribonucleoprotein	2.14	293T_cells, HS578T_cells, PRSC_con
30			Hs.132812			DU145_cells, LNCaP_cells, EB_cells
	127759	AI369384		arylsulfatase D	2.14	
	134069	U29607	Hs.78935	methionine aminopeptidase; eIF-2-associa	2.14	Lu_SC_H345, DU145_cells, MCF7
	116158	AA461187	Hs.61762	ESTs	2.14	Lu_SC_H69, MCF7, MB-MDA-453
		R35166	Hs.14881	ESTs	2.14	HT29_cells, Fibroblasts 2, BT474_cells
35	118684	N71364	Hs.109510	ESTs	2.14	OVCAR_cells, PRSC_con, HS578T_cells
		T97977	Hs.60260	ESTs	2.14	Lu_AD_H23, Lu_SQ_H520, Lu_SQ_H520
		N67515	Hs.6479	ESTs; Weakly similar to KIAA0872 protein	2.14	EB_cells, Lu_AD_H23, Lu_AD_358
		R45445	Hs 252723	H sapiens mRNA; cDNA DKFZp434D115 (fro	m	2.13 Lu_AD_H23, Lu_AD_358, BT474_cells
	114894	AA236019	Hs.188803	ESTs	2.13	MB-MDA-453, MCF7, Lu_SQ_H520
40		H08773		yl94d5.s1 Soares infant brain 1NIB H sap	2.13	Lu_SC_H69, Fibroblasts 2, HMEC (total RNA)
70		R39191	He 100445	KIAA1020 protein	2.13	Caco2, 293T_cells, Lu_SC_H69
			Hs.14158		2.13	LNCaP_cells, PC3_cells, HS578T_cells
		W86835			2.13	Lu_SC_H345, Lu_SC_H69, Lu_LC_H460
			Hs.86045		2.13	HS578T_cells, CALU6_cells, PRSC_con
45		N24581	Hs.43230	ESTs	2.13	LNCaP_cells, Cacc2, EB_cells
45			Hs.94491	H sapiens clone 23585 mRNA seq	2.13	EB_cells, Lu_AD_H23, Lu_SC_H69
		R96478	Hs.16586	ESTs	2.13	EB_cells, Lu_SC_H345, OVCAR_cells
			Hs.41371	ESTs		EB_cells, PRSC_con, LNCaP_cells
		T49891		tumor protein; translationally-controlle	2.13	
			Hs.74615	platelet-derived growth factor receptor;	2.13	EB_cells, Lu_AD_H23, Lu_SC_H69
50	124270	H79560	Hs.107840	ESTs	2.13	OVCAR_cells, 293T_cells, 293T_cells
	133766	D52420	Hs.184326	cell division cycle 10 (homologous to CD	2.12	CALU6_cells, DU145_cells, PC3_cells
	109248	AA194720	Hs.189996	ESTs; Highly similar to sec61 homolog [H	2.12	HT29_cells, MB231_cells, HMEC (total RNA)
	106724	AA465226	Hs.28631	ESTs	2.12	EB_cells, 293T_cells, DU145_cells
		HG2264-H		Atpase, Ca2+Transporting, Plasma Membra	2.12	EB_cells, Lu_AD_H23, Lu_SC_H69
55			Hs.178518		2.12	OVCAR_cells, PC3_cells, 293T_cells
55		H94650	Hs.108002		2.12	MB-MDA-453, Lu_SC_H345, HT29_cells
		T26925	He 172684	vesicle-associated membrane protein 8 (e	2.12	MB-MDA-453, PC3_cells, LNCaP_cells
	442044	TC2242	He 226126	ESTs; Moderately similar to !!!! ALU SUB	2.12	HMEC (total RNA), BT474_cells, HMEC
	113241	T63313			2.12	HT29_cells, PC3_cells, A549_cells
60		R40782	Hs.21296		2.12	PC3_cells, EB_cells, LNCaP_cells
60	113965	W86519	Hs.19631	E018	2.12	EB_cells, OVCAR_cells, 293T_cells
			Hs.62663		2.12	Fibroblasts 2, MB-MDA-453, PRSC_con
		H63994	Hs.221134			DU145_œlis, EB_œlis, Caco2
			Hs.31257	ESIS	2.12	PRSC_log, Lu_SC_H69, Lu_SC_H345
		W44798	Hs.55876	ESTs	2.12	HS578T_cells, LNCaP_cells, OVCAR_cells
65		R63068	Hs.159793	EST	2.11	H55/61_Cells, LINCAF_Cells, OVCAT_Cells
	122731	AA457549		aa92b1.s1 Stratagene fetal retina 93722		A 44 NO MON ASS DOME S MCET
				gb:X5275_ma3 LEUKOSIALIN PRECURSO		2.11 MB-MDA-453, RPWE_2, MCF7
	115348	AA281562	Hs.88860	ESTs	2.11	EB_cells, Lu_AD_H23, Fibroblasts 2
	128873	AA226768	Hs.109463	ESTs; Weakly similar to predicted using	2.11	MB-MDA-435s, EB_cells, LNCaP_cells
70		T54301	Hs.75844		2.11	EB_cells, CALU6_cells, DU145_cells
, 0		U11870	Hs 194778	interleukin 8 receptor, alpha	2.11	Lu_AD_358, PC3_cells, PRSC_con
		H05787	Hs.12064	ubiquitin specific protease 22	2.11	EB_cells, LNCaP_cells, Caco2
	100040	ANDREEN	Hs.31930		2.1	Fibroblasts 2, HS578T_cells, MB-MDA-435s
				ESTS .	2.1	Lu_SC_H69, PRSC_log, Lu_SC_H345
75	1115/6	R10334	Hs.15489	ESTs; Weakly similar to weak similarity .	2.1	HT29_cells, MB231_cells, Lu_SC_H69
75	1042/5	C02170	Hs.39387	pregnancy specific beta-1-glycoprotein 9	2.1	HT29_cells, HMEC, RPWE_2
	11/803	N48620	Hs.28483	programicy specific beta-1-glycoprotein s		

		400705	44457407	450004			
			AA45/40/ AA398233		transmembrane protease; serine 2 KIAA0108 gene product	2.1 2.1	Lu_SC_ Fibrobla
			AA403305		ESTs; Weakly similar to myosin phosphata	2.1	LNCaP
	5		N64706	Hs.137282		2.1	Lu_SC_
	5	103079	Z86000		Human DNA seq from PAC 151B14 on chror receptor subtype 3 (SSTR3), tRNA, ESTs,	поs 2.1	CALU6
		130303	L40392	Hs.180789	H sapiens (done S164) mRNA; 3' end of c	2.1	PC3_ce
			AA461080			2.1	HT29_0
1	0		AA279439		ESTs; Weakly similar to misato [D.melano	2.1	EB_œll
	U		R69088 F10720	Hs.28728 Hs.180804		2.1 2.1	HT29_c HS5781
			H40359	Hs.177256		2.09	MCF7,
			H17490	Hs.7905	ESTs; Highly similar to sorting nexin 9	2.09	EB_cell
1	5		AF006082		ARP2 (actin-related protein 2; yeast) ho	2.09	EB_cell
ī	5		AA398343 W93299	Hs.94943 Hs.59363	ESTs; Weakly similar to cytokeratin 20 [	2.09 2.09	Lu_SC_ HMEC (
			AA491208		ESTs	2.09	EB_cell
			AA243768	Hs.4232	ESTs; Highly similar to match to ESTs Z4	2.09	LNCaP_
2	0		D80354	Hs.256321		2.09	LNCaP_
	·U		AA593973 U30999	Hs.232217 Hs.10247	ESTs; Weakly similar to !!!! ALU SUBFAMI activated leucocyte cell adhesion molecu	2.09 2.09	MB231_ PC3_œ
			T96077	Hs.17738	EST	2.09	Lu_AD_
			L19779	Hs.795	H2A histone family; member O	2.09	LNCaP
_	_		R49025	Hs.22996	ESTs	2.09	Lu_AD_
2	5		AA252360		ESTs	2.08	BT474_
			F04432 F02475	Hs.17904 Hs.26370	ESTs ESTs	2.08 2.08	EB_cell: Lu_AD_
			U68142		RAB2; member RAS oncogene family-like	2.08	LNCaP_
_	^			Hs.251962	ESTs	2.08	HS578T
3	0		F10904		H sapiens clone 23605 mRNA seq	2.08	Lu_SC_
			T66813 W95068	Hs.12947 Hs.59621	EST ESTs	2.08 2.08	EB_cells HS578T
			U08471	Hs.352	folate receptor 3 (gamma)	2.08	EB_cells
_	_		AA121993		zm24d11.s1 Stratagene pancreas (#93728)		<b>_</b>
3	5	404450			similar to gb:Y433 GLUTATHIONE PEROXIE		2.08
			X70683 AA232836	Hs.83484 Hs.87363	SRY (sex determining region Y)-box 4 ESTs	2.08 2.08	EB_cells HT29_c
				Hs.16930	ESTs	2.08	DU145_
	_		T96148	Hs.17762	ESTs	2.08	EB_cells
4	U			Hs.104223		2.08	293T_cc
				Hs.181012 Hs.146090	double-stranded RNA-binding zinc finger	2.08 2.08	293T_œ Lu_SC_
			N74210	Hs.50454		2.08	Lu_SC_ Lu_AD_
	_	112399	R60920	Hs.26419	H sapiens clone 24510 mRNA seq	2.08	EB_cells
4	5				ESTs; Moderately similar to !!!! ALU SUB	2.08	DU145_
			AA600054 Z40583	Hs.65302 Hs.101259		2.08 2.08	HT29_a HMEC,
				Hs.15396		2.08	Ca∞2,
_	_		T95280		trinucleotide repeat containing 1	2.08	EB_cells
5	0		AA437378		ESTs	2.08	Lu_SC_
			AA429804 H71420	Hs.229675		2.08	HS578T
		110903	H/ 1420		ys8c12.s1 Soares fetal liver spleen 1NFL 3' similar to contains Alu repetitive e	2.08	Lu_AD_
		106703	AA463979	Hs.21264	KIAA0782 protein	2.08	EB_cells
5	5		AA427858		EST	2.07	293T_œ
		135119		Hs.94769	ESTs; Moderately similar to RAS-RELATED	2.07	HS578T
		103558 124209		Hs.2785 Hs.193433	keratin 17	2.07 2.07	RPWE_: Fibrobla
			AA045083		gamma-glutamyl carboxylase	2.07	Fibrobla
6	0	116246	AA479961	Hs.42913	ESTs; Highly similar to ubiquitin-conjug	2.07	EB_cells
				Hs.105308		2.07	Lu_AD_I
		12/3/8	AA452696		zx39b05.r1 Soares_total_fetus_Nb2HF8_9w to contains Alu repetitive element;cont	2.07	HS578T
		110464	H53013	Hs.221901		2.07	Fibrobla
6	5	135191			cytochrome P450; subfamily IID (debrisoq		
					polypeptide 7a (pseudogene)	2.07	Lu_AD_I
		101267		Hs.75339	inositol polyphosphate phosphatase-like	2.07	Lu_SC_I
		125366	AA191495 H60192	Hs.189937 Hs.76853	ESTs; Weakly similar to human homolog of	2.07 2.07	Lu_SC_I DU145_
7	0	117472		Hs.93738	DKFZP434M098 protein	2.07	EB_cells
•		114235	Z39710	Hs.25341	ESTs	2.07	DU145_0
			AA165268		ESTs	2.07	Lu_SC_I
		112596	R78212 AA194940	Hs.163705 Hs.85956	ESTs ESTs; Weakly similar to line-1 protein O	2.07 2.07	MB-MDA HS578T
7:	5		AA401144		ESTs; Weakly similar to line-1 protein O	2.07	EB_cells
•			AA488691		phenylalanine-tRNA synthetase	2.06	Lu_AD_I
					-		_ <del>_</del>

Lu\_SC\_H69, Lu\_LC\_H460, Lu\_SC\_H345 Fibroblasts 2, PRSC\_con, MCF7 LNCaP\_cells, MCF7, OVCAR\_cells Lu\_SC\_H345, HT29\_cells, HMEC

6\_cells, A549\_cells, Lu\_SC\_H345 cells, DU145\_cells, LNCaP\_cells cells, BT474\_cells, MB231\_cells ells, Lu\_SC\_H345, LNCaP\_cells cells, BT474\_cells, MB231\_cells BT\_cells, HT29\_cells, HT29\_cells A549\_cells, MB-MDA-435s ells, Fibroblasts 2, HS578T\_cells ells, HS578T\_cells, A549\_cells \_H345, PC3\_cells, LNCaP\_cells (total RNA), HS578T\_cells, HS578T\_cells ells, Lu\_AD\_H23, Lu\_SC\_H69 P\_cells, Lu\_AD\_H23, MB-MDA-453 P\_cells, DU145\_cells, RPWE\_2 \_cells, HT29\_cells, HMEC zelis, HS578T\_cells, DU145\_cells \_H23, Lu\_AD\_H23, Lu\_SQ\_H520 P\_cells, MCF7, OVCAR\_cells )\_H23, Lu\_AD\_358, Lu\_SC\_H69 \_cells, MB231\_cells, HT29\_cells lls, DU145\_cells, PC3\_cells \_H23, Lu\_SQ\_H520, Lu\_LC\_H460 \_cells, MB-MDA-453, EB\_cells T\_cells, Fibroblasts 2, Lu\_SC\_H69 \_H345, OVCAR\_cells, DU145\_cells ils, Lu\_SC\_H69, Lu\_AD\_H23 T\_cells, A549\_cells, CALU6\_cells lls, Lu\_AD\_H23, Lu\_AD\_358

Lu\_SQ\_H520, HT29\_cells, BT474\_cells lls, Lu\_SC\_H345, Lu\_SC\_H69 cells, 293T\_cells, 293T\_cells \_cells, MB-MDA-435s, HS578T\_cells ils, Lu\_SQ\_H520, Fibroblasts 2 cells, CALU6\_cells, A549\_cells cells, PC3\_cells, OVCAR\_cells \_H69, Lu\_SC\_H345, RPWE\_2 \_H23, Lu\_SC\_H69, Lu\_SC\_H345 lls, Lu\_AD\_H23, Lu\_SC\_H69 \_cells, EB\_cells, HS578T\_cells cells, BT474\_cells, Lu\_AD\_H23 HMEC (total RNA), EB\_cells HT29\_cells, LNCaP\_cells lis, Lu\_AD\_H23, Lu\_SC\_H69 \_H345, Lu\_AD\_H23, Lu\_AD\_358 T\_cells, 293T\_cells, OVCAR\_cells

Lu\_AD\_H23, EB\_cells, PRSC\_con EB\_cells, Caco2, PRSC\_con 293T\_cells, Lu\_SC\_H345, CALU6\_cells HS578T\_cells, PRSC\_con, OVCAR\_cells RPWE\_2, HMEC (total RNA), HMEC Fibroblasts 2, OVCAR\_cells, 293T\_cells Fibroblasts 2, MB-MDA-453, PRSC\_con EB\_cells, LNCaP\_cells, LNCaP\_cells Lu\_AD\_H23, Lu\_SC\_H69, Lu\_SC\_H345

HS578T\_cells, LNCaP\_cells, EB\_cells Fibroblasts 2, Lu\_SQ\_H520, Lu\_SQ\_H520

Lu\_AD\_H23, Lu\_SC\_H69, Lu\_AD\_358
Lu\_SC\_H345, OVCAR\_cells, Cacc2
Lu\_SC\_H69, Lu\_AD\_H23, Lu\_SC\_H345
DU145\_cells, Lu\_LC\_H460, Lu\_AD\_358
EB\_cells, Lu\_SC\_H69, 293T\_cells
DU145\_cells, BT474\_cells, Lu\_SC\_H69
Lu\_SC\_H69, Lu\_SC\_H345, PC3\_cells
MB-MDA-435s, Lu\_SQ\_H520, MB-MDA-453
HS578T\_cells, 293T\_cells, OVCAR\_cells
EB\_cells, 293T\_cells, PRSC\_con
Lu\_AD\_H23, Lu\_SC\_H345, PRSC\_log

	122529	AA449828	Hs 99229	ESTs	2.06	DU145_cells, HS578T_cells, 293T_cells
		R99199		transducin-like enhancer of split 2; hom	2.06	MB-MDA-435s, 293T_cells, 293T_cells
				ESTs; Weakly similar to KIAA0734 protein	2.06	MB231_œlis, HT29_œlis, Lu_AD_358
		AA488414				
5				domain (RLD) 1	2.06	DU145_cells, CALU6_cells, PC3_cells
		AI073373	Hs.183275		2.06	LNCaP_cells, EB_cells, DU145_cells
		N80749		ESTs; Weakly similar to predicted using	2.06	CALU6_cells, PRSC_log, OVCAR_cells
		R77869	Hs.28506		2.06 2.06	EB_cells, BT474_cells, Lu_AD_H23 Lu_SQ_H520, Fibroblasts 2, EB_cells
10		AA252028 T67231	Hs.39168	ESTs succinate dehydrogenase complex; subunit	2.06	Caco2, LNCaP_cells, EB_cells
10		L35545	Hs.82353	endothelial cell protein C/activated pro	2.06	EB_cells, RPWE_2, DU145_cells
		AA281951		H sapiens mRNA; cDNA DKFZp566J2146 (fro		2.06 OVCAR_cells, LNCaP_cells, DU145_cells
		N26536		ATPase; Cu++ transporting; beta polypept	2.06	Cacc2, Cacc2, 293T_cells
	103967	AA303711	Hs.144700	ephrin-B1	2.06	HT29_cells, HMEC (total RNA), HMEC
15		T92935		ESTs; Highly similar to nucleolar protei	2.06	HMEC, EB_cells, HMEC (total RNA)
		R66080	Hs.191268	H sapiens mRNA; cDNA DKFZp434N174 (fro	m	2.06 LNCaP_cells, DU145_cells, OVCAR_cells
		M93405		methylmalonate-semialdehyde dehydrogenas		LNCaP_cells, MB-MDA-453, EB_cells
		T24024	Hs.7387	DKFZP564B116 protein	2.05	EB_cells, A549_cells, A549_cells MCF7, HS578T_cells, PRSC_con
20		R72632 AA583825	Hs.29282 Hs.235860		2.05 2.05	MB231_cells, HT29_cells, Fibroblasts 2
20		M57763		ADP-ribosylation factor 6	2.05	DU145_œils, LNCaP_œils, PC3_œils
		W51835	Hs.231082	•	2.05	EB_cells, Fibroblasts 2, Lu_AD_H23
		AA425943		acyl-Coenzyme A dehydrogenase; very long	2.05	OVCAR_cells, PC3_cells, EB_cells
		AA236796		follistatin	2.05	HMEC (total RNA), PC3_cells, HMEC
25	105267	AA227956	Hs.25348	follistatin-like 3 (secreted glycoprotei	2.05	HMEC, RPWE_2, HMEC (total RNA)
				ESTs; Weakly similar to CGI-128 protein	2.05	EB_cells, CALU6_cells, A549_cells
		AA417012		ESTs	2.05	HS578T_cells, EB_cells, Lu_SC_H345
		R72637	Hs.26343		2.05	EB_cells, Lu_SC_H69, Lu_AD_H23 Lu_AD_H23, Lu_SC_H69, BT474_cells
30		R08260	Hs.20131		2.05 2.05	HT29_cells, Lu_AD_H23, Lu_SC_H345
30		T79840	Hs.111798	H sapiens mRNA; cDNA DKFZp564M0264 (fr		2.05 DU145_cells, CALU6_cells, PC3_cells
		AA449789			2.05	HS578T_cells, PRSC_log, PRSC_con
		AA740921		heat shock 10kD protein 1 (chaperonin 10	2.05	DU145_cells, LNCaP_cells, OVCAR_cells
		AA196287		ESTs; Moderately similar to !!!! ALU SUB	2.05	EB_cells, MB-MDA-453, Fibroblasts 2
35	120683	AA290987	Hs.49657	ESTs; Weakly similar to contains similar	2.04	Lu_AD_358, Lu_SQ_H520, Lu_LC_H460
		X60655	Hs.99967	even-skipped homeo box 1 (homolog of Dro	2.04	Lu_AD_H23, RPWE_2, Lu_SQ_H520
				DKFZP434A033 protein	2.04	293T_cells, HS578T_cells, LNCaP_cells
		M97287	Hs.74592	special AT-rich seq binding protein 1 (b	2.04	EB_cells, Lu_SC_H69, 293T_cells  BBSC_con_HT29_cells_MB231_cells
40		M22490	Hs.68879	bone morphogenetic protein 4	2.04 2.04	PRSC_con, HT29_cells, MB231_cells 293T_cells, MB-MDA-435s, Lu_SC_H69
40		T95005 W88946	Hs.209587 Hs.18508	putative glycine-N-acyttransferase	2.04	HT29_cells, Fibroblasts 2, MB-MDA-435s
		AA262417		ESTs	2.04	DU145_cells, OVCAR_cells, PC3_cells
		N63706	Hs.104573		2.04	Caco2, 293T_cells, DU145_cells
	123062	AA482069	Hs.100847	ESTs	2.04	Lu_AD_358, HT29_cells, HT29_cells
45		AA232857			2.04	DU145_cells, Lu_AD_H23, LNCaP_cells
		AA610116		tetraspan NET-6 protein	2.04	BT474_cells, Cacc2, LNCaP_cells
		AA935809			2.04	BT474_cells, MB-MDA-435s, MB-MDA-453
		R73427	Hs.235712		2.04 2.04	Cacc2, OVCAR_cells, MCF7 EB_cells, Lu_SC_H345, PRSC_con
50		T93263		ESTs; Weakly similar to hypothetical pro midline 1 (Opitz/BBB syndrome)	2.04	A549_cells, 293T_cells, Caco2
30		Z21124	N3.27 033	HSAAADNVE TEST1, Human adult Testis tiss		Fibroblasts 2, Fibroblasts 2, MCF7
		R00841	Hs.172069	DKFZP434C212 protein	2.04	HT29_cells, Lu_SQ_H520, BT474_cells
		T19477		A1426R Heart H sapiens cDNA clone A1426,	2.04	EB_cells, Lu_AD_H23, Lu_SC_H69
	125244	W86466	Hs.132756	ESTs; Weakly similar to KIAA0591 protein	2.04	EB_cells, Lu_AD_H23, Lu_LC_H460
55		M91036	Hs.242985	hemoglobin; gamma G	2.04	MB231_cells, Lu_AD_358, HT29_cells
		W38206	50700	Accession not listed in Genbank	2.04	BT474_cells, HT29_cells, Lu_AD_H23
				clock (mouse) homolog	2.04 2.04	PC3_cells, OVCAR_cells, PRSC_log 293T_cells, MB-MDA-435s, A549_cells
		AI337031	Hs.180195	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.04	EB_cells, Lu_AD_358, Lu_LC_H460
60		N45120	Hs.22305		2.03	Lu_AD_H23, RPWE_2, Lu_LC_H460
00		AA442742		ESTs: Weakly similar to !!!! ALU SUBFAMI	2.03	EB_cells, Fibroblasts 2, Lu_SC_H345
		D38024		Humn facioscapulohumeral muscular dystro	2.03	Lu_AD_H23, Lu_AD_358, Lu_SQ_H520
	120431	AA236884	Hs.247323	H sapiens mRNA for G4 protein (G4 gene;	2.03	Lu_SC_H69, EB_cells, Lu_SC_H345
	122449	AA447638	Hs.104977	ESTs	2.03	Lu_SC_H345, Lu_SC_H345, Lu_SQ_H520
65		J00148		Accession not listed in Genbank	2.03	HT29_cells, BT474_cells, HMEC
		W86389	Hs.21122	ESTs; Moderately similar to KIAA0438 [H.	2.03	293T_cells, Lu_SC_H345, OVCAR_cells
		U67849	Un 422440	Human beta-galactoside alpha2,6-sialyttr	2.03 2.03	HT29_cells, 293T_cells, Lu_SC_H345 EB_cells, Lu_SC_H345, Lu_SC_H69
		AA398510			2.03	Lu_SQ_H520, Lu_SC_H345, Lu_SC_H69
70		AA190906 U62962		eukaryotic translation initiation factor	2.03	EB_cells, DU145_cells, MCF7
70		N51702	Hs.101392		2.03	HT29_cells, Fibroblasts 2, HMEC (total RNA)
		AA076672			2.03	Caco2, LNCaP_cells, EB_cells
	124164	H30667	Hs.7535	ESTs; Highly similar to COBW-like placen	2.03	CALU6_cells, CALU6_cells, A549_cells
				ESTs; Moderately similar to cAMP inducib	2.03	MB231_cells, BT474_cells, Fibroblasts 2
75	129683	W05348		DKFZP434B103 protein	2.03	HT29_cells, MB-MDA-435s, Lu_AD_H23
	105350	AA235737	HS.1865/1	ATPase; Na+/K+ transporting; alpha 3 pol	2.03	MB-MDA-453, Lu_SQ_H520, Lu_AD_358

				a di a coloria a lattatian factor	2.03
			Hs.14520	Calcal 1000 dalloration ambatter	2.03 2.03
			Hs.54673	millor ricorosis incon (name) coborrers	2.03 2.03
	119096	R41672	Hs.91471	Will and the Life brooking the games	
	133866	L36151	Hs.171625	priospriado y mitodior y rando e se y	2.03
5	132055	N69440	Hs.38132	LUIS	2.03
	125691	AI034361	Hs.135150		2.03
	121376	AA405699	Hs.166232	ESTs; Moderately similar to SODIUM- AND	0.00
			•	TRANSPORTER 2 [H.sapiens]	2.03
	105289	AA233178	Hs.103000	KIAA0831 protein	2.02
10	100967	J02621	Hs.251064	high-mobility group (nonhistone chromoso	2.02
		N38913	Hs.221575	ESTs	2.02
		Al306331	Hs.133296		2.02
		X91809	Hs.22698	G alpha interacting protein	2.02
		AA040923	Hs.92200	KIAA0480 gene product	2.02
15		AA001045	Hs.46783	ESTs	2.02
		AA233159	Hs.87131	ESTs	2.02
		R00144	Hs.189771	ESTs	2.02
		N32495	Hs.151560	ESTs	2.02
		AA257955		ESTs; Weakly similar to !!!! ALU CLASS C	2.02
20		N39306	Hs.20237	DKFZP566C134 protein	2.02
		AA486571	Hs.105696	ESTs; Moderately similar to !!!! ALU SUB	2.02
		N71704	Hs.4310	eukaryotic translation initiation factor	2.02
		R42362	Hs.91785	ESTs	2.02
		N92915	Hs.94631	brefeldin A-inhibited guanine nucleotide	2.02
25		T67261	Hs.154431		2.02
23		AA460273		KIAA0517 protein	2.02
		AA291970		KIAA0821 protein	2.01
		AA235985		Human DNA seq from clone 126A5 on chrom	0
	100000	70 200000	1.0.2000	genes (one with DnaJ domains); the gene	
30				family member HKR3. Contains ESTs; STSs;	2.01
50	125052	AA017723		small inducible cytokine A5 (RANTES)	2.01
	103478		Hs.38991	S100 calcium-binding protein A2	2.01
		T33873	Hs.74624	protein tyrosine phosphatase; receptor t	2.01
	112746		110 1021	yq11e10.s1 Soares fetal liver spleen 1NF	
35	112740	1130201		IMAGE:196650 3', mRNA seq.	2.01
55	119513	N67504	Hs.40061	ESTs	2.01
		AA598484			2.01
		AA769520	-	ESTs; Weakly similar to REGULATOR OF M	IT
	Lu_SQ			2010, 1102, 1	
40		R36969	Hs.18888	ESTs	2.01
40		D28383	113.1000	Human mRNA for ATP synthase B chain, 5'U	2.01
		AA452237	He 104443	ESTs; Weakly similar to BC37295_2 [H.sap	2.01
		AA478968		ESTs	2.01
		AA085374		zn13d5 s1 Stratagene hNT neuron (#937233	
45	114030	744000017		gb:L8441 CYTOCHROME C OXIDASE POL	YPEPTI
43	425249	H21585	Hs.191277		2.01
		) AA233245		FSTs	2.01
	106471			ESTs; Weakly similar to ZINC FINGER PRO	T 2.01
	134175	·	Hs.7966	ESTs	2
50		1 N22289	. 13.7 500	yw36g08.s1 Morton Fetal Cochlea H sapien	2
50		U47635	Hs.79877		2
		3 047655 3 AA129545		5 eukaryotic translation elongation factor	2
		5 R42569	Hs.22444		2
		1 AA449433			02
55			Hs.15501		2
23		6 X84373	Hs.26921		2
	11406			ESTs	2
	10/13	6 AA62079:	110.0201	20.0	

EB\_cells, Lu\_AD\_358, Lu\_AD\_H23 Lu\_AD\_358, HT29\_cells, HT29\_cells HT29\_cells, MB231\_cells, BT474\_cells 293T\_cells, DU145\_cells, LNCaP\_cells Lu\_SC\_H345, MB-MDA-453, MB-MDA-435s Lu\_SC\_H345, LNCaP\_cells, DU145\_cells

LNCaP\_œlis, HT29\_œlis, RPWE\_2 PC3\_cells, Lu\_AD\_H23, MB231\_cells MCF7, DU145\_cells, OVCAR\_cells MB-MDA-435s, Fibroblasts 2, EB\_cells HT29\_cells, MB-MDA-435s, Lu\_SC\_H345 Lu\_AD\_H23, RPWE\_2, MCF7 MCF7, Fibroblasts 2, DU145\_cells DU145\_cells, PC3\_cells, OVCAR\_cells HT29\_cells, MB-MDA-435s, Lu\_SC\_H69 HT29\_cells, Fibroblasts 2, HMEC HT29\_cells, HMEC (total RNA), Fibroblasts 2 MCF7, Fibroblasts 2, LNCaP\_cells EB\_cells, Lu\_AD\_H23, Lu\_LC\_H460 CALU6\_cells, 293T\_cells, PRSC\_log 293T\_cells, PC3\_cells, EB\_cells CALU6\_cells, MB-MDA-453, PC3\_cells EB\_cells, OVCAR\_cells, LNCaP\_cells Lu\_SC\_H345, Lu\_SC\_H69, PRSC\_con EB\_cells, MB-MDA-435s, OVCAR\_cells Lu\_SC\_H69, EB\_cells, MB-MDA-453

Lu\_AD\_H23, Lu\_LC\_H460, Lu\_SQ\_H520 LNCaP\_cells, DU145\_cells, MB231\_cells HMEC (total RNA), HMEC, RPWE\_2 Lu\_SC\_H345, BT474\_cells, HT29\_cells

PC3 cells, LNCaP\_cells, OVCAR\_cells Lu\_SC\_H345, Lu\_SC\_H69, PRSC\_con EB\_cells, Lu\_AD\_H23, Lu\_SC\_H345 HS578T\_cells, CALU6\_cells,

Lu\_AD\_H23, Lu\_AD\_358, Lu\_SQ\_H520 EB\_cells, Lu\_AD\_H23, LNCaP\_cells Lu\_SC\_H345, Lu\_SC\_H69, DU145\_cells EB\_cells, Lu\_AD\_H23, Lu\_LC\_H460

EB\_ceils, CALU6\_ceils, OVCAR\_ceils EB\_cells, HS578T\_cells, PC3\_cells EB\_cells, DU145\_cells, 293T\_cells OVCAR\_cells, LNCaP\_cells, EB\_cells Lu\_SC\_H345, Fibroblasts 2, Lu\_AD\_H23 MB-MDA-453, OVCAR\_cells, CALU6\_cells EB\_cells, PC3\_cells, LNCaP\_cells Lu\_SC\_H69, EB\_cells, Lu\_SC\_H345 Lu\_AD\_H23, PRSC\_log, Lu\_AD\_358 HT29\_cells, RPWE\_2, MB231\_cells DU145\_cells, PC3\_cells, MCF7 293T\_cells, MB-MDA-435s, HT29\_cells LNCaP\_cells, PC3\_cells, EB\_cells

60

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigeneID: Unigene number
Unigene Title: Unigene gene title

10	Pkey	Ex Accn	UG_ID	Complete_Title	Ratio BS/Met	Top 3 expressing cell lines
	302347	AF039400	Hs.19465	9 chloride channel; calcium activated; fam	19.71	EB, NCI-H520, NCI-H23
	316304	AI936587	Hs.22159	9 ESTs	14.49	PRSC_con, RPWE-2, OVCA-R
1.5	339196			CH22_FF113D11.GENSCAN.3-1	10.37	NCI-H69, PRSC_con, NCI-H345
15	336171			CH22_FGENES.708_3	9.45	NCI-H69, NCI-H460, NCI-H23
	338895			CH22_DJ32I10.GENSCAN.9-2	9.31	PC3, BT474, OVCA-R
	333625			CH22_FGENES.223_2	8.96	NCI-H69, PRSC_con, NCI-H345
	333730		LI <sub>2</sub> 40077	CH22_FGENES.258_1	8.82	NCI-H69, BT474, MB-MDA-231
20	333643	AA290922	ms. 12977	8 gastrointestinal peptide	8.22	BT474, CALU6, DU145
	333423			CH22_FGENES.232_2 CH22_FGENES.147_3	7.66	MCF7, NCI-H69, LnCap
		AI833168	Hs 18450	7 H sapiens Chromosome 16 BAC clone CIT9	7.57	HT29, MB-MDA-231, EB
	333588	7	7.10.10100	CH22_FGENES.206_2	7.46	7.55 MB-MDA-231, HT29, MB-MDA-453 HT29, OVCA-R, BT474
		AL137507		EST duster (not in UniGene)	7.35	PRSC_con, PRSC_log, NCI-H345
25	308601	AI719930		EST singleton (not in UniGene) with exon	6.83	PC3, DU145, DU145
	339044			CH22_DA59H18.GENSCAN.27-5	6.46	NCI-H69, NCI-H345, PRSC_log
		AA371513	Hs.231748	B ESTs	6.41	EB, OVCA-R, Caco2
	327805			CH.05_hs gi 5867968	6.28	NCI-H69, NCI-H345, PRSC_con
30	334239			CH22_FGENES.364_2	6.09	NCI-H520, MB-MDA-435s, MB-MDA-453
30	332958	14/05770	11- 47000	CH22_FGENES.48_15	6.04	NCI-H69, PRSC_con, PRSC_log
	31/350	W85772	Hs.173924	ESIS	5.88	MB-MDA-231, OVCA-R, BT474
	337170	ALU3/92/	ms. 1900/5	ESTs; Moderately similar to !!!! ALU SUB	5.84	OVCA-R, CALU6, EB
	337503			CH22_FGENES.564-1 CH22_FGENES.803-1	5.67	LnCap, CALU6, NCI-H69
35	337562			CH22_C65E1.GENSCAN.1-2	5.66	NCI-H345, PRSC_∞n, RPWE-2
	337219			CH22_FGENES.614-3	5.53 5.45	HT29, MB-MDA-453, BT474
		AI679622	Hs.32225	immunoglobulin alpha 1	5.43	NCI-H69, NCI-H345, PRSC_log NCI-H69, NCI-H23, NCI-H345
		AA713589		EST cluster (not in UniGene)	5.41	PC3, EB, LnCap
40	336246			CH22_FGENES.746_5	5.34	NCI-H69, NCI-H345, PRSC_log
40	335009			CH22_FGENES.472_13	5.31	EB, EB, NCI-H69
	339365			CH22_BA354I12.GENSCAN.34-1	5.25	PRSC_con, NCI-H69, PRSC_log
	336088			CH22_FGENES.688_17	5.21	PRSC_con, Cacc2, PRSC_log
	334966			CH22_FGENES.465_36	5.16	DU145, BT474, MB-MDA-231
45	334666	AW182106	<b>⊔</b> ₀ 427024	CH22_FGENES.418_18	5.15	NCI-H69, NCI-H345, PRSC_log
	339413	ATT 102 100	113.12/021	CH22_DJ579N16.GENSCAN.5-8	5.12	NCI-H345, PRSC_con, PRSC_log
	337951			CH22_EM:AC005500.GENSCAN.94-1	5.06 5.01	NCI-H69, NCI-H345, PRSC_log
	330153			CH.21_p2 gi[4325335	5	NCI-H345, NCI-H69, PRSC_con PRSC_con, PRSC_log, NCI-H69
	333987			CH22_FGENES.310_11	4.96	MB-MDA-231, MB-MDA-453, MB-MDA-453
50	334304			CH22_FGENES.373_7	4.96	OVCA-R, CALU6, NCI-H23
	338990			CH22_DA59H18.GENSCAN.6-6	4.95	PRSC_log, PRSC_con, NCI-H69
	333152			CH22_FGENES.89_1	4.89	MB-MDA-435s, OVCA-R, A549
	327049			CH.21_hs gi 6531965	4.87	PRSC_con, NCI-H345, PRSC_log
55	337225 333496			CH22_FGENES.626-3	4.83	DU145, CALU6, EB
33	334451			CH22_FGENES.168_6 CH22_FGENES.387_11	4.81	NCI-H69, NCI-H345, PRSC_con
	333594				4.79 4.78	RPWE-2, PRSC_con, NCI-H69
	333635				4.78	OVCA-R, PC3, HT29 NCI-H69, PRSC_log, PRSC_con
	336796			01100 0001100 100	4.73	NCI-H69, NCI-H345, PRSC_log
60	333313			01100 0001100 100 0	4.72	NCI-H69, NCI-H345, PRSC_log
	336833				4.7	NCI-H345, NCI-H69, PRSC_con
	336090				4.7	NCI-H69, PRSC_con, PRSC_log
	336645				4.63	HT29, OVCA-R, DU145
65	334565				4.62	NCI-H345, PRSC_log, RPWE-2
65	333242				4.56	NCI-H345, PRSC_log, PRSC_con
	326304 337445				4.48	OVCA-R, EB, DU145
	327413				4.47	RPWE-2, NCI-H69, PRSC_log
	327990				4.46	NCI-H69, PRSC_log, NCI-H345
70	325038 H	138304 F	ts.21782		4.44 4.43	PRSC_con, PRSC_log, RPWE-2
-	314923		ds.136370		4.43 4.4	PRSC_con, MB-MDA-231, HT29 HT29, MB-MDA-231, NCI-358
	328859				4.4	OVCA-R, BT474, A549
	334476				4.38	OVCA-R, PC3, EB
7.5	336092			CH22_FGENES.689_6	4.35	PRSC_con, Caco2, PRSC_log
75	333965				4.35	NCI-H69, NCI-H345, PRSC_log
						= =

	336402			CH22_FGENES.823_17	4.34	RPWE-2, HT29, OVCA-R
	337947			CH22_EM:AC005500.GENSCAN.90-5	4.33	OVCA-R, DU145, PC3
	337504			CH22_FGENES.803-2	4.33	NCI-H345, PRSC_con, PRSC_log
5	336813			CH22_FGENES.213-6	4.33	DU145, HT29, OVCA-R
3	338069		11- 74004	CH22_EM:AC005500.GENSCAN.166-14	4.33	NCI-H69, PRSC_con, NCI-H345
		N28625	Hs.74034		4.31	PC3, A549, BT474
	333631			CH22_FGENES.227_2	4.3	OVCA-R, PRSC_con, LnCap
	336049	M14268		EST	4.27	PRSC_con, PRSC_log, RPWE-2
10	335667			CH22_FGENES.681_2	4.26	HT29, DU145, DU145
10		Y13323	He 445200	CH22_FGENES.590_18 6 disintegrin protease	4.25	NCI-H520, Caco2, MB-MDA-453
		AA430373			4.25	MB-MDA-231, DU145, BT474
	327273			EST singleton (not in UniGene) with exon	4.22	NCI-358, NCI-H460, NCI-H23
	334540			CH.01_hs gi 5867466	4.22	NCI-H69, NCI-H345, PRSC_con
15	334719			CH22_FGENES.403_5	4.17	NCI-H69, NCI-H345, PRSC_log
13	327827			CH22_FGENES.421_30 CH.05_hs gi 5867968	4.17	NCI-H69, NCI-H345, RPWE-2
	333599			CH22_FGENES.212_2	4.17 4.17	OVCA-R, NCI-H69, CALU6
	329638			CH.12_p2 gij3779004	4.16	PRSC_log, NCI-H69, PRSC_con DU145, MB-MDA-231, HT29
		Al281651		EST singleton (not in UniGene) with exon	4.16	BT474, HT29, CALU6
20	336836			CH22_FGENES.247-11	4.15	PRSC_con, NCI-H345, NCI-H69
		AL121180	Hs.240038	FSTs	4.14	NCI-H345, MB-MDA-435s, RPWE-2
	336397			CH22_FGENES.823_12	4.13	NCI-H345, PRSC_con, RPWE-2
		AA736429		EST duster (not in UniGene)	4.13	NCI-H69, PRSC_con, NCI-H345
		AI304386	Hs.150836		4.11	NCI-H345, PRSC_con, PRSC_log
25	335832			CH22_FGENES.620_6	4.08	NCI-H69, NCI-H345, PRSC_log
	312778	AI631655	Hs.197919		4.07	NCI-358, NCI-H23, PRSC_con
		AA765301		ESTs	4.06	NCI-H23, A549, HT29
		AW135312			4.05	MB-MDA-231, EB, MCF7
	337452			CH22_FGENES.775-1	4.02	PRSC_con, PRSC_log, NCI-H345
30	335265			CH22_FGENES.521_1	4.01	NCI-H69, MCF7, RPWE-2
	335200			CH22_FGENES.508_9	4.01	NCI-H69, PRSC_log, PRSC_con
	336917			CH22_FGENES.346-4	3.99	PRSC_con, NCI-H345, PRSC_log
	336584			CH22_FGENES.847_1	3.98	PRSC_log, PRSC_con, RPWE-2
~ =	333382			CH22_FGENES.143_21	3.97	EB, A549, HT29
35	329436			CH.Y_hs gi 5868883	3.97	BT474, PC3, HT29
	336929			CH22_FGENES.349-3	3.94	NCI-H69, NCI-H345, PRSC_log
	337238			CH22_FGENES.641-3	3.92	NCI-H69, NCI-H345, PRSC_log
	333875			CH22_FGENES.291_11	3.92	PRSC_con, RPWE-2, PRSC_log
40	337069			CH22_FGENES.448-2	3.9	NCI-H69, LnCap, RPWE-2
40		M24470	Hs.1435	guanosine monophosphate reductase	3.86	OVCA-R, MB-MDA-435s, CALU6
		AA521331		EST singleton (not in UniGene) with exon	3.86	OVCA-R, DU145, PC3
	335348			CH22_FGENES.537_4	3.85	HT29, MB-MDA-231, PC3
	334568			CH22_FGENES.405_9	3.85	NCI-H69, NCI-H345, PRSC_log
45	336924	1104705		CH22_FGENES.347-9	3.84	NCI-H345, PRSC_log, RPWE-2
40		H81795		EST	3.84	NCI-H520, LnCap, NCI-358
	334677 326688			CH22_FGENES.418_30	3.83	PRSC_con, NCI-H345, NCI-H69
	327790			CH.20_hs gi 5867582 CH.05_hs gi 5867977	3.83	NCI-H345, PRSC_con, PRSC_log
	334591			CH:05_1IS 9()5607977 CH22_FGENES.408_1	3.8	PRSC_con, PRSC_log, NCI-H345
50	337974			CH22_EM:AC005500.GENSCAN.106-3	3.8 3.78	NCI-H69, PRSC_log, NCI-H345 PRSC_log, PRSC_con, NCI-H345
-		AW293128	Hs 197101		3.78	NCI-H345, PRSC_con, RPWE-2
	326668	7111200120	113.137101	CH.20_hs gij6552455	3.78	NCI-H345, NCI-H69, PRSC_log
		N35382		EST singleton (not in UniGene) with exon	3.77	NCI-H69, RPWE-2, PRSC_con
	336294			CH22_FGENES.786_4	3.77	PRSC_con, PRSC_log, NCI-H69
55		AL046311	Hs.252443	ESTs; Weakly similar to !!!! ALU SUBFAMI	3.76	HT29, BT474, MB-MDA-231
	338123			CH22_EM:AC005500.GENSCAN.195-5	3.75	MB-MDA-231, HT29, BT474
	318230	AA558125		EST cluster (not in UniGene)	3.74	RPWE-2, PRSC_con, NCI-H345
	303985	AW514501	Hs.156110	Immunoglobulin kappa variable 1D-8	3.73	MB-MDA-231, BT474, PRSC_con
	336502		•	CH22_FGENES.833_8	3.72	NCI-H345, RPWE-2, PRSC_con
60	334063			CH22_FGENES.327_17	3.71	NCI-H69, NCI-H345, PRSC_con
	333600			CH22_FGENES.213_2	3.7	NCI-H69, OVCA-R, PC3
	339424			CH22_DJ579N16.GENSCAN.14-3	3.69	NCI-H69, NCI-H345, PRSC_con
	336862			CH22_FGENES.297-2	3.67	NCI-H345, PRSC_con, PRSC_log
	334823			CH22_FGENES.437_5	3.67	RPWE-2, PRSC_log, PRSC_con
65	329940			CH.16_p2 gi 6165199	3.66	CALU6, EB, MCF7
		AI632123	Hs.231521	ESTs	3.66	PRSC_con, NCI-H69, RPWE-2
	328820			CH.07_hs gi 5868330	3.66	NCI-H69, NCI-H345, PRSC_∞n
		AA446446	Hs.104788	H sapiens done 24554 unknown mRNA	3.66	PRSC_con, PRSC_log, NCI-H345
70	325791	-44		CH.14_hs gi 6682476	3.65	NCI-H345, BT474, LnCap
70 ,	300672	K14469	Hs.256573		3.65	MCF7, MB-MDA-453, MB-MDA-435s
	338344			CH22_EM:AC005500.GENSCAN.312-8	3.65	NCI-H345, PRSC_log, PRSC_con
	333257	A A COO 70 4	U= 440000	CH22_FGENES.118_5	3.65	DU145, EB, OVCA-R
		AA620724	ns.112890		3.65	MB-MDA-453, DU145, MCF7
75	337489 305167	AA663080		CH22_FGENES.799-2	3.63	NCI-H345, NCI-H69, PRSC_log
	336200	~~000000		EST singleton (not in UniGene) with exon CH22_FGENES.719_4	3.63 3.61	OVCA-R, MB-MDA-231, MB-MDA-435s
	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			United Ocition 13_4	3.61	NCI-H69, PRSC_log, NCI-H345

		3392			CH22_FF113D11.GENSCAN.6-3	2.50	DD00
		3200	90 AB002	058 Hs.113	275 purinergic receptor P2X-like 1; orph	3.59	PRSC_con, NCI-H69, PRSC_log
		3359	199		CH22_FGENES.657_1		OVCA-R, LnCap, NCI-H69
		3329			CH22_FGENES.03/_I	3.57	NCI-H345, NCI-H69, PRSC_con
	5		31 AA9914	100	CH22_FGENES.36_13	3.57	NCI-H345, PRSC_con, PRSC_log
				123	EST singleton (not in UniGene) with	n exon 3.56	BT474, MB-MDA-453, MB-MDA-435s
		3332			CH22_FGENES.119_1	3.55	HT29, CALU6, MB-MDA-231
		3030	83 AA1/6	396 Hs.169		3.54	NCI-H69, NCI-H345, RPWE-2
		3358			CH22_FGENES.620_5	3.53	MCF7, BT474, OVCA-R
	10	3339			CH22_FGENES.310_7	3.52	NCI H245 DBCC DDCC -
	10	3336	23		CH22_FGENES.222_2	3.51	NCI-H345, PRSC_con, PRSC_log
		3339	97		CH22_FGENES.310_22		NCI-H69, PRSC_con, PRSC_log
		3256	23		CH.14_hs gi 5867000	3.5	NCI-H345, PRSC_con, PRSC_tog
		3091	51 AI93582	29 Hs.140	immunoalohulin aamma 2 /O d	3.5	CALU6, HT29, BT474
		3050	30 AA6414	85	immunoglobulin gamma 3 (Gm mark	ker) 3.49	EB, MCF7, MB-MDA-453
	15	3392		65	EST singleton (not in UniGene) with	exon 3.49	NCI-H23, NCI-H460, NCI-358
	10				CH22_BA354I12.GENSCAN.10-6	3.47	NCI-H69, NCI-H345, PRSC_con
		31004	8 AI19835	2 Hs.1050	077 ESTs	3.47	Caco2, PRSC_con, NCI-H69
		314/	8 AA5214	58 Hs.1927	38 ESTs	3.46	NCI-H23, NCI-H23, NCI-H520
		33466			CH22_FGENES.418_15	3.45	NCI HER DRCC In DRCC
		33466			CH22_FGENES.418_9		NCI-H69, PRSC_log, PRSC_con
	20	33098	4 H38678	Hs.3276	6 H sapiens clone 24803 mRNA seq	3.45	NCI-H69, PRSC_con, PRSC_log
		33346		110.027	CH33 ECENEO 400 4	3.44	OVCA-R, MCF7, PC3
		33358			CH22_FGENES.160_1	3.44	NCI-H69, MB-MDA-231, MCF7
				4 11- 4000	CH22_FGENES.199_2	3.42	PRSC_con, NCI-H69, PRSC_log
			6 Al26625	4 Hs.1329	29 ESTs	3.42	RPWE-2, PRSC_con, NCI-H345
	25	33451			CH22_FGENES.400_1	3.41	PRSC_log, PRSC_con, RPWE-2
	23	33362			CH22_FGENES.225_2	3.4	HT20 PT474 PT474
		30964	1 AW1942	30 Hs.2531	00 EST	3.4	HT29, BT474, BT474
		33822	1		CH22_EM:AC005500.GENSCAN.246	5.40	HT29, MB-MDA-453, MCF7
====		31299	3 AI392673	3 Hs.1252	0 FCTe		NCI-H69, PRSC_log, NCI-H345
ائيد		31833	6 AI971806	Hs.1641	SO ESTA	3.4	PRSC_log, NCI-H345, NCI-H345
7	30	32621		/ 113.1041,		3.38	OVCA-R, EB, CALU6
	50				CH.17_hs gi 5867226	3.38	NCI-H460, NCI-H69, NCI-H345
Ų		33623			CH22_FGENES.736_3	3.38	NCI-H69, NCI-H345, PRSC_log
Ĵ			2 Al382224		EST singleton (not in UniGene) with e	exon 3.37	NCI-H345, PRSC_con, RPWE-2
¥		33616			CH22 FGENES 707 6	3.37	MOI HOU MOI HOME DOWN A
‰ 1 <sub>6.6</sub> 4 1 <sub>6.4</sub> 4 1 <sub>6.71</sub>		300875	AW13475	6 Hs.19247	7 ESTs		NCI-H69, NCI-H345, RPWE-2
-	35	336593	}		CH22_FGENES.135_1	3.37	RPWE-2, PRSC_log, PRSC_con
*****		310696	AI431620	Hs.16087	E ECT	3.37	PRSC_con, NCI-H69, RPWE-2
7			AA57777			3.36	HT29, OVCA-R, BT474
		308011	A1060207	Un 45044	EST singleton (not in UniGene) with ex	xon 3.36	NCI-H345, RPWE-2, PRSC_con
		220247	A100U201	ns. 15611	0 Immunoglobulin kappa variable 1D-8	3.36	EB, DU145, CALU6
tun fart	40	336347			CH22_FGENES.815_3	3.36	NCI-H69, PRSC_log, PRSC_con
ē	70	334906			CH22_FGENES.452_21	3.33	Ca∞2, CALU6, MB-MDA-453
f		334548			CH22_FGENES.403_13	3.33	NCI-H345, PRSC_con, NCI-H69
		336695			CH22 FGENES 48-4	2 22	NCI HEQ DDCC Ion DDCC
į		316684	AA807187	' Hs.22078	3 ESTs: Weakly similar to WNT-1 PROT	O ONCO	NCI-H69, PRSC_log, PRSC_con
		315901	AI521558	Hs.17971	v-myb avian myeloblastosis viral oncog	22	3.31 DU145, EB, MB-MDA-231
Ì	45	320115	T93574		EST cluster (not in UniGene)		Caco2, LnCap, NCI-H69
				Hs.15727	EST GOSTEI (HOT III CHIGGETE)	3.3	DU145, HT29, CALU6
		327899		113.10727		3.3	NCI-H345, PRSC_con, PRSC_log
			AA514207		CH.06_hs gij5868156	3.28	BT474, MB-MDA-231, A549
			AND 14207		EST singleton (not in UniGene) with ex	on 3.28	DU145, CALU6, LnCap
	50	330021			CH.16_p2 gi 6671889	3.27	A549, HT29, EB
	50	338132			CH22_EM:AC005500.GENSCAN.200-2	2 3.27	MB-MDA-231, CALU6, EB
		323690	AA317497	Hs.188897	ESTs	3.27	RPWE-2, NCI-H345, MCF7
		327362			CH.01_hs gi 6552412	3.26	NCI-H69, RPWE-2, PRSC_log
		333488			CH22_FGENES.167_3	3.26	NOT HER NOT HAVE BROOK
		334106			CH22_FGENES.330_5	3.26	NCI-H69, NCI-H345, PRSC_log
	55	306990	Al129298	Hs.146491	EST; Weakly similar to FERRITIN HEA	3.20 NA CH 2 2C	NCI-H69, PRSC_con, PRSC_log
		328420			CH 07 ha silescoded		NCI-H345, PRSC_log, PRSC_con
		336214			CH.07_hs gij5868411	3.26	NCI-H69, NCI-H345, PRSC_log
		330565	LIETODE	Un 4545	CH22_FGENES.722_8	3.26	MCF7, EB, OVCA-R
			031093	Hs.1545	caudal type homeo box transcription fac	at 3.25	EB, DU145, HT29
	60	333879			CH22_FGENES.291_15	3.25	PRSC_con, PRSC_log, NCI-H69
	UU		AI240850	Hs.232016	ESTs	3.25	NCI-H345, PRSC_con, PRSC_log
		327581			CH.03_hs gi 5867825	3.25	EB 01145 MD MDA 452
		308153	Al500429	Hs.1103	transforming growth factor, beta 1	3.24	EB, DU145, MB-MDA-453
		308337	Al608947		EST singleton (not in UniGene) with exo	0.24 n 2.24	MCF7, EB, EB
		329406			CH.X_hs gi 6682547		PRSC_log, PRSC_con, NCI-H345
-	65	325482				3.23	DU145, HT29, MB-MDA-231
		337544			CH.12_hs gij5866957	3.23	NCI-H69, NCI-H345, PRSC_con
					CH22_FGENES.833-7	3.22	NCI-H69, NCI-H345, PRSC_con
		337204	A14/40E400	11- 04000-	CH22_FGENES.595-1	3.22	NCI-H69, PRSC_con, PRSC_log
		327050	NVV 105128	Hs.246687	ESI	3.22	PRSC_∞n, RPWE-2, NCI-H345
,	70	337259			CH22_FGENES.649-3	3.2	PRSC_con, NCI-H345, NCI-H69
	70	336489			CH22_FGENES.831_10	3.2	CALLIE MR MDA 425- C
		334804			CH22_FGENES.435_4	3.18	CALU6, MB-MDA-435s, Caco2
		335739			CH22 FGENES 601 10		PRSC_log, PRSC_con, RPWE-2
			VA935305	Hs.179779	ribosomal protein L37	3.18	NCI-H69, RPWE-2, PRSC_con
		329386				3.17	LnCap, NCI-H69, EB
- 7		323479	A27824R		CH.X_hs gi 6004484	3.17	RPWE-2, NCI-H345, PRSC_log
•					EST duster (not in UniGene)	3.16	PRSC_con, NCI-H345, RPWE-2
		304731	v~10003		EST singleton (not in UniGene) with exor	n 3.16	NCI-H69, LnCap, DU145
							·

locsyoso "ceja

	339419			CH22_DJ579N16.GENSCAN.11-11	3.15	NCI-H69, PRSC_log, RPWE-2
		AI536797	Hs.173155	ESTs	3.15	LnCap, NCI-H69, Caco2
	333608			CH22_FGENES.216_3	3.15	NCLH345, PRSC_con, PRSC_log
_	339193			CH22_FF113D11.GENSCAN.1-5	3.14	NCI-H69, NCI-H345, PRSC_con PRSC_log, PRSC_con, RPWE-2
5	310527	AW293404	Hs.211986	ESTs	3.14 3.14	PRSC_con, NCI-H69, PRSC_log
		AA707443	Hs.183983	ESTS	3.13	NCI-H345, NCI-H69, RPWE-2
	333271			CH22_FGENES.121_2 CH.05_p2 gi 6671910	3.13	NCI-H69, NCI-H345, PRSC_log
	330280	AWAE1663		EST singleton (not in UniGene) with exon	3.13	PRSC_con, PRSC_log, RPWE-2
10		AW451663 AI285535		EST singleton (not in UniGene) with exon	3.13	MB-MDA-231, BT474, BT474
10		U39840	Hs.105440	hepatocyte nuclear factor 3; alpha	3.13	MB-MDA-453, LnCap, Ca∞2
		AW104203			3.13	DU145, EB, OVCA-R
	334030			CH22_FGENES.320_2	3.13	NCI-H69, NCI-H345, PRSC_con
		A1925949		EST singleton (not in UniGene) with exon	3.13	BT474, MCF7, EB OVCA-R, EB, MB-MDA-453
15		AI733250	Hs.192262	ESTs	3.12 3.12	PRSC_con, NCI-H69, RPWE-2
		H71886		EST singleton (not in UniGene) with exon	3.12	NCI-H69, NCI-H345, PRSC_con
	334590			CH22_FGENES.407_13 CH22_FGENES.145_6	3.11	PRSC_log, RPWE-2, PRSC_con
	333408	H14624	Hs.31386		3.11	DU145, OVCA-R, PC3
20		N23730	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	3.11	EB, MB-MDA-453, MCF7
20	333682	1120100		CH22 FGENES.247_10	3.1	PRSC_con, PRSC_log, RPWE-2
		A1680562	Hs.246192	ESTs; Weakly similar to REGULATOR OF MI	T	3.1 PC3, MB-MDA-453, DU145
		AI638441	Hs.195649	ESTs	3.1	PRSC_con, RPWE-2, PRSC_log RPWE-2, NCI-H345, PRSC_log
	333441			CH22_FGENES.151_5	3.1 3.09	EB, CALU6, PC3
25	326459			CH.19_hs gi 5867400	3.09	NCI-H345, PRSC_con, RPWE-2
		AA910339	H\$.126868	CHOO BASEALLS CENSCAN 31-1	3.08	NCI-H69, NCI-H345, PRSC_log
	339356			CH22_BA354I12.GENSCAN.31-1 CH22_FGENES.226_5	3.08	NCI-H69, NCI-H345, PRSC_log
	333629	H42981		EST singleton (not in UniGene) with exon	3.07	LnCap, PRSC_∞n, DU145
30	325691	N42501		CH.14_hs gi 5867021	3.07	NCI-H345, PRSC_con, NCI-H69
50	333014			CH22_FGENES.61_6	3.07	PRSC_con, PRSC_log, NCI-H345
	327379			CH.02_hs gi 5867795	3.07	PRSC_con, PRSC_log, NCI-H69
	337816			CH22_EM:AC005500.GENSCAN.13-1	3.06	NCI-H69, PRSC_con, PRSC_log PRSC_log, NCI-H69, NCI-H345
	337954			CH22_EM:AC005500.GENSCAN.96-3	3.06 3.05	HT29, BT474, MB-MDA-231
35	328109			CH.06_hs gi 5868020	3.05	NCI-H69, NCI-H345, PRSC_∞n
	338527			CH22_EM:AC005500.GENSCAN.396-15 EST cluster (not in UniGene)	3.05	BT474, MB-MDA-435s, MCF7
		T87761		CH22_FGENES.161_2	3.05	NCI-H345, RPWE-2, PRSC_log
	333466 334788			CH22_FGENES.432_13	3.04	EB, A549, CALU6
40		X97550		EST	3.04	OVCA-R, EB, MB-MDA-453
••	336238			CH22_FGENES.743_3	3.03	NCI-H69, PRSC_log, PRSC_con
	337606			CH22_C20H12.GENSCAN.17-2	3.02	HT29, BT474, MB-MDA-231 NCI-H69, NCI-H345, RPWE-2
	333545			CH22_FGENES.180_1	3.02 3.02	PRSC_log, PRSC_con, RPWE-2
4.5	309782	AW275156	Hs.156110	Immunoglobulin kappa variable 1D-8	3.02	BT474, MB-MDA-231, HT29
45	324277	AA429440	Hs.20726	ESTS	3.02	PC3, BT474, MB-MDA-231
	337094	H38098	113.327.30	CH22_FGENES.465-19	3.01	PRSC_con, PRSC_log, RPWE-2
	313913	AW391342	2	EST cluster (not in UniGene)	3	NCI-H345, RPWE-2, PRSC_log
	329140			CH.X_hs gi 6017060	3	EB, DU145, PC3
50	335331			CH22_FGENES.535_4	3	MB-MDA-435s, HT29, BT474 CALU6, EB, DU145
	334827	7		CH22_FGENES.437_9	2.99	NCI-H345, RPWE-2, PRSC_con
	326029			CH.17_hs gi 5867176	2.99 2.99	MB-MDA-453, NCI-H345, RPWE-2
		T09353		EST CH.07_hs gi 6017031	2.99	NCI-H345, PRSC_con, NCI-H69
55	32876			CH.X_hs gij6478815	2.98	NCI-H69, NCI-H345, PRSC_con
55	329392	AA663105	i	EST singleton (not in UniGene) with exon	2.98	LnCap, NCI-H345, MCF7
	30099	AA601213	Hs.19179	B ESTs	2.98	Caco2, HT29, NCI-358
	33447	\$		CH22_FGENES.394_5	2.98	NCI-H69, PRSC_con, RPWE-2
	32264	7 AA007534			2.98	HT29, OVCA-R, A549 PRSC_con, RPWE-2, PRSC_log
60		) AI341328	Hs.17895	3 ESTs	2.97 2.97	NCI-H345, NCI-H69, RPWE-2
	32827		11- 04040	CH.07_hs gij6004471 ESTs; Weakly similar to FK506/rapamycin-	2.96	Ca∞2, NCI-H460, A549
		8 N26904	Hs.24048	5 ESTs; Weakly similar to cDNA EST yk414cs		PRSC_con, PRSC_log, NCI-H345
	33928	3 H78472	113. 13 132	CH22_BA354I12.GENSCAN.14-12	2.96	NCI-H69, PRSC_log, NCI-H345
65	30526	7 AA886428	3	EST singleton (not in UniGene) with exon	2.96	NCI-H520, NCI-358, MB-MDA-453
05	33575			CH22_FGENES.604_4	2.95	EB, A549, MB-MDA-453
	32390	7 AL043098	3 Hs.16538	7 ESTs	2.95	PRSC_con, NCI-H345, PRSC_log
	33037			CH.X_p2 gi 6580495	2.95	EB, DU145, MB-MDA-435s EB, MCF7, DU145
	33452			CH22_FGENES.402_9	2.94 2.94	NCI-H69, NCI-H345, PRSC_∞n
70	33925			CH22_BA354I12.GENSCAN.7-11	2. <del>94</del> 2.94	A549, Caco2, PC3
	33478			CH22_FGENES.432_8 CH22_FGENES.521_2	2.94	NCI-H69, PRSC_con, PRSC_con
	33526	6 7 AA84595	7 He 12839		2.94	NCI-H345, PRSC_con, PRSC_log
	33619			CH22_FGENES.719_3	2.93	NCI-H69, NCI-H345, PRSC_log
75	33832	6		CH22_EM:AC005500.GENSCAN.308-2	2.93	NCI-H69, NCI-H345, NCI-358
	33365			CH22_FGENES.239_1	2.93	PC3, OVCA-R, BT474

		336479	CH22_FGENES.829_39	2.00	NO. 100 BEES
		336086	CH22_FGENES.688_15	2.92	NCI-H69, PRSC_con, PRSC_log
		338516	CH22_EM:AC005500.GENSCAN.392-6	2.92	PRSC_con, Caco2, CALU6
		320121 T93657	EST duster (not in UniGene)	2.92	NCI-H69, NCI-H345, PRSC_con
	5	305782 AA844730	EST singleton (not in UniGene) with exon	2.92	EB, BT474, HT29
		339304	CH22_BA354I12.GENSCAN.20-16		MB-MDA-453, MCF7, DU145
		327472	CH.02_hs gij5867775	2.91	PRSC_con, PRSC_log, NCI-H69
		311458 AW139426 Hs.244718	B FSTs	2.91	PRSC_log, PRSC_con, RPWE-2
		338431	CH22_EM:AC005500.GENSCAN.351-4	2.91	PRSC_con, PRSC_log, RPWE-2
	10	339230	CH22_BA354I12.GENSCAN.1-6	2.9	BT474, MCF7, MB-MDA-453
		320586 NM_00365	EST cluster (not in UniGene)	2.89	NCI-H69, NCI-H345, PRSC_log
		304777 AA581692 Hs.2186	eukaryotic translation elongation factor	2.89	OVCA-R, HT29, MB-MDA-231
		337768	CH22_EM:AC000097.GENSCAN.119-6	2.89	OVCA-R, EB, MCF7
		319465 AA319115 Hs.191558	FSTe	2.88	NCI-H69, LnCap, DU145
	15	319068 W93011 Hs.110155		2.88	NCI-H460, NCI-H520, NCI-358
		330958 H08815 Hs.159824		2.87	BT474, MB-MDA-453, MB-MDA-435s
		334215	CH22_FGENES.357_7	2.87	OVCA-R, PC3, A549
		333568	CH22_FGENES.185_1	2.87	NCI-H69, PRSC_con, PRSC_log
		333142	CH22_FGENES.85_5	2.87	PRSC_con, PRSC_log, NCI-H69
	20	330239	CH.05_p2 gi 6671857	2.87	NCI-H69, HT29, HT29
		302120 R55140 Hs.31075	ESTs; Weakly similar to Weak similarity	2.87	MB-MDA-453, MB-MDA-453, EB
		338679	CH22_EM:AC005500.GENSCAN.470-1	2.87	CALU6, MB-MDA-435s, BT474
		329041	CH.X_hs gij5868564	2.86	NCI-H345, PRSC_log, PRSC_con
		333541		2.86	LnCap, PRSC_con, RPWE-2
	25	337011	CH22_FGENES.178_3 CH22_FGENES.427-6	2.86	NCI-H69, NCI-H345, PRSC_con
		324031 AA375646		2.86	NCI-H69, PRSC_log, PRSC_con
1	<u>.</u>	331842 AA416586 Hs.98232	EST duster (not in UniGene) ESTs	2.86	NCI-H345, PRSC_log, LnCap
-	<del>.</del>	336599		2.86	DU145, OVCA-R, HT29
-		337586	CH22_FGENES.350_3	2.85	LnCap, NCI-H69, NCI-H345
	30	336177	CH22_C20H1Z.GENSCAN.5-4	2.85	NCI-H345, NCI-H69, PRSC_con
700		337522	CH22_FGENES.712_2	2.85	NCI-H69, PRSC_log, RPWE-2
Ţ	į.	338596	CH22_FGENES.819-1	2.85	CALU6, OVCA-R, HT29
720			CH22_EM:AC005500.GENSCAN.437-2	2.85	NCI-H69, PRSC_con, NCI-H345
		309522 AW150044 Hs.252259 336981	OUGO FORMED COT T	2.85	MB-MDA-453, MB-MDA-435s, MB-MDA-435s
	35	000000	CH22_FGENES.397-7	2.85	NCI-H69, PRSC_con, PRSC_log
Ш	55		CH.05_p2 gi 6671913	2.84	NCI-H345, PRSC_log, NCI-H69
		333713	CH22_FGENES.251_2	2.84	RPWE-2, PRSC_con, NCI-H69
		335068 305075 AAS41389 Up 404405	CH22_FGENES.483_5	2.83	MB-MDA-231, NCI-H345, RPWE-2
			eukaryotic translation elongation factor	2.83	EB, LnCap, DU145
	40		CH.19_hs gi 5867327	2.82	NCI-H69, PRSC_con, PRSC_log
T.	70		CH22_FGENES.466_3	2.82	PRSC_∞n, NCI-H69, RPWE-2
I tagi			CH22_FGENES.471-1	2.82	NCI-H345, NCI-H69, PRSC_log
N		323676 AI702835	EST cluster (not in UniGene)	2.82	LnCap, A549, CALU6
. 54		333785	CH22_FGENES.274_4	2.82	OVCA-R, Caco2, MB-MDA-453
. =	45	334175	CH22_FGENES.349_10	2.81	RPWE-2, BT474, MCF7
	43	337865	CH22_EM:AC005500.GENSCAN.46-5	2.81	Caco2, NCI-H23, BT474
N		302585 AA083564 Hs.249220	H sapiens mRNA for hTbr2; complete cds	2.81	EB, DU145, MB-MDA-453
. –			CH22_FGENES.4-5	2.81	NCI-H345, PRSC_con, NCI-H69
			CH22_FGENES.22_1	2.8	RPWE-2, PRSC_log, PRSC_con
	50		CH22_FGENES.384-10	2.8	PRSC_con, NCI-H345, RPWE-2
	30	326874	CH.20_hs gi 6682507	2.8	RPWE-2, NCI-H345, PRSC_log
		315121 AA565011 Hs.105902 I		2.8	NCI-H345, PRSC_log, RPWE-2
		311185 Al638294 Hs.224665 I		2.8	NCI-H69, NCI-H345, PRSC_log
		334682	CH22_FGENES.419_4	2.8	NCI-H69, PRSC_log, RPWE-2
	55	316845 AW418715 Hs.250388 E		2.79	RPWE-2, NCI-H345, PRSC_log
	33	331599 N74626 Hs.50535 E	ESTs	2.79	A549, MB-MDA-453, MB-MDA-435s
		315681 AW022054 Hs.136591 E	STS	2.78	NCI-H460, MB-MDA-453, MCF7
		313012 Al207390 Hs.143929 E		2.78	DU145, MB-MDA-453, MCF7
			ST duster (not in UniGene)	2.78	NCI-H520, NCI-H460, HT29
	60	327277	CH.01_hs gi 5867473	2.78	DU145, CALU6, EB
	60	310981 Al494514 Hs.171380 E	STs	2.78	LnCap, RPWE-2, NCI-H460
		335090	CH22_FGENES.490_1	2.77	NCI-H69, PRSC_tog, PRSC_con
		328581	CH.07_hs gi 6006033	2.77	HT29, MB-MDA-453, MCF7
			CH22_FGENES.104_11	2.77	NCI-H69, PRSC_log, NCI-H345
	65	308311 Al581855 E	ST singleton (not in UniGene) with exon	2.77	MB-MDA-231, HT29, CALU6
	65	329760 C	H.14 p2 gil6048280	2.77	CALU6, DU145, EB
		303925 AW469999 Hs.258523 E	STs	2.77	NCI-H69, LnCap, MB-MDA-231
		337628 C	CH22_C20H12.GENSCAN.28-31	2.77	NCI-H69, LnCap, MB-MDA-453
		333520 C	H22_FGENES.174_3	2.77	NCI-H69, NCI-H345, PRSC_con
	70	303168 AA872479 Hs.197770 E	STs: Weakly similar to estrogen-respons	2.76	DU145, OVCA-R, MB-MDA-453
	70	313451 AW138189 Hs.122672 E	STs	2.76	OVCA-R, EB, DU145
		328474 C	H.07_hs gi 5868446	2.76	NCI-H69, NCI-H345, RPWE-2
		331988 AA477414 Hs.9242 pi	urine-rich element binding protein B	2.76	MB-MDA-435s, A549, OVCA-R
		306180 AA922503 E	ST singleton (not in UniGene) with exon	2.76	NCI-H69, DU145, LnCap
	75	321071 AA013011 Hs.241502 C	dc42 effector protein 4	2.76	PRSC_log, PRSC_con, NCI-H345
	75	302972 W73400 E	ST	2.76	NCI-H345, RPWE-2, NCI-H69
		305185 AA663985 Hs.248038 m	ajor histocompatibility complex; class	2.75	DU145, A549, BT474

	335998	3		CH22_FGENES.656_16	2.75	NCI-H69, PRSC_con, RPWE-2
	319138	R11699	Hs.73818	ubiquinol-cytochrome c reductase hinge p	2.75	NCI-H345, NCI-H69, PRSC_∞n
	336387	•		CH22_FGENES.822_7	2.75	PRSC_con, RPWE-2, PRSC_log
_	338054			CH22_EM:AC005500.GENSCAN.158-2	2.75	OVCA-R, EB, DU145
5	316041	AA71918	3	EST duster (not in UniGene)	2.74	DU145, MCF7, MB-MDA-453
	336863			CH22_FGENES.297-4	2.74	MB-MDA-453, MCF7, OVCA-R
	335975			CH22_FGENES.652_9	2.74	CALU6, EB, A549
		AF103179	9	EST	2.74	CALU6, MB-MDA-435s, BT474
10	326122			CH.17_hs gi 5867194	2.74	HT29, Caco2, PC3
10	337427			CH22_FGENES.761-4	2.74	RPWE-2, NCI-H69, PRSC_log
		Al469244	Hs.119252	2 tumor protein; translationally-controlle	2.74	NCI-358, NCI-H23, Ca∞2
	325433			CH.12_hs gi 5866936	2.74	NCI-H345, PRSC_con, RPWE-2
		AI572633			2.74	OVCA-R, MCF7, A549
15		Al418688			2.74	NCI-H345, PRSC_con, RPWE-2
15			5 Hs.257676		2.74	HT29, MCF7, MB-MDA-231
	335455			CH22_FGENES.562_15	2.74	NCI-H69, LnCap, PRSC_con
			Hs.29797	•	2.73	EB, OVCA-R, MB-MDA-453
			Hs.105322		2.73	MCF7, BT474, NCI-H460
20	336198		Un 407407	CH22_FGENES.719_2	2.73	NCI-H69, PRSC_con, PRSC_log
20		AI660452	Hs.187127		2.73	MB-MDA-231, LnCap, BT474
		AI419692	He 124702	EST singleton (not in UniGene) with exon	2.73	HT29, HT29, EB
	327833	Al088590	Hs.134702		2.73	PRSC_log, NCI-H345, PRSC_con
			2 He 247052	CH.05_hs gi 5867968	2.73	BT474, PC3, MB-MDA-231
25	326039		2 115.217500	ESTs; Highly similar to NK-TUMOR RECOG		2.73 NCI-H520, NCI-358, MB-MDA-453
23			Hs.143952	CH.17_hs gi 5867179	2.73	MB-MDA-453, EB, EB
	336753		113.143332	CH22_FGENES.128-9	2.72	PRSC_con, PRSC_log, NCI-H345
	330086			CH.19_p2 gij6015293	2.72 2.72	MB-MDA-435s, NCI-H520, MCF7
	333566			CH22_FGENES.183_2	2.72	HT29, MB-MDA-453, MCF7
30	339384			CH22_BA232E17.GENSCAN.3-22	2.72	HT29, BT474, OVCA-R
50	338668			CH22_EM:AC005500.GENSCAN.465-1	2.71	NCI-H69, NCI-H345, PRSC_log
		Al382618	Hs.194613		2.71	NCI-H69, RPWE-2, PRSC_con PRSC_con, NCI-H345, PRSC_log
		AI142379	113.101010	EST	2.71	PRSC_log, PRSC_con, RPWE-2
		AA666301		EST singleton (not in UniGene) with exon	2.71	EB, NCI-H520, OVCA-R
35	338725			CH22_EM:AC005500.GENSCAN.499-1	2.7	CALU6, MB-MDA-453, PC3
		Al351112		EST singleton (not in UniGene) with exon	2.7	HT29, BT474, MCF7
			2 Hs.250106		2.69	NCI-358, NCI-H69, NCI-H23
		L10141		EST	2.69	OVCA-R, BT474, PC3
		AI695133		EST singleton (not in UniGene) with exon	2.69	HT29, CALU6, MB-MDA-435s
40	322877	AA079727		EST cluster (not in UniGene)	2.69	NCI-H345, NCI-H69, PRSC_∞n
	325695			CH.14_hs gi 6552446	2.69	NCI-H69, NCI-H460, NCI-H460
	307728	AI335557		EST singleton (not in UniGene) with exon	2.68	NCI-H69, PRSC_log, NCI-358
	302399	N79624		EST	2.68	NCI-H69, PRSC_con, NCI-H345
	309343	AW028652	?	EST singleton (not in UniGene) with exon	2.68	HT29, MB-MDA-231, MB-MDA-231
45	339360			CH22_BA354I12.GENSCAN.32-2	2.68	NCI-H69, PRSC_log, PRSC_con
	337821			CH22_EM:AC005500.GENSCAN.13-11	2.68	PRSC_con, PRSC_log, PRSC_log
	337338			CH22_FGENES.717-7	2.68	NCI-H69, PRSC_con, PRSC_log
	334510			CH22_FGENES.398_8	2.68	NCI-H460, NCI-H23, NCI-358
50		AA491286	Hs.128792		2.68	MB-MDA-435s, CALU6, DU145
50	335536			CH22_FGENES.574_2	2.67	NCI-H69, NCI-H345, PRSC_log
	335311			CH22_FGENES.532_4	2.67	MB-MDA-435s, Ca∞2, A549
	338959			CH22_DJ32I10.GENSCAN.23-31	2.67	NCI-H345, PRSC_con, NCI-H69
	339081			CH22_DA59H18.GENSCAN.37-10	2.67	NCI-H345, RPWE-2, NCI-H69
55	334068			CH22_FGENES.327_23	2.67	PRSC_con, RPWE-2, PRSC_log
55	338976 325524			CH22_DA59H18.GENSCAN.1-3	2.66	PRSC_con, PRSC_log, RPWE-2
	333069			CH.12_hs gi 5866981 CH22_FGENES.76_5	2.66	NCI-H345, RPWE-2, PRSC_∞n
	336203				2.66	NCI-H69, NCI-H345, PRSC_∞n
	333133			CH22_FGENES.719_7 CH22_FGENES.83_9	2.66	OVCA-R, PC3, A549
60	304074	T77842	Hs.142528		2.66 2.65	HT29, OVCA-R, A549
00		AA224594		ESTs	2.65	DU145, CALU6, EB PRSC_con, RPWE-2, LnCap
	333248	70 022 1001	113.00541	CH22_FGENES.115_5	2.65	NCI-H345, PRSC con, MB-MDA-231
	336665			CH22_FGENES.42-2	2.65	NCI-H69, PRSC_log, PRSC_con
		AA770599		EST cluster (not in UniGene)	2.65	A549, MB-MDA-453, MB-MDA-435s
65		AI264023		EST singleton (not in UniGene) with exon	2.65	NCI-H69, NCI-H345, RPWE-2
			Hs.127384	DKFZP564C196 protein	2.65	MB-MDA-453, MCF7, HT29
		AW361892		EST	2.65	NCI-H345, PRSC_con, PRSC_log
	327246	· <b>-</b>		CH.01_hs gi 5867547	2.65	EB, OVCA-R, DU145
	337403			CH22_FGENES.752-2	2.65	PRSC_con, PRSC_log, RPWE-2
70	328221			CH.06_hs gij5868099	2.64	MCF7, MB-MDA-231, BT474
	336759			CH22_FGENES.133-2	2.64	NCI-H69, PRSC_log, PRSC_con
	327532			CH.02_hs gij6469818	2.64	PC3, CALU6, A549
	305621	AA789095		EST singleton (not in UniGene) with exon	2.64	HT29, MB-MDA-231, MB-MDA-453
~~		AA099329	Hs.151764		2.64	PRSC_con, RPWE-2, NCI-H345
75	327278			CH.01_hs gi 5867473	2.64	EB, NCI-H460, NCI-H69
	332235	N51413	Hs.109284	ESTs	2.64	DU145, EB, OVCA-R

		332792		CH22_FGENES.3_2	2 62	11700 0 0 1011
		312340 AI8	62668 Hs.176	333 ESTs	2.63	HT29, Caco2, A549
		337484		CH22_FGENES.795-8	2.63	NCI-358, NCI-358, HT29
		325783			2.63	NCI-H69, NCI-H345, PRSC_∞n
	5		502380 Hs.210	CH.14_hs gi 6456780	2.63	EB, OVCA-R, PC3
	_	306009 AAE	002500 115.Z10		2.63	PRSC_log, NCI-H345, NCI-H69
		200003 AAC	054000	EST singleton (not in UniGene) with exon	2.63	HT29, MB-MDA-231, CALU6
		308548 AI69	90484	EST singleton (not in UniGene) with exon	2.63	PC3, A549, NCI-358
		337930		CH22_EM:AC005500.GENSCAN.81-3	2.62	PC3, OVCA-R, MCF7
	10	327791		CH.05 hs oil5867977	2.62	PPSC for PPSC con MCLUDAS
	10	330925 AA2	32678 Hs.870	73 ESTs	2.62	PRSC_log, PRSC_con, NCI-H345
		327259		CH.01 hs gil5867454	2.62	OVCA-R, MCF7, LnCap
		302150 AF0	61756 Hs.1529	531 heart and neural crest derivatives expre		NCI-H345, PRSC_con, RPWE-2
		304881 AA5	98501 Hs.1951	188 glyceraldehyde-3-phosphate dehydrogena	2.61	OVCA-R, PC3, A549
		335956		CH22_FGENES.647_3		MB-MDA-435s, NCI-H23, MCF7
	15	326506		CH 10 ha = 1150C7405	2.61	DU145, PRSC_con, PC3
		335863		CH.19_hs gi 5867435	2.61	RPWE-2, NCI-H460, NCI-358
		334752		CH22_FGENES.629_8	2.61	PC3, HT29, NCI-358
				CH22_FGENES.428_1	2.61	PRSC_con, NCI-H69, PRSC_log
		333288		CH22_FGENES.128_19	2.61	HT29, NCI-358, Caco2
	20	306709 AI02	4215 Hs.1314	77 EST	2.61	MB-MDA-435s, MCF7, BT474
	20	305816 AA85	54776	EST singleton (not in UniGene) with exon	2.6	MP MDA 452 MCC7 MP MPA 405
		327264		CH.01 hs gil5867461	2.6	MB-MDA-453, MCF7, MB-MDA-435s
		310905 AW0	75527 Hs.2522	59 ribosomal protein S3		MB-MDA-435s, MB-MDA-435s, MB-MDA-453
		324492 AA47	9507 Hs.1351	79 FSTs	2.6	OVCA-R, EB, DU145
		322649 AA52	6549		2.6	DU145, EB, OVCA-R
	25	329384	.0010	EST duster (not in UniGene)	2.6	PRSC_con, RPWE-2, PRSC_log
		321240 M623	79	CH.X_hs gi 5868869	2.6	NCI-H69, NCI-H345, PRSC_con
		302754 4420	0670 U- 4504	EST duster (not in UniGene)	2.6	BT474, CALU6, MB-MDA-231
===		30E044 AA00	93/0 MS.1361	10 Immunoglobulin kappa variable 1D-8	2.59	MCF7, MB-MDA-453, OVCA-R
		305841 AA86	0348	EST singleton (not in UniGene) with exon	2.59	NCI-H345, PRSC_log, PRSC_con
=	20	32418U AA4U	2242 Hs.12279	9 ESTs	2.58	EB, PC3, HT29
#	30	334196		CH22_FGENES.353_4	2.58	NCI-H345, NCI-H69, PRSC_con
Ï		338451		CH22_EM:AC005500.GENSCAN.359-39	2.58	MP MDA 425- NOLLIOS AMORT
. #		300333 AW29	7396 Hs.22705	2 ESTs	2.58	MB-MDA-435s, NCI-H23, MCF7
Į.		305046 AA632	2201	EST singleton (not in UniGene) with exon		PRSC_con, PRSC_log, NCI-H69
		305648 AA807	7652 Hs.15611	0 Immunoglobulin kappa variable 1D-8	2.58	NCI-H460, MB-MDA-453, MB-MDA-435s
	35	301744 W222	30	EST	2.57	PRSC_con, RPWE-2, NCI-H345
Ų.		329182	••		2.57	PRSC_con, PRSC_log, NCI-H345
3		318178 AW13	7425 No 15040	CH.X_hs gi 6056331	2.57	PRSC_con, RPWE-2, NCI-H345
		330057	7423 113.13040		2.57	MB-MDA-231, PRSC_con, BT474
				CH.17_p2 gi 6478962	2.57	NCI-H345, RPWE-2, PRSC_con
կուռ հրու գուֆ	40	326552		CH.19_hs gi 5867308	2.57	NCI-H345, PRSC_con, RPWE-2
E .	70	311956 T6708	5 Hs.18846		2.57	HT29, MB-MDA-453, NCI-H460
ŧ		327185		CH.01_hs gi 6117805	2.57	CALU6, HT29, EB
Ē		302183 NM_00	0224	EST	2.57	MCF7, PC3, OVCA-R
5		327263		CH.01_hs gi 6525274	2.56	PROC NOLUGE PROC
ı		339164		CH22_DA59H18.GENSCAN.69-4		PRSC_con, NCI-H69, PRSC_log
	45	332763 AA063	554 Hs.90959	ESTs	2.56	NCI-H69, PRSC_con, NCI-H345
5		330579 U6773		phosphodiesterase 2A; cGMP-stimulated	2.56	RPWE-2, NCI-H345, PRSC_con
		329948		CH.16_p2 gij5540101	2.55	HT29, CALU6, PC3
			305 He 236131	ESTs; Highly similar to homeodomain-inte	2.55	NCI-H460, MCF7, MB-MDA-453
		335448	113.230131	CURS FOR ISSUED FOR THE COMPONENT OF THE	2.55	NCI-H460, NCI-H23, NCI-H23
	50	330959 H09174	1 11-00404	CH22_FGENES.562_5	2.55	MB-MDA-453, BT474, MCF7
	50	207262 A12004	Hs.26484	HIRA-interacting protein 3	2.55	MB-MDA-453, HT29, MCF7
		307262 Al2021	00	EST singleton (not in UniGene) with exon	2.55	MCF7, DU145, MB-MDA-435s
		335806		CH22_FGENES.616_8	2.55	NCI-H345, NCI-H69, PRSC_∞n
		335782		CH22_FGENES.609_4	2.55	Caco2, MB-MDA-453, MB-MDA-435s
		301703 AW301	478	EST	2.55	PC3, MCF7, MB-MDA-453
	55	329018		CH.X_hs gi 6249620	2.54	NOLUGO DECO 4 DECO
		329870		CH.14_p2 gil6706435	2.54	NCI-H69, PRSC_log, PRSC_con
		334504		CH22_FGENES.398 2		NCI-H23, NCI-H460, NCI-358
		304707 AA5648	46	EST singleton (not in UniGene) with exon	2.54	HT29, BT474, MB-MDA-231
		329326		CH.X_hs gi[5868806	2.53	NCI-H520, EB, NCI-H460
	60	334418		CHO. FOENED 204 -	2.53	MB-MDA-231, NCI-H345, NCI-H69
		338124		CH22_FGENES.384_5	2.53	NCI-H23, NCI-358, NCI-H460
			4 11- 044404	CH22_EM:AC005500.GENSCAN.196-2	2.53	NCI-H69, PRSC_con, PRSC_log
		318423 AI36267	'1 Hs.214491	I	2.53	OVCA-R, EB, DU145
		333006		CH22_FGENES.60_3	2.53	NCI-H69, PRSC_con, PRSC_log
	65	333668		CH22_FGENES.245_2	2.53	NCI-H69, PRSC_log, PRSC_con
	65	333567		CH22_FGENES.184_2	2.53	MCI HER MCI HOAF DROG
		309592 AW1723	84	EST singleton (not in UniGene) with exon	2.52	NCI-H69, NCI-H345, PRSC_con
		328989				LnCap, NCI-H69, DU145
		326725		011.00 1 110.000	2.52	MB-MDA-435s, OVCA-R, EB
		302996 AF05466		ECT .	2.52	PRSC_con, NCI-H345, NCI-H69
•	70	335733		C1100 FORUES *** *	2.52	HT29, BT474, CALU6
		336000		CU22 FORNES SES 4	2.52	NCI-H69, PRSC_log, NCI-H345
		327774			2.52	LnCap, OVCA-R, DU145
		328557		CH.05_hs gij5867964	2.52	DU145, CALU6, HT29
				CH.07_hs gij5868489	2.52	MB-MDA-453, MB-MDA-435s, MCF7
•		328228		CH.06_hs gi[5868105	2.52	NCI-H69, NCI-H345, PRSC_con
•		328305		CH.07_hs gi 6004478	2.52	NCI-H69, NCI-H460, PRSC_log
		334010	(		2.51	NCI-H69, PRSC_log, PRSC_con

	335281			CH22_FGENES.524_4	2.43	PC3, LnCap, A549
		AI675790	Hs.132453		2.43	NCI-H345, RPWE-2, PRSC_log
	306511	AA988891		EST singleton (not in UniGene) with exon	2.43	OVCA-R, EB, DU145
_	333298			CH22_FGENES.133_4	2.43	EB, DU145, PC3
5	328436			CH.07_hs gi 5868417	2.43	EB, LnCap, A549
	333420			CH22_FGENES.146_11	2.43	NCI-H345, NCI-H69, PRSC_log
	338113			CH22_EM:AC005500.GENSCAN.188-13	2.42	DU145, EB, CALU6
	335188			CH22_FGENES.507_3	2.42 2.42	EB, A549, BT474
10	329164 336316			CH.X_hs gi 5868691 CH22_FGENES.799_11	2.42	RPWE-2, PRSC_con, PRSC_log MB-MDA-435s, MCF7, NCI-H69
10		AI927594	Hs.161142		2.42	NCI-H345, PRSC_con, PRSC_log
	327334	70200.		CH.01_hs gi 5902477	2.42	MB-MDA-453, MB-MDA-435s, MCF7
	334017			CH22_FGENES.315_2	2.42	PRSC_con, PRSC_log, RPWE-2
	308138	AI494446		EST singleton (not in UniGene) with exon	2.42	DU145, LnCap, EB
15	333074			CH22_FGENES.76_10	2.42	NCI-H69, RPWE-2, PRSC_log
		AA993109		EST singleton (not in UniGene) with exon	2.42	HT29, CALU6, LnCap
	336516	41040007		CH22_FGENES.836_1	2.42	NCI-H69, PRSC_con, PRSC_log
		AI042387		EST singleton (not in UniGene) with exon	2.42	CALU6, DU145, EB
20	329411	A1750001		CH.X_hs gi 6682549	2.42 2.41	OVCA-R, EB, LnCap EB, DU145, CALU6
20		AI750091 AI190405	Hs.143127	EST singleton (not in UniGene) with exon	2.41	DU145, EB, CALU6
	326073	A1130400	113.170127	CH.17_hs gi]6682495	2.41	DU145, A549, MB-MDA-435s
	334047			CH22_FGENES.326_5	2.41	PRSC_con, PRSC_log, NCI-H345
	325464			CH.12_hs gi 5866947	2.41	NCI-358, NCI-H23, NCI-H460
25	334764			CH22_FGENES.428_13	2.41	NCI-H69, NCI-H345, RPWE-2
	312737	AI033500	Hs.132895	ESTs	2.41	OVCA-R, DU145, CALU6
		AI000248		EST singleton (not in UniGene) with exon	2.41	MB-MDA-231, MCF7, DU145
	333582			CH22_FGENES.201_2	2.41	NCI-H69, PRSC_con, PRSC_log
30	337843			CH22_EM:AC005500.GENSCAN.30-8	2.4	EB, LnCap, A549
30	335284	A A C E 24 E O		CH22_FGENES.526_6	2.4 2.4	NCI-H69, NCI-H345, PRSC_log DU145, HT29, MB-MDA-453
	335527	AA653159		EST singleton (not in UniGene) with exon CH22_FGENES.572_7	2.4	DU145, OVCA-R, EB
	336795			CH22_FGENES.176-5	2.4	NCI-H69, NCI-H345, PRSC_log
		AF202889		EST	2.4	PRSC_con, PRSC_log, NCI-H69
35	334948			CH22_FGENES.465_15	2.4	PRSC_con, PRSC_log, RPWE-2
	328860			CH.07_hs gi]6381928	2.4	PRSC_con, PRSC_log, NCI-H345
	322929	AI365585	Hs.146246	ESTs	2.4	NCI-H460, A549, HT29
	333561			CH22_FGENES.180_18	2.4	OVCA-R, EB, DU145
40	338239		11. 404700	CH22_EM:AC005500.GENSCAN.264-5	2.4	NCI-H69, NCI-H345, PRSC_con
40			HS.161/63	ESTs; Weakly similar to KIAA0738 protein	2.4 2.4	DU145, MB-MDA-453, EB
		AA873085 AW297673	Hs.190526	EST singleton (not in UniGene) with exon	2.4	MCF7, A549, NCI-H520 LnCap, NCI-H460, NCI-H23
	334470	A11231013	113.130320	CH22_FGENES.394_1	2.4	NCI-H520, HT29, NCI-H23
	333272			CH22_FGENES.122_1	2.39	NCI-H345, PRSC_con, RPWE-2
45		AW518383	Hs.177592	ribosomal protein; large; P1	2.39	DU145, CALU6, EB
	337316			CH22_FGENES.692-1	2.39	MCF7, BT474, OVCA-R
		AI914939	Hs.212184		2.39	PRSC_con, NCI-H345, RPWE-2
	336280			CH22_FGENES.763_4	2.39	NCI-H345, PRSC_log, PRSC_con
50	331223	198872	Hs.194181		2.39	DU145, HT29, PC3
30	337172	AIC74002	Un 142621	CH22_FGENES.565-2 ESTs; Weakly similar to WASP-family prot	2.39 2.39	EB, OVCA-R, DU145 EB, NCI-H520, LnCap
	337092	AI0/ 1332	H3. 14303 I	CH22_FGENES.465-12	2.39	PRSC_con, PRSC_log, NCI-H69
	334528			CH22_FGENES.402_8	2.39	NCI-H345, PRSC_con, NCI-H69
	338411			CH22_EM:AC005500.GENSCAN.341-7	2.39	NCI-H345, NCI-H69, PRSC_con
55		AA357927	Hs.70208	ESTs	2.39	PC3, EB, A549
	334044			CH22_FGENES.323_2	2.38	MB-MDA-231, MCF7, LnCap
	333918			CH22_FGENES.296_7	2.38	RPWE-2, NCI-H345, EB
		AI042614	Hs.125910		2.38	NCI-H345, PRSC_con, RPWE-2
60	333424	AMM450545	LI- 400204	CH22_FGENES.147_4	2.38	DU145, MCF7, OVCA-R
UU			Hs.128381 Hs.190219		2.38 2.38	EB, DU145, OVCA-R OVCA-R, EB, CALU6
			Hs.149596		2.38	NCI-H460, NCI-H23, NCI-H23
				ESTs; Weakly similar to centaurin beta2	2.38	PRSC_con, RPWE-2, NCI-H345
		AA670431		EST singleton (not in UniGene) with exon	2.38	MB-MDA-453, MB-MDA-231, A549
65	337760			CH22_EM:AC000097.GENSCAN.116-8	2.38	PRSC_con, PRSC_log, RPWE-2
	311502	AW204380	Hs.208662	ESTs	2.38	NCI-H345, NCI-H69, LnCap
	337548			CH22_FGENES.844-5	2.38	MB-MDA-453, MCF7, CALU6
	326981	4144444		CH.21_hs gi 6588016	2.38	NCI-H345, NCI-H69, PRSC_con
70		AW182066		EST singleton (not in UniGene) with exon	2.37	RPWE-2, NCI-358, NCI-H69
70	328936			CH.08_hs gi 5868500 CH.06_hs gi 5868192	2.37 2.37	OVCA-R, MB-MDA-453, CALU6 RT474 FR OVCA-R
	327937 328282			CH.06_hs gi 5868192 CH.07_hs gi 5868353	2.37 2.37	BT474, EB, OVCA-R DU145, CALU6, CALU6
		AL046388	Hs.208206	ESTs; Weakly similar to Naf1 alpha prote	2.37	LnCap, PRSC_log, NCI-H345
	304227			ribosomal protein S4; X-linked	2.37	EB, PC3, OVCA-R
75			Hs.257542		2.37	OVCA-R, CALU6, CALU6
	325026	AI671168	Hs.12285	ESTs	2.37	NCI-H345, PRSC_con, PRSC_log

	315015	Al659989	Hs.132625	ESTs	2.37	MB-MDA-453, MB-MDA-231, LnCap
	328662			CH.07_hs gij6004473	2.37	NCI-H345, RPWE-2, PRSC_con
	305867	AA864572		EST singleton (not in UniGene) with exon	2.37	MCF7, MB-MDA-453, MB-MDA-231
_	333296			CH22_FGENES.132_3	2.37	EB, PC3, CALU6
5		R01116	Hs.182059		2.36	OVCA-R, MB-MDA-453, A549
	333698	A A 750756	Un 424200	CH22_FGENES.250_12	2.36	HT29, OVCA-R, Ca∞2
		AA758756 AL121194			2.36 2.36	HT29, MCF7, MB-MDA-435s
		Z43296	Hs.18720	programmed cell death 8 (apoptosis-induc	2.36	PC3, NCI-H460, DU145 OVCA-R, A549, MB-MDA-453
10	334237	L10200	110.107.20	CH22_FGENES.362_1	2.36	NCI-H345, NCI-H69, LnCap
		AI700148	Hs.117328		2.36	MCF7, NCI-H345, DU145
	326884			CH.20_hs gi 6682511	2.36	A549, EB, PC3
	333132			CH22_FGENES.83_8	2.36	NCI-H69, HT29, EB
1.5		AA995719		heat shock 27kD protein 1	2.36	RPWE-2, PRSC_log, PRSC_con
15		AI669524	Hs.194115		2.36	NCI-H345, RPWE-2, PRSC_con
	329496	H22381		CH.10_p2 gi 3983518	2.35 2.35	HT29, MCF7, MB-MDA-231
		AA461139	Hs 24372	EST cluster (not in UniGene) ESTs; Weakly similar to dJ207H1.1 [H.sap	2.35	NCI-H23, A549, CALU6 PRSC_con, RPWE-2, PRSC_log
		AW444488	. 10.2 10. 2	EST singleton (not in UniGene) with exon	2.35	NCI-H345, PRSC_con, PRSC_log
20	327009			CH.21_hs gi 5867664	2.35	HT29, BT474, MCF7
	309594	AW172821	Hs.181165	eukaryotic translation elongation factor	2.35	HT29, DU145, EB
	335468			CH22_FGENES.567_4	2.35	NCI-H69, PRSC_∞n, NCI-H345
		AA069029		EST singleton (not in UniGene) with exon	2.35	PRSC_con, PRSC_log, RPWE-2
25		AA865649		EST singleton (not in UniGene) with exon	2.35	A549, MCF7, OVCA-R
25		AA815428		EST singleton (not in UniGene) with exon	2.35	PRSC_con, NCI-H345, PRSC_log
	326423 334560			CH.19_hs gi 5867369	2.34 2.34	PC3, MCF7, LnCap
	337100			CH22_FGENES.404_3 CH22_FGENES.472-3	2.34	HT29, NCI-H460, MB-MDA-435s PRSC_log, PRSC_con, RPWE-2
		AW014374	Hs.144849		2.34	CALU6, MB-MDA-231, DU145
30		AW298359			2.34	PRSC_con, RPWE-2, PRSC_log
	305787	AA845035		EST singleton (not in UniGene) with exon	2.34	NCI-H23, NCI-H520, NCI-H460
	338686			CH22_EM:AC005500.GENSCAN.472-5	2.33	BT474, MB-MDA-231, MB-MDA-453
		AA465207			2.33	OVCA-R, A549, MB-MDA-435s
35		M79114	Hs.135177		2.33	NCI-H69, PRSC_con, NCI-H345
33	336089 338952			CH22_FGENES.688_18	2.33 2.33	PRSC_con, Cacc2, PRSC_log
	334612			CH22_DJ32I10.GENSCAN.23-22 CH22_FGENES.411_11	2.33	PC3, OVCA-R, HT29 OVCA-R, MB-MDA-453, EB
	338223			CH22_EM:AC005500.GENSCAN.250-10	2.33	DU145, MB-MDA-453, MCF7
	327845			CH.05_hs gi 6531962	2.32	OVCA-R, MB-MDA-453, PC3
40	308187	AI538108	Hs.156110	Immunoglobulin kappa variable 1D-8	2.32	NCI-H69, NCI-358, PRSC_con
			Hs.128340	ESTs; Weakly similar to Cdc42 GTPase-act	2.32	BT474, CALU6, MB-MDA-231
	330468		Hs.112341	protease inhibitor 3; skin-derived (SKAL	2.32	PC3, Ca∞2, HT29
		R17712	Un 1220CE	EST duster (not in UniGene)	2.32	MCF7, PC3, MB-MDA-453
45	303148	AI066733	Hs.133865	ESTS; Weakly similar to CYTOCHROME P45	2.32	CALU6, MB-MDA-231, DU145 2.32 NCI-H345, PRSC_∞n, RPWE-2
-1.5		AW250314	113.127317	EST	2.32	NCI-H345, PRSC_con, PRSC_log
	318891		Hs.196208	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.32	NCI-H69, LnCap, NCI-H345
	336653			CH22_FGENES.33-4	2.32	DU145, EB, LnCap
50	333329			CH22_FGENES.138_22	2.32	DU145, BT474, MB-MDA-231
50	301980	U69962	Hs.121498	potassium voltage-gated channel; Shab-re	2.31	NCI-H345, MB-MDA-231, LnCap
	336968	A1004404		CH22_FGENES.375-28	2.31	HT29, BT474, EB
	326417	Al694191		EST singleton (not in UniGene) with exon CH.19_hs gij5867362	2.31 2.31	NCI-H345, NCI-H69, PRSC_log HT29, MCF7, BT474
	328851			CH.07_hs gi 6381923	2.31	NCI-H520, NCI-H460, NCI-H23
55	329254			CH.X_hs gi 5868733	2.31	RPWE-2, NCI-H345, PRSC_con
	303075	W88779	Hs.59125	ESTs	2.3	DU145, OVCA-R, EB
	335131			CH22_FGENES.497_15	2.3	NCI-H69, NCI-H345, PRSC_log
		AA308334		MUF1 protein	2.3	LnCap, DU145, HT29
60	327067	A14/407050		CH.21_hs gi 6531965	2.3	NCI-H345, NCI-H69, MB-MDA-435s
00	325965	AW137650		EST duster (not in UniGene)	2.3 2.3	DU145, HT29, EB
	334525			CH.16_hs gi 5867147 CH22_FGENES.402_4	2.3	NCI-H69, NCI-H345, RPWE-2 NCI-H345, PRSC_con, NCI-H69
	336654			CH22_FGENES.34-2	2.3	BT474, PC3, MB-MDA-453
		AF100779		WNT1 inducible signaling pathway protein	2.3	LnCap, CALU6, DU145
65		AI989570		EST singleton (not in UniGene) with exon	2.3	NCI-H460, NCI-H23, NCI-H520
	329246			CH.X_hs gi 5868732	2.3	NCI-H69, NCI-H345, PRSC_log
		AA774834		EST singleton (not in UniGene) with exon	2.3	CALU6, CALU6, MCF7
		AA084941		EST cluster (not in UniGene)	2.3	MB-MDA-231, CALU6, EB
70		AI703241 AI971416		ESTs; Weakly similar to Xin (M.musculus) EST singleton (not in UniGene) with exon	2.29 2.29	NCI-H345, PRSC_∞n, RPWE-2 CALU6, OVCA-R, EB
, ,				ribosomal protein L13a	2.29	MB-MDA-435s, MCF7, HT29
	335827			CH22_FGENES.620_1	2.29	PRSC_con, PRSC_log, RPWE-2
	334066			CH22_FGENES.327_21	2.29	PRSC_con, PRSC_log, NCI-H345
75		AW293005	Hs.220905	ESTs	2.29	NCI-H23, Ca∞2, CALU6
75		AI872290		immunoglobulin gamma 3 (Gm marker)	2.29	CALU6, A549, NCI-H69
	333607			CH22_FGENES.216_2	2.29	OVCA-R, MCF7, A549

	335174			CH22_FGENES.504_4	2.29	HT29, A549, MB-MDA-453
	332028	AA48968	0 Hs.13440	6 ESTs; Weakly similar to Dim1p homolog [H	2.29	EB, A549, DU145
	336417			CH22_FGENES.823_39	2.29	NCI-H69, NCI-H345, PRSC_log
5		AA25140	1	EST duster (not in UniGene)	2.29	HT29, MB-MDA-231, BT474
,	336618	Al188739	Hs.14848	CH22_FGENES.2-1	2.29	NCI-358, NCI-H460, NCI-H69
	334055		ITS. 14040	CH22_FGENES.327_6	2.29	NCI-H345, PRSC_log, PRSC_con
	337168			CH22_FGENES.562-28	2.28 2.28	DU145, OVCA-R, MB-MDA-453
	329824			CH.14_p2 gij6630758	2.28	NCI-H69, PRSC_log, NCI-H345 NCI-H23, CALU6, RPWE-2
10	333891			CH22_FGENES.292_13	2.28	NCI-H69, MB-MDA-231, RPWE-2
	339127			CH22_DA59H18.GENSCAN.55-1	2.28	PRSC_con, NCI-H345, RPWE-2
		AA812726	3	EST singleton (not in UniGene) with exon	2.28	NCI-H520, NCI-H23, NCI-H460
	329782			CH.14_p2 gi 5912597	2.28	NCI-H69, NCI-H345, PRSC_log
15		AI810001	Hs.17534		2.28	MCF7, BT474, MB-MDA-435s
13	336934	A A7C4000		CH22_FGENES.351-1	2.28	BT474, HT29, MB-MDA-435s
		AA761093 N72574	Hs.50220	EST duster (not in UniGene)	2.28	OVCA-R, HT29, DU145
		AA258559		ESTs  ESTs: Wookly similar to DELTA LIVE DOOT	2.28	A549, MCF7, NCI-358
	338285	7420000	113.3730	ESTs; Weakly similar to DELTA-LIKE PROT CH22_EM:AC005500.GENSCAN.293-3	2.20 2.27	MB-MDA-231, CALU6, MCF7
20		AI245127	Hs.179331		2.27	NCI-H69, PRSC_log, PRSC_con
				ribosomal protein L29	2.27	NCI-H23, NCI-H520, NCI-358 RPWE-2, NCI-H345, PRSC_log
	309005	A1884454		EST singleton (not in UniGene) with exon	2.27	A549, MCF7, BT474
	332995			CH22_FGENES.58_2	2.27	RPWE-2, NCI-H345, PRSC_log
25	337426			CH22_FGENES.761-3	2.27	DU145, EB, CALU6
25	337778			CH22_EM:AC000097.GENSCAN.119-20	2.27	NCI-H69, PRSC_con, PRSC_log
	329705			CH.14_p2 gi 6065790	2.27	PRSC_con, PRSC_log, RPWE-2
	335971	A1075046	U= 422000	CH22_FGENES.652_4	2.27	PRSC_log, MB-MDA-231, NCI-H23
		AI075846 AI911204	Hs.133996 Hs.126365	· ·	2.27	HT29, MB-MDA-435s, OVCA-R
30	334430	A1311204	113.120300	CH22_FGENES.385 3	2.27	NCI-H460, NCI-358, BT474
		AA452257	Hs.99272		2.27 2.26	NCI-H345, NCI-H69, PRSC_con
			Hs.153019		2.26	PRSC_con, LnCap, PRSC_log NCI-H345, PRSC_log, NCI-H520
	317394	AI935024	Hs.190518	ESTs	2.26	NCI-H345, PRSC_con, PRSC_log
		AA928363		EST singleton (not in UniGene) with exon	2.26	NCI-H345, PRSC_con, PRSC_log
35	304134	H54627		EST singleton (not in UniGene) with exon	2.26	DU145, CALU6, PC3
	335421			CH22_FGENES.551_1	2.26	NCI-H69, PRSC_con, PRSC_log
	305260	AA679280	Hs.156110	Immunoglobulin kappa variable 1D-8	2.26	NCI-H345, NCI-H69, PRSC_con
		AA421129	Un 420007	EST	2.26	CALU6, OVCA-R, DU145
40	325304	A1004985	Hs.130607		2.26	PC3, MB-MDA-435s, A549
40	334118			CH.11_hs gij5866910 CH22_FGENES.330_19	2.26	MCF7, CALU6, A549
	335687			CH22_FGENES.596_2	2.26 2.26	PRSC_con, NCI-H69, PRSC_log
	334035		•	CH22_FGENES.322_3	2.26	A549, CALU6, LnCap NCI-H345, PRSC_con, RPWE-2
	305454	AA738413		EST singleton (not in UniGene) with exon	2.25	EB, HT29, CALU6
45	335902			CH22_FGENES.635_10	2.25	EB, DU145, HT29
	339215			CH22_FF113D11.GENSCAN.6-10	2.25	PRSC_con, PRSC_log, RPWE-2
	328810			CH.07_hs gi 5868327	2.25	PC3, OVCA-R, MB-MDA-453
	337396			CH22_FGENES.749-1	2.25	EB, A549, DU145
50	336808	AA853958		CH22_FGENES.205-3	2.25	NCI-H345, NCI-H69, PRSC_con
50	333571	MAGDOSTO		EST singleton (not in UniGene) with exon	2.24	MB-MDA-453, DU145, EB
		AA225188	Hs.258539	CH22_FGENES.188_2	2.24 2.24	MCF7, MB-MDA-453, PC3
	334626	7 1220 100	110.20000	CH22_FGENES.416_2	2.24	EB, DU145, CALU6 NCI-H69, NCI-H345, PRSC_log
	333593			CH22_FGENES.210_2	2.24	NCI-H69, NCI-H345, PRSC_con
55	326708			CH.20_hs gi 5867593	2.24	NCI-H460, NCI-H23, NCI-H520
		AI041717	Hs.132141		2.23	NCI-H345, RPWE-2, PRSC_con
	309181			EST singleton (not in UniGene) with exon	2.23	PRSC_con, PC3, MB-MDA-231
	324926	H56196	Hs.117798		2.23	EB, EB, DU145
60	333632 328243			CH22_FGENES.227_3	2.23	CALU6, CALU6, MB-MDA-453
00	327037			CH.06_hs gi 6056292	2.23	PC3, LnCap, LnCap
	307380	A1222985		CH.21_hs gi 6531965 EST singleton (not in UniGene) with exon	2.23 2.23	LnCap, DU145, EB
	334766			CH22_FGENES.428_15	2.23	NCI-H345, PRSC_con, PRSC_log PRSC_log, NCI-H345, RPWE-2
	335236				2.23	OVCA-R, MCF7, BT474
65	336615				2.23	NCI-H69, PRSC_log, PRSC_con
	307558				2.23	DU145, OVCA-R, CALU6
	308029				2.23	EB, OVCA-R, MB-MDA-453
	331508			EST	2.23	MB-MDA-453, MCF7, BT474
70	320980 /	WZ3/672			2.23	OVCA-R, EB, EB
70	304241 A		He 17000C	EST singleton (not in UniGene) with exon	2.23	BT474, MB-MDA-435s, MB-MDA-231
	308382 A	1624301			2.23	MB-MDA-231, MCF7, OVCA-R
			Hs.169604		2.22 2.22	OVCA-R, BT474, CALU6
_	327864				2.22 2.22	DU145, EB, A549 NCI-H69, PRSC_log, PRSC_con
75	337279				2.22 2.22	NCI-H345, PKSC_IOG, PKSC_CON NCI-H345, NCI-H69, PRSC_CON
	302263 A	VA325517			2.22	BT474, NCI-H520, DU145

	222040	4.4000744				
		AA083710		EST duster (not in UniGene)	2.22	HT29, MB-MDA-453, CALU6
		A1283549		EST singleton (not in UniGene) with exon	2.22	OVCA-R, CALU6, BT474
		AA716612		EST duster (not in UniGene)	2.22	LnCap, NCI-H69, NCI-H69
5		AA877883	3	EST singleton (not in UniGene) with exon	2.22	NCI-H345, NCI-H69, NCI-H69
J	329725	414/00050	0.11.055	CH.14_p2 gi 6065785	2.22	NCI-H69, PRSC_con, NCI-H345
			9 Hs.25577		2.22	CALU6, EB, NCI-H520
		AF142579	,	EST	2.22	A549, OVCA-R, EB
	333815			CH22_FGENES.282_4	2.22	MB-MDA-435s, EB, MB-MDA-453
10	334358	. =		CH22_FGENES.378_1	2.22	NCI-H345, RPWE-2, PRSC_con
10		AFU43250	Hs.30928	3		Ca∞2, NCI-H23, NCI-H520
	335593			CH22_FGENES.581_32	2.21	NCI-H345, PRSC_log, RPWE-2
	334026	4 5000004		CH22_FGENES.318_3	2.21	NCI-H69, PRSC_con, NCI-H345
		AF086064		EST cluster (not in UniGene)	2.21	PRSC_con, PRSC_log, RPWE-2
15			7 Hs.15739		2.21	NCI-H345, PRSC_con, RPWE-2
13		M33374	Hs.661	NADH dehydrogenase (ubiquinone) 1 beta		NCI-H520, CALU6, OVCA-R
		AI300246		EST singleton (not in UniGene) with exon	2.21	MB-MDA-231, MB-MDA-453, HT29
		T87841		EST	2.21	PC3, EB, CALU6
	330064			CH.19_p2 gi 6165044	2.21	NCI-H69, PRSC_con, BT474
20	338819			CH22_DJ246D7.GENSCAN.1-24	2.21	NCI-H69, RPWE-2, PRSC_log
20	337797			CH22_EM:AC005500.GENSCAN.3-4	2.21	LnCap, NCI-H69, NCI-H520
	328025			CH.06_hs gi 5902482	2.2	RPWE-2, PRSC_con, PRSC_log
	326240	ANNONESSE	11- 47200	CH.17_hs gi 5867260	2.2	EB, LnCap, MB-MDA-453
		AVVUUDS/C	Hs.173280		2.2	DU145, DU145, OVCA-R
25	338450	1160404	U= 04044	CH22_EM:AC005500.GENSCAN.359-36	2.2	MCF7, MB-MDA-453, MB-MDA-435s
23	302532		MS.240113	growth hormone secretagogue receptor	2.2	PRSC_con, PRSC_log, PRSC_log
		AA081495		EST duster (not in UniGene)	2.2	NCI-H23, NCI-H520, NCI-358
	337787			CH22_EM.AC000097.GENSCAN.123-3	2.2	EB, PC3, LnCap
	337032	1444507		CH22_FGENES.438-3	2.2	NCI-H69, NCI-H345, RPWE-2
30	300026	M11507		AFFX control: transferrin receptor	2.2	HT29, EB, MB-MDA-231
30	333139			CH22_FGENES.83_16	2.2	HT29, MB-MDA-453, Ca∞2
	334298		•	CH22_FGENES.372_4	2.2	PRSC_con, PRSC_log, RPWE-2
	335002			CH22_FGENES.470_7	2.2	PRSC_con, NCI-H345, NCI-H345
	335000			CH22_FGENES.470_5	2.2	EB, PC3, A549
35	337298	AE4040E2	11- 044004	CH22_FGENES.678-3	2.2	NCI-H69, A549, HT29
55	224940	AF 104253	MS.241301	cofactor required for Sp1 transcriptiona	2.2	EB, CALU6, LnCap
	334819	AVAIAEOCCO	11- OF0000	CH22_FGENES.436_15	2.19	CALU6, BT474, Caco2
	300420	MVV43Z00U	Hs.253296		2.19	DU145, CALU6, HT29
		AC004472		multiple UniGene matches	2.19	RPWE-2, PRSC_log, PRSC_con
40	339401			CH22_BA232E17.GENSCAN.7-7	2.19	NCI-H345, NCI-H69, PRSC_log
70	328791			CH.07_hs gi 5868309	2.19	DU145, PC3, HT29
	337333			CH22_FGENES.711-3	2.19	NCI-H69, NCI-H345, PRSC_log
	339363			CH22_BA354I12.GENSCAN.33-6	2.19	NCI-H69, PRSC_log, PRSC_con
	329429 336927			CH.Y_hs gi 5868882	2.19	CALU6, HT29, OVCA-R
45	336351			CH22_FGENES.348-3	2.19	NCI-H69, PRSC_log, NCI-358
73		AAAA4724	Un 140076	CH22_FGENES.816_3	2.19	DU145, EB, MB-MDA-231
		AI244895	Hs.148876		2.19	CALU6, DU145, OVCA-R
	336590	NIZ44033		EST singleton (not in UniGene) with exon	2.19	NCI-H23, NCI-H23, NCI-358
		A1770001	Hs.209445	CH22_FGENES.51_2	2.19	PRSC_con, NCI-H69, PRSC_log
50	327823	ni//0001	ns.20 <del>344</del> 5		2.18	EB, MB-MDA-231, BT474
50	313257	N02638		CH.05_hs gij5867968	2.18	PRSC_con, NCI-H69, NCI-H345
	335377	132000		EST duster (not in UniGene)	2.18	PRSC_log, RPWE-2, PRSC_con
	303958	AL 042024		CH22_FGENES.543_17	2.18	PC3, MB-MDA-435s, CALU6
			He 120260	EST singleton (not in UniGene) with exon phospholipase A2; group VI	2.18	NCI-H345, RPWE-2, PRSC_∞n
55	335201	11 004004	115.120300		2.18	LnCap, PC3, MB-MDA-435s
55	338591			CH22_FGENES.508_10	2.18	OVCA-R, DU145, HT29
		AA455960	Ha 00405	CH22_EM:AC005500.GENSCAN.434-4	2.18	NCI-H69, NCI-H345, RPWE-2
	337218	*************	113.33403	ESTS	2.18	MCF7, NCI-H23, NCI-H460
		AW118833		CH22_FGENES.614-2	2.18	CALU6, A549, MCF7
60		AA435495	U- 07474	EST singleton (not in UniGene) with exon	2.18	PC3, EB, MB-MDA-435s
00	330275	V1433433	NS.5/1/4	H sapiens mRNA; cDNA DKFZp566E164 (fro		2.18 RPWE-2, NCI-H69, PRSC_log
	335817			CH.05_p2 gi 6671904	2.18	NCI-H345, PRSC_log, PRSC_con
	332896			CH22_FGENES.618_5	2.18	A549, Caco2, PC3
	303294	V 30E300		CH22_FGENES.35_10	2.18	NCI-H345, RPWE-2, PRSC_log
65	338703	V-20000		CH22 ENACONSEGO CENICOAN AGO O	2.17	MB-MDA-435s, A549, MCF7
05	300115 A	1215044	Un 200120	CH22_EM:AC005500.GENSCAN.480-2	2.17	HT29, BT474, NCI-H69
			Hs.208130		2.17	PC3, OVCA-R, HT29
	330979 H		Hs.31795 Hs.155690	ECT <sub>0</sub>	2.17	MCF7, EB, MB-MDA-435s
	317240 A 329078	111100032	ns. 10009U		2.17	MB-MDA-453, DU145, EB
70	312554 A	1222630	He 100200	CH.X_hs gi 5868597	2.17	MB-MDA-453, MB-MDA-231, BT474
, 0	323207 A		Hs.109390		2.17	NCI-H520, OVCA-R, MCF7
		A484435	Hs.192201		2.17	NCI-H69, NCI-H345, PRSC_log
	329097	V-101133	13.4 133/	alpha-1-B glycoprotein	2.17	PRSC_con, LnCap, PRSC_log
	328328			CH.X_hs gi 5868624 CH 07_hs gi 5868375	2.16	MB-MDA-231, MCF7, NCI-358
75		A522440	Hs.135917	CH.07_hs gi 5868375 FSTs	2.16	NCI-H345, PRSC_con, NCI-H69
	329201	TU		CH.X_hs gi 5868718	2.16	BT474, DU145, A549
	J2424 I			OTTO SILVOOT IO	2.16	OVCA-R, PC3, MB-MDA-435s

=

V D III

		303358	AI199714	Hs.158149		2.11	CALU6, OVCA-R, DU145
		306558	AA994743			2.11	HT29, MB-MDA-453, CALU6
		337781			CH22_EM:AC000097.GENSCAN.121-3	2.11	PRSC_log, PRSC_con, RPWE-2
		333140			CH22_FGENES.84_1	2.11	HT29, NCI-H69, OVCA-R
	5			Hs.155281		2.11	MB-MDA-453, MCF7, HT29
		302965	AA446441	Hs.138842	ESTs	2.11	NCI-358, NCI-H23, CALU6
		302138	N83965		EST	2.11	PRSC_log, PRSC_con, NCI-H345
		320802	D83824	Hs.185055	BENE protein	2.11	A549, PC3, HT29
		322152	AA565332		EST duster (not in UniGene)	2.11	A549, CALU6, EB
1	10	326418			CH.19_hs gij5867365	2.1	EB, OVCA-R, DU145
_		308709	A1783498	Hs.181165	eukaryotic translation elongation factor	2.1	MB-MDA-435s, MB-MDA-453, DU145
				Hs.84359	hypothetical protein	2.1	NCI-H23, A549, DU145
		333283			CH22_FGENES.128_13	2.1	NCI-H345, RPWE-2, PRSC_con
		328636			CH.07_hs gi]6004473	2.1	DU145, EB, MB-MDA-453
1	15	329187			CH.X_hs gij5868713	2.1	NCI-358, NCI-H23, NCI-H460
			AA889603		EST singleton (not in UniGene) with exon	2.1	HT29, OVCA-R, PC3
		333220			CH22_FGENES.104_12	2.1	PRSC_con, PRSC_log, RPWE-2
		335092			CH22_FGENES.492_2	2.1	NCI-H69, PRSC_con, NCI-H345
			AA599355		EST singleton (not in UniGene) with exon	2.1	DU145, EB, MCF7
-	20	325359			CH.12_hs gi 5866920	2.1	MB-MDA-453, EB, MB-MDA-435s
-	20		H08730	Hs.6933	ESTs	2.1	NCI-H520, PRSC_∞n, NCI-H345
		323786	AW449315			2.1	OVCA-R, A549, LnCap
		333619	711110010	1.0.100.00	CH22_FGENES.219_3	2.1	BT474, OVCA-R, HT29
			AW502979		EST cluster (not in UniGene)	2.09	CALU6, A549, DU145
	25		AA308601		EST	2.09	DU145, CALU6, NCI-H69
4	25	328570	77300001		CH.07_hs gi 5868231	2.09	LnCap, MB-MDA-231, DU145
			AI871218	Hs.224731		2.09	NCI-H23, NCI-H460, NCI-358
			K02268	Hs.22584	prodynorphin	2.09	PC3, BT474, MB-MDA-453
		334793	N02200	113.22507	CH22_FGENES.433_5	2.09	EB, DU145, LnCap
	30	300000	A A 6 1 8 3 3 5	He 146137	ESTs; Weakly similar to putative [C.eleg	2.09	NCI-H345, PRSC_log, PRSC_con
•	30	300500	AW107060	He 105188	glyceraldehyde-3-phosphate dehydrogenase		A549, NCI-H23, NCI-H460
		330063	AR020041	He 200646	KIAA1118 protein	2.09	PRSC_con, PRSC_log, NCI-H345
			AW295351			2.09	PC3, LnCap, MB-MDA-453
		335693	A11233331	113.103100	CH22_FGENES.596_8	2.09	NCI-H69, LnCap, PRSC_log
	35	325966			CH.16_hs gi 5867147	2.09	MCF7, CALU6, MB-MDA-453
•	33				CH.X_hs gi 6381976	2.09	NCI-H460, EB, DU145
		329319			CH22_EM:AC005500.GENSCAN.396-14	2.09	NCI-H69, NCI-H345, PRSC_log
		338526			CH22_FGENES.128-5	2.09	NCI-H69, NCI-H345, PRSC_log
		336751			CH.12_hs gi 5866974	2.09	HT29, OVCA-R, CALU6
	40	325510	AA292626	He 122854		2.08	NCI-H345, RPWE-2, NCI-358
•	+0	326343	AA232020	113.122054	CH.17_hs gi 6525295	2.08	EB, LnCap, DU145
					CH22_FGENES.568_3	2.08	NCI-H69, PRSC_con, PRSC_log
		335470	T02694	Hs.187515		2.08	MCF7, MB-MDA-453, BT474
			T93681	HS. 107 J 13	CH22 FGENES.534_7	2.08	BT474, MB-MDA-231, HT29
	45	335320	AI184343		EST singleton (not in UniGene) with exon	2.08	HT29, MCF7, PC3
•	43		AIIO4343		CH22_EM:AC005500.GENSCAN.172-11	2.08	LnCap, PC3, HT29
		338080	AI056258	He 122523	ESTe	2.08	MCF7, DU145, MB-MDA-453
				N3. 122323	CH22_EM:AC000097.GENSCAN.77-1	2.08	NCI-H69, NCI-H345, PRSC_log
		337685			CH.02_hs gi 6004455	2.08	NCI-H23, BT474, NCI-358
	50	327461			CH:02_IS \$1,000+35 CH22_FGENES.635_3	2.08	HT29, MB-MDA-231, NCI-H520
	50	335895	414/474 470		EST singleton (not in UniGene) with exon	2.08	MB-MDA-231, BT474, NCI-H345
		303933	AW471472		ESTs; Weakly similar to MYOSIN LIGHT CHA		
		314803	A1935159	HS. 10004 I	NON-MUSCLE ISOZYMES [H.sapiens]	2.08	PC3, A549, BT474
		000700	1150500			2.08	DU145, MB-MDA-435s, OVCA-R
	55		U53530		EST singleton (not in UniGene) with exon	2.08	HT29, MB-MDA-435s, CALU6
	55		AI318588	U- 470070		2.08	A549, LnCap, PC3
			A1334965	Hs.176976		2.08	PC3, MCF7, OVCA-R
			AA860090		EST cluster (not in UniGene) EST singleton (not in UniGene) with exon	2.07	OVCA-R, PC3, EB
			AA976950		EST singleton (not in UniGene) with exon	2.07	HT29, OVCA-R, CALU6
	<b>60</b>		A1421059			2.07	EB, HT29, OVCA-R
	60	329735			CH.14_p2 gi 6065780	2.07	EB, A549, A549
		335193		004505	CH22_FGENES.507_8	2.07	CALU6, A549, EB
		320347	R34423	Hs.221535		2.07	MB-MDA-453, PC3, HT29
		316153	AA724474	HS.14/208	ESIS	2.07	HT29, CALU6, CALU6
			AW293224	Hs.232165			MB-MDA-453, MCF7, CALU6
	65		T65096		EST duster (not in UniGene)	2.07	OVCA-R. DU145, EB
		330204			CH.05_p2 gi 6013606	2.07	PRSC_con, NCI-H345, OVCA-R
		317070	AI142037	Hs.125379	ESTS	2.07	
		337645	i		CH22_EM:AC000097.GENSCAN.10-8	2.07	NCI-H345, PRSC_log, NCI-H69 NCI-H520, CALU6, MCF7
		312501	AW450490	) Hs.132886		2.07	
	70	335587			CH22_FGENES.581_26	2.07	NCI-H69, NCI-H345, PRSC_log
		311482	AI917706	Hs.129997		2.07	NCI-H520, MCF7, MB-MDA-435s
			AF161441		EST	2.07	EB, DU145, CALU6
		304692	AA554202	Hs.76067		2.07	MCF7, MB-MDA-453, PC3
		325369			CH.12_hs gi 5866920	2.07	DU145, DU145, MB-MDA-453
	75	306284	AA936835		EST singleton (not in UniGene) with exon	2.07	BT474, MB-MDA-231, HT29
		337402	2		CH22_FGENES.752-1	2.07	A549, BT474, DU145

	327418	3		CH.02_hs gij5867750	2.07	MCF7, MB-MDA-453, MB-MDA-435s
	31797	7 Al004775	Hs.20509	1 ESTs; Weakly similar to WW domain bindin	2.07	BT474, MB-MDA-453, PC3
			D Hs.16184	5 EST	2.07	MB-MDA-231, MB-MDA-435s, BT474
5			5 Hs.10546		2.07	HT29, BT474, BT474
,	336657 336035			CH22_FGENES.35-14 CH22_FGENES.678_6	2.07	MB-MDA-453, MCF7, NCI-H460
	325320			CH.11_hs gij5866870	2.07 2.06	NCI-H69, PRSC_con, RPWE-2 NCI-H69, PRSC_log, PRSC_con
		AA90531	2	EST singleton (not in UniGene) with exon	2.06	HT29, OVCA-R, MB-MDA-231
10	333175			CH22_FGENES.95_2	2.06	LnCap, HT29, DU145
10			Hs.11550		2.06	MB-MDA-435s, CALU6, CALU6
	310532		Hs.17699		2.06	NCI-H69, PRSC_log, NCI-H345
	334900			CH22_EM:AC005500.GENSCAN.395-35 CH22_FGENES.452_14	2.06 2.06	NCI-H345, PRSC_log, PRSC_log
	337451			CH22_FGENES.774-2	2.06	A549, CALU6, NCI-H69 PRSC_con, PRSC_log, RPWE-2
15	308792	AI815153	Hs.195188	glyceraldehyde-3-phosphate dehydrogenase	2.06	DU145, BT474, MB-MDA-453
	336854			CH22_FGENES.280-1	2.06	LnCap, EB, MB-MDA-435s
		AA434076	i	EST singleton (not in UniGene) with exon	2.06	MB-MDA-231, BT474, CALU6
	326458 303506		Hs. 105887	CH.19_hs gi 5867400	2.06	EB, DU145, LnCap
20	333628		113.103007	CH22_FGENES.226_2	2.06 2.06	LnCap, MCF7, CALU6
		AA190753	1	EST	2.06	NCI-H520, NCI-358, NCI-358 NCI-H69, NCI-H345, PRSC .∞n
	334836			CH22_FGENES.439_6	2.06	NCI-H345, PRSC_con, RPWE-2
	335217			CH22_FGENES.512_3	2.06	PRSC_log, PRSC_con, NCI-H69
25	338970			CH22_DJ32I10.GENSCAN.26-3	2.06	A549, MB-MDA-453, LnCap
23	334842		3 Hs.232857	CH22_FGENES.439_21	2.06	DU145, HT29, CALU6
	332949	A11000720	113.232037	CH22_FGENES.47_12	2.06 2.06	EB, DU145, OVCA-R EB, DU145, OVCA-R
		AW369663	3 Hs.150150	ESTs	2.06	PRSC_con, PRSC_log, RPWE-2
20	329401			CH.X_hs gi 6682544	2.06	NCI-H69, PRSC_con, RPWE-2
30		AA837332		EST duster (not in UniGene)	2.06	OVCA-R, MCF7, MB-MDA-453
		W95840	Hs.59745	NADH dehydrogenase (ubiquinone) flavopro		Cacc2, NCI-358, OVCA-R
	329839 306668	AI004890		CH.14_p2 gi 6672062	2.05	MB-MDA-231, RPWE-2, CALU6
			Hs.136965	EST singleton (not in UniGene) with exon ESTs	2.05 2.05	DU145, MB-MDA-453, MCF7 LnCap, EB, PC3
35		AI909951		tyrosyl-tRNA synthetase	2.05	NCI-H345, PRSC_con, RPWE-2
	339344			CH22_BA354I12.GENSCAN.28-1	2.05	BT474, MB-MDA-231, A549
		A1632098	Hs.198099		2.05	NCI-H69, RPWE-2, MCF7
	327051 336827			CH.21_hs gi 6531965	2.05	PRSC_con, NCI-H345, PRSC_log
40		AI078033	Hs 177170	CH22_FGENES.236-2 ESTs; Moderately similar to !!!! ALU SUB	2.05 2.05	NCI-H345, A549, MB-MDA-231
	335036			CH22_FGENES.475_14	2.05	OVCA-R, DU145, CALU6 NCI-H69, PRSC_con, NCI-H345
		N52880	Hs.122817	ESTs	2.05	RPWE-2, NCI-H345, PRSC_log
	301927	AF014459	Hs.113250	retinoschisis (X-linked; juvenile) 1	2.05	MB-MDA-231, NCI-H345, PRSC_∞n
45	326070			CH.17_hs gi 5867175	2.05	MB-MDA-435s, MB-MDA-231, BT474
73	338514 328098			CH22_EM:AC005500.GENSCAN.392-4 CH.06_hs gij5868020	2.05 2.05	PRSC_con, PRSC_log, RPWE-2
		AA679361	Hs.249487		2.05	DU145, CALU6, EB NCI-H460, PRSC_∞n, NCI-H23
	306193	AA923457		EST singleton (not in UniGene) with exon	2.05	NCI-H345, PRSC_con, RPWE-2
50		AA883808	Hs.174148		2.05	EB, DU145, CALU6
50	336102	AIDOODE	Hs.130555	CH22_FGENES.693_2	2.04	LnCap, NCI-H69, PRSC_log
	333252	A1239093	ns. 130333	CH22_FGENES.116_4	2.04	PRSC_con, RPWE-2, PRSC_log
		AW372340	Hs.159717	ESTs	2.04 2.04	NCI-358, A549, HT29 HT29, MB-MDA-231, BT474
		AA393624		EST cluster (not in UniGene)	2.04	RPWE-2, PRSC_con, MB-MDA-231
55	338770			CH22_EM:AC005500.GENSCAN.520-1	2.04	PRSC_con, NCI-H69, NCI-H460
		Al798611	Hs.157277		2.04	EB, PC3, LnCap
	333004	AW245825	He 21101/	CH22_FGENES.60_1 NADH dehydrogenase (ubiquinone) Fe-S pro	2.04	A549, NCI-358, DU145
		AI905527		ESTs; Moderately similar to !!!! ALU SUB	2.04	NCI-H520, CALU6, Ca∞2 EB, A549, HT29
60		AI276278	Hs.157176		2.04	PC3, MB-MDA-453, BT474
		Al149878	Hs.143519	ESTs; Weakly similar to testicular tekti	2.04	NCI-H69, RPWE-2, NCI-H345
	325851	****		CH.16_hs gi 5867067	2.04	MB-MDA-231, HT29, EB
		AI125604 AW160951	Hs.155117		2.04	MCF7, DU145, DU145
65	334135	AW 10099 I		EST CH22_FGENES.336_2	2.04 2.04	LnCap, OVCA-R, DU145
	329793			CH.14_p2 gi 6522661	2.04	PC3, A549, MB-MDA-435s DU145, CALU6, HT29
	332595	AA256431		G protein pathway suppressor 2	2.04	A549, CALU6, NCI-H23
			Hs.250181	ESTs	2.04	MCF7, HT29, A549
70			Hs.133122		2.04	Ca∞2, A549, MCF7
70	338096	AI052653		EST singleton (not in UniGene) with exon	2.03	EB, LnCap, PC3
	327544			CH22_EM:AC005500.GENSCAN.181-14 CH.03_hs gij5867797	2.03 2.03	DU145, HT29, CALU6 PRSC_con, NCI-H69, NCI-H345
	318813	F13195		<i>.</i>	2.03	PRSC_con, RPWE-2, PRSC_log
75	325289				2.03	EB, OVCA-R, A549
75	311099				2.03	HT29, BT474, EB
	3100/9	MAY22213	Hs.121735	ESIS	2.03	LnCap, OVCA-R, EB

	30953	3 AW15113	1	EST singleton (not in UniGene) with exon	2.03	MB-MDA-231, BT474, LnCap
	338579	9		CH22_EM:AC005500.GENSCAN.431-3	2.03	NCI-H69, NCI-H345, RPWE-2
	326549	)		CH.19_hs gij5867307	2.03	NCI-H69, Ca∞2, NCI-H345
	320012	2 AI628384	Hs.19374	5 ESTs	2.03	BT474, MB-MDA-453, MCF7
5	33411			CH22_FGENES.330_10	2.03	NCI-H69, MB-MDA-231, BT474
	327123			CH.21_hs gi 6531971	2.03	
		AW50231	1	EST cluster (not in UniGene)	2.03	NCI-H345, NCI-H69, RPWE-2
		AA896989				NCI-H345, NCI-H520, NCI-H460
		AA012877		EST singleton (not in UniGene) with exon EST	2.03	NCI-H69, PRSC_log, PRSC_con
10		U52219			2.03	RPWE-2, OVCA-R, EB
10	326646		Пъ. 13632	9 G protein-coupled receptor 50	2.03	NCI-H520, NCI-H23, PC3
				CH.20_hs gi 5867562	2.03	NCI-H460, OVCA-R, HT29
		T61464		EST singleton (not in UniGene) with exon	2.03	NCI-H345, PRSC_con, PRSC_log
		AA535602		EST singleton (not in UniGene) with exon	2.03	A549, DU145, EB
15		M83652	Hs.53155		2.02	NCI-H23, NCI-H460, NCI-358
15		Al473273	Hs.15967	ESTs; Weakly similar to GLUTAMATE [H.sap	2.02	NCI-H345, MB-MDA-231, BT474
	330327			CH.08_p2 gi 5919194	2.02	NCI-H345, NCI-H69, PRSC_log
	308447	AI659985		EST singleton (not in UniGene) with exon	2.02	NCI-H345, RPWE-2, PRSC_log
	307778	AI344972	Hs.231496	S EST	2.02	NCI-H69, CALU6, OVCA-R
• •		T87351	Hs.194121		2.02	NCI-H460, NCI-358, NCI-H520
20	300935	AA513644	Hs.222815	ESTs; Weakly similar to Wiskott-Aldrich	2.02	DU145, EB, OVCA-R
	314318	AL037405	Hs.176141	ESTs	2.02	PRSC_con, LnCap, PRSC_log
	334779			CH22_FGENES.432_1	2.02	EB, HT29, DU145
	336994			CH22_FGENES.410-2	2.02	
	334076			CH22_FGENES.327_31		NCI-H345, PRSC_con, NCI-H69
25		AW452865	Hs.132339	ECTo	2.02	OVCA-R, CALU6, EB
	326783	A1145200	7 113.132333		2.02	MB-MDA-231, NCI-H69, NCI-H345
	336142			CH.20_hs gi 6525298	2.02	NCI-H69, PRSC_con, RPWE-2
		A A C C 2 7 2 2		CH22_FGENES.705_4	2.02	NCI-H69, PRSC_log, PRSC_con
		AA663733		EST cluster (not in UniGene)	2.02	DU145, EB, CALU6
30		AW239364		EST	2.02	PRSC_con, RPWE-2, PRSC_log
30	300944	AW081072	HS.164624	ESTs; Weakly similar to Slit-3 protein [	2.01	RPWE-2, NCI-H69, NCI-H23
			Hs.144857		2.01	PRSC_con, NCI-H345, PRSC_log
			Hs.195078	ESTs	2.01	NCI-H345, NCI-H69, RPWE-2
		R87679		EST duster (not in UniGene)	2.01	HT29, A549, NCI-H460
25	334760			CH22_FGENES.428_9	2.01	NCI-358, NCI-H69, PRSC_log
35	338368			CH22_EM:AC005500.GENSCAN.325-2	2.01	NCI-H23, NCI-H520, NCI-H460
	317300	AI417007	Hs.166338	ESTs	2.01	NCI-H460, DU145, NCI-H23
		AW178750		EST duster (not in UniGene)	2.01	MCF7, MB-MDA-453, OVCA-R
	301366	AA907713	Hs.221667	'	2.01	PRSC_con, NCI-H345, RPWE-2
	333306			***** - * - · · · · · · · · · · · · · ·	2.01	NCI-H69, NCI-H345, PRSC_con
40	328031			<b>****</b>	2.01	MB-MDA-231, NCI-H345, PRSC_con
	301806	AA326007	Hs.12056		2.01	
	300993	AA584930	Hs 191777		2.01	MB-MDA-453, DU145, EB
	320042	T84520			2.01 2.01	HT29, NCI-H23, NCI-358
	331082		Hs.22100	'		PRSC_con, NCI-H345, NCI-H69
45		AI829820	113.22100		2.01	EB, DU145, MB-MDA-435s
		AA732066			2.01	DU145, EB, PC3
		AA576428			2.01	OVCA-R, PC3, MB-MDA-435s
	334855	~~31 0420			2.01	LnCap, MB-MDA-453, DU145
	337121				2.01	NCI-H345, RPWE-2, PRSC_log
50		4 4 4 4 0 4 0 0	11- 404770		2.01	NCI-H69, NCI-H345, PRSC_∞n
50	331030	AA412498	Hs.104778	ESIS	2.01	BT474, BT474, MCF7
	339181				2.01	NCI-H345, PRSC_con, NCI-H69
	327564				2.01	BT474, HT29, DU145
	304108		Hs.28467		2	BT474, OVCA-R, MCF7
			Hs.163297		2	MB-MDA-435s, MB-MDA-453, LnCap
55	312777	W92809	Hs.138557	ESTs 2	2	PRSC_con, NCI-H345, MB-MDA-231
	305888	AA868536	Hs.126145	EST	2	HT29, HT29, BT474
	323185	R52177		EST cluster (not in UniGene)		EB, A549, BT474
		AI761307		EST singleton (not in UniGene) with exon		RPWE-2, PRSC_con, NCI-H345
	325755			CH.14_hs gi 6682474		NCI-H345, PRSC_con, PRSC_log
60	324376	AW499705		EST duster (not in UniGene)		DU145, BT474, PC3
		AA432166		succinate dehydrogenase complex; subunit 2		CALU6, MB-MDA-453, A549
				z z z z z z z z z z z z z z z z z z z	-	בויטת וטודרושוורשווו ויטבויים

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title

10	Pkey	Exr_Accn	UniG_ID	Complete_Title	Ratio Met/BS	Top 3 expressing cell lines
	313166	AI801098	Hs.151500	ESTs	12.23	Caco2, EB, OVCA-R
	334593			CH22_FGENES.408_3	8.06	NCI-H69, OVCA-R, OVCA-R
	331084	R20655	Hs.81281	Human clone 23732 mRNA; partial cds	7.89	LnCap, OVCA-R, EB
15		AA502659			7.77	OVCA-R, EB, CALU6
		AA192455			7.76	CALU6, EB, DU145
		AW362945			6.81	OVCA-R, EB, CALU6
	325519			CH.12_hs gi 6017036	6.34	NCI-H69, NCI-H345, PRSC_con
		H68097	Hs.161023		6.16	OVCA-R, A549, EB
20		AA533447		EST cluster (not in UniGene)	6.15	PC3, EB, CALU6
	337695			CH22_EM:AC000097.GENSCAN.84-1	5.84	NCI-H69, NCI-H345, DU145
		AA378739		EST duster (not in UniGene)	5.77	OVCA-R, DU145, EB
		AA731209		EST duster (not in UniGene) with exon h	5.72	MB-MDA-453, MCF7, MB-MDA-435s
		AI093177	Hs 134923		5.68	A549, NCI-H345, NCI-H69
25				nuclear receptor co-repressor 2	5.68	LnCap, A549, OVCA-R
20		AA421163			5.66	OVCA-R, DU145, Caco2
		H40988	Hs.131965		NCI-H345, OVCA	
		AF086372	113.131303	EST duster (not in UniGene)	5.31	OVCA-R, DU145, PC3
			He 100/10			
30		AA582082			5.17	PRSC_con, PRSC_log, NCI-H345
30		AA565051			5.16	OVCA-R, PC3, EB
		AW271974			5.15	NCI-H69, PRSC_log, PRSC_con
		AW292247			5.05	Ca∞2, OVCA-R, EB
				ESTs; Moderately similar to IIII ALU CLA	5.04	EB, DU145, HT29
25				ESTs; Weakly similar to !!!! ALU SUBFAMI	4.93	OVCA-R, DU145, Ca∞2
35		AW162263			4.84	NCI-H460, NCI-H345, NCI-H23
		AI539443			4.84	DU145, Caco2, MB-MDA-231
				H sapiens clone 24838 mRNA seq	4.83	PC3, OVCA-R, DU145
		AA135159	Hs.203349		4.82	OVCA-R, PC3, Caco2
40		AA078493		EST duster (not in UniGene)	4.81	DU145, EB, OVCA-R
40	325169			ESTs; Weakly similar to !!!! ALU SUBFAMI	4.8	NCI-H345, DU145, LnCap
				ESTs; Moderately similar to !!!! ALU SUB	4.78	DU145, DU145, DU145
	321226	AA311443	Hs.251416	H sapiens mRNA; cDNA DKFZp586E2317 (fr	om	4.75 DU145, OVCA-R, MB-MDA-453
	327772			CH.05_hs gi 5867964	4.74	HT29, MB-MDA-231, NCI-H345
	315642	AA742222	Hs.120634	ESTs	4.7	DU145, EB, MB-MDA-453
45	311905	AA555215	Hs.151913	ESTs	4.7	DU145, Caco2, PRSC_con
	312754	R99834	Hs.250383	ESTs	4.59	OVCA-R, PC3, EB
	336637			CH22_FGENES.13-7	4.58	NCI-H69, PRSC_log, NCI-H345
	331644	T99544	Hs.173734	ESTs; Weakly similar to !!!! ALU CLASS B	4.55	OVCA-R, NCI-H345, Caco2
	336984			CH22_FGENES.401-2	4.55	Caco2, Caco2, EB
50	316261	AW134485	Hs.144967	ESTs	4.53	NCI-H460, NCI-H345, Ca∞2
	300417	AW139492	Hs.245887	ESTs	4.52	DU145, CALU6, EB
	300610	N72596	Hs.99120	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	4.52	OVCA-R, PC3, EB
	324718		Hs.116467			LnCap, PC3, PRSC_con
	332170	F04112	Hs.177178	ESTs		Cacc2, DU145, DU145
55	324042	AA377589		EST duster (not in UniGene)		NCI-H345, PRSC_con, PRSC_log
	331148		Hs.17385	ESTs		CALU6, OVCA-R, EB
	328981			CH.09_hs gi 5868527		HT29, BT474, NCI-H69
	321920	N63915		EST duster (not in UniGene)		Caco2, A549, A549
		AA214584		EST cluster (not in UniGene)		NCI-H23, CALU6, OVCA-R
60		AI680459	Hs 201441			DU145, HT29, CALU6
• •		AI707882		EST singleton (not in UniGene) with exon		MCF7, NCI-H345, OVCA-R
		AF169255		EST cluster (not in UniGene) with exon h		MB-MDA-231, OVCA-R, LnCap
	321847			EST cluster (not in UniGene)		MB-MDA-453, MB-MDA-435s, MB-MDA-231
	337884	100-101		CH22_EM:AC005500.GENSCAN.54-2		HT29, NCI-H23, MB-MDA-435s
65		AI269188	Hs.175656			NCI-H23, NCI-H520, NCI-358
03						
		MASISUIZ	ns. 10//40	ESTs; Weakly similar to !!!! ALU SUBFAMI		PC3, OVCA-R, Caco2
	336638	T01442	Un 400000	CH22_FGENES.14-2		NCI-H69, NCI-H345, PRSC_log
	319379		Hs.193963			PC3, OVCA-R, LnCap
70	312332		Hs.106200			NCI-H69, OVCA-R, NCI-H460
70	331445		Hs.41215			EB, HT29, DU145
		AW136397				Caco2, MB-MDA-453, LnCap
				ESTs; Moderately similar to !!!! ALU SUB		LnCap, NCI-H345, OVCA-R
		AA773876				NCI-H345, Ca∞2, DU145
	300791	AL138455	Hs.256135	ESTs; Moderately similar to !!!! ALU SUB	4.13	NCI-358, RPWE-2, NCI-H460

	312129 AW	300867		EST cluster (not in UniGene)	4.12	OVCA-R, MCF7, A549
		111263 Hs.12			4.11	OVCA-R, Ca∞2, PRSC_con
		71981 Hs.11			4.1	OVCA-R, DU145, Ca∞2
	314022 AW4	452420 Hs.24	48678	ESTs	4.1	OVCA-R, EB, PC3
5	321359 AW4	474412	1	EST cluster (not in UniGene)	4.1	DU145, OVCA-R, PC3
	328841			CH.07_hs gi 6381920	4.09	NCI-H69, PRSC_log, NCI-H345
	337898			CH22_EM:AC005500.GENSCAN.56-5	4.09	NCI-H345, NCI-H69, OVCA-R
	333245	4=4=0 11.44		CH22_FGENES.115_2	4.09 4.06	PRSC_log, PRSC_con, NCI-H345 EB, DU145, CALU6
10	311958 AI24		32965		4.06	OVCA-R, PC3, EB
10	314775 AI14	150944 Hs.25	88809 50541		4.06	BT474, MB-MDA-453, MB-MDA-435s
	309985 AW		30341	EST singleton (not in UniGene) with exon	4.05	MB-MDA-453, NCI-H23, NCI-H520
	311004 AA6			EST duster (not in UniGene)	4.05	MB-MDA-453, OVCA-R, EB
	323497 AI52		21544		4.04	LnCap, OVCA-R, EB
15	332347 W60		21716		4.04	EB, CALU6, PC3
				suppressor of white apricot homolog 2	4.01	A549, EB, Ca∞2
	313197 AI73	38851 Hs.22	22487		3.96	OVCA-R, EB, PC3
	315710 AA9		92785		3.95 3.94	EB, MB-MDA-231, OVCA-R OVCA-R, A549, MB-MDA-453
20	316897 AA8			EST duster (not in UniGene)	3.94 3.94	NCI-H460, Caco2, EB
20	322564 W86 304605 AA5		18344	ESTS singleton (not in UniGene) with exon	3.9	NCI-H345, RPWE-2, BT474
	325726	013223		CH.14_hs gi]6552447	3.9	OVCA-R, LnCap, LnCap
	320190 R32	2047 Hs 14	41012	ESTs; Weakly similar to !!!! ALU SUBFAMI	3.89	DU145, NCI-H23, PRSC_log
	331566 N63		8703		3.87	NCI-H23, NCI-H460, NCI-358
25	319403 T98			EST duster (not in UniGene)	3.86	NCI-H345, PRSC_log, LnCap
	324643 AI4		30729		3.84	OVCA-R, DU145, NCI-H345
	315298 AI96		11377		3.82	NCI-H345, PRSC_con, PRSC_log
	321632 AA4	419617		EST duster (not in UniGene)	3.81	EB, OVCA-R, A549
	313219 N74		82099		3.8	EB, Caco2, OVCA-R
30	330833 AAC	046804		ESTs; Weakly similar to !!!! ALU SUBFAMI	3.8	LnCap, DU145, PC3 EB, HT29, DU145
	327289	.000740		CH.01_hs gi 5867481	3.79 3.79	OVCA-R, PC3, PRSC_con
	314429 AW			EST duster (not in UniGene)	3.79	DU145, CALU6, NCI-H69
		11160 Hs.1: /293995 Hs.1:			3.78	EB, PC3, Caco2
35	336635	233333 113.11	JEET	CH22_FGENES.13-5	3.77	NCI-H69, NCI-H345, PRSC_log
33	333323			CH22_FGENES.138_16	3.76	NCI-H460, NCI-H23, PRSC_∞n
		620331 Hs.2	45351		3.75	NCI-H345, A549, Ca∞2
	316979 AA8	861087		EST cluster (not in UniGene)	3.75	NCI-H345, NCI-H69, RPWE-2
	316435 Al6			ESTs; Weakly similar to !!!! ALU CLASS C	3.74	MB-MDA-435s, MCF7, MB-MDA-453
40	315422 AW	/135357 Hs.1	92374		3.73	OVCA-R, A549, EB
	336616			CH22_FGENES.613_5	3.72 3.71	NCI-H69, NCI-H345, RPWE-2 MB-MDA-231, NCI-H69, EB
	320258 W9		06470	EST cluster (not in UniGene)	3.69	OVCA-R, A549, DU145
	300463 N52 306881 AIO		86470	EST singleton (not in UniGene) with exon	3.68	CALU6, HT29, EB
45	337304	00033		CH22_FGENES.681-6	3.67	MCF7, MB-MDA-453, LnCap
43		/297758 Hs.2	249721		3.67	OVCA-R, MB-MDA-453, DU145
	331073 R07		8628	ESTs; Weakly similar to !!!! ALU SUBFAMI	3.67	RPWE-2, NCI-H345, OVCA-R
		/296277 Hs.1			3.67	MB-MDA-231, DU145, CALU6
	318042 AW	/294522 Hs.1	149991	ESTs	3.66	EB, HT29, CALU6
50	308069 AI4	70895		EST singleton (not in UniGene) with exon	3.64	Ca∞2, Ca∞2, NCI-H23 NCI-H460, NCI-H345, NCI-H69
	327614			CH.04_hs gij6525283	3.62 3.62	NCI-1460, NCI-1343, NCI-169 NCI-358, NCI-H23, NCI-H460
	337514	C00704 Us 4	142502	CH22_FGENES.809-7	3.6	EB. OVCA-R, DU145
		608794 Hs.1	112592	CH.05_hs gi 5867979	3.59	LnCap, OVCA-R, EB
55	327793 331053 N70	∩242 He 1	183146		3.59	OVCA-R, EB, Caco2
55		134888 Hs.1			3.58	HT29, CALU6, CALU6
	319872 R9		189699		3.58	PRSC_con, LnCap, RPWE-2
	317902 AI8		211265	ESTs	3.57	CALU6, NCI-H345, OVCA-R
	324090 AI6		116070		3.57	PRSC_con, NCI-H345, PRSC_log
60		/204314 Hs.1	170784	ESTs	3.57	NCI-H69, NCI-H345, PRSC_con
	307752 AI3		407054	EST singleton (not in UniGene) with exon	3.56	NCI-358, HT29, MB-MDA-231 NCI-H345, NCI-H69, Caco2
	322438 W4		167851		3.55 3.55	MB-MDA-231, PRSC_con, LnCap
	311275 Al6	339100 HS.2	207144	CH22_DJ246D7.GENSCAN.6-7	3.54	LnCap, PC3, OVCA-R
65	338830 315647 AA	648983 Hs.2	212911		3.53	OVCA-R, MB-MDA-453, CALU6
05	331469 N2		39140		3.52	EB, A549, CALU6
	313445 Al1		127264		3.51	EB, OVCA-R, A549
	330139			CH.21_p2 gil4210430	3.5	EB, CALU6, DU145
	304450 AA	404521 Hs.1	10326	coatomer protein complex; subunit epsilo	3.49	NCI-H345, NCI-H69, NCI-H460
70	325763			CH.14_hs gi 6682475	3.49	PC3, BT474, OVCA-R
	312803 AA	677934 Hs.1	117864	ESTs	3.47	OVCA-R, Cacc2, MB-MDA-453
	303654 AA	436942 Hs.1	168308	ESTS Worlds similar to since finance and	3.46	DU145, NCI-H460, NCI-H69 PRSC_con, PRSC_log, NCI-H69
				ESTs; Weakly similar to zinc finger prot	3.46 3.44	Cacc2, MB-MDA-435s, NCI-H460
75		.036955 Hs.1	10/040	CH22_FGENES.814-6	3.43	NCI-H69, HT29, PC3
13	337517 324865 AA	702138 Hs.1	114103		3.42	NCI-H23, NCI-H460, NCI-H520
	J2400J AM	1102100 113.1	. 17 100			•

	323755	AW300094		EST duster (not in UniGene)	3.42	PRSC_con, RPWE-2, NCI-H345
	314452	AL042699	Hs.209222		3.42	NCI-H345, PRSC_con, PRSC_log
	337911			CH22_EM:AC005500.GENSCAN.59-6	3.42	OVCA-R, PC3, HT29
_		AI025499			3.41	CALU6, LnCap, OVCA-R
5	311859	AA704705	Hs.181044	ESTs; Weakly similar to Chain A; Human O		
				Complexed With L-Canaline [H.sapiens]	3.41	LnCap, MB-MDA-435s, A549
		H15560	Hs.131833		3.41	NCI-H69, LnCap, LnCap
		AA228883		EST duster (not in UniGene)	3.41	Caco2, OVCA-R, NCI-H69
10	325690	AA398216	He 100002	CH.14_hs gi 5867021	3.4 3.4	HT29, CALU6, DU145
10		AI691065			3.4	MB-MDA-231, BT474, EB PRSC_con, NCI-H345, NCI-H69
		S77356	113.130700	transcript ch21=oligomycin sensitivity c	0.4	7 1100_001, 110141040, 11014103
				8 stomach cancer cell lines, mRNA, 262 n	3.39	NCI-H23, Ca∞2, A549
	314660	AA436007	Hs.188780		3.39	OVCA-R, BT474, Caco2
15	321321	AB033072		EST duster (not in UniGene)	3.39	NCI-358, EB, Caco2
		AA234009	Hs.188715		3.38	DU145, CALU6, CALU6
	328592	11004405	11. 000400	CH.07_hs gi 5868227	3.38	MCF7, NCI-358, MB-MDA-231
		AI631195	HS.232193		3.36	NCI-H520, NCI-H23, PRSC_log
20	327740	AA393460		EST duster (not in UniGene)	3.36 3.35	DU145, EB, Caco2 EB, LaCap, OVCA B
2,0	326857			CH.05_hs gi 5867943 CH.20_hs gi 6552460	3.33	EB, LnCap, OVCA-R NCI-H69, MCF7, NCI-H345
		AW339612	Hs 249364		3.31	NCI-H345, PRSC_con, PRSC_log
	325760			CH.14_hs gi 6552449	3.3	EB, CALU6, HT29
_ 0	337513			CH22_FGENES.809-4	3.29	LnCap, NCI-H23, NCI-H460
25	336606			CH22_FGENES.429_3	3.29	NCI-H69, A549, NCI-H23
	322895	AW470295	Hs.192152	ESTs	3.29	DU145, Ca∞2, EB
		AA814971	Hs.257634		3.29	RPWE-2, NCI-H69, NCI-H345
	328224			CH.06_hs gi 5868101	3.28	DU145, NCI-H345, LnCap
20	336128	4.4004202	U- 4047	CH22_FGENES.701_16	3.27	BT474, NCI-H520, MB-MDA-231
30		AA281323	MS.4947	ESTs	3.27	Ca∞2, PC3, NCI-H345
		M14269 AW450376	He 120902	EST duster (not in UniGene) with exon h	3.27 3.26	DU145, CALU6, NCI-H520 OVCA-R, NCI-H69, DU145
		AI681578			3.26	LnCap, NCI-H345, PRSC_log
	334690	7.100 1070	113.114104	CH22_FGENES.420_3	3.25	NCI-H69, RPWE-2, PRSC_con
35		AI761036		EST singleton (not in UniGene) with exon	3.25	DU145, MB-MDA-231, HT29
			Hs.111334	ferritin; light polypeptide	3.24	OVCA-R, DU145, A549
		AA648314			3.24	NCI-H460, NCI-H23, MB-MDA-453
				KIAA0953 protein	3.24	EB, MCF7, MB-MDA-435s
40		AA810788	Hs.123337		3.23	DU145, OVCA-R, BT474
40	326942			CH.21_hs gi 6004446	3.22	HT29, BT474, NCI-H23
		AI826999	MS.224624		3.21	OVCA-R, MB-MDA-453, EB
		R78712 AW131368	He 186736	EST cluster (not in UniGene)	3.21 3.21	DU145, LnCap, EB Ca∞2, NCI-358, NCI-H460
		AW241987			3.19	OVCA-R, PC3, LnCap
45		AI884313			3.19	NCI-358, NCI-H345, MCF7
		AA130859		EST cluster (not in UniGene)	3.18	MB-MDA-231, HT29, BT474
	336634			CH22_FGENES.13-4	3.18	NCI-H69, NCI-H345, BT474
				ESTs; Weakly similar to NG26 [H.sapiens]	3.17	NCI-H345, NCI-H345, NCI-358
50		AW136836	Hs.144583		3.17	Ca∞2, EB, OVCA-R
50		AI188864	H= 400000	EST singleton (not in UniGene) with exon	3.17	EB, CALU6, CALU6
		AI174861	Hs.190623 Hs.128064		3.17	OVCA-R, DU145, PC3
		AI307359 AA770682	NS. 120004	EST singleton (not in UniGene) with exon	3.17 3.17	MB-MDA-231, BT474, EB NCI-358, Ca∞2, HT29
		AA446131	Hs. 124918		3.17	EB, OVCA-R, Caco2
55		AI431345	Hs.161784		3.17	EB, BT474, MCF7
	303388	AL039604		EST cluster (not in UniGene) with exon h	3.17	HT29, NCI-358, Caco2
	332273	R05818	Hs.173830	ESTs	3.16	MCF7, DU145, EB
		AW088739	Hs.243770	ESTs	3.16	MB-MDA-453, DU145, MCF7
<b>CO</b>	335344			CH22_FGENES.536_3	3.15	PRSC_log, NCI-H345, PRSC_con
60	326162	4 4 4 0 4 7 0 0		CH.17_hs gi 5867168	3.15	BT474, HT29, HT29
		AA424703		EST singleton (not in UniGene) with exon	3.15	NCI-H23, RPWE-2, NCI-H460
	339340 325393			CH22_BA354I12.GENSCAN.27-8 CH.12_hs gij5866921	3.15 3.13	LnCap, OVCA-R, MB-MDA-453 Ca∞2, NCI-H23, NCI-358
		AA732484	Hs 169399		3.13	OVCA-R, EB, MB-MDA-453
65		AI160868		EST singleton (not in UniGene) with exon	3.12	RPWE-2, PRSC_con, PRSC_log
	313001		Hs.249591	ESTs; Moderately similar to !!!! ALU SUB	3.12	NCI-H345, OVCA-R, Caco2
	307606	Al290006		EST singleton (not in UniGene) with exon	3.12	MB-MDA-231, HT29, NCI-H23
	325710			CH.14_hs gi 6682473	3.09	NCI-H69, MB-MDA-453, BT474
70		AA400079	Hs.257854		3.09	EB, DU145, CALU6
70	335482			CH22_FGENES.570_11	3.09	NCI-H460, NCI-358, NCI-H23
	326310			CH.17_hs gi 5867277	3.08	MCF7, MB-MDA-453, PC3
	325742 312467	AI241809	Hs.75458	CH.14_hs gij6552448	3.08 3.08	NCI-H23, NCI-H460, HT29
	312467	A124 1003	1 15.7 3430	ribosomal protein L18 CH.01_hs gi 6456757	3.07	NCI-358, NCI-H23, NCI-H460 NCI-H69, MB-MDA-435s, MB-MDA-435s
75		AW205632	Hs.211198		3.07	OVCA-R, A549, Caco2
	322373		Hs.130829		3.07	NCI-H69, PRSC_con, NCI-H345
						-

	324497	AW152624	Hs.136340	ESTs	3.06	NCI-H345, RPWE-2, PRSC_∞n
	315095	AA831815	Hs.243788	ESTs	3.06	Caco2, DU145, EB
		N79647		EST cluster (not in UniGene) with exon h	3.05	OVCA-R, A549, NCI-H460
_	302842	AW383226	Hs.163834	ESTs; Highly similar to Chp [R.norvegicu	3.05	A549, DU145, NCI-H23
5		AA952875	Hs.221274	ESTs	3.04	BT474, HT29, HT29
	334650			CH22_FGENES.417_17	3.04	MCF7, BT474, OVCA-R
		AI002913		EST singleton (not in UniGene) with exon	3.04	CALU6, MCF7, BT474
		Al110679		EST duster (not in UniGene)	3.03	NCI-H345, RPWE-2, OVCA-R
10			Hs.224906		3.03	PRSC_log, PRSC_con, NCI-H460
10			Hs.151547		3.03	DU145, MB-MDA-435s, HT29
		AA617735	Hs.121774	EST singleton (not in UniGene) with exon	3.03 3.03	CALU6, BT474, MB-MDA-435s EB. NCI-H460, Ca∞2
		U66199		fibroblast growth factor 11	3.03	HT29, DU145, PC3
	336202	000100	110.240100	CH22_FGENES.719_6	3.02	NCI-H69, NCI-H23, NCI-H23
15		AL117539	Hs.173515	H sapiens mRNA; cDNA DKFZp586H021 (f		3.02 EB, DU145, CALU6
			Hs.158528		3.01	Ca∞2, EB, NCI-H69
	335606			CH22_FGENES.582_3	3.01	NCI-H23, NCI-H520, NCI-H345
	330058			CH.17_p2 gij6634847	3.01	OVCA-R, HT29, LnCap
20		AA071215		EST cluster (not in UniGene) with exon h	3.01	MCF7, RPWE-2, MB-MDA-453
20		AI299617		EST singleton (not in UniGene) with exon	3	MB-MDA-231, LnCap, BT474
		AL119445	Hs.203213		3	NCI-H23, NCI-H520, NCI-H460
	336232 334915			CH22_FGENES.736_7	3 3	HT29, BT474, MB-MDA-231
	329116			CH22_FGENES.457_4	3	NCI-H345, PRSC_con, NCI-H69
25	333495			CH.X_hs gi 5868650 CH22_FGENES.168_5	3	NCI-H69, PRSC_∞n, RPWE-2 OVCA-R, NCI-H69, NCI-H345
25		A1738488	Hs.115838		2.99	HT29, PRSC_con, DU145
				DKFZP564F1422 protein	2.99	EB, A549, MCF7
			Hs.154091		2.99	DU145, DU145, OVCA-R
	318050	AI052093	Hs.133132	ESTs	2.99	NCI-H345, DU145, NCI-H520
30			Hs.98722		2.99	NCI-358, NCI-H69, MB-MDA-435s
		AA587773	Hs.136494	ESTs	2.98	MB-MDA-231, BT474, LnCap
	339251			CH22_BA354I12.GENSCAN.7-5	2.98	NCI-H69, PRSC_log, HT29
	303835			EST cluster (not in UniGene) with exon h	2.97 .	BT474, NCI-H345, LnCap
25			Hs.256832		2.97	DU145, A549, OVCA-R
35		AB028953	HS.204121	KIAA1030 protein	2.97	LnCap, DU145, PC3
	327624 329029			CH.04_hs gi 5867871	2.97	EB, DU145, LnCap
		A A 8 6 8 5 8 A	Hs.126154	CH.X_hs gi 6525302	2.96 2.96	NCI-H69, PRSC_log, LnCap
	328016	~~0000	113.120134	CH.06_hs gi 5902482	2.96	DU145, EB, LnCap NCI-H345, PRSC_∞n, DU145
40		AI762475	Hs 151327	ESTs; Moderately similar to !!!! ALU SUB	2.96	OVCA-R, NCI-H69, NCI-H69
	332301		Hs.127826		2.96	OVCA-R, DU145, MB-MDA-231
				ESTs; Weakly similar to 25 kDa trypsin i	2.95	NCI-358, NCI-H460, Caco2
	318226	AI078446	Hs.134125	ESTs	2.95	NCI-H460, NCI-H23, NCI-358
4.5			Hs.254110		2.94	EB, DU145, OVCA-R
45			Hs.183817		2.94	DU145, LnCap, LnCap
			Hs.158381		2.94	PRSC_con, PRSC_log, RPWE-2
				Mediterranean fever	2.93	EB, NCI-H69, DU145
			Hs.243468 Hs.214028	· -	2.93 2.92	NCI-H345, LnCap, LnCap
50	336632	AA340124	H3.2 14020	CH22_FGENES.13-2	2.92	EB, Cacc2, HT29 NCI-H69, NCI-H345, MB-MDA-231
30	328886			CH.07_hs gij6588003	2.92	HT29, PC3, LnCap
	301859	T61587		EST cluster (not in UniGene) with exon h	2.92	LnCap, EB, EB
			Hs.143022		2.92	PRSC_con, PRSC_log, RPWE-2
2.2			Hs.128171		2.92	CALU6, EB, A549
55	322264	AF086242		EST cluster (not in UniGene)	2.92	Cacc2, OVCA-R, DU145
	315135	AA627561	Hs.192446		2.91	EB, HT29, DU145
	327982			CH.06_hs gi 5868216	2.91	LnCap, MB-MDA-453, NCI-H69
			Hs.131741		2.91	NCI-H460, NCI-H520, RPWE-2
60		AA527650	Hs.156037		2.9	PRSC_∞n, RPWE-2, MB-MDA-231
00	339032	A1623950	Hs.2186	CH22_DA59H18.GENSCAN.25-1	2.9	NCI-H69, PRSC_con, RPWE-2
	312133		Hs.221665	eukaryotic translation elongation factor	2.89 2.88	BT474, MB-MDA-231, HT29 Caco2, MB-MDA-453, MCF7
		AI434166	113.22 1005	EST singleton (not in UniGene) with exon	2.88	NCI-H520, MCF7, NCI-H23
			Hs.181165	eukaryotic translation elongation factor	2.88	Caco2, NCI-H69, NCI-H345
65			Hs.119559		2.88	MB-MDA-453, DU145, EB
	331496		Hs.171984		2.86	MB-MDA-453, PC3, MCF7
	320016	H57622	Hs.194574	ESTs	2.86	PRSC_con, RPWE-2, PRSC_log
			Hs.220751		2.86	NCI-H345, PRSC_con, PRSC_log
70	301822			integrin; alpha 2 (CD49B; alpha 2 subuni	2.86	PC3, BT474, CALU6
70				Rhesus blood group-associated glycoprote	2.85	DU145, HT29, MB-MDA-231
			Hs.210655	_	2.84	PRSC_con, RPWE-2, NCI-H345
				ESTs; Weakly similar to hypothetical L1	2.83	HT29, MB-MDA-231, BT474
			Hs.159914		2.83 2.83	Cacc2, MB-MDA-453, A549
75			Hs.213724	ESTs; Weakly similar to !!!! ALU CLASS C	2.83	NCI-H345, MCF7, Cacc2 LnCap, Cacc2, NCI-H460
			Hs.254669		2.82	BT474, LnCap, RPWE-2
						ar ir ij wioup; iti iiw t

	310950	AI582758	Hs.170561	ESTs	2.82	EB, MB-MDA-453, LnCap
			Hs.207604		2.82	PC3, HT29, CALU6
	325410			CH.12_hs gi 5866921	2.81	MB-MDA-453, PRSC_∞n, NCI-358
_		AI565458	Hs.116385		2.81	PRSC_∞n, EB, RPWE-2
5	334244			CH22_FGENES.365_5	2.81	OVCA-R, PC3, MB-MDA-453
		AW025709		EST singleton (not in UniGene) with exon	2.81 2.81	NCI-H460, NCI-H23, NCI-358
	328467	AW250501		CH.07_hs gi 5868434 EST cluster (not in UniGene)	2.81	EB, OVCA-R, HT29 BT474, NCI-H23, MB-MDA-231
	326412	AVV230301		CH.19_hs gi 5867362	2.81	BT474, PRSC_log, RPWE-2
10		AA309616		EST cluster (not in UniGene) with exon h	2.8	CALU6, NCI-H345, DU145
	328462			CH.07_hs gi 5868433	2.8	BT474, CALU6, MCF7
	335157			CH22_FGENES.501_7	2.8	NCI-H69, NCI-H345, PRSC_log
			Hs.255853		2.79	OVCA-R, DU145, LnCap
1.5		AI695047	Hs.202395		2.79	DU145, MB-MDA-435s, PC3
15		AI435973	Hs.128056		2.79	NCI-H460, NCI-358, DU145
		AI377596	Hs.3337 Hs.170651	transmembrane 4 superfamily member 1	2.79 2.79	A549, PC3, OVCA-R OVCA-R, MCF7, EB
				ESTs; Moderately similar to hypothetical	2.79	PC3, OVCA-R, DU145
		AI870248	113.223101	EST singleton (not in UniGene) with exon	2.78	BT474, MB-MDA-231, EB
20	329107	/ IIO		CH.X_hs gij5868626	2.78	DU145, MCF7, MB-MDA-435s
	313975	AW025024		keratin 18	2.78	Ca∞2, EB, DU145
	330901	AA157818	Hs.238380	Human endogenous retroviral protease mRN		PC3, NCI-H520, BT474
	311749	R06249	Hs.13911	ESTs	2.78	OVCA-R, MB-MDA-453, MCF7
25	329853			CH.14_p2 gi 6682295	2.78	BT474, BT474, HT29
25		AF088076		EST duster (not in UniGene)	2.77	NCI-H345, Cacc2, LnCap NCI-H69, NCI-H345, MB-MDA-231
	326806	A A 42C 422		CH.20_hs gi[6469835	2.77 2.77	NCI-H460, MB-MDA-435s, CALU6
		AA436432 AF075082		EST cluster (not in UniGene) EST cluster (not in UniGene)	2.77	NCI-358, NCI-H460, Caco2
			Hs.193767		2.77	DU145, EB, CALU6
30				ESTs; Weakly similar to D(4) DOPAMINE RE		NCI-H69, RPWE-2, PRSC_con
	327739	7		CH.05_hs gij5867942	2.76	EB, PC3, LnCap
		AI445116		EST singleton (not in UniGene) with exon	2.76	LnCap, HT29, MB-MDA-231
	331549	N56866	Hs.237507	EST	2.76	MB-MDA-453, MCF7, OVCA-R
25		AA418599		caveolin 3	2.75	MB-MDA-231, NCI-H345, BT474
35		AA533505	Hs.185844		2.75	PRSC_con, OVCA-R, EB
	335565	A A D 4 C 4 7 C		CH22_FGENES.579_1	2.75 2.74	OVCA-R, EB, A549 EB, LnCap, DU145
		AA916176 N54803		EST singleton (not in UniGene) with exon yv31d2.s1 Soares fetal liver spleen 1NFL	2.17	LB, Gloap, BO 143
	332240	110-1000		3' similar to contains L1.t3 L1 repetit	2.74	DU145, EB, CALU6
40	313246	N90762	Hs.159454		2.74	NCI-H69, NCI-H345, PRSC_log
	303642	AW299459		EST duster (not in UniGene) with exon h	2.74	EB, A549, Caco2
	325513			CH.12_hs gi 6017035	2.74	MB-MDA-231, NCI-H345, BT474
	337236			CH22_FGENES.639-2	2.74	MCF7, MB-MDA-453, NCI-H69
15		AW407892	Hs.244807		2.74	BT474, NCI-H345, NCI-H69
45	339266	A14/02064E	Un 225224	CH22_BA354I12.GENSCAN.10-4 ESTs; Weakly similar to KIAA0422 [H.sapi	2.73 2.73	CALU6, DU145, OVCA-R NCI-H345, RPWE-2, PRSC_log
		R00099	Hs.193642		2.72	LnCap, PC3, OVCA-R
			Hs.201893		2.72	DU145, EB, MB-MDA-435s
	324982			ESTs	2.71	PRSC_con, PRSC_log, RPWE-2
50		AA629988		EST singleton (not in UniGene) with exon	2.71	DU145, DU145, NCI-358
	315396	AW296107	Hs.152686		2.69	OVCA-R, Caco2, EB
		AI908374		EST cluster (not in UniGene)	2.69	RPWE-2, LnCap, PC3
				EST; Moderately similar to PK-120 precur	2.69 2.68	LnCap, NCI-H23, NCI-358 Caco2, OVCA-R, HT29
55		A1291330	Hs.233482	EST cluster (not in UniGene)	2.68	NCI-H460, Caco2, PRSC_log
55		AA425688	Hs 41641	ESTs; Weakly similar to CAGH4 [H.sapiens	2.68	MB-MDA-435s, NCI-H520, NCI-H460
	339116			CH22_DA59H18.GENSCAN.49-4	2.68	DU145, EB, CALU6
		A1565566	Hs.168587		2.68	PRSC_con, OVCA-R, PRSC_log
	318728	Z30201		EST duster (not in UniGene)	2.68	LnCap, Ca∞2, PC3
60		AA584540		EST singleton (not in UniGene) with exon	2.68	BT474, OVCA-R, RPWE-2
	312393			ESTs; Weakly similar to !!!! ALU CLASS E	2.68	NCI-H345, PRSC_con, EB
			HS.92236	KIAA0304 gene product	2.67	NCI-358, OVCA-R, Cacc2
		AA723860 H08778	Hs.133521	EST singleton (not in UniGene) with exon	2.66 2.66	OVCA-R, EB, MCF7 EB, PC3, OVCA-R
65		AI871129		ESTs; Weakly similar to zinc finger prot	2.66	NCI-H23, NCI-H520, NCI-H460
05		W76021	113.17.2007	EST duster (not in UniGene)	2.66	DU145, OVCA-R, PC3
			Hs.165954		2.66	EB, OVCA-R, Ca∞2
		Al217394	Hs.242447	ESTs	2.65	PRSC_con, A549, HT29
70		AF062275		EST duster (not in UniGene) with exon h	2.65	NCI-H23, BT474, MCF7
70				ESTs; Weakly similar to !!!! ALU SUBFAMI	2.65	PC3, EB, OVCA-R
		AI631546	Hs.159732		2.65 2.65	PRSC_con, PRSC_log, NCI-H69 RT474 FR MCF7
	300694	AA063406		EST cluster (not in UniGene) with exon h EST cluster (not in UniGene)	2.64	BT474, EB, MCF7 EB, OVCA-R, DU145
	336538	1120010		CH22_FGENES.840_2	2.64	DU145, NCI-H460, NCI-358
75		AA829961		EST cluster (not in UniGene)	2.64	LnCap, OVCA-R, EB
	328134			CH.06_hs gij5868039	2.64	LnCap, EB, CALU6

		329330	CH.X_hs gil5868806	264	50 04440 Duta
		316664 AI042101	EST duster (not in UniGene)	2.64 2.64	EB, CALU6, DU145
		328015	CH.06_hs gi 5902482	2.63	NCI-H345, MB-MDA-231, PRSC_log
	_	308991 Al879831 ·	EST singleton (not in UniGene) with exon	2.63	BT474, HT29, MB-MDA-231 BT474, EB, NCI-H23
	5	323899 AL042966	EST duster (not in UniGene)	2.62	DU145, A549, CALU6
		321708 AA476817	EST duster (not in UniGene)	2.62	EB, A549, CALU6
		301752 T75247	EST duster (not in UniGene) with exon h	2.62	HT29, BT474, NCI-H345
		309351 AW057547	EST singleton (not in UniGene) with exon	2.62	NCI-H23, PRSC_con, LnCap
	10	314412 Al864270 Hs.155654	4 ESTs	2.62	CALU6, MB-MDA-231, BT474
	10	309441 AW103055 Hs.244230 335993		2.62	BT474, MB-MDA-231, MB-MDA-453
			CH22_FGENES.656_6	2.61	NCI-H460, NCI-358, NCI-H520
		318196 Al056776 Hs.133397	ESTs; Weakly similar to KIAA0862 protein	2.6	EB, CALU6, HT29
		300558 AI540051 Hs.122638	ESTS, Weakly Similar to KIAAU862 protein		DU145, A549, PC3
	15	318594 AA918320 Hs.224581	FSTe	2.6	OVCA-R, NCI-H69, MCF7
		308554 Al698132 Hs.201923	EST	2.6 2.6	PC3, MB-MDA-453, DU145
		335108	CH22_FGENES.494_14	2.6	LnCap, EB, NCI-H345
		312483 Al417526 Hs.184636	ESTs	2.59	NCI-H69, NCI-H345, MB-MDA-231 PC3, DU145, OVCA-R
	20	311981 AW452773 Hs.257612	EST	2.59	NCI-H460, MB-MDA-453, NCI-H23
	20	319359 F13458	EST cluster (not in UniGene)	2.59	LnCap, NCI-H460, MB-MDA-231
		300230 Al377746 Hs.158846	ESTs	2.59	HT29, NCI-358, NCI-H345
		316504 AW135854 Hs.132458		2.59	DU145, EB, CALU6
		322337 AA249804	EST cluster (not in UniGene)	2.59	NCI-H69, NCI-H345, NCI-H345
	25	301775 AW247670 301089 AA666396 Hs.220727	EST duster (not in UniGene) with exon h	2.59	NCI-H345, RPWE-2, PRSC_log
	23			2.58	PRSC_log, PRSC_con, RPWE-2
=å		331213 T88698 Hs.163862 321121 W23285		2.58	DU145, EB, OVCA-R
		316634 AW241910 Hs.122254	EST cluster (not in UniGene)	2.58	NCI-H69, MB-MDA-435s, PC3
===		322141 AF075092	EST cluster (not in UniGene)	2.58	MCF7, HT29, BT474
	30	312108 T82331 Hs.127453	FSTs	2.58 2.58	PC3, OVCA-R, HT29
Ü		339071	CH22 DA59H18.GENSCAN 34-1	2.58	A549, CALU6, Ca∞2 CALU6, DU145, EB
		311666 AW389509 Hs.223747	ESTs	2.57	OVCA-R, MB-MDA-231, BT474
₩ ==		318662 AI285898 Hs.115367		2.57	OVCA-R, MB-MBA-231, B1474 OVCA-R, DU145, EB
4n# 4mp 4mp 4Em	25	317010 AA863395	EST duster (not in UniGene)	2.57	NCI-H520, PRSC_con, NCI-358
1	35	324710 Al742028 Hs.120884	ESTs; Weakly similar to RAS-RELATED PR	ROT	2.57 LnCap, DU145, MB-MDA-453
4		32/888	CH.06_hs gi 5868149	2.56	NCI-H345, MB-MDA-435s, RPWE-2
		336149	CH22_FGENES.706_5	2.56	NCI-H69, PC3, A549
2		312816 H74319 Hs.188620 327999		2.56	EB, Ca∞2, NCI-H460
Ì	40	316761 Al911173 Hs.213722	CH.06_hs gi 5867994	2.56	NCI-358, NCI-H520, NCI-H23
B	10			2.55	NCI-H345, NCI-H460, MB-MDA-231
3			CH22_FGENES.367-1 inositol polyphosphate-4-phosphatase; ty	2.55	HT29, CALU6, CALU6
F F		315417 AW452360 Hs.186770	FSTe	2.55	NCI-H460, NCI-H23, HT29
į		331603 N78656 Hs.161535		2.55 2.55	NCI-H345, NCI-H69, PRSC_∞n
	45		EST singleton (not in UniGene) with exon	2.55	NCI-H345, PRSC_con, PRSC_log BT474, MB-MDA-231, MCF7
		337289	CH22 FGENES 672-8	2.54	BT474, MIS-MIDA-231, MCP7 BT474, HT29, MB-MDA-231
		314242 Al570943 Hs.246280	ESTs	2.54	Cacc2, MB-MDA-435s, MB-MDA-453
			CH.06_hs gi 5902482	2.54	MB-MDA-231, DU145, MB-MDA-453
	50	307215 Al193189	EST singleton (not in UniGene) with exon	2.53	HT29, CALU6, MB-MDA-231
	30	327566	CH.03_hs gij5867811	2.53	NCI-H69, NCI-H520, NCI-H345
		326338 318115 Al384027 Hs.159130 I	CH.17_hs gi 6056311	2.53	PC3, A549, DU145
			ESTs; Moderately similar to !!!! ALU SUB	2.53	DU145, EB, PC3
		322059 AA412371 Hs.121344 E	EST singleton (not in UniGene) with exon	2.52	NCI-H23, NCI-H520, NCI-358
	55		EST cluster (not in UniGene)	2.52	EB, DU145, OVCA-R
		314032 AW081897 Hs.193211 E	-St Guster (not in OniGene) -Ste	2.52	PRSC_con, RPWE-2, NCI-H69
		336125	CH22_FGENES.701_12	2.52 2.51	NCI-H345, LnCap, DU145
		312765 Al692908 Hs.181873 E	STs	2.51	NCI-H69, LnCap, DU145
			CH22_FGENES.572_3	2.51	NCI-H23, NCI-358, NCI-H520 HT29, BT474, OVCA-R
	60	327585	CH.03_hs gi 5867825	2.51	HT29, NCI-H460, MB-MDA-453
		323183 AW393850 E	ST cluster (not in UniGene)	2.51	MB-MDA-231, LnCap, RPWE-2
		314418 Al478722 Hs.232275 E	STs; Moderately similar to !!!! ALU SUB	2.51	EB, DU145, DU145
		313361 Al359782 Hs.137312 E	STs	2.5	CALU6, HT29, DU145
	65	305632 AA805276 E	ST singleton (not in UniGene) with exon	2.5	MB-MDA-453, NCI-H460, NCI-H23
	05	331689 W90131 Hs.184675 E		2.5	NCI-H69, EB, A549
		323438 AI540243 Hs.113817 E		2.5	NCI-H345, PRSC_con, MB-MDA-231
		315742 Al821724 Hs.143198 H 305971 AA886874 E	sapiens PAC clone DJ0872F07 from 7q31	2.5	MCF7, MB-MDA-453, MB-MDA-435s
		000000	ST singleton (not in UniGene) with exon	2.5	NCI-358, NCI-H23, NCI-H520
	70		H22_FGENES.13-3 ST singleton (not in UniCana) with aver	2.5	NCI-H69, NCI-H345, PRSC_log
	-	207005 -	ST singleton (not in UniGene) with exon H.06_hs gij5868172	2.49	NCI-H69, BT474, MB-MDA-231
		200000	H22_FGENES.683_4	2.49	NCI-358, NCI-358, NCI-H460
		000000	H.07_hs gi 6588003	2.49 2.48	EB, HT29, MB-MDA-231
		311244 AW016694 Hs.197689 E	STs	2.48	MB-MDA-435s, MB-MDA-453, PRSC_log NCI-H345, MCF7, PC3
·	/5	327155 C	H.01_hs gi 5867549	2.48	NCI-H345, MC-7, PC3 NCI-H69, MB-MDA-231, NCI-H345
			H22_FGENES.453_2	2.48	DU145, NCI-H345, MB-MDA-231
					· · · · · · · · · · · · · · · · · ·

	314887	AA910236	Hs.139469	ESTs	2.48	DU145, A549, A549
	339435			CH22_DJ579N16.GENSCAN.18-10	2.48	NCI-H69, MCF7, BT474
	334172			CH22_FGENES.349_5	2.48	NCI-H69, NCI-H345, PRSC_log
_	320767	AA299525		EST duster (not in UniGene)	2.48	NCI-358, NCI-H23, NCI-H460
5	336772			CH22_FGENES.156-1	2.47	NCI-358, NCI-358, NCI-H23
	326957			CH.21_hs gi 6469836	2.47	BT474, RPWE-2, PRSC_con
			HS.200778	EST; Weakly similar to SALIVARY PROLINE-	2.47 2.47	MCF7, MB-MDA-453, MB-MDA-435s EB, CALU6, A549
		AB033100	Hs.201058	EST cluster (not in UniGene)	2.47	NCI-H345, PRSC_con, RPWE-2
10	338325	AV1231032	H3.201030	CH22_EM:AC005500.GENSCAN.307-7	2.46	BT474, LnCap, EB
10	307877	AI368880		EST singleton (not in UniGene) with exon	2.46	NCI-H23, PRSC_log, NCI-H520
		AI799444	Hs.247095	ESTs; Moderately similar to !!!! ALU SUB	2.46	PRSC_con, PRSC_log, NCI-H345
	337023			CH22_FGENES.433-12	2.46	OVCA-R, CALU6, PRSC_con
	300916	AI361798	Hs.164675		2.45	LnCap, DU145, CALU6
15		AL137382		EST duster (not in UniGene) with exon h	2.45	LnCap, MB-MDA-231, CALU6
				H sapiens mRNA full length insert cDNA c	2.45	BT474, MB-MDA-231, MB-MDA-453
		AI097439	Hs.135548		2.45 2.45	NCI-H460, MB-MDA-453, NCI-H345 OVCA-R, PC3, EB
		AA53584U	HS.162203	ESTs; Weakly similar to alternatively sp	2.45	NCI-H69, NCI-H345, RPWE-2
20	326763	AW408392		CH.20_hs gi 6598307 EST cluster (not in UniGene)	2.45	Caco2, NCI-H460, NCI-H23
20			Hs.190232		2.45	PRSC_con, NCI-H345, MB-MDA-231
			Hs.118346		2.44	NCI-H345, PRSC_log, PRSC_con
		AW299374		EST duster (not in UniGene)	2.44	PC3, DU145, OVCA-R
	336510			CH22_FGENES.834_5	2.44	NCI-H69, RPWE-2, PRSC_con
25	326876			CH.20_hs gi 6682507	2.44	NCI-H23, NCI-H460, NCI-H520
	307753	AI340509	Hs.182426	ribosomal protein S2	2.44	NCI-H23, NCI-H460, Ca∞2
		M78728	Hs.132694		2.44	NCI-H345, NCI-H69, RPWE-2
	313877	AA767869	Hs.250113	ESTs; Moderately similar to thyroid horm	0.44	DUIAS LaCon CALLIS
20	045074	*****	11- 404050	component TRAP150 [H.sapiens]	2.44	DU145, LnCap, CALU6 EB, DU145, OVCA-R
30			Hs.191952		2.43 2.43	NCI-H345, RPWE-2, EB
		A1885052 A1028257	Hs.132317	ESTs; Weakly similar to !!!! ALU CLASS F	2.43	CALU6, RPWE-2, OVCA-R
			Hs.136742		2.42	NCI-H460, NCI-358, NCI-H520
		AA305198	110.1001 12	EST cluster (not in UniGene)	2.42	PRSC_con, NCI-H460, RPWE-2
35			Hs.254296	:	2.41	MCF7, OVCA-R, PC3
			Hs.252924		2.41	PRSC_con, PRSC_log, RPWE-2
	308695	A1763350		EST singleton (not in UniGene) with exon	2.41	RPWE-2, NCI-H69, NCI-H345
	330166			CH.02_p2 gi[6648220	2.41	CALU6, DU145, A549
40			Hs.127019		2.41	NCI-358, NCI-358, NCI-H23 CALU6, HT29, A549
40		AI929508	HS.159590	tymphocyte antigen 6 complex; locus H ESTs; Weakly similar to TRANSCRIPTION FA	2.41	OVCA-R, Ca∞2, MB-MDA-231
			Hs.154029 Hs.54681	ESTS; Weakly Similar to TRANSCRIPTION FA	2.41	NCI-H23, NCI-H520, NCI-358
		N91109	Hs.246875		2.41	NCI-H69, NCI-H345, PRSC_con
	318571		Hs.8053	ESTs	2.4	NCI-358, NCI-H23, NCI-H520
45	334958	_ 10000		CH22_FGENES.465_27	2.4	DU145, PRSC_∞n, RPWE-2
	323570	AL038623	Hs.208752	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.4	OVCA-R, EB, BT474
	301685	W67730		EST cluster (not in UniGene) with exon h	2.4	MB-MDA-231, NCI-H345, EB
	303849	AW163324		EST duster (not in UniGene) with exon h	2.4	RPWE-2, PRSC_log, NCI-H345
50	325702			CH.14_hs gi 5867028	2.4	NCI-H23, NCI-H460, NCI-H520
50	313074	N48261	Hs.127171	ESTS ingleton (not in UniGene) with exon	2.4 2.4	MB-MDA-231, RPWE-2, PRSC_log RPWE-2, EB, PRSC_con
	330338	AI880051		CH.08_p2 gi[5457162	2.4	DU145, EB, LnCap
	327274			CH.01_hs gi 5867470	2.4	OVCA-R, DU145, MB-MDA-231
	325953			CH.16_hs gij5867140	2.4	MB-MDA-453, MB-MDA-435s, MCF7
55	333281			CH22_FGENES.128_7	2.4	NCI-H23, HT29, DU145
	314778		Hs.152258		2.39	EB, CALU6, Ca∞2
	317005	AI800251	Hs.197773		2.38	MB-MDA-231, BT474, HT29
	334257			CH22_FGENES.367_5	2.38	HT29, NCI-358, MB-MDA-231
<i>c</i> 0		AA640770	400400	EST cluster (not in UniGene)	2.38	EB, OVCA-R, MB-MDA-453 NCI-H69, NCI-H345, PRSC_log
60	300949	AA534325	Hs.162183	ESTS; Moderately similar to !!!! ALU SUB	2.38 2.38	LnCap, DU145, DU145
	314937	AVVUZ9Z/4	Ho 157174	ESTs; Weakly similar to similar to SH3-b	2.38	HT29, NCI-H23, NCI-H23
	338235	A11232301	ns.13/1/4	CH22_EM:AC005500.GENSCAN.260-16	2.38	NCI-H69, NCI-H460, NCI-H23
		AW297302	Hs.255631	<u> </u>	2.38	PRSC_log, PRSC_con, PRSC_con
65			Hs.170623		2.38	A549, DU145, EB
		AI742120	Hs.116506	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.38	NCI-358, NCI-H460, BT474
	338306			CH22_EM:AC005500.GENSCAN.302-2	2.38	NCI-H69, PRSC_con, PRSC_log
		Z42071	Hs.23961	ESTs	2.38	LnCap, NCI-H23, NCI-H520
70		Al239811	Hs.157491		2.37	OVCA-R, DU145, EB
70		AA649244	Un 040040	EST singleton (not in UniGene) with exon ESTs; Moderately similar to !!!! ALU SUB	2.37 2.37	CALU6, MB-MDA-435s, MB-MDA-453 EB, DU145, OVCA-R
		AL045285	ns.240849	EST cluster (not in UniGene)	2.37	OVCA-R, EB, A549
	335745	AA131111		CH22_FGENES.601_16	2.37	PRSC_log, PRSC_con, NCI-H69
		AI979100	Hs.211518	ESTs	2.37	NCI-H69, NCI-H345, PRSC_log
75	338809			CH22_EM:AC005500.GENSCAN.531-10	2.37	NCI-H23, NCI-H69, NCI-H520
. •		AI480204	Hs.177131		2.37	NCI-H345, PRSC_con, PRSC_log

	321308	AI247480	Hs.117029	ESTs	2.37	BT474, NCI-H69, HT29
	323578	AA299492	Hs.168166	ESTs	2.37	LnCap, EB, MB-MDA-453
	335747			CH22_FGENES.601_20	2.36	NCI-H69, LnCap, PRSC_con
_		AF039697		EST duster (not in UniGene)	2.36	DU145, PRSC_con, NCI-H345
5		N76302	Hs.78110		2.36	DU145, MB-MDA-453, CALU6
		AA586422		EST singleton (not in UniGene) with exon	2.36	NCI-H23, NCI-H460, CALU6
	337432	AA887654		CH22_FGENES.765-1	2.36 2.36	MB-MDA-231, BT474, HT29
			Hs.247186	EST singleton (not in UniGene) with exon	2.36	DU145, HT29, CALU6 DU145, A549, CALU6
10		AI889109	Hs.212032		2.36	NCI-358, NCI-H520, NCI-H23
		AI679966	Hs.150603		2.35	NCI-H460, Caco2, NCI-H23
	334198			CH22_FGENES.354_4	2.35	NCI-H69, PRSC_log, PRSC_con
		AI217440	Hs.143873		2.35	Caco2, A549, PC3
1.5	333346		•	CH22_FGENES.139_15	2.35	CALU6, DU145, LnCap
15	325408	4 4 0 7 0 7 4 2	Us 400770	CH.12_hs gi 5866921	2.35	NCI-H460, NCI-H520, NCI-H23
		AW293701	Hs.129770		2.35 2.35	NCI-H23, MB-MDA-435s, NCI-H345
		R55497		EST singleton (not in UniGene) with exon ESTs; Moderately similar to H beta 58 ho	2.35	NCI-H460, NCI-H23, NCI-H520 DU145, CALU6, NCI-H520
		N51583	Hs.133756		2.35	NCI-H23, NCI-H520, NCI-358
20		T16981	Hs.21963		2.34	NCI-H345, PRSC_log, NCI-H460
	327710			CH.04_hs gi 5867860	2.34	BT474, MB-MDA-231, NCI-H345
	306351	AA961356		EST singleton (not in UniGene) with exon	2.34	BT474, MB-MDA-231, MB-MDA-435s
		AA614308		EST singleton (not in UniGene) with exon	2.34	CALU6, HT29, MB-MDA-453
25	334015		11 404050	CH22_FGENES.313_7	2.34	HT29, MB-MDA-231, BT474
25		AI091370	Hs.134852		2.33	CALU6, NCI-H520, DU145
	337697	AI057134		EST singleton (not in UniGene) with exon CH22_EM:AC000097.GENSCAN.86-1	2.33 2.33	PC3, DU145, EB
	329630			CH.11_p2 gi 6729060	2.33	RPWE-2, PRSC_log, NCI-H345 NCI-H520, NCI-H23, NCI-H460
	326577			CH.19_hs gij5867317	2.33	NCI-H460, NCI-358, NCI-H23
30	333428			CH22_FGENES.149_1	2.33	NCI-H345, PRSC_con, RPWE-2
	301080	Al479391	Hs.155405	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.33	OVCA-R, MCF7, MCF7
		AA714311		EST cluster (not in UniGene)	2.33	NCI-H460, NCI-358, NCI-H23
		AJ133798		EST cluster (not in UniGene) with exon h	2.32	NCI-H23, NCI-H460, NCI-H520
35	325801	4.4.000000	11- 44000	CH.14_hs gi 6552451	2.32	PRSC_log, MCF7, NCI-H23
33			Hs.112389 Hs.208983		2.32 2.32	DU145, HT29, PC3
			Hs.214226		2.32	DU145, MCF7, PC3 DU145, NCI-H345, EB
		NM_00589	113.214220	EST cluster (not in UniGene)	2.31	A549, OVCA-R, PC3
	312217			EST cluster (not in UniGene)	2.31	NCI-H23, Caco2, NCI-H69
40	321304	AA078293		EST duster (not in UniGene)	2.31	DU145, OVCA-R, EB
		AA527359	Hs.154366	ESTs	2.31	NCI-H345, DU145, EB
	336455			CH22_FGENES.829_13	2.31	NCI-H345, PRSC_con, RPWE-2
			Hs.144758		2.31	MCF7, DU145, OVCA-R
45	331457 333054	H93133	Hs.41840	ESTs CH22_FGENES.73_8	2.31 2.31	Ca∞2, NCI-H460, NCI-H23 NCI-H69, NCI-358, NCI-H23
		AI719237		EST singleton (not in UniGene) with exon	2.31	OVCA-R, CALU6, Caco2
	327059			CH.21_hs gil6531965	2.3	NCI-H460, LnCap, LnCap
	334120			CH22_FGENES.333_1	2.3	NCI-H69, RPWE-2, MB-MDA-435s
<b>5</b> 0	324154	AI457449	Hs.192817		2.3	NCI-H460, MB-MDA-453, NCI-358
50	326509			CH.19_hs gi 6682496	2.3	NCI-H345, CALU6, OVCA-R
		AW291384	Hs.254974		2.3	NCI-H345, NCI-H460, BT474
	337918	AI825351	Hs.144084	CH22_EM:AC005500.GENSCAN.66-4	2.3 2.29	RPWE-2, NCI-H345, PRSC_log
	331023		Hs.5856	ESTs	2.29	HT29, OVCA-R, DU145 OVCA-R, LnCap, A549
55	332231		Hs.102629		2.29	CALU6, DU145, EB
		AW339671		EST singleton (not in UniGene) with exon	2.29	MB-MDA-435s, PRSC_con, NCI-358
		AI241019	Hs.145644		2.29	Caco2, HT29, EB
		AW293704	Hs.122658		2.29	OVCA-R, DU145, Ca∞2
60	335019	F200F4	U- 450400	CH22_FGENES.474_7	2.29	HT29, CALU6, MB-MDA-231
00	324394 339357	F20004	ns. 152 126	ESTs; Moderately similar to !!!! ALU SUB	2.29 2.29	NCI-H345, MB-MDA-231, RPWE-2
		AI346033		CH22_BA354I12.GENSCAN.31-2 EST cluster (not in UniGene)	2.28	NCI-H69, OVCA-R, BT474 NCI-H23, NCI-H520, NCI-H460
		AI239457	Hs.130794		2.28	OVCA-R, DU145, MB-MDA-231
		Al929130		ESTs; Moderately similar to finger prote	2.28	BT474, RPWE-2, PRSC_con
65	323409	AL135534		EST cluster (not in UniGene)	2.27	NCI-H345, NCI-358, Caco2
		A1634885		EST singleton (not in UniGene) with exon	2.27	OVCA-R, EB, HT29
		AI133446		EST cluster (not in UniGene)	2.27	DU145, MB-MDA-435s, OVCA-R
	338381	44704504	11- 440000	CH22_EM:AC005500.GENSCAN.330-10	2.27	NCI-H69, PRSC_con, PRSC_log
70		AA/04584 Al161024	Hs.119993	ESTS singleton (not in UniGene) with exon	2.27 2.27	NCI-358, NCI-H520, NCI-H23 NCI-H345, DU145, RPWE-2
			Hs.121335		2.27	LnCap, NCI-H460, Caco2
•			Hs.98660		2.27	NCI-358, NCI-H520, CALU6
	330951			H sapiens mRNA; cDNA DKFZp434N174 (fro		2.27 OVCA-R, BT474, BT474
<b>7</b> .5		AA773111		EST singleton (not in UniGene) with exon	2.27	LnCap, DU145, BT474
75		AA776743	Hs.191589		2.26	NCI-H345, RPWE-2, PRSC_con
	333929			CH22_FGENES.300_2	2.26	HT29, CALU6, EB

	319845	AA649011	Hs.187902	? ESTs	2.26	LnCap, DU145, MCF7
		AI028393		EST singleton (not in UniGene) with exon	2.26	MB-MDA-435s, NCI-358, CALU6
	306919	AI096832		EST singleton (not in UniGene) with exon	2.26	HT29, BT474, PC3
-	333312			CH22_FGENES.138_4	2.26	OVCA-R, DU145, PC3
5	334955			CH22_FGENES.465_24	2.25	RPWE-2, PRSC_con, NCI-H345
			Hs.173863		2.25	OVCA-R, DU145, NCI-H345
		AI302124 AA421989		EST singleton (not in UniGene) with exon	2.25 2.25	CALU6, CALU6, OVCA-R
		AW271805		EST cluster (not in UniGene) EST singleton (not in UniGene) with exon	2.25 2.25	OVCA-R, EB, A549 DU145, NCI-H460, CALU6
10		AW410240		ribosomal protein L28	2.25	NCI-H69, NCI-H460, NCI-H520
		H05392	Hs.230597		2.25	Cacc2, EB, DU145
	327125			CH.21_hs gi 6531971	2.25	HT29, NCI-358, BT474
	316919	AA845382	Hs.204520	ESTs	2.24	NCI-H23, NCI-H345, NCI-H520
1.5				ESTs; Weakly similar to !!!! ALU SUBFAMI	2.24	DU145, EB, PC3
15			3 Hs.158893		2.24	OVCA-R, EB, LnCap
		H03688	U- 004707	EST cluster (not in UniGene)	2.24	NCI-358, DU145, NCI-H23
	313444	AW138821	Hs.221737		2.24	NCI-358, CALU6, PRSC_con
	335234			CH22_FGENES.294_1 CH22_FGENES.515_3	2.24 2.24	MB-MDA-231, BT474, A549
20	333727			CH22_FGENES.256_1	2.24	NCI-H69, PRSC_con, PRSC_log MB-MDA-231, NCI-H69, BT474
- •		AA482009	Hs.105104		2.23	EB, NCI-H520, HT29
	329611			CH.10_p2 gi 3962478	2.23	BT474, HT29, MB-MDA-231
	310559	AI783594	Hs.155718		2.22	BT474, MCF7, MB-MDA-231
0.5	327315			CH.01_hs gi 5867508	2.22	NCI-H69, EB, EB
25		U83527		EST duster (not in UniGene)	2.22	EB, DU145, LnCap
		N49309	Hs.117012		2.22	A549, LnCap, DU145
			Hs.142805		2.22	OVCA-R, PC3, LnCap
		R97191	Hs.134106		2.22	BT474, MCF7, OVCA-R
30	337895	Z44631	Hs.21658	CH22_EM:AC005500.GENSCAN.56-2	2.22 2.22	MB-MDA-453, DU145, CALU6
50		AI185762		EST singleton (not in UniGene) with exon	2.22	NCI-H345, PRSC_log, PRSC_con NCI-H520, NCI-H460, EB
		W76005	Hs.32094	ESTs	2.21	EB, NCI-H345, PRSC_con
		X85153	110102001	EST duster (not in UniGene) with exon h	2.21	BT474, MB-MDA-231, MCF7
	322644	AA340904		EST duster (not in UniGene)	2.21	NCI-H460, NCI-H23, NCI-H520
35	330415	D83777	Hs.75137	KIAA0193 gene product	2.21	CALU6, A549, Caco2
		AF120491		EST cluster (not in UniGene) with exon h	2.21	NCI-H69, NCI-H345, PC3
	326710			CH.20_hs gi 5867593	2.21	NCI-H520, NCI-358, NCI-H23
		AA825426	Hs.238832	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.21	NCI-H345, DU145, NCI-H69
40	337706 339309			CH22_EM:AC000097.GENSCAN.87-11	2.21	MB-MDA-435s, NCI-358, NCI-H520
70		HG2724-H		CH22_BA354I12.GENSCAN.22-7 Oncogene Tls/Chop, Fusion Activated	2.21 2.21	BT474, HT29, PC3
		AI922972	Hs.196073		2.21	PRSC_con, NCI-H69, Caco2 OVCA-R, MB-MDA-435s, DU145
		AF053356	. 10. 10007 0	multiple UniGene matches	2.2	NCI-H69, HT29, NCI-H23
	331192		Hs.152571	ESTs; Highly similar to IGF-II mRNA-bind	2.2	OVCA-R, PC3, CALU6
45		AW051819	Hs.204516		2.2	LnCap, OVCA-R, EB
	337904			CH22_EM:AC005500.GENSCAN.56-17	2.2	OVCA-R, LnCap, EB
		Al565612		EST singleton (not in UniGene) with exon	2.2	DU145, MB-MDA-231, CALU6
	320965	H18166		EST duster (not in UniGene)	2.2	DU145, EB, LnCap
50	333910	AA080921		CH22_FGENES.295_3 EST cluster (not in UniGene) with exon h	2.2 2.2	DU145, MB-MDA-231, EB
50	336011	AA000321		CH22_FGENES.668_9	2.2 2.19	BT474, MCF7, HT29 NCI-H460, BT474, NCI-H345
	325712			CH.14_hs gi 6682473	2.19	NCI-H460, NCI-H23, NCI-358
		AF201832		EST cluster (not in UniGene)	2.19	PC3, RPWE-2, PRSC_con
	335339			CH22_FGENES.535_16	2.19	HT29, PRSC_log, MCF7
55			Hs.134407		2.19	DU145, EB, Caco2
		AA679426	Hs.187505		2.19	NCI-H345, PRSC_log, PRSC_con
	337132	NICEACEA		CH22_FGENES.526-3	2.19	NCI-H69, NCI-H345, PRSC_con
	325285	AI951651	Hs.224290		2.19	PRSC_con, MB-MDA-231, NCI-H23
60	338280			CH.11_hs gij5866903 CH22_EM:AC005500.GENSCAN.290-11	2.18 2.18	PRSC_∞n, PRSC_log, MB-MDA-231 PC3, NCI-358, HT29
•		AI701635	Hs.207077		2.18	RPWE-2, NCI-H345, NCI-358
	330638			matrix metalloproteinase 17 (membrane-in	2.18	HT29, MB-MDA-435s, MB-MDA-453
	326603			CH.20_hs gi 6056312	2.18	CALU6, DU145, HT29
		AA412305		EST cluster (not in UniGene)	2.18	A549, OVCA-R, MB-MDA-435s
65	335451			CH22_FGENES.562_9	2.18	DU145, LnCap, CALU6
•			Hs.130664		2.18	NCI-H345, NCI-H69, NCI-H520
		AA334384	U- 040054	EST duster (not in UniGene)	2.18	Ca∞2, PC3, NCI-H520
			Hs.240951		2.18	NCI-358, A549, EB
70	304022 330082	102330		EST singleton (not in UniGene) with exon	2.18	NCI-H23, NCI-358, NCI-H460
, 0		AA363245	Hs.189831	CH.19_p2 gi 6015314 ESTs	2.18 2.18	NCI-H23, Ca∞2, Ca∞2 BT474, HT29, MB-MDA-231
	333932			CH22_FGENES.300_5	2.17	PC3, Cacc2, EB
	308115	Al479071		EST singleton (not in UniGene) with exon	2.17	BT474, OVCA-R, OVCA-R
	320184		Hs.123036		2.17	NCI-H520, NCI-358, NCI-H23
75		AA464510		EST duster (not in UniGene)	2.17	CALU6, RPWE-2, HT29
	320882	AI832098		EST cluster (not in UniGene)	2.17	OVCA-R, PC3, BT474

	312251	H03952		EST cluster (not in UniGene)	2.17	NCI-H460, NCI-H23, NCI-358
	315049	AW34048	6 Hs.12121	D ESTs	2.17	NCI-H520, NCI-358, NCI-H23
		AA62712		EST singleton (not in UniGene) with exon	2.17	MB-MDA-231, MB-MDA-453, EB
5			Hs.13043		2.16	NCI-H345, PRSC_con, PRSC_log
,			Hs.19612 Hs.12522		2.16 2.16	NCI-H345, PRSC_con, LnCap
	328863		7 113.12322.	CH.07_hs gi 6381929	2.16	OVCA-R, PC3, MCF7 PRSC_con, NCI-H345, NCI-H460
		R00371		EST duster (not in UniGene)	2.16	PRSC_con, RPWE-2, NCI-H345
10		T86541	Hs.189732		2.16	NCI-H23, NCI-358, NCI-H345
10	320235	AF064090	Hs.12970	tumor necrosis factor (ligand) superfami	2.16	NCI-H23, NCI-H460, NCI-H520
	338880	AI091349	Un 16112	CH22_DJ32I10.GENSCAN.6-2	2.16	BT474, MCF7, OVCA-R
		D86973		GCN1 (general control of amino-acid synt	2.16 2.16	NCI-H23, NCI-H520, NCI-H460 A549, PC3, DU145
		AA406133		KIAA0682 gene product	2.16	PC3, EB, MB-MDA-231
15	339019			CH22_DA59H18.GENSCAN.21-15	2.15	LnCap, EB, OVCA-R
		Al127042		EST singleton (not in UniGene) with exon	2.15	MB-MDA-435s, NCI-H520, NCI-358
			Hs.131540		2.15	Ca∞2, Ca∞2, BT474
			6 Hs.135130	DKFZP586H2123 protein	2.15	NCI-H460, NCI-H23, NCI-358
20	335049	AA-100000	113.33077	CH22_FGENES.481_5	2.15 2.15	PRSC_con, HT29, CALU6 NCI-H69, NCI-H345, PRSC_log
		AA429772	Hs.191610	ESTs	2.15	MB-MDA-453, MB-MDA-435s, MCF7
	330363			CH.X_p2 gi[3126882	2.15	NCI-H23, NCI-H460, NCI-358
			Hs.144830		2.15	HT29, CALU6, EB
25		AA948204	Hs.127361		2.15	MB-MDA-231, DU145, HT29
23	333294 330170			CH22_FGENES.130_6	2.14	EB, DU145, MB-MDA-453
		AI123346	Hs.135241	CH.02_p2 gi 6648220 ESTs	2.14 2.14	HT29, MB-MDA-453, PC3 LnCap, DU145, EB
			Hs.201449		2.14	NCI-H520, NCI-H23, LnCap
20		T10019	Hs.4194	ESTs	2.14	NCI-H460, NCI-H23, NCI-358
30			Hs.192298		2.14	HT29, BT474, MB-MDA-435s
		AA310/11 AI474896	Hs.124340		2.14	RPWE-2, PRSC_con, PRSC_log
		AF086244		EST singleton (not in UniGene) with exon EST duster (not in UniGene)	2.14 2.14	BT474, MCF7, MB-MDA-231 NCI-H345, RPWE-2, PRSC_∞n
		AA746272		EST duster (not in UniGene) with exon h	2.14	DU145, MB-MDA-453, EB
35	312102	AW439340	Hs.189720		2.14	NCI-H23, NCI-H460, MB-MDA-435s
		AI249468	Hs.228251	EST	2.14	NCI-H460, NCI-358, NCI-H23
	338486	A1005444	U= 040050	CH22_EM:AC005500.GENSCAN.382-8	2.14	NCI-H520, NCI-H23, NCI-H69
		AI825444 AI650372	Hs.210956 Hs.195979		2.14 2.14	BT474, HT29, MB-MDA-231
40		AA732301	113. 133313	EST cluster (not in UniGene)	2.14	CALU6, CALU6, Cacc2 NCI-H23, NCI-H520, NCI-358
	326559			CH.19_hs gij5867310	2.14	DU145, NCI-H460, NCI-H23
	324062	AA525291		ESTs; Weakly similar to !!!! ALU SUBFAMI	2.13	OVCA-R, DU145, EB
		AI811303	Hs.143490	<del>-</del>	2.13	MB-MDA-453, MCF7, MB-MDA-435s
45	333895	A156711A	Hs.171454	CH22_FGENES.293_2	2.13	CALU6, LnCap, DU145
43		AA908472	115.17 1454	EST singleton (not in UniGene) with exon	2.13 2.13	DU145, CALU6, MB-MDA-453 HT29, BT474, MB-MDA-231
	333101			CH22_FGENES.79_6	2.13	NCI-H345, NCI-H69, PRSC_log
	328544			CH.07_hs gi 5868486	2.13	NCI-H23, NCI-H69, PRSC_log
50	333355	41554545		CH22_FGENES.141_6	2.13	DU145, EB, CALU6
50		AI524519 AA814956	Hs.239699		2.13	EB, NCI-H460, NCI-H345
	327809	AA0 14330		EST singleton (not in UniGene) with exon CH.05_hs gij5867968	2.13 2.13	NCI-H520, NCI-H460, NCI-358
	325092	T10115	Hs.92423		2.13	HT29, PC3, OVCA-R HT29, NCI-358, MB-MDA-231
			Hs.252784		2.13	PRSC_∞n, DU145, DU145
55			Hs.126706		2.12	OVCA-R, A549, MB-MDA-435s
		AA319421	Hs.193577		2.12	Caco2, LnCap, OVCA-R
	328971 325338			CH.08_hs gi 6478806	2.12	NCI-358, NCI-H23, NCI-H520
		AA282554	Hs.89034	CH.11_hs gi 5866883 ESTs	2.12 2.12	LnCap, NCI-H69, NCI-H345 NCI-H520, NCI-H23, Cacc2
60	327159			CH.01_hs gij5867550	2.12	EB, DU145, PC3
	335180			CH22_FGENES.505_2	2.12	LnCap, NCI-H69, A549
	338062	41000040		CH22_EM:AC005500.GENSCAN.162-3	2.12	PRSC_con, PRSC_log, NCI-H69
			Hs.135538 Hs.108790		2.12	EB, HT29, DU145
65	328314	A11233 140	ris. 1007 50	CH.07_hs gij5868371	2.11 2.11	Ca∞2, NCI-H23, A549 HT29, NCI-H23, NCI-H460
		AI033547	Hs.132826	ESTs	2.11	BT474, CALU6, MCF7
	339246			CH22_BA354I12.GENSCAN.5-9	2.11	CALU6, CALU6, BT474
	329921			CH.16_p2 gi 6165205	2.11	BT474, MB-MDA-231, HT29
70	324981		Hs.4947	ESTs	2.11	A549, NCI-H460, NCI-H520
70			Hs.109929 Hs.83190	ESTS fatty acid synthase	2.11 2.11	NCI-H345, A549, PRSC_con
	325448	. 3 .000001	. 10.00 100	CH.12_hs gij5866941	2.11	NCI-358, LnCap, MB-MDA-453 DU145, MCF7, CALU6
		AW188286	Hs.143612	ESTs	2.1	EB, BT474, MB-MDA-231
75	301063	A1057634	Hs.124596	ESTs	2.1	NCI-H23, NCI-H460, BT474
75		AB029016		KIAA1093 protein	2.1	OVCA-R, A549, CALU6
	326309			CH.17_hs gi 5867277	2.1	MB-MDA-435s, NCI-H69, MB-MDA-453

		0.15.400			D		
		315406	AI823453	Hs.14662	5 ESTs	2.1	OVCA-R, DU145, EB
		302376	AB007867	Hs.20048	0 KIAA0407 protein	2.1	OVCA-R, Ca∞2, HT29
				Hs.19159		2.1	OVCA-R, A549, DU145
	5	334254			CH22_FGENES.366_4	2.1	LnCap, OVCA-R, DU145
,		3180/3	AW16708	7 Hs.13156	2 ESTs	2.1	A549, CALU6, EB
				Hs.65114		2.1	NCI-H23, NCI-H520, NCI-H460
			W87704	Hs.21155		2.1	MB-MDA-435s, PRSC_con, NCI-H460
				Hs.98721		2.1	NCI-H345, MB-MDA-231, PRSC_con
	10		Al559106	Hs.18116	eukaryotic translation elongation factor	2.1	EB, CALU6, OVCA-R
	10	3242/9	AA501412	Hs.19168	B ESTs; Weakly similar to Pro-Pol-dUTPase	2.09	OVCA-R, LnCap, PC3
		337203			CH22_FGENES.591-3	2.09	NCI-H69, NCI-H345, MB-MDA-231
		322346	AA227618	Hs.10882	HMG-box containing protein 1	2.09	HT29, BT474, MB-MDA-231
		3044/0	AA426654	Hs.19518	3 glyceraldehyde-3-phosphate dehydrogenase		NCI-H23, CALU6, NCI-H520
	1.5	325977			CH.16_hs gi 6249602	2.09	NCI-H23, NCI-H520, HT29
	15		AA554758		EST singleton (not in UniGene) with exon	2.09	MB-MDA-435s, NCI-H23, BT474
			AI301528			2.09	Ca∞2, EB, NCI-358
			AI860360	Hs.160316		2.08	PRSC_con, PRSC_log, NCI-H345
		327341			CH.01_hs gi 6017016	2.08	MB-MDA-231, PRSC_con, NCI-H69
	20	327431			CH.02_hs gi 5867754	2.08	NCI-H23, NCI-358, NCI-H520
	20		AI870811	Hs.158709	ESTs; Weakly similar to KIAA0938 protein	2.08	MB-MDA-453, MCF7, OVCA-R
		328624		_	CH.07_hs gi 5868246	2.08	MCF7, NCI-358, RPWE-2
			AW303377	<b>'</b>	EST cluster (not in UniGene) with exon h	2.08	RPWE-2, PRSC_con, PRSC_log
		336717			CH22_FGENES.81-1	2.08	BT474, HT29, MCF7
	25	317370	AW204139	Hs.174424	ESTs; Weakly similar to p140mDia [M.musc	2.08	NCI-H23, NCI-H460, NCI-H69
	25			Hs.172971		2.08	OVCA-R, EB, NCI-H345
			N62228		EST singleton (not in UniGene) with exon	2.08	BT474, MCF7, MB-MDA-231
			AW137420	Hs.192311	ESTs	2.08	PRSC_con, PRSC_log, PRSC_log
		325636			CH.14_hs gi 5867002	2.08	NCI-358, NCI-H460, MB-MDA-453
	20	336406			CH22_FGENES.823_21	2.08	HT29, EB, DU145
	30		F06529		EST duster (not in UniGene) with exon h	2.08	LnCap, PRSC_log, PRSC_con
			R45159	Hs.221804	ESTs	2.08	PRSC_con, LnCap, RPWE-2
		318970	R21114	Hs.21383	ESTs	2.08	NCI-H23, NCI-H520, NCI-H460
		334115			CH22_FGENES.330_15	2.08	BT474, NCI-H69, HT29
	~ -		AI473682		EST singleton (not in UniGene) with exon	2.08	MB-MDA-435s, NCI-H345, MB-MDA-231
	35	308282	AI569456		EST singleton (not in UniGene) with exon	2.08	LnCap, EB, PRSC_con
		313038	AW451618	Hs.124195	ESTs	2.07	NCI-H345, PRSC_con, LnCap
		317974	AW444468	Hs.144900	ESTs	2.07	NCI-358, NCI-H23, NCI-H520
		324063	AW292740	Hs.254815	ESTs	2.07	Ca∞2, NCI-358, NCI-H520
		334759			CH22_FGENES.428_8	2.07	CALU6, HT29, NCI-H520
	40		AI367417		EST singleton (not in UniGene) with exon	2.07	NCI-H460, NCI-358, NCI-H23
		304356	AA196027	Hs.195188		2.07	HT29, MCF7, MB-MDA-435s
			AW470753	·	EST singleton (not in UniGene) with exon	2.07	NCI-H345, PRSC_con, RPWE-2
		331857	AA421160	Hs.9456	SWI/SNF related; matrix assocd; actin de	2.07	EB, A549, PC3
		322814	AI824495	Hs.211038		2.06	PRSC_con, RPWE-2, Caco2
	45	303650	AA430709		EST cluster (not in UniGene) with exon h	2.06	RPWE-2, NCI-H345, PRSC_con
		333403		•	CH22_FGENES.144_21	2.06	OVCA-R, CALU6, PC3
		313663	AI953261	Hs.169813		2.06	NCI-H345, OVCA-R, NCI-H23
		338594			CH22_EM:AC005500.GENSCAN.435-4	2.06	DU145, LnCap, EB
		334676				2.06	NCI-H69, PRSC_log, PRSC_con
	50	310046	AI198032	Hs.210356		2.06	MB-MDA-435s, NCI-H23, Cacc2
			AI949216			2.06	CALU6, EB, NCI-358
		329752				2.06	CALU6, HT29, DU145
		325085	T10001	Hs.4188		2.06	EB, OVCA-R, MB-MDA-435s
				Hs.185375		2.06	OVCA-R, MB-MDA-453, MCF7
	55					2.06	LnCap, EB, NCI-H69
		326344				2.06	HT29, BT474, MB-MDA-453
			AA079318		zm98c2.s1 Stratagene colon HT29 (#937221	2.00	יייבט, טוידי די, וווט דווטר דיטט
						2.06	RPWE-2, LnCap, PRSC_con
		302525	AF024690	Hs 248056		2.05	NCI-358, NCI-H23, DU145
	60		AA436673		H sapiens mRNA; cDNA DKFZp586B0323 (fro		
				Hs.120637		2.05	2.05 Ca∞2, DU145, A549 BT474, MB-MDA-453, OVCA-R
		321525				2.05	NCI-H23, PRSC_con, NCI-H520
			AA640579			2.05	
		326033				2.05	MB-MDA-231, BT474, HT29
,	65	334730				2.05 2.05	HT29, DU145, BT474
	•		AA704235		=_= T : = :		BT474, EB, OVCA-R
		320521		Hs.24743		2.05 2.05	MCF7, OVCA-R, MB-MDA-453
		333515	1401404			2.05	MB-MDA-453, MB-MDA-231, PC3
			AI918672	Hs.213783		2.04	NCI-H345, RPWE-2, PRSC_con
,	70					2.04	NCI-H460, NCI-H23, NCI-H520
	, 0		AA393739			2.04	OVCA-R, PC3, LnCap
			AA748889			2.04	NCI-H345, PRSC_log, CALU6
		312162				2.04	NCI-H520, NCI-H23, NCI-358
		330980				2.04	MCF7, MB-MDA-453, MB-MDA-435s
,	75			Hs.130462		2.04	NCI-H23, Ca∞2, NCI-H69
	, ,	337435		Hs.117900	E013	2.04	DU145, EB, CALU6
		JJ14JJ			CH22_FGENES.766-2	2.03	NCI-H345, OVCA-R, LnCap

		AA742425 AI383496	i	EST singleton (not in UniGene) with exon	2.03	CALU6, NCI-H520, NCI-358
				EST singleton (not in UniGene) with exon	2.03	NCI-H23, BT474, MB-MDA-231
		H89360		EST cluster (not in UniGene)	2.03	DU145, OVCA-R, MB-MDA-453
5	325886	AVV205190	3 Hs.149146		2.03	NCI-H23, NCI-H460, NCI-358
,	329719			CH.16_hs gi[5867087	2.03	NCI-H345, NCI-H345, RPWE-2
				CH.14_p2 gi 6065785	2.03	NCI-H69, RPWE-2, PRSC_con
		AI972768		EST singleton (not in UniGene) with exon	2.03	LnCap, PRSC_∞n, RPWE-2
	328277			CH.07_hs gi 6004471	2.03	LnCap, RPWE-2, A549
10		AI205705	Hs.147222		2.03	NCI-H460, NCI-358, NCI-H23
10	327203			CH.01_hs gi 5867447	2.03	HT29, BT474, MB-MDA-231
		AI086683		EST singleton (not in UniGene) with exon	2.03	BT474, NCI-H345, HT29
	333339			CH22_FGENES.139_8	2.03	HT29, DU145, CALU6
		AI921875		EST duster (not in UniGene)	2.03	BT474, BT474, MB-MDA-231
15		AA584361		EST singleton (not in UniGene) with exon	2.03	NCI-H23, NCI-358, NCI-H460
13	323372	AL135125	Hs.13913	ESTs	2.02	DU145, EB, A549
	312854	AA828713		EST duster (not in UniGene)	2.02	NCI-H345, PRSC_con, PRSC_log
		Al381019		EST singleton (not in UniGene) with exon	2.02	HT29, MCF7, MB-MDA-453
		AA608983		af5d4.s1 Soares_testis_NHT H sapiens cDN	2.02	PRSC_con, NCI-H345, RPWE-2
20		AI684571	Hs.175831		2.02	NCI-H460, Caco2, NCI-358
20	335721			CH22_FGENES.599_24	2.02	NCI-H69, PRSC_log, NCI-H345
		AI692643	Hs.172749		2.02	HT29, Ca∞2, MB-MDA-231
	325396			CH.12_hs gi 5866921	2.01	HT29, NCI-H520, NCI-H460
	328770			CH.07_hs gi 6017031	2.01	NCI-H23, NCI-H460, NCI-358
25	335585			CH22_FGENES.581_24	2.01	MB-MDA-453, DU145, MCF7
25	335634			CH22_FGENES.584_14	2.01	NCI-H23, NCI-H460, NCI-H69
	338271			CH22_EM:AC005500.GENSCAN.287-1	2.01	MCF7, DU145, PC3
	328607	414 470 44		CH.07_hs gi 5868233	2.01	NCI-H460, NCI-H23, NCI-358
		Al147341	Hs.146734		2.01	NCI-H520, NCI-H23, NCI-358
30	334946	DECCCO		CH22_FGENES.465_13	2.01	CALU6, BT474, DU145
30	319793			EST cluster (not in UniGene)	2.01	NCI-H460, HT29, NCI-358
		AI193698	HS.184776	ribosomal protein L23a	2.01	NCI-358, NCI-H520, NCI-H23
		AA344698	Hs.133169		2.01	PC3, LnCap, MB-MDA-231
	329221	4 4 0 5 0 5 0 0		CH.X_hs gi 5868727	2.01	NCI-H345, NCI-H69, NCI-358
35		AA653589		EST singleton (not in UniGene) with exon	2.01	LnCap, EB, OVCA-R
55	328428	4 4 0 0 0 0 0 0			2.01	NCI-H69, MB-MDA-453, BT474
	300000		Hs.125919		2.01	NCI-H520, NCI-358, NCI-H23
	319368		Hs.133171		2	OVCA-R, LnCap, PC3
	201420	AA340430	Hs.131350		2	NCI-H460, NCI-H23, NCI-358
40	204676	MA/191/9	Hs.189419		2	NCI-H69, NCI-H23, PRSC_con
70	304675 A 326194	1/4U		EST singleton (not in UniGene) with exon	2	NCI-H460, NCI-H520, MB-MDA-231
	J20 134		(	CH.17_hs gi 5867213	2	HT29, NCI-358, BT474

## Table 5: H chip – B survivor vs Met query – up in Mets

5	Pkey: ExAccn: UnigeneID:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number
	Unigene Tit	
10		

10						
10	Pkey	Ex Accn	UniG_ID	Complete_Title	Ratio Met/B surv.	
	102193	U20758	Hs.313	secreted phosphoprotein 1 (osteopontin;	5.56	
	128530	AA504343	Hs.183475	Homo sapiens clone 25061 mRNA sequence	4.62	
15	129093	AA262710	Hs.108614	KIAA0627 protein	4.23	
	124690	R05818	Hs.173830	ESTs	3.96	
	115558	AA393806	Hs.1010	regulator of mitotic spindle assembly 1	3.39	
	134261	AA227678	Hs.8084	Humn DNA sequence from done 465N24 on	c3.22	
	104792	AA029288	Hs.29147	ESTs; Highly similar to ZINC FINGER PROT	3.17	
20	133770	M69197	Hs.242279	haptoglobin-related protein	3.07	

# Table 6: H chip – B survivor vs Met query – down in Mets

5				The second secon			
10							
	Pkey	Ex Accn	UniG_ID	Complete_Title	Ratio Met/B surv.		
	100116		Hs.77443	actin; gamma 2; smooth muscle; enteric	0.07		
1.5		S75256		HNL=neutrophil lipocalin [human, ovarian	0.2		
15		M87789	Hs.140	immunoglobulin gamma 3 (Gm marker)	0.2		
	130064	T67053	Hs.181125	immunoglobulin lambda gene cluster	0.2		

# Table 7: I chip – B survivor vs Met query – up in Mets

5	Pkey: Unique Eos probeset identifier number ExAccn: Exemplar Accession number, Genbank accession number UnigenelD: Unigene number
	Unigene Title: Unigene gene title

10					
	Pkey	Ex_Accn	UniG_ID	Title	Ratio Met/B surv
15		T91443 N63915	Hs.193963	ESTs	19.65 11.9
		AA543008		ESTs; Weakly similar to !!!! ALU SUBFAMI	9.31
		AI732331	Hs.187750	ESTs; Moderately similar to !!!! ALU CLA	5.79
		H68097	Hs.161023	EST	4.79
20		AI436356			4.59
20	332471	AA416967	Hs.120980	nuclear receptor co-repressor 2	4.58
	314915	AA573072	Hs.187748	ESTs; Weakly similar to !!!! ALU SUBFAMI	4.3
		AA078493		EST cluster (not in UniGene)	4.26
		AF086372		EST duster (not in UniGene)	3.89
0.5		T10265	Hs.116122	ESTs; Weakly similar to coded for by C.	3.81
25		AA192455	Hs.188690	ESTs	3.74
		AW362945	Hs.162459	ESTs	3.66
	330987	H40988	Hs.131965	ESTs; Weakly similar to !!!! ALU SUBFAMI	3.51
	337898			CH22_EM:AC005500.GENSCAN.56-5	3.21
20	319403			EST cluster (not in UniGene)	3.2
30	331469		Hs.39140	ESTs	3.15
			Hs.237507	EST	3.14
		T99544	Hs.173734	ESTs; Weakly similar to !!!! ALU CLASS B	3.14
	313220	AI971981	Hs.118241	ESTs	3.04
35					

#### Table 8: I chip – B survivor vs Met query – down in Mets

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigeneID: Unigene number

Unigene Title: Unigene gene title

10					
	Pkey	Ex_Accn	UniG_ID	Title	Ratio Met/B surv
	333658			CH22_FGENES.241_4	0.06
	333657			CH22_FGENES.241_2	0.07
15	333654			CH22_FGENES.240_2	0.07
	332859			CH22_FGENES.27_2	0.07
	333656			CH22_FGENES.240_4	0.07
	304480	AA430373		EST singleton (not in UniGene) with exon	0.08
	333737			CH22_FGENES.261_1	0.09
20	308601	AI719930		EST singleton (not in UniGene) with exon	0.1
	334030			CH22_FGENES.320_2	0.1
	333637			CH22_FGENES.229_2	0.13
	302347	AF039400	Hs.194659	chloride channel; calcium activated; fam	0.16
	333653			CH22_FGENES.239_2	0.16
25	333635			CH22_FGENES.228_2	0.19
	333647			CH22_FGENES.235_2	0.19
	307588	AI285535		EST singleton (not in UniGene) with exon	0.2
	337954			CH22_EM:AC005500.GENSCAN.96-3	0.2
• •	333588			CH22_FGENES.206_2	0.21
30	320244	AA296922	Hs.129778	gastrointestinal peptide	0.22
	333642			CH22_FGENES.231_2	0.23
	337951			CH22_EM:AC005500.GENSCAN.94-1	0.23
	333730			CH22_FGENES.258_1	0.23
~ ~	333646			CH22_FGENES.234_2	0.24
35					

## Table 9: H chip – B survivor vs Met query – up in Mets

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

Unigene Title: Unigene gene title

	10						
		Pkey	Ex Accn	UniGID	Complete_Title	Median Mets Al	vs Median B-Sur Al
		100655	HG2841-	IT2970	Albumin, Alt. Splice 5	11.98	
		124875	R70506	Hs.207693	ESTs; Weakly similar to !!!! ALU SUBFAMI	9.21	
	15		U20758	Hs.313	secreted phosphoprotein 1 (osteopontin;	6.73	
		100654	HG2841-H	IT2969	Albumin, Alt. Splice 3, Missplicing In Alloalbur	nin Venezia	6.18
			N79496	Hs.50824	EST	5.93	
		128046	AA873285	Hs.137947		5.9	
	20	128896	D14446	Hs.107	fibrinogen-like 1	5.17	
	20	127917	AA211895	Hs.118831	EST; Highly similar to dJ1163J1.2.1 [H.s	5.11	
			T91518		ye20f05.s1 Stratagene lung (#937210) Hom	4.47	
			N68905		small inducible cytokine A5 (RANTES)	4.23	
			AA608657		ESTs; Moderately similar to !!!! ALU SUB	4.21	
	25			Hs.193155	ESIS	4.14	
	23		R71234	U= 400475	yi54c08.s1 Soares placenta Nb2HP Homo sa	4.11	
M		110404	T92950	ms. 1634/5	Homo sapiens clone 25061 mRNA sequence	4.09	
<u> </u>			N66845	Un 465414	ye27c10.s1 Stratagene lung (#937210) Hom		
			K00629	Ho 100200	ESTs; Weakly similar to !!!! ALU CLASS B	3.96	
W	30			He 180294	Human kpni repeat mma (cdna clone pcd-k ESTs; Weakly similar to !!!! ALU SUBFAMI	3.87	
72.5	50	123963	C13961	Hs.210115	ESTS, WEARY SIMILAR TO IIII ALU SUBFAMI	3.85 3.8	
				Hs.193634		3.76	
<u></u>		128230	AA984074	Hs.176757	FSTs	3.75	
Щ			H09570		ESTs; Weakly similar to neuronal thread	3.67	
	35		R05818	Hs.173830		3.58	
			AA227678		Human DNA sequence from clone 465N24 on	0.00	3.57
=				Hs.193929		3.52	0.01
		126050	H27267	Hs.75860	hydroxyacyl-Coenzyme A dehydrogenase/3-k		
ΠI		126649	AA856990	Hs.125058		3.42	
	40			Hs.175319		3.4	
14			H39216	Hs.239970		3.38	
7			AA480909		aa28f10.s1 NCI_CGAP_GCB1 Homo sapiens	¢D	3.38
		106145	AA424791		KIAA0679 protein	3.38	
Ū	45	125191	W67257	Hs.138871	ESTs; Weakly similar to !!!! ALU CLASS B	3.36	
lu	43	108836	AA132061	Hs.222727		3.3	
		128710				3.27	
			AA598981	Hs.251122		3.25	
		124696	MC002045	HS.231920		3.24	
	50			HS. 10040/	ESTs; Moderately similar to !!!! ALU SUB	3.24	
	50	133770	M60107	He 2/2270		3.21	
			Al242720			3.17 3.14	
			AA235803			3.14 3.12	
		128088				3.08	
	55	124055			Homo sapiens clone 23605 mRNA sequence	3.00 3.06	
		124896		Hs.101594		3.06	
				Hs.168851		3.04	
		116802		Hs.194026		3.01	
		· <del>-</del>					
	60						

# Table 10: H chip – B survivor vs Met query – Down in Mets

5					
			Pkey:	Unique Eos probeset identifier number	
			ExAcct Unigen	Exemplar Accession number, Genbank acelD: Unigene number	ccession number
			Unigen	e Title: Unigene gene title	
10					
	Pkey	Ex Accn	UniG_ID	Complete_Title	Ratio Met/B surv.
1.5	100116	D00654	Hs.77443	actin; gamma 2; smooth muscle; enteric	0.09
15	130064	T67053	Hs.181125	immunoglobulin lambda gene cluster	0.11
	129982		Hs.140	immunoglobulin gamma 3 (Gm marker)	0.12
	131219	C00476	Hs.24395	small inducible cytokine subfamily B (Cy	0.13
	133806	M12759	Hs.76325	Human Ig J chain gene	0.17
20		L02326	Hs.198118	immunoglobulin lambda-like polypeptide 2	0.18
20			Hs.181125	immunoglobulin lambda gene cluster	0.18
	131791	S71043	Hs.32225	immunoglobulin alpha 1	0.2
	133725	V00563	Hs.179543	immunoglobulin mu	0.22
		S75256		HNL=neutrophil lipocalin [human, ovarian	0.23
25	101461	M22430	Hs.76422	phospholipase A2; group IIA (platelets:	0.24
25	103448	X99133	Hs.204238	lipocalin 2 (oncogene 24p3)	0.24

# Table 11: H chip – Met vs Normal query – up in Mets

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigeneID: Unigene number
Unigene Title: Unigene gene title

			Onige	onigene gene nue	
10	Pkey	Ex Accı	n UniG_ID	Complete_Title	Median Mets Al vs Median Normal Al
	10065	55 HG2841	-HT2970	Albumin, Alt. Splice 5	15.91
		33 U20758	Hs.313	secreted phosphoprotein 1 (osteopontin;	6.83
1.5		75 R70506	Hs.20769	3 ESTs; Weakly similar to !!!! ALU SUBFAMI	6.68
15		4 HG2841	-HT2969	Albumin, Alt. Splice 3, Missplicing In Alloalbur	min Venezia 5.28
		9 F13673	Hs.99769	ESTs	5.11
		6 D14446	Hs.107	fibrinogen-like 1	5.05
		3 X70683	Hs.83484	SRY (sex determining region Y)-box 4	4.82
20	13136	4 AA49146	55 Hs.28792	ESTs	4.78
20	11500	AAZIIBS	95 MS.11883	1 EST; Highly similar to dJ1163J1.2.1 [H.s	4.76
	10455	8 R56678	Hs.17531		4.67
		6 AA60865	П5.00909 7	Human DNA sequence from done 967N21 on	
		0 T91518	,,	ESTs; Moderately similar to !!!! ALU SUB	4.61
25		6 M77349	He 11878	ye20f05.s1 Stratagene lung (#937210) Hom transforming growth factor; beta-induced	4.59
	11882	8 N79496	Hs.50824		4.58
	12804	6 AA87328	5 Hs.137947		4.56
	13342	1 AA43656	0 Hs.7327	_t tr 41	4.45 4.09
	12915	8 J05257	Hs.109	dipeptidase 1 (renal)	4.04
30	12806	2 AA37950	0 Hs.193155		4.03
	12469	R06273	Hs.186467	FOT 14.1 1 1 1 m	4.01
		5 N66845	Hs.165411		3.96
	104755	AA02448	2 Hs.9029	DKFZP434G032 protein	3.83
25			B Hs.19322	ESTs	3.74
35		N68905		small inducible cytokine A5 (RANTES)	3.7
	123/96	AA620390	D Hs.247444	ESTs	3.62
	10/140	/ AA88838/ : AA42242	HS.243845	FAT.	3.61
		D86974	3 Hs.42457	1414 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.55
40		T51832	ms. 1 10613		3.54
70			3 Hs.110659		3.53
		AA487595			3.52
		X63629	Hs.2877		3.48
		T92950	113.2077	ye27c10.s1 Stratagene lung (#937210) Hom	3.48
45		C13961	Hs.210115		3.47
	116480	C14088	Hs.195188	glyceraldehyde-3-phosphate dehydrogenase	7.47 R.A
	108836	AA132061	Hs.222727	ESTs: Weakly similar to ubiquitous TPR m 3	3.39
	120748	AA303153	Hs.237994	EST; Weakly similar to !!!! ALU SUBFAMIL 3	3.38
60	133770	M69197	Hs.242279	haptoglobin-related protein 3	3.38
50		X60486	Hs.46423		3.37
		Al369384		arylsulfatase D 3	1.37
		L12350	Hs.108623	thrombospondin 2	3.37
		AI061213	Hs.13179	ESTs; Moderately similar to !!!! ALU SUB 3	.36
55		AA169866		ESTs; Weakly similar to !!!! ALU SUBFAMI 3	.36
55		N32118 R71234	HS.209100	DKFZP434C171 protein 3	.34
			He 110397	yi54c08.s1 Soares placenta Nb2HP Homo sa 3 KIAA0792 gene product 3	
	128230	AAQR4074	Hs.176757	FOT	.32
	126649	AA856990	Hs.125058		.3 25
60	124620	N74051	Hs.194092	FOT- M. II I II I M. I M. I M. I M. I M. I	.25 24
	135427				.24 .23
		H99653	Hs.138618		.23 .22
		W67257		FOT 111 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2
	124684	R02401	Hs.221078	ESTs 3.	
65		AA856953	Hs.23348	S-phase kinase-associated protein 2 (p45 3)	17
	119423		Hs.173734	ESTs; Weakly similar to !!!! ALU CLASS B 3.	16
	123022	AA480909		aa28f10.s1 NCI_CGAP_GCB1 Homo sapiens ct	3.15
	103654			H.sapiens mitochondrial 16S rRNA gene (p 3.	13
70		AI242720	HS.146043		12
, 0	124690		Hs.173830	V.	
	129791	AA028924	ПS.1/388/ 1	KIAA0876 protein 3.	07
	115420	AA284139	113.17/4U/		07
					06 02
75	126050	H27267	Hs.75860 I	ESTs; Weakly similar to HNK-1 sulfotrans 3.0 hydroxyacyl-Coenzyme A dehydrogenase/3-k 3.0	UO NE
				-,,,	w.

10057050 .ch=

	129906	H39216	Hs.239970	ESTs; Weakly similar to ZNF91L [H.sapien	3.04
	123422	AA598484	Hs.238476	EST	3.03
	103059	X57351	Hs.174195	interferon induced transmembrane protein	3.02
_	124253	H69742	Hs.102201	ESTs	3.02
5	123523	AA608588	Hs.193634	ESTs	3.02
	132669	AA188378	Hs.54602	ESTs; Weakly similar to 60S RIBOSOMAL PR	₹3.02
	123196	AA489250	Hs.59403	serine palmitoyttransferase; subunit II	3.01
	122948	AA477483		zu44h2.s1 Soares ovary tumor NbHOT Homo	3.01
4.0	119053	R11501		yf28f1.s1 Soares fetal liver spleen 1NFL	3.01
10	125953	H40829		yo05d11.r1 Soares adult brain N2b5HB55Y	3
	119155	R61715	Hs.138237	ESTs	3

## Table 12: H chip – Met vs Normal query – down in Mets

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
Unigene Title: Unigene gene title

	10						
	10	Pkey	Ex Acon	UniG_ID	Complete_Title	Median Mets	Al vs Median Normal Al
			6 Y00339		7 carbonic anhydrase II	0.01	
	15		8 AF00721		solute carrier family 4; sodium bicarbon	0.02	
	13		9 AA 13600 6 K01160	4 Hs.72115		0.04	
			5 H57056	Hs.20483	Accession not listed in Genbank	0.04 0.05	
		10134	6 L76465	Hs.77348	hydroxyprostaglandin dehydrogenase 15-/N	0.05	
	20	12313	7 AA48746	8 Hs.100686	ESTs; Weakly similar to secreted cement	0.05	
	20	13453	4 X73501	Hs.84905	H. Sapiens mRNA for cytokeratin 20	0.05	
			3 N79237 5 U11313	HS.50813	ESTs; Weakly similar to long chain fatty	0.06	
			5 R37362	Hs.21351	sterol carrier protein 2	0.06	
		12910	AA22435	1 Hs.108681	ESTs	0.06 0.07	
1	25		U19495	Hs.237356	stromal cell-derived factor 1	0.07	
1	- h		W15263	Hs.5422	ESTs	0.07	
1	7		H25836	Hs.83429	tumor necrosis factor (ligand) superfami	0.07	
			D00654	Hs.77443 5 Hs.106106		0.07	
Q	30	107032	ΔΔ5QQ47	7 He 247200	succinate-CoA ligase; GDP-forming; beta	0.07	
		106605	AA457718	B Hs.21103	Homo sapiens mRNA; cDNA DKFZp564B076	0.08	0.08
		128906	AA487557	7 Hs.10706	ESTs	0.08	0.00
m		130016	AA055811	l Hs.143131	transmembrane glycoprotein	0.08	
	35	113523	T90037	Hs.16686	ESTs	0.08	
	33		U67319 H93575	Hs.9216	caspase 7; apoptosis-related cysteine pr	0.09	
=				Hs.112242	Homo sapiens mRNA; cDNA DKFZp564J142		0.09
		134749	L10955	Hs.89485		0.09 0.09	
TU		130366	L11708	Hs.155109	hydroxysteroid (17-beta) dehydrogenase 2	0.09	
n i	40			Hs.86030	ESTs	0.09	
			U14528	Hs.29981	solute carrier family 26 (sulfate transp	0.1	
			N73702 D11925	Hs.238927		0.1	•
			M12759	Hs 76325		0.1	
N	45	102571	U60115			0.1 0.1	
				Hs.44343	ESTs	0.11	
			V01512	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	0.11	
			AA455983 Z11793			0.11	
	50		C02386	Hs.3314 Hs.107139		0.11	
		120914	AA377254	Hs.97107	505	0.11 0.11	
			J04093	Hs.2056	UDP glycosyltransferase 1	0.11	
			N30796	Hs.17424	ESTs; Weakly similar to semaphorin F [H.	0.12	
	55		M97496	Hs.778	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.12	
	55	12017	AA171913	Hs 108740	01/070000000000000000000000000000000000	0.12	
		133435	T23983			0.12 0.13	
		132836	F09557	Hs.57929	slit (Drosophila) homolog 3	0.13 0.13	
	<b>CO</b>	125832	AA628600	Hs.117587	ESTs (	0.13	
	60	104613	AA001049	Hs.24713	Homo sapiens mRNA; cDNA DKFZp586G0123	(f	0.13
			AA235404 W32094		Homo sapiens clone 25186 mRNA sequence (		
		131273	AA421139	Hs.55501 Hs.173542		).14 ).44	
		106674	AA461303			).14 ).14	
	65	108980	AA151676	Hs.33455	peptidyl arginine deiminase; type II	).14 ).14	
		103211		Hs.205126	polymeric immunoglobulin receptor 0	).14	
		131219		Hs.24395		).15	
		116459				).15	
	70	113863		Hs.15285   Hs.21288		).15 \ 45	
		101564	M32886	Hs.117816 s		).15 ).15	
		109502	AA233837			).15 ).15	
		107222	D51235	Hs.82689 t	umor rejection antigen (gp96) 1 0	.15	
		135237	AA454930	Hs.9691	ESTs 0	.15	

# Table 13: H chip – Met vs Normal query – up in Mets

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigeneID: Unigene number
Unigene Title: Unigene gene title

10						
	Pkey	Ex Accn	UniG_ID	Complete_Title	Ratio Met/Norm	al
	102193		Hs.313	secreted phosphoprotein 1 (osteopontin;	8.457	
1.5	111307		Hs.37477	ESTs; Weakly similar to CGI-141 protein	6.05	
15		X63629	Hs.2877	cadherin 3; P-cadherin (placental)	5.207	
	131564		Hs.28792	ESTs	5.136	
		W69747	Hs.94806	KIAA1062 protein	4.667	
	124059		Hs.99769	ESTs	4.398	
20		C21171	Hs.95497	ESTs; Weakly similar to GLUCOSE TRANS		4.292
20	128817	N47524	Hs.28491	spermidine/spermine N1-acetyltransferase	3.964	
	133770	M69197	Hs.242279	haptoglobin-related protein	3.823	
	130412	AA406554	Hs.241572	golgi autoantigen; golgin subfamily a; 5	3.719	
	104755	AA024482	Hs.9029	DKFZP434G032 protein	3.702	
	132676	AA283035	Hs.54813	ESTs	3.645	
25	134453	X70683	Hs.83484	SRY (sex determining region Y)-box 4	3.581	
		R05818	Hs.173830	ESTs	3.446	
	106949	AA496805	Hs.177425	KIAA0964 protein	3.42	
	130724	AA370091	Hs.179680		3.402	
	128992	R49693	Hs.107708	ESTs	3.32	
30	133421	AA436560	Hs.7327	daudin 1	3.255	
	103047	X55990	Hs.73839	ribonuclease; RNase A family; 3 (eosinop	3.229	
	102990	X51441	Hs.181062	serum amyloid A1	3.149	
		AA284139	Hs.89295	EST		
		J05257	Hs.109	dipeptidase 1 (renal)	3.114	
35		AA608751	Hs.244904	ESTs; Weakly similar to !!!! ALU SUBFAMI	3.019	
			110.2.17007	COTO, TTOORY SHIMAI TO !!!! ALU SUBFAMI	3.011	

## Table 14: H chip – Met vs Normal query – down in Mets

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigeneID: Unigene number
Unigene Title: Unigene gene title

	10					
	10	PkeyY Ex Accn	UniG_ID	Complete_Title	Ratio Met/Norma	al
		103466 Y00339	Hs.15509	7 carbonic anhydrase II	0.012	
	15	104258 AF00721		solute carrier family 4; sodium bicarbon	0.025	
	13	108999 AA15606 101046 K01160	34 Hs.72115	ESTs Accession not listed in Genbank	0.034	
		133565 H57056	Hs.20483	ESTs	0.041 0.042	
		101346 L76465	Hs.77348	hydroxyprostaglandin dehydrogenase 15-(I	N 0.043	
	20	102095 U11313	Hs.75760	sterol carrier protein 2	0.054	
	20	111855 R37362 130320 U19495	Hs.21351	ESTs stromal cell-derived factor 1	0.055	
			8 Hs.100686	ESTs; Weakly similar to secreted cement	0.058 0.06	
		107222 D51235	Hs.82689	tumor rejection antigen (gp96) 1	0.06	
	25	102638 U67319	Hs.9216	caspase 7: apoptosis-related cysteine nr	0.063	
-	23	128906 AA48755 129105 AA22435	/ MS.1U/U6 1 He 108681	ESIS EST.	0.065	
rooszasa		110837 N30796	Hs.17424	ESTs; Weakly similar to semaphorin F [H.	0.069 0.069	
		100116 D00654	Hs.77443	actin; gamma 2; smooth muscle; enteric	0.071	
m	30	116786 H25836	Hs.83429	tumor necrosis factor (ligand) superfami	0.074	
, F	30	130867 J04093 132836 F09557	Hs.2056 Hs.57929	UDP glycosyltransferase 1	0.075	
<u></u>		131861 D11925		slit (Drosophila) homolog 3 KIAA0929 protein Msx2 interacting nuclea	0.076 0.081	
÷		106674 AA461303	3 Hs.7946	DKFZP586D1519 protein	0.084	
빌	35	109272 AA195718	3 Hs.86030		0.088	
	33	132711 N73702 106569 AA455983	Hs.238927	ESTs	0.091	
<b>3</b>		104636 AA004415	Hs.106106	FSTs	0.092 0.093	
		118823 N79237	Hs.50813	ESTs; Weakly similar to long chain fatty	0.093	
T.	40	134534 X73501	Hs.84905	H. Sapiens mRNA for cytokeratin 20	0.095	
Ш	40	119479 W32094 113778 W15263	Hs.55501	ESTS	0.096	
72.		128482 U83908	Hs.5422 Hs 100407	ESTs programmed cell death 4	0.098 0.102	
		124653 N92884	Hs.109641	ESTs	0.102	
T	A.E	133407 AA093348		secreted frizzled-related protein 1	0.108	
H	45	135237 AA454930 116250 AA480975	Hs.9691	ESTs	0.109	
		132617 AA171913		ESTs carbonic anhydrase XII	0.111	
		131273 AA421139	Hs.173542	ESTs	0.112 0.113	
	50	116710 F10577	Hs.70312	ESTs	0.114	
	50	131791 S71043 112483 R66534		immunoglobulin alpha 1	0.114	
		132017 W67251		ESTs Homo sapiens vav 3 oncogene (VAV3) mRN	0.115	
		124308 H93575	Hs.227146	Homo sapiens mRNA: cDNA DKF7n564.1143	2 (fr a	.117
	55	114846 AA234929	Hs.44343	ESTs	0.119	
	55	116551 D20458	Hs.229071	EST ATP-binding cassette; sub-family G (WHIT	0.12	
		130366 L11708	Hs.155109	hydroxysteroid (17-beta) dehydrogenase 2	0.122 0.122	
		133806 M12759	Hs.76325	Human Ig J chain gene	0.122	
	60	104776 AA026349	Hs.31412	ESTs	0.125	
	UU	129565 X77777	Hs.198726	vasoactive intestinal peptide receptor 1 paternally expressed gene 3	0.125	
		105774 AA348014	Hs.23412	Paternally expressed gene 3	0.127 0.128	
		134604 M22995		RAP1A; member of RAS oncogene family	0.128	
	65	134711 X04011	Hs.88974 (	cytochrome b-245; beta polypeptide (chro	0.128	
	05	129113 AA147646 123995 D51119	Hs.108740 (	DKFZP586A0522 protein	0.133	
		129168 T90621	Hs.100090 1	etraspan 3 chromosome 14 open reading frame 2	0.133 0.133	
		123891 AA621103	Hs.99216	ESTs; Moderately similar to !!!! ALU SUB	0.135	
	70	132694 M60830	Hs.5509	ecotropic viral integration site 2B	0.135	
	70		Hs.99120 [	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep		
				ESTs; Weakly similar to similar to 1-acy	0.137	
				arbonic anhydrase IV	0.137 0.139	
		106586 AA456598	Hs.256269	STs	0.139	

		100000	A A 400C	00 11-0505			
		100093	AA489b	36 Hs.2525		0.139	
			L02785	Hs.1650		0.14	
			Z40718	Hs.2019		0.14	
	5		W86600			0.141	
	5		L19872	Hs.1700	87 aryl hydrocarbon receptor	0.145	
		131492	AA39387	6 Hs.1255	nuclear receptor subfamily 2; group F; m	0.145	
		133889	AA09939	11 Hs.2115	82 myosin; light polypeptide kinase	0.145	
				4 Hs.9710		0.147	
	10		N74690	Hs.5054		0.149	
	10			3 Hs.2526		0.151	
			R41771	Hs.2214	6 ESTs	0.153	
				9 Hs.1033		0.154	
			Z38161	Hs.1973	35 plasma glutamate carboxypeptidase	0.154	
	1.0	133011	AA04299	0 Hs.17192	21 sema domain: immunoolohulin domain (In)	0.154	
	15	115967	AA44688	7 Hs.42911	I ESTs	0.154	
			U60115		Homo sapiens skeletal muscle LIM-protein	0.155	
		100687	HG3115-	HT3291	Golli-Mbp (Gb:L18862)	0.155	
		132903	AA23540	4 Hs.5985	Homo sapiens done 25186 mRNA sequent	æ 0.155	
	20	125832	AA62860	0 Hs.11758	37 ESTs	0.155	
	20	130064	T67053	Hs.18112	25 immunoglobulin lambda gene cluster	0.157	
		123264	AA49100	3 Hs.99824	BCE-1 protein	0.159	
		130919	AA29171	D Hs.21276		0.159	
			Z11793	Hs.3314	selenoprotein P; plasma; 1	0.161	
	25		M23379	Hs.758	RAS p21 protein activator (GTPase activa	0.162	
	25	108921	AA142913	3 Hs.71721	ESTs	0.164	
		100642	HG2743+	1T3926	Caldesmon 1, Alt. Splice 6, Non-Muscle	0.167	
1		132109	AA599801	I Hs.40098	ESTs	0.167	
<i></i>		115719	AA416997	7 Hs.59622	ESTs	0.169	
		128915	C02386	Hs.10713		0.171	
ليا	30	117634	N36421		4 ESTs; Weakly similar to SODIUM- AND CH	0	0.172
m		129462	D84239		2 IgG Fc binding protein	0.174	0.172
- F			V01512	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	0.176	
		130343	AA490262	Hs.15485	ESTs: Weakly similar to APICAL-LIKE PRO	T 0.177	
		115764	AA421562	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	0.177	
m	35	122261	AA436830	Hs.98902	ESTs	0.179	
1 I I I I I I I I I I I I I I I I I I I		106605	AA457718	Hs.21103	Homo sapiens mRNA; cDNA DKFZp564B07	'6 (fr	0.179
		109991		Hs.12896		0.181	0.175
≅		101300	L40391	Hs.6445	Homo sapiens (clone s153) mRNA fragment	0.101	
		123080	AA485303	Hs.205126	polymeric immunoglobulin receptor	0.182	
<del></del>	40	130016	AA055811	Hs.143131	transmembrane glycoprotein	0.186	
ΠJ		122666	AA455052	Hs.99387	ESTs	0.188	
nı		105453	AA252893	Hs.9001	ESTs	0.189	
1 mg		108980	AA151676	Hs.33455	peptidyl arginine deiminase; type II	0.19	
		100248		Hs.78398		0.192	
	45	130036	AA195260	Hs.206738	ESTs; Moderately similar to !!!! ALU SUB	0.192	
T.		110882	N36001	Hs.17348	ESTs; Weakly similar to !!!! ALU SUBFAMI	0.193	
= <del>1</del>		131676	C20785	Hs.30514	ESTs	0.195	
		111029	N54792	Hs.24697	cytidine monophosphate-N-acetylneuramini	0.196	
		131257	4A256042	Hs.24908	ESTs	0.196	
	50	133348	T23517	Hs.7149	ESTs	0.196	
		133784	AA214305	Hs.76173	ESTs	0.196	
		113863 \		Hs.21288	ESTs; Weakly similar to KIAA0704 protein	0.197	
		103158	(67235	Hs.118651	hematopoietically expressed homeobox	0.198	
		102347 U	J37518	Hs.83429	tumor necrosis factor (ligand) superfami	0.2	
	55	111351 N		Hs.23392		0.2	
			A599850		ESTs; Weakly similar to similar to BPTI/	0.2	
		123802 A	A620448	Hs.61408	Homo sapiens clone 24760 mRNA sequence	0.2	
		129243 F	188033	Hs.109727	KIAA0733 protein	0.2	
		130219 F	777539	Hs.15285	ESTs	0.2	
	60	131171 F	104644	Hs.167619	ESTs; Weakly similar to !!!! ALU SUBFAMI	0.2	
		133746 L	J44378	Hs.75862	MAD (mothers against decapentaplegic; Dr	0.2	
		116459 A	A621399	Hs.64193	ESTs	0.201	
		109613 F	03031	Hs.27519	ESTs	0.202	
		133435 T	23983	Hs.7365	ESTs	0.202	
	65	103002 X	52001	Hs.1408	endothelin 3	0.204	
		125153 W	V38294		Accession not listed in Genbank	0.204	
		131919 A	A121266	Hs.34641	ESTs	0.204	
		100749 H	G3521-HT	3715	Ras-Related Protein Rap1b	0.205	
		105085 A			ESTs	0.208	
	70	124571 N	67470	Hs.173074	DKFZP564O1863 protein	0.20	
			A298786	Hs.112242	ESTs	0.21	
		116724 F				0.21	
		132932 T				0.21	
		113803 W				0.211	
	75	110792 N	24899	Hs.6630		0.212	
		105178 A		Hs.21941		0.212	

			5 T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	0.212	
		11526	2 AA27911	2 Hs.88594	ESTs	0.213	
		11583	9 AA42903	8 Hs.40541	ESTs	0.213	
		10321	1 X73079	Hs.20512	6 polymeric immunoalobulin recentor	0.214	
	5	10860	4 AA09982	0 Hs.49696	ESTs	0.215	
		10517	3 AA18203	0 Hs.8364	ESTs	0.217	
			9 AA08467			0.217	
			4 H09594	Hs.10299		0.217	
			6 Y00264		amyloid beta (A4) precursor protein (pro	0.217	
	10		5 T71333	Hs.13854	ESTs		
			2 AA05576			0.219	
			2 L02326		immunoglobulin lambda-like polypeptide 2	0.219	
			M86849	113.15011	Homo sapiens connexin 26 (GJB2) mRNA, o	0.22	
				5 Hs.17448	ESTs; Weakly similar to !!!! ALU SUBFAMI		
	15	132119	H99211	Hs.40334		0.222	
			R25385		KIAA0824 protein	0.222	
				He 110824	trinucleotide repeat containing 9	0.222	
		113083	T40530	Hs.8241		0.222	
		107053	AA600147		ESTs; Weakly similar to heat shock prote	0.223	
	20		Z70295		ESTs; Weakly similar to NADH-cytochrome	0.224	
	20			Hs.32966 Hs.24713		0.225	
			R18070	Hs.3712			0.225
			D11900		ubiquinol-cytochrome c reductase; Rieske	0.227	
		130616	AA222762	Hs.3731 Hs.16726	ESTs	0.227	
	25	132883	AA047151	Ho 5007		? (fr	0.227
		123160	AAA99902	118.3097	Homo sapiens mRNA; cDNA DKFZp586P162		0.23
		115187	AA261906	Hs.44021	ESTs; Weakly similar to Gag-Pol polyprot	0.233	
			H28581		ESTS	0.234	
			T57112	Hs.15641	ESTs	0.234	
A	30		W45457	Un 202550	yc20g11.s1 Stratagene lung (#937210) Hom		
	50		R45480	Hs.203559		0.235	
Ш		116944	H64938	Hs.164866		0.235	
* Tage			U81607	Hs.38331	ESTs (PRICA)	0.235	
roosyoan aeeyoe		120504	0010U/	Hs.788	A kinase (PRKA) anchor protein (gravin)	0.238	
	35	122240	D24464	TIS. 160641	tumor necrosis factor receptor superfami	0.238	
	55	122052	D31161	Hs.68613	ESTs	0.238	
7				Hs.61426	ESTs	0.239	
<del>إسما</del>			Z69881	Hs.5541	ATPase; Ca++ transporting; ubiquitous	0.24	
Ħ			D62965	Hs.31297	ESTs	0.24	
	40		R38678	Hs.12365	ESTs	0.241	
7	70	102323	U35139	Hs.50130		0.244	
14		104500	AA084602	HS.29009	ESTs (CALIFICATION OF THE CALIFORNIA CONTRACTOR OF THE CALIFORNIA CONTRACT	0.244	
Ŋ.		1000/4	AA264/33	HS.214/42	CDW52 antigen (CAMPATH-1 antigen)	0.244	
7- 11		120019	AA258585	HS.129887	cadherin 19 (NOTE: redefinition of symbo	0.244	
===	45	1340/3	AA250/45	Hs.87773	protein kinase; cAMP-dependent; catalyti	0.244	
	73		M63438	MS.156110	Immunoglobulin kappa variable 1D-8	0.245	
ΠI			R78190	Hs.82933	ESTs; Weakly similar to cDNA EST EMBL:T0	0.245	
- 442			AA257976	HS.56156	ESTs	0.245	
		131713		MS. 181125	immunoglobulin lambda gene cluster	0.246	
	50	108931	AA147186	Hs.250746		0.246	
	<b>J</b> U	106609	AA458652	Hs.32181		0.248	
			AA393810		ESTs	0.25	
		133985		Hs.78146		0.25	
		134088		Hs.79025	KIAA0096 protein (	0.25	
	55	134487	K38185	Hs.83954	Homo sapiens unknown mRNA (	0.25	
	JJ		•				

# Table 15: I chip – Met vs Normal query – up in Mets

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

Unigene Title: Unigene gene title

10					
	Pkey	Ex_Accn	UniG_ID	Title	Ratio Met/Normal
		T91443	Hs.193963		18.71
1.5		N63915		EST cluster (not in UniGene)	11.9
15		AI732331		ESTs: Moderately similar to !!!! ALLI CLA	7.23
	315720	AW291875	Hs.163900	ESTs	6.06
	308010	Al439190	Hs.181165	eukaryotic translation elongation factor	5.76
	313774	AW136836	Hs.144583	ESTs	5.01
• •	300734	AW205197	Hs.240951	ESTs	3.98
20	337895			CH22_EM:AC005500.GENSCAN.56-2	3.98
	312339	AA524394		EST duster (not in UniGene)	3.66
	331644	T99544	Hs.173734	ESTs; Weakly similar to !!!! ALU CLASS B	3.53
	324643	AI436356	Hs.130729	ESTs	3.52
	324302	AA543008		ESTs; Weakly similar to !!!! ALU SUBFAMI	3.41
25	314912	Al431345	Hs.161784	ESTs	3.33
		T98413		EST cluster (not in UniGene)	
		AI761036		EST singleton (not in UniCone) with even	3.32
		AA421163		EST singleton (not in UniGene) with exon	3.27
		AW362945			3.22
30		AA078493	113.102433		3.21
50	337898	77070433		EST cluster (not in UniGene)	3.18
		Al110679		CH22_EM:AC005500.GENSCAN.56-5	3.16
			11- 000407	EST duster (not in UniGene)	3.15
			Hs.222487		3.1
35		AI879831		EST singleton (not in UniGene) with exon	3.08
55	310016	AW449612	Hs.152475	ESTs	3.05

## Table 16: I chip – Met vs Normal query – down in Mets

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
Unigene Title: Unigene gene title

	10			
	10	Pkey Ex_Accn UniG_ID title	Ratio Met/N	iormai
		303041 AF127035 EST cluster (not in UniGene) with exon h	0.02	
	15	302360 AJ010901 Hs.198267 mucin 4; tracheobronchial	0.03	
	13	301948 AA344647 Hs.116724 aldo-keto reductase family 1; member B1 336091 CH22 FGFNFS 689 3		
		336091 CH22_FGENES.689_3 333657 CH22_FGENES.241_2	0.04	
		333658 CH22_FGENES.241_4	0.04	
		333737 CH22_FGENES.261_1	0.04 0.05	
	20	333656 CH22 FGENES.240 4	0.05	
		302347 AF039400 Hs.194659 chloride channel; calcium activated; fam	0.06	
		336084 CH22 FGENES.688 13	0.06	
		330385 AA449749 Hs.31386 ESTs; Highly similar to secreted apoptos	0.06	
	25	304487 AA434241 EST singleton (not in UniGene) with exon EST cluster (not in UniGene) with exon be		
		302292 AF067797 EST cluster (not in UniGene) with exon h 334030 CH22_FGENES.320_2	0.07	
		332859 CH22_FGENES.27_2	0.07 0.07	
		333654 CH22_FGENES.240_2	0.07	
77	20	303270 AL120518 Hs.105352 ESTs	0.08	
14.3	30	320352 Y13323 Hs.145296 disintegrin protease	0.08	
10087080		333637 CH22_FGENES.229_2	0.08	
		324094 AA382603 EST cluster (not in UniGene)	0.08	
$\Box$		320590 U67058 Hs.168102 Human proteinase activated receptor-2 mF 330622 X63597 Hs.2996 sucrase-isomaltase		
	35	330622 X63597 Hs.2996 sucrase-isomaltase 331441 H75860 Hs.39720 ESTs	0.08	
		308601 Al719930 EST singleton (not in UniGene) with exon	0.08 0.09	
B 		323770 AA722425 EST cluster (not in UniGene)	0.09	
		335188 CH22_FGENES.507_3	0.09	
Ų	40	333730 CH22_FGENES.258_1	0.09	
U	70	304480 AA430373 EST singleton (not in UniGene) with exon 336081 CH22 FGENES 688 10	0.09	
#****		336081 CH22_FGENES.688_10 332071 AA598594 Hs.112475 ESTs	0.1	
- 1945 - 1945 - 1945		318538 N28625 Hs.74034 caveolin 1; caveolae protein; 22kD	0.1	
		311331 Al679622 Hs.32225 immunoglobulin alpha 1	0.1 0.1	
Ŋ	45	319668 NM_002731 EST duster (not in UniGene)	0.11	
		332567 N23730 Hs.25647 v-fos FBJ murine osteosarroma viral onco	0.11	
		319395 AW062570 Hs.13809 ESTs	0.11	
		315594 Al983437 Hs.155145 ESTs 321539 N98619 Hs.62461 ARP2 (actin-related protein 2: yeast) bo	0.11	
	50	321539 N98619 Hs.62461 ARP2 (actin-related protein 2; yeast) ho 333647 CH22_FGENES.235_2	0.12	
		333588 CH22_FGENES.206_2	0.12 0.12	
		321286 Al380940 EST cluster (not in UniGene)	0.12	
		320727 U96044 EST cluster (not in UniGene)	0.13	
	55	335687 CH22_FGENES.596_2	0.13	
	55	324611 AA743462 Hs.165337 ESTs 335115 CH22 EGENES 496 2	0.14	
		335115 CH22_FGENES.496_2 324660 AA541644 Hs.186044 ESTs	0.14	
		337951 CH22_EM:AC005500.GENSCAN.94-1	0.14 0.14	
		302332 Al833168 Hs.184507 Homo sapiens Chromosome 16 BAC clone (	0.14 CIT	0.14
	60	300921 AW293224 Hs.232165 ESTs	0.14	0.14
		333646 CH22_FGENES.234_2	0.14	
		335116 CH22_FGENES.496_3	0.14	
		320211 AL039402 Hs.125783 DEME-6 protein 336092 CH22 EGENES 689 6	0.15	
	65	336092 CH22_FGENES.689_6 330673 D57823 Hs.92962 Sec23 (S. cerevisiae) homolog A	0.15	
		303042 AF129532 EST duster (not in UniGene) with exon h	0.16 0.16	
		337954 CH22_EM:AC005500.GENSCAN.96-3	0.16	
		336645 CH22_FGENES.26-1	0.16	
	70	335651 CH22_FGENES.590_2	0.16	
	70	314499 AL044570 Hs.147975 ESTs 336124 CH22 FGENES 701 9	0.17	
		336124 CH22_FGENES.701_9 315199 AA877996 Hs.125376 ESTs	0.17	
		324525 AW044647 Hs.196284 ESTs	0.17 0.17	
		320825 NM_004751 EST cluster (not in UniGene)	0.17	
		,,		

	302049	AA377072	Hs.12979	2 Homo sapiens Chromosome 16 BAC don	e CIT
	336083	3		CH22_FGENES.688_12	0.18
	333653	•		CH22_FGENES.239_2	0.18
_		W44372		EST duster (not in UniGene)	0.19
5		AW087973	3 Hs.126731	ESTs	0.19
		AI493046	Hs.146133		0.19
	330551	U39840	Hs.105440	hepatocyte nuclear factor 3; alpha	0.19
	333642			CH22 FGENES 231 2	0.19
• •	301281	AA843986	Hs.190586	ESTs	0.2
10	333626			CH22_FGENES.224_2	0.21
		C75094	Hs.199839	ESTs; Highly similar to NG22 [H.sapiens]	0.21
	332325	T79428	Hs.191264	ESTs	0.21
	321223	AA431366		EST cluster (not in UniGene)	0.21
	333635			CH22_FGENES.228_2	0.22
15	314645	AI808999	Hs.207570	ESTs	0.22
	322929	AI365585	Hs.146246	ESTs	0.22
	324718	AI557019	Hs.116467	ESTs	0.22
	335652			CH22_FGENES.590_3	0.22
	307783	Al347274		EST singleton (not in UniGene) with exon	0.22
20	331344	AA357927	Hs.70208	ESTs	0.22
	336088			CH22_FGENES.688_17	0.22
	320802	D83824	Hs.185055		0.23
	335692			CH22_FGENES.596_7	0.23
	333593			CH22_FGENES.210_2	0.23
25	335667			CH22_FGENES.590_18	0.24
	314853	AA729232	Hs.153279	ESTs	0.24
	320244	AA296922	Hs.129778	gastrointestinal peptide	0.24
	300601	AI762130	Hs.165619	ESTs	0.24
		AA641485		EST singleton (not in UniGene) with exon	0.25
30	335189			CH22 FGFNFS 507 4	0.25

### Table 17: B survivor vs Mets – Up in B survivor

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigeneID: Unigene number
Unigene Title: Unigene gene title

Unigene gene title

	10						
	10	Pkey	Ex Acci	n UniG_ID	Complete Title	Ratio BS/Met	
			06 J04132	Hs.97087	7 CD3Z antigen; zeta polypeptide (TiT3 com	7.28	
	15		73 Z39050 34 X82206			6.13	
	10		37 HG3872		61 ARP1 (actin-related protein 1; yeast) ho	5.77	
		13246	1 AA4057	75 Hs.49005	Immunoglobulin Gamma Heavy Chain, V(6 hypothetical protein	5.62 (Gb:U13200)	5.63
		13380	6 M12759	Hs.76325	5 Human Ig J chain gene	5.46	
	•	13374	7 D86972	Hs.75863	KIAA0218 gene product	5.45	
	20			38 Hs.10540	3 EST	5.28	
			1 X76302	Hs.54649	putative nucleic acid binding protein RY	5.25	
				4 Hs.3737		5.22	
		10018	6 D17516	Hs.4748 12 Hs.7946	adenylate cyclase activating polypeptide		
	25	10713	6 Z22555			5.1	
1		11335	5 T79203	Hs.14480	6 CD36 antigen (collagen type I receptor;	5.06	
		12904	0 U38864	Hs.10813	9 zinc finger protein 212	4.99 4.00	
F			4 H78003	Hs.15266	ESTs	4.96 4.93	
100	• •			1 Hs.11302	5 ESTs	4.92	
ļ.	30	12970	4 W81301	Hs.12064	ubiquitin specific protease 22	4.91	
254		11642	5 AA60957	7 113.5 1705	LOIA	4.77	
		10516	6 AA17978	7 Hs.30570	polyglutamine binding protein 1 5 ESTs	4.65	
m		11876	5 N74442	Hs.183696	6 ESTs	4.6	
=	35			4 Hs.72115		4.57	
آ	33		5 R93908 5 R16884			4.54	
<b>2</b>			2 T90672			4.48	
		131957	7 AA60900	Hs.183232	7 E318 ) FQT <sub>e</sub>	4.42	
n i		129275	D82061	Hs.109993	Ke6 gene; mouse; human homolog of	4.41	
- :	40		T95085		ESTs	4.4 4.4	
		127187	AA297138	Hs.207422	P ESTs	4.32	
***		101147	L13266	Hs.105	glutamate receptor: innotronic: N-methyl	4.3	
m		134901	S78873	Hs.90875	RAB interacting factor	4.26	
Ū	45	100896	HG4593-	IT4998	Sodium Channel 1	4.24	
ı	43	100687	HG3115-F	T3291	RAB interacting factor Sodium Channel 1 Golli-Mbp (Gb:L18862) Homo sapiens mRNA: cDNA DKF7n566P23	4.21	
		105440	AA399332	Hs.183770 Hs.22851	Homo sapiens mRNA; cDNA DKFZp566P23		
		131551	AA202240 AA107867	Hs.28608	ESTS	4.16	
			T99373	Hs.189786		4.15	
	50		AA401091		ESTs	4.09 4.07	
				Hs.239676	ESTs	4.06	
		103436	X98206		H.sapiens mRNA for UV-B repressed sequen	4.03	
				Hs.20010	ESTs	4.03	
	55		L36720	Hs.106880	bystin-like	4.02	
	33	100/02	HG3236-H	T3413	Neurofibromatosis 2 Tumor Suppressor (Gb:l	L27065) 3.99	
		123347	AAA66244	Hs.124085 Hs.90527	KIAA0921 protein	3.98	
		123650	AA600333	Hs.180696	ESTS	3.97	
		106482	AA451672	Hs 108824	ESTs; Weakly similar to cDNA EST yk415c1	3.94	
	60	101909	S69265	113.100024	Homo sapiens mRNA for PLE21 protein; com	3.94	
		108390	AA075070		zm86b6.s1 Stratagene ovarian cancer (#93	3.33	
					LYMPHOCYTE ANTIGEN LY-6A.2/LY-6E.1	PREC 3.93	
			U06643	Hs.99923	lectin; galactoside-binding; soluble; 7	3.89	
	65		AA398536	Hs.97365	ESTs	3.88	
	65	128496		Hs.100610		3.86	
			AA128946		ESTs	3.86	
		130109	W79499		ESTs	3.85	
		134538			retinoic acid receptor; gamma	3.84	
	70	110310			KIAA0513 gene product EST	3.83	
		110433			ESTs	3.81	
		111834		Hs.152458		3.78 3.76	
		130903	N27086	Hs.21068		3.74	
			AA164851		ESTs; Weakly similar to HERV-E envelope	3.73	

	120700	1140400	11- 40420			
		3 U40490 3 L40399	Hs.18136	nicotinamide nucleotide transhydrogenase 0 hypothetical protein	3.23	
			0 Hs.29383	ESTs	3.22 3.22	
		HG4194-		Sodium/Hydrogen Exchanger 5	3.22	
5	123026	AA48107	2 Hs.99743	ESTs	3.21	
		AA070204		zm68b3.s1 Stratagene neuroepithelium (#9	3.2	
		AF007833		Homo sapiens kruppel-related zinc finger	3.2	
		J04130	Hs.75703		3.2	
10		R52145 W38053	Hs.25894	ESTs; Highly similar to hypothetical pro Accession not listed in Genbank	3.19	
10		AA446221	Hs 6092	F-box protein containing leucine-rich re	3.19 3.19	
	109157	AA179161	Hs.73562	ESTs	3.19	
	119903	W85707	Hs.75936		3.18	
1.5		AA491317	7	aa65c01.r1 NCI_CGAP_GCB1 Homo sapie		3.18
15		H62793	Hs.221892		3.18	
	129221	AA417126	Hs.109571	translocase of inner mitochondrial membr	3.17	
		AA481404	Hs.98110	ESTs ESTs	3.16	
		T79868		hypothetical protein	3.16 3.16	
20		U12897	Hs.5022	imprinted in Prader-Willi syndrome	3.16	
		X60382		collagen; type X; alpha 1 (Schmid metaph	3.15	
	129654	AA019943	Hs.118463	H.sapiens mRNA for unknown liver orphan	3.15	
		N22360	Hs.43153	ESTs	3.15	
25		U48224	Hs.158321	beaded filament structural protein 2; ph	3.14	
23		X99459 AA235056		adaptor-related protein complex 3; sigma	3.14	
		AA398551			3.14 3.13	
		U22963		major histocompatibility complex; class	3.13	
		R78565	Hs.138395		3.13	
30	113170	T54342	Hs.222506	ESTs	3.13	
		R23146	Hs.23466	ESTs	3.13	
		R33616	Hs.24688	EST	3.12	
		AA278961 X75546			3.11	
35	129944		Hs.230 Hs.1361	fibromodulin cytochrome P450; subfamily I (aromatic c	3.11	
55		AA028915			3.11 3.11	
		H94949		trophinin-assisting protein (tastin)	3.1	
	125742		Hs.183654	ESTs; Weakly similar to unknown [S.cerev	3.1	
40	134802		Hs.89709	glutamate-cysteine ligase (gamma-glutamy	3.1	
40	112560		Hs.6179	Homo sapiens mRNA; cDNA DKFZp586K23		3.1
		AA343881	Hs.209061	sudD (suppressor of bimD6; Aspergillus n	3.09	
	131594	AA211419	Hs.29261	small inducible cytokine A5 (RANTES)	3.09	
		AA431320		ESTs; Weakly similar to serine protease ESTs	3.08 3.08	
45	103505		Hs.33102	transcription factor AP-2 beta (activati	3.08	
	110525	H57330	Hs.37430	EST	3.07	
		AA491270			3.06	
	130519		Hs.10669	ESTs; Moderately similar to KIAA0400 [H.	3.06	
50		AA192638	Un 470742	zq01h08.r1 Stratagene muscle 937209 Homo		
30	103513	Y1020Q	ns.1/0/43	death-associated protein 6 H.sapiens mRNA for CD3L protein	3.04 3.04	
	131243	R16667	Hs.24752	spectrin SH3 domain binding protein 1	3.04	
		AA261805		ESTs	3.04	
	107543		Hs.4552	Homo sapiens HRIHFB2157 mRNA; partial or		
55	134051		Hs.78846	heat shock 27kD protein 2	3.04	
	113461		Hs.193536		3.03	
	130490		MS.158164	ATP-binding cassette; sub-family B (MDR/ katanin p80 (WD40-containing) subunit B	3.03	
		HG862-HT8		Transition Protein 2	3.03 3.03	
60			Hs.178202		3.02	
	107425			ESTs	3.02	
	130930	U19261		TNF receptor-associated factor 1	3.02	
	132958			KIAA1075 protein	3.02	
65	100973		Hs.73956	NAD(P)H menadione oxidoreductase 2; diox	3.01	
65	104924 /	AA058532	HS.28774	ESTs	3.01	
	130023		MS. 162808	phosphoinositide-3-kinase; catalytic; de	3.01	
	129536			calmodulin-like 3 tryptase; alpha	3.01	
	112015			rypiase; aipha ESTs	3 3	
70	103036			matrix metalloproteinase 1 (interstitial	2.99	
		HG3565-HT		Zinc Finger Protein (Gb:M88357)	2.99	
	103425	K97301		H.sapiens mRNA for Ptg-11 protein	2.99	
	118291		Hs.138746		2.98	
75	125877 F	115229		ym30g04.r1 Soares infant brain 1NIB Homo	0.00	
, ,	101371 A	M13232		repetitive element ;, mRNA sequence. coagulation factor VII (serum prothrombi	2.98	
	.010/1 /			Acquation ractor vir (Securit protitionitis)	2.98	

	1029	58 X15675	⊌e 0217	74 Human andaranan arkaria a 115 4 (55) m		
		83 AA4001			) 2.97 2.97	
		41 T12559		882 ESTs	2.96	
5		67 AA2534 96 AA0843			2.96	
•		42 R16153		zn05g10.s1 Stratagene hNT neuron (#93723 40 ESTs; Highly similar to DNb-5 [H.sapiens	2.96 2.95	
		98 HG4638	3-HT5050	Spliceosomal Protein Sap 49	2.95	
		70 AA2878		96 ESTs; Moderately similar to GTP-binding	2.94	
10		15 C02386 58 M96233		39 ESTs	2.94	
10		34 N29724		1 glutathione S-transferase M4 gamma2-adaptin	2.94 2.93	
		59 Z19585	Hs.7577		2.93	
		32 AA0256			2.93	
15		19 T99639 3 H30258	Hs.9114 Hs.3716		2.92	
	13243	3 AA0825	46 Hs.4851	5 collagen; type IX; alpha 2 6 ESTs	2.92 2.92	
	12734	7 AA4283	50	ESTs	2.92	
	12197	6 AA4298	07 Hs.9863		2.91	
20		3 S72043	92 Hs.6318 Hs.7313		2.91	
		4 R22035	Hs.2333		2.91 2.91	
		9 F12681	Hs.20530	00 ESTs	2.9	
		4 U49260	Hs.3828	The same (alphaeophile) accordingly (accordingly)	2.9	
25		8 C21431 1 AA11328	Hs.99486 37 Hs.65905		2.9	
		5 U20230	77 113.00300	ESTs; Weakly similar to PTB-ASSOCIATED S Human guanyl cyclase C gene, partial cds	2.89	
			7 Hs.98762	? EST	2.89	
		0 U06088	Hs.15947	9 galactosamine (N-acetyl)-6-sulfate sulfa	2.89	
30	13511	7 T15817	5 Hs.19901	8 nitric oxide synthase 2A (inducible; hep	2.88	
	11872	N73717	Hs.16152	6 EST	2.88 2.88	
		3 AA36980			2.88	
		R74309 U57971	Hs.44499		2.87	
35		H30751	Hs.18285	4 ATPase; Ca++ transporting; plasma membra 9 lifeguard	2.87 2.87	
	100779	HG37314		Immunoglobulin Heavy Chain, Vdjrc Regions (	z.o/ Gb:L23566)	2.87
		M13299		9 blue cone pigment	2.86	2.07
		M21574 W37833	Hs.74615 Hs.55563	TOT	2.86	
40		AA19051		05.40 404 4 44 4 44 4	2.86 2.86	
	134184	X53742	Hs.79732	fibulin 1	2.86	
		AI339609	Hs.152733	potassium voltage-gated channel; lsk-rel	2.86	
	107135	AA620782	Hs.23247	NADH dehydrogenase (ubiquinone) Fe-S pro ESTs		
45		N47317	Hs.141858		2.85 2.85	
		F04143	Hs.151032	Homo sapiens clone 23856 unknown mRNA: n		2.85
	135120	AA449841 U17977	Hs.108300	NOT3 (negative regulator of transcriptio	2.84	
		AA401401	Hs.11127	HSU17977 Humn fibroblast cDNA H sapiens 2 PET112 (yeast homolog)-like	2.84 2.84	
50	103222	X74795	Hs.77171	minichromosome maintenance deficient (S. 2	2.84	
		W38001	T0005	Accession not listed in Genbank 2	2.83	
	105370	HG2228-H	Hs.22791		2.83	
	127036	AI468598		ESTs 2	2.83 2.83	
55			Hs.105685	ESTs 2	.83	
		W38041 N31224	Un 044670		.82	
		R15866	Hs 170263	A	.82	
<b>60</b>		N59287	Hs.48361	EST 2	.82 .82	
60		L40387	Hs.118633	2'-5'oligoadenylate synthetase-like 2	.81	
		U33054 H41281	Hs.32959 Hs.107619	FOT	.81	
		U32581	113.107013		.81 .81	
<i>(5</i>		N66396	Hs.167766	ESTs: Moderately similar to Pro-a2(XI) [ 2	.81	
65	126573	AA482023	Hs.155218	E1B-55kDa-associated protein 5 2	81	
	1204//	Al270093 AA451896	Hs 7922	aquaporin 3 2. ESTs; Weakly similar to contains similar	81	
		10 1030	· 13.1 322	p19; an RNA polymerase II elongation fa 2.	8	
70	132881	T86118	Hs.58875	ESTs 2.		
70	114733	AA133778	Hs.95734	ESTs 2.	79	
	134137	F10045	Hs.186494 Hs.79347	141.10044	79 70	
	133212	U82979	Hs.67846	leukocyte lg-like receptor, subfamily B 2.	79 78	
75	100882	HG4460-HT	r4729	Immunoglobulin Heavy Chain, Vdic Regions (Gb.	:L23564)	2.78
	104756 129861	AA024622 N69507	Hs.15813	solute carrier family 22 (organic cation 2.	78	
	.25001		1 13. 123043	Dra zmootivi toz protein 2.1	78	

	120924 AA247540 Up 00070	SOT.	
	120824 AA347548 Hs.96876 100684 HG3107-HT3283	ESTs Plasma Membrane Calcium Pump Hpmca.	2.78
	121789 AA423970 Hs.178111	ESTs	2a 2.78 2.78
-	101647 M59941 Hs.118200	colony stimulating factor 2 receptor; be	2.78
5	113722 T97957 Hs.202948	B ESTs; Weakly similar to alternatively sp	2.77
	115107 AA256371 Hs.186645 111464 R05518 Hs.19521	ESTS	2.77
	108446 AA079120	zm95e1.s1 Stratagene colon HT29 (#9372	2.77
10		Hu DNA seg frm clone 1163J1 on chr 22g1	13
10		prot (similar to mouse Celsr1; rat MEGF	2.77
	134445 M59488 Hs.83384 114132 Z38688 Hs.24192	S100 calcium-binding protein; beta (neur ESTs	2.76
	120500 AA256430 Hs.132525		2.76 2.76
1.5	101860 M95610 Hs.37165	collagen; type IX; alpha 2	2.76
15	134430 H52105 Hs.8309	KIAA0747 protein	2.76
	124152 H27216 Hs.107635 132268 AA058833 Hs.23445	ESTs; Weakly smlr to similar to M. muscu	2.76
	116257 AA481493 Hs.88537	ESTs	2.76 2.76
20	102438 U46570 Hs.7733	tetratricopeptide repeat domain 1	2.75
20	122393 AA446334 Hs.99064	ESTs	2.75
	107653 AA010210 Hs.47041 123674 AA609473 Hs.105187	ESTs ESTs; Moderately similar to kinesin like	2.75
	129858 T66906 Hs.12970	ESTs Woderately similar to kinesin like	2.75 2.75
25	130117 U06641 Hs.150207	UDP glycosyltransferase 2 family; polype	2.75
25	133464 M13982 Hs.73917	interleukin 4	2.75
	127039 AA233366 Hs.256491 128318 AA418202 Hs.13810	ESTs ESTs	2.74
	123363 AA504818 Hs.171279		2.74 2.74
20	127654 AA649249 Hs.75640	natriuretic peptide precursor A	2.74
30	132067 L20860 Hs.178382	glycoprotein lb (platelet); beta polypep	2.74
	125664 AA948418 Hs.25744 132354 L05187 Hs.211913	ESTs; Weakly similar to Ydr412wp [S.cere	2.73
		small proline-rich protein 1A omithine decarboxylase 1	2.73 2.73
25	101438 M20777 Hs.159263	Homo sapiens; alpha-2 (VI) collagen	2.73
35	116233 AA479082 Hs.61142	ESTs	2.73
		ESTs ESTs	2.72
	124251 H68286 Hs.107924		2.72 2.71
40	120583 AA281304 Hs.78614	complement component 1; q subcomponent	
40	134958 U72507 Hs.234216 124280 H85835 Hs.100058	Human 40871 mRNA partial sequence	2.71
		dihydropyrimidinase-like 4 heat shock transcription factor 1	2.71 2.71
		ESTs; Weakly smir to PHOSPHATIDYLETH,	ANOL
45	132023 F01927 Hs.3743	ESTs; Weakly similar to proline-rich pro	2.7
43		ESTs	2.7
	444444 4444444	ESTs ESTs	2.7 2.7
	119070 R27788 Hs.52302	ESTs	2.7
50		Homo sapiens mRNA for HRX-like protein	2.7
30	108225 AA058843 Hs.161620 E 105829 AA398290 Hs.21965 E	EST ESTs	2.7
	127749 Al251757 Hs.145234 E		2.69 2.69
	128428 Al185718 Hs.143900 E	STs	2.69
55	108409 AA075578 z 114739 AA134923 Hs.103833 E	rm88h3.s1 Stratagene ovarian cancer (#93	2.69
55	400004	ESTs; Weakly similar to predicted using nultiple UniGene matches	2.68
	400440 14400400	ESTs	2.68 2.68
	117012 H85893 Hs.194387 E	STs; Weakly similar to !!!! ALU SUBFAMI	2.68
60		STs	2.68
00		STs daptor-related protein complex 1; beta	2.68 2.68
	400000 444000	STs	2.68
	125093 T92930 Hs.186750 E		2.68
65	119340 T61899 Hs.90677 E 132603 H62900 Hs.53066 h	STs; Highly similar to CGI-82 protein [	2.67
05	113733 T98386 Hs.184548 E	sp70-interacting protein	2.67
	123564 AA608902 Hs.112612 E		2.67 2.66
	116059 AA454165 Hs.53455 E	STs	2.66
70	125803 R79373 Hs.29852 E 123012 AA479962 Hs.139636 E	STs ST	2.66
		STs	2.66 2.66
	128809 T59668 Hs.102267 ly		2.66
	104354 H08988 Hs.113759 E	STs	2.66
75		STs N51 (BHK21) temperature sensitivity com	2.65
-		RY (sex-determining region Y)-box 20	2.65 2.65
		,	

	123312 AA49625	R He 9960-	ESTs	0.05
	130034 C00350	Hs.14454		2.65 2.65
	103897 AA248870		B ESTs	2.65
5	117771 N47961 109980 H09529	Hs.46794 Hs.98693		2.65
_	121966 AA429653			2.64 2.64
	114233 Z39652	Hs.27457		2.64
	129594 R70379 102319 U34587	Hs.11539 Hs.66578	6 Human germline IgD chain gene; C-region;	2.63
10	111700 R22212	Hs.23361		2.63 2.63
	127365 AA001628	Hs.74335	heat shock 90kD protein 1; beta	2.63
	104205 AA496240 124559 N66223			2.63
	106351 AA442772	715.13592 Hs 19198	8 ESTs; Weakly similar to !!!! ALU SUBFAMI 7 ESTs; Weakly similar to !!!! ALU SUBFAMI	2.63 2.63
15	121903 AA427605	Hs.25874	2 myosin-binding protein C: cardiac	2.62
	116442 AA620310 127041 F06090	Hs.18434	3 ESTs; Weakly similar to KIAA0585 protein	2.62
	132860 U93049	Hs.58435	HSC0WG031 normalized infant brain cDNA FYN-binding protein (FYB-120/130)	H 2.62 2.62
20	131591 L22454		nuclear respiratory factor 1	2.62
20	118118 N56901	Hs.47995	ESTs	2.61
	134809 X52611 117706 N45091	Hs.18387 Hs.46472	transcription factor AP-2 alpha (activat ESTs	2.61
	127488 AA312179	Hs.178617	' ESTs; Weakly similar to CGI-82 protein [	2.61 2.61
25	114891 AA235984	Hs.87469	ESTs	2.6
23	116426 AA609668 132589 AA432197		ESTs ESTs; Weakly similar to CGI-08 protein [	2.6
	128410 AA452788	113.3200	zx39g11.r1 Soares_total_fetus_Nb2HF8_9w	2.6 2.6
	106081 AA418394	Hs.25354	ESTs	2.6
30	129919 R02003 124672 R00307	Hs.191208 Hs.188504	ESTs; Weakly similar to weak similarity	2.59
	122758 AA459013	Hs.99742	X-ray repair complementing defective rep	2.59 2.59
	125656 AA040118		neutral sphingomyelinase (N-SMase) activ	2.59
	130052 J00220 134878 U28055	Hs.145288 Hs.250826		2.59
35	131908 L05624	Hs.3446	macrophage stimulating; pseudogene 9 mitogen-activated protein kinase kinase	2.59 2.59
	126470 AA843339	Hs.193168	ESTs; Weakly similar to CGI-52 protein [	2.59
	132353 M31651 119588 W44559	Hs.46319 Hs.142525	sex hormone-binding globulin	2.58
	131757 D17532	Hs.316	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.58 2.58
40	118114 N56875	Hs.143212	cystatin F (leukocystatin)	2.58
	128200 AI279952 131208 C14586	Hs.158037 Hs.24220	ESTs; Weakly similar to transcription re	2.58
		Hs.154966	Homo sapiens mRNA; cDNA DKFZp566M05 <sup>-</sup> ESTs	1 (17 2.57
45	108706 AA121820		Homo sapiens mRNA for KIAA0842 protein;	2.57
43		Hs.50838 Hs.44033	ESTs ESTs	2.57
	107233 D59322	Hs.22595	ESTs	2.57 2.57
	129559 AA234945		ESTs	2.57
50		Hs.127286 Hs.63168	ESTs ESTs	2.56
		Hs.172694		2.56 2.56
		Hs.25374	ESTs	2.56
	108384 AA074891 ( 131779 R49047 (	Hs.124917 He 170770	ESTs; Highly similar to KIAA0838 protein ribosomal protein L37	2.56
55	*****		EST	2.56 2.55
	103424 X97267	Hs.155975	protein tyrosine phosphatase; receptor t	2.55
		Hs.80986 Hs.15250	ATP synthase; H+ transporting; mitochond	2.55
		ds. 102907		2.55 2.55
60	106511 AA452865 H	ls.206713	UDP-Gal:betaGlcNAc beta 1:4- galactosytt	2.55
	128467 AA176446 F			2.55
		Is.172856		2.55 2.55
65		Is.25318	Homo sapiens clone 25194 mRNA sequence	2.54
05		ls.203237   ls.192966	44.4444	2.54
	130660 T95262 H			2.54 2.54
	112983 T23443 H	ls.7111 (	STs	2.54
70	128279 H08885 106415 AA447994 H			2.54
		is.23100 E	·~-	2.53 2.53
	103148 X66362 H	ls.2994 F	PCTAIRE protein kinase 3	2.53
		ls.45073		2.53
75				2.53 2.53
	116880 H68380 H	s.144174 E		2.53

131185 M25753

155

	123708 AA60964	18 He 2077	87 EST	0.00		
	107875 AA02530	08 Hs.6118	2 ESTs	2.39 2.39		
	111711 R22891	Hs.7093	ESTs	2.39		
5	131405 U79255	Hs.26468	amyloid beta (A4) precursor protein-bind	2.39		
3	127454 AA50295 132341 AA44841	7 Hs.15359	00 ESTs	2.39		
	133673 D87673	Hs.75486		2.38		
	113213 T58607	113.73400	ya94a02.s1 Stratagene placenta (#937225)	2.38 2.38		
	106230 AA42935	6 Hs.12047	ESTs	2.38		
10	116692 F09261	Hs.66103	ESTs	2 38		
	126197 AA17228	4 Hs.10365	7 ESTs; Weakly similar to CH-TOG PROTEIN	[ 2.38		
	110906 AA44686	6 Hs.71371	ESTs	2.38		
	132636 U65785 109965 H09077	Hs.5417 Hs.30895	oxygen regulated protein (150kD) EST	2.38		
15	130203 L14754	Hs.1521	immunoglobulin mu binding protein 2	2.38		
	131332 R50487	Hs.25717	ESTs	2.38 2.38		
	119105 R42357	Hs.91453		2.37		
	129253 W69316	Hs.10977	8 ESTs; Weakly similar to similar to beta-	2.37		
20	113602 T92558	Hs.17036	· -	2.37		
20	118102 N55272 100734 HG34324	Hs.14579 HT3620		2.37		
	111533 R08548	Hs.25165	Fibroblast Growth Factor Receptor K-Sam, A		Sam III	2.37
	130813 U12259	Hs.198	paired box gene 3 (Waardenburg syndrome	2.37 2.37		
25	119180 R80413	Hs.92520	ESTs	2.37		
25	109335 AA211443	3 Hs.86492	ESTs	2.37		
	107386 U97698	Hs. 159593	mucin 6; gastric	2.36		
	122486 AA448328 112997 T23548	Hs.115527 Hs.167467		2.36		
	109674 F09051		ESTs; Weakly similar to KIAA0927 protein	2.36		
30		Hs.106730	hypothetical protein	2.36 2.36		
	127027 R17261		yg12g07.r1 Soares infant brain 1NIB H sa	2.36		
	123099 AA485931	Hs.79	aminoacylase 1	2.36		
	115/16 AA416767	Hs.43498	ESTs; Weakly similar to ORF YKL201c [S.c	2.36		
35	130830 D86982 109051 AA159920	Hs.20060	KIAA0229 protein	2.36		
55	130181 R39552	Hs 151608	Homo sapiens clone 23622 mRNA sequence	2.36		
	131114 R46233	Hs.23107	ESTs	2.36		
	123589 AA609047	Hs.188922	ESTs	2.36		
40	130872 U03891		phorbolin (similar to apolipoprotein B m	2.36		
40	131962 H78550 130502 M55067	Hs.2780	jun D proto-oncogene	2.36		
	121785 AA423883	Hs.1583 Hs.142442	neutrophil cytosolic factor 1 (47kD; chr	2.36		
	125405 T97171	Hs.121570		2.35 2.35		
	103682 AA000993		ESTs	2.35		
45	125649 T77395	Hs.194816	stomatin-like protein 1	2.35		
	115452 AA285019	Hs.55263	ESTs; Highly similar to mitochondrial di	2.35		
	129338 T56800	HS.47274	Homo sapiens mRNA; cDNA DKFZp564B176 putative tumor suppressor		2.35	
	134770 R72079	Hs 89575	00300 " " "	2.35		
50	119422 T99496	Hs.229598	EST EST	2.35 2.35		
	109869 H02849	Hs.30345	EST	2.35		
	134314 AA263032	Hs.81634	ATP synthase; H+ transporting; mitochond	2.35		
	114989 AA251097	Hs.189119	E0-	2.35		
55	122619 AA453755 133129 AA428580	Ms. 191010		2.35		
	128465 AA416762	Hs.100221	-	2.35 2.35		
	115636 AA402715	Hs.58389		2.35 2.35		
		Hs.2012	transcobalamin I (vitamin B12 binding pr	2.34		
60	132385 Y10256	Hs.47007	serine/threonine protein-kinase	2.34		
UU	107776 AA018820 109791 F10669	HS.221147	ESTS	2.34		
		Hs.107197	FA=	2.34		
	131068 AA397916	Hs.22595		2.34 2.34		
	121079 AA398719	Hs.14169		2.34		
65	124662 N94340	Hs.171835	ESTs; Weakly smir to PUT PRE-MRNA SPLICE		2.34	
	133820 M13686	Hs.177582 :	Surfactant; pulmonary-associated protein	2.34		
	129424 M55593	HS.111301 I		2.34		
	109066 AA161377 I 100339 D63485 I			2.34		
70	100809 HG3991-HT4	4261 (		2.34		
	120844 AA349417 I	Hs.96917		2.34 2.33		
	124927 R96146	Hs.221459 [	STs	2.33		
		Hs.3353 I	tomo sapiens done 24940 mRNA sequence 2	2.33		
75	101171 L16842   110805 N26904	⊓S.119251 เ ผ่₀ 24040 - ก	ubiquinol-cytochrome c reductase core pr	.33		
		Hs.24048 E Hs.31895 E		2.33		
			2	.33		

	133159 AC000061 Hs.663 cystic fibrosis transmemb conductance re	2.33
	101829 M91368 Hs.129763 solute carrier family 8 (sodium/calcium	2.33
	126492 AA778565 Hs.142505 ESTs 102774 U83303 Hs.164021 small inducible cytokine subfamily R (CX	2.33
5	102774 U83303 Hs.164021 small inducible cytokine subfamily B (CX 130480 N50809 Hs.15760 ESTs; Weakly similar to similar to Yeast	2.33
	126878 AI424759 Hs.238928 ESTs	2.33 2.33
	117338 N23889 Hs.43466 ESTs	2.32
	118662 N70877 Hs.13055 ESTs	2.32
10	130354 AA416685 Hs.155001 UNC13 (C. elegans)-like 106760 AA477330 Hs.12293 ESTs	2.32
10	106760 AA477330 Hs.12293 ESTs 124294 H90573 Hs.102298 EST	2.32
	119428 W02129 Hs.55242 EST	2.32 2.32
	132629 Z40942 Hs.5383 ESTs	2.32
15	127998 AA854161 Hs.143585 ESTs	2.32
13	132728 AA293334 Hs.5566 ESTs; Highly similar to RAS-RELATED PRI 120292 AA189116 Hs.96168 ESTs	
	120292 AA189116 Hs.96168 ESTs 107598 AA004528 Hs.169444 ESTs	2.32 2.32
	128164 Al478174 Hs.144846 ESTs	2.32
20	105753 AA299789 Hs.15277 ESTs	2.31
20	131256 AA262340 Hs.24907 coronin; actin-binding protein; 2B	2.31
	110891 N38863 Hs.234392 platelet-activating factor acetylhydrola 116767 H13689 Hs.92530 ESTs	2.31
	100545 HG2147-HT2217 Mucin 3, Intestinal (Gb:M55405)	2.31 2.31
	125264 W88995 Hs.167641 ESTs; Weakly similar to C15H9.5 [C.elega	2.31
25	118387 N645/9 yz51d11.s1 Morton Fetal Cochlea H sanien	2.31
	104335 D83847 Hs.183864 elastase 3B	2.31
	107464 W42944 Hs.171939 ESTs 112304 R54798 Hs.26239 ESTs	2.31
	134313 AA136100 Hs.6673 trinucleotide repeat containing 15	2.31 2.31
30	116322 AA490900 Hs.58643 ESTs; Highly similar to JAK3B IH saniens	2.31
	111275 N70970 Hs.35006 ESTs	2.31
	100109 AJ000480 Hs.143513 phosphoprotein regulated by mitogenic pa 109338 AA211717 Hs.86507 ESTs	2.31
	109338 AA211717 Hs.86507 ESTs 134432 AA053022 Hs.8312 ESTs	2.31
35	129649 AD000092 Hs.182628 Homo sapiens DNA from chr 19p13.2 cosmi	2.31
	EKLF: GCDH: CRTC: and RAD234 genes:	gen
	122623 AA453990 Hs.99248 ESTs	2.31
	112070 R43976 Hs.236310 EST 127683 AA668123 Hs.134170 ESTs	2.31
40	104920 AA057620 Hs.30807 ESTs; Highly similar to dJ186O1.1 [H.sap	2.31 2.31
	106064 AA417373 Hs.15898 ESTs	2.31
	106782 AA478487 ESTs	2.31
	126709 AA028159 Hs.47234 ESTs 105129 AA158386 Hs.186476 ESTs	2.3
45	105129 AA158386 Hs.186476 ESTs 105719 AA291644 Hs.36793 ESTs	2.3
	121698 AA418399 Hs.10351 KIAA0308 protein	2.3 2.3
	119069 R27619 Hs.231046 EST	2.3
	130388 U72515 Hs.189583 putative protein similar to nessy (Droso 103444 X98801 Hs.74617 dynactin 1 (n150: Glued (Drosophila) home	2.3
50	tion to it dynamic typion, Glaca (Diosophila) floil	2.3
	114604 AA076128 zm18g4.s1 Stratagene pancreas (#93728) H 3' similar to SW:RS1A_HUMAN P3927 4S RI	23
	1030/0 AA22/635 HS.202588 ESTs	2.3
	105828 AA398276 Hs.11962 ESTs	2.3
55	119778 W72920 Hs.58244 ESTs 120401 AA234309 Hs.193011 ESTs	2.3
	116290 AA488691 Hs.57969 phenylalanine-tRNA synthetase	2.3 2.3
	130479 R44163 Hs.12457 Homo sapiens clone 23770 mRNA sequence	2.3
	104253 AF002672 Hs.152944 loss of heterozygosity; 11; chromosomal	2.29
60	132615 H66367 Hs.53358 ESTs; Weakly similar to !!!! ALU SUBFAMI 121954 AA429598 Hs.98587 ESTs	2.29
•	121954 AA429598 Hs.98587 ESTs 101336 L49169 Hs.75678 FBJ murine osteosarcoma viral oncogene h	2.29 2.29
	127247 AA313802 Hs.6289 growth factor receptor-bound protein 2	2.2 <del>9</del> 2.29
	11/300 N22565 Hs.43212 ESTs	2.29
65		2.29
55	420002 D40400 II 400400 DO	2.29
	434370 AA000053 H- 05407 OTHE	2.29 2.29
	133838 M97796 Hs.180919 inhibitor of DNA binding 2; dominant neg	2.29 2.29
70	111837 R36447 Hs.24453 ESTs	2.29
70	111435 R01620 Hs.19198 ESTs	2.29
	1225CO AA25C2C5 11-740C	2.29
	122896 AA469952 Hs.97899 ESTs; Weakly similar to dal2; len:343: C	2.29 2.29
75	113378 T80627 Hs.14757 ESTs	2.29
75	12/1/4 AA293204 Hs.139352 ESTs	2.29
	120153 Z39582 Hs.65777 EST	2.29

110926 N48252

Hs.135287 ESTs

2.26

2.28

2.28

	102795 U88667 Hs.1983	396 ATP-binding cassette; sub-family A (ABC1	2.24
	118643 N70324 Hs.4984 103304 X82240 Hs.2484		2.24
_	134814 Z48475 Hs.8977		2.24 2.24
5	125912 AA171719 Hs.5233	eukaryotic translation initiation factor	2.24
	134365 R32377 Hs.8224 117224 N20300 Hs.2187	0 syntaxin 3A 07 ESTs	2.24
		46 ESTs; Weakly similar to small GTP-bindin	2.24 2.24
10	133948 M59916 Hs.7781	3 sphingomyelin phosphodiesterase 1; acid	2.24
10	101426 M19483 Hs.25 119922 W86196 Hs.1773	ATP synthase; H+ transporting; mitochond	2.24
	123361 AA504810 Hs.1396	84 ESTs 49 EST	2.24 2.24
	123915 AA621298 Hs.1129	67 ESTs	2.24
15	123540 AA608792 Hs.1125		2.24
13	124978 T40560 Hs.2217 102354 U38268	59 ESTs  Human cytochrome b pseudogene, partial c	2.24 2.24
	124198 H53099 Hs.1982	71 NADH dehydrogenase (ubiquinone) 1 alpha	2.24
	102160 U18235 Hs.1215	61 ATP-binding cassette; sub-family A (ABC1	2.24
20	107520 X76091 Hs.1000 131589 U52100 Hs.2919	77 regulatory factor X; 2 (influences HLA c epithelial membrane protein 2	2.24
	126633 AA206993 Hs.15414	15 guanine nucl binding protein (G protein)	2.24 2.23
	130887 AA258379 Hs.15598	36 angiotensin receptor-like 2	2.23
	119894 W84670 Hs.58518 124544 N63837 Hs.40500		2.23
25	103104 X61587 Hs.75082		2.23 2.23
	110119 H17306 Hs.17722	9 ESTs	2.23
	131411 AA464043 Hs.26506 102346 U37359 Hs.22729		2.23
••	106003 AA411167 Hs.8734	7 meiotic recombination (S. cerevisiae) 11 ESTs; Moderately similar to !!!! ALU CLA	2.23 2.23
30	122564 AA452251 Hs.98669	ESTs	2.23
	133688 U42031 Hs.7557 132096 AA131410 Hs.3964		2.23
	110038 H11746 Hs.31097	Homo sapiens clone 24877 mRNA sequence ESTs	2.23
35	123788 AA620293 Hs.11285	3 ESTs	2.23
33	135070 X99350 Hs.93974 104908 AA055841 Hs.15439		2.23
	128674 AA025001 Hs.16945		2.22 2.22
	100810 HG3992-HT4262	Cpg-Enriched Dna, Clone E35	2.22
40	120065 W93579 Hs.59478 122775 AA459692 Hs.11214;		2.22
			2.22 2.22
	118617 N69666 Hs.183413	B ESTs; Moderately similar to !!!! ALU SUB	2.22
	128001 Al167814 Hs.166664 128160 Al279080 Hs.149971		2.22
45	106608 AA458644 Hs.27115		2.22 2.22
	103485 Y08409 Hs.248415	thyroid hormone responsive SPOT14 (rat)	2.22
	135008 AA173423 Hs.92918 110122 H17333 Hs.159837	within the tree dots [0.0090 /	2.22
	128397 Al393421 Hs.14032		2.22 2.22
50	110231 H24359 Hs.28733	ESTs	2.22
	123188 AA489092 Hs.177726 131903 AA481723 Hs.3436		2.22
	122649 AA454616 Hs.90336		2.22 2.22
55	133090 AA448228 Hs.6468	ESTs	2.22
55	108002 AA037664 Hs.55067 133120 X64559 Hs.65424		2.22
	114263 Z40073 Hs.6045		2.21 2.21
	125518 R20148 Hs.193851	ESTs 2	2.21
60	128613 U78551 Hs.102482 102773 U83192 Hs.23731	Homo sapiens gallbladder mucin MUC5B mRN discs; large (Drosophila) homolog 4 2	24
	119526 W38049		2.21 2.21
	126844 AA299325 105860 AA399251 Hs.180933	EST11903 Uterus tumor I Homo sapiens cDN 2	.21
	126957 AA733145 Hs.194560		.21 .21
65	108959 AA150107 Hs.81810		.2
	131663 AA423926 Hs.30318	ESTs 2	.2
	127468 H02941 Hs.8888 104483 N42776 Hs.146233		.2
70	123848 AA620773 Hs.221996	ESTs 2	.2 .2
70	101623 M55905 Hs.75342	malic enzyme 2; NAD(+)-dependent; mitoch 2.	.2
	120872 AA357993 Hs.96996 135033 AA173241 Hs.93454		.2
	122286 AA437259 Hs.104944	EST 2.	.2 .2
75	114862 AA235174 Hs.50250	ESTs 2.	2
, 5	100255 D38047 Hs.78466 103063 X58234 Hs.123178	proteasome (prosome; macropain) 26S subu 2. translocase of inner mitochondrial membr 2.	
		translocase of inner mitochondrial membr 2.	4

	132777 R56898 Hs.56663 ESTs	2.2
	133082 AA457129 Hs.6455 RuvB (E coli homolog)-like 2 127529 AA558980 Hs.191750 ESTs	2.2
_	114602 AA075642 Hs.103594 deleted in malignant brain tymors 1	2.2 2.2
5	120722 AA293435 Hs.97277 ESTs	2.2
	102675 U72512 Human B-cell receptor associated protein N-acetylglucosamine-phosphate mutase;	2.2
	112020 R43001 Hs.22298 EST	DK 2.2 2.2
10	123625 AA609216 Hs.112666 EST 120315 AA194266 Hs.178393 ESTs	2.2
10	120315 AA194266 Hs.178393 ESTs 122081 AA431992 Hs.104920 ESTs	2.2 2.19
	101798 M85220 Accession not listed in Genbank	2.19
	111501 R07444 Hs.163118 ESTs 132832 D63482 Hs.57734 KIAA0148 gene product	2.19
15	132832 D63482 Hs.57734 KIAA0148 gene product 100544 HG2147-HT2217 Mucin 3, Intestinal (Gb:M55405)	2.19 2.19
	106835 AA482077 Hs.33713 ESTs; Weakly similar to hypothetical pro	2.19
	132934 AA076145 Hs.61053 ESTs 108762 AA127515 Hs.71787 ESTs: Highly similar to 30S ribosomal or	2.19
20	120164 Z39733 Hs.158159 FAT tumor suppressor (Drosophila) homole	2.19 2.19
20	135395 L08096 Hs.99899 tumor necrosis factor (ligand) superfami	2.19
	101717 M69013 Hs.1686 guanine nucleotide binding protein (G pr 121172 AA400013 Hs.97750 EST	2.19
	114861 AA235123 Hs.40719 ESTs	2.18 2.18
25	120851 AA349662 Hs.174248 ESTs 121083 AA398736 Hs.97653 EST	2.18
23	121083 AA398736 Hs.97653 EST 107171 AA621624 Hs.28088 Homo sapiens clone 24515 mRNA sequence	2.18 ~ 2.18
	128754 D31446 Hs.10488 Breakpoint cluster region protein; uteri	2.18
	100149 D13897 Hs.169249 peptide YY	2.18
30	132405 AA323787 Hs.4770 KIAA1068 protein 114666 AA112274 zm27g6.s1 Stratagene pancreas (#93728) l	2.18 H
	element; contains element LTR8 repetitiv	2.18
	127008 AA223879 zr10g05.r1 Stratagene NT2 neuronal precu 110373 H42896 Hs.29438 ESTs	2.18
25	119354 T66942 Hs.100651 golgi SNAP receptor complex member 2	2.18 2.18
35	130115 M31627 Hs.149923 X-box binding protein 1	2.18
	130514 AA161085 Hs.15871 ESTs; Weakly similar to acid phosphatase 12848 H08077 Hs.217179 ESTs; Weakly similar to T27A1.5 [C.elega	2.18
	110161 H19312 Hs.28096 ESTs	2.18 2.18
40	132367 X82224 Hs.46634 cysteine conjugate-beta lyase; cytoplasm Hs.101448 metastasis associated 1	2.18
	125882 H45538 Hs.101448 metastasis associated 1 113837 W57698 Hs.8888 ESTs	2.17 2.17
	106376 AA444004 Hs.6084 ESTs	2.17
	113755 T99075 Hs.18570 ESTs 107525 X91817 Hs.102866 transketolase-like 1	2.17
45	119207 R93186 Hs.84298 CD74 antigen (invar polypept of maj hist	2.17 2.17
	131862 AA236365 3-phosphoglycerate dehydrogenase	2.17
	115514 AA297739 Hs.55609 ESTs; Weakly similar to ISOLEUCYL-TRNA 112290 R53940 Hs.26016 ESTs	
50	126136 H83353 yv82f02.r1 Soares melanocyte 2NbHM Homo	2.17 2.17
50	121574 AA412712 Hs.119325 Huntingtin-interacting protein A 118530 N67900 Hs.118446 ESTs	2.17
	132327 AA203285 Hs.44892 ESTs: Weakly similar to d 1733D15 1 ILL ca	2.16 2.16
	100564 HG2239-HT2324 Potassium Channel Protein (Gb:Z11585)	2.16
55	129376 AA022622 Hs.13543 ESTs; Weakly similar to hypothetical pro 135317 X86012 Hs.98602 Human DNA sequence from intron 22 of the	2.16
	9.5kb repeated region; int22h-1; involv	2.16
	1149/3 AA250845 Hs.87762 ESTs	2.16
	107559 AA001504 Hs.59860 ESTs 111014 N53787 Hs.191117 ESTs	2.16 2.16
60	101250 L34060 Hs.79133 cadherin 8	2.16
	110697 H93721 Hs.20798 ESTs 126843 AA450166 Hs.22641 ESTs; Moderately similar to predicted or	2.16
	108272 AA063616 Hs.43773 ESTs	2.16 2.16
65	125012 T66935 Hs.104859 ESTs	2.16
00	111639 R16101 Hs.140834 EST 123157 AA488443 Hs.100426 DKFZP564A063 protein	2.15
	102315 U34252 Hs.2533 aldehyde dehydrogenase 9 (gamma-aminobut	2.15 t2.15
	131897 AA287623 Hs.3426 GTPase; human homolog of E. coli essenti	2.15
70	121528 AA412253 Hs.238909 ESTs; Weakly similar to POLYPOSIS LOCUS 122806 AA460707 Hs.106397 ESTs	2:15 2:15
	125727 H00958 Hs.181641 ESTs	2.15
	1332/9 AA069571 Hs.6957 Homo sapiens clone 24616 mRNA sequence	2.15
76	120881 AA362144 Hs.104601 EST	2.15 2.15
75	134060 D42039 Hs.78871 KIAA0081 protein	2.15
	106598 AA457140 Hs.11411 DKFZP566O084 protein	2.15

	125576 R66208	yi30h03.r1 Soares placenta Nb2HP H sapie	
	400707	contains Alu repetitive element contain	2.15
	126727 AA037230 Hs.13508 101490 M25629 Hs.12310	4 cystatin C (amyloid angiopathy and cereb	2.15
5	129708 AA417181 Hs.12085	7 kallikrein 1; renal/pancreas/salivary	2.15
	100627 HG2702-HT2798	Serine/Threonine Kinase (Gb:Z25424)	2.14 2.14
	121703 AA418671 Hs.10480	7 ESTs	2.14
	106809 AA479704 Hs.22032	Humn DNA seq frm clone 283E3 on chr 1p3	
10	129525 F03873 Hs.11230	Female Reproductive tract MIFR1; -2; MM 6 Homo sapiens clone 24955 mRNA sequence	2.14
	100478 HG1067-HT1067	Mucin (Gb:M22406)	e; 2.14 2.14
	118593 N69020 Hs.207689	EST '	2.14
	114047 W94427 Hs.3807	ESTs; Weakly similar to PHOSPHOLEMMAI	
15	128823 AA478207 Hs.10632 100534 HG1980-HT2023	ESTs; Moderately similar to sex-determin Tubulin, Beta 2	2.14
	105757 AA321146 Hs.30596	ESTs	2.14 2.14
	109617 F03192 Hs.26789	ESTs; Weakly similar to dJ162H14.1 [H.sa	2.14
	121547 AA412448 Hs.104777		2.14
20	119420 T98291 Hs.102484 120274 AA177051		2.14
	1232/4 /04///001	nc02a02.s1 NCI_CGAP_Pr3 Homo sapiens repetitive element;contains element LTR	2.14
	132933 AA598702 Hs.6101	bone morphogenetic protein 6	2.14
	133405 X07881 Hs.73031	proline-rich protein BstNI subfamily 3	2.14
25	119811 W73922 Hs.49047 134536 AA457735 Hs.850	ESTs	2.14
20	105125 AA157799 Hs.6980	IMP (inosine monophosphate) dehydrogenas aldo-keto reductase family 7; member A2	2.14
	101398 M15881 Hs.1137	uromodulin (uromucoid; Tamm-Horsfall gly	2.14
	132751 AA397901 Hs.55993	ESTs	2.13
30	115777 AA424142 Hs.39384 123193 AA489228 Hs.136956	putative secreted ligand homologous to f	2.13
	116875 H67749 Hs.161022		2.13 2.13
	107271 D60607 Hs.34931	EST	2.13
	134551 R44839 Hs.8526	i-beta-1;3-N-acetylglucosaminyttransfera	2.13
35	113413 T83739 Hs.186512 120522 AA258843 Hs.258748		2.13
	119965 W87738 Hs.59039	EST	2.13 2.13
	131283 AA101601 Hs.183986	herpesvirus entry mediator B (poliovirus	2.13
	107347 U43628 Hs.102598 116490 C14265 Hs.66450		2.13
40	116490 C14265 Hs.66450 100563 HG2239-HT2324	ESTs Potassium Channel Protein (Gb:Z11585)	2.13 2.13
	110441 H50302 Hs.19845	ESTs; Highly similar to protein phosphat	2.13
	101035 J05158 Hs.73858	carboxypeptidase N; polypeptide 2; 83kD	2.13
	132500 AA047297 Hs.50107 129807 L34820 Hs.5299	ESTs; Moderately similar to CDO [H.sapie	2.13
45	106250 AA430466 Hs.28890	aldehyde dehydrogenase 5 family; member ESTs	2.13 2.13
	113569 T91086 Hs.162070	EST	2.13
	122911 AA470087 Hs.239726		2.13
	107452 W28988 Hs.250746 111824 R35661 Hs.25006	EST EST	2.12
50		•	2.12 2.12
	110244 H26742 Hs.25367	ESTs; Weakly similar to ALR [H.sapiens]	2.12
	128918 H85347 Hs.107164 133728 M10901 Hs.75772	spectrin; beta; non-erythrocytic 1	2.12
			2.12 2.12
55	132004 L37360 Hs.37054		2.12
	113971 W86760 Hs.220682		2.12
	103386 X92972 Hs.80324 131120 AA443676 Hs.23133	COT 141 11 4 W	2.12
			2.12 2.12
60	103694 AA018541 Hs.60580	zinc finger protein	2.12
			2.12
		· · · · · · · · · · · · · · · · · · ·	2.12 2.12
	400000 1400000		2.12
65	115092 AA255903 Hs.80975 (	CD39-like 4	2.11
	121579 AA416543 Hs.111981 E 127101 Al349351 Hs.118944 E		2.11
			2.11 2.11
70	112721 R91484 Hs.30853 E		2.11 2.11
70	113253 T64207 Hs.55296 H	ILA-B associated transcript-1	2.11
	444444		2.11
			2.11 2.11
75	103785 AA095600 Hs.225647 E	STs	2.11
75	128260 AA331445 E	ST35277 Embryo, 8 week I Homo sapiens c 2	2.11
	122987 AA479155 Hs.103364 E	2018	2.11

	115723 AA417345 Hs.54846 EST 123895 AA621192 Hs.112949 EST	S	2.07 2.07	
	119906 W85818 EST	s; Moderately similar to !!!! ALU SUB	2.07	
5	IMA	2c5.s1 Stratagene hNT neuron (#93723 GE:54728 3' similar to TR:G1151228 (	33 3 2.07	
	101246 L33799 Hs.202097 proc	ollagen C-endopeptidase enhancer	2.07	
	114178 Z39063 Hs.17930 Hum	r Histocompatibility Complex, Class I, in DNA seq frm clone 1033B10 on chr	E (Gb:M20022) 6p	2.07
10	125672 AA152281 Hs.78601 urop	GaIT3 (beta3-Galactosyltransferase) orphyrinogen decarboxylase	2.07 2.07	
	118052 N53360 Hs.165133 ESTs	3	2.07	
	102387 U41163 Hs.229731 soluti 127305 AA535148 Hs.255277 ESTs	e carrier family 6 (neurotransmitte	2.07	
15	101182 L19711 Hs.76111 dystr	oglycan 1 (dystrophin-associated gl	2.07 2.07	
15	131111 R33245 Hs.23076 ESTs	; Weakly similar to putative [C.eleg	2.07	
	112441 R63388 Hs.28412 ESTs 117796 N48571 Hs.46689 EST		2.06 2.06	
	116099 AA456309 Hs.58831 regula	ator of Fas-induced apoptosis	2.06	
20	125559 AA307550 Hs.119571 collag 135271 AA397763 Hs.97562 ESTs	jen; type ill; alpha 1 (Ehlers-Dani	2.06	
		d hormone receptor-associated prot	2.06 2.06	
	133419 U6/369 Hs.73172 growt	h factor independent 1	2.06	
	127816 AA743646 Hs.120604 ESTs 127502 AA614422 Hs.183502 ESTs		2.06	
25	129371 M10321 Hs.110802 von W		2.06 2.06	
	108417 AA075716 zm89e	e5.s1 Stratagene ovarian cancer (#93		
	102837 U94585 Hs.13495 requie	STERIN PRECURSOR (HUMAN);, mR em; apoptosis response zinc finger	NA sequ 2.06	2.06
20	124226 H62396 Hs.190266 ESTs		2.06	
30	102254 U28131 Humai 128472 X87212 Hs.10029 cather	n HMGI-C chimeric transcript mRNA, p		
		sin C yl-phosphate (UDP-N-acetylglucosam	2.06 2.06	
	135311 M36089 Hs.98493 X-ray i	repair complementing defective rep	2.06	
35	121727 AA420973 Hs.104234 ESTs 131846 U02619 Hs.331 genera	l transprintion foster IIIC.	2.06	
	120415 AA235810 Hs.182522 ESTs	al transcription factor IIIC; polyp	2.06 2.06	
	110529 H57686 Hs.37486 ESTs		2.06	
	104996 AA112307 Hs.105894 Homo 110351 H41222 Hs.196459 ESTs	sapiens mRNA; cDNA DKFZp434G23		2.06
40	131261 AA223746 Hs.171776 inositol	(myo)-1(or 4)-monophosphatase 1	2.06 2.06	
	110585 H62223 Hs.133526 ESTs;	Weakly similar to !!!! ALU SUBFAMI	2.06	
		DNA sequence from clone 1042K10 c	2.06	
45	lyase (	EC 4.3.2.2; Adenylosuccinase; AS	A1	
43	3). Cor 119782 W72982 Hs.58262 ESTs	ntains ESTs; STSs; GS	2.06	
		nthase; H+ transporting; mitochond	2.06 2.06	
	1348/5 U66672 Hs.180513 ATP-bir	nding cassette; sub-family A (ABC1	2.06	
50	106832 AA482015 Hs.30114 ESTs; H 109403 AA224413 Hs.86937 ESTs	lighly similar to C8 [H.sapiens]	2.06	
	115485 AA287667 Hs.188804 ESTs		2.06 2.06	
	102923 X12517 Hs.1063 small nu 123320 AA496792 Hs.139572 EST	uclear ribonucleoprotein polypept	2.06	
	111901 R39066 Hs.17638 ESTs		2.05 2.05	
55	106558 AA455111 Hs.182447 heterog	eneous nuclear ribonucleoprotein	2.05	
	126885 AA293052 Hs.10101 ESTs; V 113429 T85190 Hs.179808 ESTs	Veakly similar to coded for by C.	2.05	
			2.05 2.05	
60	103204 X72475 Hs.192989 H.sapiei		2.05	
00	106666 AA461072 Hs.37916 ESTs 100947 HG907-HT907 Mg44		2.05	
	102578 U60666 Hs.57693 testis sp		2.05 2.05	
	105827 AA398255 Hs.31520 ESTs		2.05	
65			2.05 2.05	
	115861 AA431768 Hs.90259 ESTs: W		2.05 2.05	
	108081 AA045306 Hs.42996 ESTs 133994 X74929 Hs.242463 keratin 8		2.05	
	119131 R46700 Hs.129692 ESTs: M		2.05 2.05	
	129793 AA300151 Hs.126857 ESTs		2.05 2.05	
	101653 M60284 Hs.161305 tachykini 120300 AA191648 Hs.131476 ESTs		2.05	
	106519 AA453415 Hs.8763 Hu DNA:	sequence from done 889N15 on chr	2.05	
75	Thymoc	vte Marker CTX: the possibly afte 2	2.05	
	105747 AA293719 Hs.30251 ESTs; W	piens mRNA full length insert cDN 2 eakly similar to GLUCOSE-6-PHOSPH	2.05	2.04
	2070, 11	, W GEOGGE-OF HOSPH		2.04

		AA286819			2.02	
		H65776	Hs.22240	3 ESTs	2.02	
	101234	L29277	Hs.14225	B signal transducer and activator of trans	2.02	
_	121208	AA400470	) Hs.97805	ESTs	2.02	
5	122598	AA453465	Hs.99329	ESTs	2.02	
		H84882	Hs.33791	ESTs; Weakly similar to K:Cl cotransport	2.02	
	117137	H96670	Hs.42221	ESTs	2.02	
		T88826	Hs.90973	ESTs	2.01	
	102940	X13956	Hs.24998	Human 12S RNA induced by poly(rl); poly(	2.01	
10	100748	HG3517-H	fT3711	Alpha-1-Antitrypsin, 5' End	2.01	
	103012	X52638	Hs.739	6-phosphofructo-2-kinase/fructose-2;6-bi	2.01	
	132755	AA609201	Hs.182635		2.01	
	130842	H39589	Hs.20159	ESTs; Highly similar to CGI-92 protein [	2.01	
	133599	M64788	Hs.75151	RAP1; GTPase activating protein 1	2.01	
15		N21081	Hs.15299	HMBA-inducible	2.01	
	115124	AA256666	Hs.39156	ESTs	2.01	
	128155	AA926843	Hs.143302	ESTs	2.01	
	130574	AA379087	Hs.16178	apoptosis antagonizing transcription fac	2.01	
••		R78838	Hs.54943	fracture callus 1 (rat) homolog	2.01	
20	117428	N27366	Hs.43933	EST	2.01	
	121108	AA399053	Hs.97529	EST	2.01	
		X69550	Hs.159161	Rho GDP dissociation inhibitor (GDI) alp	2.01	
		H66049	Hs.19085	ESTs; Weakly similar to putative p150 [H	2.01	
0.5	120606	AA282956		zt15h4.s1 NCI_CGAP_GCB1 Homo sapiens	cDN	
25				SW:CADR_MOUSE P3938 RETINAL-CADH	IERIN PR	2.01
		T47969	Hs.194660	ceroid-lipofuscinosis; neuronal 3; juven	2.01	
		Z80783	Hs.239884	H2B histone family; member L	2.01	
	109599		Hs.6749	ESTs	2.01	
20		W78211	Hs.31547	ESTs; Highly similar to NADH:ubiquinone	2.01	
30	129463	AA376905	Hs.111742	ESTs: Weakly similar to IIII ALLI SURFAMI	2.01	
	114880	AA235698	Hs.65862	ESTs	2.01	
	114745	AA135523	Hs.139064		2.01	
	115637	AA402727	Hs.76925	ESTs; Highly similar to R31167_2; partia	2.01	
25	109043	AA159605	Hs.72580	ESTs	2.01	
35	128901		Hs.107040		2.01	
	124427		Hs.178663		2	
		HG3033-HT	3194	Spliceosomal Protein Sap 62	2	
		AA078801		zm94a9.s1 Stratagene colon HT29 (#937221	2	
40	123764	AA610019	Hs.112654		2	
40	129343		Hs.180060		2	
	122794	AA460254	Hs.105043	EST	2	
	128688	AA161469	Hs.103755	receptor-interacting serine-threonine ki	2	
	115592	AA399543	Hs.48026	ESTs	2	
45	111693			EST	2	
43	113353	179186	Hs.14468	ESTs	2	

Table 18: B survivor vs Mets – Up in Mets

	5			Pkey	Unique Eos probeset identifier number	_	
				ExAc		cression number	
					eneID: Unigene number	ccession number	
				Unige	ene Title: Unigene gene title		
	10	Dkov	Ev Ass.		A		
	10	Pkey	Ex Acci	n UniG ID	Complete Title	Ratio BS/Met	
		1060	24 44120	50 He 1117	42 ECTs: Woolds similar to UU ALLA CUREAS		
		1109	30 N48603	Hs.1494	42 ESTs; Weakly similar to !!!! ALU SUBFAMI 7 ESTs		
				73 Hs.2211	7 E313 32 E9Te	0.18	
	15		71 Z48633	Hs.6940		0.2	
				43 Hs.3279	B ESTs	0.2 0.24	
		10959	3 F02506	Hs.15959	31 thyroid hormone receptor interactor 8	0.24	
		12301	6 AA48010	03 Hs.11173	30 ESTs; Weakly similar to alternatively sp	0.24	
		10073	9 HG3484	HT3678	Protein Kinase (Gb:M59287)	0.25	
	20		2 U92014	Hs. 15352	7 Human clone 121711 defective mariner tra	0.26	
		10514	9 AA16925	3 Hs.8958	ESTs	0.26	
		11541	2 AA28380	4 Hs.19355	2 ESTs	0.27	
		10595	2 AA40526	3 Hs.18140	0 ESTs	0.28	
	25	10659	6 AA45698	11 Hs.35349	ESTs	0.28	
	25	12024	9 AA16756	7 Hs.13332	5 ESTs	0.28	
			6 R19414	Hs.16645	9 ESTs	0.29	
1			1 N66767	Hs.12414	5 ESTs	0.29	
76				9 Hs.50418	ESTs	0.29	
thus that they think	20		6 U28831		Human protein immuno-reactive with anti-	0.3	
1	30		D AA36313	1 Hs.22299	2 ESTs; Weakly similar to TRANSFORMATIO	N-S	0.3
Ì			5 F13663	Hs.16798	ESTs	0.3	0.0
E			N63165	Hs.23618	ESTs	0.31	
Ē			5 W90583	Hs.9853	ESTs	0.32	
	35	104792	2 AA02928	8 Hs.29147	ESTs; Highly similar to ZINC FINGER PROT	0.33	
	33	123562	2 AA60889	3 Hs.19006		0.33	
				6 Hs.54982		0.33	
			H87770	Hs.153800	ESTS	0.33	
		108819	AA13098	Hs.193253		0.34	
	40	110000	AA393800	Hs.1010	regulator of mitotic spindle assembly 1	0.34	
	+0	104781	AAU26617	HS.21610	ESTs; Highly similar to BAI1-associated	0.34	
			N69324	Hs.12526		0.34	
			T77866	Hs.189703		0.35	
			A1084676	HS.133266	ESTs; Moderately similar to Sqv-7-like p	0.35	
	45	113650	T91116	Ho 45742	ESTs; Weakly similar to CGI-73 protein [	0.35	
				Hs.15713 Hs.175663	ESIS	0.35	
		105489	AA256157	Hs.24115		0.35	
			AA490866		ESTs	0.35	
			R39882	Hs.21397	ESTs	0.36	
	50		T53722	113.2 1037	ya91c06.r3 Stratagene placenta (#937225)	0.36	
		123541	AA608794	Hs.112592	ESTs	0.36 0.36	
		123131	AA487207	Hs.193272	ESTs	0.36	
			T86914	Hs.194485		0.36	
		114757	AA136725	Hs.161990	ESTs	0.37	
	55	132778	AA446695	Hs.5671	Homo sapiens done 23926 mRNA sequence	0.37	
		123132	AA487233	Hs.106711	eukaryotic translation initiation factor	0.37	
		134029	AA378597	Hs.143601	ESTs; Moderately similar to 67A9.b (D.me	0.37	
		126956	AI434405	Hs.171957	triple functional domain (PTPRF interact	0.38	
	60	106869	AA487563	Hs.188813	ESTs	0.38	
	60		AA020957			0.38	
			K00629	Hs.199300	Human kpni repeat mma (cdna clone pcd-k	0.38	
			D49728	Hs.1119	nuclear receptor subfamily 4: group A: m	0.38	
			T79020	Hs.245915	ESTs; Weakly similar to kinase-related p	0.39	
	65		W91995	Hs.16145		0.39	
	UJ		AA431296		EST	0.39	
			N50959	Hs.143102	amine oxidase; copper containing 2 (reti	0.39	
		110163		MS.22073	ESTs; Highly similar to J KAPPA-RECOMBIN		
			AA004652		FOT.	0.39	
	70	124777		Hs.140237	ESIS	0.39	
	, 0	120302	AA224000	ris.194660	ceroid-lipofuscinosis; neuronal 3; juven	0.4	
		132734	<b>かんとうようごう</b>	Hs.1112/9 Hs.164250		0.4	
		117001				0.4	
		120905	AA371602	He 182020	ESTs; Highly similar to PHOSPHATIDYLINOS	0.4	
	75	125488	AA355158	Hs 41181	Homo sapiens mRNA; cDNA DKFZp727C191	U.4 /_	٠,
		5-50	100	10.71101	nomo sapiens mikina; cuna UKFZp/2/C191	(π	0.4

₽

	13060	6 AA40210	9 Hs.16593	ESTs	0.47
	116067	7 AA45482	7 Hs.12482	3 ESTs	0.47
		1 AA775807	7 Hs.15074	1 2';3'-cyclic nucleotide 3' phosphodieste	0.47
_	124028	3 F04112	Hs.177178	B ESTs	0.47
5		AA155574	Hs.172702	2 ESTs	0.47
		2 T95105	Hs.173772	? ESTs	0.47
		H48462	Hs.36093	ESTs; Weakly similar to reverse transcri	0.47
	105658	AA282914	Hs.10176	ESTs	0.47
10	129046	AA195678	Hs.108258	actin binding protein; macrophin (microf	0.47
10	113639	T95128	Hs.17529	ESTs	0.48
		AA045365		ESTs; Weakly similar to 60S RIBOSOMAL	PR0.48
		AA129390		ESTs	0.48
		AA004955			0.48
1.5		N70907	Hs.230619		0.48
15		AA917801			0.48
		R55615	Hs.26432	to the same of the got processing	0.48
		T95087	Hs.15543		0.48
		T62969	Hs.193348		0.48
20		AA398720			0.48
20		X83378	Hs.211614	chloride channel 6	0.48
		R54534	Hs.87889		0.49
		AA563806			0.49
	1329/1	AA033951	Hs.61700	ESTs	0.49
25	12/132	AA721156	Hs.190440		0.49
23		T72661	Hs.13969	ESTs	0.49
		AA234112		ESTs	0.49
		AA018937			0.49
			Hs.60179		0.49
30		AB002296		Human mRNA for KIAA0298 gene; complete	
50		AA927308			0.49
		H83465 H30721	Hs.221934		0.49
		U45974	Hs.30172 Hs.25156	ESTs	0.49
		C20633	Hs.24129	Human phosphatidylinositol (4;5) bisphos	0.49
35		AI127843	Hs.155071	ESTs	0.49
55	113327		Hs.12097	ESTS	0.5
		AA017146	He 34570		0.5
		AA423972		ESTs; Moderately similar to !!!! ALU SUB ESTs	0.5
	118296		Hs.48723	ESTs	0.5
40	131453			KIAA0457 protein	0.5
		AA019528		ESTs	0.5
	119358			ESTs; Weakly similar to alternatively sp	0.5
	. 10000		113.133031	CO13, TTEAMY SHIMAI TO AILEITHAUVERY SP	0.5

### Table 19: B survivor vs Mets – Up in B survivor

Pkey: Unique Eos probeset identifier number

ExAccn: Exemplar Accession number, Genbank accession number

Unigene Ittle: Unigene gene title

10					
10	Pkey	Ex Acon	UniG_ID	Complete Title	Ratio BS/Met
	33360			CH22_FGENES.213_4	5.5
15	32530			CH.11_hs gi 5866908	4.67
13	33364			CH22_FGENES.231_2	4.64
	33359			CH22_FGENES.208_4	4.46
	33285		72 Un 45C44	CH22_FGENES.27_2	4.39
	33379	3 AVV3103.	/3 MS.13611	0 Immunoglobulin kappa variable 1D-8	4.23
20	32764			CH22_FGENES.274_10	4.18
		2 H49160	Hs.13347	CH.04_hs gi 5867890	4.03
	33412		113.15547	CH22_FGENES.334_4	3.9
	33364			CH22_FGENES.234_2	3.88 3.88
	32655	4			3.84
25	333650	0	_	CH.19_hs gij5867308 CH22_FGENES.238_3	3.82
	333647	7		CH22_FGENES.235_2	3.79
m	333626			CH22_FGENES.224_2	3.68
<del></del>	314671	1 AW23655	0 Hs.13191	4 ESTs	3.68
₩ 20			Hs.161282		3.67
□ □ 30 □	333657			CH22_FGENES.241_2	3.65
#4.	338522			CH22_EM:AC005500.GENSCAN.395-36	3.64
Ä	329464 328868			CH.Y_hs gij6456788	3.6
	333637			CH.07_hs gi 6381930	3.6
□ □ 35	329737			CH22_FGENES.229_2 CH.14_p2 gi 6065779	3.59
		AI791749	Hs.128896		3.5
≡		M96995		growth factor receptor-bound protein 2	3.44 3.44
_	339271			CH22_BA354I12.GENSCAN.11-2	3.44
	314927	AI735482	Hs.159580	ESTs	3.42
∏ 40	334782			CH22_FGENES.432_7	3.42
NI .	313138	AW138842	2 Hs.196669	ESTs	3.4
กี 40 กับ ั⊻		H51596	Hs.5541	ATPase; Ca++ transporting; ubiquitous	3.38
75 <u>5</u> 	338648			CH22_EM:AC005500.GENSCAN.460-6	3.38
□  U 45	325677		11-040004	CH.14_hs gi 5867017	3.34
U 73	326545	H50648	MS.213221	ESTs; Weakly similar to !!!! ALU SUBFAMI	
-		R44616	He 120200	CH.19_hs gij5867307	3.32
		AI625428	ns. 130200	ESTs; Moderately similar to !!!! ALU SUB	3.3
	328569			EST singleton (not in UniGene) with exon CH.07_hs gij6004480	3.26 3.26
50	328582			CH.07_hs gi/6006033	3.24
	310975	AI492857	Hs.170940	ESTs	3.24
	336883			CH22 FGENES.322-2	3.21
		AW236939	Hs.172154	ESTs	3.2
55	337870			CH22_EM:AC005500.GENSCAN.48-3	3.19
55		AI001043		EST singleton (not in UniGene) with exon	3.17
		Z45264		EST cluster (not in UniGene)	3.16
	335247	A A 000760		CH22_FGENES.516_8	3.12
		AA088768 R06504		EST duster (not in UniGene)	3.1
60			He 192662	EST cluster (not in UniGene) ESTs; Weakly similar to ZINC FINGER PROT	3.09
	321215	AW378128	Hs 120243	ESTs; Weakly similar to CGI-56 protein [	
	328507			CH.07_hs gil5868473	3.04 3.03
	330266			CH.05_p2 gi/6671885	3.02
	326249			CH.17_hs gi 5867263	3.01
65	325649			CH.14_hs gi 6588011	2.99
		AA496437		EST singleton (not in UniGene) with exon	2.98
		AA488050		EST singleton (not in UniGene) with exon	2.97
	338412			CH22_EM:AC005500.GENSCAN.341-25	2.96
70		AI769997	11- 40 4000	EST singleton (not in UniGene) with exon	2.95
70	313027		ms.184003	ESTs; Weakly similar to !!!! ALU SUBFAMI	2.95
		AI000246 AA922622		EST singleton (not in UniGene) with exon	2.95
			He SUSESU	EST singleton (not in UniGene) with exon EST; Moderately similar to TRANSLATIONAL	2.94
	332454	T63265	Hs.11186		
	10 1	. 30250	1100	CO.O, Freday Summar to Bansionnabori-	2.94

		330061			CH.17_p2 gi 6721261	2.94
		317671 338705	I AW138139	9 Hs.244598	B ESTs CH22_EM:AC005500.GENSCAN.480-4	2.93 2.93
	_	333737			CH22_FGENES.261_1	2.93
	5	337756 333572			CH22_EM:AC000097.GENSCAN.109-3	2.9
		335349			CH22_FGENES.189_1 CH22_FGENES.539_2	2.89 2.89
		328835			CH.07_hs gi 5868339	2.89
	10		6 AA984628 7 Al655313		EST duster (not in UniGene)	2.88 2.87
	10		R72672		ESTs; Weakly similar to Similarity with	2.86
		337564			CH22_C65E1.GENSCAN.1-7	2.85
		333225 314938	AA515635		CH22_FGENES.107_3 EST cluster (not in UniGene)	2.84 2.83
	15	305803	AA846052		EST singleton (not in UniGene) with exon	2.83
			AA679505 AA386264		EST singleton (not in UniGene) with exon	2.83
		338508		П3.3337	isocitrate dehydrogenase 2 (NADP+); mito CH22_EM:AC005500.GENSCAN.391-1	2.81 2.81
	20		Al475411		EST singleton (not in UniGene) with exon	2.81
	20	301130		HS.149418	ESTs; Weakly similar to salivary proline CH.12_hs gij6552439	2.8 2.8
		307054	AI148181	Hs.176835	EST	2.8
		337456	A1797066	Un 20400E	CH22_FGENES.777-2	2.79
	25		AA065003		hypothetical protein	2.79 2.78
		333717			CH22_FGENES.253_3	2.76
<del>} -</del> ≥			AW505368 AA602697		EST duster (not in UniGene) with exon h EST singleton (not in UniGene) with exon	2.76 2.76
			R00371		EST duster (not in UniGene)	2.75
	30	336072			CH22_FGENES.685_4	2.74
		336127	AA897764		EST singleton (not in UniGene) with exon CH22_FGENES.701_15	2.74 2.74
A		337355			CH22_FGENES.728-1	2.73
	35	337885	Al686791	₩c 110509	CH22_EM:AC005500.GENSCAN.54-3 ribosomal protein L3	2.73 2.73
Q	33				ATP synthase; H+ transporting; mitochond	2.73
		333043			CH22_FGENES.70_4	2.72
圧		327736 333007			CH.05_hs gij5867940 CH22_FGENES.60_4	2.72 2.72
	40		AL122111		EST cluster (not in UniGene)	2.72
П			AW452576			2.72
Ŋ		326224	AA003023	ns.112933	Homo sapiens Tax interaction protein 40 CH.17_hs gi 5867230	2.71 2.71
F	15	329114			CH.X_hs gi 5868650	2.7
	45	333577 300413	AW090347	Hs 243443	CH22_FGENES.196_2 FSTs	2.69 2.67
N		304055	R07994		EST singleton (not in UniGene) with exon	2.67
		301013 337848	Al935304	Hs.125262	DKFZP586G1624 protein	2.67
	50	327946			CH22_EM:AC005500.GENSCAN.33-1 CH.06_hs gij5868206	2.66 2.66
			AA937573		EST singleton (not in UniGene) with exon	2.66
			R01646 AA587541	Hs.200538	EST singleton (not in UniGene) with exon	2.65 2.65
		301321	A1860987	Hs.189097		2.65
	55	311280 338843	Al767957	Hs.197737	ESTs; Weakly similar to Y38A8.1 gene pro CH22_DJ246D7.GENSCAN.8-1	2.65 2.64
		335720			CH22_FGENES.599_23	2.64
		333670	41000004	11- 000007	CH22_FGENES.245_4	2.64
	60	335750	Al803591	Hs.209667	CH22_FGENES.602_4	2.64 2.63
		333240			CH22_FGENES.111_4	2.63
		332721 338747	R70212	Hs.79630	CD79A antigen (immunoglobulin-associated CH22_EM:AC005500.GENSCAN.511-1	2.62 2.62
			AA377444		EST cluster (not in UniGene) with exon h	2.62
	65	336898			CH22_FGENES.330-1	2.62
		325835 301660	F13112		CH.16_hs gi 6552452 EST cluster (not in UniGene) with exon h	2.62 2.61
		335968			CH22_FGENES.652_1	2.61
	70	336705	AW292760		CH22_FGENES.63-2 EST singleton (not in UniGene) with exon	2.6 2.6
	, 0	339220	A11232/00		CH22_FF113D11.GENSCAN.6-15	2.6 2.6
			AI709056		EST singleton (not in UniGene) with exon	2.6
		334260 309963	AW449073		CH22_FGENES.367_8 EST singleton (not in UniGene) with exon	2.6 2.6
	75	300178		Hs.166969	ESTs	2.59
		335690			CH22_FGENES.596_5	2.59

	308127 337835 333251 330319	I		EST singleton (not in UniGene) with exon CH22_EM:AC005500.GENSCAN.22-4 CH22_FGENES.116_3	2.58 2.58	
5	314490	AI758114 AA878815			2.58 2.57 2.57 2.57	
10	328558 336094	3		CH.07_hs gi 5868489 CH22_FGENES.691_3 EST singleton (not in UniGene) with exon	2.57 2.57	
		R60848		CH22_BA354112.GENSCAN.22-10 CH22_FGENES.827_8 EST cluster (not in UniGene)	2.57 2.57 2.56	
15	327304 308859	AI830787		Mucin 5b, Tracheobronchial (Gb:X74955) CH.01_hs gij5867494 EST singleton (not in UniGene) with exon KIAA1094 protein	2.56 2.56 2.55 2.55	
20		AA137045		EST singleton (not in UniGene) with exon CH22_EM:AC005500.GENSCAN.176-3 CH22_FGENES.434_5	2.54 2.53 2.52	
	339037 327846			EST cluster (not in UniGene) with exon h CH22_DA59H18.GENSCAN.26-5 CH.05_hs gi 6531962	2.52 2.52 2.52	
25	302816	R42885	Hs.204112	ESTs; Weakly similar to alternatively sp	2.52 2.51 2.51	
H G H 30	300184 333762	Al285912	Hs.254515		2.5 2.5 2.5 DEP	2.5
☐ 30 ☐ 30 ☐ 35 ☐ 35	326266 326005 301971	AJ003125		CH.17_hs gij5867264 CH.16_hs gij5867112 a disintegrin-like and metalloprotease (	2.49 2.49 2.48	
口 35 四	326539 338896 306773 336279			CH.19_hs gijS867307 CH22_DJ32I10.GENSCAN.9-4 EST singleton (not in UniGene) with exon	2.48 2.48 2.47	
□ □ 40	321017	AL050345 AA908609	Hs.227637	CH22_FGENES.763_3 hypothetical protein EST singleton (not in UniGene) with exon CH22_FGENES.104_8	2.47 2.47 2.47 2.46	
		AW295466	Hs.232051	CH22_EM:AC005500.GENSCAN.435-2 CH22_FGENES.205_2 ESTs	2.46 2.46 2.45	
¥ 45 □	338934 325751 334137	AA554263		EST singleton (not in UniGene) with exon CH22_DJ32I10.GENSCAN.18-2 CH.14_hs gij6682474 CH22_FGENES.337_1	2.45 2.45 2.45 2.45	
50	307318	Al208577		CH22_FGENES.200_1 C1q-related factor EST singleton (not in UniGene) with exon Homo sapiens chromosome 19; cosmid R2	2.45 2.44 2.44 2689	2.44
55	337425 336227 314657	AI015953		CH22_FGENES.761-1 CH22_FGENES.730_2 ESTs	2.44 2.44 2.44	
33		AJ003258 AA642917	Hs.250891	CH22_EM:AC005500.GENSCAN.398-10 CH22_FGENES.247_7 ESTs EST singleton (not in UniGene) with exon	2.44 2.43 2.43 2.43	
60	329382	AI655206	Hs.121512	CH22_FGENES.611_3 ESTs; Moderately similar to kinesin like CH.X_hs gij5868868	2.43 2.43 2.42	
65	334785 330130 327206 319235 334691	F11330	Hs.177633		2.42 2.42 2.41 2.41	
70	327610 327646 337093			CH22_FGENES.420_4 CH.04_hs gij5867868 CH.04_hs gij5867894 CH22_FGENES.465-18	2.4 2.4 2.4 2.4	
70	335081 333576 337604 329879			CH22_FGENES.488_4 CH22_FGENES.193_2 CH22_C20H12.GENSCAN.16-5 CH.15_p2 gij6466518	2.4 2.4 2.4 2.4	
75	328444 335700 331255	Z4100 <del>9</del>		CH.07_hs gij5868420 CH22_FGENES.598_1 ESTs; Weakly similar to HYPOTHETICAL P	2.39 2.39	2.39

	327927		CU 00 ha = 115000472	
	334354		CH.06_hs gi 5868173 CH22_FGENES.377_1	2.39 2.39
	308517 AI689279		EST singleton (not in UniGene) with exon	2.39
_	303669 AW49964	B Hs.233750	copine V	2.39
5	333648		CH22_FGENES.237_2	2.38
	318318 Al653893 338336	Hs.174463	ESTs; Weakly similar to alpha3b subunit	2.38
	304125 H40976		CH22_EM:AC005500.GENSCAN.310-8 EST singleton (not in UniGene) with exon	2.38
	304983 AA617786		EST singleton (not in UniGene) with exon	2.38 2.38
10	334935		CH22_FGENES.464_3	2.38
	314326 AW170057		ESTs	2.38
	330406 D49490	Hs.76901		2.38
	307646 Al302236 338911		EST singleton (not in UniGene) with exon	2.38
15	319952 T79532	He 225725	CH22_DJ32I10.GENSCAN.11-3 ESTs; Moderately similar to CGI-101 prot	2.38
	336878	113.223723	CH22_FGENES.318-5	2.37 2.37
	338140		CH22_EM:AC005500.GENSCAN.203-6	2.37
	300564 Al383878	Hs.225588	ESTs	2.37
20	304635 AA523976		EST singleton (not in UniGene) with exon	2.37
20	334091 336328		CH22_FGENES.327_47	2.37
	325310		CH22_FGENES.812_7 CH.11_hs gij5866864	2.37 2.37
	338043		CH22_EM:AC005500.GENSCAN.153-2	2.37
0.5	307090 Al161024		EST singleton (not in UniGene) with exon	2.37
25	335768		CH22_FGENES.607_2	2.37
	334969 333640		CH22_FGENES.466_2	2.37
⊨	330002		CH22_FGENES.230_2 CH.16_p2 gij6623963	2.36
	338829		CH: 10_p2 gij0023963 CH22_DJ246D7.GENSCAN.5-12	2.36 2.36
□ 30	323808 AW250114		EST duster (not in UniGene)	2.36
m	327755		CH.05_hs gi 5867955	2.35
© `\ □ 35 □	306426 AA975039		EST singleton (not in UniGene) with exon	2.35
	336481		CH22_FGENES.830_1	2.35
₹ 35	335163 322012 AL137357		CH22_FGENES.502_7 EST cluster (not in UniGene)	2.35
	337345		CH22_FGENES.723-1	2.35 2.35
	334625		CH22_FGENES.414_3	2.35
=	320957 Al878933		EST cluster (not in UniGene)	2.35
	334915		CH22_FGENES.457_4	2.35
	336295 321556 N46402		CH22_FGENES.787_1 ESTs	2.35
<u>N</u>	338491		CH22_EM:AC005500.GENSCAN.385-2	2.35 2.35
N	335517		CH22_FGENES.571_34	2.34
<b>↓</b> 45		Hs.75854	SULT1C sulfotransferase	2.34
급 45		Hs.145596		2.34
T	331526 N49967 334396		ESTs	2.34
i tr	332993		CH22_FGENES.381_2 CH22_FGENES.57_2	2.34 2.34
	327487		CH.02_hs gi 5867785	2.34
50	335920	(	CH22_FGENES.636_16	2.33
	336463		CH22_FGENES.829_22	2.33
	319000 Z44318 332992	į	EST duster (not in UniGene)	2.33
	332920		CH22_FGENES.57_1 CH22_FGENES.37_6	2.33
55	337590		CH22_C20H12.GENSCAN.6-5	2.33 2.33
	327059	(	CH.21_hs gi 6531965	2.33
	334399		CH22_FGENES.382_5	2.33
	300982 AA837754		ST duster (not in UniGene) with exon h	2.32
60	327430 326808		CH.02_hs gi 5867754 CH.20_hs gi 6682504	2.32 2.32
	309324 AW015373		ST singleton (not in UniGene) with exon	2.32
	329779		CH.14_p2 gi[6002090	2.32
			TPase; H+ transporting; lysosomal (vacu	2.31
65	330080 334342		CH.19_p2 gi 6015314	2.31
UJ	336306		CH22_FGENES.375_20 CH22_FGENES.793_5	2.31
	336400		H22_FGENES.793_5 H22_FGENES.823_15	2.31 2.31
	323735 AA323714	E	ST duster (not in UniGene)	2.31
70	334496	C	H22_FGENES.397_12	2.31
70	336075		H22_FGENES.687_1	2.31
	335566 337657		H22_FGENES.580_1	2.31
	327816 ´		:H22_EM:AC000097.GENSCAN.32-9 :H.05_hs gij5867968	2.31
	308465 AI672480	F	ST singleton (not in UniGene) with exon	2.3 2.3
75	330112	ā	H.19_p2 gi 6015238	2.3
	304465 AA421948		ST singleton (not in UniGene) with exon	2.3
			·	

	308449 Al660854	EST singleton (not in UniGene) with exon	2.3
	328171	CH.06_hs gi 5868071	2.3
	328271	CH.06_hs gi 6552415	2.3
5	328803 330063	CH.07_hs gi 6004475	2.3
	312281 H11643	CH.19_p2 gi 6165044 EST cluster (not in UniGene)	2.29 2.29
	328974	CH.09_hs gij5868520	2.29
	333859	CH22_FGENES.290_18	2.29
10	326253	CH.17_hs gi 5867263	2.29
10	325703	CH.14_hs gij5867028	2.29
	338925 328552	CH22_DJ32I10.GENSCAN.14-3	2.29
	337244	CH.07_hs gij5868489 CH22_FGENES.646-8	2.29
	******	7694 ESTs	2.29 2.29
15	324560 AW502208	EST cluster (not in UniGene)	2.29
	310603 AW376860 Hs.15	5398 ESTs	2.29
	337363	CH22_FGENES.733-2	2.29
	308015 Al440174 Hs.22	3907 EST; Weakly similar to GUANINE NUCLEO	
20	309206 Al961962 337455	EST singleton (not in UniGene) with exon	2.28
	327605	CH22_FGENES.777-1 CH.03_hs gij6004463	2.28 2.28
	301611 W22172 Hs.590	038 ESTs	2.28
		0051 ESTs	2.28
25	338278	CH22_EM:AC005500.GENSCAN.290-3	2.28
25	337291	CH22_FGENES.673-2	2.27
	337913 306406 AA971973	CH22_EM:AC005500.GENSCAN.59-10	2.27
ļb	332947	EST singleton (not in UniGene) with exon CH22_FGENES.47_10	2.27
	321763 W01148	EST duster (not in UniGene)	2.27 2.27
〒 30	304424 AA293494	EST singleton (not in UniGene) with exon	2.27
<del>-</del>	303782 T64737	EST cluster (not in UniGene) with exon h	2.27
0 30 0 30 0 35 0 0	326943	CH.21_hs gi 6004446	2.27
7	324977 R14439 Hs.209 325480	194 ESTs	2.27
<b>⊒</b> 35	327743	CH.12_hs gi 5866957 CH.05_hs gi 5867944	2.27
<b>W</b>	333221	CH22_FGENES.105_1	2.27 2.26
	336498	CH22_FGENES.833_3	2.26
<u></u>	321583 H84421	EST duster (not in UniGene)	2.26
	334191	CH22_FGENES.352_6	2.26
<b>40</b>	327089 310001 F18939 Hs.153	CH.21_hs gi 6531965	2.26
ΠJ	304056 R08577	327 ESTs EST singleton (not in UniGene) with exon	2.26
T.		913 ESTs; Moderately similar to !!!! ALU SUB	2.25 2.25
<u>ا</u> 45	330637 X86371 Hs.9568		2.25
_ 45	307642 AI302103	EST singleton (not in UniGene) with exon	2.25
T.	336985	CH22_FGENES.402-6	2.25
; <del>'</del>	334425 321216 Al078042 Hs.1266	CH22_FGENES.384_13 691 ESTs	2.25
	315785 AW205946 Hs.1503		2.25 2.25
50	305809 AA853998 Hs.1245	i80 EST	2.25
	331334 AA284858 Hs.8913	4 ESTs	2.25
		09 ESTs	2.25
	334216 330330	CH22_FGENES.358_1	2.24
55	326923	CH.08_p2 gi 5670267 CH.21_hs gi 6456782	2.24 2.24
	333774	CH22_FGENES.272_5	2.24
	324311 AA443061 Hs.2025	20 ESTs	2.24
	338551	CH22_EM:AC005500.GENSCAN.413-2	2.24
60	306716 Al024916 Hs.2513 337689	54 ESTs	2.24
00	300079 Al192520 Hs.1471	CH22_EM:AC000097.GENSCAN.77-5	2.24
	334617	CH22_FGENES.411_16	2.23 2.23
	336890	CH22_FGENES.326-10	2.23
<i>(</i>	334495	CH22_FGENES.397_10	2.23
65	327301	CH.01_hs gi 5867493	2.23
	337856 307072 Al150424 Hs.1468	CH22_EM:AC005500.GENSCAN.41-3	2.23
	307072 Al150424 Hs.1468 330515 M85247		2.23
	325943	H.sapiens dopamine D1A receptor gene, co CH.16_hs gij5867138	2.22 2.22
70	338947	CH22_DJ32I10.GENSCAN.21-4	2.22
	317465 AW197361 Hs.13136	SO ESTs	2.22
	332458 M33493 Hs.18450	4 tryptase; alpha	2.22
	333195 304837 AA587139	CH22_FGENES.98_17	2.22
75	307602 Al288843 Hs.23123	EST singleton (not in UniGene) with exon	2.22 2.22
-	337078	CH22_FGENES.457-1	2.22

	335862		CH22_FGENES.629_7	2.22
	301979 L28168	Hs.12149	5 potassium voltage-gated channel; Isk-rel	2.22
	335668 305068 AA6396	12	CH22_FGENES.590_19	2.22
5	329034	10	EST singleton (not in UniGene) with exon CH.X_hs gij5868561	2.21 2.21
	318403 AI13124	1 Hs.14323	4 ESTs	2.21
	328058 335513		CH.06_hs gij5902482	2.21
		9 Hs 15058	CH22_FGENES.571_28 0 putative translation initiation factor	2.21 2.21
10	331427 H54764	Hs.23733	9 EST	2.21
	338973		CH22_DJ32I10.GENSCAN.27-6	2.2
	336723 327290		CH22_FGENES.85-3 CH.01_hs gij5867483	2.2
	337240		CH22_FGENES.644-1	2.2 2.2
15	306201 AA92681		EST singleton (not in UniGene) with exon	2.2
	303659 AA86846 334517	4 Hs.12626	BESTs; Highly similar to FIBRILLARIN [H.s	2.2
	334189		CH22_FGENES.399_7 CH22_FGENES.352_4	2.2 2.2
20	335199		CH22_FGENES.508_8	2.2
20	333705		CH22_FGENES.250_19	2.2
	305794 AA84532 303273 AA31606		EST singleton (not in UniGene) with exon	2.2
	313384 W85694		EST cluster (not in UniGene) with exon h	2.2 2.2
25	329158		CH.X_hs gi 5868687	2.2
25	337551		CH22_FGENES.847-8	2.2
	328792 303737 AW50271	1	CH.07_hs gi 5868309	2.2
<u>lat</u>	324529 AW50246		EST cluster (not in UniGene) with exon h EST cluster (not in UniGene)	2.19 2.19
☐ 30 ☐ 30 ☐ 35 ☐ 35	323103 Z45529	Hs.92030	ESTs	2.19
□ 30	333773 337006		CH22_FGENES.272_4	2.19
<u>M</u>	337906 327129		CH22_EM:AC005500.GENSCAN.56-19 CH.21_hs gij6531976	2.19
A 30 TO	305710 AA826544	1	EST singleton (not in UniGene) with exon	2.19 2.19
	335595		CH22 FGENES.581 34	2.19
₩ 35	323646 AA310926	Hs.154412	ESTs	2.19
	328368 325802		CH.07_hs gi 5868388 CH.14_hs gi 6552451	2.19
	337167		CH22_FGENES.562-27	2.19 2.19
= 40	305059 AA635756		EST singleton (not in UniGene) with exon	2.18
□ 40	321445 AW245524 332790	4 Hs.121590	ESTs; Weakly similar to ZINC FINGER PROT	
U	336750		CH22_FGENES.2_4 CH22_FGENES.128-4	2.18 2.18
TU TU TU TU TU TU TU TU TU TU TU TU TU T	310999 Al520706	Hs.171012		2.18
45	329798		CH.14_p2 gi 6523160	2.18
	327012 304599 AA506638		CH.21_hs gi 5867664 EST singleton (not in UniGene) with exon	2.18
Ŋ	335351		CH22 FGENES.539 4	2.18 2.18
	310661 Al354717	Hs.223908	ESTs	2.18
50	332791 333022		CH22_FGENES.3_1	2.17
50	310502 Al458973	Hs.170422	CH22_FGENES.65_1 ESTs	2.17 2.17
	324963 AA853440		EST duster (not in UniGene)	2.17
	325275		CH.11_hs gi 5866902	2.17
55	328338 333063		CH.07_hs gij5868377 CH22_FGENES.75_6	2.17
	308895 AI858423		EST singleton (not in UniGene) with exon	2.17 2.17
	338685		CH22_EM:AC005500.GENSCAN.472-4	2.16
	325655 332420 H49570		CH.14 hs ail5867007	2.16
60	337216	rts. 1080/4	ESTs; Weakly similar to CEREBELLIN 1 PRE CH22_FGENES.613-10	
	335660		CH22_FGENES.590_11	2.16 2.16
	337145		CH22_FGENES.542-2	2.16
	335753 301766 R02224			2.16
65	303442 Al953998		EST cluster (not in UniGene) with exon h ESTs; Weakly similar to L-SERINE DEHYDRA	2.16
	311009 Al949701	Hs.210589	ESTs	2.16
	307093 Al167606		EST singleton (not in UniGene) with exon	2.16
	300262 AI874402 337989	Hs.170810		2.16
70	326263			2.16 2.16
=	319402 W21298	1	ST duster (not in UniGene)	2.16 2.16
	321010 Y17456	Hs.227150 I	domo sapiens LSFR2 gene; last exon	2.16
	301706 Al929150	Hs.241496 1		2.16
75	307412 Al241753 335662	ns.24150/		2.16 2.15
	332480 AA092932			2.15 2.15
			F	

	000070			
	329273 339383	CH.X_hs gij5868762	2.15	
	332795	CH22_BA232E17.GENSCAN.3-20 CH22_FGENES.5_1	2.15	
_	335227	CH22_FGENES.513_13	2.15 2.15	
5	326925	CH.21 hs ail6456782	2 15	
	332403 AA424199 Hs.106	529 ESTs; Highly similar to CGI-65 protein I	2.15	
	317786 AI859605 Hs.1556	S86 ESTs	2.15	
	326582 336494	CH.19_hs gi 5867318	2.15	
10	329656	CH22_FGENES.832_11 CH.14_p2 gij6448516	2.15	
	307581 AI284415	EST singleton (not in UniGene) with exo	2.15 n 2.15	
	335670	CH22 FGENES.591 2	2.14	
	332452 AA040369 Hs.1117	0 SYT interacting protein	2.14	
15	308427 AI652677 Hs.1950	10 Immunoglobulin kappa variable 1D-8	2.14	
10	322027 NM_004551	EST cluster (not in UniGene)	2.14	
	301693 Z45023	EST cluster (not in UniGene) with exon h	2.14 1 2.14	
	334308	CH22 FGENES.373 11	2.14	
20	301131 AW134518 Hs.1318		2.13	
20	338495 329600	CH22_EM:AC005500.GENSCAN.387-1		
	307980 Al431696	CH.10_p2 gi 3962481 EST singleton (not in UniGene) with exor	2.13	
	337260	CH22_FGENES.652-15	1 2.13 2.13	
25	304655 AA527887	EST singleton (not in UniGene) with exor	2.13	
25	303141 AF195951	EST duster (not in UniGene) with exon h	2.13	
_	327957 334317	CH.06_hs gi 5868210	2.13	
<del>                                     </del>	302870 AF011407	CH22_FGENES.374_1 EST cluster (not in UniGene) with exon h	2.13	
G.	333806	CH22_FGENES.278_2	2.13 2.13	
∃ 30	329947	CH.16_p2 gi 5540101	2.13	
M	309602 AW182523	EST singleton (not in UniGene) with exon	2.13	
#_   #=	322790 A1700273 Hs.12216 337706	ESTs; Weakly similar to KIAA0557 protein	1 2.13	
<del></del>	306894 AI092731	CH22_EM:AC000097.GENSCAN.87-11 EST singleton (not in UniGene) with exon	2.13	
<u> </u> 35	325530	CH.12_hs gi/6525289	2.13 2.12	
# 0 30 0 0 35 0 0 0 0 0 0 0 0 0 0 0 0 0 0	321087 AL110227 Hs.24153	3 Homo sapiens mRNA; cDNA DKFZp434J	194 (fr	2.12
	309853 AW298169 Hs.57553	tousled-like kinase 2	2.12	
8	326822 328776	CH.20_hs gij6117831	2.12	
<b>40</b>	335112	CH.07_hs gi 5868309 CH22_EGENES_494_20	2.12	
ī	334564	CH22_FGENES.494_20 CH22_FGENES.405_4	2.12 2.12	
	333455	CH22_FGENES.157_4	2.12	
14	317395 R55044 Hs.12413	D ESTs	2.12	
45	334221 331374 AAAA2134 He 70573	CH22_FGENES.360_1 ESTs; Weakly similar to HINT PROTEIN [I	2.12	
-	304473 AA428343 Hs.140	immunoglobulin gamma 3 (Gm marker)	7. 2.12 2.12	
N	328907	CH.08_hs gi 5868493	2.12	
	319448 R05539 Hs.10873		2.12	
50	333676 324767 AA630931 Hs.34348	CH22_FGENES.247_3	2.12	
	318585 Z43405	Homo sapiens mRNA; cDNA DKFZp434P( EST duster (not in UniGene)	2.12	2.12
	331732 AA251192 Hs.177708	ESTs	2.12	
	329553	CH.10_p2 gi 3962492	2.12	
55	336910 326959	CH22_FGENES.343-6	2.12	
55	305417 AA725228	CH.21_hs gi 6469836 EST singleton (not in UniGene) with exon	2.12	
		ESTs; Weakly similar to mitochondrial ci	2.11 2.11	
	326935	CH.21_hs gi 6004446	2.11	
60	335176	CH22_FGENES.504_6	2.11	
00	337210 311284 AW027025 Hs.239262	CH22_FGENES.603-5	2.11	
	330240	CH.05_p2 gi 6671858	2.11 2.11	
	327463	CH.02_hs gi 6004455	2.11	
65	332938	CH22_FGENES.41_3	2.11	
65	332785 301035 A1359105 Ho 422464	CH22_FGENES.1_1	2.11	
	301035 Al358105 Hs.123164 305712 AA826701	ESTs EST singleton (not in UniGene) with exon	2.1	
	318651 AW003150 Hs.240165	ESTs	2.1 2.1	
70	302753 M74299	EST cluster (not in UniGene) with exon h	2.1	
70	334635	CH22_FGENES.417_2	2.1	
	319447 AA456745 301204 AW008544 Hs.239994	EST cluster (not in UniGene)	2.1	
	333950	CH22_FGENES.303_6	2.1	
	325947	CH.16_hs gij5867138	2.1 2.1	
75	337683	CH22_EM:AC000097.GENSCAN.76-1	2.1	
	328962	CH.08_hs gi 6456775	2.1	

	336655		CH22_FGENES.34-3	2.1
	336596		CH22_FGENES.163_2	2.1
	330486 M13755		interferon-stimulated protein; 15 kDa	2.1
5	314356 AA53160 314976 AA52472	7 ms. 123 143 5 Hs. 162108	B ESIS	2.09 2.09
•	336650	J 113.102100	CH22_FGENES.29-6	2.09
	339026		CH22_DA59H18.GENSCAN.22-6	2.09
	302395 AW29735			2.09
10	323280 Al910263 338857		EST duster (not in UniGene) CH22_DJ32I10.GENSCAN.1-1	2.09
	335374		CH22_FGENES.543_12	2.09 2.09
	308766 AI808510		EST singleton (not in UniGene) with exon	2.09
	331027 N48584	Hs.6168	KIAA0703 gene product	2.09
15	337853 302498 NM_0029	91	CH22_EM:AC005500.GENSCAN.37-1 EST cluster (not in UniGene) with exon h	2.09
	312607 Al337440		ESTs	2.09 2.09
	314309 Z44049	Hs.184352	ESTs; Weakly similar to cDNA EST EMBL:D	3 2.09
	311695 Al142078 333280	Hs.135562		2.09
20	333518		CH22_FGENES.126_2 CH22_FGENES.173_3	2.09 2.09
	337199		CH22_FGENES.583-11	2.09
	337819		CH22 EM:AC005500.GENSCAN.13-9	2.08
	300546 AA214450			2.08
25	322577 AA354452 336028	113.050/0	ESTs; Weakly similar to WD40 protein Cia CH22_FGENES.672_1	2.08 2.08
	300238 Al394673	Hs.254030		2.08
<u>}_</u> _	307429 Al243573		EST singleton (not in UniGene) with exon	2.08
'n	326444 310641 Al345597	Hs.254727	CH.19_hs gi 5867385	2.08
☐ 30 ☐ 30 ☐ 35	337633	NS.204121	CH22_C20H12.GENSCAN.32-1	2.08 2.08
	336008		CH22_FGENES.668_6	2.08
	339030		CH22_DA59H18.GENSCAN.24-1	2.08
	333952 329149		CH22_FGENES.303_8 CH.X_hs gij5868685	2.08
∃ 35	335192		CH22_FGENES.507_7	2.08 2.08
<b>U</b>	308225 AI557713	Hs.177592	ribosomal protein; large; P1	2.08
	330519 M94172		calcium channel; voltage-dependent; L ty	2.08
3	331809 AA402482 324837 AJ003669		ESTs FSTe	2.07
<b>40</b>	332608 D00749		CD7 antigen (p41)	2.07 2.07
	327291		CH.01 hs qil5867483	2.07
N	315936 AW069807 317917 AI143593	Hs.247094 Hs.129419	ESTs; Moderately similar to !!!! ALU SUB	2.07
7-1	328674		CH.07_hs gi 5868254	2.07 2.07
<b>45</b>	338654		CH22 EM:AC005500.GENSCAN.460-55	2 07
Ū	320828 AJ012590	Hs.194728	hexose-6-phosphate dehydrogenase (glucos	
? <del>; ;</del>	337896 335310		CH22_EM:AC005500.GENSCAN.56-3 CH22_FGENES.532_3	2.07
	300076 AW074835	Hs.145223	ESTs	2.07 2.07
50	303588 AL046182		EST duster (not in UniGene) with exon h	2.07
	328848 318723 C18060		CH.07_hs gi 6381921	2.07
	335352		EST duster (not in UniGene) CH22_FGENES.539_5	2.07 2.07
<i>c.</i> c	339316		CH22_BA354I12.GENSCAN.22-15	2.06
55	335873		CH22_FGENES.631_1	2.06
	335261 322032 AL079807		CH22_FGENES.520_2 EST cluster (not in UniGene)	2.06
	308771 AI809301		EST singleton (not in UniGene) with exon	2.06 2.06
<i>(</i> 0	310024 AI252661	Hs.145224 E	STs	2.06
60		Hs.235534		2.06
	319314 T74062 334642		EST cluster (not in UniGene) CH22_FGENES.417 9	2.06 2.06
	335767		<del>-</del>	2.06
65	336159	(	CH22_FGENES.707_3	2.06
65	336358 334687	9		2.06
	339389			2.06 2.06
	335898			2.06
70	328847	C	CH.07_hs gij6381920	2.06
70	313431 W91884 313270 Al374993		'	2.06
	339211	Hs.159611 E		2.06 2.06
	333860			2.06 2.06
75		ds.224226 E	ST	2.06
75	305471 AA743947 300619 AA991438 I	46 222202 E		2.06
	000013 PV331430 1	13.233233 E	313	2.06

	302962 Al693349 Hs.	228081 EST	2.00
	332446 AA112799 Hs.	238756 ESTs; Weakly similar to unknown [H.sapie	2.06 2.06
	334972	CH22_FGENES.468 2	2.05
_	330196	CH.05_p2 gi 6165140	2.05
5	304754 AA579795	EST singleton (not in UniGene) with exon	2.05
	309726 AW248521 Hs.	195188 glyceraldehyde-3-phosphate dehydrogenase	2.05
	333939	CH22_FGENES.301_5	2.05
	304836 AA587008	EST singleton (not in UniGene) with exon	2.05
10	302087 AA324163	EST cluster (not in UniGene) with exon h	2.05
10	308424 Al650714 304347 AA176914	EST singleton (not in UniGene) with exon	2.05
	333141	EST singleton (not in UniGene) with exon CH22_FGENES.85_1	2.05
	310573 AW292180 Hs.	156142 ESTs	2.05 2.05
	337565	CH22_C65E1.GENSCAN.1-11	2.05
15	304295 AA084082	EST singleton (not in UniGene) with exon	2.05
	326624	CH.20_hs gi 5867553	2.05
	326443	CH.19_hs gi 5867385	2.04
	339012	CH22_DA59H18.GENSCAN.19-2	2.04
20	337384 332326 T79623 Hs.	CH22_FGENES.745-1	2.04
20	303706 AW501525	11787 ESTs EST cluster (not in UniGene) with exon h	2.04
	336046	CH22_FGENES.679_8	2.04 2.04
	301770 R05887	EST cluster (not in UniGene) with exon h	2.04
	326726	CH.20_hs gij5867597	2.04
25	330485 M11186 Hs.1	13216 oxytocin; prepro- (neurophysin I)	2.04
	332956	CH22_FGENES.48_13	2.04
<del>]                                    </del>	300021 M97935	AFFX control: STAT1	2.04
je,	306872 Al086920	EST singleton (not in UniGene) with exon	2.03
₹ 30	302744 L03151 338507	EST duster (not in UniGene) with exon h	2.03
	334020	CH22_EM:AC005500.GENSCAN.390-11 CH22_FGENES.317_1	2.03
M	333870	CH22_FGENES.291_3	2.03 2.03
Par		48157 pyrimidinergic receptor P2Y; G-protein c	2.03
<u>-</u>	335486	CH22_FGENES.570_18	2.03
≒ 35	339374	CH22_BA232E17.GENSCAN.2-5	2.03
☐ 30	328384	CH.07_hs gi 5868392	2.03
	334690	CH22_FGENES.420_3	2.03
3	310318 AI733942 Hs.14 325893	15338 ESTs	2.03
□ 40		CH.16_hs gij5867088 78170 ESTs; Weakly similar to DUAL SPECIFICITY	2.03
F11	329784		
	335087		2.03 2.03
N			2.03
<b>H</b>	332611 R06751 Hs.16		2.03
<b>45</b>	339258		2.03
TU	336851	CH22_FGENES.274-1	2.03
I U	305596 AA780664 Hs.87		2.03
	330364 302940 AL137619	CH.X_p2 gij3126882	2.03
50			2.03 2.03
	309869 AW300314		2.03 2.03
	333422		2.03
	325233	CH.10_hs gij6381943	2.03
55	330586 U77968 Hs.79	The state of the s	2.03
33	336725		2.02
	334157 303357 AW006352 He 15		2.02
	328533		2.02
	309210 Al962817		2.02 2.02
60	327412		2.02
	333172		2.02
	334869	CH22_FGENES.447_3	2.02
	301047 AA971465 Hs.11		2.02
65	329394		2.02
03	301736 F12128 335591		2.02
	338234		2.02
	334433	01100 =0=11== 00= 0	2.02 2.02
	334904		.02
70	318443 Al939323 Hs.157	714 ESTs; Weakly similar to NEUR ACETYLCHOLI	··
	300151 Al243445 Hs.189	9654 ESTs 2	.01
		519 ESTs 2	.01
			.01
75	332860 301699 Al879117		.01
, 5	332554 W96450 Hs.231	44 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	.01
	113.20	prompassino-unity symmetase-like 2	.01

	327994			CH.06_hs gi 5868218	2.01	
		AW137420	Hs.192311	ESTs	2.01	
	335356			CH22_FGENES.541_3	2.01	
_	334028			CH22_FGENES.318_7	2.01	
5	335277			CH22_FGENES.523_3	2.01	
	308657	AI749855	Hs.236497			2.01
	305913	AA876109		EST singleton (not in UniGene) with exon	2.01	2.0
	323681	AW247730	Hs.102548	glucocorticoid receptor DNA binding fact	2.01	
	333533			CH22_FGENES.175_20	2.01	
10	328753			CH.07_hs gij5868298	2.01	
	302397	L01694	Hs.211523	guanine nucleotide binding protein (G pr	2.01	
	304643	AA526588		EST singleton (not in UniGene) with exon	2.01	
	333065			CH22_FGENES.75_8	2.01	
	316192	AA904441	Hs.221286		2.01	
15		L36149		chemokine (C motif) XC receptor 1	2	
		AA813689	Hs 123436	FSTe	2	
	333612	7 5 45 15 500	110.120400	CH22_FGENES.217_7	2	
	333615			CH22_FGENES.217_7	-	
		AI027959	Hs.132300		2	
20	337936	A1027333	113.132300		2	
		H18467	He 110002	CH22_EM:AC005500.GENSCAN.85-7	2	
	330312	1110407	□3.110903	ESTs; Weakly similar to diaphanous 1 [H.	2	

#### Table 20: B survivor vs Mets – Up in Mets

5	Pkey: Unique Eos probeset identifier number  ExAccn: Exemplar Accession number, Genbank accession number  UnigenelD: Unigene number
	Unigene Title: Unigene gene title

10	Pkey	Ex Accn	UniG_ID	Complete Title	Ratio BS/Met
	316625	AA780307	Hs.122156		0.28
	316076	AW297895	Hs.116424	ESTs	0.20
	315943	AA699756	Hs.117335	ESTs	0.38
15	317198	AI810384	Hs.128025	ESTs	0.38
	320082	AA487678	Hs.189738	B ESTs	0.39
	313510	Al147291	Hs.154006	S ESTs	0.39
	323683	AI380045	Hs.225033	S ESTs	0.39
20	318558	AW402677	Hs.90372	ESTs	0.4
20	310264	AI915771	Hs.148867	ESTs	0.4
	314945	AW276866	Hs.192715	ESTs	0.41
	313403	W86995	Hs.113157	ESTs	0.42
	321505	H73183	Hs.129885	ESTs	0.43
25	312171	AW444619	Hs.138211	ESTs	0.43
25	324585	AI823969	Hs.132678	ESTs	0.44
		AA809844		EST cluster (not in UniGene)	0.44
H	319818	AA825819	Hs.136952	FSTs	0.44
	337522			CH22_FGENES.819-1 ESTs ESTs	0.45
₫ 30	324/14	AA574312	Hs.245737	ESTs	0.45
<u> </u>	315060	AA551104	Hs.189048	ESTs	0.46
			Hs.114689		0.47
أجيأ		AA431441	11- 400000	EST singleton (not in UniGene) with exon	
1000 -01	300504	AI422367	MS.163533		0.47
\	329086	AA987294		EST singleton (not in UniGene) with exon	
		AA167566	Un 122225	CH.X_ns gijo868604	0.47
<u> </u>	3201/0	Al674461	Ha 400020	CH.X_hs gi 5868604 ESTs	0.47
	3020410			20.0	0.47
3		AW207535		ESTs; Weakly similar to C2H2-type zinc f	
☐ 40 ☐ ☐ 45	317056	AA904908	He 250643	ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	0.48
TI.	314361	AL038765	He 161304	EGTs	0.48
: <del>L</del>	315169	AI371390	Hs 158667	EQT <sub>e</sub>	0.49
i U	323743	AA324992	Hs. 257168	FSTs	0.49 0.49
F.	313903	AW167439	Hs. 190651	FSTs	0.49
<b>=</b> 45	315061	AA551196	Hs.188952	FSTs	0.49
<del></del>			Hs.76230	ribosomal protein S10	0.49
ħJ.		AA454595	Hs.99369	ESTs	0.5
	315076	AI623817 I	Hs.168457	ESTs	0.5
	300975	AI283548	Hs.149668	ESTs	0.5

## TABLE 1-20A

Table 1-20A, shows the accession numbers for those pkeys lacking unigeneID's for Tables 1-20. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number Gene cluster number Genbank accession numbers

	20	Pkey	CAT Number	Accesssion
	25	108474	112224_1 116896_1 10605_34	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA115179 AA079667 AA115897 AA079771 BE259039 W29128 AW410299 X72990 BE246492 NM_005243 X66899 AI909006 AW248151 AL031186 AA012966 BE273549 BE311429 BE253102 Y07848 BE538102 BE256863 BE261240 BE312156 BE618412 BE257322 BE620446 AW806629 AA376777 AA325384 BE256808 BE251039 BE257878 BE275352 AA357169 AW403562 AA204995 AA093259 W95953 BE256279 BE336683 BE252465 BE251266 AA380754 BE294942 AA380941 AA380999 BE297164 BE249995 BE294719 BE295372 AI270673 BE305132 BE563752 BE295357 AI525421 BE263980 AA057505 AA020915 BE266318 BE206948
	30			AA357571 AW361285 AA436908 AA301019 AA301022 N20202 BE408777 BE548638 BE167415 AA071260 BE088429 BE280092 W23117 T19568 R51681 AW402216 W22784 BE185607 Al457224 BE544120 AL134874 S72620 AA375079 D51319 AW818280 BE514686 AW853024 BE563744 AA300469 T07592 BE622190 BE272834 W21781 BE315450 BE542367 BE393120 AA988441 H55137 BE562296 BE622502 BE395960 AA329733 AA332348 AI768317 AA456866 AI407832 AW8726437 AA857740
	35			01016 BE621418 AIB1879U AI949907 BE397693 AI885545 AI858854 AI355147 BE169028 S62138 AW732191 AA856891 BE266060 X71427 BE268557 AF095890 AW001288 AI799634 AI623498 AA071346 BE547662 BE261446 AI564543 BE559759 U35622 BE314249 BE264915 AI638591 AI538385 AW090025 BE384754 AI886889 AW778800 AI925273 AA075797 AW949130 AV660275 AW438697 AI587137 AI524121 AA806249 AW628247 AA808241 AI244388 AI761125 AW117672 AA911782 AI129250 AA654447 H55291 BE258055 BE206162 W95867 AA857187 AI871378 AI650103 AW13897 AI230020 AW1440340
7 CI	40			D12765 AI911646 D82208 D82187 AW074031 AI358527 AW338497 AA970893 AW072573 AA205364 AI858886 AA012830 AW148763 AI863056 AA548656 BE250325 AI016994 AI864005 BE046122 AI497746 C75340 R58896 D82141 AW168240 C19048 AI741090 D29465 AI222365 AA948288 AI583522 AW572212 AI091290 AA582727 AA579897 AA570629 W60883 AW516989 AL038160 AA577334 AI865872 AA994043 AA922583 AA464778 AA209478 AI820479 AI270236 BE346570
	45			AA384177 AA456255 Al699730 W60654 AL035744 AA862042 R32756 Al886886 AA993087 Al289479 AA627840 AA464184 Al619503 R32755 AW075358 Al432315 AA457024 AA020865 R92132 AA454629 AA746059 AA454643 AA456240 AA826984 BE163738 Al806470 Al991074 Al802560 AA587095 AA558714 AA968521 N87780 Al538246 N71794 AV661738 Al368903 AA362570 Al989445 Al674962 S75762 BE245204 AA975296 D20123 AW005704 AA693328 AA582270 Al918474 AW205707 Al696299 AA220990 AA101538 T29030 H27201 AW262526 Al610530 AA126840 AA126790 X92120 AW367868 BE299644
	50			DE259431 AA410361 BE300044 AA134363 BE295222 AA307504 N42337 AA319098 N39502 AW964461 N57241 BE299049 N86332 R51156 AA085859 T75212 AA133939 AA147129 AA156161 BE543953 BE538848 AA133676 BE299745 AA135050 AA218535 AW406401 AW411287 BE410528 C01410 NM_004083 BE314959 AA836413 AA085862 AW024370 AA471059 AW467508 AA001025 AI828231 AA633221 T95517 AA147038 AA476447 AW027012 AW078627 BE513200 AI192297 AA886279 AW081806 AA316185 AA010506 A1269929 W93139 A1682935 AA609555 AA328028 A1032877 AA200007 AA328028
	55			AA632978 AA015892 AW204713 AA156495 AA824613 AA133630 N29826 AA527476 A1633352 T27908 AA134364 AA133940 AA632978 AA015892 AW204713 AA156495 AA824613 AA133630 N29826 AA527476 A1633352 T27908 AA134364 AA133940 AW043601 H37775 AA772375 AA057871 AA047888 AA054225 H86568 AA001511 H25718 AW189507 AA165589 AA054433 H85549 AA165486 AA058972 AA454911 AA464064 AA493802 AA428253 R85508 AW302469 A1611812 BE162582 F11073 T95518 N26811 A1783929 H40669 AW611745 A1658803 R511042 R45276 AA528736 AA782875 AW880318 AL138291 AA244580
	60	100643 3		ANY 99338 AA 199466 AA 149552 AI346513 AA216776 BE349131 AW007654 AI141803 AA622688 AI185131 AW057635 AA 101539 AA627986 H27202 AI536847 W93084 AI973148 AI246788 AW572108 AI469414 AA454835 AA612707 AA430746 AI084991 AA010400 AA856636 AA463928 AI248310 R07170 AA834033 D12244 AI655670 AA054350 AA639480 AI702067 AI475389
(	65		- , , , ,	NM_005032 M34427 AA332167 AW409711 AL119718 BE297581 BE299855 AA082284 AA226855 AA149568 AW391953 M22299 BE163594 AW847881 AW366993 BE142871 AW847885 AW604137 AW847753 AW847886 AW376442 U48350 AW607478 AA373011 AA334080 BE294177 AL121355 AA302236 BE540666 BE170588 AA346884 BE541512 AA226818 AA082001 AA366490 AW604122 AA205784 AW607791 BE168496 AA058497 T64373 BE165633 AW802804 AW847878 AA187408 AA088397 AI751745 AA344103 AA034463 AI906008 AA363580 AA379193 AI332642 AI143569 W52748 W52754 AA385532 AA085967 F05943 AA363422 AA133444 AA133477 AA029541 N48387 N83348 AA376066 AA147671 W70187
,	70		Ä	A316255 BE174987 AA452776 AA089605 AL047776 BE162673 H39532 BE168406 AA357654 AA328728 AW813442 D57844 AW839748 AW839663 D57357 AA334536 AW268674 AW950788 AW409888 AI160544 D57821 AW664382 D25884 AI755101 AW130365 AI609094 AI984064 AI806523 AA492516 AI7555258 BE157210 AA374884 AI983923 AI831088 AA706501 AI754957

		Al688651 Al088623 Al336114 N38752 T56004 AA845200 AA858377 BE157397 AW069347 AA045366 AW316918 AW130372 Al355398 BE157396 Al751746 Al375820 AA12935 W60002 N24781 Al805924 W60009 AA044283 AA121161 Al539277 AA301885 AW019944 AA133445 AA101108 AA033559 W70060 AA617751 Al986261 Al023234 D82235 AA085846 AW754181
5		D82093 D82100 AA147653 AA600256 D57884 AI753982 AI568050 AI146490 AW302280 AI433051 AA329188 AW572150 AW166345 AI337981 AA778973 N67577 AA227207 AA838281 C06190 AL046997 AI217662 AI752979 AW627538 AI127171 AI440461 T64184 AA845190 AA227111 AA877394 R60962 AA505646 AA770545 AI696264 AA953747 AA904094 AA058318 D57026 T17158 AA578545 AW085082 BE148939 AW815069 BE152843 BE149068 BE149036 AW815073 AW753691 BE149040 AW815065 BE152842 BE149072 AW753692 AW815055 BE152837 BE152849 BE152840 AW815070 BE152829 BE152846
10		R65797 F02189 AA483448 AI954410 AA865375 BE152832 BE152838 BE152839 T17300 BE152844 BE152852 BE152847 R65797 F02189 AA483448 AI954410 AA865375 BE152836 BE152838 BE152839 T17300 BE152844 BE152833 BE152834 AA029542 AI567601 AI362353 BE162140 AI381384 BE152851 D57038 D57043 AI418363 AA133478 BE149051 BE149083 BE152850 BE149052 BE149084 AA866686 BE149064 BE149032 AA044093 AA129934 AA303976 BE157211 AA187291 BE152830 AA046552 BE149047 BE149079 BE149033 BE149065 BE149076 BE149076 BE149085 BE149086
15	100670 22023_1	BE149066 BE149048 BE149080 BE149038 BE149070 BE149045 BE149077  AA332178 BE259177 BE545625 T09105 S62076 M16424 NM_000520 BE244309 F13516 BE251567 BE514981 AL119537  AA336739 BE261801 AA278642 N32708 T77034 W24621 W42478 AW630382 AW856214 AA134234 M13520 BE379212  AA287459 BE019379 BE297192 BE162970 AW405668 AW403322 BE272280 BE208703 BE304428 BE162807 BE162828  BE162887 BE078944 BE163025 BE162878 BE162909 BE162898 BE162791 BE162880 BE073563 BE163086 BE162896
20		BE162770 BE073565 BE162906 BE162913 BE162947 BE162803 BE262199 BE162811 BE080697 BE315095 AW206024 Al291054 BE087364 AL046839 AA304422 AA847660 AA669876 BE392765 Al567798 AW026644 AW151258 AA996314 Al828660 Al571158 T61941 AW103503 AW172698 Al923115 Al823709 T62167 AW771381 AW151782 Al799284 AW242271 AA128031 BE261306 BE312241 Al674880 BE261057 AA630684 AA831305 Al139546 AW082447 AA916854 AA916855 T05970 AA599395 AA921680 Al244674 Al041920 AA424998 Al362999 W42543 T51260 Al362486 Al699366 Al827925 Al027381
25		Al027370 Al209049 AA782220 Al334014 Al279051 Al217711 Al674210 Al193370 Al701683 T23782 Al027545 Al784291 AA128007 Al370630 Al972736 AA853763 N92379 Al916746 AA639633 AA907603 Al479452 AW950971 T28985 Al685825 AA563654 AA745291 AW089417 F10858 Al354227 R38108 Al668647 AA994088 Al740910 AW880973 Al739410 Al480346 N78987 Al473892 BE162903 BE254430 BE260426 AA650012 AW006426
<u> </u>	100673 21517_2 108559 41469_9	AW403342 AW248986 BE561709 AA357312 BE311834 BE389496 BE294887 AW732696 BE047868 AI702383 BE019155 AI702367 BE408966 BE280458 BE313759 BE513492 BE535404 BE280258 AC005263 NM_007165 L21990 AW732711 AI564920 AW249094 BE265365 AW607186 AW607346 BE005217 H27211 U46230 BE260066 BE207043 BE546782 AW248659 AA085228 AA085161
<u>U</u>	108569 118606 1	AA082885 AA114265 AA085398 AA113184
334 fi	100700 17137_1	AA932794 BE540417 AW409802 AW410765 BE296651 BE294197 BE164813 AW381886 AW281896 ALGARSTA AW402053
		BE207228 AA464654 AW966967 AA326831 BE407277 BE408669 AA476527 AA115576 AA359697 AA476357 AA449339 BE263719 AL045304 W21442 R28919 BE395990 AA252273 Al346812 BE538487 AA507160 W93950 N42025 Al088439 AL134931 AA031524 Al887287 AW470017 AA476423 AA464553 AW410766 Al569421 AA577476 Al248935 Al912371 AW615674 AA824237 AA807746 AA827377 AA890268 AA476309 Al086424 AW409698 AA031553 AW451901 Al520934 AW050554 R49825 N30302 AA532541 W94004 N93402 AA115549 AA331202 L25665 NM_005275 AA436745 Al122671 R49779 R18508
1 40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	100734 35197_1	Al807481 Al500404 Al092260 BE348962 Al143675 AA772399 AA772398 Al368565 Al379172 Al083781 Al871363 AA843793 NM_000141 M87770 X52832 M55614 Z71929 W05259 AA548551 Al498743 BE081295 BE162251 F05643 Al127918 H83199 W07463 BE551725 R28404 AW206461 AW590506 Al885536 N69800 R93496 R25381 AA443093 Al143063 Al28464 R31793144 AA309032 AA309031 AW949426 AW949428 Al638387 Al638368 R77173 R38513 T80263 E01000 M87070 B70376 AA664375
45 L		AA723410 BE537575 AA236812 AI218552 AI264866 AI290617 AA424365 AA424505 AW073347 AA032183 AI142488 N55322 AA723410 BE537575 AA236812 AI218552 AI264866 AI290617 AA424365 AA424505 AW073347 AA032183 AI142488 N55322 AI884363 AI336070 N67307 AA608928 T94993 AW514184 AA724695 N66630 AI379638 AI274671 AW628470 AA235346 AA687581 AI073906 AI263602 AI869111 AI805693 AI423808 AI076491 AI374640 H82967 AA776567 AA256191 T29856 AA953586 AI140801 AI805484 AA984329 R93497 AI017114 AI263355 N81103 AW418776 D57474 AI018467 AA256150
50	100739 2738_3 117040 46956_1 100748 41861_1	A1003200 A1042028 AW196050 C00195 AI918567 T28903 N95383 R13671 T94939 AI275235 AA235751 T84335 M59287 L29222 AI251890 BE244986 AI708332 AW970600 AA503323 H89218 AF086031 H89112
	100740 41081_1	X06096 X05826 AW794626 M27126 M27014
55	100779 458_127 100787 458_127	BE561958 BE561728 BE397612 BE514391 BE269037 BE514207 BE562381 BE514256 BE514403 BE514250 BE397832 BE269598 BE559865 BE396881 BE560031 BE514199 BE560037 BE560454 BE561728 BE397612 BE514391 BE269037 BE514207 BE562381 BE514256 BE514403 BE514250 BE397832 BE566003 BE56003 BE50003 BE500003 BE500003 BE500000 BE50000 BE5000 BE50000
		DE209090 BE009800 BE396881 BE560031 BE514199 RE560037 RE560454
	130872 21268_1	U61084 NM_004900 U61083 AI761325 AI826909 H79385 T81886 AI222763 N68038 AI281048 H79274 AA603662 AA721720 T71211 C00488 AA994672 AW136970 AW368715 AA380767 AL022318
60	108641 85313	AA112059
	100818 19604_3	U79251 AA843851 R38201 R66461 R44908 AA683289 H17477 R37364 R52832 AW298336 AA351391 NM_002545 L34774
65	130930 2773_1	AA296886 AW967001 T28889 R13451 T77331 AL119196 AL118830 H08459 AW892812 AW905838 H17585 R52878 NM_005658 U19261 BE622108 AA313592 AW950162 H25107 R71725 R50630 Al524201 Al476301 AW014547 AW195770 Al378122 Al554908 Al927196 Al913959 AW044513 R50534 Al379950 Al311593 BE043305 R82981 AA769375 R77429 AW196220 Al269033 AA883433 R71691 F11489 AW771234 AA402642 AA399408 AW771244 Al400707 R55446
	124394 5590_5	AISSUMM AWUZ/4Z/ AIB4U151 AI139433 AI400708 AW779975 AI739122 AI38ADDD AWD70A1D AI472A25 AA4504DD AI706570
70	100882 458_127 100885 12707_3	BE561958 BE561728 BE397612 BE514391 BE269037 BE514207 BE562381 BE514256 BE514403 BE514250 BE397832 BE269598 BE559865 BE396881 BE560031 BE514199 BE560037 BE560454
, ,	100896 205_6	X07881 NM_006249 X07637 AA376715 AA376677 X07715 X07704 S80916 M91803 X65362
75	100898 8542_1	BE387614 R51501 AA199714 AW674779 F08178 BE269071 AA376313 H08264 AA380420 H18785 AL042151 BE277758 BE267438 NM_005850 L35013 BE540833 BE390902 BE391494 BE277459 BE385592 BE390612 BE384263 BE387779 BE388647 BE537373 BE547158 AW409585 AW374033 AW602185 AA355725 AW577548 AW935015 AW935160 W40232 AW938647 AW374332 AA434040 BE293488 AL138361 BE560260 AI745075 AA317980 AW949382 AI834311 AI653582 AI831042 AI361878 AA618606 AA729052 AI424969 AA199715 AW769374 AI828422 AW044307 AI862816 AI203583 AW084461

			AW514655 AA831883 AA290672 AA831286 AA578510 AW089965 AW150746 AA292743 H22232 AI469275 AW439312 AA292744 AW471443 AI473989 AA593336 AA464070 AI678937 AW069451 AA970763 AA610480 AA593328 AA464009
	5		AA768985 Al298928 AA436600 AA464718 AA699361 D61482 D55935 Al369591 AA470695 Al809135 AA640627 Al568446 R51502 W45467 Al655316 AA463934 AW168609 AW518663 BE045525 Z41251 Al868091 AA908160 Al026697 Al886259 Al612932 AA215437 Al956014 BE541087 BE255652 BE265878 BE394102 W27502
		108706 132553 108710 133560_1 108712 14671_1	AA121820 AA121959 AA121960
	10	100/12 140/1_1	AA335738 AI817426 AA099503 AA643106 AA650582 AW188499 AA155785 AW024305 AA992590 AW793619 AA121250 H93101 AA994582 AW007456 AW799974 AA535738 AI460362 AI571942 AW517220 BE044613 AI830018 H50382 AW391334 AA741035 AI697291 W37616 AA866185 AW264926 H52854 AW796893 AI660673 AA464961 AI808376 H13850 H81969
			W92615 H41636 H73900 H66731 AA281556 AA026801 AA479538 AA588901 AA446262 R86974 H84761 R62958 H70493 Al991716 Al833075 AW800109 R54692 W94542 R78651 Al694890 AW845181 W31325 AA224371 AA359813 AW178868 H53738 F22305 Al874075 Al567440 AA853303 H25886 AA550734 Al874064 AW148463 Al586928 T28979 AW950966 Al828723
	15		AI918890 F16942 AA223763 AA622370 AA630985 AA402644 N70971 AI147210 AW410026 AA485517 AI129376 AW337522 AW136362 AI123362 AI281243 AW339600 AI478990 AI339256 AW768289 AI660065 AI309560 AI141111 AI280844 AI338227 AI310719 AA733112 AA903203 AI073351 AI348225 AA974151 AI141386 AI311925 AI042124 AI193176 AI186999 AI735528 AI335702 BE550806 W47157 W70086 W44788 AI218741 AI074049 AI168088 AW050904 AI083978 AI131084 AW328532
	20		Al969255 AA069140 AA328735 F20431 Al625929 AA621514 AA384576 H98823 Al371848 Al360520 AW079514 AW845177 AA948626 N52236 AA464158 H43126 AA465035 AA464221 AA365164 Al539264 AW250430 N27769 AA157036 Al124029
	20		Al635488 AA374090 AA515126 AA614763 Al872210 Al160916 Al002016 AA813669 AA190550 Al262671 Al460058 Al690719 AA805473 AA523207 AA477649 H13898 Al056086 H42356 R32267 R99431 AA481898 Al130779 AA769777 AA910293 Al284079 AA936692 AA903953 AA947753 Al568924 AA902966 AA807082 AA489337 N58247 AA872223 AA485362 AA024906 Al092224 AA443621 AA603059 N58248 AA927262 AA329524 AA026369 N73450 Al244031 Al192676 N25190 W32248 W32324
	25		AI284307 AA074470 N33116 AA947399 H52855 T52343 AA643260 AA573752 AI031889 AA877690 AA531409 X13710 AI500538 R32315 BE168562 AA401993 AA883251 W37615 AA305694 W78964 AA024905 H53678 W47278 AA224423
1	•		AA371881 AA335679 AA336008 T52416 H69646 AA300266 AA325728 N73204 N77626 R54691 W24032 AA868340 BE407766 H81968 W46665 AA883934 AA187290 AW571425 AI280505 AI079662 AI470373 AA991617 AA173165 AI244032 AA922440 AA856918 W80458 AA121251 AI160062 H50349 T67744 W46574 AA969287 W01485 BE615302 BE388184 AA314246 H85693
	30		W31948 AV650437 AW160467 W44891 AA723773 AW328531 AA313224 AA299527 R86894 AA312505 H21582 AA157493 H78480 N36060 N77627 BE218674 W02853 AW954844 AA429974 BE382847 AJ541225 H93229 BE281553 AA147790
ā V			AA327374 AW839840 AA969229 R99337 BE278812 AI190450 AA479549 AA156012 R78705 AA224081 N44944 D56066 AA969012 AW178878 AW105500 N52391 AA622301 AA858204 AI290372 AI205676 H51289 AA548013 BE544240 AA280160 BE170901 AI192429 R77056 AA310925 AI219128 AA121993 AA070432 R63012
	35	108785 49626 102156 33676_1	AA128946 H08948 AA353935 R14985 U17977 H15387 F05567 R88476 AW968314 R89646 R87941 AA258917 AW895155 AW947450
			AA223175 AA223559 W92508 W02327 AA322882 AW960879 H39040 H39039 R90891 AA580343 BE155037 BE154984 N40110 AL137683 BE265131 R17329 AL096733 M79202 AA625234 AA427472 AW361296 AA658045 AA322177 R54596 AA171880 AL042331 U18920 AA298036 AW051888 AI378803 AW601640 AI885103 AA297019 AI192706 AW055183 BE312004 H42382
	40		AA534726 AA205943 AA204917 AA298966 AW015511 AA223176 H08864 AW028026 R45676 Al023345 AW263046 Al161297 Al168747 AW024885 AI832106 R88436 R86849 W92509 AA857908 N26989 AI589169 AI570370 AA223525 AA171552 AA405862 AW001095 AI864651 H39060 AA776342 AI682761 AA768233 R86855 AI367878 R42675 AA832040 R89042 AI984848 AI524629 AI289021 AW014020 AI241757 AI421241 AA430654 AI360728 AW299692 AA258155 AA782959 AI684411
	45	102186 33745_1	AA531501 H41286 Al125231 H15388 M62002 R88819 Al203108 Z38537 Al432593 AA887767 AW023638 H39016 Al424700 U20285 AW674959 W69617 NM_004127 AU076538 BE245805 AW250694 AW248164 BE294678 AA298083 BE266030 BE262348 AL038115 BE253256 AA330082 AW401492 BE070159 BE619216 AW379955 AW379968 BE266381 AL046753
N			AW379969 Z45804 H12155 BE543514 Z44978 AA026010 AA776140 AA337940 AA315980 AA308668 BE156554 R33383 BE271569 BE378456 AA972517 AW748739 R73336 AA302223 AA279618 BE561802 AI693878 BE560858 BE513865 BE267975 R36064 AI056387 AI961737 AW167515 AA280965 AI479985 AI859762 AA309009 AA573934 AI669053 BE046497 H14545
	50		BE222639 AI910094 AA484398 AA521025 AA807224 AW247126 AW732050 AA377850 AW951499 R73316 AI458542 AI564292 AA974663 AI951858 AA595162 AI685726 AA604679 AI813703 AI091930 AI567797 AI521316 AI377236 AA583446 W79901 AI743281 AA913078 AI139695 AA994505 AI202810 AA662524 AI810703 AA988395 AI272746 AA569807 AI299166 AI799551 AI492268 AI131335 AA969251 AI240890 AA580208 AI928074 AA716051 AA657992 AA988396 AA994504 AI952561 AW188344
	55		AW246831 AI471309 AA757891 AA931856 AI272794 AA766100 F24931 F24930 AA749404 AA708597 AA732155 AI796670 AI825867 BE245682 AI638230 AA434157 AW249881 AA481945 AI090239 AA923622 R72864 F25087 AW674940 AI808546 AI470209 AI285895 AW189219 AW474426 AI818261 AW300960 AW513345 AW073126 AI868353 AA862926 AW592528 AA502647 AW591711 AI354982 R49145 AI360724 AI458656 AW304052 Z41443 AI864783 AW651615 AI270639 AW316592
			R43/41 AA482068 R72852 AW190442 AW651631 AW470902 AA911918 AW779251 R72820 AA279995 AI394715 AW105688 AI097434 AA670473 F08806 AA035597 AW008688 AI689117 AI911859 BE387696 AW166880 AA847278 W78016 AI886548
	60	125077 1814028_1 124440 22853_1	N35512 T86152 T88822 T80794 AA532519 AA770627 BE326342 AW073299 AW205539 Z83851 AA725380 AI457288 AA976882 BE220181 AA988940 AI914073 N46435
	<i></i>	100941 3303_2 117286 558874_1	U15422 NM_005425 X63758 X63759 Z46940 L03378 Al220577 AA634325 Al381479 AA994994 AA994988 AA416961 Al188710 Al032142 AW078833 N30308 AW675632 Al219028 Al341201 N22181 H95390
	65	117291 1047256_1 132316 10556_2	N81189 AW172914 N22182 N22289 U28831 AA088359 N56023 AA069486 AL038872 AI683185 AA632516 AI281643 AA447146 AI699884 AI281642 AA832250 AI909017 AA781851 BE090060 AA058888 AI440090 AA040563 AA069449 AI702237 AA045495 AA088258 AA220820 AI925213
	70	102295 26281_1	AA928183 N90591 AW794070 Al884470 AA219147 Al632560 AA553416 T10311 AB007881 U32581 AW131202 AW995994 W31964 N24261 Al033045 H98694 AW364848 Al222031 AA907216 Al215730 AA776981 AW473826 W31373
		132380 166896_2	AW373665 AW373648 AW373647 AW393531 AA284401 AA253299 BE168092 AA196249 AA810695 AA278353 AI806177 BE552269 AW001862 AA749299 AA253300 W37080 AA805586 H72533 AI698623 AA292703 AA748852 H75291 H68018
	75	102337 553_1	AA883728 N48304 N49030 BE168089 AI814663 AA806761 AA765241 AA019317 AA092255 AA035405 T85079 AA890151 AI373959 T85080 BE153728 AA740848 BE080682 AL048137 AW182316 AI699468 AW274481 AW407538 AA306562 AW950024 AW949943 AL045703 AW843196 W25132 BE612794 AA304266 AW958054 H25673 AV646563 AV646573 BE172990 AW593488 AA385181 AA164998 AI246476

		AA345406 AI277554 AA134749 AA856624 BE613247 AA299003 AL048138 AA028121 T92510 AI923835 AW020440 AI401594
		A1889401 N93290 AA044247 AA028100 A1582845 AA811151 A1741811 A1925878 AA448277 AA172221 A1214783 BE220793 AA022746 A1082882 AA022849 A1928385 AA573472 A1420686 AW072902 A1799493 A1873506 A1468977 A1192079 A1468976
5		AAU442/2 AW015701 AW316979 AA933042 AA609017 Al318393 Al424571 Al934945 AA172023 AW050017 AA946490
3		AA134/48 A1003947 A1766769 AW006697 AA653517 AW575680 A1474214 AA401478 U36922 AA027064 AA868000 D62664
		T91745 AW500202 AA194764 AA746346 AA130464 AW117498 AA054526 N26432 H02534 H04964 AW303367 BE300931 Al218049 Al208073 AW182749 AA983630 Al147585 AA194765 AA054534 AA922720 Al436585 Al346535 AA134269 AA280923
		AAB9/4ZZ AAU19559 AW274010 AA035406 AA917879 H99327 W32908 AI216046 AW496823 AA019414 H82288 W35284
10		A1936621 A1/6/113 AA866177 AW367874 H82398 AF032885 AW300151 AW467069 AA809346 A1188507 A1404478 AA879759
10		AI631631 U02310 NM_002015 AA815006 AI382453 AW197658 AI761654 AI804396 AI382221 AI813640 AI439635 AI523901 AW517242 AI221705 AW298104 AW204560 AW573095 AW028783 AW014650 AI766744 AI808294 AI698758 AI041809
	424000 0000 44	A1/0000/ A14/91U3 AA8/2/97 AA769305 AA765080 AA334166 A1472322
	131862 3673_14	AI541246 AW055046 BE312897 NM_006623 AF006043 AL038012 BE256739 BE272577 AA143633 AA143643 BE464595
15		Al312112 H01791 R26319 BE170902 AW131612 F29120 AA455866 Al540181 Al885777 F36716 Al149501 Al246028 Al373003 AL046700 AA455869 W69120 AA146617 Al188256 Al937281 Al806751 Al087240 Al123219 Al589686 Al332501 W69087
		AI494321 AA725793 AI222350 AA625736 AA644568 AI472282 AI370905 AA934652 AA913035 AI128576 AW344700 AI260425
		AA9/5139 AI620890 AI969828 AI356660 W95879 F32252 AI218442 AI928601 AI474470 AI245400 AI604444 AA026504
20		Al809316 F19498 Al373442 Al218893 AA573914 AA906869 Al833041 AA993899 AW250763 AA887142 AA884655 R26108 Al919414 H01042 AA534622 AA723368 AW005753 Al871394 AA661885 BE171317 BE271194 AW249310 T83902 BE246962
20		BE2/981/ BE562094 BE513363 AL045369 BE561008 RE267526 RE544065 RE550570 RE561747 T25706 RE250506 RE260704
		T31298 BE536521 BE561183 BE269560 BE269944 BE514005 BE561068 BE268145 BE267559 BE559744 BE560930 BE278335 BE513832 BE561017 BE396371 BE562260 BE281009 BE281327 AW410446 BE259628 BE547443 BE311971 T83809
		AW249441 BE270204 BE295488 R90868 BE269359 BE397222 RE396604 AW248304 RE307708 RE308474 AM247676
25		AW248404 AA093721 BE397622 AA093706 T09027 RF408338 RF261454 RF260628 RF205110 AF174227 RF205425
23		BE407534 BE536635 BE264727 BE296052 BE270265 BE546712 BE298269 BE547732 BE548734 BE253463 BE312238 BE261042 BE545186 BE313055 BE542602 BE538530 BE535215 BE208107 BE513616 BE295982 BE561273 BE560057
		DED02000 BE2803/1 AW247443 BE259311 AA126209 AA171445 AW674121 AA134700 BE018733 AA232357 AA134604
		MAI 14201 BE200020 BE200086 BE313195 BE313434 RE261587 AA223432 AL030212 RE260762 AL036464 RE640067
<u>ā</u> 30		AA316523 BE259727 BE260759 BE208754 BE019077 AA206899 T33021 BE255340 AA182643 BE258057 BE258040 BE254759 BE544454 AF171236 AA224410 T08700 AL037155 BE279638 W78185 BE545040 BE261376 BE261692 BE259694 AA313254
M		109090 AA397719 BED19103 BE018472 BE277966 BE278390 AA353616 AA378769 AA356685 RE564039 RE300326
		BE200308 BE543245 AF171235 BE384461 BE408141 AA137039 AI355285 RE535442 AA356783 AW675000 AI840354 W47290
O 30 W 35 M 35		BE074695 AI978750 AA316052 BE278523 BE619725 BE270953 AW026987 R89415 BE271359 BE515234 AW008497 AW386938 AI038839 AI862998 AI719458 AA113414 AI855984 AI870773 AA129452 BE047253 AW673881 AA827034 BE302302
<b>量</b> 35	•	AID/ 29 ID AW 2040/5 BE29456/ AA805899 AI625116 AA310115 AI460065 AA169760 AA955009 RE302084 AA620846
		AA640597 W63787 AI805738 W94207 AA114165 AI240462 BE349066 AA668794 AA134085 AW050730 AA13408A BEE40730
<u>=</u>		AA910015 AW248892 AW247299 AA564678 AI139117 T16008 AI754100 AI091937 AA856537 BE205770 AI199445 AA603509 AW771741 AI126994 AI000820 AI023844 AW250047 AI673263 T35536 AA126049 AI668802 T35470 AA224348 BE247113
<b>40</b>		MISO/000 AAZZ3Z33 AAZU6815 AIZ84773 AAU93396 AA113268 TU3547 AA234268 AA1U14U4 AA001274 AIZ75024 AA040055
TU TO		AA236365 AA226966 AI685723 AI284774 AW248023 AI754314 H09057 AA844271 AI272992 AA315077 AA205718 D57244 AA742550 AA219567 AI927435 AI042620 AW247957 T35545 T15567 R90845 AA719914 AI085499 AI970845
TU	117435 23179_1	AF1510/4 AF070529 AI969222 AW874125 AI198308 AW470316 AI079388 AW134783 AW206208 AI093223 AI024780 AI26420
		AISS443U AISS/9/9 AA928091 NM_016496 AI074817 AA663800 AW300768 AW264438 AIRRASOR AI025102 NI27628 AI400456
₩ □ 45	102459 3556_1	BE044999 Al277491 BE044964 AA095316 Al076515 AA836677 Al942491 T80147 Al417945 Al668895 U48936 L36592 X87160 NM_001039 AL036606 AL036420 U35630 AW298574
	125324 1692163_1	R07785 T85948 T86972
3 727	101809 32963_1	M86849 AA315280 NM_004004 AA315269 BE142653 AA461400 AW802042 BE152893 AW383155 AA490688 AW117930
••		AW384563 AW384544 AW384566 AW378307 AW378323 AW839085 AA257102 AW378317 AW276060 AW271245 AW378298 AW384497 AI598114 AW264544 AI018136 AW021810 AA961504 AW086214 AW771489 AW192483 AI290266 AW192488
50		AW30449U AWUU/451 AW890895 AA554460 AA613715 AW020066 AI783695 AI580408 AI047637 AW264474 AW204404
		MID 10/32 AW308530 AW368521 AW368463 AA461087 AI341438 AIQ70613 AIA49400 AAQ47494 AAQ67746 AIQ90000
		AW769275 AW023591 AI160977 AA055400 N71882 AA490466 AW243772 AW316636 AI076554 AW511702 N69323 H88912 AA257017 AI952506 H88913 AI912481 AA600714 BE465701 N64149 C00523 N64240 AA677120
55	125375 163544 126008 190485_1	H/Z9/1
33	126027 327799 2	AA827860 AA253460 AW971543 M61982 AA491766
	103163 43223_1	AU077018 X67683
	102515 10404_1	U89337 AF019413 Y17868 AL044866 M25813 AL042665 N77388 R00971 BE392997 W52502 AW797536 X71937 BE394176
60		T29553 AA114976 AA114835 AW316671 AI799888 BE044614 W51953 AI498690 AW580466 AI972232 T58430 AW137401 T58462 AI870560 AI696138 F33285 U52696 Y13782 AW292936 AW375206 AW751873 AW352417 AW375162 AW375201
	120055 14020 4	AW3/5188 AW3/5198 AW3/5178 Al024335 AW375169 X71927 U52701
	126055 14930_1	H65527 N28990 AA359399 N24306 H65329 AA056928 AW504127 AA486661 AA040017 AA634817 AA595340 T93478 AW015508 CO2093 BE513950 AW410741 AW193200 AA813934 AW439574 AI077876 AI954356 AW629350 AI612865
65		AW6/3063 AAZZ6255 AI816714 AA010653 AA973778 AW276616 AI277607 AI218492 AW275190 AA911289 AI302550 NE2061
65		MIZ44400 MA/US434 AAB/0151 AIZU6461 AI354477 AA954030 AI241127 AI187313 AWAAAAA AWATA28A AI2659AA AA272400
		Al202853 AA906037 Al241581 AA134769 AW074122 Al004585 BE300852 AA873196 Al813620 AW504945 BE619639 AA037624 AA641954 AA037625 AW814771 AA134768 N73248 R02524 AA226533 AA216115 R29049
	126065 34268_1	AAZZ1U3Z AKUU1651 AW732625 BE140495 Al366484 BE297579 AL039675 AL042804 AL678076 AL042802 DE200962
70		AISO 1404 AW 19050 1 AWU2/201 AAB64499 AI344032 AI432437 AIQ34618 AA572961 AI499074 AW769929 AA947994 AI955647
. •		Al342638 AW974120 Al761488 Al289643 Al564533 AW272378 Al796156 Al867205 AA884306 Al766564 AA456581 AW769937 AA713594 Al383037 F24965 AL 137599 BE259667 BE313085 BE383358 AA322347 H67555 AA298993 AA304712 AA377693
	122640 470 4	DE321037 ALOH 1340 BE273248
	132640 179_1	AW162087 AA224538 AA471218 AA088655 AA375275 BE440052 AF090891 AA324435 AF063549 AI110675 AA322223
75		AW953306 AA233590 AW949864 AW949859 AA383721 AA081878 U33821 NM_006024 AA350900 AA081588 AI148087 AF268075 AA088185 AI142478 AA081824 AI887930 AA070570 BE185248 AI459825 BE257794 AA420459 AA420859
		AA777997 AA081219 AW815721 AW854758 AA157932 BE018208 AW378974 AL041212 Al247564 AW581897 Al002897

	5		BE543242 Al811690 AW852076 AW852270 AA360969 AA094943 AA090680 AW601554 AA099673 AA662226 AA356814 AA330174 AA187544 C02751 AA315460 BE168358 AW080447 Al813764 Al624222 AW156901 Al954032 AW473780 Al861975 AA173643 AW511541 Al951492 BE301686 AA669760 BE182212 AA081009 T69431 Al186207 AA604124 AA707346 AA173953 Al016700 Al125916 AA358962 Al673719 T90593 T90497 T10776 AW513002 AW304292 AA724885 AW474759 Al811621 AW068925 AA666305 Al580161 Al128023 AW471151 AA534849 AA666358 Al078833 Al139223 Al244874 Al381658 AW263441 Al432440 AW802882 N66401 AA224251 Al167469 Al141060 AA099214 Al537130 AL120428 AA948655 D53110 AA076099 AA938617 AA826543 Al357914 AA565098 AA807994 Al288812 AA632832 AA157933 AA639802 AA634268 AA282337
	10		AA551431 AA557374 AA256923 AA872943 AA009665 H89626 AA810386 T92925 T36145 AA632190 AA130436 A1686635 AA130437 AW392904 AW392839 AW392848 AW392836 AA729737 AA070450 AW392890 W04825 AA771848 AA084634 AA481985 AI263840 AI801006 AA235380 AI954229 AI559330 AI208724 AA887638 T25894 AA041269 W44443 AI581770 W46171 AA878485 W46535 AA197336 AA894945 AA394224 AI766834 AI582590 AI033007 AA481889 AW190598 AW392855 R27279 AA398137 AI248407 AI241386 AI991753 AI826585 AA865699 AI096806 AI833030 AA041279 AW888745 AI703279 N70572 AI912553 BE549931 AI240422 AW376187 AW591692 AA975905 AW614967 AA009666 W44332 AA664659 T06561
	15		BE468150 Al650695 AA587920 Al473310 Al032991 AA256499 AW104241 BE163782 Al984973 BE163613 Al263906 AA628191 AA282072 BE163769 BE163775 Al492939 Al473315 D56907 AA587930 H89480 Al362373 AA598483 D56595 Al167590 C16223 Al935415 D62555 D62884 D63130 Al760286 Al650286 AW173598 Al499145 Al122566 AW903408 Al810569 AA854936 BE049510 D62065 D61900 D62101 R27475 Al469835 Al669086 N80399 N48922 N48746 AA481381 R22858 H13912 AC004549 AW602500 AW768788
	20	102571 315	61_1 U60115 NM_001449 U29538 F01103 U60118 AW612050 F33160 F37125 Al138362 AA853999 Al700031 AA868700 AA411791 AA782026 AA861693 AA430022 F29006 Al026854 AA236496 AA100266 R60856 AW606023 AW380619 BE150801 AW391508 Al682304 AA947687 Al284419 AA782989 F00277 Al202147 F01221 BE161576 AW385226 AW361913 R30713 AW607124 AA505577 W96539 T74511 AA211624 Z41920 AA263163 AA216297 BE164746 H56334 W03318 H51047 AA104746 AA214637
H	25		219273 N35688 AA702365 130562 F00587 AW367294 R58121 W47367 AW608017 N45005 N42952 N69255 AA179110 AA196349 AW376390 Z19411 H56335 AA197096 AA651681 AA873207 H61734 BE140426 AA047105 R64437 W45585 AA149058 AW984577 AA192500 AW984588 AW984523 AA037874 W93436 AA195586 Z19330 AA523870 T92443 AA149059 BE166015 Al033716 AA725097 AA456394 AA180784 W02792 AI921585 AA211488 AA192626 AW364704 AI819174 AA193240 AA130173 AI337854 AA181265 W45548 AA779753 AA211417 AA197031 AA037875 AW60501 AA037344 AW024376 F00540
	30		W96433 Al394501 Al150206 Al827777 AW130567 Al932997 T17424 Al288559 R52400 Al806130 AA126040 AA669576 F25175 Al148159 Al041869 AA860296 F25175 Al948570 AA77424 Al288559 R52402 Al806130 AA126040 AA669576 F25175 Al148159 Al041869 AA860296 F25175 Al948570 AA77478131 Al276508 Al948577 AA114870 F32631 AW028047 F35241 Al373951 AA114869 AW138423 Al889537 F24663 F27705 F37165 Al392774 F29432 Al090589 AA450321 F24561 W93346 F29070 F25579 F31362 F33440 F22652 F31494 RF169905 Al818513 Al88075A F36378 N38874 F23629
	35		A362282 Al131185 Al763075 AA868225 F22733 F35957 F33418 F34871 AA085944 AA035499 F28471 Al653552 BE047474 Al362282 Al131185 Al763052 Al028105 AA211569 AW241290 Al086746 F33041 Al767780 Al080600 AA101717 AA086422 F32855 AA047242 F33893 F29113 F21510 F21509 AA039540 F26344 F29047 Al937919 W19338 N40995 F31929 Al084510 AA026507 AA086200 AA207130 Al399877 F21370 AA733197 AA086205 AW340573 F33682 H05220 F25782 F25048 Al127208 F29940 W47368 Z19261 N29900 F25141 F32890 R63826 F35206 F30119 AA706742 F35143 F25142 F33509 Al550403 F35934
	40		F24027 F33960 AW028172 F24674 F36597 F21959 AA729612 F34366 AA732967 AI582660 F29363 F22674 AI086792 AI804183 F33102 AW075510 AI367611 AI784054 AI453418 F34901 AI161157 F26622 AA651987 F35237 AA013303 F32632 AA664876 F21736 AA928616 F21384 F25357 F23467 F31185 AI537850 AI8689852 F31707 AW089232 AI363826 AI702766 AA136298 AI767887 AW089312 AA578225 AA130181 F19251 AA581649 AA449418 F23171 AA455236 AAA69333 AA464070
W Du	45	404000 000	AA455054 AA729265 F04647 AA746994 AI658702 AA478718 AA747182 Z38215 AW075230 AI159764 AA134668 F00420 F33094 AA455054 AA729265 F04647 AA746994 AI658702 AA478718 AA578161 AI080025 AI352604 AA989440 H30904 Z28506 F22649 F34880 D45580 C20561 T32638 AA020946 AI439878 AA746991 AA194883 AI219226 Z45773 AA089657 AA180825 W25548 R58180 W46675 N38870 AA137104 AA026506 AW984583 AW984539 AA020945 AA035101 AA039539 F30993 H14793 AA211688 T91484 F34313 AW815933 F39167 F31099 F31949
	50	101923 30543	U47734 AA837575 NM_005564 AA329732 AA421943 BE171567 S75256 A1750047 AI762213 AA100735 AW612993 AI474120 AW062884 AI940001 AW062852 AW062889 BE182639 AW778875 AA528093 AW517424 AI939989 AA076188 BE182636 AA169569 AA167439 AI283967 AA167783 AA076140 AI749649 AA166792 AI708618 AA400973 AA514773 AA514789 AA164458 AA167440 AA074845 AA421944 AA514874 AA079557 AA102361 AA587027 AA647870 AA674780
	55		AW176400 AW470086 AA857522 AA148193 AA838234 AA593897 AI284506 AW193324 AA148194 AW583341 AI669077 AW264913 AA074902 AI680515 AA169874 AA169614 AA079651 AW591737 AW190644 AA076565 AA662747 AA075896 AA535642 N27757 AI306666 AA074727 N79823 AA524360 AI826800 AI73827 BE140374 BE004062 AW265060 BE184103 AI199258 AA857853 AA299459 AA837890 AI626104 AA503624 BE183618 BE183717 AA573267 AI833071 AW270590 AA506601 BE004010 AA837854 AI675895 AI810491 AI184883 AW664712 AA075046 AA515574 AW262367 AI707419
	60	126117 16104 126122 82445 126136 28536 126168 20960 126196 21198	.1 H80181 AA005287 )_1 H85525 H83353 AA418447 .4 L44530 AA322034 T79009
	65	102675 5145_4 118387 65081 126256 10840 126291 86990 104008 27385_	U72512 T98357 R31335 F18090 -5 N64579 1 AK001774 R02029 Z21327 R02030 Z21124 1 AA017609 N42090 AA984485 BE177239 Al912269
,	70	101000 21303_	W38395 W24693 AB033047 AA159179 AA588310 AA654615 AA630891 AA639240 AL121157 N79820 AA653941 AA279925 AA132883 AA253947 BE502673 Al191149 AF208847 NM_016620 AA132773 AA532724 AA933782 AW997589 AA749442 AA356531 AK001587 AW500170 AA369990 AW582815 AW582838 AA451773 AA233995 AA427982 AA334630 AA282933 BE349308 AA300682 Al384093 AW364014 R31977 R69849 AW364012 AW364015 AW364019 N76465 BR0458 AL987670
1	75		AI760785 AW628405 AI224905 N59362 AI351352 AA513728 AA729606 R80659 AA573139 AW614666 AA310325 AW471080 AI091339 AA830587 AI051323 N67319 AA621436 AA449856 AA648966 AA954973 N51766 AI952427 AA829053 AI468601 AA649186 AW592210 AA449968 AA465374 AI474865 AI185456 R31932 AA621108 AA975015 AL121156 AW962752 R69850

	103417	15279_1	L34657 M28526 NM_000442 M37780 AW407571 AA488822 AF281299 AF281296 AF281297 AF281295 AF281301 AF281298 AF281287 AF281294 AF281293 AF281289 AF281289 AF281290 AF281291 AF281292 AF281300 BE140137 AA082477 AA182953 AI902545 BE185251 D58483 T73117 AW902845 AA303912 AW403488 AA039356 AW401604 S66450 AW371090
5			AA477959 T97049 AA486710 AW607916 R76264 AA303959 AA385484 AA181062 AI218959 AI384084 AW387030 BE044508 AI942423 AI910438 W04423 AI148494 D58775 C18167 C18011 R68293 AW340705 AI587613 AW772278 AI942486 AA304612 AW276352 N41586 AI248619 AA151818 AW593959 AW137371 AI470913 AI916891 AA181063 AW261863 AI271376 AW007613 AA359765 AW874428 AI033514 AA181110 AA181092 H57149 AW514341 AI971318 R95876 AA713790 W93076 AI936184 AW665574 R82381 R82269 R53795 R26391 AA989385 AI076568 R68262 AA716613 AA933639 AA678079 AI686366
10			AW294984 N30812 AA486245 AA693877 T95097 T72992 AW193473 AA001726 AI808737 AI247488 N53545 R08174 AA305676 N76004 AA761616 R78126 AA564715 AI031710 AI913454 AI475239 AI081733 AW264881 AW518741 AI783794 AA449390 C15249 AI922914 AI498549 AI808250 AA486711 AA002005 AA035777 AA151817 AI834300 AI168387 T96940 AI675272 AA056355 AA299130 AI127297 T95197 AI818125 X96849 AA486244 W93075 H57223 AA302220 R22071 R33251 AA301548 R95875 AA372192 AW838188 H01353 R78125 R22459
15	103425	30014_1	AB016092 AB016089 AW161159 AW160794 AW163150 AA776677 AW168207 AW161625 AW157477 AW157176 AI739521 AI906428 AW073890 AW467016 AI745171 AA738238 AW090343 BE245923 AW002703 AW293743 AA249074 AW328076 AW328075 AF161338 AI991472 AW515714 AI655953 AW393827 AI653282 AI652717 AW393832 BE550526 AI654896 AI203310 AW590658 BE550597 AW390889 AW390900 N93494 AI654677 AW573041 AB016087 AI874387 728839 AW890640 BE168075
20			Z25196 AA743746 Al906104 AW402640 AA833814 W03404 AW881095 Al863478 BE019680 BE163120 AW939109 AW939159 AB016090 AW939112 AW939162 AW939157 AW939107 AA229457 AB002322 BE081002 AW895217 AW367778 AW502353 AW502650 AW372535 AW372524 AW372551 AW372527 AW372544 AW893113 BE147617 AA347209 AA772783 AW892035 H38889 T19958 T19957 BE171421 Al902871 M78867 BE167584 Al902950 AW862975 AB016091 BE168093 BE087521 AW603182 AW499660 AW499661 AW503473 Al902486 AW752292 BE174018 AW752296 AL041888 AW363953 AW605221 AW605216 BE142816 Ak35786 AA683040 Al907872 AW369725 AA380303 AA836230 AW419434 AW501816 AW502342
25			AW502333 AW499671 AW502991 AW501843 BE168376 AW501486 BE245921 AW372603 AW319434 AW501818 AW502342 AW302609 AW372601 AW372601 AW372608 AW372609 AW372612 AW372607 AW753096 AI902532 AI902594 AI902533 BE062377 AW811106 X97301 AA315458 AL041463 AA287787 BE544417 BE311801 AW797378 AI940181 AA326261 AA326712 AW964943 AW751304 AW751303 AI940199 AI940192 AI940189 AW751305 AI940167 AW176500 AI940202 AI940190 AI940201 AI940196 AI940203 AI940210 AI940193 AI940177 AI940179 AI940204 AI940171 AW382746 AW382738 AW751312 AI940753 AW062939 AW803210
30			BE17/5400 BE17/5388 BE094921 F28478 BE066456 AW372263 BE066575 BE066320 AW372262 BE066580 BE066455 AW576937 AW392415 BE183395 AA381175 BE388469 BE066460 BE066315 AA377951 AA171585 AW605004 AW605007 AW934766 AW934869 AW580606 AW605280 AW834728 R83817 AL121069 R20109 AA291361 AA524293 AW374653 H30144 H44678 W24212 W06948 BE247374 BE180909 AA778442 AL041464 AA172255 AI962941 H26136 AA995288 AI921770 AL040081 AI913019 AI829562 AI339531 AA837865 AI375317 AI762975 AW338852 AA938195 AI982701 AA682389 AW001082
35			AW591316 AW173712 AW005552 AA039605 AW002560 AI559320 AW272286 AA045667 AI799670 AI803146 AI374801 AI811885 BE326490 AW276312 BE049418 AI986113 AA286830 AI634266 AI198953 AI202521 AI380918 AA999947 AI492102 R83376 AI337411 AI962358 AI635535 AW241544 AW003959 AI144276 AW576619 AI926506 AI889528 H43845 AW050926 AI380249 R43161 AA581617 AI983302 BE465975 AI345956 AI341427 AW576619 AI989035 BE350636 AI582500 AW316665 AI439844 AI804761 AI470679 T32375 AI570375 AI273528 AW796804 AA658160 AA652859 AA573941 AA573555 AI388272
40			AA373947 Z24817 AW576624 AA428059 AW023495 Al033000 N49249 Al969076 AA205445 Al636203 T30328 Al394724 AA403302 Al968272 Al492974 Al582619 Al470826 AA894924 Al912962 AA569977 Al675362 Al473131 BE046814 AW300260 T31879 AW168376 Al659621 Al810463 F35064 Al271700 Al699563 AA776537 T36184 AA565451 Al678338 AW438921 R16094 N91497 AV662182 Al432919 AA910303 N91964 F18684 AA381902 AW364462 Al276689 AB015644 AW247214 BE047724 AA347210 BE391395 H81815 N67777 BE208123 AW939117 AW939167 AW939172 AW939172 AW939173 AW939188
45	103436 4: 102806 8: 103491 3:	441_2	AW605520 AW605509 AW605515 AW939122 AW939171 AA229095 AA229096 AA229232 BE382710 AI902544 M78278 AW799890 AW889685 AW863018 X98206 AA693431 AA244304 AI246240 AF124733 NM_016358 U90306 BE407995 BE281254 AI566193 AI652266 AI671516 AI950190 AF264750 AA904457 AW884708 BE183627 Y08478 AW962945 AA305849 Y08478 BE255205 BE2558400 Y08468 AB040020
50			AA913906 AW73059 AA904722 AA135076 AW997220 AA090128 AW137099 Al640514 AW592676 H01987 AA134913 AA599219 AA913906 AW773059 AA904722 AA904721 AA368411 W04955 H82698 AA077280 AW014128 A1191700 Al298476 Al540051 H82435 AA774512 N53899 Y08482 AA332025 AW965281 AA331817 AW803125 AW992770 AA329962 AV659521 R78277 R75636 Al681382 AL079859 AV659778 AA314956 AA127627 AA116095 AA121529 Al693624 BE612540 R21914 AA135986 Al697706 AA234595 Al189138 AW055042 Al144389 Al263904 Al400175 Al275540 AW907221 Al742468 Al078032
55	400000 40	N5000 4	AW196435 AW291117 N68458 H73663 AA116096 AA236552 AI983684 H73722 AA282356 AA932090 AA811462 AA737189 AI636190 AW873132 AI468635 H01064 H13088 R22563 BE539692 AI581680 Y08470 AW836778 BE080692 AI091839 AI572125 BE006050 BE006047 AW836837 AW501631 R09599 AW973566 AW263143 H61053 AA553507 AI214982 H02081 AW997046 AW505183 BE143139 Y08836 Y08477 H73356 Y08465 H73223 N91302 AA641936 Y08464 Y08466 Y08483 Y08481 AA506064 AW807922
60	126363 18 127008 17	- '5968_1	N94706 AW302202 N54724 W01777 Al949662 AA917338 N50068 Al857652 BE550711 Al340079 N63025 AA971513 Al467976 Al694919 BE328279 AW206626 Al310369 Al307346 AA425773 Al862813 AA628674 AW475016 H10786 Al932791 AA244420 Al567886 AA621126 AA244453 AA369087 Al678489 AA223753 AA223879
65	127027 41	793_1	AL390088 BE207034 Z42964 BE242833 AW583731 BE616399 BE621126 BE272661 BE561537 AW328160 BE513636 AW732368 AA367575 AA317809 AA325684 AL043346 AW997819 BE207681 AA442690 N33908 AA329967 AV661996 AA364929 AA132857 R41876 W30718 AA340232 AA923628 BE618790 BE383719 BE384891 AW973886 AI680631 AL042633 AL044048 T64995 AI814372 AA046927 AA707444 AI351042 AW157778 AW303835 AA559116 AW157476 AW440951 AI146410 AI570583 AW473765 AA931145 AI654587 AI089717 AA132763 AI199778 AI144493 AW473769 AW087749 BE166742 AI089476 AW363264 BE206437 BE222620 AW615413 AI356436 198622 AI674887 AW583314 AI081960 AA133159 AI932568 AA641830 AW265135 AA54366 AI390458 AIS64368 AIS64368 AIR64887 AW583314 AI081960 AA133159 AI932568 AA641830
70			AW245125 AA543056 Al289158 Al538987 N67489 AW836308 Al042462 AA639343 AA706144 AA653493 Al363727 AA724790 AA596032 BE277184 Al126007 Al241020 AW627956 AW440961 N30676 Al806651 AA583594 AA732028 AA731516 Al439229 AW995619 AA133204 AW248060 Al914553 Al689519 Al521043 Al566390 Al245111 AA594407 Al797417 AA131580 AA035240 T33853 Al362604 AA535337 Al273040 R68453 AA043655 Al587360 AW572022 AA935227 Al697259 AA749181 BE263051 R68454 BE560435 BE277826 Z49985 U30174 D61707 BE390825 BE618267 U30173 D61706 Z49984 BE268853 N99057 Al874052 AA568135 R68452 H21498 AA043654 AA046984 AA362959 AA035318 R17261 AA131629 BE166750 BE298260
75	127036 115	50_2	N25142 Al468598 AA232868 AL043752 AW881016 AW881015 AW881214 AW880761 AW881018 AA255767

	103513 42559_1 127041 1534405_ 126406 95703_1 127064 1690305_	N76683 AA034096 AA034082
5	133660 27207_1	H14843 C14857 F06523 AA322683 AW964649 H83334 AW894647 AW894608 AW578353 BE007437 AW894648 AW894609 AW896993 AW897085 AW581270 R36029 AL117536 AW896412 AW993019 AW859782 AW859772 AW376619 BE082963 AW376687 H24066 AW847946 AA091541 D51576 D52043 D52146 D51628 D52155 D51675 D51777 D52101 D51603 D51843
10		D51878 D51751 D51820 AA319632 AA351569 AW630840 BE073033 D51985 AW838560 AW838633 AW838631 AW838554 AW838557 AW838559 AW608175 AW608194 AW838558 AW838562 AW838564 AW838571 AW608170 AI926544 AW608177 AA296774 AW838624 AA318941 AA319199 AW960724 BE073078 AA773508 AI925495 AI889128 AI633207 BE221497 AI126062 AI344458 AW608176 AW838627 AW194765 AW838630 H24379 T23982 R62391 BE620113 W02397 R87373 AA364488 AW963466 AI696793 AA012998 N72571 C18550 AI298061 AI084648 D51984 C14379 D52154 T03606 AI499301 AA017178 AA017170 BE077301 AI889566 AI002790 AI205010 AW104793 AA298374 AI049720 D51575 D52042 D51627
15	102934 1611011	AI281148 AW104111 AI142928 D51601 D51842 D51819 D52600 AI242074 ALGAD247 ALGAD265 ALGAD265 D45004
13	126479 1297811 1	
	125877 18687_2	T78141 T75126 AW953462 AW956923 T08967 AW969436 AK000755 AA176076 BE258269
	103650 43833_1	H16443 T66760 H11411 Z70220 F12208 T66258 AW950931 AA350846 H06005 F12617 N51174 T74154 R87613 T33928
		Z45881 AW961235 T31307 AW891440 H24171 R18227 R19098 W26891
20	127191 206872_1	AA625286 AA297581 AA303053 AA303052
	103682 41323_1	AF275815 AA018302 AA000993 AA021290 H86017 R69197 AA056286 R88858 AI570404 H43774 AA059385 AA010839 AA056237 AI436578 AI769179 AA019840 H86715 H84086 AA000994 H85881 AI762043 AI079265 AI738426 AI654986 AI738440 AW197623 AA021232 AW161646
25	126568 163056_1	AW749469 W68106 BE162986 AA190515
25	125925 1502610_1	BE550996 H28737
	125952 87085_1	AA017723 H40709
<u>ļ</u>	125953 1582862_1 104328 243947_1	H41682 H40829
	104340 46289_10	R11272 D81932 AA426189 F15201
<u>_</u> 30	127231 221630_1	AA317400 AA434584
	126619 186375_1	AA247746 Z28861 Z18915
Ш	126621 164483_1	F01180 F22065 F21334 AA192638 Z28873 F31558 F33176 F30552 F35761 F18952
74 H	119404 115373_1	AA302840 T93016 T92950 AA077551
□ 35	127331 379388_1 127347 133106 1	F20186 AA622352
口 35 即 口	_	Al922293 Al123420 AA833906 Al417534 AA402715 AW275969 AA470879 AA402585 AA425800 W74482 AA410632 AW051466 AW057511 AA443121 AA121406 F09029 F37501 Al909933 Al909928 Al909925 Al909932 Al909931 Al909926 W79080 AW958666 AA312211 AA428350 AA410631 BE382380 BE394251 AA122083 F11368 F05224
5	127357 288073_1	AA424107 AA452788
□ 40	127359 163544 127378 299674_1	H72971
mi TO	126730 297653_1	AA446387 AA452696 AA442429 T19477
	126759 109907_1	AA063089 AA679118 AA063642
TJ	126762 110350_1	AA064613 AA064671
ا الم	126767 327401_1	AW968865 AA491199 C17148
_ 45	112309 1576900_1	R55021 H26613
Ū	128099 501940_1 127452 327502_1	AA905327 AI148973 AA504447 AA491317
	126808 121207_1	AA662559 AA086320
	126844 133298_1	AW881997 AA121637 AA299325
50	103985 19574_1	AB032251 AW852071 AA279887 AW852124 AW129468 AI583544 AA704421 AW999851 BF081960 AW390494 AW582002
		AI862331 AA/00432 AI186130 AI720707 AA236286 AI336961 AW015054 N91172 AI698141 W32818 AW896124 AI701519 AW894048 H87416 AA234040 W17142 R84565 AI803033 AW867682 H27242 AA366224 AA357157 H86935 BE090270 AW753846 AW362772 BE464864 AA704907 AA704948 AA704938 H27235 AI033427 AW850923 AA480900 AW502880
55		AW851237 AW851374 BE252815 AA084307 AA313880 AW961200 AA480961 AF114105 AF114103 AA486042 AW375963 AW752365 AW375959 AI290321 AA488659 AI242380 M85386 AI825492 AW499531 AW502114 AW502349 AI825312 H45002 AA177096 AA248058 AA252844 BE327236 AW418631 W74679 AW582000 AW390459 AW609218 F05276 AA425478 R14173
		AW609219 AW868913 AW868954 AW868905 AA333683 H02382 T35574 D12400 C14910 AW894285 AW903587 N64611 AW975302 AA541375 AI479002 AW006220 N51384 AI142472 AA659902 AA534253 D58103 H02279 W74710 H44955 AA425278 N59267 H28589 AA804452 AI191286 AW197903 AI864639 AI122991 AA469450 H28584 AA252812 AA467779
60		AW130113 AW872897 AA789290 AA935730 AA906959 AI990477 BE504778 D57881 AA721144 AI341486 AI638797 AA765502
		210003
	126872 142696_1	AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE 168945 AA809054 AW238038 BE011212 BE011359
	127553 202308 2	BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
65	127568 479942_1	AA505046 AW969109 AA505047 AW892676 AA853877 D44747
	126977 171173_1	AA210697 AW962138 AA309665 AA210819
	126982 171753_1	AA211419 AA211566
	113195 178688_1	H83265 T63524 AA304359 AW960551 AI672874 AI749427 AA227777 AW027055 AA971834 T49644 T54122 AI983230
70		AI608233 191264 196544 AI350945 AI709114 R72382 T48788 R48726 AW385418 AI095484 T49645 AA928653 AA570082
70	400000 00404 4	AWUU/545 T5/1/8 AA516413 AA913118 T5/112 AA564433 AA774503 AA367671 T59757
	128260 38164_1	AF119848 AI132994 AA505575 AI307657 AW205687 AW291922 AI347642 AI308117 AA398902 AA741579 AW269612 D73957
		AW418818 123611 Al016388 AA641630 AW009309 Al078310 AW263980 Al971867 732873 P00068 AW028860 P57007
	128279 1561282 1	AA402507 AW965254 AA114126 AA331445 AA333324 H18818 H08885

		113213	23798_1	NM_001395 Y08302 Al434619 Al470328 Al261807 AW024965 Al806537 Al830549 Al640337 Al219065 AW271700 AW028488 Al133339 Al859205 R51175 U87167 BE379324 BE392008 AA340819 AA343110 T57275 D59164 AW299312 Al434422 Al936390 AW024975 R40262 AW269126 R09430 T56590 Al367247 Al253132 BE464248 T58658 AW207785 T58607
		120461	22556_18	AA810830 AA251301 AW962926 AW962922 AW962925 AA371510 AW817535 AW817579 AA251629 AW837817
	5		966283_2	AJ003322 AJ003324
			458957_1	AA809310 AW975709
			93768_1	AA541537 AW009489 AW950203 F25552 AA834645 N56270 AA029543 AI633587 F30948 C04983 AI628613 AA885458 T49449
				F13651 AW004753 AA369573 AA356955 AA355112 T49448 AA918022 AI910358 H40428 AI292038 AI684655 AI244426
				AA522725 AA352551 AA909796 AA494329 AA873880 AW957305 AW955082 AA552169 AA974888 AA977363 R93237
	10			AI865725 AI201852 AI244721 H40429 AI204631 AA029544 AI015353 AI245274 AI191342 AA662656 AA829667 AW001837
				AA626833 AA585220 AA522987 AI339186
		128410	288073_1	AA424107 AA452788
		128440	210591_1	AW090340 R52194 T87269 R17095 T91445 N76763 R82785 AW512315 AA534961 AW002002 H41133 AI985800 AI278720
			_	AI762576 AI798477 AW081499 AA314880 AI918168 W92216 T91358 T79785 F04683 AI824664 T78491 AA302483 AW958008
	15			T85160 T87183 R11236 R16208 F01406 AW150480 AW627337 T79354
		. 127854	443883_1	AW976796 AA769520
			39874_1	AF169690 F08337 AA282956 AA282955
		120734	208882_1	AA299948 AA299949
	20	105897	8177_1	H03573 AA310766 AL133603 Al700910 H00505 R82804 H60605 T10498 BE176241 N99617 BE537165 AA443413 H02733
	20			AI267539 AA094718 AI299771 N50199 R64087 AA709363 R26971 AI962859 H03899 H03888 R63010 AI346026 AA328951
				AI025251 H89260 AI472009 AW029442 AA211594 AI310418 AI913561 AW515607 AW593597 AI926843 AW073920 AW002745
				R62957 Al439422 AA401091 H58246 R82805 Al174264 Al590100 AW510481 R26739 H02624
			17246_13	AF002224 AA017358 AL119785 Al379446 Al632616
	25	106782	83684_1	AW054886 R48313 Al200750 Al358095 H28124 AW613845 AA010033 AW182407 AA010034 Al986052 Al032851 Al719051
	23	444040		AA478487 AW410484 R48418
			117244_1	AA525225 AA525299 AA081079
H		114636	109698_1	AA075488 AA129081 AA074851 AA082852 AA074732 AA084908 AA084751 AA076042 AA131172 AA085374 AA079519
				AA074510 AA113824 AA102437 AA070833 AA070143 AA084693 AA084389 AA076373 AA075492 AA062834 AA084335
=	30	407540	45045 4	AA078829 AA079344 AA069916 AA079275 AA070914 AA654069 AA081976 AA080957 AA083115 AA070942 AA085296
	50		45315_1	X60152 Al871483 Al871473 Al871251 Al631860
Œ		120/321	44111_1 23038_2	X78262 AL037659
7.		130420	23036_2	NM_003105 U60975 Y08110 AW501858 AA984813 AL042811 C14671 D59983 AW996611 AW502726 AW408730 AL120016
				T07220 AA972515 BE169618 AA053753 N45548 AV655750 AA485180 AW080066 T51689 AA714788 AI089413 AA748187
	35			AA744864 AA977151 AW167224 AA465100 Al692864 Al800689 Al419483 Al915371 Al264290 Al919227 AA687175 Al498499
				Al089844 AA721674 AW291409 Al377801 Al049681 AA767458 AA053631 AW473092 AW079490 N48698 R38875 AW501274 Al817699 AA847277 AA761843 T07221 AA873077 AA568215 T51538 Al474852 AW505117 N50751
		100403	19804_1	AA302974 AW952936 AA297841 T17453 AL040862 AL042305 R18514 Z45908 H09477 R51937 H02949 AW672666 AA339081
				AW024007 AI910124 R41507 R02276 W72600 AW606045 T30584 AI968122 AA532894 AA047712 AA024602 AI814501
₽				Al479333 H09478 Al801077 R63410 Al469769 R63363 AA731181 W67437 AA613000 AA125822 W60322 Al199934 Al032499
	40			AI673744 AW675418 AA594241 AA047679 AI148807 AA948543 AI805752 AI362640 AA883795 AI873413 AW292015 BE503009
T.				AA960821 Al302435 AA911051 Al192308 T31342 AW589705 T32492 AW384043 Al968407 BE501316 AA074832 Al611662
; \( \frac{1}{2} \)				AI969799 AI216685 AL117466 NM_016733 D85527 AW992053 Z44073 BE078508 R70709 AL046533 AA402079 AA125952
N				AA337799 BE252284 BE253079 AA325230 C18518 W67436 T83901 AA353025 AA024601 BE068484 AA782927 AA401915
, 				AA369003 R53606 W76565 AL040863 W60241 Al967950 Al424849 Al582302 Al769611 Al394573 Al949294 Al656190 Al885933
	45			AA670336 BE465592 T17452 Al569505 AA075098 Z41532 T35104 Al699545 R02275 AA368470
Ū		100476	24092_2	NM_001907 X71877 X71874 BE140276 AA748397 AA213801 AA830996 AA765114 AW874469 AA811623 AA844904 AI371956
ΙΨ				AW451919
		108360	112653_1	AA129037 AA071539 AA071460 AA129036
	50	108390	112416_1	AA121999 AA121985 AA071108 AA071116 AA071434 AA148869 AA075070 AA122000 AA121986 AA071117 AA071109
	50	100202	112540 4	AA148655 AA075232
		108392 100534		AA075124 AA075208
		100004	20000_30	T85231 AW161503 AW401856 BE397508 BE387085 BE514425 BE387606 BE391894 BE562022 BE561561 BE537755
				AA326129 BE397421 T49865 BE259375 BE562435 AA206146 BE272379 AA206012 BE252021 BE264415 BE559498 BE622499
	55			BE560425 AF141349 AF070600 BE260687 BE267430 BE273769 BE409463 BE378506 BE410826 BE540360 BE514334 BE265991 BE259493 BE257982 BE541302 BE275305 BE249816 BE263407 AA306533 BE312339 BE537252 BE313173
				N44590 BE397957 BE314066 AF070593 AF070561 BE395620 BE539980 BE278635 BE622457 BE561276 BE561240 BE539757
				BE398025 BE539587 BE264804 BE312816 BE618175 BE312236 BE536880 BE275163 BE409064 BE268157 BE256878
				BE396565 AA094095 BE512689 BE539943 BE613640 BE561500 BE314652 BE560895 BE270780 BE394023 BE314771
				BE258043 BE545484 BE539560 AI524946 BE268922 BE313646 R21491 BE257007 J00314 T55776 BE514288 AA079759
(	60			V00599 AA090885 BE268939 Al424151 BE393150 BE513223 BE311978 AA427899 Z36874 BE267470 BE270600 BE270542
				AA092574 BE513746 T56664 BE260686 BE561863 T80533 BE614348 AI003020 AA196886 BE395929 BE256732 T80512
				BE561248 H10806 N23553 AA090625 BE378633 BE299481 BE251134 F03598 RE158989 RE271056 RE271117 H30074
				BE537728 T95426 T93847 R15283 T82017 BE561756 BE254463 BE250916 AA522520 BE562294 BE561853 BE562013
	c <b>c</b>			BE410876 R17504 BE254605 BE254904 BE315454 BF408837 RF256847 BF259444 RF265700 RE305378 AM/860350
(	55			BE019791 BE378840 BE270975 AW246214 AA352945 AA378509 BE275472 BE389534 AI609281 BE205688 AI072188
				BE388702 AW351598 BE617054 Al922439 BE258416 AL119346 AW351963 AW351971 RE388178 Al624652 AA780708
				BE268311 R35263 BE251613 AW366022 AW177828 AW057797 AW366021 AW177888 AW366065 RF140045 AA670130
				AA773017 BE539636 BE139520 BE270946 AW058238 AA191567 BE312975 AW089641 BE398147 BE268285 AW272508
-	70			AL119339 AW079784 Al829482 Al982828 Al862019 Al816169 Al633046 N59068 AW731944 AA093100 H03237 AW575087
•	, 0			BE301207 AW780181 BE141633 AW664164 AA626909 AW516663 AW872823 AA551910 AW571502 AI954158 AA548713
				AA599912 AA301057 AW574903 AA614152 AA613830 AW771103 AA706556 AI023390 AA551248 AA780901 AA633446
				AW419192 AA404660 W58436 AA523401 AA578734 AW615710 T65580 T57191 AA486211 AA604684 BE208800 AA669875
				AA622085 BE302083 BE263081 AA548072 AW156997 AI568868 AI627575 AA565217 AI870317 AI282474 AA704034 AI253598
7	75			BE328271 AA564664 AA161128 AA604105 AA609087 AW103504 AA605238 AA704108 AI221585 AW574515 AW117994 AA058521 AA604281 BE251293 BE017988 AI754462 AW245235 BE094031 AW862436 AW105529 BE544089 AW303918
•	-			AW130826 AI721132 AA433888 AL038189 AW474816 AW182745 AA551345 AI445794 AA398452 AI224993 AI689213
				AIDS9213

AW249709 H15542 AW196813 AA618551 Al445281 Al638121 AA807410 AA911530 Al334093 BE269844 AA847782 AW276513 AW589524 T03418 AW170654 AW468976 AA570676 AA570715 H41474 AA010074 AA600283 AI755222 AI193239 AA774176 AW770036 Al332603 Al129785 Al280055 AA666338 AW732127 AW028394 AA102641 Al920834 AA602712 H06697 Al095237 AA401908 AW250765 AA631796 AA550854 BE260391 BE614352 AI690333 AA452272 AW575264 AA878265 AA190483 AI832049 AA195830 BE439812 BE208085 AA826727 AI929438 H10785 AI520704 AI364235 AA605138 AA513116 AI250046 BE263592 BE538689 AA171900 T03755 AW241170 AA565529 AA186883 AA872245 AI251930 BE538023 AA181759 AA187178 H28109 AA115169 AA513309 BE545993 AA714730 AW897950 AA143782 T15562 T49475 AA196794 AA219637 AW574805 R61459 BE294610 AA653641 AW246595 AA122178 AA079030 BE259347 AA125802 AA223509 AA071105 AA056515 AA115965 H98828 AA975764 R44928 AA122173 AW499013 W68765 AI306457 H70716 AI866327 AA101102 AA523008 Al567597 AA146744 R88666 AA197332 Al086825 AA197306 AA127186 AA648686 Al758939 H66791 AA158684 Al423641 BE622207 H96899 AW748838 Al683391 T57141 Al360649 AA084328 AA205369 AA605035 AA730337 AA190782 AA622674 H70715 AL035929 R53569 BE410471 AA826991 BE304945 T57181 AA190793 AI826886 R61544 AA357249 AA730680 AA349636 AA598937 AW075466 W52142 AI270583 AA693372 D53633 T78875 AI874190 AI926336 AI744448 AA458786 AW019919 AI903107 AA243188 AA127188 AA085973 R50969 AW674943 AW674933 N33158 T99016 AA386238 H05817 AA227228 T93797 BE408530 AL035916 AA199872 AA196440 T61038 AI193541 T03458 H04813 T26581 AW074308 F28259 AI420254 AW406597 AI752919 AA349540 AI961511 AI026726 T16511 T61589 AI872394 AW069694 AA350697 AI766468 N84462 AA085828 AI049703 F09606 AW247712 T16319 T95336 AA427580 AA219549 N54075 BE383804 AI934238 T23636 T23966 Al540707 AA852250 AA480844 F03543 Al682148 AW029145 AA350647 T57116 AA121780 AA362506 T89452 F03033 BE544518 BE537982 Al400848 AW249805 R40175 BE547154 AW194658 BE304905 F03972 Al887116 AW662060 N64153 AW090474 AA111861 BE544487 AW247971 AW189742 AA083676 AI689361 AI865447 AA205201 AA995389 T57070 AI749217 AA620398 Al205275 BE278095 W25238 AW498851 AA361225 W24643 BE293452 T60878 BE378902 AW675067 AW419249 BE546138 BE622685 H37989 BE298837 W02581 W03143 W03350 BE090146 D56472 AA477356 AA369046 BE617569 AW405756 BE068241 H94917 R93689 BE536003 H78709 BE293724 BE207577 AA324949 AW406102 R66280 AW404427 AW498515 AA283600 BE091536 N78168 N94034 H13896 H40383 AA426247 H38210 AW381001 AW381031 AW384779 Al187246 AA356920 BE614174 AA361144 AA954817 AA373947 N51059 AA714393 AA361010 AA858368 AA128860 AA186577 R97861 BE300605 BE617658 AW407835 AA007136 W04495 AA714521 W01702 AW675093 AI129627 W23528 BE622513 D52760 AA580710 D54714 D54912 H39979 AI189140 AA604554 AA379346 AA379753 BE293739 AI247952 H19587 H23957 H22624 AA022986 H80389 H80376 W32684 H74304 W73673 BE619989 H46803 AA326012 BE256750 BE293868 AI687073 BE540791 Al554627 Al669399 Al052649 N74381 BE254994 W35343 R83888 AW405482 BE300603 AA190680 AW409945 AI565178 Z25891 H95714 AI587135 AW881291 N74433 AW580801 AI126014 AW583313 AW385805 BE392285 AI002971 R86251 AA928186 AW883103 AW577705 N47822 AW245647 AI186441 AA455487 AA876464 AA512933 R48210 AA167661 AA715724 T56604 BE315352 R25751 BE163471 W77978 AA617822 AA618045 AW973348 AA641395 N32598 N58159 AA604336 AA617894 AA748311 AA599921 AA617899 H94863 AA029390 AA706656 AA206124 AA778101 BE300604 T15728 W57648 AW575696 AA029389 AA599861 AA640585 AA613863 AA526077 AA577614 AW575035 BE183827 AI709081 BE183680 AA330412 AA580149 AW574766 AI609157 AA557458 AI801804 AW085646 AW339731 AA907669 AA489663 AA486665 AW166938 Al500319 AA181843 AA605173 AA486566 W94458 Al623349 AA858195 AA558201 Al249662 Al092843 AA905720 AI682690 AA773433 AA434385 AA022948 AI249681 AI619676 AI084530 AA554408 AI376770 W35304 AW574722 AA279871 AA641309 W00970 AA564566 AA206053 AI682641 AI686270 AA216784 AI371057 BE208021 AI816060 AA977763 AA988221 W56716 R66281 T60692 AI371108 AW316667 AW090548 AW263786 AI688536 BE300865 AW118162 AW089606 AW157567 AW439435 AW673929 AW027607 AW474885 AI984259 AW571884 AI880916 AA758525 AA070410 AW190306 AW246746 BE221650 Al630670 H28485 AW468627 AW651608 AA360204 AW513778 Al608753 BE302410 Al750057 AW674261 AW510365 W94350 AA761293 AI869840 AA301790 AA933607 AA227144 AA716677 AA181762 R83889 AI079599 A1000208 N99897 AA070466 AW245167 W68620 N83377 A1361698 AA464157 AA496711 AA205826 A1361699 H80288 R50934 H98743 AA179708 D52483 AW249546 T49476 H80293 W73625 AA099853 H03238 AA179703 A1880803 AA653206 AA457733 AA931701 AA190330 AA906004 H79483 Al084626 T57243 AA079760 T55734 AA507899 W73915 T74565 AA523607 N69544 R97811 AA190335 R86252 AI359329 AA157496 AA070716 AW162385 AI929421 AW651618 AW087897 AW770466 AW073321 AI813809 AA113799 AI342925 AI754395 W60153 AA665490 AA653483 AW087840 AW169380 AI754330 AA181774 AW243958 R76858 AA936814 AA477111 H80279 AA496723 AA633000 AA243218 AW16988 H80274 R48211 AA743251 AI221630 AW593584 H40328 W56761 H95640 R93010 AW250165 AA497004 AA279793 W20432 AA775006 AA401150 T34421 T29637 AA678773 W23704 AA723093 AW073071 AI140379 AI188662 AA680074 AI081730 AW874489 AA226908 AI452689 AA531164 AW498837 AA670295 Al061112 D20132 Al937246 AA580593 N70277 AW993170 AA205918 AA581651 AA129695 AA548261 AW673898 Al000118 C13991 BE247777 AA653439 Al198072 R26594 AA282708 C14467 C14444 Al000629 C14510 AA775369 AA885560 F30063 D51934 D51834 D51478 D51931 D52011 D51918 D52160 D52045 D51888 AW245330 D52030 AA936639 D51494 D52144 D51448 D52138 D51730 Al419648 D52007 AW021403 AA935494 AA935487 AW770291 Al702431 AA687083 AA362527 D51696 R29267 AA653197 AA888552 D54444 C15448 AA478045 Al589903 D55942 H40340 Al864969 Al341782 AA353097 AW439647 AW305322 N54940 AA935976 AW248042 Al783806 BE349217 AA969923 AA383726 AA357323 AA007135 AI915436 N71185 AI123662 AA328354 AA331419 N21981 T03306 D54551 AA983808 D54942 D55074 AA113880 D52740 AW020376 AW020367 AA936029 AA555005 AA969180 AW812036 BE544746 N89212 M55405 AW752552 M55405 AW752552 H08773 R37687 Z99916 U71216 NM\_004076 X15144 X15145 X15146 AA652300 L14561 AW496834 AW059849 Z99413 T29666 R14900 R93603 R51525 S49852 U15687 U15686 AI033177 W94597 AI056839 R02057 AA134349 F05667 H73767 BE326691 AI984023 AI695688 AI750184 AI434336 AW029158 AI440089 BE046108 R51526 R53074 AA025218 AW083388 R93604 AA732638 H47642 AI859270 R41222 AA593057 AA760815 H43399 N29456 AI337321 H98205 AI752749 AA442913 AW961129 AL134557 AW439527 AI341304 AW190061 AW613371 AW439931 AA806627 AA781883 W05800 AA731599 AI863791 AI370277 Z38623 AI470448 H15877 R53656 D82513 D82467 D82386 D82515 R15295 AA096386 AW892808 AA300686 AW954282 AW959453 H29807 R25259 N46722 N46679 D60314 AA736829 Z99414 AI076802 AW576457 H16400 AA933075 AI752748 N75064 AW873040 N39235 AI310710 BE328592 N39576 AI672714 AA747547 AW769967 AI625462 AW169755 AW615361 R53545 AI758375 R46612 AW273091 AA736697 H29808 R42200 C14108 AW769967 AI029402 AW 169739 AW1613031 R3003 AI760317 R3009 AI270395 AA952981 AA746745 R37023 C75654 Z39578 C75656 AW956278 AA338702 AA338701 AA279433 W58753 AA041264 R02056 AW842224 AI215415 AW951238 AW022139 AA658234 AL119699 BE537020 AI795941 AA927068 AI765979 AV655427 AA041498 AI436090 AI190267 AA397563 H43344 AI718564 AW192067 BE328781 AW768573 AI358433 AW631373 AA262804 AW235152 AI570253 AA934641 AA776029 AW182028 AA279606 AV657690 AV657727 AV657350 N41480 AI926218 T29285 BE143058 N72769 AA385114 M60495 M60499 M60500 M24355 M62201 BE389102 M96943 L01090

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

100544 22955\_11

100545 22955\_11

124087 1561179\_1

100560 30266\_1 100571 7592\_1

100572 13049\_1

10057050

=

```
100582 26433 2
                                  D13897 Al183955 NM_004160 D13899 L25648 AW136574 Al654355 AA913288
               108409 113869 1
                                  AA075631 AA075578
               100627 tigr_HT2798
                                  Z25424
               123526 genbank_AA608657
                                            AA608657
        5
              100663 tigr_HT3059
                                  M20022 M32505 M32506 M32507 M32508 X64880 X87678 X87680
              100684 tigr_HT3283
                                  S66933 U15688
              100687 tigr_HT3291
                                  L18862
              100695 tigr_HT315
                                  M31126 M38243 M74197 M94890 U04323 U08196 U08197
              116389 genbank_AA599011
                                            AA599011
      10
              100702 tigr_HT3413
                                  L27065
              100756 tigr_HT3768
                                 M88357
              100809 tigr_HT4261
                                  L33990
              100810 tigr_HT4262
                                 L33994
              100854 tigr_HT4464
                                 U08607
     15
              102185 entrez_U20230U20230
              125090 genbank_T91518
                                           T91518
              100961 entrez_J00148 J00148
              102254 entrez_U28131U28131
              125145 NOT_FOUND_entrez_W38001
                                                     W38001
     20
              125153 NOT_FOUND_entrez_W38294
                                                     W38294
              116797 genbank_H40486
                                           H40486
              102354 entrez_U38268U38268
             102474 entrez_U49973U49973
             116902 genbank_H70739
                                           H70739
     25
             116905 genbank_H71420
                                           H71420
             102643 entrez_U67849U67849
             125576 205199_1
                                 R21635 R66208
             118579 genbank_N68905
                                           N68905
120256 genbank AA169801
                                           AA169801
     30
             120274 genbank_AA177051
                                           AA177051
             113149 genbank_T51588
             127759 808057_1
                                 Al369384 AA719568
             113518 5697_40
                                 AW367788 AI093217 AA533602 AI300430 AI860318 AI869201 AA933015 AA077695 AA649045 AI016319 AW084216 AI969650
AW169170 AI440341 AI744376 AA905125 AA194528 AA971323 AW510721 AA194483 AA076744 AW182167 AI955513
    35
                                 AA578875 T89731 T89829 AA828731
             113608 genbank_T93113
                                           T93113
             101046 entrez_K01160K01160
             122731 genbank_AA457549
                                          AA457549
5
             108316 genbank_AA070160
                                          AA070160
40
             108328 genbank_AA070204
                                          AA070204
             108394 482708_1
                                AA642953 AA075144 AA084113 AA070130
             108395 482708_1
                                AA642953 AA075144 AA084113 AA070130
N
             108417 483241_1
                                AA070853 AA075749 AA075716
             108436 genbank_AA078801
                                          AA078801
    45
            108491 genbank_AA082973
                                          AA082973
             108499 genbank_AA083103
                                          AA083103
            122922 genbank_AA476268
                                          AA476268
            122938 genbank_AA477119
                                          AA477119
            122948 genbank_AA477483
                                          AA477483
    50
            117046 genbank_H89505
                                          H89505
            101427 entrez_M19508
                                          M19508
            101559 entrez_M32053
                                          M32053
            117437 genbank_N27645
                                          N27645
            101798 entrez_M85220
                                          M85220
    55
            117590 genbank_N34904
                                         N34904
            110349 genbank_H40988
                                         H40988
            101909 entrez_S69265S69265
            103392 entrez_X94563X94563
            119053 genbank_R11501
                                         R11501
   60
            103457 entrez_X99728X99728
            119174 genbank_R71234
                                         R71234
            119229 genbank_T03229
                                         T03229
            103654 entrez_Z70759Z70759
            103679 entrez_Z86000Z86000
   65
           119329 genbank_T51832
119343 genbank_T62873
                                         T51832
                                         T62873
           119347 genbank_T64349
                                         T64349
            119523 NOT_FOUND_entrez_W38041
                                                   W38041
           119526 NOT_FOUND_entrez_W38049
                                                   W38049
   70
           119529 NOT_FOUND_entrez_W38053
                                                   W38053
           119564 NOT_FOUND_entrez_W38206
                                                   W38206
           119566 NOT_FOUND_entrez_W38209
                                                   W38209
           126908 533102_1
                               AA180024 AA169866
           119906 genbank_W85818
                                         W85818
   75
           123022 genbank_AA480909
                                         AA480909
           114604 485245_1
                               AA075966 AA076128 AA128755 AA128339
```

	10022	6 genbank_A 1 entrez_D28 3 genbank_A	383D28383
5	11471	8 480609_1	AA080912 AA075318 AA083403 AA078992 AA076594 AA062835 AA084926 AA081881 AA082953 AA113913 AA083821 AA070343 AA134801 AA113892 AA075419 AA063293 AA071252 AA078900 AA113888 AA071406 AA075072 AA100879 AA112153 AA062836 AA113865 AA074554 AA643251 AA084110 AA078783 AA084346 AA078993 AA079022 AA079776 AA070181 AA085031 AA082954 AA082971 AA131328 AA063179 AA083366
	100476 100541	8 tigr_HT1067 7 tigr_HT2219	′ M22406 ) M57417
10	100563	3 tigr_HT2324	Z11585
	12347	4 tigr_HT2324 3 genbank_AA	5 211585 NS99143 AA599143
	123490	0 genbank_A/	N599723 AA599723
15	322024	4 43541_1 3 33332_1	AA334384 AL137436 AA352089 AW341247 BE327629 AI669284 AI274156 AI123562 AL137507 AW879790 AA349971 AI624899 AW294742 AW271762 T06484 AA788895 R35098
		1 194954_1	BE011657 AA713589 Al440513 AA278620
	414/500	320825	29807_1 NM_004751 AF102542 AW360893 AF038650 BE304708 AW360892 AW360931 AW842622 AA307800 BE292814
			2 AW374998 AW374874 AI587061 AA583339 AW662377 AW192901 AW887756 AW887761 AI955582 AI150400 AA568218
20			AA294858 AI445680
20	320882	2 170589_1 2 41486_1	AA214584 D56572 D57294 AA207006 AA210987 AA601292 AK000655 AW024515 AI499162 AI673527 AA903900 AW084419 AI219549 D60890 AW243134 AI832098 AI811630 BE348831
		_	Al022831 Al475320
		3 46785_2 5 46801_1	R95860 AF085903 R95859 AI346033 AF075082 H48639
25	322141	46810_1	AF075092 H53478 H53853
H	322152 321525	? 78409_4 5 27440_1	BE614761 AA263136 W00335 W00327 AJ006077 AA377082 H78875 AA263148 AW958548 AA381830 AA381631 AW748909 H47990 AW402973 R31722 R82733
		<b>_</b> .	AW195851 Al650977 Al635744 AW136376 Al913496 Al569147 AW263050 AW075972 Al538882 Al762430 Al924045 AW613027
<u>m</u> 30			R74454 Al638560 Al476181 AA873030 AA936769 Al862049 Al955522 H00589 R31680 C20629 Al799176 AA835126 AA310578 H13126 Al858430 AA377081 BE244193 AF288208 W26453 AV659072 AF288209 BE622910
7		24943_3	AA663733 D62598 D62472
		87512_1 39063_1	AA018518 AA059305 AF151534 AI929478 W40378 H17557 AW163309 BE074271 AW854041 AW604408 AW853903 AA206576 AA133144
□ □ 35			AW854378 BE271915 F08002 AW293257 R58383 W95032 AI022248 H18001 R19681 F11341 AA778166 AI435068 AA702525
			AW176505 AA318946 AA705230 AW136167 AA704931 AW157512 W93328 Al694445 AW157539 Al301999 AA975516 AA722698 Al569683 Al674496 H17453 Al910812 Al598186 D53709 N80796 AA285026 AA704939 AA159340 AA565703
2			BE464932 AA477953 AA402072 AA476988 AI929436 AA133096 AI912377 H61238 AI457179 H18002 BE047110 H56139
<b>g</b> .			AA633441 Al500607 AA401959 H55753 Al767655 N93886 AA402908 H78194 D80936 R44236 H61239 BE551612 Al638233 Al953226 Al744095 F09000 Z41080 Al700837 AW768854 Al872712 AA283182 BE383452
<u>I</u> 40		9353_4	BE618027 H22381 AA326465 AA326466 AW962215 BE207339
N.		46967_1 47029_1	H89360 AF086037 H89546 AF086064 AA013034 N50099 AW903279
	315021	344728_1	AA533447 AF158241 AI240598
<b>1</b> 45		47231_1 47233_1	AF086242 W67679 AF086244 W68829 AI539008 W68737 AI685168 AI351133 AI633948
: #F	321632	286374_1	AW812795 AA419617 H87827 AW299775 AW382168 AW382133 BE171659 AW392392 BE171641 AA541393
		238740_1 25108_1	BE146577 AA339680 AA972551 BE146576 AA329384 S49006 AW405735 AW404287 AW405848 AW405979 BE538908 H70947 AI814190 AA381896 AW582731
50		20.00	AW975580 T94914 AW474500 AW869616 AW974125 AW946246 H44560 AW802184 AI538108 AW609912 AW865715
50			BE007659 AA443571 AW376161 AW797783 AA713566 AW577973 AA745472 AW270172 AA910107 AA713717 AW364122 AA533898 AI523353 AA715899 H44507 AW947263 AW390753 T89943 R66359 H44320 T64100 AA715879 R54661 AW579645
			H68597 Al499528 Al699010 AW605041 AW605043 AA236700 Al290767 H27472 AW079688 T69967 T87728 AW869468
			AW873389 Al250670 AA617786 Al566627 AW627605 AW302334 AA617836 AW793186 H16015 R83107 T85409 AA643479 AA582449 AW794654 Al819995 AW865810 AW380149 AW793863 Al281629 T64021 AA501599 R49882 AA565066 R69406
55			N23918 T59642 R54662 AW973199 R53006 AA401087 AA496563 AW934874 BE171294 AW793133 AI581595 AW605835
			AW605040 AW605055 AW605033 AW605058 AA291844 AW382472 AW605005 AA421881 AA513106 AA744190 AW386065 AW613785 AW605829 AA580905 AW605027 AW364134 AA464027 BE012096 BE008565 AA809035 AA809154 AA911395
			AA713636 AA745324 AA826230 AW368498 AV646747 T89967 H61164 AI540661 AA721571 C02031 AA523762 AA523746
60			Al287256 AW841164 AA962139 AW797014 AA515246 AW364140 H45842 T94267 T72111 R49771 T70151 H42664 R83656 R83590 AW380297 AW380263 X95750 T57717 AW391436 AA293355 AW380185 X95749 X95748 X95747 AW796510
			AA318628 Al001043 AA744404 AA745567 AA650437 AA715526 AW392762 AA516228
	306669	34348_2 7570 1	BE263222 BE312445 Al002913 Al340462 Al583268 AA079086 Al950777 Al301866 Al925108 AW876954 AW877000 AA525418 AA888549 Al934220 AW380220
65			AA804858 AI927576 T61151 AW384053 BE391691 AA533856 AA248400 T48202 N57156 R68346 R26020 AL050332 W30806
65			H61369 AA092592 AA230324 BE271217 AW372903 T48772 AA358002 AA094302 AA559856 AW373308 AW373315 AW373297 AW373311 AW373314 AW373309 AW877055 AW770140 AW379805 AI581609 AW364144 AA078921 AA715432 AA654210
			AI004899 AA602209 W47464 AA506588 R26822 AU076528 AI535743 AI535704 AI535681
	322302 322309		W76021 AF088052 W72465 W76622 AF086372 W72660
70	322337	47496_1	AA249804 AF086490 W93549
	322340 322362		AF088076 W95222 W92523 AF039697 AI860821 AW406650 AW515052 R49969 AA834501 AI951401 AA761660
	321708	64670_1	AA126365 AA055269 AI768638 N46910 BE047017 AA488423 AW021548 AW612323 AW007669 AI333685 AI633142 AI638022
			AI765587 AI151494 AA443764 AI373599 AI140433 AW295946 AA088183 AI811417 AI277748 AL079978 AI341834 AI144434

		AA055404 AIROSPAN AA404 AA
		AA055164 AI765262 AI140147 AI160673 AI686050 AA130038 AI699503 AI580411 AI276910 AW296875 AI927239 AW470427 AI174424 AI675518 N20396 AI308224 BE221055 AI926097 H89681 H90776 AW023381 AA126261 AA025391 AA347308 AA476817 N25488 AA442811 AW297971 AA025454 D81551 D81214 D61126 C15599 AA130037 AA088653 AV654662
5	321763 166644_1 313913 653504_2	AA195602 W01148 N40632 AW391342 AI813778 AW190911 AI963486 BE049275 AI922735 AI935914 AI263291 AI679178 AW192178 AW338885 AW473496
	306710 52443_1 313960 130872 1	BE564350 Al024221 AA113301 AA130859 Al805438 AA846950 AA130915 AW862833
	306773 563488_1	A1040750 BE062532
10	323014 140817_1	AA305198 AW962351 AA134366 AA259244
	315276 383168_1 321847 45225_1	AA860090 AI961138 AW592114 AW087700 AI798907 AW340674 T08401 Z83934 T16897
	308069 33294_5	AI470895 BE386951 BE391680 BE277351 BE385202 BE300283 BE299619 BE254885 BE391698 T17015 AL048342 BE387417
1.5		BE315548 AA345769 AA374932 AA304724 BE277135 T31443 BE387617 AW582877 T33057 AA054826 AA305115 RE378081
15		BE615689 W07028 BE537075 BE615271 BE252353 BE563255 BE391752 BE545875 AW580149 AA747256 AW276731 N85015
		AA299609 AA365061 AA302265 AW951660 BE538115 AW404883 AW583622 AA374519 AA225917 AA037286 W24285
		BE255801 BE254061 BE278256 AA377959 AA319628 AA316739 AA378914 W24421 AA658882 N87533 AA526881 AA376559 AA378175 AA300193 AA330503 W69498 C03856 N85298 AW957966 C02647 H19560 BE616753 BE263169 AW250280
20		AW162197 AW163162 AA301672 AW249055 BE616277 AA225272 AI557298 AW276939 AA327042 NR3648 AW404841
20		AI903202 AA314875 AI546852 BE616559 BE262330 AA385891 BE182717 AI557551 AA082310 AA354304 AI541330 AA327616
		AA344981 D53311 AA363102 AA171801 AA089673 AW162085 AA379891 BE277324 AA157651 AA304574 W52799 AA186652 AW328567 AA187480 BE386732 AA369717 AI815603 AA303651 AW160407 AA056711 AA082790 AA329861 T39426
		AA650419 Al268280 AA471236 AA308712 AW733012 BE256165 AA745013 W06997 W21418 AA531583 AA308604 AL133371
25		AA324238 W24570 N88175 W45648 AL022721 AA378455 AA378168 BE393810 AA317384 W21121 AA371342 N31367
23		AA359623 NM_007104 U12404 BE388017 AA374579 AA380618 AA334401 AI557552 AA337150 AW732322 AA327632 BE263809 AA657772 D30933 AW663232 AA315817 AA314480 AA370766 AA317760 AA315084 BE383638 AW327814
<del> </del>		BE302619 W21304 BE390854 AA373219 R94330 H84395 AA377636 BE252526 AW732866 AA299524 AW328563 AW674382
h		W38535 W06840 AA332645 AA355580 BE258503 BE256923 BE271400 AA380757 AA385628 BE256989 AA332349 AA344985
□ □ 30		AA186515 AA305031 AA357482 AA316998 AA379264 BE390621 BE255056 Al207414 BE252354 BE254152 BE254578 BE252547 BE266591 BE257651 BE294792 BE277990 BE391235 C15642 BE391151 AA301280 AA384750 BE273056
		BE312333 BE296962 AA314715 BE256346 BE313459 BE269894 AA310988 BE300029 AA157523 BE250757 AA545754
*		AA083546 AA315252 AA224003 AV655919 AA315169 AA310685 AA301191 W19623 RE392967 AA303515 AA379649
<del></del>		AW327286 BE560669 AW580113 AA352149 AA360956 AA316107 BE563100 N31353 AW675322 AA379584 BE019308 AW583963 W37951 BE295910 BE251482 BE385588 BE270412 BE378750 BE396426 BE295210 AA336973 BE314395
□ □ 35		AA354788 BE295227 D55985 BE615081 BE260566 AA320506 BE278254 AA285366 AA303825 BE275375 BE313367
		BE260703 BE279256 BE382903 BE315113 BE313341 BE260804 BE620531 BE615973 RE266048 AA003478 BE616106
		AA360276 BE253746 AA314344 AA315622 BE386557 BE313445 BE253355 BE561084 BE296088 BE531299 BE255860
E		BE408279 BE273842 BE378885 BE255055 BE271521 BE563765 BE252792 BE391016 BE258218 BE273725 BE273968 BE272901 BE313660 BE304527 BE257956 BE254227 BE275320 BE253909 BE407614 BE614755 BE378776 BE613909
<b>40</b>		BE40//08 BE395973 BE513022 BE157875 BE615399 BE252775 BE279463 BE257109 BE271307 BE256275 BE276484
		BE25/302 BE384605 BE258461 BE546662 BE409191 BE280351 BE252294 AA285364 BE378324 BE264740 BE202822
N		BE620927 BE296544 BE271710 BE257492 BE252712 BE395931 BE266143 BE255921 BE255720 BE300136 BE531292 BE391204 BE409180 AA320604 BE295038 BE390679 AF075335 BE315084 BE394350 W04926 Al110836 BE615235 BE295593
~ 45		DE2/3080 BE409184 BE253595 BE294473 BE253714 BE512867 BE295544 RE295544 AA296596 RE255540 RE278700
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		BE513852 BE512932 BE257734 R31451 BE293044 AA379511 BE261311 BE397180 RE278214 RE407490 D56163 RE563686
N		AA070681 BE255940 AA348975 BE253849 BE390468 BE396140 AA186986 W20120 BE389750 AA307189 BE376407 AA125980 BE407415 BE276230 AA304996 BE389228 BE512779 BE617120 BE512670 BE272223 AW407102 AA370834
		H21183 W07800 BE562889 W05304 H02179 AA327191 H18595 H22622 BE257450 W46597 BE262207 AA002219 AW405652
50		AA33403/ BE294871 AW606479 AW384255 AA085885 Al903205 AW405432 BE298839 BE292956 BE262232 AA363253
•		BE276322 AA300909 BE389123 AI909563 BE407174 AI535831 BE260382 BE382583 AA532637 AA380091 AI114568 AA193129 AA192984 BE384600 BE407214 BE182724 BE539061 AW733001 AW406350 AA374881 BE384674 W87442
		BE2/0000 BE299430 BE274869 BE378528 BE396131 AW239494 AIG30538 AA053478 BE280557 AA21974G AA200674
		AW406770 W07830 AA808817 AA146904 BE272999 AW408211 AW580062 AW606478 W07669 AW580120 AA379387 AW580130 AA101207 BE394409 AA362957 AW392453 AA101121 W03827 AA166722 AI909564 R30769 AW580069 T58944
55		BE261760 BE313004 BE312309 BE260766 BE314007 AA724391 BE538878 W04777 AA657588 BE259359 AA631041
	244664 206444 4	AA070065
	314661 296144_1 307474 25106_2	AA578229 AA436432 AA481375 AA481363 AB037864 AI223793 AI916099 AI332699 AI264023 AW962587 AA412310 R37910 R37827 AI191724 N22920 AI916409
	00. II 1 20,00 <u>_</u> 2	AA932668 AA782068 AA865648 AW467014
60	323115 155930_1	AI921875 AA170835 AA866613
	322505 38889_1 323170 980026_1	AF147315 AW173079 T53029 U83527 AL120938 U83522
	322518 38914_1	Al133446 T50819 AF147343 T50665
65	323183 3032_1	X73874 NM_002637 F00757 BE172051 BE081451 AW891243 W20171 BE619896 AA927528 AW374434 N90546 F01171
03		Al681314 Al621208 Al366791 T27589 AW960206 AW393850 AW892627 AW892626 AW833974 AW833971 AA194696 AW274557 Al813660
	323185 18915_3	R52177 AL121177 AW749837 AA354099 AA318422 AA318513 AA318429 AW961486 AW964802 AW961475 F12011 R12085
	_	K12113 R20096 AW836716 W87916 F12265 T64809 R96961 AA340929 R88075 F11199 H11127 W68153 RE465310 W67653
70		AA///659 AA630420 AI423300 AI744317 AI681159 N81151 AI758899 AI991528 AI640256 AI361200 AA030678 D52082
		Al161215 Al240851 AA806482 Al159875 AW452889 AA987856 Al581408 AA746962 Al277132 AW802982 Al567611 AA761163 Al277294 AW244127 H11684 Al381224 Al277139 AW952835 Al480237 AA188967 AA041517 Al798651 AA906163 Al081406
		AIU32939 R41802 H95399 AW023038 AA890250 T65065 AA340673 F09658 AI248293 H11039 AA340628 AIQ55106 E11007
		AA028186 H98922 AA810707 AI769491 N21690 AI670911 AW005066 AI692255 AA028093 AA748907 AI919266 H11597
75	315322 444861_1	H95373 R36867 R36878 A1222427 T23945 AA770599 A1215099 AA992267
	321920 1023421_1	AW089866 N63915

		32196 32198	66 30334_1 86 22722_2	AL122111 M79226 Al656413 BE502197 F32670 AL133656 AW269409 Al138865 AA954306
	_	32324	3 140566_2	W47525 AA134047 BE391212 AA330333 AA376355 BE304871 BE167342 H87402 AA631722 W45724 AA715517 AI925438 AI804849 AW241617 AW403807 AI653435 AA134048 AW747874 AI922327 AI814967 AI935895 AA228865 AW504076
	5	24004	4 447040 4	AA225008 AW673858 C03914
			1 417912_1 4 82848_1	AA719183 AA736442 AA709125 AW841642 AW747992 AW748000 AA007413 AA568664 AA779192 AW188983 AI471878
		32264	9 24892_1	F01266 NM_016549 AF239742 BE219554 AA902371 AI298989 AA533735 AA599216 AW025283 AI336116 N75315 AA621418
	10			AI6/1706 AI373650 NM_014556 AF216184 AI269271 AA780274 AA772950 AA932592 AA496722 A1186107 AA000748
	10	32268	2 37364_1	AA477144 AA788812 BE384172 AA009407 AA526549 D25270 AW882122 AW972929 BE174659 AF063553 AI110679 AF090893
			5 10562_13	AA768239 T98699 AW207784 AA343876 AW963055 AI299617
			3 3084_2 3 62251 1	AW969114 AA761093 AW082191 AA505065 AW087800 AI719655 AA576454 AW375968 AI804392 AV651680 AA228883 AA367341 AW962458 AA628024 AW172426 AI767785 AA313012 AW963323
	15		0 59496_1	18/841 AA233726 AV648314 BE545191 AW969738 AA579641 AA516077 AA483490 BE612779 AA460132 AA659710 A1149891
				AA1132// Alb89233 Al028588 AA461487 AA074311 AA682750 Al421205 AA985248 Al753378 Al914588 Al493749 AA936668
				AA633392 AA722409 Al424537 AW609606 AW815447 AW268600 AW609594 AW601214 AW082930 Al752615 BE550576 Al989665 AA046575 Al201331 AA169112 AA169113 AV648431 AV648389
	20	32273	8 26089_1	AF200496 Al343258 Al014548
	20	308337	7 3328_20	J00124 AA158848 AW452899 NM_000526 AW384139 BE140708 BE140690 H28274 BE140404 AW844922 BE157342 AW580043 AW384049 BE157333 BE157179 H44127 BE140671 BE614947 AW380727 BE184532 AA808075 R73201
				AW949948 AW950242 BE183306 BE183297 AA587174 BE183243 AI591112 AI609229 AI590690 AW606369 AI609238
				AI608848 AI590885 AW084944 AI609220 AI609210 AA583890 AI609274 AI609226 AI608878 AA550914 AW170430 AI609047
	25			Al608606 R88146 M28646 AA587248 AA583985 AW872988 AA583993 AA586980 Al284481 AA584051 AA587024 AW800015 AA587313 Al283394 Al143314 AA595434 AA583917 AA922332 AA584021 AA583576 AA862004 AW873168 AW796060
				AA862U49 AW8/3161 AW0/9705 Al366769 AA583724 AA583889 D29065 AA113288 AW083705 AA584334 AA586711
H				AA583558 AW117878 R72295 AA583842 AW996598 R73138 H28224 R88223 AA586985 AW369022 AA602252 AA641063
	20			R72845 AA861952 AA587149 AA587308 AW369033 AA584344 AW799955 AA583732 AW368990 AA862083 D29595 R53012 AA587254 D29462 AA158849 R72649 BE181541 D29604 AI127631 D29297 H44051 AA583575 AA586762 D29122 AA583878
	30	322774	104619_1	AA595946 AW368880 AA587318 AW368881
Щ			337806_1	AA131111 AA132859 AA053057 AA515635 AA516338 AI801993
# # # # # # # # # # # # # # # # # # #			697809_1	Al347274 AW844024
	35	301119	33384_1	BE621320 BE266806 BE276582 AW516729 AF142579 AW451687 AK000069 AA325236 BE168997 W73105 AA715365 BE278873 AA808894 AA386371 AW517942 AW750993 BE140314 BE392384 BE621757 AA318192 BE548173 AW152607
브				AW166898 AA352215 AW841506 T59802 AF147378 AA335719 AW956069 T59668 AA826362 AIG61329 AIC90469 AW197275
				Al805651 AA160748 AA581089 Al968889 AA581100 AA501478 Al621069 AA468534 AA503715 AA658457 Al144504 BE387827 AA159880
# 	40		427639_1	AA732066 AA807070
	40		265007_1 431366_1	AA376108 AA375646 AA376551 AW963816
U			266490_1	AA828385 AA769592 AA742234 AA742235 BE387327 AA377589 AJ903826
		324048	267284_1	AA378739 AW964174 AA570564 AI076833 AW265063 AW006805 AA480656 AW004789
Ī	45	323409	421551_1 218874_1	AL046841 AA721199 AL046079 AW137650 AL135534 AA366767 AA313599 AA333787 AW966106 AW844387
Ū		323426	188613_1	AA485236 AA830637 AA251401 AA749343
1 🗠			270098_1 427772_1	BE395109 AW663898 AW237041 Al492154 BE046906 Al651285 Al983290 AW002590 Al201040 F32424 AA992272 AW271836 AA732301 AA764985 AA732300
		323479	194627_1	AA278246 AW292815 AA278703
	50	322840	109637_1	AA083710 AA122195 AA081984 AA134650 AA080983 AA080954 AA062747 AA083876 AA079025 AA113855 AA074687
		322877	116942_1	AA078914 AA078873 AA074126 AA079727 AA079728 AA824267
		308447	106072	AI659985
	55	324148 300694	273755_1 110146_1	AA393624 AI190160 AI342032 AI015092 AA992047 AA860917 AA400867 AA063406 AA063407
		322907		BE252579 BE255945 BE314749 BE260141 BE260121 AA084941 BE206830 BE256911 BE256464 BE277162 AA488032
				BE206992 AA158178 BE265680 BE164838 BE164881 AA411651 AA036706 AA411652 AA480595 R53714 AK000381
		300707	114644_1	AA191114 BE314072 AA079132 AA080921 AA076662
	60		485212_1	AA863389 AA863395 AI969882 AI695443
		300763	287622_1 163257_1	AW629965 AW975427 AA421989 AI051821 AW748356 AW129223 AA715470 BE000150 AA190753 AA760634 AI685862
		300781	23981_2	AA731209 AA236961 AW971508
	65		220254_1 439976 1	AI702835 AI758919 AI685405 AI952108 AI299207 AI400767 AW105389 AI952710 AA845312 AI784118 AI537315 AA811452 AA829961 AA815116 AA764935 AW976998
			222860_1	AW178750 AW178736 BE141842 AW178683 AW178714 AW178684 AW178679 AW178716 AW178685 AW178718 AW178717
				AW178081 BE141834 BE141835 AW178711 AW178735 AW178712 AW178734 AW178715 AW178680 AW178713 AW178677
	~^	308659	3723_5	AW178719 AW178748 AW178710 BE141843 BE141844 AW751119 AW178682 AW178737 AW178749 AA318993 BE141841 AI174911 AF116710 BE250634 BE513651 BE513483 AW973114 AW973111 BE407498 BE387872 BE255662 AW575394
	70			AW15/150 BE383339 BE045072 BE382560 AA535472 BE389253 RE274463 RE076283 AW157403 W20446 AW663762 ND2007
				AI816181 AI879111 AA603287 AA809812 T03060 AA531063 AI815578 AA534177 F26418 AA527007 AW157453 AA557931 AA742784 AW163466 AA513251 AI816220 AI816077 AI929498 BE299421 AW163056 AA502024 AW160897 AA651678
				AA534185 AW663233 H46043 AI815950 AA635243 AW161304 AA532646 RE619905 AW163000 AIG28082 AIG20122 AA560180
•	75			H94/52 AW163120 BE619294 N84679 AA639280 AW161846 AA524657 N76560 H60985 AA318407 P98166 AA316834
	-			AA534172 AA353056 AA375240 D16959 AW328044 AA603503 AA531077 AA330098 AA244141 AA377880 AW161054 AA070576 AA326867 AA370759 AA378306 AA055146 AA311016 AA356827 AW827213 AA318418 N84051 AA322649 T72970

	AW630001 AA376419 AA343976 AA311126 F20273 AA308824 N84783 AA373006 AA374318 AA356480 AA300347 AA314040
	AW328346 AA092658 AA181308 C04940 AA329907 AA587591 AA300042 AA301309 AW674942 W21264 W47074 AA310460 W31811 AW630251 AA332208 AA299335 AA360053 AA360318 AA328721 AA378343 AA299584 AA345747 T49611 AA376010
	AA186475 AW957009 AA305013 Al064911 AA330372 AV655922 AA314027 AA354481 AA313645 AA314699 AA314084
	AA358279 AA311170 AW327387 AW327464 D58829 AW973106 AA375740 AA308783 AA316940 AA315588 AA380257
	BE397919 AA181856 AI557351 N83566 AA315879 AA369434 AA357016 AA314419 AA130919 AA308111 AA314139 AA354095 AA095733 AA247440 AA316663 AA307418 AA131136 AW157088 AA375200 AA316192 AA315616 AA360129 F26579
	AA363700 BE539203 AA379637 AA147978 AI340513 AA307861 AA467839 AA384626 AW328308 AW248834 AA379269
	BE621558 AA355664 AW404712 BE613747 AA507275 BE206816 AW270699 C13959 AW966785 AA310386 BE394115 AA131219 BE385515 BE262339 AA095023 AA315277 AA364046 AA535741 AA188339 AA316095 BE312188 AA176667 T53669
	BE258138 BE258239 AA303587 BE272248 BE545416 BE250615 AA371845 AW839835 AA314570 AA330923 AA311279
	BE261310 AA320246 H95461 AA587557 AA308437 BE540153 BE390839 F25801 AA480575 N89472 AA302013 F29054 AA375385 F19527 Al816119 AA227104 BE536936 BE535875 BE269659 BE536267 AA339654 AA771729 BE396514 BE263080
	BE312046 BE298027 AA771710 M13934 BE618296 AA807646 AI951409 BE613262 AA857346 RE294539 RE296371 E31870
	BE254168 BE621136 BE295564 BE612812 N88740 AA352787 AW475090 BE270398 BE618807 AI566936 NM_005617 AW008274 BE392312 AI928878 AW162655 AI624147 AA854344 AW952982 AW085710 F01238 AA344919 AA641196
	AA720860 AA572870 AW161654 AI001113 AI862725 AI811592 AA320775 AI420790 AI207364 AI951381 BE270095 AI027794
	BE513425 BE252494 AA865409 BE294421 AI719767 AA897029 AI564328 AW628239 AI809839 AW082072 BE255143 A1189653 AW515889 AA578771 AW162621 N86168 AA935172 BE384561 AW157031 BE295195 AI659958 AW263875
	AA533391 BE513648 Al445700 Al034465 H65716 AW272557 AW302286 BE271816 AW196996 Al953988 AW157372
	AA580376 Al191251 AA572856 Al027798 AA884282 BE268198 R92688 AW731956 Al261239 BE260070 BE253635 AA603422 BE258354 Al810163 AA130398 AA861165 BE257787 BE408032 H96956 AA593399 BE275262 AA180066 BE395867 Al439795
	AA845816 AW572567 AA999943 AA301818 BE615972 T67509 AA152224 BE393104 AA857300 AA828978 AA812299
	AA834249 AW157807 BE253390 AA883769 BE382656 AA484099 AA759089 AA501594 AA742887 BE391312 AA304434 AA091576 AW939788 AA989550 AA301655 AA374299 Al000013 AA379938 AA985668 AA293111 AA838481 AA302129
	BE255097 R48458 AA659479 AA311090 AW262218 AA864655 R70415 AA782420 F29372 BF301374 AA345410 AA152252
	AA664047 AA626811 Al092022 AA300592 Al204107 AA936560 AA349088 Al365000 AA311155 AA854688 AA176832 AW338622 AW246720 Al096811 BE390455 AA181218 BE274363 AA320085 AA854819 AA379935 AA961683 AA706429
	AA301855 AA903668 AI167880 AA912490 AA736633 AA978322 AA306985 AA492120 AW613649 AI026088 AI500692
	AA642146 AA834125 AA970750 AA954809 AI937927 AA605094 AI000445 AW592871 AA642613 AI708961 AA664208 AA935984 N78708 AW263613 AA379400 F30530 BE382934 AI347719 H44065 AA876331 AA642115 AW439014 AW613635
	AW592031 H02916 AI720155 AA661949 N24052 T72191 AI343917 AW000828 F20434 AI040902 AI189222 AW615066 AI364998 AI833275 F20713 AA884055 AA603404 F32779 AI927611 AA582556 U91916 H44037 AA641501 AI718241 H44109
	AA971206 AA782740 AA311211 AA947800 N23272 AI590880 AI742000 AW651617 AI040892 AI051117 AA554857 AA782075
	R19307 AW515187 AA622350 Al284864 Al002194 Al339662 AA535783 AA480434 Al951550 W46973 Al936248 AA492016 AA972511 AA071036 AW170504 AW629056 AA658282 AA843949 AA846986 Al335690 Al985054 Al335679 Al660582 F26201
	AA810379 AA187195 Al274712 Al300958 H99863 AA563821 Al973025 Al186080 AA533122 Al205703 AA166781 AA857765
	F37969 AA578216 F28780 AI972670 AI709163 AI749751 AI087008 AA186713 AA506638 AI298400 H62141 AA524656 AA532581 AA136078 R48459 AI002336 AA617627 AA130399 AI870668 AI991186 AA293498 AW088368 AI929232 AA143219
	AA629414 A1859102 H73727 AA186706 A1581697 AA747261 A1718130 W73976 F26566 A1816041 AA633944 AA878094
	H61558 AI857355 H45978 F25943 AI879870 F27056 AA244085 AI927367 W69664 W69843 AI298014 N91111 AA229474 AW969539 N95295 AW023874 AW572321 AA481820 AA580774 AI870680 AI568052 AI831105 AI750091 AI141652 AI833250
	AW001251 AA180067 Al554189 Al719251 AA807645 Al298013 T52779 AW264018 F21944 Al253714 AA342880 AA985284
	T49612 AW263695 AA508894 AA181908 AA533851 N84414 AI277062 T78929 AA534250 AA569444 R11589 AA022468 T60272 AA582353 AA335709 AI929540 AW613761 BE327851 AA533776 W72345 AI601210 AA366049 AA719887 F22515 AI523442
	T07133 AA230206 AA827438 AA728986 AI718076 AA504069 AA469341 BE546614 AI434088 AW170241 T52780 AA629409
	BE543516 AA484074 W04709 Al582317 BE045496 AA737847 AA535491 AA628352 AA558076 AA864201 AW610533 Al707857 R94198 AA522868 AA226911 AA857018 AA548787 AA627142 H65717 AW166287 AA564007 BE547258 AA330345 C15020
	AA166754 AW244086 AA844918 F32317 Al424155 AA228718 N89046 N91894 AA894498 AA995502 AA533354 BE222086
	F27737 AI887199 AA506272 AA558503 AA578345 F22227 AA352404 AA805843 N88511 AI628216 AW341732 AA300401 AA648148 F19238 AI200285 BE041727 F29059 T92628 AW589349 F30549 AA653059 H61217 AA501652 AI919597 AA903957
	F31025 N34998 R96850 AA938689 AI919025 AI310209 AA975769 AW338225 AA342924 F25408 AA130863 AW087264 T72994 AW873946 AW327429 AI186381 AW327428 AA974301 AW768990 AI690826 AA652111 AA467888 AA187218 AI183905
	AI424323 AA548057 AW051027 AW080306 AI803806 AA642861 F31183 AW406529 AI619660 AA918081 AA491673 F21729
	Al874177 AA715051 F33182 AA652773 AA659091 AW339904 AA662483 AA857275 AW105417 AA548056 AA601164 AA622675 AA494257 AA036629 T60772 AA653018 AW673531 Al613161 AA668312 Al817429 AW195254 R93615 R69436
	F02292 AA995267 AA247239 AA320193 AA782878 AA994819 AA054936 AW151254 F17418 AA908823 AI890234 AA534130
	Al468869 AW149483 N22520 AA343231 AW001178 AA602740 Al352348 AA932611 AW273549 Al766324 AW118402 AA888486 AA503847 AW300756 AA585120 AA496674 AA629998 Al619509 Al799389 T25968 AA535332 AA535126 AA467830
	AI915716 AA320648 AA585125 AA658579 AW451040 AI735214 F16590 AA284984 AA643858 AA283217 RF178572 AI921154
	AA344918 AA557543 AA308479 AA872892 AA481963 AA658578 AW004717 AA290824 H61178 AW474724 AA321490 AA936492
308681 352627_1 324316 298498_1	AI761307 BE161415 AW005281 AA558937 BE161404
324323 273867_1	AI291330 AA452220 AA443354 AA393739 AL138137 AA393796
324368 33663_1	AW861185 AW991306 Al623237 Al018451 AA159072 BE294536 N40680 AA248594 AA332177 AA353889 AW136671
	AA063492 AW082601 AI734889 AI479298 AI690289 AA514475 AI827201 AA954932 AI375429 AW305231 AI078116 AI807586 AI224855 AW025809 AA718988 AI093059 AI912915 AA456139 AI341411 N63437 N95744 AI830516 AA846245 N25902
	AW469026 AI042513 AI241692 AA988159 AW662812 C03567 AA594584 AW082516 BE068964 AW299374 AI636034 BE172420 AB029022 NM_014914 AW896987 AA765269 BE077785 AA459768 AA436896 AL040331 AA285281 BE244301
	T54938 AA093121 F21778 AA150155 AW968251 AA258877 AW663766 AW470130 AI857358 AI469756 AI299480 AI672560
324376 1154206_1	AW089174 AW518770 AA081121 AW014387 Al869379 AA985193 AA152265 W94876 AW499705 AW502537 AW503016
323735 6884_44	BE615406 AA323714 BE515303 AA464826 AA453149 AA442802 BE387695 BE394179 BE392472 BE394406 BE393601
323755 229275_1	BE394088 BE388690 BE395181 AW300094 AA805026 AA700077 AI702882 AA327146

			0 230698_1 8 228984 1	AA722425 AA329212 AI572177 N83965 AA326737 H14153
			7 428607 1	AA931484 AA758140 Al033284 AA931461 AA757895 AA877176 AA736429 R11591 Al017256
	_		2 24588_1	AF119046 NM_014481 AJ011311 AB021260 BE091822 BE091819 BE280661 BE548576 BE531337 AW605371 BE547006
	5			BE076387 BE275532 AW386829 AW189348 AA554484 AW028935 AW080283 AW444648 AI538979 AI674393 N59092 C01178
		200400	05040 4	Al612817 Al347385 Al190577 Al918533 BE265083
		302183	3 25243_1	NM_002248 U69883 F11363 M62043 AA350009 Al937237 Al363154 AA351095 AA325431 D60120 D61063 D60321 C15510
		324432	312487_1	AW292489 BE504989 AW594619 AI825516 F09023 AA464510 AA631257 AI740516 AI739132 AW972467 AI741376 AW068935 AI467852 AI752240 AI123717 AI754551 AW205510
	10	021102	012407_1	AW044211 AW028889 AW198033 Al538632 AA513096
		323808	3 247059_1	AW250114 Z43124 AA431421 Al879054 AA351616 AA351035 AL048999
		300982	361671_1	AA837754 AA581115
			238221_1	AA393460 AA338940 AW966277 AA419006
	15		455916_1	AI042101 AA805541 AA812130 AW977868
	13		48373_1 10280891	AL042966 AW403294 BE294048 BE274337 BE261318 BE544865 AW118833
		308859	995_8	AW110033 A1830787 BE563334
		302263	227972_1	AA325517 H19549 R53308
	••	302270	1734192_1	R56151 W91936
	20		27735_1	AF067797 AB013456 NM_001169 AI791955 AW843925 AI732659 AA577625 AW083143 AW138645
			867855_1	AW239364 AI792390
			103655_1 171572_1	H81795 Z42291 R20973 AA046920
			1156268_1	F13112 Z42752 T77015 AA211163 AW502082 AW502979 AW502807 AW501876
	25		326972_1	W67730 Z44630 AA490699 W67596 W76661 R21207
		324560	1156518_1	AW502208 AW502366 AW502148
H		324568	1135567_1	AW502311 AW502370 AW403858
		324575	65704_1	AW502257 Al014241 AA100360 BE298534
Ē	30		79433_1	BE261877 AI880051 BE242392
ا <u>نا</u>	30		29269_1 916575_1	AF120491 AF187963 NM_004980 AF205857 AF048713 AL049557 AW301478 AW301560 AI889207
Ф			1534796_1	F06529 R19994
Paris,			1570217_1	N79624 H18620
	35	301744	50221_6	BE277526 AW854299 AA356083 BE257389 F12667 T74316 BE251675
			259807_1	F13486 T75247 AA368304
		301767	8416_1	AK001579 H15317 AW361892 R38240 R02257 R41005 T84341 AW963098 AW516794 AW664706 AI377637 BE463865 H15706
				AI452461 AW089869 AI986480 AA636063 AI123920 AI911424 AI123930 AI963282 AW170740 AA564654 AW136832
÷				AW468248 Al393655 Al656932 Al358006 Al968742 R38241 AA928629 R77428 AA705932 AA458491 Al755108 AA913331 Al351287 AW044222 AA301591 R81470 AA344045
	40	301775	24697_1	AW250572 AW247670 BE067043 BE067049 AL080159 T48255 Al628030 Al401612 AW246476 AA365210 T48256 T81697
U				H62983 AA909497 AI864565 AI801862 AI247137 Z25119
N			473541_1	AW979189 AA837332 AA856946 AA876935
74.II	45		474090_1	AA838114 AW629478 AA883713 AI620552
		303021	110136_1	BE277604 BE276408 BE265007 BE410545 BE407265 BE272589 BE263600 BE407970 BE303032 W39612 BE244678
		303041	31134_1	AA321272 BE244631 AW405664 AW673342 BE244379 BE280236 AK000072 AW840683 AW843764 AW844444 AW844515 AW603469 AW862395 AI860838 AW511708 AF127035 NM_012128
T.J		000071	01104_1	AK000138
		303042	5058_1	AW505345 AF129532 AF126028 AA852108 BE169359 R83701 Z43904 BE613543 AA283163 AA905463 AW067849 R13544
	50			R12337 R14020 H98970 Al474918 N56139 AL135669 AW067702 AW372065 AW631389 AA083416 AA287511 AA602923
				AA488914 AI167215 AW946829 R82855 AI948792 AA371333 AW953883 AW956152 C02539 AA298280 AI932587 AA022742
				AI983021 AA195252 N58991 R78733 AW083996 H39614 AI365249 AW615389 AI927744 AI089971 N52205 AA083417
				BE326666 BE349514 AI743785 AI640148 AI378211 AW181881 AI949484 W31374 AW628233 AA418406 AW068010 AI708085 AI092696 AI089823 AI277828 AA022660 AI440527 AW054937 AW474104 AI017436 AI159819 AI356716 AW473140 AW316518
				N34522 Al675092 Al866697 AA864593 AW511185 AA488844 AA904975 N49111 Z39951 R37265 Al141362 T25856 R20664
	55			F03163 Al767927 AA805942 D79905 Al914645 AW190553 Al934213 Al458796 AA195385 R82854 W31965
		302445	16351_2	W37653 AW881001 AW840685 AW840696 N79647 AV648691 H25494 AW885394 AW001940 AI362793 N63970 H25448
		200450	24754 4	AI963184 AA324156 W37514
			31751_1 32135_1	AF169255 NM_006028 AF080582 AC005551 AF161441 AA431001 AA336054 AW965560 AW376266 AA758808 AW024675 AA946948 AA306783 AA910368
	60	302400	32133_1	AA335971
		301855	33235_2	W25940 AF053356 AF053356
			1799608_1	T61587 T61035
			389615_1	AA640770 Al683112 AA913009
	65		483302_1 44550_1	AA861087 A1200951 A1026779
	03		85273 1	T09353 U72943 U64597 R52598 R61404 R20022 R18898 U67037 AA012877 AA021074
			40757_1	AF202889 AF202890
			2628_10	X58801 X58802 X58803 X58804 Al312844 AA283290 X51791 X86140 X51795 X86110 X86106 X86105 X86104 X86141
				AJ296352 AF020642
	70		112488_1	AA071215 AA071444
			1589284_1	H48676 W04984
			17513_2 193526_1	AC004472 BE312721 BE273942 F11928 T65358 BE612432 BE261576 BE179884 AW407564 AA262049 W19405 AA504733 T12641 AW973724 AA558125 AW993087 T12640 T11447 AA521285 AI820042
		310230		ANNAU 7004 AA222049 W19403 AA304733 112641 AW973724 AA538125 AW993087 112640 111447 AA521285 AI820042 AA457028 AI674737 AI688648 N92749 AI439620 AI218005 AA731321 AA828303 T12590 AI685371 AA504636 AA825573
	75			AW172614 AA291292 AA649919 AW576505 AA262152 H29888 AA830757 AA910433 AA808481 AI971807 AI767874 AI216422
				AA831483 AI566351 H41305 AA879438 AA807123

	324829	7288_14	AI537407 AW131277 AA714311 AW816039
		344894_1	AW191647 AW973241 AA632846 AA533681 T51580
	309825	331299_2	AW293701 BE348286
		130271_1	BE281058 BE276139 AW250314 BE336754 AA112498 BE265334 AW732954
5		155956_1	AA171403 AW160951
		72494_1	AA205300 BE612585 Al393918
		2628_31	X58808 AF071471
	324945	47710_1	AL360202 AA088768 R61018 T36114 AW966404 M85891 AW296810 AA421905 H29985 AI810129 AI798786 AI338041 H29886
10	200042	14912_1	AA088702 R60901 Al648560 AA411400
10	309912	14912_1	H19255 AA324634 BE398078 AW749970 AA309733 AA769449 BE501906 Al686211 Al280426 Al401680 AW235634 Al954773 Al762656 AW082924 Al223790 AF160973 Al127758 AW009952 Al440473 AW136694 AW008937 Al492112 AW294956 H12044
			AA609256 Al400622 AA778657 Al342773 BE501767 BE048879 Al187333 AW025304 Al191550 AA383780 BE350769
			AW024606 Al244835 AA228447 AA983651 AA027332 Al167499 AA913695 Al479796 AA960843 AW272340 C02052 Al433299
			AB032994 AL136549 Al126781 Al339656 AA324178 AW274942 AW404411 AA351287 AW503975 AA978021 H19254
15			AA826207 AA365760 AA887252 W35146 AW299327 AW593902 AA932287 AI940307 AW955721 M62008 AA034345 BE048271
			AA365723 AA682987 AA324179 T08342 BE396592 BE269097 BE242683 AA351288 AA317743 AA323517 AW950991
			BE169813 AW500399 AL119581 AW401530 AW501601 AW501500 AA663641 AW892664 AW501520 AW501448 AW501591
	•		AW500843 AW499580 BE396829 AA143673 AI834230 AW500792 AI909739 AW845214 BE140556 AW845213 AW500505
20			AW500506 AW845216 AW574989 AI834238 AI929491 AW576513 BE245479 BE241953 AW505039 AI263367 H12043
20	300063	22431_1	AA033638 AW339671 AW963748 AW449073 NM_016507 AF227198 BE062563 AW893244 Al695667 AW370607 AW370608 AW505230 AL121377 T19010
	303303	22431_1	AA397553 AI138391 T86408 R78328 AA829647 AI797062 AW502286 AI703352 AI298289 AA730053 AA047200 AW083099
			AW370617 AI128124 AI264202 AI350744
	319000	1534458_1	Z44318 F06149 R20136 R14907
25	319003	174731_1	R18085 AA219028 R17712 Z44345
	319027	6267_1	AK002182 AW842140 BE391303 AW807017 AW604195 AW604194 AK000527 AA716612 AW291848 C17004 D78698
ļui.			AA633316 AW085548 AW954620 AA351081 AW377003 AA594606 AA290880 R35913 Z44526 T74413 H39831 H03611 H70235
			AA410732 AA404618 AA026902 N87562 R49433 AI346545 H03501 AW189821 AA235590 AI188349 AW262971 AA283775
□ 30			Al431671 AA026903 Al246417 Al636152 Al370910 T74039 Al128930 BE208355 Z40426 AA291429 R01208 Al824714
☐ 30 □	302722	44456 1	AW075793 AA576559 U53530 L23958 AA775976 BE003131 Al903793
Ш		969232_1	AL039604 AL039497
		167464_1	Z44855 AA196906 AA196723 BE278458 AA412305
<b>F</b>		23857_1	AJ133798 NM_014427 AJ133799 R19516 AA071126 AI278055 AA071125 AI915130 AI582322 AW070237 Z39757
35		1237615_1	BE392792 H55196 Z45264
<del>11</del>		922966_1	Al908374 Z45366 R11479 H79927
		226420_1	AA323682 Z44357 F11306 R49705 R60252 T09440 T09172 H09876 F06094 R60848 H06625 T07793
=		215022_1	AA308601 AW411014
<b>40</b>	303407	6848_4	AB040958 AA309616 AA322942 AA331675 BE257729 AW806959 AW860144 AW806968 AW512751 AI239617 R68424 R72046
ī v	318504	1703724_1	H85465 N28472 Al971920 Al459052 Al082821 H49714 Al218903 AA244036 T26453 Z44226 R20425
1 <b>2</b> 71 :	318563		AB037724 BE260227 R21318 BE538345 AW250501 AW403023 R46363 Z43008 R14654 AW953148 AW953149 T33110
N			R20231 H30838 F05454 Z45790 AW965595 T08819 H06568 H29913 R16617 AW006449 AA588448 Al909629 R10832
<b>~</b> ]			AW245067 AI479004 H29825 AI097108 AI829928 AI636607 AI079390 AA353858 AI374890 BE247041 R43324 R10833
<b>45</b>			AA603730 AI298051 AI580953 AA400088 R16559 AI369715 AA401378 AW976688 BE245314 AW249837 AI869249 AA349796
U	004404	04050 0	AA783040 AW474996 Al028378 R45633 Al864452 AA470470 AA629126 Al262201 H06513
		340562 252948_1	H71886 R23313 R23323 Z25059 AA359123 AW965886 BE167187 AI808503
		244029_2	AA746272 AA504079 AA347316 BE084755
50		972533_1	AL043430 N79419
		1071625_1	R87679 H16883 F07785 AW245503
		34022_1	AL137382 AA305545
		29065_6	BE145971 BE146046 BE146316 BE146148 AA421129 AA382152 AW836960 AW836945 AW836851
55		270128_1	AW303377 AW270092 AA382636
33		247031_1 47307_1	T65096 F12013 AA351004 F11787 T66093 AF086321 W73400 W73375
		2136611	N62228
		84545_1	AA010976 AW611600
		284260_1	AW299459 AA417112
60		290929_1	AA430709 AA427966
		1541128_1	F13458 R17813 T74431
		226757_2	R00371 R09720 R09711 AW873586 AI703426 AW016769 R36969 R00259 AI216256 R09712
		323486_1	Z30201 AA486132 T72025
65		338029_1 423491_1	T87431 AW300867 T87330 AA515973 Al242970 Al660245 Al950027 AA971142 Al302981 AW771990 AA723809 AW195235
05		54759_3	A1142379 AA905379
		1688716_1	T86043 R01431 T75579 T75580 T83765 T98413
		174437_1	AW505368 AA218610 F11852 T65345 AA397806
	303782	2213_1	AA325129 AV655735 AW408703 AW505411 T64737
70		1691029_1	R06504 T99600 T95769
		1540877_1	F13195 Z42617 T75318
		551394_1 1764305_1	A1017510 T91374 T87761 P06036 W87407
		1764305_1 382018_1	T87761 R95026 W87407 AA627706 F28433 D63189
75		193841_1	AA323400 AW968650 AA262398 H03952 AA824430
		1563872_1	H46445 H22490 H19702 H46328

	305064 114227 303835 1305867_1 303849 43707_1	AA636012 T05645 T32180 AW961890 T08680 AA249439 BE256642 AW163324 AF012357 AL359617 H95481 AI217156 AI332310 AI016751 H94962 AW105657 AW082779
5		AA815334 AA954302 AA628321 Z42118 AA737794 F08727 F06339 F07626 AI829971 T89928 AW970824 AW157525 AI979018 AI537885 AI636077 AW439894 AI687692 AI476254 AI870810 AI860351 AI248264 Z40675 F05012 F02632 AA564443 AW298565 BE091953 BE091884 F01656 BE091886 BE091841 BE091851 BE241581 AA403051
10	320115 5823141 320121 452027_1 318946 92484_1	T93574 AA780365 AA909233 Al275542 AI122843 Z43800 R19718 R59259 N74752 W20097 N46928 AA215691 AW672684 AW672673 AL044945 H93163 H92772 AW451096 AW675432 AW675425 AA844417 AW674797 AA855104 AA291320 AA770259 AI749837 AA034362 AW370463
10	312339 151127_1	Al825998 AA027067 AA744373 AA732336 AW674014 AA291321 AA029285 AA766450 R59201 AA588329 AI168449 AA215692 AI079651 Z39868 R05650 F03066 AA357760 AW955291 AI992075 AW020148 N90519 AA524394 AW015969 AA158731 AI831401 AI955800 AW272596 AW272595 AI281799 R34231 R35558 AW378527
15	304576 25108_1	AA329384 S49006 AW405735 AW404287 AW405848 AW405979 BE538908 H70947 AI814190 AA381896 AW582731 AW975580 T94914 AW474500 AW869616 AW974125 AW946246 H44560 AW802184 AI538108 AW609912 AW865715 BE007659 AA443571 AW376161 AW797783 AA713566 AW577973 AA745472 AW270172 AA910107 AA713717 AW364122 AA533898 AI523353 AA715899 H44507 AW947263 AW390753 T89943 R66359 H44320 T64100 AA715879 R54661 AW579645 H68597 AI499528 AI699010 AW605041 AW605043 AA236700 AI290767 H27472 AW079688 T69967 T87728 AW869468 AW873389 AI250670 AA617786 AI566627 AW627605 AW302334 AA617836 AV793186 H16015 R83107 T85409 AA643479
20		AA582449 AW794654 Al819995 AW865810 AW380149 AW793863 Al281629 T64021 AA501599 R49882 AA565066 R69406 N23918 T59642 R54662 AW973199 R53006 AA401087 AA496563 AW934874 BE171294 AW793133 Al581595 AW605835 AW605040 AW605055 AW605033 AW605058 AA291844 AW382472 AW605005 AA421881 AA513106 AA744190 AW386065 AW613785 AW605829 AA580905 AW605027 AW364134 AA464027 BE012096 BE008565 AA809035 AA809154 AA911395
25	303958 10830 7	AA713636 AA745324 AA826230 AW368498 AV646747 T89967 H61164 AI540661 AA721571 C02031 AA523762 AA523746 AI287256 AW841164 AA962139 AW797014 AA515246 AW364140 H45842 T94267 T72111 R49771 T70151 H42664 R83656 R83590 AW380297 AW380263 X95750 T57717 AW391436 AA293355 AW380185 X95749 X95748 X95747 AW796510 AA318628 AI001043 AA744404 AA745567 AA650437 AA715526 AW392762 AA516228 AL042931 T70163
□ □ 30	319668 17848_1 320236 321288_1	NM_002731 M34181 AA091596 AA090564 AW498491 AA383248 AA018979 AA352938 AL133918 T28731 AA984398 AL134676 AW898293 M77877 Al124701 BE567802 Al288466 AA719614 BE622570
O 30 O V O 35	320258 217516_3 319793 1698018_1	AA528811 AA482942 BE396475 AW814056 AA311866 H05207 R94015 AA504370 AW962851 T70351 R56360 R20336 R67291 R14290
□ 35 □ □	320360 259694_1 319886 22717_1	H12405 H12404 AA368159 AK000906 AA603325 AI123244 AI742610 AI742621 AW451297 AI963292 N94395 AI122654 AI869312 AA693938 AI913241 R69552 AI925715 AI243319 AI085752 AI094469 AI922008 AI521658 AI288451 AA627433 BE327863 AI417213 AA937953 AW301143 AI827213 AW444808 AI056464 AA736786 AA968590 AI425075 AI420510 AI445367 AI866676 H25733 AI356146 AI803734 AI194056 AI872656 AI222629 Z38818 H25937 AI547263 AI656165 AW590474 T73549 BE392068 H14735 H27088
급 40 ቢ	306023 38159_2 313257 452953_1	H45935 AA359427 AW167511 BE463655 AA897764 N92638 AA781521 AA846225
T _ 45 T	305406 3483676 304831 13890_7	AA723860  AA314337 AI805587 AA402097 AA293631 AA658356 BE566333 AI557276 AV651311 NM_001011 Z25749 AI525506 R97869 BE546683 AA155861 AA532947 AA329269 H63470 AA187471 AV660956 AV650019 AA380909 AW327895 BE313243 N93984 AA354585 W19057 AA428966 T55686 AW958123 AA315872 AA081305 AA083776 AW961442 AA352331 H00860 AA206205 W21515 AA149180 H13044 AA372080 AV658875 AV658874 AA337727 BE276865 AA247683 AA209449 AA393619 AA147378 AW404839 W19374 AW247081 AA311228 BE615971 AA308572 W01826 AA310230 AA412606 AA420575 AA362646 H70797 AA525988 AA311440 BE564044 AW967302 AA302565 AA313021 AA312653 D52864 AA312582 AV654672 AA308096
50		AA308509 AA308491 AA305867 AA306813 W75940 AV653876 AA365315 AW408185 AA308217 AA122395 AA314083 AA315981 AA311782 AA310647 W46668 N31114 AA180871 AA187276 N72805 AA312418 AA304985 AA167580 AA307881 AA310961 AW674912 AA310126 H82669 AA132497 AA809088 AA155963 AA640361 BE618580 AA229152 AW404970 AA306621 AA308276 N98583 AV660766 AA654587 AA206190 AA312305 AA580740 AI568153 AI718253 AI860477 AI872388 AA873460 AA405147 AA315435 AI129479 AI888709 AW583033 AW089596 AW264185 AI653503 AA858344 BE619226
55		AA187721 AA306691 AW439857 BE616042 Al889905 Al862869 AA309960 AA307823 Al148769 BE619772 AA582168 Al963414 AW168760 AW167856 BE619400 BE378974 BE619933 AW958117 W49703 Al951380 AA306263 AA583192 AA356605 AA897095 AA149141 T53975 AI744255 AA845352 BE312890 AW961435 AW583101 W24684 BE619333 T96513 Al491903 BE272296 AA315556 BE539380 BE619999 AW084687 BE465646 BE262138 AA999923 BE260616 BE276306 D55310 Al186578 AI707735 AW404371 BE274614 AW512395 AA650425 Al439470 AA513739 AW404673 AW404664 M77233 AI970731 AI880754
. 60		Al418821 AW273410 AA069936 AW058084 AA719351 AW404422 AW405314 Al523106 AA393107 BE408961 BE252375 AA578681 BE513748 Al749494 N36979 N43025 D11774 AW391958 R34130 BE394953 Al865715 Al018059 N46292 AA908866 AA907443 AW081633 AA622318 AW438511 BE262297 AA565643 Al018057 Al440067 Al719291 AA135054 BE222834 AW262240 AA081120 AA442581 N86460 AA583569 Al061357 W72482 AA148278 Al186761 AA512934 AW615804 AA595332 Al831069 AA778136 AA657641 Al433175 AA398698 Al735084 BE183158 Al566940 AW304785 Al401846 AA506149 AA102508
65		AA736531 Al027939 AW000716 AA861339 Al027937 AA575877 AA639090 AW129111 Al421179 AA506553 AA936780 AA972869 AA563975 AA582448 Al802748 Al471162 AA586422 N86248 AA528142 AA551225 Al566307 Al206730 AA513485 AA363629 AA436824 AW575828 AA180774 Al001103 AA932070 AA613667 Al337566 AA582127 AW327319 AA610833 Al333738 Al708124 Al349480 Al240444 Al225152 AA570790 Al539813 W80674 Al333517 AA181299 AA315527 Al719857 BE087137 AW474616 Al510739 AA614724 AW337476 AW951820 AA149181 AA149142 AA523097 AA428873 Al708760
70		Al978984 AA946913 AA844685 Al440225 AA306527 BE349026 Al659593 AA845752 AW327366 AA311945 AA595594 Al027199 Al499554 Al262336 AA398535 Al333388 AW575598 Al472745 Al476623 Al150520 AW897766 Al864033 AW584030 AA148411 BE348977 AA420550 AW768575 T27844 Al349314 Al371037 Al675707 AW102842 Al203978 Al719821 AW768495 AW021575 Al686981 R36541 Al346551 AW888705 R25390 AA209335 Al342426 AA056446 AA582981 AA890201 AW026850 AA857587 N91141 AW768541 T55235 AA401942 AA080860 Al291273 Al312669 AA412271 AA890649 AA846264 BE019907 BE090895
75		T56904 H70798 Al500573 AW327642 F17734 AA157192 AA152417 AW327670 AA985481 H71524 AW439687 AA968516 AW327857 AA405330 Al342315 H01239 AA878156 AA148279 H71525 N52399 Al991878 AA878100 N93956 H56020 AA132515 W49704 H63414 Al717990 Al814318 AA912383 AA922317 R97819 Al860255 Al335093 Al187843 AW270357 AA187646

5		Al190237 Al991126 W07024 BE539453 Al819841 H75424 AA102446 AW026974 Al923973 AW001389 AA337759 N70772 AW022155 AA336624 Al219252 N89590 AA664546 AW339690 AA651993 AA608735 H65064 AA857788 T81916 AA860215 Al031685 AA133689 AA186954 R16825 N27213 AA857155 N69981 AA318664 Al735334 H82411 Al460293 AA205819 AW803086 Al922965 N33363 AA580622 AA664756 AA651961 Al201624 Al066494 AA834187 AA187722 AA652066 W80675 AW051553 AW263699 R34131 AA340971 AA364263 Al824574 Al356913 Al439263 AA205822 Al540881 AA640625 Al206794 Al198883 AA167581 AA970474 AA299068 AA157088 N90120 Al371330 AA090914 Al889887 Al274617 AA730747 AI745000 AW265227 Al358313 AA122396 AA501489 AA918963 AA953637 Al434343 Al707767 AA603889 W04799 T55604 AA614231
10		AA071264 AA083777 Al880809 Al185259 AA747112 AA908459 AA134970 Al192649 BE046107 Al358698 AA310968 AW517574 AA984892 W46578 AW105597 AA224970 AA747937 T96514 Al472689 AA283670 Al186789 F35482 AW873463 AW361039 AA583072 Al872660 AA040277 AA224895 N85343 AA484723 AA937597 Al304419 AA228409 AA501488 AA664896 AA664966 AA482963 AA736806 AA528814 AA927560 AA328094 N83225 AA582536 AA938377 AA916871 AA507716 AA101182 Al720885 AA876858 AA483322 AA362647 N75592 N23917 Al193949 N74054 Al352629 D51754 Al570783 AA470923 AW975162 AA328256 AA659768 Al919411 W40458 F00799 AA147346 AA728856 AA528675 Al676101 AA523785 T52866 AA533842
15		AW516442 AA554875 AA886066 AW518472 AA971169 AA908345 AI561318 AA482746 AA482735 AA482882 AA188350 AA62989 AA482917 AW263351 T52867 D52318 AI696386 AA689276 AI719128 AI719124 AA541702 X85626 AA640165 AA228408 AI832575 AI143550 AI281727 N73099 AA733095 AI749387 X85625 AA640766 AA652170 AA652139 AW606146 AA649563 T25406 AA327330 AA080984 X74803 AA746016 AW957997 AI005578 BE547070 AA886825 AA927742 AI927866 AA528573 AA665260 AW270340 AI698507 AA501524 AA483113 AA506345 N91789 AI933429 AW904843 BE092709 BE093487
20	319900 1138215_1 321121 1545647_1 321132 117535_1 320503 25164_1	BE093472 BE092712 F22641 N80062 AW455220 BE079292 AW408392 AW847299 AW847302 T86065 T85884 T77135 W23285 H42714 F25381 F37215 AA081495 R87345 H43858 BE266428 BE263090
25	320586 26170_1 305557 41560_1 304978 28800_7	NM_005897 AF156857 AA346876 BE545147 AI003306 N45644 AW889728 BE007236 NM_003658 AF031924 AJ243512 AI792204 AI675861 AI915798 AI733496 AI823489 AI370544 AI696665 AA991537 AA774834 AK001079 BE293936 AW372365 BE271898 F00113 AA424108 AI950409 W70049 N56481 BE046416 W70050 AI619669 AL040446 AA996189 AA962427 W37166 AA179135 Z21574 N64837 BE562818 BE259406 BE379716 AA147786 BE300171 BE267161 BE515287 AU076914 AW374229 AA069647 BE561555 D53431 D54395
) 30	3043/10 20000_/	AA191250 D52650 BE208576 BE566731 BE387383 AA373416 R23516 T68691 T69334 AA355791 R02636 BE566591 BE407444 A1982546 H49682 AA094446 BE515225 D54740 AA095796 AA196716 AA353034 AW955137 D53869 AA100150 AA188091 A1524940 D54982 AA090373 D53479 AA247363 BE567604 BE391813 N41527 BE410575 AA380139 BE616028 AW881909 AW963736 BE276064 BE380156 BE566181 BE567132 BE561903 A1205098 X52851 AW881897 BE616573 BE298397 AA127519 R88890 BE616648 BE279162 BE559666 BE514563 BE312454 BE407312 BE276098 BE394047 BE267326 BE276908 BE56569 BE385054 BE265740 BE409229 H44489 AA207193 AI525570 BE304612 BE396965 BE386123
35		BE264758 BE266121 AA215851 BE295137 BE512683 BE388849 AA223494 BE263350 BE408879 BE386132 BE382906 BE271789 BE539264 BE378507 BE567995 BE208471 Y00052 BE256484 BE260931 AL021395 BE260620 BE512892 Al906447 BE615419 BE560786 BE279517 H46528 BE258084 BE535992 BE274774 BE274916 BE260585 BE563269 BE249941 BE264782 BE408521 BE312750 BE559964 AA147099 T70141 AV661600 AA581711 AA186462 T69259 AA521058 AA563932 BE397758 T68848 BE514531 H50191 AA641322 Al869370 AA653502 T70072 AW139957 AA069924 Al953984 C06029
		AA190399 AA617735 AA085181 AA506423 AI470746 C05982 BE077432 AW945661 BE272794 AA011065 AA922406 BE183113 AA564289 AA374410 AI264729 AW957628 T68610 AA143328 AW381780 AW381880 AA135191 AA857453 AA112231 AA011066 F36776 AW798236 H00395 BE272608 AW798123 AA532416 AI936732 BE183271 AA129828 AA741102 BE164382 AW799104 AW997926 AA211136 AW601437 AW602618 H11277 AA083462 AA056516 AW364819 R01694 AA086193 BE171120 BE093136 AW796864 AA663009 AW605266 AA247458 AW796905 BE171125 AW392363 BE171106 BE171110 AW796810 AW796854 AW578648 AI221714 AW151499 AW937186 BE293542 BE249842 AW363879 AI701218 AW084288
45	304983 25108_1	AA489447 AW798124 AW798256 AA658272 U46266 AA329384 S49006 AW405735 AW404287 AW405848 AW405979 BE538908 H70947 AI814190 AA381896 AW582731 AW975580 T94914 AW474500 AW869616 AW974125 AW946246 H44560 AW802184 AI538108 AW609912 AW865715 BE007659 AA443571 AW376161 AW797783 AA713566 AW577973 AA745472 AW270172 AA910107 AA713717 AW364122
50		AA533898 Al523353 AA715899 H44507 AW947263 AW390753 T89943 R66359 H44320 T64100 AA715879 R54661 AW579645 H68597 Al499528 Al699010 AW605041 AW605043 AA236700 Al290767 H27472 AW079688 T69967 T87728 AW869468 AW873389 Al250670 AA617786 Al566627 AW627605 AW302334 AA617836 AW793186 H16015 R83107 T85409 AA643479 AA582449 AW794654 Al819995 AW865810 AW380149 AW793863 Al281629 T64021 AA501599 R49882 AA565066 R69406 N23918 T59642 R54662 AW973199 R53006 AA401087 AA496563 AW934874 BE171294 AW793133 Al581595 AW605835
55		AW605040 AW605055 AW605033 AW605058 AA291844 AW382472 AW605005 AA421881 AA513106 AA744190 AW386065 AW613785 AW605829 AA580905 AW605027 AW364134 AA464027 BE012096 BE008565 AA809035 AA809154 AA911395 AA713636 AA745324 AA826230 AW368498 AV646747 T89967 H61164 AI540661 AA721571 C02031 AA523762 AA523746 A1287256 AW841164 AA962139 AW797014 AA515246 AW364140 H45842 T94267 T72111 R49771 T70151 H42664 R83656 R83590 AW380297 AW380263 X95750 T57717 AW391436 AA293355 AW380185 X95749 X95748 X95747 AW796510
60	321223 249691_1 321240 2628_30 321286 236538_2 313476 83849_1	AA318628 Al001043 AA744404 AA745567 AA650437 AA715526 AW392762 AA516228 AA431366 AA490423 H96381 AA361614 H56121 AA354669 X58799 AF071472 BE245833 BE539992 Al380940 AW952644 AA535470 R84610 AA010267 AA720674 AA010209
65	312854 467476_1 321304 115882_1 321321 32811_1 321325 28266_1	AA837782 AA828713 H84206 AW979069 BE260893 AA078319 R85057 AW803024 H85811 AA078293 AB033072 AW163387 AW161566 T08007 AW161909 AW157331 AB033100 AA347036 BE260325 AW961669 AL047207 AA347037 AI766894 AA601045 AI559897 AW139033 AW274622 AW172884 AW089070 AA804340 AW798925
70	321354 1160282 321359 41877_1 320727 36759_63	AA078493 AW972301 AW474412 AJ227863 AA516297 AA641949 AW995029 AW003360 Al971548 AA017585 X80306 X91133 AJ276100 X91132 AF064499 AF064495 AF063768 X83713 AW951310 AW975565 AA721610 AA715972
75	320767 18895_2 322012 22619_2	H54398 AA700844 AW895023 BE549308 AW834812 AA299525 AW957027 AA001789 BE219218 R73244 AL137357 AW173064 AW662837 AI222955 AI138884 AW438842 AA883686 AA978208 AA653137 AA906477 AI150554 BE295082 BE243550
	306406 AA971973	

```
306426 AA975039
               306443 AA976950
               306511 AA988891
               320965 266751_1
                                    H18166 R86173 H19851
       5
               306531 AA991423
               306546 AA993109
               306549 AA993796
               306558 AA994743
               306590 Al000246
      10
               306591 Al000248
              329464 c_y_hs
336695 CH22_4181FG_48_4_
              329496 c10_p2
              336705 CH22_4209FG_63_2_
336717 CH22_4234FG_81_1_
     15
              306668 AI004890
              306739 AI028393
              306791 AI042387
              329665 c14_p2
     20
              336883 CH22_4625FG_322_2_
              336898 CH22_4647FG_330_1_
              308016 Al445116
              308082 AI473682
              338177 CH22_6725FG__LINK_EM:AC00
     25
              308092 Al474896
              308097 Al475411
              306801 AI052653
              306809 AI057134
336908 CH22_4670FG_343_2_
     30
              336917 CH22_4688FG_346_4_
306839 Al077385
              306866 AI086683
              306881 Al088695
308115 Al479071
     35
              308127 AI492187
             308138 Al494446
306919 Al096832
306930 Al124518
₽
             329824 c14_p2
329839 c14_p2
306975 Al127042
40
              308258 Al565612
Ñ
             308282 Al569456
             308311 Al581855
    45
             308382 AI624301
             308385 Al625428
Ш
             308406 Al634885
             308449 Al660854
             308465 Al672480
             308517 Al689279
    50
             308539 Al694191
             308544 AI695133
             308548 Al695484
             338648 CH22_7413FG__LINK_EM:AC00
    55
             308572 AI707882
             338668 CH22_7441FG__LINK_EM:AC00
             308582 AI709056
             338679 CH22_7453FG__LINK_EM:AC00
             308598 AI719237
    60
             338686 CH22_7461FG__LINK_EM:AC00
             308601 AI719930
             338703 CH22_7483FG__LINK_EM:AC00
338705 CH22_7485FG__LINK_EM:AC00
338725 CH22_7521FG__LINK_EM:AC00
    65
             338747 CH22_7561FG__LINK_EM:AC00
             308676 AI761036
             338770 CH22_7593FG__LINK_EM:AC00
             308695 AI763350
             308707 AI769997
    70
             308718 AI798009
             308851 AI829820
             308954 AI868958
             308961 AI870248
             333043 CH22_269FG_70_4_LINK_EM:A
    75
             333054 CH22_280FG_73_8_LINK_EM:A
             308991 Al879831
```

			647662_1 AA377444 AI458965
			AA627127
			AA629988 AA632201
	5		CH22_2463FG_497_15_LINK_E
		335157	CH22_2493FG_501_7_LINK_EM
			AA640579
			CH22_2499FG_502_7_LINK_EM
	10		AA641485 CH22_2510FG_504_4_LINK_EM
	10		AA642917
			AA649244
			CH22_2538FG_508_9_LINK_EM
	15		CH22_2539FG_508_10_LINK_E
	13		CH22_2556FG_512_3_LINK_EM AA653159
			AA653589
			c_6_hs
	20		c_6_hs
	20		CH22_2573FG_515_3_LINK_EM
			CH22_2577FG_515_8_LINK_EM c_6_hs
			CH22_2589FG_516_8_LINK_EM
			AA663080
	25		AA663105
			C_6_hs
			CH22_2604FG_520_3_LINK_EM CH22_2607FG_521_1_LINK_EM
			CH22_2608FG_521_1_LINK_EM
	30		c_6_hs
ā			AA666301
2_ E			CH22_2623FG_524_4_LINK_EM
			CH22_2626FG_526_6_LINK_EM c_6_hs
呈	35		AW470753
Щ			AW471472
		326806	
=			c20_hs
	40	326857 326874	
īŪ	40	326876	
N		326884	
1 <del>1 1</del> 1			CH22_2654FG_532_4_LINK_EM
7	45		AA670431 CH22_2664FG_534_7_LINK_EM
	73	328109	
N			CH22_2675FG_535_4_LINK_EM
		335339	CH22_2686FG_535_16_LINK_E
	50		AA679225
	50	335340 335344	
		000011	CH22_2695FG_537_4_LINK_EM
			CH22_2696FG_539_2_LINK_EM
			AA679505
	55	328134	
			CH22_2720FG_543_9_LINK_EM CH22_2726FG_543_17_LINK_E
		328171	
		326942	
	60	326943	c21_hs
		326957	
		326981 326997	
			AA704235
	65		CH22_2772FG_551_1_LINK_EM
		328221	
		328224	
		328228 335448	CH22_2799FG_562_5_LINK_EM
	70		AA708902
		335451	CH22_2802FG_562_9_LINK_EM
		328236	
		335455 328243	CH22_2806FG_562_15_LINK_E
	75		CH22_2819FG_567_4_LINK_EM
	. •		CH22_2821FG_568_3_LINK_EM
			<del>-</del> -

		335482 CH22_2834FG_570_11_LINK_E 335485 CH22_2837FG_570_17_LINK_E
		328271 c_6_hs
	5	328276 c_7_hs 328277 c_7_hs
	3	328282 c 7 hs
		305403 AA723748
		335517 CH22_2872FG_571_34_LINK_E
	10	328305
	10	335527 CH22_2882FG_572_7_LINK_EM
		305443 AA736653
		328314 c_7_hs
	15	335536 CH22_2891FG_574_2_LINK_EM 305454 AA738413
		328328 c_7_hs
		305464 AA742425
		335565 CH22_2921FG_579_1_LINK_EM
	20	335566 CH22_2922FG_580_1_LINK_EM 305486 AA748889
		335585 CH22_2943FG_581_24_LINK_E
		335587 CH22_2945FG_581_26_LINK_E
		335593 CH22_2951FG_581_32_LINK_E
	25	335606 CH22_2964FG_582_3_LINK_EM 305536 AA770682
		305547 AA773111
		335634 CH22_2994FG_584_14_LINK_E
F		328420 c_7_hs
<del>=</del>	30	328428 c_7_hs 335651 CH22_3011FG_590_2 LINK EM
<del>-</del>	50	335652 CH22_3012FG_590_3_LINK_EM
		328436 c_7_hs
 [		328444 c_7_hs
	35	335667 CH22_3027FG_590_18_LINK_E 328462 c_7_hs
	<b>J</b>	328467 c_7_hs
		335687 CH22_3048FG_596_2_LINK_EM
3		335690 CH22_3051FG_596_5_LINK_EM
	40	328474 c_7_hs 335692 CH22_3053FG_596_7_LINK_EM
U	. •	335693 CH22_3054FG_596_8_LINK_EM
71		328484 c_7_hs
ال <sup>ا</sup> الم		335700 CH22_3061FG_598_1_LINK_EM 305621 AA789095
	45	305632 AA805276
-		335720 CH22_3081FG_599_23_LINK_E
Ų		335721 CH22_3082FG_599_24_LINK_E
		328504 c_7_hs 328506 c_7_hs
	50	328507 c_7_hs
		335733 CH22_3095FG_601_3_LINK_EM
		335739 CH22_3102FG_601_10_LINK_E 335745 CH22_3108FG_601_16_LINK_E
		335745 CH22_3108FG_601_16_LINK_E 335747 CH22_3111FG_601_20_LINK_E
	55	335750 CH22_3115FG_602_4_LINK_EM
		335755 CH22_3122FG_604_4_LINK_EM
		328544 c_7_hs 335768 CH22 3137FG 607 2 LINK EM
		305686 AA812726
	60	328552 c_7_hs
		335774 CH22_3143FG_607_10_LINK_E
		328557 c_7_hs 328558 c_7_hs
		335777 CH22_3146FG_607_13_LINK_E
	65	305697 AA814956
		335782 CH22_3151FG_609_4_LINK_EM
		335783 CH22_3152FG_610_3_LINK_EM 328569 c_7_hs
		335787 CH22_3156FG_611_3_LINK_EM
	70	328570 c_7_hs
		328581 c_7_hs 328582 c_7_hs
		328592 c_7_hs
	76	337011 CH22_4876FG_427_6_
	75	337023 CH22_4894FG_433_12_
		337032 CH22_4910FG_438_3_

		337069 CH22_4967FG_448_2_
		337092 CH22_5016FG_465_12_ 337093 CH22_5017FG_465_18_
		337094 CH22_5018FG_465_19_
	5	337097 CH22_5028FG_471_1
		305700 AA815428 335806 CH22_3178FG_616_8_LINK_EN
		335806 CH22_3178FG_616_8_LINK_EN 335817 CH22_3189FG_618_5_LINK_EN
		328607 CH22_3169FG_616_5_LINK_EN
	10	335827 CH22_3200FG_620_1_LINK_EM
		335831 CH22_3204FG_620_5_LINK_EM
		335832 CH22_3205FG_620_6_LINK_EM
		328620 c_7_hs 328624 c_7_hs
	15	328636 c_7_hs
		335863 CH22_3238FG_629_8_LINK_EM
		305782 AA844730
		305787 AA845035
	20	328662 c_7_hs 335895 CH22_3272FG_635_3_LINK_EM
	20	337100 CH22_5031FG_472_3_
		337114 CH22_5060FG_494_17_
		337121 CH22_5096FG_519_1_
	25	337132 CH22_5112FG_526_3_
	25	337168 CH22_5188FG_562_28_ 307085 AI160868
: :		337170 CH22_5190FG_564_1_
<b>1</b> -		337172 CH22_5192FG_565_2_
	••	307090 Al161024
	30	305803 AA846052
Ш		305808 AA853958
F		305816 AA854776 335902 CH22_3279FG_635_10 LINK E
Ō		335920 CH22_3297FG_636_16_LINK_E
Ö	35	305841 AA860348
Ö		305867 AA864572
		335956 CH22_3334FG_647_3_LINK_DJ 305877 AA865649
Ε		335968 CH22_3347FG_652_1_LINK_DJ
	40	335971 CH22_3350FG_652_4_LINK_DJ
N		335975 CH22_3354FG_652_9_LINK_DJ
ŢĮ.		335980 CH22_3360FG_653_2_LINK_DJ
###		328768 c_7_hs 328770 c 7 hs
j	45	335993 CH22_3373FG_656_6_LINK_DJ
	-	335998 CH22_3379FG_656_16_LINK_D
H		335999 CH22_3380FG_657_1_LINK_DJ
		328791 c_7_hs 337203 CH22_5256FG_591_3_
	50	337203 CH22_5256FG_591_3_ 337204 CH22_5261FG_595_1_
		307120 Al184343
		307140 Al185762
		307177 Al188864
	55	305903 AA873085 305925 AA877883
	33	328803 c_7_hs
		330002 c16_p2
		328810 c_7_hs
	60	328820 c_7_hs
	OU	330021 c16_p2 305967 AA886428
		328835 c_7_hs
		305971 AA886874
	65	328841 c_7_hs
	03	305984 AA887654 328851 c_7_hs
		328859 c_7_hs
		330057 c17_p2
	70	330058 c17_p2
	70	305999 AA889603
		307215 Al193189 307262 Al202100
		307318 AI208577
		307380 Al222985
	75	307433 Al244895
		307437 AI245683

		307558	AI281651 AI281998		
		337645	CH22_596	OFG_LINK_EM:ACOO	
	5		CH22_59/0 AI283549	6FG_LINK_EM:AC00	
	•		AI285535		
		307592	AI285739		
				0FG_LINK_EM:AC00	
	10	337695	CH22_6033	3FGLINK_EM:AC00	
	10		AI290006	7FGLINK_EM:AC00	
		30, 300	AIZOOOO		
			AI300246		
	15		AI302103		
	13		Al302124 Al302236		
			AI318588		
			AI335557		
	20		AI339447		
	20		AI351112 AI884454		
		307864	AI367417		
		307877	AI368880		
	25		A1380270		
	23		AI925949 AI949216		
L			AI951727		
			AI381019		
블	20		AI382224		
블	30		AI383496 AI419692		
O			Al421059		
			AI434166		
	25		AI961962		
	35		AI971416 AI972447		
Ö			AI972768		
			AI989570		
	40		AW015373		
Ū	40		AW025709 AW028652		
Ū			AW057547		
<u>.                                    </u>			AW082954		
	45		AW151131		
₫.	73	325271	AW172384 c11 hs		
U		325285			
		325289			
	50		AW182066 AW182800		
	50		AW268822		
		309767	AW271805		
			AW292760		
	55	302681	AW298760	X97550 X97552	
		302683	31326_1	X85153 T63701	
			AW444488		
		309977	AW451663		
	60	302727	AW452919 32493_1	L10141 L10151 L10148 L0909	95
		302747	32813_1	AF062275 L03830	-
		304022			
		304055   304056			
	65	304060			
		304125	H40976		
		304127			
		304134 I 304195 I			
	70	302952		AF103179 U82961	
		302996	41196_1	AF054663 AF124197 R70292	
			AA069029		
			AA137045 AA157834		
	75		AA293494		
			AA421948		

		304467 AA424	702
		304480 AA430	
		304485 AA434	76
	5	304487 AA434	
	)	304559 AA488 304575 AA496	
		304605 AA513	
		304612 AA514	
	10	304623 AA521	
	10	304635 AA5239 304667 AA5359	
		304674 AA541	
		304675 AA541	
	15	304693 AA554	
	15	304696 AA5547	
		304707 AA5640 304731 AA5760	
		304734 AA5764	
		304745 AA5777	
	20	304746 AA5777	
		306009 AA8945 306012 AA8965	
		306053 AA9053	
		306081 AA9084	
	25	306090 AA9086	
		304811 AA5843	
1		304813 AA5845 304817 AA5847	
		304833 AA5865	
	30	304841 AA5875	
Ф		304887 AA5993	
7		306137 AA9161 306180 AA9225	
		306183 AA9226	
	35	306193 AA9234	
Ш		304918 AA6026	
		304968 AA6143	
8		306200 AA9268 306220 AA9283	
	40	306221 AA9286	
		306300 AA9375	73
Ñ		320789 252516	
-1		306351 AA9613 330435 41165_	0 U63836 AW842139 X74956 U78550 AW840802 X74954 AW388241 AW842709 AF253321 X74955 X74370 AW363799
Ō	45	330433 41100_	BE073386 AI791962 AA587390 AW840865
	.5	330436 10605_3	4 BE259039 W29128 AW410299 X72990 BE246492 NM_005243 X66899 AI909006 AW248151 AL031186 AA012966 BE273549
IJ			BE311429 BE253102 Y07848 BE538102 BE256863 BE261240 BE312156 BE618412 BE257322 BE620446 AW806629
			AA376777 AA325384 BE256808 BE251039 BE257878 BE275352 AA357169 AW403562 AA204995 AA093259 W95953
	50		BE256279 BE336683 BE252465 BE251266 AA380754 BE294942 AA380941 AA380999 BE297164 BE249995 BE294719 BE295372 Al270673 BE305132 BE563752 BE295357 Al525421 BE263980 AA057505 AA020915 BE266318 BE206948
			Al474020 BE296420 BE297374 BE408545 BE019366 BE407372 BE266180 BE279437 R58233 T19567 BE300738 AW381179
			AA357571 AW361285 AA436908 AA301019 AA301022 N20202 BE408777 BE548638 BE167415 AA071260 BE088429
			BE280092 W23117 T19568 R51681 AW402216 W22784 BE185607 AI457224 BE544120 AL134874 S72620 AA375079 D51319
	55		AW818280 BE514686 AW853024 BE563744 AA300469 T07592 BE622190 BE272834 W21781 BE315450 BE542367 BE393120 AA988441 H55137 BE562296 BE622502 BE395960 AA329733 AA332348 AI768317 AA456866 AI497832 AW878437 AA857042
	55		U18018 BE621418 Al818790 Al949507 BE397693 Al885545 Al858854 Al355147 BE169028 S62138 AW732191 AA856891
			BE266060 X71427 BE268557 AF095890 AW001288 AI799634 AI623498 AA071346 BE547662 BE261446 AI564543 BE559759
			U35622 BE314249 BE264915 Al638591 Al538385 AW090025 BE384754 Al888689 AW778800 Al925273 AA075797 AW949130
	60		AV660275 AW438697 Al587137 Al524121 AA806249 AW628247 AA808241 Al244388 Al761125 AW117672 AA911782 Al129250 AA654447 H55291 BE258050 BE206162 W95867 AA857187 Al871378 Al660103 AW103827 Al220929 AW149949
	00		BE465561 Al302857 AW168841 D82190 AW249814 Al623432 Al687358 AW951077 R51592 W60458 Al092863 AW474693
			D12765 Al911646 D82208 D82187 AW074031 Al358527 AW338497 AA970893 AW072573 AA205364 Al858886 AA012830
			AW148763 Al863056 AA548656 BE250325 Al016994 Al864005 BE046122 Al497746 C75340 R58896 D82141 AW168240
	65		C19048 AI741090 D29465 AI222365 AA948288 AI583522 AW572212 AI091290 AA582727 AA579897 AA570629 W60883
	05		AW516989 AL038160 AA577334 Al865872 AA994043 AA922583 AA464778 AA209178 Al829479 Al370235 BE246529 AA384177 AA456255 Al699730 W60654 AL035744 AA862042 R32756 Al886886 AA993087 Al289479 AA627840 AA464184
			AI619503 R32755 AW075358 AI432315 AA457024 AA020865 R92132 AA454629 AA746059 AA454643 AA456240 AA826984
			BE163738 Al806470 Al991074 Al802560 AA587095 AA558714 AA968521 N87780 Al538246 N71794 AV661738 Al368903
	70		AA362570 Al989445 Al674962 S75762 BE245204 AA975296 D20123 AW005704 AA693328 AA582270 Al918474 AW205707
	70		Al696299 AA220990 AA101538 T29030 H27201 AW262526 Al610530 AA126840 AA126790 X92120 AW367868 BE299644 BE299451 AA476561 BE300044 AA134363 BE295222 AA307504 N42337 AA319098 N39502 AW964461 N57241 BE299049
			N86332 R51156 AA085859 T75212 AA133939 AA147129 AA156161 BE543953 BE538848 AA133676 BE299745 AA135050
			AA218535 AW406401 AW411287 BE410528 C01410 NM_004083 BE314959 AA836413 AA085862 AW024370 AA471059
	75		AW467508 AA001025 Al828231 AA633221 T95517 AA147038 AA476447 AW027012 AW078627 BE513200 Al192297
	75		AA886279 AW081806 AA316185 AA010506 Al269929 W93139 Al682935 AA609555 AA378028 Al093877 AA999997 AA730698
			AI143923 AW575315 AA890550 AA494353 AW576601 AI796336 AA826130 AA609207 AI539618 AI088539 AI089090 AA825505

AA632978 AA015892 AW204713 AA156495 AA824613 AA133630 N29826 AA527476 AI633352 T27908 AA134364 AA133940 AW043601 H37775 AA772375 AA057871 AA047888 AA054225 H86568 AA001511 H25718 AW189507 AA165589 AA054433 H85549 AA165486 AA058972 AA454911 AA464064 AA493802 AA428253 R85508 AW302469 AI611812 BE162582 F11073 T95518 N26811 AI783929 H40669 AW611745 AI658803 R51042 R45276 AA528386 AA782875 AW880218 AL138391 AA314536 AW949338 AA149466 AA149552 AI346513 AA216776 BE349131 AW007654 AI141803 AA622688 AI185131 AW057635 AA101539 AA627986 H27202 AI536847 W93084 AI973148 AI246788 AW572108 AI469414 AA454835 AA612707 AA430746 AI084991 AA010400 AA856636 AA463928 AI248310 R07170 AA834033 D12244 AI655670 AA054350 AA639480 AI702067 AI475389

10 330527 14658\_-15 S77356 330833 103550\_1 AA046804 AA046821 330855 111881\_1 AA070316 AA079318 332099 genbank\_AA608983 AA608983 332240 genbank\_N54803 N54803

## **TABLE 1-20B**

Table 1-20B, shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Tables 1-20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

	10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.					
	15	Strand: Nt_position:	Indicates DNA stran	d from which exons were pred positions of predicted exons.	· · · · · · · · · · · · · · · · · · ·			
		<u> </u>						
			Pkey	Ref Strand	Nt_position			
			332792 332843	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	73381-73768 1142859-1143494			
	20		332909	Dunham, I. et al. Plus	1946582-1946735			
			332920	Dunham, I. et.al. Plus	2007562-2007785			
			332947	Dunham, I. et.al. Plus	2431726-2432006			
			332949	Dunham, I. et.al. Plus	2436245-2436348			
roosyoso	25		332958	Dunham, I. et.al. Plus	2516164-2516310			
	25		332992	Dunham, I. et al. Plus	2699997-2701093			
			332993 333004	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	2701550-2701685 2759056-2759165			
m			333006	Dunham, I. et al. Plus	2762853-2762953			
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			333007	Dunham, I. et al. Plus	2763569-2763709			
7-1	30		333132	Dunham, I. et.al. Plus	3358040-3358153			
L			333133	Dunham, I. et al. Plus	3360058-3360195			
Ф			333139	Dunham, I. et.al. Plus	3369495-3369571			
			333152 333205	Dunham, I. et.al. Plus	3612171-3612354 3942727-3943009			
2	35		333221	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	3978070-3978187			
	55		333225	Dunham, I. et al. Plus	3992229-3992386			
			333245	Dunham, I. et.al. Plus	4157587-4157668			
IU			333248	Dunham, I. et.al. Plus	4162041-4162139			
Ш	40		333261	Dunham, I. et.al. Plus	4336597-4337752			
F	40		333272	Dunham, I. et al. Plus	4381561-4382212			
-			333281	Dunham, I. et.al. Plus	4506230-4506342			
느			333283 333288	Dunham, I. et.al. Plus	4514226-4514360 4516844 4516030			
П			333298	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	4516841-4516939 4581537-4581947			
	45		333306	Dunham, I. et al. Plus	5396233-5396310			
			333382	Dunham, I. et.al. Plus	4905796-4905913			
			333403	Dunham, I. et.al. Plus	4925140-4925256			
			333420	Dunham, I. et.al. Plus	4954302-4954465			
	50		333428	Dunham, I. et.al. Plus	4973869-4974007			
	50		333464	Dunham, I. et.al. Plus	5210762-5211300			
			333465 333488	Dunham, I. et al. Plus	5211385-5211858 5306333 5306310			
			333515	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	5396233-5396310 5564299-5564851			
			333520	Dunham, I. et al. Plus	5586133-5586296			
	55		333566	Dunham, I. et.al. Plus	5954226-5954473			
			333567	Dunham, I. et.al. Plus	5959139-5959515			
			333571	Dunham, I. et al. Plus	6007916-6008058			
			333572	Dunham, I. et.al. Plus	6026896-6027189			
	60		333576	Dunham, I. et al. Plus	6090345-6090721			
	00		333577 333580	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6123950-6124281 6142935-6143145			
			333587	Dunham, I. et al. Plus	6250599-6250966			
			333588	Dunham, I. et al. Plus	6255445-6255779			
			333591	Dunham, I. et.al. Plus	6285884-6286251			
	65		333592	Dunham, I. et al. Plus	6297731-6297976			
			333593	Dunham, I. et al. Plus	6304132-6304428			
			333594	Dunham, I. et al. Plus	6308990-6309450			
			333599	Dunham, I. et al. Plus	6337885-6338255			
	70		333600 333601	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6355629-6355925 6360075-6360442			
	70		333607	Dunham, I. et al. Plus	6504431-6504690			
			333608	Dunham, I. et al. Plus	6510834-6511130			

	333619	Dunham, I. et.al. Plus	6562799-6562926
	333623	Dunham, I. et.al. Plus	6584559-6584956
	333625 333626	Dunham, I. et.al. Plus	6603020-6603310
5	333627	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6614174-6614467 6620584-6620903
	333628	Dunham, I. et al. Plus	6629004-6629233
	333629	Dunham, I. et al. Plus	6636915-6637205
	333631	Dunham, I. et al. Plus	6650904-6651011
10	333632 333635	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6651520-6651658 6663683-6663973
1	333637	Dunham, I. et al. Plus	6674968-6675134
	333640	Dunham, I. et.al. Plus	6688350-6688624
	333642 333643	Dunham, I. et al. Plus	6708760-6709139
15	333646	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6728053-6728343 6739110-6739379
	333647	Dunham, I. et.al. Plus	6772502-6772779
	333648	Dunham, I. et.al. Plus	6787465-6787782
	333650 333652	Dunham, I. et.al. Plus	6796852-6797128
20	333653	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6809455-6809573 6811130-6811392
	333654	Dunham, I. et.al. Plus	6816731-6816993
	333656	Dunham, I. et.al. Plus	6822087-6822406
	333657	Dunham, I. et al. Plus	6831369-6831445
25	333658 333668	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6835282-6835474
20	333670	Dunham, I. et.al. Plus	7011009-7011223 7027945-7028181
L.A.	333680	Dunham, I. et.al. Plus	7071730-7071794
H	333682	Dunham, I. et al. Plus	7076641-7076760
<b>=</b> 30	333698 333710	Dunham, I. et al. Plus	7205279-7205383
	333717	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	7230314-7230476 7308714-7308815
	333727	Dunham, I. et.al. Plus	7373219-7373311
1	333785	Dunham, I. et.al. Plus	7775317-7775415
□ 35	333791 333859	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	7795972-7796082
	333875	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	8041203-8041359 8135505-8136179
	333879	Dunham, I. et.al. Plus	8146919-8147062
5	333891	Dunham, I. et.al. Plus	8156437-8156709
□ 40	333918	Dunham, I. et.al. Plus	8307124-8307215
다 40 다 다 다 45 다	333929 333932	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	8479486-8479580 8489124-8489205
1 <del>L.</del> Fi 1	333983	Dunham, I. et.al. Plus	8813593-8813668
	333987	Dunham, I. et.al. Plus	8824245-8824376
<del>4</del> 45	333997 334010	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	8866668-8867255
	334015	Dunham, I. et.al. Plus	8996696-8998236 9055452-9055595
Ū	334017	Dunham, I. et.al. Plus	9139516-9139634
	334026	Dunham, I. et.al. Plus	9196549-9196681
50	334030 334044	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	9288463-9288782 9373898-9374065
	334047	Dunham, I. et al. Plus	9428152-9428211
	334055	Dunham, I. et.al. Plus	9662077-9662270
	334063	Dunham, I. et al. Plus	9731991-9732085
55	334066 334068	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	9739568-9739680 9746279-9746477
	334076	Dunham, I. et al. Plus	9801613-9801693
	334091	Dunham, I. et.al. Plus	9872327-9872527
	334106	Dunham, I. et.al. Plus	10261155-10261841
60	334109 334111	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	10267679-10267864 10279365-10279531
	334115	Dunham, I. et.al. Plus	10316414-10316608
	334118	Dunham, I. et.al. Plus	10344273-10344384
	334120	Dunham, I. et.al. Plus	10402389-10403196
65	334135 334235	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	10457085-10457183 12983601-12983703
	334239	Dunham, I. et al. Plus	13056569-13056693
	334244	Dunham, I. et al. Plus	13159198-13159302
	334257	Dunham, I. et al. Plus	13213243-13213429
70	334260 334298	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	13223819-13223968
. •	334342	Dunham, I. et al. Plus	13424763-13425914 13646844-13646980
	334354	Dunham, I. et.al. Plus	13702598-13702747
	334430	Dunham, I. et.al. Plus	14269664-14270102
75	334435 334451	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	14275597-14275689
	334504	Dunham, I. et al. Plus Dunham, I. et al. Plus	14315572-14315741 14510206-14510398
		,	

	334510	Dunham, I. et al. Plus	14522303-14522418
	334518 334525	Dunham, I. et al. Plus	14630584-14630669
	334528	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	14781066-14781137 14787558-14787675
5	334529	Dunham, I. et.al. Plus	14788825-14788971
	334565	Dunham, I. et al. Plus	14989033-14989353
	334568	Dunham, I. et.al. Plus	14992698-14993210
	334590	Dunham, I. et al. Plus	15033247-15033753
10	334612 334626	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	15170470-15170535
	334661	Dunham, I. et.al. Plus	15299954-15300077 15477716-15477786
	334664	Dunham, I. et.al. Plus	15501941-15502119
	334666	Dunham, I. et al. Plus	15504203-15504279
15	334676	Dunham, I. et.al. Plus	15516334-15516412
13	334677 334719	Dunham, I. et.al. Plus	15517449-15517560
	334730	Dunham, I. et al. Plus Dunham, I. et al. Plus	15778859-15779026 15967830-15967934
	334797	Dunham, I. et.al. Plus	16383231-16383458
20	334819	Dunham, I. et.al. Plus	16758514-16758711
20	334855	Dunham, I. et.al. Plus	18402556-18402735
	334900	Dunham, I. et.al. Plus	19315678-19315743
	334906 334907	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	19323493-19323590
	334914	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	19336829-19336938 19495158-19495275
25	334915	Dunham, I. et.al. Plus	19505267-19506101
	334935	Dunham, I. et.al. Plus	20108247-20108373
<b> -</b> -	335019	Dunham, I. et al. Plus	20689525-20689582
	335036 335049	Dunham, I. et al. Plus	20755250-20756375
□ 30	335081	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	20877184-20877309
# 30	335131	Dunham, I. et.al. Plus	21113871-21113937 21449834-21450003
F i	335157	Dunham, I. et.al. Plus	21543302-21544341
	335163	Dunham, I. et.al. Plus	21583508-21583655
⊒ 35	335174	Dunham, I. et.al. Plus	21631301-21631447
<b>4</b> 33	335180 335188	Dunham, I. et.al. Plus	21641226-21641603
	335189	Dunham, I. et al. Plus Dunham, I. et al. Plus	21669118-21669328 21673403-21673472
2	335193	Dunham, I. et.al. Plus	21692208-21692362
	335200	Dunham, I. et.al. Plus	21743499-21743881
1 40 1 7 45	335201	Dunham, I. et al. Plus	21745249-21745664
14	335284 335311	Dunham, I. et.al. Plus	22272583-22272712
П	335320	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	22501602-22501676 22542132-22542246
	335371	Dunham, I. et.al. Plus	22849529-22849808
<b>45</b>	335377	Dunham, I. et.al. Plus	22869909-22870188
	335421	Dunham, I. et.al. Plus	23250433-23250498
2 702	335448 335451	Dunham, I. et al. Plus	23477532-23477831
	335455	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	23480611-23480711 23486127-23486216
50	335468	Dunham, I. et.al. Plus	23787245-23787367
	335470	Dunham, I. et.al. Plus	23812877-23813365
	335482	Dunham, I. et.al. Plus	24087956-24088114
	335485 335517	Dunham, I. et.al. Plus	24098953-24099123
55	335536	Dunham, I. et al. Plus Dunham, I. et al. Plus	24226461-24226531 24498783-24499762
	335565	Dunham, I. et al. Plus	24881886-24882470
	335585	Dunham, I. et.al. Plus	24988240-24988405
	335587	Dunham, I. et.al. Plus	24991457-24991618
60	335593	Dunham, I. et.al. Plus	25037253-25037370
00	335634 335651	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	25163837-25164042
	335652	Dunham, I. et.al. Plus	25317560-25317696 25325625-25325883
	335667	Dunham, I. et.al. Plus	25345735-25345856
65	335687	Dunham, I. et.al. Plus	25445952-25446064
65	335690	Dunham, I. et.al. Plus	25455442-25455625
	335692 335693	Dunham, I. et.al. Plus	25468557-25468725
	335700	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	25471363-25471524
	335720	Dunham, I. et.al. Plus	25512222-25512890 25596542-25596646
70	335721	Dunham, I. et.al. Plus	25599118-25599228
	335733	Dunham, I. et.al. Plus	25686486-25686626
	335739 335745	Dunham, I. et.al. Plus	25698550-25698826
	335745 335747	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	25718164-25718332
. 75	335783	Dunham, I. et al. Plus	25723304-25723494 25941882-25942040
	335968	Dunham, I. et al. Plus	27743843-27744029
	6		

	335971	Dunham, I. et.al. Plus	27752808-27753017
	335975	Dunham, I. et al. Plus	27801321-27801391
	335993	Dunham, I. et al. Plus	28006396-28006571
5	335998	Dunham, I. et.al. Plus	28026247-28026356
J	336011	Dunham, I. et al. Plus	28570760-28570900
	336035 336049	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	29016748-29017410
	336055	Dunham, I. et.al. Plus	29124451-29124606 29166352-29166573
	336072	Dunham, I. et.al. Plus	29269409-29269575
10	336075	Dunham, I. et.al. Plus	29343938-29344050
	336081	Dunham, I. et.al. Plus	29372270-29372407
	336083	Dunham, I. et.al. Plus	29379738-29379881
	336084 336086	Dunham, I. et al. Plus	29380664-29380792
15	336087	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	29385594-29385713 29387122-29387253
	336088	Dunham, I. et al. Plus	29389001-29389124
	336089	Dunham, I. et.al. Plus	29401421-29401625
	336090	Dunham, I. et.al. Plus	29413020-29413162
20	336091	Dunham, I. et al. Plus	29415486-29415617
20	336092	Dunham, I. et.al. Plus	29438816-29438948
	336094 336102	Dunham, I. et.al. Plus	29567934-29568099
	336124	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	29681500-29681687 30053441-30053500
	336125	Dunham, I. et al. Plus	30056541-30056622
25	336127	Dunham, I. et al. Plus	30058870-30059029
	336128	Dunham, I. et.al. Plus	30059294-30059367
<b>1</b> 4	336171	Dunham, I. et.al. Plus	30223877-30224048
	336214	Dunham, I. et.al. Plus	30561988-30562044
<b>=</b> 30	336306 336316	Dunham, I. et al. Plus	33172949-33173281
	336333	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	33338776-33338919 33673947-33677345
LJ.	336387	Dunham, I. et.al. Plus	34013939-34014124
	336442	Dunham, I. et.al. Plus	34187937-34188061
⊒ م	336481	Dunham, I. et.al. Plus	34231611-34231720
H 35	336489	Dunham, I. et.al. Plus	34239511-34239619
ra Fig	336498	Dunham, I. et al. Plus	34267340-34267424
<del>1_2</del>	336502 336516	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	34268953-34269083
부	336548	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	34296068-34296249 34353881-34354826
<b>40</b>	336590	Dunham, I. et.al. Plus	2569428-2570275
N	336593	Dunham, I. et.al. Plus	4617967-4618783
Ti	336606	Dunham, I. et al. Plus	16170215-16170415
- I	336623	Dunham, I. et.al. Plus	167287-167616
45	336632 336633	Dunham, I. et.al. Plus	983890-985529 985591-986221
	336634	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	986296-986670
u	336635	Dunham, I. et.al. Plus	987908-988364
	336637	Dunham, I. et.al. Plus	989276-990813
50	336638	Dunham, I. et.al. Plus	991906-993240
50	336654	Dunham, I. et.al. Plus	1588782-1588858
	336665 336695	Dunham, I. et.al. Plus	2007241-2007363
	336705	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	2464609-2464739 2817668-2817723
	336751	Dunham, I. et.al. Plus	4499629-4499739
55	336753	Dunham, I. et.al. Plus	4509509-4509601
	336757	Dunham, I. et.al. Plus	4541167-4541466
	336759	Dunham, I. et al. Plus	4560526-4560699
	336808 336813	Dunham, I. et.al. Plus	6251639-6251761
60	336827	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6436416-6436719
•	336833	Dunham, I. et.al. Plus	6773762-6774057 6856506-6856634
	336836	Dunham, I. et.al. Plus	7077262-7077326
	336878	Dunham, I. et.al. Plus	9200300-9200399
(6	336898	Dunham, I. et.al. Plus	10138365-10138458
65	336917	Dunham, I. et al. Plus	11228329-11228403
	336924	Dunham, I. et.al. Plus	11525273-11525527
	336934 336958	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	11854506-11854792
	336968	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	13203550-13203973 13660250-13660530
70	336985	Dunham, I. et.al. Plus	14785058-14785225
	337032	Dunham, I. et.al. Plus	16949229-16949306
	337121	Dunham, I. et.al. Plus	22050289-22050370
	337132	Dunham, I. et.al. Plus	22255234-22255437
75	337168	Dunham, I. et.al. Plus	23503596-23504240
13	337170 337172	Dunham, I. et.al. Plus	23533763-23534008
	331112	Dunham, I. et.al. Plus	23608358-23608526

	337218	Dunham, I. et al. Plus	26126466-26126565
	337219	Dunham, I. et.al. Plus	26129629-26130053
	337236	Dunham, I. et.al. Plus	27114318-27114571
5	337238 337259	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	27141465-27141776
3	337291	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	27674026-27674142 28823308-28823412
	337298	Dunham, I. et.al. Plus	29002509-29002806
	337304	Dunham, I. et.al. Plus	29131691-29131823
10	337333	Dunham, I. et al. Plus	30281383-30281673
10	337338	Dunham, I. et.al. Plus	30427592-30427775
	337345	Dunham, I. et.al. Plus	30649387-30649467
	337355 337363	Dunham, I. et al. Plus	30832838-30833042
	337396	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	30942712-30942840 31585902-31586067
15	337402	Dunham, I. et al. Plus	31691134-31691482
	337403	Dunham, I. et.al. Plus	31692319-31692611
	337425	Dunham, I. et.al. Plus	32072241-32072334
	337426	Dunham, I. et al. Plus	32076190-32076349
20	337427	Dunham, I. et.al. Plus	32078958-32079076
20	337435 337484	Dunham, I. et al. Plus	32255716-32255844
	337489	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	33238033-33238176 33295724-33295872
	337503	Dunham, I. et al. Plus	33385583-33385857
	337504	Dunham, I. et.al. Plus	33386053-33386236
25	337522	Dunham, I. et al. Plus	33963188-33963979
	337544	Dunham, I. et.al. Plus	34268412-34268495
<u>L.</u>	337548	Dunham, I. et.al. Plus	34472882-34472957
<del></del>	337562	Dunham, I. et.al. Plus	278105-278281
<b>∃</b> 20	337564	Dunham, I. et.al. Plus	285643-285788
□ 30	337586	Dunham, I. et al. Plus	952102-952250
<b>W</b>	337628 337657	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	2013838-2014032
1-1	337685	Dunham, I. et.al. Plus	2844851-2845055 3547161-3547245
	337695	Dunham, I. et.al. Plus	3609670-3609808
<b>≟</b> 35	337697	Dunham, I. et.al. Plus	3644971-3645195
11	337756	Dunham, i. et.al. Plus	3975015-3975172
₩	337781	Dunham, I. et.al. Plus	4116049-4116265
<b></b>	337797	Dunham, I. et.al. Plus	4325712-4325811
Q 40 N U W 45 D 45	337835 337843	Dunham, I. et al. Plus	4792299-4792423
₩ 70 Fil	337865	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	4984966-4985082 5377705-5377861
<u> </u>	337870	Dunham, I. et al. Plus	5442516-5442636
N	337904	Dunham, I. et.al. Plus	5685819-5686012
محمر المحتول	337918	Dunham, I. et.al. Plus	6031241-6031358
iii 45	337930	Dunham, I. et al. Plus	6393566-6393692
71	337947	Dunham, I. et al. Plus	6675643-6675781
부	337951 337954	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	6766321-6766382
	337964	Dunham, I. et.al. Plus	6831483-6831620 7032720-7032802
50	338043	Dunham, I. et al. Plus	8222138-8222430
	338054	Dunham, I. et.al. Plus	8429258-8429382
	338062	Dunham, I. et.al. Plus	8578852-8579012
	338080	Dunham, I. et.al. Plus	9212114-9212220
55	338090	Dunham, I. et.al. Plus	9488619-9488858
33	338096 338120	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	9698397-9698469
	338123	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	10765673-10765820 10815824-10815886
	338124	Dunham, I. et.al. Plus	10860311-10860471
	338177	Dunham, I. et.al. Plus	12781530-12781724
60	338239	Dunham, I. et.al. Plus	14669918-14670016
	338278	Dunham, I. et.al. Plus	16168714-16168840
	338280	Dunham, I. et.al. Plus	16171884-16172039
	338326	Dunham, I. et.al. Plus	17358806-17358964
65	338336 338344	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	17453324-17453448 17780512-17780623
03	338411	Dunham, I. et.al. Plus	19299273-19299522
	338412	Dunham, I. et.al. Plus	19340661-19340737
	338491	Dunham, I. et.al. Plus	21168430-21168556
70	338514	Dunham, I. et al. Plus	21379420-21379655
70	338516	Dunham, I. et.al. Plus	21382180-21382383
	338521	Dunham, I. et.al. Plus	21471358-21471476
	338522	Dunham, I. et al. Plus	21471617-21471711
	338526 338527	Dunham, I. et al. Plus	21551136-21551250
75	338529	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	21552237-21553280 21635616-21635867
	338579	Dunham, I. et al. Plus	22774968-22775132

	338596	Dunham, I. et al. Plus	23078273-23078348
	338648	Dunham, I. et al. Plus	24091259-24091434
	338679	Dunham, I. et.al. Plus	24684836-24684940
5	338703	Dunham, I. et al. Plus	25219881-25220046
3	338705	Dunham, I. et.al. Plus	25231397-25231551
	338747 338770	Dunham, I. et al. Plus	26336372-26336460
	338809	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	26784513-26784714
	338830	Dunham, I. et.al. Plus	27271920-27272000 27759923-27760055
10	338880	Dunham, I. et.al. Plus	28420713-28420826
	338895	Dunham, I. et al. Plus	28598893-28599135
	338896	Dunham, I. et al. Plus	28618487-28618552
	338911	Dunham, I. et.al. Plus	28804184-28804445
15	338925 338952	Dunham, I. et.al. Plus	28883892-28884036
	338959	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	29418831-29418968 29478431-29478589
	338970	Dunham, I. et al. Plus	29645468-29645613
	339081	Dunham, I. et al. Plus	30927871-30928080
20	339116	Dunham, I. et.al. Plus	31462304-31462382
20	339164	Dunham, I. et al. Plus	32207441-32207802
	339246	Dunham, I. et al. Plus	32844518-32844586
	339271 339304	Dunham, I. et al. Plus	32999935-33000078
	339309	Dunham, I. et al. Plus Dunham, I. et al. Plus	33323712-33323821
25	339312	Dunham, I. et al. Plus	33366900-33367198 33378992-33379172
	339356	Dunham, I. et.al. Plus	33573387-33573517
<u> </u>	339357	Dunham, I. et.al. Plus	33575210-33575416
는 C 30 C 35 C 35	339360	Dunham, I. et al. Plus	33579433-33579593
<u>=</u> 30	339384	Dunham, I. et al. Plus	33950591-33950697
	339413 339419	Dunham, I. et.al. Plus Dunham, I. et.al. Plus	34268734-34268875
U	332854	Dunham, I. et.al. Plus Dunham, I. et.al. Minus	34359680-34359777 1283611-1283053
المراجع المراج	332859	Dunham, I. et al. Minus	1358943-1358861
	332896	Dunham, I. et al. Minus	1631641-1631422
등 35	332995	Dunham, I. et al. Minus	2708847-2708685
	333014	Dunham, I. et al. Minus	2772479-2772387
	333043 333054	Dunham, I. et al. Minus	2920906-2920781
E	333069	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	2995314-2995219
<b>40</b>	333074	Dunham, I. et al. Minus Dunham, I. et al. Minus	3040771-3040661 3054171-3054008
TI .	333101	Dunham, I. et.al. Minus	3208966-3208908
1 40 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	333140	Dunham, I. et.al. Minus	3377220-3376309
*=	333142	Dunham, I. et al. Minus	3474264-3474145
<b>45</b>	333175 333216	Dunham, I. et al. Minus	3768113-3768051
<b>L</b>	333219	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	3967627-3967512
T <b>U</b>	333220	Dunham, I. et.al. Minus	3968531-3968423 3969363-3968789
	333240	Dunham, I. et al. Minus	4100495-4100281
50	333242	Dunham, I. et.al. Minus	4104544-4104259
50	333251	Dunham, I. et.al. Minus	4168970-4168870
	333252	Dunham, I. et.al. Minus	4172550-4172390
	333257 333258	Dunham, I. et al. Minus	4300724-4300578
	333271	Dunham, I. et al. Minus Dunham, I. et al. Minus	4301348-4301269 4377786-4377589
55	333294	Dunham, I. et al. Minus	4538728-4538642
	333296	Dunham, I. et al. Minus	4550766-4550644
	333312	Dunham, I. et al. Minus	4638794-4638635
	333313	Dunham, I. et al. Minus	4639397-4639277
60	333323 333329	Dunham, I. et al. Minus	4655333-4655166
	333339	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	4661779-4661672
	333346	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	4679691-4679610 4704564-4704466
	333355	Dunham, I. et al. Minus	4727555-4727460
65	333408	Dunham, I. et al. Minus	4936879-4936661
65	333423	Dunham, I. et al. Minus	4958233-4957593
	333424	Dunham, I. et al. Minus	4959694-4958713
	333441 333466	Dunham, I. et.al. Minus	2708847-2708685
	333495	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	2708847-2708685
70	333496	Dunham, I. et.al. Minus	5404039-5403881 5404643-5404523
	333541	Dunham, I. et al. Minus	5859241-5859098
	333545	Dunham, I. et.al. Minus	5885539-5885064
	333561	Dunham, I. et.al. Minus	5903659-5903590
75	333568	Dunham, I. et al. Minus	5965072-5964999
13	333581 333582	Dunham, I. et.al. Minus	6151638-6151159
	3330Z	Dunham, I. et al. Minus	6158522-6158322

	333665	Dunham, I. et.al. Minus	6975471-6975215
	333713	Dunham, I. et.al. Minus	
	333730	Dunham, I. et.al. Minus	7489326-7489007
5	333737	Dunham, I. et.al. Minus	7551981-7551842
•	333762 333815	Dunham, I. et.al. Minus	7679466-7679343
	333895	Dunham, I. et al. Minus Dunham, I. et al. Minus	7871914-7871764
	333903	Dunham, I. et al. Minus	8193845-8193735 8216956-8216810
10	333910	Dunham, I. et.al. Minus	8230221-8230116
10	333944	Dunham, I. et.al. Minus	8557051-8556936
	333965	Dunham, I. et.al. Minus	8627484-8626258
	334035	Dunham, I. et al. Minus	9323508-9323292
	334125 334137	Dunham, I. et al. Minus	10433521-10432612
15	334172	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	10461063-10460708 11644142-11644008
	334175	Dunham, I. et.al. Minus	11668659-11668597
	334191	Dunham, I. et al. Minus	11932215-11932091
	334196	Dunham, I. et.al. Minus	11966322-11966182
20	334198	Dunham, I. et al. Minus	12032364-12032146
20	334215 334237	Dunham, I. et.al. Minus	12670395-12670077
	334254	Dunham, I. et al. Minus Dunham, I. et al. Minus	12994394-12993954
	334304	Dunham, I. et al. Minus Dunham, I. et al. Minus	13199268-13198999 13455315-13455219
0.5	334358	Dunham, I. et.al. Minus	13724372-13724201
25	334396	Dunham, I. et al. Minus	14164482-14164340
	334399	Dunham, I. et.al. Minus	14186289-14186163
<u></u>	334418	Dunham, I. et al. Minus	14237235-14237028
	334470 334474	Dunham, I. et al. Minus	14389581-14389442
₩	334476	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	14391920-14391809
77	334496	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	14394777-14394589 14480743-14480669
<del>U</del>	334540	Dunham, I. et.al. Minus	14832365-14832224
**************************************	334548	Dunham, I. et.al. Minus	14837304-14837150
<b>□</b> 35	334560	Dunham, I. et.al. Minus	14980648-14980485
	334591	Dunham, I. et.al. Minus	15035270-15035057
Ä	334593 334625	Dunham, I. et al. Minus	15036374-15036242
	334650	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	15244936-15243666
■ □ 40 □ □ □ 45 □	334682	Dunham, I. et al. Minus	15371251-15371178 15520806-15520668
<b>4</b> 0	334690	Dunham, I. et al. Minus	15603055-15602918
N	334691	Dunham, I. et.al. Minus	15615920-15611418
nj	334745	Dunham, I. et al. Minus	16049960-16049653
 	334752	Dunham, I. et al. Minus	16118059-16117848
<b>45</b>	334759 334760	Dunham, I. et al. Minus	16134427-16134207
	334764	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	16136658-16136578
	334766	Dunham, I. et.al. Minus	16151208-16151104 16154663-16154529
	334779	Dunham, I. et al. Minus	16276881-16276815
50	334782	Dunham, I. et.al. Minus	16291693-16291574
30	334783	Dunham, I. et.al. Minus	16293336-16293226
	334784 334785	Dunham, I. et al. Minus	16294548-16294360
	334788	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	16295583-16295408
	334793	Dunham, I. et al. Minus	16301237-16301081 16330748-16330681
55	334804	Dunham, I. et al. Minus	16428342-16428208
	334823	Dunham, I. et al. Minus	16851360-16851189
	334827	Dunham, I. et al. Minus	16905877-16905684
	334836	Dunham, I. et.al. Minus	17215581-17215418
60	334842 334946	Dunham, I. et al. Minus Dunham, I. et al. Minus	17464352-17464181
	334948	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	20140514-20140410
	334955	Dunham, I. et.al. Minus	20141727-20141583 20151753-20151684
	334958	Dunham, I. et.al. Minus	20156046-20155932
65	334966	Dunham, I. et.al. Minus	20169171-20169079
03	334969	Dunham, I. et.al. Minus	20188176-20188020
	334970	Dunham, I. et al. Minus	20195886-20195554
	335000 335002	Dunham, I. et al. Minus	20455403-20455348
	335002	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	20479143-20479008
70	335068	Dunham, I. et.al. Minus	20602011-20601951 20955606-20955458
	335090	Dunham, I. et al. Minus	21192979-21190943
	335092	Dunham, I. et.al. Minus	21298638-21298571
	335108	Dunham, I. et.al. Minus	21324221-21324030
75	335115 335116	Dunham, I. et al. Minus	21388250-21388146
	335217	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	21388573-21388414
		IVIIIII	21801622-21801195

	*****	_	
	335234 335236	Dunham, I. et al. Minus	21904287-21904080
	335247	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	21915016-21914870
_	335262	Dunham, I. et al. Minus	21944287-21944209 22065821-22065630
5	335265	Dunham, I. et.al. Minus	22102127-22102000
	335266	Dunham, I. et.al. Minus	22108492-22108411
	335281	Dunham, I. et.al. Minus	22237614-22237503
	335331	Dunham, I. et al. Minus	22556823-22556708
10	335339 335340	Dunham, I. et al. Minus	22569208-22569045
	335344	Dunham, I. et al. Minus Dunham, I. et al. Minus	22570500-22570342 22600566-22600498
	335348	Dunham, I. et al. Minus	22646377-22646122
	335349	Dunham, I. et.al. Minus	22661861-22661271
15	335523	Dunham, I. et al. Minus	24235282-24235175
13	335527	Dunham, I. et.al. Minus	24241519-24241370
	335566 335606	Dunham, I. et al. Minus	24892522-24891998
	335750	Dunham, I. et al. Minus Dunham, I. et al. Minus	25056719-25055010
	335755	Dunham, I. et.al. Minus	25732501-25731972 25763806-25763747
20	335768	Dunham, I. et al. Minus	25819821-25819690
	335774	Dunham, I. et.al. Minus	25883733-25883572
	335777	Dunham, I. et al. Minus	25885770-25885599
	335782	Dunham, I. et.al. Minus	25908578-25908440
25	335787 335806	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	25947022-25946835
	335817	Dunham, I. et al. Minus Dunham, I. et al. Minus	26217475-26217146
1	335827	Dunham, I. et al. Minus	26321875-26321750 26380557-26380472
교 30 교 지 교 35 교	335831	Dunham, I. et al. Minus	26321526-26321349
₩ 30	335832	Dunham, I. et.al. Minus	26383701-26383583
□ 30	335863	Dunham, I. et.al. Minus	26693017-26692763
Ф	335895 335902	Dunham, I. et.al. Minus	26975307-26975239
تعية	335920	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	26985491-26985358
<b>n</b>	335956	Dunham, I. et al. Minus	27034927-27034811 27653729-27653635
≟ 35	335980	Dunham, I. et al. Minus	27846751-27846614
<u>u</u>	335999	Dunham, I. et.al. Minus	28033986-28033848
	336000	Dunham, I. et.al. Minus	28105547-28105354
B	336029	Dunham, I. et.al. Minus	28732042-28731966
<b>40</b>	336142 336149	Dunham, I. et.al. Minus	30135157-30135054
22 1	336161	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	30148185-30148059 30169370-30169185
## ## 45	336177	Dunham, I. et.al. Minus	30306638-30303284
I U	336198	Dunham, I. et.al. Minus	30459668-30459460
<sup>™</sup> 45	336199	Dunham, I. et.al. Minus	30461245-30461040
	336200	Dunham, I. et.al. Minus	30462971-30462895
Ti	336202 336203	Dunham, I. et al. Minus	30468933-30468781
	336227	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	30470796-30470653 30902014-30901946
<b>5</b> 0	336231	Dunham, I. et.al. Minus	30967656-30967471
50	336232	Dunham, I. et al. Minus	30977707-30977645
	336238	Dunham, I. et al. Minus	31160083-31159959
	336243	Dunham, I. et al. Minus	31402237-31402104
	336246 336279	Dunham, I. et al. Minus	31425669-31425253
55	336280	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	32103203-32102860
	336294	Dunham, I. et al. Minus	32103588-32103497 32946997-32946890
	336295	Dunham, I. et.al. Minus	32950291-32950162
	336328	Dunham, I. et.al. Minus	33584461-33584201
60	336347	Dunham, I. et.al. Minus	33843218-33843104
00	336351 336397	Dunham, I. et al. Minus	33865890-33865681
	336400	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	34021504-34021389
	336402	Dunham, I. et al. Minus	34023437-34023298 34024090-34023981
C 5	336406	Dunham, I. et al. Minus	34030774-34030564
65	336417	Dunham, I. et.al. Minus	34047771-34047675
	336455	Dunham, I. et.al. Minus	34209155-34209018
	336463 336470	Dunham, I. et.al. Minus	34212236-34211968
	336479 336510	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	34218224-34218139
70	336538	Dunham, I. et.al. Minus	34277046-34276928 34329270-34329189
	336584	Dunham, I. et al. Minus	34516566-34516468
	336599	Dunham, I. et.al. Minus	11736500-11734418
	336615	Dunham, I. et.al. Minus	26020622-26016546
75	336616 336619	Dunham, I. et al. Minus	26021027-26020848
, 0	336618 336645	Dunham, I. et al. Minus	25799-25612
	550045	Dunham, I. et al. Minus	1351268-1351168

	336653	Dunham, I. et.al. Minus	1568327-1568216
	336657	Dunham, I. et.al. Minus	1705497-1705415
	336717	Dunham, I. et al. Minus	
_	336772	Dunham, I. et al. Minus	
5	336795	Dunham, I. et.al. Minus	
	336796	Dunham, I. et.al. Minus	5683253-5683016
	336854	Dunham, I. et al. Minus	7884839-7884767
	336858	Dunham, I. et.al. Minus	8200946-8200789
10	336862	Dunham, I. et.al. Minus	8394593-8394369
10	336863	Dunham, I. et.al. Minus	8396673-8396425
	336883	Dunham, I. et al. Minus	9322767-9322554
	336908	Dunham, I. et al. Minus	10791347-10791256
	336927	Dunham, I. et.al. Minus	
	336929	Dunham, I. et al. Minus	11548111-11547937 11603040-11602908
15	336978	Dunham, I. et.al. Minus	14241223-14241030
	336981	Dunham, I. et.al. Minus	14478638-14478472
	336984	Dunham, I. et.al. Minus	14725450-14725309
	336994	Dunham, I. et.al. Minus	15104752-15104656
• •	336999	Dunham, I. et al. Minus	15389579-15388897
20	337011	Dunham, I. et al. Minus	
	337023	Dunham, I. et.al. Minus	16106423-16106080
	337069	Dunham, I. et al. Minus	16346174-16346065
	337092	Dunham, I. et al. Minus	19014379-19014222
	337093	Dunham, I. et al. Minus	20140132-20139980 20145693-20145570
25	337094	Dunham, I. et.al. Minus	
	337097	Dunham, I. et al. Minus	20146915-20146778
1 :	337100		20498648-20497686
	337114		20543830-20543751
을 30 때 기 35 대 35	337203	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	21328259-21328050
三 30	337204		25349286-25349156
	337225		25419024-25418931
Ш	337244		26607638-26607468
`*~	337279		27362048-27361952
<u></u>	337289		28430185-28430033
<b>₩</b> 35	337316		28756246-28756163
<u>u</u>	337431		29657129-29656997
A	337432		32110529-32110475
	337445	Dunham, I. et.al. Minus	32199134-32198922
<b>5</b>	337451	Dunham, I. et al. Minus	32292380-32292228
<b>40</b>	337452	Dunham, I. et al. Minus	32408680-32408576
7	337455	Dunham, I. et al. Minus	32415187-32415117
## 45   ##	337456	Dunham, I. et al. Minus	32434517-32434425
T	337513	Dunham, I. et al. Minus	32438887-32438828
العير ال	337514	Dunham, I. et.al. Minus	33478692-33478562
<b>45</b>	337517	Dunham, I. et.al. Minus	33484408-33484339
<u></u>	337590	Dunham, I. et.al. Minus Dunham, I. et.al. Minus	33795568-33795385
	337592		982397-982246
	337604		1007791-1007634
	337606	Dunham, I. et al. Minus Dunham, I. et al. Minus	1329838-1329759
50	337612	Dunham, I. et.al. Minus	1346786-1346617
	337645	Dunham, I. et al. Minus	1570235-1570142 5141462-5141329
	337704	Dunham, I. et.al. Minus	3658670-3658545
	337706	Dunham, I. et.al. Minus	
	337760	Dunham, I. et.al. Minus	3672056-3671922 4008389-4008037
55	337768	Dunham, I. et.al. Minus	4050134-4049973
	337771	Dunham, I. et.al. Minus	4060797-4060707
	337778	Dunham, I. et.al. Minus	4087301-4087157
	337787	Dunham, I. et.al. Minus	4135097-4135025
	337816	Dunham, I. et al. Minus	4523203-4523090
60	337821	Dunham, I. et al. Minus	4538189-4538075
	337848	Dunham, I. et.al. Minus	5053964-5053829
	337911	Dunham, I. et.al. Minus	5866504-5866154
	337913	Dunham, I. et.al. Minus	6149843-6149786
	337974	Dunham, I. et.al. Minus	7153401-7153085
65	337984	Dunham, I. et al. Minus	7282160-7282020
	338069	Dunham, I. et.al. Minus	
	338087	Dunham, I. et.al. Minus	8728655-8728580
	338113	Dunham, I. et.al. Minus	9362067-9361878
	338132	Dunham, I. et.al. Minus	10481242-10481089
70	338140	Dunham, I. et.al. Minus	10989617-10989530
	338151	Dunham, I. et.al. Minus	11237977-11237876
	338221	Dunham, I. et al. Minus	11519629-11519501
	338223	Dunham, I. et al. Minus	14183649-14183568
	338235	Dunham, I. et.al. Minus	14287001-14286830
75	338271	Dunham, I. et al. Minus	14484254-14484179
	338285	Dunham, I. et al. Minus	16048151-16047985
			16275030-16274895

	338306	Dunham, I	. etal. Minus	16966519-16966247
	338325	Dunham, I	. et.al. Minus	17241596-17241507
	338368 338381	Dunham, I		18272087-18272025
5	338431	Dunham, I Dunham, I		18534404-18534234 19747608-19747496
	338450	Dunham, I		20172384-20172200
	338451	Dunham, I.		20174286-20174193
	338486	Dunham, I.	et.al. Minus	21063152-21063049
10	338508	Dunham, I.		21308161-21307923
10	338576 338591	Dunham, I.		22676619-22676368
	338593	Dunham, I. Dunham, I.		22959271-22959182 22992718-22992531
	338594	Dunham, I.		23026144-23026029
15	338668	Dunham, I.		24500606-24500442
13	338686	Dunham, I.		24836463-24836246
	338725 338819	Dunham, I.		25904148-25904017
	338829	Dunham, I. Dunham, I.		27539222-27539058 27739328-27739163
20	338843	Dunham, I.		27899321-27899045
20	338934	Dunham, I.	etal. Minus	29036147-29036048
	338976	Dunham, I.	etal. Minus	29867484-29867259
	338990 339019	Dunham, I.		30019967-30019837
	339032	Dunham, I. Dunham, I.		30498278-30498118 30613407-30613275
25	339033	Dunham, I.		30621102-30620830
	339037	Dunham, I.		30634104-30633988
1.5	339044	Dunham, I.		30721853-30721740
	339071 339127	Dunham, I. (		30885702-30885511
上	339130	Dunham, I. e Dunham, I. e		31688232-31688072 31743961-31743767
<b>L</b>	339181	Dunham, I.		32321697-32321571
Ф	339188	Dunham, I. e		32347554-32347250
## E	339193	Dunham, I. e		32415060-32414928
<b>□</b> 35	339196 339208	Dunham, I. e		32431422-32431097
M	339213	Dunham, I. e Dunham, I. e		32491714-32491657
F	339215	Dunham, I. e		32496590-32496440 32502559-32502383
	339220	Dunham, I. e		32519184-32519081
』 140 11 11 12 145 12 13	339230	Dunham, I. e		32729004-32728929
<b>⊒</b> 70	339251 339256	Dunham, I. e		32894314-32894216
	339266	Dunham, I. e Dunham, I. e	t.al. Minus t.al. Minus	32926055-32925967 32976148-32976041
N	339268	Dunham, I. e		32984700-32984500
<u></u> 45	339280	Dunham, I. e	tal. Minus	33114230-33114010
	339340	Dunham, I. e		33485220-33485144
ni	339342 339344	Dunham, I. et Dunham, I. et		33494677-33494541
; <del></del>	339363	Dunham, I. et		33503675-33503520 33589964-33589665
50	339365	Dunham, I. et		33641615-33641446
50	339401	Dunham, I. et		34045393-34045138
	339424 339435	Dunham, I. et Dunham, I. et		34392464-34392311
	337884	Dulliant, I. et	Lai. Minus	34538987-34538876
5.5	337885			
55	337895			
	337898 329611	2062470		44700 44877
	329496	3962478 3983518	Minus Plus	11780-11875 13570-13686
60	325310	5866864	Minus	17256-17357
60	325320	5866870	- Minus	33200-33646
	325338	5866883	Minus	62747-62928
	325271 325285	5866901 5866903	Plus	87318-87378
	325289	5866903	Plus Minus	107772-107864 129715-129877
65	325300	5866908	Minus	7940-8059
	325304	5866910	Minus	37468-37884
	329630	6729060	Minus	167326-167511
	325369 325359	5866920 5866920	Minus	1018736-1018830
70	325408	5866921	Plus Plus	392668-392781 599118-599289
	325409	5866921	Plus	599438-599655
	325410	5866921	Plus	615477-615580
	325393 325396	5866921	Minus	350513-350691
75	325433	5866921 5866936	Plus Minus	476868-477200 480706-480926
	325448	5866941	Minus	480706-480826 392834-392982

	325464	E000047	-	*****
	325480	5866947	Plus	323995-324279
		5866957	Plus ·	20558-21112
	325482	5866957	Plus	47957-48078
5	325510	5866974	Plus	219958-220917
. 3	325524	5866981	Minus	117837-117997
	325513	6017035	Minus	34295-34490
	325519	6017036	Minus	186804-186915
	325571	6552439	Minus	184952-185135
	329638	3779004	Minus	4636-5127
10	325623	5867000	Plus	
	325636	5867002		84366-84472
	325677		Minus	149928-150033
		5867017	Minus	58414-58518
	325691	5867021	Plus	65467-65629
15	325690	5867021	Plus	7391-7530
13	325702	5867028	Pius	139925-140061
	325703	5867028	Plus	155806-156098
	325790	6381957	Minus	105385-105524
	325783	6456780	Plus	102815-102957
	325695	6552446	Minus	199599-199778
20	325726	6552447	Plus	
	325742	6552448		154262-154623
	325760		Minus	38225-38306
		6552449	Plus	343394-343549
	325801	6552451	Plus	49269-49542
25	325803	6552451	Plus	53355-53558
23	325649	6588011	Minus	215659-215815
	325710	6682473	Plus	204538-204822
1 -	325712	6682473	Pius	
<u>ļ.</u>	325755	6682474		208541-208926
O 30 O 35 O 35	325751		Plus	406603-407037
₹ 30		6682474	Plus	130437-130520
	325763	6682475	Minus	327530-327910
<del></del>	325791	6682476	Plus	344059-344841
<del>pu</del>	329782	5912597	Plus	123410-123499
7-1	329779	6002090	Minus	195353-195669
F	329760	6048280	Minus	51419-51528
□ 35	329752	6065777	Plus	132916-133335
O	329737	6065779	Plus	
=	329735	6065780		70136-70236
	329719		Plus	63923-64213
9		6065785	Plus	46970-47762
<b>40</b>	329725	6065785	Plus	133747-133842
Tarana Tarana	329705	6065790	Minus	63183-63724
<b>n</b>	329665	6272129	Plus	91791-91891
	329793	6522661	Minus	96556-96698
t Li	329824	6630758	Minus	126072-126254
	329839	6672062	Plus	34377-34537
<b>= 45</b>	329853	6682295	Plus	68945-69009
₩ ₩ 45	329870	6706435		
n i	329879		Minus	5729-5870
r tar	329902	6466518	Minus	12266-12356
		6634760	Plus	106906-106984
50	325851	5867067	Minus	51751-51981
30	325886	5867087	Plus	194694-194915
	325887	5867087	Plus	195052-195485
	326005	5867112	Minus	7827-8117
	325945	5867138	Minus	123079-124086
66	325953	5867140	Minus	4721-4901
55	325965	5867147	Plus	216364-216516
	325966	5867147	Plus	
	325977	6249602		217235-217356
	325835		Plus	60638-60759
		6552452	Minus	81182-81414
60	329995	4567166	Minus	150014-150315
00	329948	5540101	Minus	134056-134261
	329940	6165199	Minus	33718-33882
	329921	6165205	Minus	33759-33891
	330002	6623963	Plus	46097-46158
	330021	6671889	Plus	120938-121032
65	326162	5867168	Minus	
	326070	5867175		5870-6291
			Plus	132181-132731
	326029	5867176	Minus	112558-112669
	326033	5867178	Plus	37261-37333 •
70	326039	5867179	Minus	15157-15227
70	326122	5867194	Plus	144397-144683
	326136	5867202	Minus	155973-156065
	326194	5867213	Plus	75271-75522
	326206	5867219	Plus	
	326218			113881-115080
75		5867226	Minus	259784-259920
	326224	5867230	Plus	21528-21667
	326240	5867260	Plus	94843-96127

	326253	5867263	Minus	222216-222341
	326249 326266	5867263	Minus	80253-80323
	326304	5867264 5867277	Plus	337993-338192
5	326309	5867277	Minus Plus	367450-367559
	326310	5867277	Plus	614150-614294 621555-621698
	326338	6056311	Minus	161972-162333
	326343	6525295	Minus	2699-2777
10	326344	6525295	Minus	3207-3365
10	326073	6682495	Minus	248865-249009
	330057 330058	6478962 6634847	Plus	75145-75287
	330061	6634847 6721261	Plus Plus	100602-100963 4254-4388
	326539	5867307	Plus	198357-198504
15	326545	5867307	Plus	600850-601425
	326549	5867307	Plus	698004-698069
	326552	5867308	Minus	6988-7107
	326554 326559	5867308	Plus	16259-18271
20	326577	5867310 5867317	Plus	159233-159439
	326380	5867327	Pius Plus	215987-216127 32474-32668
	326412	5867362	Minus	9263-9436
	326417	5867362	Plus	89132-89383
25	326418	5867365	Plus	23609-23745
23	326423	5867369	Minus	142311-142500
A. a	326458 326459	5867400	Plus	128045-128147
☐ 30 ☐ 35 ☐ 35	326506	5867400 5867435	Plus	137590-138212
	326509	6682496	Minus Plus	9368-9509 92406-92680
<b>高 30</b>	330112	6015238	Plus	32059-32163
<del>T</del>	330086	6015293	Plus	29518-29662
<del>दिर्देश्चर्य</del> भू. त	330080	6015314	Minus	4890-4972
Te_[]	330082	6015314	Plus	27158-27296
<b>□</b> 35	330064 330063	6165044	Minus	5619-5696
Ø 33	330065	6165044 6165044	Minus	948-1025
	326646	5867562	Minus Plus	9876-9948 100426-100608
<del></del>	326688	5867582	Plus	104875-105531
	326708	5867593	Minus	39203-39310
<b>40</b>	326710	5867593	Minus	80204-80468
U V 45	326746	5867611	Plus	129366-129565
T.	326793 326603	5867631	Plus	136295-136518
1	326806	6056312 6469835	Minus Plus	50323-50575
<b>45</b>	326783	6525298	Plus	101628-102149 196378-196863
T T	326668	6552455	Plus	146726-146838
1 LF	326725	6552456	Minus	223005-223125
	326857	6552460	Minus	120142-120345
50	326763 326808	6598307	Plus	239690-239902
	326874	6682504 6682507	Minus Minus	65107-65214
	326876	6682507	Minus	4643-4888 46203-46499
	326884	6682511	Plus	33403-33479
55	326997	5867660	Minus	71389-72147
33	327009	5867664	Plus	933145-933266
	327015 326942	5867664	Plus	1030457-1030534
	326943	6004446 6004446	Minus	88675-88785
	326957	6469836	Minus Plus	89242-89427 37529-37694
60	327049	6531965	Minus	1924026-1924110
	327051	6531965	Plus	2222592-2222717
	327056	6531965	Plus	2374323-2374751
	327059	6531965	Plus	2421032-2421799
65	327067	6531965	Minus	3726023-3726668
32	327089 327037	6531965 6531965	Plus	5238983-5239187
	327123	6531971	Minus Minus	387854-388045 23980-24340
	327125	6531971	Plus	48884-48975
70	326981	6588016	Plus	105091-106038
70	330139	4210430	Plus	112089-112450
	330153	4325335	Plus	146951-147475
	330130	6002196	Minus	241903-241967
	327203 327206	5867447 5867447	Plus	36485-36577
75	327259	5867447 5867454	Plus Plus	177855-178031
. =	327264	5867461	Plus	87268-87438 47014-47367
	<del></del> -			110 IT TI 301

	327273	5867466	Plus	73451-73549
	327274	5867470	Minus	84027-84128
	327277	5867473	Minus	165616-165715
	327278	5867473	Minus	166350-166439
5	327289	5867481	Plus	49296-49536
	327304	5867494	Plus	20664-20850
	327315	5867508	Minus	78409-79245
	327246	5867547	Plus	136212-136325
	327155	5867549	Plus	90343-90876
10	327159	5867550	Minus	8219-8331
	327334	5902477	Minus	142655-142745
	327341	6017016	Minus	122906-123014
	327185	6117805	Minus	3287-3451
1.5	327309	6456757	Minus	10219-10457
15	327263	6525274	Minus	153814-154920
	327362	6552412	Minus	62459-62805
	327413	5867750	Plus	101410-101508
	327418	5867750	Minus	153453-153547
20	327430	5867754	Plus	1320-1403
20	327431	5867754	Plus	1853-1958
	327472	5867775	Plus	74628-74937
	327487	5867785	Minus	146220-146326
	327379	5867795	Plus	1368-1820
25	327461	6004455	Plus	209031-209210
23	327532	6469818	Plus	71994-72137
	330170	6648220	Plus	103280-103849
	330166	6648220	Plus	86542-86867
<u>.                                    </u>	327544	5867797	Minus	18105-18332
≒ 30	327564	5867811	Plus	13850-14018
	327566	5867811	Plus	33383-33901
m	327581	5867825	Plus	5318-5434
<u> </u>	327585	5867825	Plus	85660-85764
	327605	6004463	Plus	199214-199579
<b>□</b> 35	327710 327610	5867860	Minus	131012-131790
m	327624	5867868	Minus	174109-174278
130 0 30 0 35 0 35	327641	5867871	Minus	37699-37788
	327646	5867890 5867894	Plus	13583-13702
2	327614	6525283	Minus Plus	3043-3258
<b>5</b> 40	327736	5867940	Minus	3634-4001
F71 9	327739	5867942	Minus	37781-37887
<b>5</b> 45	327740	5867943	Plus	182187-182548 25716-26077
T.	327743	5867944	Minus	155930-156098
*a	327755	5867955	Minus	61969-62145
<b>45</b>	327772	5867964	Minus	26185-26285
	327774	5867964	Minus	127659-127899
T.	327823	5867968	Minus	170359-170433
	327827	5867968	Minus	201918-202048
50	327833	5867968	Minus	303618-303732
50	327805	5867968	Plus	19952-20019
	327809	5867968	Plus	54610-54761
	327816	5867968	Minus	79202-79552
	327790	5867977	Plus	19822-19985
55	327791	5867977	Plus	22491-22610
33	327793	5867979	Plus	18874-19254
	327845	6531962	Plus	193402-193549
	327846	6531962	Pius	195216-195373
	330204	6013606	Plus	86663-86811
60	330189 330239	6165182	Minus	26732-26991
00		6671857	Plus	117484-118092
	330266 330275	6671885	Minus	129505-129832
	330280	6671904 6671910	Plus	103585-103716
	330286	6671913	Plus	2109-2377
65	327999	5867994	Minus Plus	31050-31171 94710-94841
	328109	5868020		
	328098	5868020	Minus Minus	353895-354525 261745-261920
	328134	5868039	Plus	72354-72487
	328171	5868071	Plus	101102-101224
70	328221	5868099	Minus	37489-37829
	328224	5868101	Plus	105563-105832
	328228	5868105	Minus	21488-21596
	328236	5868117	Plus	13864-14371
	327864	5868130	Plus	59139-59358
75	327888	5868149	Minus	51964-52120
	327899	5868156	Minus	102288-102697

	327925	5868172	Minus	118396-118490
	327927	5868173	Plus	50989-51246
	327937	5868192	Minus	33127-33485
5	327946 327982	5868206	Plus	44102-44319
•	327990	5868216 5868218	Plus	30307-30527
	328015	5902482	Minus Minus	36225-36503 477679-478113
	328016	5902482	Minus	507572-508519
10	328025	5902482	Minus	931937-932171
10	328031	5902482	Plus	1176372-1177283
	328053	5902482	Minus	2709850-2710010
	328243 328271	6056292	Plus	1-243
	328592	6552415 5868227	Plus Minus	39015-39098 252407-252565
15	328570	5868231	Plus	89210-89816
	328607	5868233	Minus	246798-246944
	328620	5868241	Minus	15651-15788
	328624	5868246	Minus	120666-120836
20	328791 328810	5868309	Plus	171592-171929
20	328820	5868327 5868330	Plus	101730-101914
	328835	5868339	Plus Plus	90446-90602 88053-88461
	328282	5868353	Plus	72692-72819
25	328314	5868371	Minus	288397-288505
25	328328	5868375	Plus	169210-169407
	328420	5868411	Plus	53612-53886
☐ 30 ☐ 30 ☐ 35 ☐ 35	328428 328436	5868417	Plus	13599-13780
	328444	5868417 5868420	Plus Plus	203760-203904 65393-66103
<b>=</b> 30	328462	5868433	Plus	49649-49768
ind in	328467	5868434	Minus	15954-16073
<u>u</u>	328474	5868446	Minus	128777-128970
**	328484	5868454	Minus	21974-22140
□ 35	328504	5868471	Plus	47064-47217
m	328506 328507	5868471	Plus	60716-60830
<u>L.</u>	328544	5868473 5868486	Minus	199637-199990
	328552	5868489	Plus Plus	145659-145829 47328-47607
E 40	328557	5868489	Plus	138094-138161
<b>40</b>	328558	5868489	Plus	143648-144108
를 보고 	328276	6004471	Plus	13282-13450
ΠÎ	328277	6004471	Minus	279901-280181
p=1	328662 328636	6004473 6004473	Plus Plus	1184773-1184855
<b>45</b>	328803	6004475	Minus	192484-192543 291716-291948
<del>L_i</del>	328305	6004478	Minus	34730-34851
	328569	6004480	Plus	232896-233243
	328581	6006033	Minus	121249-121400
50	328582 328768	6006033	Minus	134177-134282
•	328770	6017031 6017031	Minus Minus	223741-224238 363933-364166
	328841	6381920	Minus	5214-5479
	328851	6381923	Plus	2502-2606
<i>E E</i> `	328859	6381928	Plus	69045-69138
55	328860	6381928	Plus	83265-83366
	328863	6381929	Minus	29313-29506
	328868 328876	6381930 6525286	Plus	112825-112993
4.5	328886	6588003	Plus Plus	94053-94185 31068-31429
60	328888	6588003	Minus	111901-111999
	328936	5868500	Minus	1352202-1352259
	328938	5868500	Plus	1522923-1522986
	328971	6478806	Minus	23976-24105
65	330338 330327	5457162	Plus	48406-48518
00	330327	5919194 5932415	Plus	121561-121683
	328974	5868520	Plus Plus	49095-50132 31557-31668
	328981	5868527	Minus	105677-105764
. 70	328989	5868535	Plus	182088-182198
70	330363	3126882	Minus	61838-61901
	330370	6580495	Plus	10826-11669
	329041 329078	5868564 5868507	Plus	141592-141785
	329097	5868597 5868624	Plus Plus	326798-326860 12002-12170
75	329107	5868626	Plus	101063-101190
	329114	5868650	Minus	23792-23910
			•	

	329116	5868650	Minus	43389-43493
	329164	5868691	Plus	62305-62517
	329187	5868713	Plus	29909-30175
5	329201	5868718	Plus	79266-79539
5	329221	5868727	Minus	105837-105894
	329246	5868732	Minus	250541-250792
	329254	5868733	Plus	4133-4214
	329326	5868806	Plus	155884-155992
10	329330	5868806	Minus	340278-340403
10	329382	5868868	Plus	41401-41655
	329384	5868869	Minus	116524-116662
	329386	6004484	Plus	160502-161110
	329140	6017060	Plus	290842-290905
1.5	329182	6056331	Minus	662206-663423
15	329018	6249620	Plus	103950-104034
	329319	6381976	Plus	721390-721470
	329392	6478815	Plus	109786-109854
	329029	6525302	Plus	281445-282490
20	329401	6682544	Plus	21342-24014
20	329406	6682547	Plus	47249-47395
	329411	6682549	Minus	84558-84835
	329429	5868882	Minus	97008-97091
	329436	5868883	Plus	230265-230528
25	329464	6456788	Minus	4437-4538
/ 3				

#### **TABLE 21:**

## 310 GENES UP-REGULATED IN COLON CANCER DERIVED LIVER METASTASES COMPARED TO NORMAL COLON TISSUE

Table 21 shows 310 genes up-regulated in colon cancer derived liver metastases compared to normal colon tissue. These were selected from 59680 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the ratio of "average" colon cancer derived liver metastases to "average" normal colon tissues was greater than or equal to 3.0. The "average" colon cancer derived liver metastases level was set to the 50th percentile. The "average" normal colon tissue level was set to the 50th percentile.

15	Pkey: Unique Eos probeset identifier number  ExACUSE Exemplar Accession number, Genbank accession number
	UnigeneID: Unigene number Unigene Title: Unigene gene title
	R1: Genes up mets vs normal

	20						
		Pkey	ExAccn	UnigenelD	Unigene Title	R1	
1		440040	411070040	11: 040			_
-			AU076643		secreted phosphoprotein 1 (osteopontin,	26.7	
	25		X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	16.30	
	25	409041	AB033025	Hs.50081	KIAA1199 protein	13.9	
		444381	BE38/335	HS.283713	ESTs, Weakly similar to S64054 hypotheti	13.90	
				Hs.312989		12.24	
			L22524	Hs.2256	matrix metalloproteinase 7 (matrilysin,	11.60	)
	30		T49951	Hs.9029		9.52	
m	30	436385	BE551618	Hs.144097	ESTS	9.20	
<del></del>		418662	A1801098	Hs.151500	ESTs ESTs, Moderately similar to 138937 DNA/R	9.00	
		433312	AI241331	Hs.131765	ESTs, Moderately similar to I38937 DNA/R	8.90	
=		412093	BE242691	Hs.14947	ESTs	8.74	
	25	442369	AI565071	Hs.159983	ESTs	8.40	
	35	426101	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112		8.39
TU TU				Hs.119769		8.22	
mi			T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL		
! =			AI660840		ESTs, Weakly similar to ALUE_HUMAN !!!!	7.96	
J	40		R71264	Hs.16798		7.94	
	40		H57111	Hs.221132		7.88	
===				Hs.273766		7.82	
TŲ			C17908			7.78	
		417315	A1080042	Hs.336901	ribosomal protein S24	7.76	
	4.5	430665	BE350122	Hs.157367	ESTs, Weakly similar to 178885 serine/th	7.76	
	45			Hs.282070		7.74	
				Hs.289115	DKFZp434A0131 protein	7.58	
			N99638		gb:za39g11.r1 Soares fetal liver spleen	7.56	
				Hs.208558		7.54	
	50	428046	AW812795	Hs.155381	ESTs, Moderately similar to I38022 hypot	7.48	
	50	446682	AW205632	Hs.211198	ESTs	7.26	
					Homo sapiens done IMAGE:713177, mRNA s	e	7.19
			AI798851	Hs.283108	hemoglobin, gamma G	7.12	
		450230	AW016607	Hs.201582	ESTs	7.08	
			AA228357		gb:nc39d05.r1 NCI_CGAP_Pr2 Homo sapiens	j	7.04
	55	421814	L12350		thrombospondin 2	6.89	
				Hs.127832	ESTs	6.86	
			A1634046	Hs.157313	ESTs	6.78	
			D30783	Hs.115263	epiregulin	6.72	
		413950	AA249096	Hs.32793		6.67	
	60	438011	BE466173	Hs.145696	splicing factor (CC1.3)	6.62	
			T58283	Hs.10450		6.58	
						6.40	
		408806	AW847814	Hs.289005	Homo sapiens cDNA: FLJ21532 fis, clone C	6.38	
				Hs.155029		6.38	
	65	435812	AA700439	Hs.188490	ESTs	6.32	
				Hs.22689		3 (f	6.28
		418875	W19971	Hs.233459	ESTs	6.22	
		407284	AI539227	Hs.214039	hypothetical protein FLJ23556	6.17	
		408243	Y00787	Hs.624		6.12	
	70	434936	Al285970	Hs.183817	ESTs	6.12	

	412088 Al689496 Hs.108932 ESTs 6.04	
	450377 AB033091 Hs.74313 KIAA1265 protein 6,00 407618 AW054922 Hs.53478 Homo sapiens cDNA FLJ12366 fis, clone MA 5,98	
_	408296 AL117452 Hs.44155 DKFZP586G1517 protein 5 04	
5	456999 AA319798 Hs.298581 eukarvotic translation elongation factor 5 on	
	432559 AW452948 Hs.257631 ESTS 5.88 423349 AF010258 Hs.127428 homeo box A9 5.84	
	436100 AA704806 Hs.12/428 nomeo box A9 5.84 436100 AA704806 Hs.143842 ESTs, Weakly similar to 2004399A chromos 5.84	
10	453204 R10799 Hs.191990 ESTs 5.84	
10	429183 AB014604 Hs.197955 KIAA0704 protein 5.78 427882 AA640987 Hs.193767 ESTs 5.72	
	447033 Al357412 Hs.157601 ESTs 5.70	
	428054 AI948688 Hs.266619 ESTs 5.66	
15	414504 AW069181 Hs.115175 sterile-alpha motif and leucine zipper c 5.64 442806 AW294522 Hs.149991 ESTs 5.64	
13	418259 AA215404 Hs.137289 ESTs 5.60	
	434963 AW974957 Hs.288719 Homo sapiens cDNA FL.112142 fis clone MA 5.60	
	419999 AI760942 Hs.191754 ESTs 5.58	
20	431749 AL049263 Hs.306292 Homo sapiens mRNA; cDNA DKFZp564F133 (fr 5.5) 422790 AA809875 Hs.25933 ESTs 5.56	3
	440980 AL042005 Hs.1117 tripeptidyl pentidase II 5.48	
	432451 AW972771 Hs.292471 ESTs. Weakly similar to AUU1 HUMAN AUUS 5.49	3
	438578 AA811244 Hs.164168 ESTs 5.44 410467 AF102546 Hs.63931 dachshund (Drosophila) homolog 5.42	
25	426317 AA312350 Hs.169294 transcription factor 7 (T-cell specific, 5.42	
	450164 Al239923 Hs.30098 ESTs 5.40	
<u>1-</u>	438899 AF085833 Hs.135624 ESTs 5.38 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 5.36	
	432945 AL043683 Hs.8173 hypothetical protein FLJ10803 5.36 437176 AW176909 Hs.42346 calcineurin-binding protein calsarcin-1 5.34	
<b>=</b> 30	419829 Al924228 Hs.115185 ESTs. Moderately similar to PC4259 ferri 5 33	
m	407966 AA295052 Hs.38516 Homo sapiens, clone MGC:15887, mRNA, com 5.30	)
7. I	447342 Al199268 Hs.19322 Homo sapiens, Similar to RIKEN cDNA 2010 5.26 419682 H13139 Hs.92282 paired-like homeodomain transcription fa 5.26	
	421097 Al280112 Hs.125232 Homo sapiens cDNA FL.113266 fis. clone OV 5.22	
₩ 35	4433/3 AI/92868 Hs.135365 ESTs 5.22	
0 30 M V O 35 M	412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 443651 W22152 Hs.282929 ESTs 5.21	
	443031 W22132 Hs.282929 ES1s 5.21 411274 NM_002776Hs.69423 kallikrein 10 5.17	
= 10	421999 U50535 Hs.110630 Human BRCA2 region, mRNA sequence CG006 5 17	
<u> </u>	420981 AL0446/5 Hs.173081 KIAA0530 protein 5.14	
Ti	434966 AA657494 ab:nt66f04 s1 NCI CGAP Pr3 Homo septems 5 10	
N.	418830 BE513731 Hs.88959 hypothetical protein MGC4816 5.08	
<sup>및</sup> 45	428290 Al932995 Hs.183475 Homo sapiens clone 25061 mRNA sequence 5.07 408784 AW971350 Hs.63386 ESTs 5.04	
	408/84 AW9/1350 Hs.63386 ESTs 5.04 411975 Al916058 Hs.144583 ESTs 5.02	
TU	409760 AA302840 ab:EST10534 Adinose tissue white I Homo 4 07	
	420/17 AA284447 Hs.271887 ESTs 4.96	
50	417035 AA192455 Hs.22968 Homo sapiens clone IMAGE:451939, mRNA se 4.95 434442 AA737415 Hs.152826 ESTs 4.94	
	441328 Al982794 Hs.159473 ESTs 4.92	
	4.38962 BE046594 gb:hn41c11.x1 NCI_CGAP_RDF2 Homo sapiens 4.92	
	451277 AK001123 Hs.26176 hypothetical protein FLJ10261 4.92 438406 BE273296 Hs.254467 Homo sapiens cDNA FLJ13255 fis, clone OV 4.90	
55	424950 AA602917 Hs.156974 ESTs A 88	
	436823 AW749865 Hs.293645 ESTs, Weakly similar to I38022 hypotheti 4.87	
	444783 AK001468 Hs.62180 anillin (Drosophila Scraps homolog), act 4.82 444301 AK000136 Hs.10760 asporin (LRR class 1) 4.80	
60	445390 Al222165 Hs.144923 ESTs 4.80	
60	439608 AW864696 Hs.301732 hypothetical protein MGC5306 4.78	
	450506 NM_004460Hs.418 fibroblast activation protein, alpha 4.78 432682 Al376400 Hs.159588 ESTs 4.76	
	426086 T94907 Hs.188572 ESTs 4.76	
65	435981 H74319 Hs.188620 ESTs 4.74	
03	432340 AA534222 gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens 4.72 435756 Al418466 Hs.33665 ESTs 4.72	
	435/56 Al418466 Hs.33665 ESTs 4.72 447982 H22953 Hs.137551 ESTs 4.72	
	449509 AA001615 Hs.84561 ESTs 4.72	
70	407946 AA226495 Hs.154292 ESTs 4.70	
, 0	426215 AW963419 Hs.155223 stanniocalcin 2 4.70 414783 AW069569 Hs.278270 unactive progesterone receptor, 23 kD 4.68	
	41/601 NM_014735Hs.82292 KIAA0215 gene product 4 68	
	438461 AW075485 Hs.286049 phosphoserine aminotransferase 4.68	
75	449032 AA045573 Hs.22900 nuclear factor (erythroid-derived 2)-lik 4.68 426501 AW043782 Hs.293616 ESTs 4.67	
	4.67 409024 AW883529 Hs.173830 ESTs, Weakly similar to ALU7_HUMAN ALU S 4.67	
	4.01	

		439848 AW979249 gb:EST391359 MAGE res	sequences, MAGP Homo 4.66
		424762 AL119442 Hs.183684 eukaryotic translation initi. 442007 AA301116 Hs.142838 nucleolar phosphoprotein	ation factor 4.66
		409632 W74001 Hs.55279 serine (or cysteine) protei	
	5	432409 AA806538 Hs.130732 KIAA1575 protein	4.60
		452220 BE158006 Hs.212296 ESTs	4.60
		442577 AA292998 Hs.163900 ESTs 434001 AW950905 Hs.3697 serine (or cysteine) protein	4.58
		434001 AW950905 Hs.3697 serine (or cysteine) protein 414271 AK000275 Hs.75871 protein kinase C binding p	nase inhibito 4.58 protein 1 4.58
	10	433854 AA610649 Hs.333239 ESTs	4.56
		431315 AW972227 Hs.163986 Homo saniens cDNA: FLJ	22765 fis. clone K 4.53
		434220 Al174777 Hs.283039 Homo sapiens PRO2492 r 457752 Al821270 Hs.285643 Homo sapiens cDNA FL.1	mRNA, complete cds 4.50
		457752 Al821270 Hs.285643 Homo sapiens cDNA FLJ1 449941 AW450536 Hs.209260 ESTs	14364 TIS, CIONE HE 4.50 4.48
	15	415116 AA160363 Hs.269956 ESTs	4.47
		414386 X00442 Hs.75990 haptoglobin	A A7
		422956 BE545072 Hs.122579 hypothetical protein FLJ10 423974 AL118754 gb:DKFZp761P1910 r1 76	1461 4.44
		423974 AL118754 gb:DKFZp761P1910_r1 76 449618 Al076459 Hs.15978 KIAA1272 protein	31 (synonym: hamy2) 4.44 4.44
	20	428279 AA425310 Hs.155766 ESTs. Weakly similar to A4	47582 B-cell gr 4.42
		430573 AA744550 Hs.136345 ESTs	4.42
		430929 AA489166 Hs.156933 ESTs 433530 BE349534 Hs.281789 ESTs	4.40
		446099 T93096 Hs.17126 hypothetical protein MGC1	4.40 5912 4.40
- 2	25	447082 T85314 Hs.42644 thioredoxin-like	4.39
		407168 R45175 Hs.117183 ESTs	4 38
14		417067 AJ001417 Hs.81086 solute carrier family 22 (ext 408380 AF123050 Hs.44532 diubiguitin	
		431379 AA504264 Hs.182937 pentidylprolyl isomerase A	4.36 (cyclophilin 4.36
	30	406671 AA129547 Hs.285754 met proto-oncogene (hepat	tocyte growth fa 4.34
m		419317 AA236282 Hs.172318 ESTs	4.32
		450295 AI766732 Hs.210628 ESTs 423578 AW960454 Hs.222830 ESTs	4.32
- T		419553 N34145 Hs.250614 ESTs, Moderately similar to	4.31 7N91 HUMAN 7 4 31
₩ 3	35	429512 AA453987 Hs.144802 ESTs	4.30
<u>₩</u>		426848 H72531 Hs.36190 ESTs	4.30
		429831 AA564489 Hs.137526 ESTs 433735 AA608955 Hs.109653 ESTs	4.30
B		450546 AA010200 Hs.175551 ESTs	4.30 4.27
	10	421059 Al654133 Hs.30212 thyroid receptor interacting in	protein 15 4.27
n.		413243 AA769266 Hs.193657 ESTs 433230 AW136134 Hs.220277 ESTs	4.26
IJ √ 4		439717 W94472 Hs.59529 ESTs, Moderately similar to	4.22
h.[	. ~	439362 Al954880 Hs.134604 ESTs	4.19
<b>6</b> 4	15	450157 AW961576 Hs.60178 ESTs	4.17
Ū		451690 AW451469 Hs.209990 ESTs 418661 NM_001949Hs.1189 E2F transcription factor 3	4.17
1 ===		443135 Al376331 Hs.156103 ESTs	4.16 4.16
-		443148 AI034357 Hs.211194 ESTs. Weakly similar to AI I	IN HUMAN ALLIS 4 16
3	0	407765 AW076027 Hs 257711 FSTs Moderately similar to	ALLIQ MURAARI A 4.44
		428825 Al084336 Hs.128783 ESTs, Weakly similar to I380 447519 U46258 Hs.339665 ESTs	
		439451 AF086270 Hs.278554 heterochromatin-like protein	4.14 1 4.12
5	5	450219 Al826999 Hs.224624 ESTs	4.12
)	5	431451 AA761378 Hs.192013 ESTs 432917 NM_014125Hs.279812 PRO0327 protein	4.11
		431328 AA502999 Hs.291591 ESTs	4.10 4.09
		425992 AA367069 Hs.100636 ESTs	4.08
6	0	404571 420911 U77413 Hs.100293 O-linked N-acetylolucosamin	4.06
O.	U	420911 U77413 Hs.100293 O-linked N-acetylglucosamin 421114 AW975051 Hs.293156 ESTs, Weakly similar to I788	e (GloNAc) tr 4.06
		432731 R31178 Hs.287820 fibronectin 1	85 serine/th 4.06 4.06
		433588 AI056872 Hs.133386 ESTs	4.06
6.	5	434658 Al624436 Hs.310286 ESTs 444040 AF204231 Hs.182982 golgin-67	4.06
0.	,	444984 H15474 Hs.132898 fatty acid desaturase 1	4.06
		438543 AA810141 Hs.192182 ESTs	4.06 4.05
		413497 BE177661 gb:RC1-HT0598-020300-011	-h02 HT0598 Homo 4 04
70	0	434575 Al133446 Hs.299964 Homo sapiens done FLB772: 430256 AA470152 Hs.192195 ESTs	
, (	•	424839 AA740632 Hs.120850 ESTs, Weakly similar to ALU	4.04 1 HIMANAHH 1
		429048 Al372949 Hs.44241 Homo saniens cDNA Ft. 1214	1_HUMAN ALU S 4.02 I47 fis, clone C 4.02
		449429 AA054224 Hs.59847 ESTs	4.02
75	5	410762 AF226053 Hs.66170 HSKM-8 protein 418876 AA740616	4.00 CB4 Home series 4.00
, .	-	418876 AA740616 gb:ny97f11.s1 NCI_CGAP_G 425905 AB032959 Hs.318584 novel C3HC4 type Zinc finger	CB1 Homo sapiens 4.00 (ring finge 4.00
		The second state of the se	(1.00 mgv T.00

	429500 X78565 Hs.289114 hexabrachion (tenascin C, cytotactin)	4.0	0
	431393 AW971493 Hs.134269 ESTs. Highly similar to cytokine recento	4.0	0
	435008 AF150262 Hs.162898 ESTs 431361 AW971375 Hs.292921 ESTs	4.0	
5	444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon	3.97	
•	434701 AA460479 Hs.321707 KIAA0742 protein	3.96	
	413886 AW958264 Hs.103832 similar to yeast Upf3, variant R	3.96 3.98	
	424905 NM_002497Hs.153704 NIMA (never in mitosis gene al-related k	3.92	
10	4284/9 Y00272 Hs.184572 cell division cycle 2 G1 to S and G2 to	3.91	
10	435714 AA699325 Hs.269880 ESTs	3.86	6
	447514 Al809314 Hs.208501 ESTs, Weakly similar to B34087 hypotheti 453818 BE256832 Hs.10711 hypothetical protein FLJ13449		
		3.85	
	433586 T85301 gb:yd78d06.s1 Soares fetal liver spleen 440638 Al376551 gb:te64e10.x1 Soares_NFL_T_GBC_S1+	3.85	
15	417819 AI253112 Hs.133540 ESTs	тотю s 3.84	3.85
	409596 BE244200 Hs.55075 KIAA0410 gene product	3.83	
	423129 L44396 Hs.124106 Homo sapiens cDNA Ft.111941 fis close I	HE 3.83	
	453884 AA355925 Hs.36232 KIAA0186 gene noduct	3.83	
20	431193 AW749505 Hs.296770 KIAA1719 protein	3.81	
20	409262 AK000631 Hs.52256 hypothetical protein FLJ20624 425568 AW963118 Hs.161784 ESTs	3.80	
	441085 AW136551 Hs.181245 Homo sapiens cDNA FLJ12532 fis, clone N	3.78	
	428079 AA421020 Hs.208919 ESTs	3.77 3.77	
	412490 AW803564 Hs.288850 Homo sapiens cDNA; FLJ22528 fis clone	3.77 H 3.76	
25	433334 AA6/826/ Hs.117115 ESTs	3.75	
	436535 AW295687 Hs.254420 ESTs	3.74	•
<del>] _</del>	420439 AW270041 Hs.193053 eukaryotic translation initiation factor	3.72	
	436090 Al640635 Hs.116468 EST 416265 AA177088 Hs.190065 ESTs	3.71	
☐ 30 ☐ 30 ☐ 35 ☐ 35	417715 AW969587 Hs.86366 ESTs	3.70	
	435677 AA694142 Hs.293726 ESTs, Weakly similar to TSGA RAT TESTI	3.67 S 3.67	
Ш	438607 AW080237 Hs.252884 ESTs	3.66	
, r [	408194 AA601038 Hs.191797 ESTs, Weakly similar to S65657 alpha-1C-	3.65	
₫ 35	41/211 19/617 Hs.269092 ESTs	3.60	
33	435538 AB011540 Hs.4930 low density lipoprotein receptor-related	3.59	
	410390 AA876905 Hs.125286 ESTs 438818 AW979008 Hs.222487 ESTs	3.58	
	431416 AA532718 Hs.178604 ESTs	3.57	
=	433517 AW022133 Hs.189838 ESTs	3.57 3.56	
급 40 집 집 집 집 45	428355 BE256452 Hs.2257 vitronectin (serum spreading factor, som	3.56	
n.	432954 AI076345 Hs.214199 ESTs	3.53	
71	434466 AB037829 Hs.3862 regulator of nonsense transcripts 2; DKF	3.53	
i inf	421933 R98881 Hs.109655 sex comb on midleg (Drosophila)-like 1	3.52	
<u></u> 45	422082 AA016188 Hs.111244 hypothetical protein	3.52	_
	437135 AL038624 Hs.208752 ESTs, Weakly similar to ALU8_HUMAN ALU 424723 BE409813 Hs.152337 protein arginine N-methyltransferase 3(h		3.49
Ti .	434280 BE005398 gb:CM1-BN0116-150400-189-h02 BN0116 l	3.49	3.49
	407289 AA135159 Hs.203349 Homo sapiens cDNA FLJ12149 fis, clone M	A 3 48	J. <del>43</del>
50	41/6/0 K0/785 qb:vf15c06.r1 Soares fetal liver snleen	3.48	
50	431615 AW295859 Hs.235860 ESTs	3.48	
	429355 AW973253 Hs.292689 ESTs	3.45	
	430068 AA464964 gb:zx80f10.s1 Soares ovary tumor NbHOT F 432929 AW207166 Hs.191265 ESTs		
	437763 AA469369 Hs.5831 tissue inhibitor of metalloproteinase 1	3.44 3.44	
55	445674 BE410347 Hs.13063 transcription factor CA150	3.42	
	408113 T82427 Hs.194101 Homo sapiens cDNA: Ft.120869 fis. clone A	3.42	
	408908 BE296227 Hs.250822 serine/threonine kinase 15	3.41	
	432235 AA531129 Hs.190297 ESTs	3.41	
60	453985 N44545 Hs.251865 ESTs 415736 AA827082 Hs.291872 ESTs	3.41	
•	430220 BE378277 Hs.152230 ESTs	3.38	
	426510 AW861225 Hs.194637 BANP homolog, SMAR1 homolog	3.37 3.37	
	412104 AW205197 Hs.240951 Homo sapiens, Similar to RIKEN CONA 2210	3.36	
(5	4115/3 ABU29000 Hs.70823 KIAA1077 protein	3.33	
65	413816 AW958181 Hs.189998 ESTs	3.32	
	428057 Al343641 Hs.185798 ESTs	3.32	
	436280 Al690734 Hs.131740 Homo sapiens cDNA: FLJ22562 fis, clone H		
	449365 AW968261 Hs.118913 ESTs, Moderately similar to T46371 hypot 440659 AF134160 Hs.7327 claudin 1	3.31	
70	436110 AA704899 Hs.291651 ESTs, Weakly similar to I38022 hypotheti	3.30	
. •	433862 D86960 Hs.3610 KIAA0205 gene product	3.29 3.29	
	424624 AB032947 Hs.151301 Ca2+dependent activator protein for secr	3.29	
	439955 AW203959 Hs.149532 ESTs	3.28	
75	417333 AL157545 Hs.42179 bromodomain and PHD finger containing 3	3.28	
75	436150 AW510927 Hs.125243 ESTs	3.27	
	414900 AW452420 Hs.248678 ESTs	3.26	

	439349	AI660898	Hs.195602	ESTs	3.25	
	428255	AI627478	Hs.187670	ESTs	3.24	
	436217	T53925	Hs.107	fibrinogen-like 1	3.24	
_	429083	Y09397	Hs.227817	BCL2-related protein A1	3.24	
5	422244	Y08890	Hs.113503	karyopherin (importin) beta 3	3.22	
	430178	AW449612	Hs.152475	ESTs	3.21	
	413810	AW197644	Hs.19107	ESTs	3.20	
	428728	NM_01662	5Hs.191381	hypothetical protein	3.20	
	437151	AA745618	Hs.194637	BANP homolog, SMAR1 homolog	3.19	
10	427051	BE178110	Hs.173374	Homo sapiens cDNA FLJ10500 fis, clone NT	3.19	
	438378	AW970529	Hs.86434	hypothetical protein FLJ21816	3.19	
	439943	AW083789	Hs.124620	ESTs	3.18	
	439280	Al125436	Hs.48752	ESTs	3.18	
	452336	AA960961	Hs.305953	zinc finger protein 83 (HPF1)	3.17	
15	433713	AW976511	Hs.112592	ESTs	3.16	
		NM_00254		oxidised low density lipoprotein (lectin	3.14	
	407328	AA508857	Hs.187748	ESTs, Weakly similar to ALU1_HUMAN ALU	S	3.14
	432722	AA830532	Hs.326150	ESTs	3.14	
	419457	AA243146	Hs.209334	ESTs, Moderately similar to S23A_HUMAN P	3.11	
20	449987	AW079749		ESTs, Weakly similar to ALU1_HUMAN ALU	S	3.11
		AA605038		Homo sapiens cDNA: FLJ21950 fis, clone H	3.09	
			Hs.194258	ESTs, Moderately similar to ALU5_HUMAN A	3.08	
		AK000767	Hs.5111	hypothetical protein FLJ20729	3.08	
~ -		M31126	Hs.272620	pregnancy specific beta-1-glycoprotein 9	3.07	
25		AA251594	Hs.43913	PIBF1 gene product	3.07	
	444614		Hs.2730	heterogeneous nuclear ribonucleoprotein	3.06	
	459407	N92114		gb:za22h11.r1 Soares fetal liver spleen	3.05	
		A1878910	Hs.3688	cisplatin resistance-associated overexpr	3.04	
•		AW971063		ESTs	3.03	
30		AI932285	Hs.160569		3.03	
		AI860558		ESTs, Weakly similar to ALU2_HUMAN ALU S		3.03
		R08950	Hs.272044	ESTs, Weakly similar to ALU1_HUMAN ALU S	3	3.02
	433944	AL117518	Hs.3686	KIAA0978 protein	3.01	
2.5	440428	BE560954		gb:601347719F1 NIH_MGC_8 Homo sapiens	æ	3.00
35						

roderoso oservos

Table 21A shows the accession numbers for those pkeys lacking unigeneID's for Table 21A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

CAT number: Gene cluster number
Accession: Genbank accession numbers

15

#### Pkey CAT Number Accession

	409760 115373_1	AA302840 T93016 T92950 AA077551
	413497 1373771_1	BE177661 H06215 BE144709 BE144829
20	417670 1692163_1	R07785 T85948 T86972
	418876 179960_1	AA740616 AA654854 AA229923
	419145 182217_1	N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815
	423974 233842_1	AL118754 AA333202 H38001
	430068 312849_1	AA464964 M85405 AA947566
25	432340 345248_1	AA534222 AA632632 T81234
	433586 370470_1	T85301 AW517087 AA601054 BE073959
	434280 382816_1	BE005398 AA628622 AA994155
	434966 396504_1	AA657494 AI582663 AI581639
	438962 467390_1	BE046594 BE046667 AA828585 AI207343
30	439848 477806_1	AW979249 D63277 AA846968
	440428 493701	BE560954
	440638 499025_1	Al376551 T87714 AA897445
	456332 179104_1	AA228357 AW841786 AW841716

#### **TABLE 21B**

Pkey: 5

Unique number corresponding to an Eos probeset
Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
Indicates DNA strand from which exons were predicted.
Indicates nucleotide positions of predicted exons.

Strand:

Nt\_position:

10

Pkey Ref Strand Nt\_position

404571 7249169 Minus 112450-112648

# TABLE 22: 177 GENES DOWN-REGULATED IN COLON CANCER DERIVED LIVER METASTASES COMPARED TO NORMAL COLON TISSUE

Table 22 shows 177 genes down-regulated in colon cancer derived liver metastases compared to normal colon tissue. These were selected from 59680 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the ratio of "average" colon cancer derived liver metastases to "average" normal colon tissues was less than or equal to 0.25. The "average" colon cancer derived liver metastases level was set to the 50th percentile. The "average" normal adult tissue level was set to the 50th percentile.

15	Pkey: ExAcon:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number
	UnigeneID:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Genes down mets vs. normal

5

	20					
	20	Dkov	Fulan-	Halman ID	Atalana Pist	
<u></u> ∔		Pkey	ExAccn	Unigeneil	Unigene Title	R1
		125104	AL 027045	Un 155007	andrain articulars att	
		44452	AW518944	HS. 100097	carbonic anhydrase II	0.03
	25		W03754		step II splicing factor SLU7	0.03
m	23		AU076405	Hs.50813	,,	0.03
1. 1		40Z354	NOU/0403	70Un 44520C	solute carrier family 26 (sulfate transp	0.03
7		414709	AI286323	303.143290	disintegrin protease	0.04
		414750 422450	MIZ003Z3	ПS.9/411	hypothetical protein MGC12335	0.04
Ö	30	432130	NIM MOSTE	74.455400	hypothetical protein FLJ20217	0.04
	50	423200	AF007216	3HS. 133 109	hydroxysteroid (17-beta) dehydrogenase 2	0.05
					solute carrier family 4, sodium bicarbon	0.05
æ		44/010	MVV900110	HS.3 13300	ESTs, Moderately similar to ALU7_HUMAN A	0.05
		414007	AI738616	Hs.77348	hydroxyprostaglandin dehydrogenase 15-(N	
	35	420004	AFU394U1	HS.194659	chloride channel, calcium activated, fam	0.06
Ш	55	432231	AW9/2983	MS.232165	polycythemia rubra vera 1; cell surface	0.07
77 :			AW293464			0.07
			Y11339		GalNAc alpha-2, 6-sialyltransferase I, I	0.07
٦.			N98569	Hs.76422	phospholipase A2, group IIA (platelets,	0.08
	40		AA934589		ESTs	0.08
	40		T28160	Hs.778	guanylate cyclase activator 1B (retina)	0.08
T		422440	NM_004812	2MS.116/24	aldo-keto reductase family 1, member B10.	0.08
			AA872605		interleukin 1 receptor, type II	0.09
			T28499	Hs.89485	carbonic anhydrase IV	0.09
	45		L03678	MS.156110	immunoglobulin kappa constant	0.09
	45	422200	AA315993		regenerating gene type IV	0.09
			AF017986		secreted frizzled-related protein 2	0.09
			U03749	Hs.1/2216	chromogranin A (parathyroid secretory pr	0.09
•						0.10
	50			Hs.7306	secreted frizzled-related protein 1	0.10
	50		AI694143	MS.296251	programmed cell death 4	0.10
		423370	MINEONE	MS.227059		0.10
				Hs.24395		0.10
						0.10
	55			Hs.1790		0.11
	<i>J J</i>	421990	AW583807	HS.1460		0.11
		400744	AU076819	HS. 1000		0.11
		440741	AA058357			0.11
			BE140638			0.11
	60			Hs.646	carboxypeptidase A3 (mast cell)	0.11
,	00	424027	AVCC0030	MS.20/158		0.12
		42000Z	AV660038	HS.2000		0.12
		400001	AW009077	ПS.232947		0.12
		420920	AL049977	MS. 1622U9	daudin 8	0.13
	65	400134	AK000184	MS.42945		0.13
,	05	446500	AA505035			0.13
				Hs.15154 :	sushi-repeat-containing protein, X chrom	0.14
		400400	MJU 10901 1	⊓3.13020/ 1	nucin 4, tracheobronchial	0.14
		416436	NM_0016/4	□3.3346/3 ( □= 240472 :	carboxypeptidase M	0.14
•	70	406636	AM 100200 1		Homo sapiens cDNA FLJ14872 fis, clone PL	
	, 0	700000	L12004	į	b:Homo sapiens (clone WR4.12VL) anti-th (	0.14

	457982 AW856093 Hs.183617 ESTs	0.14	
	407744 AB020629 Hs.38095 ATP-bine	ding cassette, sub-family A (ABC1 0.14	
	430378 Z29572 Hs.2556 tumor ne	ecrosis factor receptor superfami 0.14	
5	424885 Al333771 Hs.82204 ESTs	0.14	
,	nopulation in the contract of the public of	ellular carcinoma antigen gene 52 0.14	
	444237 AA336878 Hs.9842 Human ( 445848 AA774824 Hs.13377 Homo sa	DNA sequence from done RP4-788L20 0.	14
		apiens clone 23649 and 23755 unkno 0.14	
		apiens mRNA; cDNA DKFZp564C1416 (f 0. globulin kappa constant 0.14	14
10	423655 AA722425 Hs.182785 ESTs, M	Jobulin Kappa constant 0.14 oderately similar to 1207289A rev 0.15	
	417332 AW972717 Hs.288462 hypotheti	ical protein FLJ21511 0.15	
	427506 AK000134 Hs.179100 hypothet	ical protein FLJ20127 0.15	
	430712 AW044647 Hs.196284 ESTs	0.15	
1.5	421666 AL035250 Hs.1408 endotheli	in 3 0.16	
15	425692 D90041 Hs.155956 N-acetylt	ransferase 1 (arylamine N-acety 0.16	
		nain, class 2, associating factor 0.16	
		ical protein FLJ14540 0.16	
	450085 AW293791 Hs.60162 Homo sa 417820 D87449 Hs.82635 UDP-glud	piens cDNA: FLJ21528 fis, clone C 0.16	
20		Auronic acid/UDP-N-acetylgalactos 0.16	
20	426488 X03350 Hs.4 alcohol de	piens SNC73 protein (SNC73) mRNA, 0.1 ehydrogenase 1B (class I), beta 0.16	16
	436327 AA813075 Hs.120181 ESTs		
		0.16 in 2 (phosphorylase kinase, delt 0.16	
	429524 AB033037 Hs.205293 KIAA1211	1 protein 0.16	
25		pembrane protein 2A 0.17	
		NA sequence from done RP1-304B14 0.1	7
<del> </del>	410310 J02931 Hs.62192 coagulation	on factor III (thromboplastin. 0.17	•
	432563 NM_013261Hs.198468 peroxison	ne proliferative activated recep 0.17	
<b>□</b> 20	406897 M57417 gb:Homo	sapiens mucin (mucin) mRNA, part 0.17	
□ 30		piens, clone MGC:15393, mRNA, com 0.1	7
M	447726 AL137638 Hs.19368 matrilin 2	0.17	
- i		pase C, epsilon 2 0.17	
		talloproteinase 28 0.17	
☐ 30 ☐ 35	407360 X13075 qb:Human	cocorticoid regulated kinase 0.17 n 2a12 mRNA for kappa-immunoglobu 0.1	7
<b>m</b>	430627 U61148 Hs.247685 atonal hor	n 2a12 mRNA for kappa-immunoglobu 0.15 nolog 1 (Drosophila) 0.17	′
		nuclease I-like 3 0.18	
		cyclase activator 2B (uroguany 0.18	
= 40	422994 AW891802 Hs.296276 ESTs	0.18	
<b>40</b>	432134 Al816782 Hs.122583 hypothetic	al protein FLJ21934 0.18	
īU	400417 X72475 -	0.18	
N	443506 H10661 Hs.192124 ESTs, We	akly similar to I38022 hypotheti 0.18	
1 62		iens Chromosome 16 BAC clone CIT 0.18	3
<b>45</b>		or antigen se57-1 0.18	
<b>45</b>	429576 BE242628 Hs.209061 sudD (sup) 422106 D84239 Hs.111732 Fc fragmer	pressor of bimD6, Aspergillus n 0.18 nt of IgG binding protein 0.19	
TU			
•=		iens mRNA; cDNA DKFZp434H1235 (f 0.19 al protein FLJ11110 0.19	,
	421904 BE143533 Hs.109309 hypothetical	al protein FLJ20035 0.19	
50	417165 R80137 Hs.302738 Homo sapi	iens cDNA: FLJ21425 fis, clone C 0.19	
	417771 AA804698 Hs.82547 retinoic aci	d receptor responder (tazaro 0.19	
	452802 AU076403 Hs.323468 electron-tra	ansferring-flavoprotein dehyd 0.19	
	450680 AF131784 Hs.25318 Homo sapi	ens clone 25194 mRNA sequence 0.19	
55	420061 AW024937 Hs.29410 ESTs	0.19	
55	426828 NM_000020Hs.172670 activin A re		
	408190 AB032963 Hs.43577 ATPase, Cl 437682 AA476652 Hs.94952 Homo sapid	lass I, type 8B, member 2 0.19	
	449110 H56112 ab:ya95f07	ens cDNA: FLJ23371 fis, done H 0.19	
	446727 AB011095 Hs.16032 KIAA0523	.r1 Soares fetal liver spleen 0.19	
60			
	423541 AA296922 Hs.129778 gastrointest	al protein FLJ20199 0.20 tinal peptide 0.20	
	410850 AW362867 Hs.302738 Homo sanie	ens cDNA: FLJ21425 fis, clone C 0.20	
	412420 AL035668 Hs.73853 bone morph	nogenetic protein 2 0.20	
	423942 AF209704 Hs.135723 glycolipid tr	ansfer protein 0.20	
65	421832 NM_016098Hs.108725 HSPC040 p	protein 0.20	
	459046 AA910339 Hs.26216 LOC50627	0.20	
	421360 AA297012 Hs.103839 erythrocyte		
	438091 AW373062 Hs.83623 nuclear reco	eptor subfamily 1, group I, m 0.20	
70	403047	0.20	
70	421712 AK000140 Hs.107139 hypothetical		
	427333 AF067797 Hs.176658 aquaporin 8 421964 X73079 Hs.288579 polymeric in	0.20	
	438089 W05391 Hs.83623 nuclear rece		
	445200 AA084460 Hs.12409 somatostatii		
75	404854	0.21	
	426390 AA377299 Hs.90431 ESTs	0.21	

		403381				0.21	
			R82252	Hs 106106	protein kinase (cAMP-dependent, catalyti	0.21	
			F18572	Hs.22978	ESTs, Weakly similar to ALU4_HUMAN ALU		0.21
			AB020635		KIAA0828 protein	0.21	
	5		AA743462			0.21	
	,		R28660	Hs.24305	ESTs	0.21	
			AA928829		hypothetical protein FLJ21212	0.21	
			AF038007			0.21	
					ATPase, Class I, type 8B, member 1	0.21	
	10		AA333327		plasma glutamate carboxypeptidase	0.21	
	10		R51494	Hs.71818	ESTs		
			AF088076		ESTs, Weakly similar to AC004858 3 U1 sm	0.22	
			M21388		Human unproductively rearranged lg mu-ch		
			U24683		immunoglobulin heavy constant mu	0.22	
	1.5		AW190902		cysteine knot superfamily 1, BMP antagon	0.22	
	15		BE241595		selectin L (lymphocyte adhesion molecule	0.22	
			AA465293			0.22	
			W40460		phospholipase A2, group X	0.22	
			Y07828	Hs.91096	ring finger protein	0.22	
	••		N76712	Hs.44829	ESTs, Weakly similar to I38022 hypotheti	0.22	
	20	407243	AA058357	Hs.74466	carcinoembryonic antigen-related cell ad	0.22	
		433906	Al167816	Hs.43355	ESTs	0.22	
		446203	Z47553	Hs.14286	flavin containing monooxygenase 5	0.22	
		403740				0.22	
		405701				0.22	
	25	413554	AA319146	Hs.75426	secretogranin II (chromogranin C)	0.22	
		419577	L36531	Hs.91296	integrin, alpha 8	0.23	
		451820	AW058357	Hs.337353	ESTs	0.23	
		424897	D63216	Hs.153684	frizzled-related protein	0.23	
		422880	AF228704	Hs.121524	glutathione reductase	0.23	
=	30	430832	AI073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	0.23	
<del></del>		430753	Al432401	Hs.2659	fibrinogen-like 2	0.23	
Ш			AI815867	Hs.50130	necdin (mouse) homolog	0.23	
٦ <u>.</u> ا			AW503785		complement component (3d/Epstein Barr vi	0.24	
			AA360328		RAP1A, member of RAS oncogene family	0.24	
	35		NM_006416		solute carrier family 35 (CMP-sialic aci	0.24	
Ш			AA149791		ESTs, Weakly similar to phosphatidylseri	0.24	
_			AI239607	Hs.99196	hypothetical protein MGC11324	0.24	
			BE561430				0.24
2			AA320829		protocadherin 18	0.24	
	40		BE564830		hypothetical protein FLJ12899	0.24	
च्याच्या सम्बद्धाः	-10		D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	0.24	
IU		405441	0.00.4	113.0044	processing of the original or an array of the	0.24	
ΠI			M34516		gb:Human omega light chain protein 14.1	0.24	
			AW887604	Un 79066	complement component 7	0.24	
	45		AV655843			0.24	
	73				chromosome 1 open reading frame 21	0.24	
Ñ			BE383816			0.24	
; <del>L</del>			AA150797			0.24	
			AW410035		MAD (mothers against decapentaplegic, Dr	0.24	
	50		W44877	Hs.55501	ESTs	0.24	
	20				immunoglobulin kappa constant	0.24	
			AW082597			0.25	
					CED-6 protein		
		420512	AW511656	ms.1/01//	Meis1 (mouse) homolog	0.25	

#### TABLE 22A

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Tables 21A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Accession:

Gene cluster number Genbank accession numbers

15

20

**CAT Number Accession** 

449110 798430\_1

H56112 H58047 Al630710 N58742

### TABLE 22B

5	Pkey: Ref:	Unique number corresponding to an Eos probeset  Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
,	Strand: In	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

10	Pkey Ref	Strand	Nt_position
15	403047 3540 403381 9438: 403740 76304 404854 71434 405441 7408: 405701 42637	267 Minus 382 Plus 320 Plus 324 Plus	59793-59968 26009-26178 86504-87227 14260-14537 100952-101283 93243-93364

# TABLE 23: 175 GENES UP-REGULATED IN COLON CANCER DERIVED LIVER METASTASES COMPARED TO COLON CANCER PRIMARY TUMOR SAMPLES CLASSIFIED AS DUKE'S B SURVIVOR

Table 23 shows 175 genes up-regulated in colon cancer derived liver metastases compared to colon cancer primary tumor samples classified as Duke's B stage with a positive survival outcome (Duke's B survivor). These were selected from 59680 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the ratio of "average" colon cancer derived liver metastases to "average" Duke's B survivor was greater than or equal to 3.0. The "average" colon cancer derived liver metastases level was set to the 50th percentile. The "average" Duke's B survivor level was set to the 50th percentile.

15	Pkey: Unique Eos probeset identifier number
	ExAccn: Exemplar Accession number, Genbank accession number
	UnigeneID: Unigene number
	Unigene Title: Unigene gene title
	R1: Genes up liver metastases vs Duke's B survivors
20	

	Pkey	ExAccn	UnigenelD	Unigene Title	R1
	426101	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112 (fr	
25	432572	AI660840	Hs.191202	ESTs, Weakly similar to ALUE_HUMAN !!!!	7.96
		H57111	Hs.221132		7.88
	428046	AW812795	Hs.155381	ESTs, Moderately similar to I38022 hypot	7.48
	407284	AI539227	Hs.214039	hypothetical protein FLJ23556	7.45
	439943	AW083789	Hs.124620		7.00
30	442369	AI565071	Hs.159983	ESTs	7.00
	415116	AA160363	Hs.269956	ESTs	6.98
	433517	AW022133	Hs.189838		6.70
	437176	AW176909		calcineurin-binding protein calsarcin-1	6.68
		R71264	Hs.16798	ESTs	6.62
35	408806	AW847814	Hs.289005	Homo sapiens cDNA: FLJ21532 fis, clone C	6.38
	448974	AL049390	Hs.22689	Homo sapiens mRNA; cDNA DKFZp586O1318 (	
	412088	AI689496	Hs.108932		6.04
	417670	R07785		gb:yf15c06.r1 Soares fetal liver spleen	5.95
		AI420611	Hs.127832	ESTs	5.91
40	426086		Hs.188572		5.90
	436100	AA704806	Hs.143842	ESTs, Weakly similar to 2004399A chromos	5.84
		R10799	Hs.191990		5.84
	407289	AA135159	Hs.203349	Homo sapiens cDNA FLJ12149 fis, clone MA	5.67
			Hs.282070		5.61
45				Homo sapiens cONA FLJ12142 fis, clone MA	5.60
				Homo sapiens clone IMAGE:713177, mRNA se	5.54
				ESTs, Weakly similar to ALU1_HUMAN ALU S	5.51
		AL042005		tripeptidyl peptidase II	5.48
		W22152	Hs.282929		5.42
50		AA456195		hypothetical protein FLJ14621	5.29
			Hs.208558		5.24
		AI241331		ESTs, Moderately similar to I38937 DNA/R	5.11
			Hs.157367	ESTs, Weakly similar to 178885 serine/th	5.11
		AA657494		gb:nt66f04.s1 NCI_CGAP_Pr3 Homo sapiens	5.10
55		AW976570		ESTs	5.08
		AI076345	Hs.214199		5.07
		AA532718			5.00
		AA284447			4.96
<b>C</b> O		AA602917	Hs.156974		4.94
60		BE046594		gb:hn41c11.x1 NCI_CGAP_RDF2 Homo sapiens	4.92
		AI760942	Hs.191754		4.89
			Hs.188490		4.86
		AI801098	Hs.151500		4.79
65		AI634046	Hs.157313	ESIS	4.77
65		AW054922		Homo sapiens cDNA FLJ12366 fis, clone MA	4.75
		H74319	Hs.188620		4.74
		N99638		gb:za39g11.r1 Soares fetal liver spleen	4.73
		AA534222		gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens	4.72
	447982	H22953	Hs.137551	ESIS	4.72

5

10

HODEVOED DEEVOE

4/72 4/72 4/72 4/72 4/72 4/72 4/72 4/72			449509 AA001615 Hs.84561 ESTs	
438607 AW080237 Hs. 252884 ESTS 5 438406 BE372396 Hs.254874 Homo sapiens cDNA FLJ13255 fs. clone OV 426818 AAS54827 Hs.293915 DKFZpAJ34D131 protein 4.62 43220 BE15806 Hs.212259 ESTs 4.62 43622 AW749865 Hs.293645 ESTs, Weakly similar to 138022 hypotheti 4.60 433623 AW749865 Hs.293645 ESTs, Weakly similar to 138022 hypotheti 4.60 433623 AW749865 Hs.293645 ESTs, Weakly similar to 138022 hypotheti 4.60 433623 AW749865 Hs.19398 ESTs 4.52 421097 Al220112 Hs.152522 Homo sapiens cDNA FLJ13266 fs. clone OV 4.50 47035 AA192455 Hs.29368 Homo sapiens done IMAGE:451939 mRNA se 4.84 420974 AL118754 440518 AU75455 Hs.152598 Homo sapiens done IMAGE:451939 mRNA se 4.84 5DDK/ZD/67191910 /1 761 (synonym: hamy2) 4.44 440518 AU75455 Hs.152632 Homo sapiens done IMAGE:451939 mRNA se 4.84 5DDK/ZD/67191910 /1 761 (synonym: hamy2) 4.44 440518 AU75455 Hs.153635 ESTs 4.50 40099 T39096 Hs.17126 hg. bymy97/11.13 NCL.CGAP_GCB1 Homo sapiens 4.43 40099 T39096 Hs.17126 hg. bymy97/11.13 NCL.CGAP_GCB1 Homo sapiens 4.43 40099 T39096 Hs.17126 hg. bymy97/11.13 NCL.CGAP_GCB1 Homo sapiens 4.43 40099 T39096 Hs.17126 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.43 40099 T39096 Hs.17126 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.43 40099 T39096 Hs.17126 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.44 40099 T39096 Hs.17126 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.44 40099 T39096 Hs.17126 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.44 40099 T39096 Hs.17126 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.45 40094 Hs.13462 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.45 40094 Hs.13462 hg. bymp47/11.13 NCL.CGAP_GCB1 Homo sapiens 4.45 40094 Hs.13462 hg. bymp47/11.13 NCL.CGAP_GCB1 Hs.13667 hg. bym			407946 AA226495 Hs.154292 ESTs	4.72 4.70
4.620 4.68018 AAS54827 Hs.289115 DKFZpA54AD131 protein 4.620 4.58022 AW749885 ESTs 4.58022 AW749885 Hs.2393645 ESTs, Weakly similar to 138022 hypotheti 4.60 4.33862 AW749885 Hs.189988 ESTs 4.520 4.71036 AA192456 Hs.239374 Horno sapiens done IMAGE-451939 mRNA se 4.88 4.23974 AL118754 4.98918 AU76456 Hs. 15978 Horno sapiens done IMAGE-451939 mRNA se 4.88 4.23974 AL118754 4.98918 AU76456 Hs. 15978 Horno sapiens done IMAGE-451939 mRNA se 4.88 4.23974 AL118754 4.98918 AU76456 Hs. 15978 ESTs 4.20073 AA744550 Hs. 15978 ESTs 4.20098 139090 Hs. 134604 ESTs 4.21099 U50335 Hs. 110830 Human BRCA2 region, mRNA sequence CG006 4.33 4.21299 U50335 Hs. 110830 Human BRCA2 region, mRNA sequence CG006 4.33 4.2222 AB780324 Hs.192734 ESTs 4.20084 AH26381 Hs. 159786 ESTs 4.20084 AH26388 Hs. 159796 ESTs 4.20084 AH26388 Hs. 159796 ESTs 4.20084 AH26888 Hs. 159796 ESTs 4.2019 AH2698 Hs. 159796 Hs. 159796 Hs. 159796 H			438607 AW080237 Hs.252884 ESTs	4.68
### ### ### ### ### ### ### ### ### ##		5	430406 BEZ/3296 Hs.254467 Homo sapiens cDNA FLJ13255 fis, clone OV 426818 AA554827 Hs.289115 DKFZn434A0131 protein	
43393 AA610649 Hs.333239 ESTs			452220 BE158006 Hs.212296 ESTs	
10 413316 AW955181 Hs.189998 ESTS 4.52 421097 Al200112 Hs.125202 Homo sapiens done IMAGE-451339, mRNA se 4.48 422974 AL118754 448918 AU76456 Hs.15978 Hbmo sapiens done IMAGE-451339, mRNA se 4.48 48918 AU76456 Hs.15978 Hbmo sapiens done IMAGE-451339, mRNA se 4.48 48918 AU76456 Hs.15978 Hbmo sapiens done IMAGE-451339, mRNA se 4.48 48918 AU76456 Hs.15978 Hbmo sapiens done IMAGE-451339, mRNA se 4.48 48018 AU76456 Hs.15978 Hbmo sapiens done IMAGE-451339, mRNA se 4.48 48018 AU76456 Hs.15973 Hbmo sapiens done IMAGE-451339, mRNA se 4.48 48018 AU76456 Hs.15973 EST3, Weakly similar to AU7582 B-cell gr 4.42 430573 AV744550 Hs.136345 EST3, Weakly similar to AU7582 B-cell gr 4.42 430573 AV744550 Hs.136345 EST3, Weakly similar to AU7582 B-cell gr 4.42 4406099 T39096 Hs.134646 EST3 Supply Hbmo sapiens PRO2492 mRNA, complete ods 33 421999 U50535 Hs.10630 Hbman BRCA2 region, mRNA sequence CG006 4.35 43220 AU87324 Hs.192734 EST3 432925 AA878324 Hs.192734 EST3 43281 AS54488 Hs.137576 EST3 433715 AA698955 Hs.10663 EST3 433715 AA698955 Hs.10663 EST3 433715 AA698955 Hs.10663 EST3 433715 AA698955 Hs.10663 EST3 433714 AU69263 Hs.306292 Homo sapiens mRNA; cDNA DKFZp564F133 (fr 4.23 437149 AU694261 Hs.17863 EST3, Weakly similar to 138022 hypotheti 422654 AU84368 Hs.266619 EST3 439717 W94472 Hs.17863 EST3, Weakly similar to 138022 hypotheti 422654 AU894361 Hs.192734 EST3 439717 W94472 Hs.17863 EST3, Weakly similar to 138022 hypotheti 422655 AU86336 Hs.128783 Periodylprolyl somerase A (cyclophilin 432451 AV8972771 Hs.10744 Hs.107445 EST3 45011 777418 Hs.107445 EST3 45011 777418 Hs.107445 Hs.13786 EST3, Weakly similar to ALU1_HUMAN ALU S 4.00 432722 AW30532 Hs.326190 EST3 45011 777419 Hs.107443 Hs.117863 EST3, Weakly similar to ALU1_HUMAN ALU S 4.00 432723 R31789 AL04262 Hs.22839 pelpidyprolyl somerase A (cyclophilin 452451 AV897271 Hs.107445 EST3 45011 777419 Hs.107445 EST3			430823 AW/49865 Hs.293645 ESTs, Weakly similar to 138022 hypotheti 433854 AA610649 Hs 333239 ESTs	
42097 AAA21020 Hs.208919 ESTS 421097 AI20112 Hs.122222 Homo sapiens clone IMAGE.451939, mRNA se 4.48 429397 AIA118754 49618 AI076459 Hs.15978 ByD.KFZ.p76F1P910_1761 (synonym: hamy2) 4.44 49618 AI076459 Hs.15978 BSD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 49618 AI076459 Hs.15978 BSD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 49618 AI076459 Hs.15978 ESTS ByD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 49618 AI076459 Hs.15978 ESTS ByD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 49618 AI076459 Hs.15978 ESTS ByD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 49618 AI076450 Hs.15978 ESTS ByD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44509 T33006 Hs.17625 ESTS ByD.KFZ.p761P910_1761 (synonym: hamy2) 4.42 44505 AI076450 Hs.13650 ESTS ByD.KFZ.p761P910_1761 (synonym: hamy2) 4.42 44505 AI076450 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.42 44505 AI076450 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI076450 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.44 44505 AI07640 Hs.13650 ESTS BSTS BYD.KFZ.p761P910_1761 (synonym: hamy2) 4.4		10	413816 AW958181 Hs.189998 ESTs	
417035 AA192455 Hs.32968 Homo sapiens done IMAGE-45/1939, mRNA se 4/49 449618 AI076459 Hs.15978 (KIAA127) protein 4496089 T39036 Hs.17126 AI076459 Hs.15973 (KIAA125) Hs.15978 (KIAA126) Hs.13978 (KI		10		4.52
### 42937 AL118754 ##8618 AI70F4599 Hs.15978 \$IXAA1272 protein ##8616 AI70F477 Hs.28030 Hs.15978 \$IXAA1272 protein MGC15912  ##8616 AI70F477 Hs.28030 Homo sapiens PRO2492 mRNA, complete ods ##8616 AI70F477 Hs.28030 Homo sapiens PRO2492 mRNA, complete ods ##8616 AI70F477 Hs.28030 Homo sapiens PRO2492 mRNA, complete ods ##8616 AI70F477 Hs.28030 Homo sapiens PRO2492 mRNA, complete ods ##8616 AI70F477 Hs.28030 Hs.13972 ESTs ##8616 AI70F477 Hs.28037 Hs.13972 ESTs ##8616 AI70F4777 Hs.28037 Hs.13972 ESTs ##				4.50 - 4.48
155 431615 AW295659 Hs.235860 ESTS gbm9/711.st NCL CGAP_GCB1 Homo sapiens 4.43 428279 AA425310 Hs.155766 ESTS, Weakly similar to A47582 B-cell gr 4.42 430529 AA49916 Hs.1536345 ESTS 430529 AA49916 Hs.1536345 ESTS 430529 AA4991 Hs.17126 hypothetical protein MGC15912 4.40 46099 193096 Hs.17126 hypothetical protein MGC15912 4.40 427991 US0535 Hs.17126 hypothetical protein MGC15912 4.40 427991 US0535 Hs.17126 hypothetical protein MGC15912 4.40 42791 Hs.17126 hypothetical protein MGC15912 4.40 42791 Hs.17126 Hs.17126 hypothetical protein MGC15912 4.40 42791 Hs.17126 hypothetical protein MGC15912 4.40 42791 Hs.17126 hypothetical protein MGC15912 4.40 43052 AA478324 hs.17126 hypothetical protein MGC15912 4.40 43052 AA47824 hs.18126 hypothetical pro			423974 AL118754 gb:DKFZp761P1910_r1 761 (synonym: harmy2	4.44
418876 AA740616 428279 AA243310 Hs.155766 ESTs, Weakly similar to A47582 B-ceil gr 430920 AA489166 Hs.156933 ESTs 430920 AA489166 Hs.156933 ESTs 446099 T93096 Hs.17126 439362 Al964880 Hs.17126 439362 Al964880 Hs.17126 439252 AA878324 Hs.197274 ESTs 43220 AI174777 458284 Hr.1718 Al253112 Hs.133540 ESTs 42881 AA564489 Hs.13560 ESTs 42881 AA564489 Hs.13560 ESTs 43000 Hs.19857 ESTs 4301 Al9741 Al9741 Hs.19857 ESTs 4302 Al9741 Al9741 Hs.19857 ESTs 4302 Al9741 Al9741 Hs.19857 ESTs 4303 Al9741 Al9741 Hs.19857 ESTs 4304 Al9741 Al9741 Hs.19857 ESTs 4305 Al9742 Hs.19857 ESTs 4305 Al9742 Hs.19857 ESTs 4306 Al974688 Hs.266619 ESTs 430740 Al9740 Al9741 Hs.17853 ESTs, Weakly similar to 138022 hypotheti 43074 Al4040 Al9742 Hs.198783 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 Al9740 Al9714 Hs.22830 ESTs 4501 Al97472 Hs.22830 ESTs 4501 Al97472 Hs.22830 ESTs 4501 Al97472 Hs.22830 ESTs 4501 Al97472 Hs.29827 ESTs 4501 Al97471 Hs.2982 BSTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al9745 Hs.23838 Al656872 Hs.23836 ESTs 4506 Al98687 ABA47510 Hs.238265 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al97450 Hs.238267 BSTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al97450 Hs.238267 BSTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al97450 Hs.238267 BSTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al97450 Hs.238267 BSTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al97450 Hs.238267 BSTs, Weakly similar to ALU1_HUMAN ALU S 4.04 Al97450 Hs.238267 B		15		
430929 AA489166 Hs.156933 ESTs			418876 AA740616 gb:nv97f11.s1 NCI_CGAP_GCB1 Homo sanier	ns 4.43
20 430929 AA489166 Hs.156933 ESTS 440 439362 AI954880 Hs.134604 ESTS 43920 AI714777 Hs.230339 Homo sapiens PRO2492 mRNA, complete cds 4.33 43422 AI714777 Hs.230339 Homo sapiens PRO2492 mRNA, complete cds 4.33 43725 AA678324 Hs.133540 ESTS 4.30 428848 H72531 Hs.33540 ESTS 4.30 428848 H72531 Hs.33540 ESTS 4.30 43831 AA568489 Hs.137526 ESTs 4.30 433735 AA608955 Hs.10953 ESTs 4.30 433735 AA608955 Hs.10953 ESTs 4.30 431749 AL049263 Hs.393677 ESTS 4.28 431749 AL049263 Hs.393677 ESTS 4.28 431749 AL049263 Hs.306292 Homo sapiens mRNA; cDNA DKFZp564F133 (fr 4.23 43230 AW13134 Hs.20277 ESTS 4.22 43373 AW396145 Hs.202877 ESTS 4.22 43373 AW396345 Hs.10450 Homo sapiens cDNA: FLI22063 fis, clone H 4.22 43376 AW960454 Hs.222303 ESTs 4.22 43376 AW960454 Hs.222303 ESTs 4.22 43377 Wardy Prospective Complete Com			4282/9 AA425310 Hs.155766 ESTs, Weakly similar to A47582 B-cell gr 430573 AA744550 Hs.136345 ESTs	
439362 Al954880 421999 U50535 434220 Al174777 432925 AA878324 417819 AL253112 417819 AL253112 418193 ASSA A868955 433735 AA608955 433735 AA608955 418840 AA2502021 30 418840 AA2502021 418243 AA769266 431749 AL049263 4419267 AW204431 Hs. 117853 ESTs 422 43230 AW318134 Hs. 220277 ESTs 422357 AW8060454 Hs. 220277 ESTs 422357 AW8060454 Hs. 220277 ESTs 423578 AW8060454 Hs. 220272 ESTs, Moderately similar to ALU1_HUMAN A 4.20 432578 AW8080323 Hs. 326159 ESTs, Weakly similar to 138022 hypotheti 422 43576 AW16466 Hs. 32685 ESTs 42825 Al084335 Hs. 128783 ESTs, Weakly similar to 138022 hypotheti 43576 AW16466 Hs. 32685 ESTs 42825 Al084336 Hs. 128783 ESTs, Weakly similar to 138022 hypotheti 43576 AW16466 Hs. 32685 ESTs 42825 AW808033 Hs. 181574 ESTs 42825 AW8080345 Hs. 128783 ESTs, Weakly similar to 138022 hypotheti 429 43144 AW375051 Hs. 182935 ESTs, Weakly similar to 1410 HUMAN ALU S 406 433488 Al056872 Hs. 133368 ESTs 44040 AF204231 Hs. 182932 polythylosomine (GicNAc) tr 43348 Al052572 Hs. 289864 ESTs, Weakly similar to 1401 HUMAN ALU S 406 433588 Al056872 Hs. 133086 ESTs 443049 AW362575 Hs. 289864 ESTs, Weakly similar to 1401 HUMAN ALU S 406 433588 AW362750 Hs. 182892 ESTs, Weakly similar to 1401 HuMAN ALU S 406 43368 AW362436 Hs. 310286 ESTs 443049 AW3	,	30	430929 AA489166 Hs.156933 ESTs	
## 1999 US0535 Hs. 110630 Human BRCA2 region, mRNA sequence CG006 4.35 432420 AI174777 Hs. 192734 ESTS 4.30 4787824 Hs. 192734 ESTS 4.30 42824 Hs. 192734 ESTS 4.30 428431 AAS64489 Hs. 137526 ESTS 4.30 428831 AAS64489 Hs. 137526 ESTS 4.30 428831 AAS64489 Hs. 137526 ESTS 4.30 439431 AAS64489 Hs. 137526 ESTS 4.30 439431 AAS64489 Hs. 137526 ESTS 4.30 418243 AA769266 Hs. 193657 ESTS 4.28 418243 AA769266 Hs. 193657 ESTS 4.28 428054 AI984688 Hs. 266619 ESTS 4.30 428054 AI984684 Hs. 220277 ESTS 4.20 439717 W94472 Hs. 595529 ESTS, Weakly similar to 138022 hypotheti 4.22 439717 W94472 Hs. 595529 ESTS, Moderately similar to ALU1_HUMAN A 4.20 439717 AI9846744 Hs. 148422 ESTS 4.30 439451 AF086270 Hs. 278554 heterochromatin-like protein 1 4.12 45049 AI82693 Hs. 226624 ESTS 4.33 439451 AF086270 Hs. 278554 heterochromatin-like protein 1 4.12 45049 AI82699 Hs. 224624 ESTS 4.31979 ABA042551 Hs. 278554 heterochromatin-like protein 1 4.12 450419 AI82699 Hs. 224624 ESTS 4.31979 ABA04257 Hs. 27854 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI624436 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI624436 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI624436 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI624436 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI624436 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI8368 AI624436 Hs. 100230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 42071 AI8368 AI8	4	20	100000	
432225 ARR3324 Hs.133540 ESTs 4.33 428281 ARS3324 Hs.133540 ESTs 4.30 428881 ARS3424 Hs.133540 ESTs 4.30 428881 ARS342488 Hs.137526 ESTs 4.30 433735 AA608955 Hs.109663 ESTs 4.30 433735 AA608955 Hs.109663 ESTs 4.30 431749 AL04926 Hs.193657 ESTs 4.30 43203 AW136134 Hs.20277 ESTs 4.22 432578 AW860454 Hs.222830 ESTs 4.21 432578 AW860454 Hs.222830 ESTs 4.22 432578 AW860454 Hs.19462 ESTs 4.22 433771 W94472 Hs.59529 ESTs, Moderately similar to ALU1_HUMAN A 4.20 433772 WA830532 Hs.326150 ESTs 4.20 433766 Al418466 Hs.33665 ESTs 4.30 438766 AW86044 Hs.134622 ESTs 4.30 43576 Al418466 Hs.33665 ESTs 4.30 434594 AW898533 Hs.181574 ESTs 4.32 445943 AW898533 Hs.181574 ESTs 4.32 445943 AW898533 Hs.181574 ESTs 4.32 445941 AW375051 Hs.29379 peptidylprolyl isomerase A (cyclophilin 4.12 43548 Al034357 Hs.21149 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.10293 O-linked N-acetylglucosamine (GicNAc) tr 4.06 432731 R31178 Hs.28277 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.00 43265 T96509 Hs.284549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 43265 T96509 Hs.284549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 43265 T96509 Hs.284549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 43265 T96509 Hs.284549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 43265 T96509 Hs.284549 ESTs, Moderately similar to PC4259 ferri 4.39667 Al48468 AW362803 Hs.166271 ESTs 4.44460 AF204231 Hs.18292 gogin-67 43265 AW972667 Hs.287510 Homo saplens PCNA FLU12300 fis, conce Mal 43886 AW362803 Hs.166271 ESTs 4.44984 SW3636 Hs.283742 Hs.39166 ESTs 4.44984 AW393636 Hs.2836			421999 U50535 Hs.110630 Human BRCA2 region, mRNA sequence CG00	6 4.35
25 417819 AIZ53112 Hs.133540 ESTs 4.30 42884 H72531 Hs.137526 ESTs 4.30 43373 AA669855 Hs.19537 ESTs 4.30 43373 AA669855 Hs.19537 ESTs 4.30 43373 AA669856 Hs.193657 ESTs 4.30 413243 AA769266 Hs.193657 ESTs 4.20 428054 AI94688 Hs.266619 ESTs 4.20 433230 AW136134 Hs.220277 ESTs 4.20 433230 AW136134 Hs.220277 ESTs 4.20 433230 AW136134 Hs.220277 ESTs 4.20 432578 AW960454 Hs.194529 ESTs, Moderately similar to I38022 hypotheti 4.22 433717 W94472 Hs.59529 ESTs, Moderately similar to ALU1_HUMAN A 4.20 43576 AW1860454 Hs.34622 ESTs 4.21 43576 AW1860454 Hs.34622 ESTs 4.20 437756 AW1860454 Hs.326150 ESTs 4.20 437757 ASA90534 Hs.18757 ESTs 4.20 437656 AW18605 Hs.22836 ESTs, Weakly similar to I38022 hypotheti 4.14 438451 AF086270 Hs.278554 heterochromatin-like protein 1 4.12 439451 AF086270 Hs.278554 heterochromatin-like protein 1 4.12 445963 AW898533 Hs.181574 ESTs 4.12 445943 AW898533 Hs.181574 ESTs 4.12 445943 AW898533 Hs.181574 ESTs 4.12 445941 AW375051 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292472 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292472 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292472 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 420911 U77413 Hs.292469 ESTs 4.06 43168 AW362803 Hs.166271 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.00 432152 AW972667 Hs.287510 Hono saplens cDNA FLU12300 fis, done MA 4.00 432152 AW972667 Hs.287510 Hono saplens cDNA FLU12300 fis, done MA 4.00 432152 AW972667 Hs.287510 Hono saplens cDNA FLU12300 fis, done MA 4.00 432152 AW972667 Hs.287510 Hono saplens cDNA FLU			434220 Al174777 Hs.283039 Homo sapiens PRO2492 mRNA, complete cds	4.33
	2	25		
433735 AA608955 Hs. 109653 ESTs			426848 H72531 Hs.36190 ESTs	
41884 AA230228 Hs.59197 ESTs 4.28 413243 AA769266 Hs.193657 ESTs 4.26 413149 AL049263 Hs.306292 Homo sapiens mRNA; cDNA DKFZp564F133 (fr 4.23 428054 Al948688 Hs.206619 ESTs 4.28 428054 Al948688 Hs.206619 ESTs 4.22 433230 AW136134 Hs.220277 ESTs 4.22 433230 AW136134 Hs.220277 ESTs 4.22 432578 AW9806454 Hs.222830 ESTs 4.21 432772 AW8906454 Hs.222830 ESTs 4.21 439717 W94472 Hs.59529 ESTs, Moderately similar to ALU1_HUMAN A 4.20 43576 AW1607444 Hs.134622 ESTs 4.20 439717 W94472 Hs.59529 ESTs, Moderately similar to ALU1_HUMAN A 4.20 435756 AW18466 Hs.33665 ESTs 4.18 439451 AF086270 Hs.278554 heterochromatin-like protein 1 4.14 439451 AF086270 Hs.278554 heterochromatin-like protein 1 4.12 445943 AW898533 Hs.128783 ESTs, Weakly similar to 138022 hypotheti 4.14 450219 Al826999 Hs.224624 ESTs 4.12 450219 Al826999 Hs.224624 ESTs 4.12 451144 AW975051 Hs.293716 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450174 Al8368 Al62436 Hs.30365 ESTs 4.00 420911 U77413 Hs.293471 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.08 450419 Al8686972 Hs.200230 O-linked N-acetylglucosamine (GicNAc) tr 4.06 432731 R31178 Hs.293156 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.08 44040 AF204231 Hs.182932 golgin-67 4.06 432731 R31178 Hs.293856 ESTs 4.06 43368 Al62436 Hs.310286 ESTs 4.06 43368 Al62436 Hs.310286 ESTs 4.06 432731 R31178 Hs.293826 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 43368 Al62436 Hs.310286 ESTs 4.06 433148 AW975267 Hs.182982 golgin-67 4.06 432125 AW972667 Hs.287510 Hs.182982 golgin-67 4.06 433293 AW971493 Hs.134269 ESTs, Moderately similar to DC4259 ferri 3.95 441029 AA317962 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 433688 Al62436 Hs.287820 Hs.18693 Hs.182982 golgin-67 4.06 433215 AW972667 Hs.287510 Hs.182982 golgin-67 4.06 433216 AW362803 Hs.186864 ESTs, Weakly similar to DC4259 ferri 3.95 441328 Al982794 Hs.1	<b> </b>		429831 AA564489 Hs.137526 ESTs 433735 AA608955 Hs.109653 FSTs	
### ### ### ### ### ### ### ### ### ##			418884 AA230228 Hs.59197 ESTs	
### ### ### ### ### ### ### ### ### ##		50	413243 AA769266 Hs.193657 ESTs 431749 ALM9263 Hs.306292 Home conicce mDNA - DNA DVET-5045400 W	4 26
### ### ### ### ### ### ### ### ### ##	Ш		428054 Al948688 Hs.266619 ESTs	
### ### ### ### ### ### ### ### ### ##	terest gariff		413967 AW204431 Hs.117853 ESTs, Weakly similar to I38022 hypotheti	4.22
### ### ### ### ### ### ### ### ### ##	\	35	421057 T58283 Hs.10450 Homo sapiens cDNA: FLJ22063 fis. done H	
43696 AW607444 Hs.134622 ESTs 4.20 432722 AA830532 Hs.326150 ESTs 4.18 432722 AA830532 Hs.326150 ESTs 4.18 43876 Al418466 Hs.33665 ESTs 4.18 43876 Al418466 Hs.33665 ESTs 4.18 43885 Al084336 Hs.128783 ESTs, Weakly similar to I38022 hypotheti 4.14 439451 AF086270 Hs.278554 heterochromatin-like protein 1 4.12 445943 AW898533 Hs.181574 ESTs 4.12 450219 Al826999 Hs.224624 ESTs 4.12 450219 Al826999 Hs.224624 ESTs 4.12 432451 AW972771 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.10 432451 AW972771 Hs.292471 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.08 430177 Al698091 Hs.107845 ESTs Weakly similar to ALU8_HUMAN ALU S 4.08 430177 Al698091 Hs.20196 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.20196 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.310286 ESTs Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.310286 ESTs Weakly similar to ALU1_HUMAN ALU S 4.08 434688 Al056872 Hs.310286 ESTs Weakly similar to ALU1_HUMAN ALU S 4.06 433468 Al052572 Hs.14802 ESTs 4434040 AF204231 Hs.182982 golgin-67 4.06 4339867 AA847510 Hs.161292 ESTs 430567 AA847510 Hs.161292 ESTs 41029 AA317962 Hs.248549 ESTs, Moderately similar to S65657 alpha 4.02 431333 AW971493 Hs.16271 ESTs, Moderately similar to PC4259 ferri 3.95 41029 AA317962 Hs.248549 ESTs, Moderately similar to PC4259 ferri 3.95 413294 AA31986 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 41209 AA317962 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs Moderately similar to 138022 hypotheti 3.85 448682 AW905632 Hs.291198 ESTs 41329 AB38794 Hs.18468 ESTs 3.99 45378 AA811244 Hs.164168 ESTs 3.99 45318 T97301 Hs.18626 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 449987 AW979749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76 449987 AW979749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76			423578 AW960454 Hs.222830 ESTs	
400 435756 Al48466 Hs.33665 ESTs Hs.33665 ESTs Hs.33665 ESTs Hs.33665 ESTs Hs.32667 Al484594 Al48267 Al084336 Hs.128783 ESTs, Weakly similar to I38022 hypotheti 4.14 439451 AF086270 Hs.278554 heterochromatin-like protein 1 4.12 450219 Al826999 Hs.224624 ESTs Hs.32464 Hs.182937 peptidylprolyl isomerase A (cyclophilin 4.11 432451 AW972771 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 430379 AAS04264 Hs.182937 peptidylprolyl isomerase A (cyclophilin 4.11 432451 AW972771 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450177 Al698091 Hs.107845 ESTs Weakly similar to ALU8_HUMAN ALU S 4.08 420911 U77413 Hs.201194 ESTs, Weakly similar to I78885 serine/th 4.06 432111 AW975051 Hs.293156 ESTs, Weakly similar to I78885 serine/th 4.06 432131 Rs.310286 ESTs 4.06 434658 Al624436 Hs.182982 golgin-67 4.06 429512 AA453987 Hs.14802 ESTs 4.06 425955 P9609 Hs.248549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 43349 Al052572 Hs.269864 ESTs, Weakly similar to S65667 alpha 4.02 433493 AW971493 Hs.134269 ESTs, Moderately similar to S65667 alpha 4.02 433439 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 432125 AW972632 Hs.211198 ESTs Moderately similar to PC4259 ferri 3.95 441328 Al982794 Hs.164682 KIKAO421 protein 3.86 443684 AV362803 Hs.283742 Hs.21989 ESTs, Weakly similar to 138022 hypotheti 3.85 443845 AL043683 Hs.16468 ESTs Weakly similar to 138022 hypotheti 3.86 54 44364 AV36263 Hs.292669 ESTs 444941 AW450536 Hs.292660 ESTs 3.80 4449941 AW450536 Hs.202660 ESTs 3.80 4449941 AW450536 Hs.202660 ESTs 3.80 4449841 AW450536 Hs.202660 ESTs 3.80 4449841 AW450536 Hs.202660 ESTs 3.76 4449841 AW450536 Hs.202660 ESTs 3.76 4449841 AW450536 Hs.202660 ES				
428825 Al084336 Hs. 128783 ESTs, Weakly similar to I38022 hypotheti 4.14 439451 AF086270 Hs. 278554 heterochromatin-like protein 1 4.12 45943 AW898533 Hs. 181574 ESTs 4.12 45949 Al826999 Hs. 224624 ESTs 4.12 45019 Al826999 Hs. 224624 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450177 Al698091 Hs. 107845 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450177 Al698091 Hs. 100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.06 420911 U77413 Hs. 100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.06 433588 Al056872 Hs. 33386 ESTs, Weakly similar to 178885 serine/th 4.06 433588 Al056872 Hs. 313026 ESTs 4.06 434040 AF204231 Hs. 182982 golgin-67 429512 AA453987 Hs. 144802 ESTs 4.06 43399 AW871493 Hs. 184802 ESTs 4.06 431393 AW971493 Hs. 184802 ESTs 4.06 432731 Rs. 144802 ESTs 4.06 432955 T96509 Hs. 248549 ESTs, Moderately similar to 565657 alpha 4.02 431393 AW971493 Hs. 134269 ESTs, Highly similar to cytokine recepto 4.00 432125 AW972667 Hs. 287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs. 166271 ESTs 4.06 435468 AW362803 Hs. 166271 ESTs 5.00 446682 AW205632 Hs. 21198 ESTs 3.95 446682 AW205632 Hs. 21198 ESTs 3.95 445577 BE088746 Hs. 288742 Hs. 289742 ESTs, Weakly similar to PC4259 ferri 3.95 455778 BE088746 Hs. 288742 Hs. 289742 ESTs, Weakly similar to 138022 hypotheti 3.85 43398 AW9734336 Hs. 166271 ESTs 3.95 445295 AW973253 Hs. 292689 ESTs 4.04 42935 AW973253 Hs. 292689 ESTs 4.04 42935 AW973253 Hs. 292689 ESTs 3.83 433318 T97301 Hs. 186541 ESTs 3.86 449941 AW450536 Hs. 200260 ESTs 3.86 449947 AW450536 Hs. 200260 ESTs 3.86 449947 AW979749 Hs. 184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76 449847 AW979749 Hs. 184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76		^	432722 AA830532 Hs.326150 ESTs	
4.99451 AF-086270 Hs. 278554 heterochromatin-like protein 1 4.12 450219 Al826999 Hs. 224624 ESTs 4.12 450219 Al826999 Hs. 224624 ESTs 4.12 431379 AA504264 Hs. 182937 peptidylprolyl isomerase A (cyclophilin 4.11 432451 AW972771 Hs. 292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450177 Al698091 Hs. 107845 ESTs 420911 U77413 Hs. 100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.06 421114 AW975051 Hs. 287820 FSTs, Weakly similar to 178885 serine/th 4.06 433588 Al056872 Hs. 133386 ESTs 4.06 434658 Al624436 Hs. 310286 ESTs 4.06 434040 AF204231 Hs. 182982 golgin-67 4.06 432731 AV453897 Hs. 144802 ESTs Weakly similar to ALU1_HUMAN ALU S 4.06 433458 Al056872 Hs. 269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.06 433468 Al056872 Hs. 182982 golgin-67 4.06 433458 Al056872 Hs. 182982 golgin-67 4.06 433459 Al052572 Hs. 269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 43349 Al052572 Hs. 269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 43349 Al052572 Hs. 269864 ESTs, Weakly similar to Cytokine recepto 4.00 432125 AW972667 Hs. 287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs. 1866271 ESTs 3.97 412059 AA317962 Hs. 287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs. 1866271 ESTs 3.95 446682 AW205632 Hs. 249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs. 249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs. 249721 ESTs, Weakly similar to 138022 hypotheti 3.85 44594 Al043683 Hs. 186541 ESTs 3.95 5KIAA0421 protein FLJ10803 3.85 445945 AL043683 Hs. 186541 ESTs 3.83 432945 AL043683 Hs. 186541 ESTs 48987 AW973253 Hs. 292689 ESTs 3.83 432945 AL043683 Hs. 18673 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs. 18673 hypothetical protein FLJ10803 3.83 449941 AW4505636 Hs. 200260 ESTs 3.36 449941 AW4505636 Hs. 200260 ESTs 3.36 449941 AW4505636 Hs. 200260 ESTs 3.36 449941 AW4505636 Hs. 200260 ESTs 449941 AW3505636 Hs. 200260 ESTs 449941 AW3505636 Hs. 200260 ESTs 449941 AW350560 Hs. 200260 ESTs 440540 AW350500 Hs. 200260 ESTs 440540 AW35	4	·U		
450219 Al826999 Hs.224624 ESTs 4.12 431379 AA504264 Hs.182937 peptidylprolyl isomerase A (cyclophillin 4.11 432451 AW972771 Hs.292471 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.10 443148 Al034357 Hs.211194 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.08 450177 Al698091 Hs.107845 ESTs, Weakly similar to ALU8_HUMAN ALU S 4.08 420911 U77413 Hs.100293 O-linked N-acetykglucosamine (GlcNAc) tr 4.06 421114 AW975051 Hs.293156 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.287820 Bibronectin 1 4.06 432731 R31178 Hs.287820 Bibronectin 1 4.06 43268 Al624436 Hs.310286 ESTs 4.06 434658 Al624436 Hs.310286 ESTs 4.06 434658 Al624436 Hs.310286 ESTs 4.06 4346404 AF204231 Hs.182982 golgin-67 4.06 439867 AA847510 Hs.161292 ESTs 439867 AA847510 Hs.161292 ESTs 4044404 AF204231 Hs.182982 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 439867 AA847510 Hs.161292 ESTs 4.06 431393 AW971493 Hs.134269 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs.134269 ESTs, Highly similar to cytokine recepto 4.00 4312125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.95 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 41328 Al982794 Hs.159473 ESTs 3.95 41303 AA215701 Hs.186541 ESTs 3.95 41303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 43896 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 429355 AW973253 Hs.292689 ESTs 3.83 432945 AL043683 Hs.292689 ESTs 3.83 432945 AL043683 Hs.292689 ESTs 3.83 432945 AL043683 Hs.292660 ESTs 3.83 432945 AL043683 Hs.292660 ESTs 3.80 449941 AW450536 Hs.202960 ESTs 3.80 449941 AW450536 Hs.202966 ESTs 3.80 449941 AW450536 Hs.202966 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	ni		439451 AF086270 Hs.278554 heterochromatin-like protein 1	
443148 Al034357 Hs.211194 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450177 Al698091 Hs.107845 ESTs 4.08 420911 U77413 Hs.203156 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.287820 fibronectin 1 4.06 432731 R31178 Hs.287820 fibronectin 1 4.06 434658 Al624436 Hs.310286 ESTs 4.06 434040 AF204231 Hs.182982 golgin-67 4.06 434349 Al052572 Hs.269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 4359867 AA847510 Hs.14802 ESTs 4.06 432125 AW972667 Hs.269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 435468 AW362803 Hs.16292 ESTs 4.06 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.95 441328 Al982794 Hs.168052 KIAA0421 protein 438996 AW748336 Hs.168052 KIAA0421 protein 438996 AW748336 Hs.168052 KIAA0421 protein 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.292689 ESTs 3.83 432945 AL043683 Hs.2075 Hs.209660 ESTs 3.80 449941 AW450536 Hs.20960 ESTs 3.80 449987 AW0797499 Hs.184719 ESTs 3.80 4444405 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 4.06 4.07 4.08 4.08 4.08 4.00 4.00 4.00 4.00 4.00	٠ <u>٠</u>			
443148 Al034357 Hs.211194 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 450177 Al698091 Hs.107845 ESTs 4.08 420911 U77413 Hs.203156 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.287820 fibronectin 1 4.06 432731 R31178 Hs.287820 fibronectin 1 4.06 434658 Al624436 Hs.310286 ESTs 4.06 434040 AF204231 Hs.182982 golgin-67 4.06 434349 Al052572 Hs.269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 4359867 AA847510 Hs.14802 ESTs 4.06 432125 AW972667 Hs.269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 435468 AW362803 Hs.16292 ESTs 4.06 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.95 441328 Al982794 Hs.168052 KIAA0421 protein 438996 AW748336 Hs.168052 KIAA0421 protein 438996 AW748336 Hs.168052 KIAA0421 protein 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.292689 ESTs 3.83 432945 AL043683 Hs.2075 Hs.209660 ESTs 3.80 449941 AW450536 Hs.20960 ESTs 3.80 449987 AW0797499 Hs.184719 ESTs 3.80 4444405 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.08 4.06 4.07 4.08 4.08 4.08 4.00 4.00 4.00 4.00 4.00	<u> </u>	5	431379 AA504264 Hs.182937 peptidylprolyl isomerase A (cyclonhilin	
450177 Al698091 Hs. 107845 ESTS 4.08 420911 U77413 Hs. 100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.06 421114 AW975051 Hs. 293156 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs. 287820 fibronectin 1 4.06 4332731 R31178 Hs. 287820 fibronectin 1 4.06 434658 Al624436 Hs. 310286 ESTs 4.06 434658 Al624436 Hs. 310286 ESTs 4.06 434040 AF204231 Hs. 182982 golgin-67 4.06 434349 Al052572 Hs. 161292 ESTs 4.06 433493 AW971493 Hs. 161292 ESTs 4.04 425955 T96509 Hs. 248549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 425955 T96509 Hs. 248549 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs. 134269 ESTs, Highly similar to Cytokine recepto 4.00 432125 AW972667 Hs. 287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW3628031 Hs. 168271 ESTs 3.97 412059 AA317962 Hs. 249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs. 211198 ESTs 3.95 441328 Al982794 Hs. 159473 ESTs 3.95 44328 Al982794 Hs. 159473 ESTs 3.95 44816 Z48633 Hs. 168052 KIAA0421 protein 3.86 438996 AW748336 Hs. 168052 KIAA0421 protein 3.85 44816 Z48633 Hs. 283742 H. sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs. 292689 ESTs 3.83 432945 AL043683 Hs. 28173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs. 18026 ESTs 3.80 449947 AW450536 Hs. 209260 ESTs 3.80 449947 AW450536 Hs. 209260 ESTs 3.80 449987 AW079749 Hs. 184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	ī		432451 AW972771 Hs.292471 ESTs, Weakly similar to ALU1 HUMAN ALU S	
420911 U77413 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) tr 4.06 421114 AW975051 Hs.293156 ESTs, Weakly similar to I78885 serine/th 4.06 432731 R31178 Hs.287820 fibronectin 1 4.06 433683 Al056872 Hs.133386 ESTs 4.06 434604 AF204231 Hs.182982 golgin-67 4.06 444040 AF204231 Hs.182982 golgin-67 4.06 429512 AA453987 Hs.144802 ESTs 4.06 433467 AA847510 Hs.161292 ESTs 4.04 433867 AA847510 Hs.161292 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 425955 T96509 Hs.248549 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs.134269 ESTs, Moderately similar to cytokine recepto 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.95 4455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.85 44816 Z48633 Hs.168052 KIAA0421 protein 3.85 44816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 432945 AL043683 Hs.16405 ESTs 3.83 432945 AL043683 Hs.16406 ESTs 3.83 432945 R42755 Hs.23096 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76			450177 Al698091 Hs.107845 ESTs	
432731 R31178 Hs.287820 fibronectin 1 4.06 433588 Al056872 Hs.133386 ESTs 4.06 434658 Al624436 Hs.310286 ESTs 4.06 444040 AF204231 Hs.182982 golgin-67 4.06 443349 Al052572 Hs.269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 43349 Al052572 Hs.269864 ESTs, Weakly similar to S65657 alpha 4.02 4331393 AW971493 Hs.134269 ESTs, Moderately similar to cytokine recepto 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.95 4455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 44816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 438578 AA811244 Hs.164168 ESTs 439941 AW450536 Hs.209260 ESTs 449941 AW450536 Hs.209260 ESTs 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	5	n	420911 U77413 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) tr	4.06
433588 Al056872 Hs.133386 ESTs 4.06 434658 Al624436 Hs.310286 ESTs 4.06 444040 AF204231 Hs.182982 golgin-67 4.06 429512 AA453987 Hs.144802 ESTs 4.06 439867 AA847510 Hs.161292 ESTs 4.04 425955 T96509 Hs.248549 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 425955 T96509 Hs.248549 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs.134269 ESTs, Highly similar to cytokine recepto 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435486 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.241198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.95 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 444816 Z48633 Hs.263742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 R42755 Hs.23096 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	J.	•	432731 R31178 Hs.287820 fibronectin 1	
444040       AF204231       Hs.182982       golgin-67       4.06         429512       AA453987       Hs.144802       ESTs       4.06         433449       Al052572       Hs.269864       ESTs, Weakly similar to ALU1_HUMAN ALU S       4.04         439867       AA847510       Hs.161292       ESTs       4.04         425955       T96509       Hs.248549       ESTs, Moderately similar to Cytokine recepto       4.00         431393       AW971493       Hs.134269       ESTs, Highly similar to cytokine recepto       4.00         432125       AW972667       Hs.287510       Homo sapiens cDNA FLJ12300 fis, clone MA       4.00         435468       AW362803       Hs.166271       ESTs       3.97         412059       AA317962       Hs.249721       ESTs, Moderately similar to PC4259 ferri       3.95         441328       Al982794       Hs.159473       ESTs       3.92         455778       BE088746       gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90       438996       AW748336       Hs.168052       KIAA0421 protein       3.85         44816       Z48633       Hs.283742       H.sapiens mRNA for retrotransposon       3.84         429355       AW973253       Hs.292689       ESTs       3.83			433588 AI056872 Hs.133386 ESTs	4.06
429512 AA453987 Hs.144802 ESTs 4.06 443349 Al052572 Hs.269864 ESTs, Weakly similar to ALU1_HUMAN ALU S 4.04 439867 AA847510 Hs.161292 ESTs 4.04 425955 T96509 Hs.248549 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs.134269 ESTs, Highly similar to cytokine recepto 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.92 445682 AW205632 Hs.211198 ESTs 3.92 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.85 418303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 429355 AW973253 Hs.292689 ESTs 3.83 429355 AW973253 Hs.292689 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	_	_		
439867 A&847510 Hs.161292 ESTs 4.04 425955 T96509 Hs.248549 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs.134269 ESTs, Highly similar to cytokine recepto 4.00 432125 AW972667 Hs.287510 Horno sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.92 65 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.85 418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti 3.85 444816 Z48633 Hs.283742 Hs.apiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs.209260 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	5:	5	429512 AA453987 Hs.144802 ESTs	4.06
425955 T96509 Hs.248549 ESTs, Moderately similar to S65657 alpha 4.02 431393 AW971493 Hs.134269 ESTs, Highly similar to cytokine recepto 4.00 432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.92 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164165 ESTs 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76				
432125 AW972667 Hs.287510 Homo sapiens cDNA FLJ12300 fis, clone MA 4.00 435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.95 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti 3.85 444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164168 ESTs 3.83 435318 T97301 Hs.18026 ESTs 3.83 435318 T97301 Hs.18026 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76			425955 T96509 Hs.248549 ESTs. Moderately similar to S65657 alpha	
435468 AW362803 Hs.166271 ESTs 3.97 412059 AA317962 Hs.249721 ESTs, Moderately similar to PC4259 ferri 3.95 446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTS 3.92 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti 3.85 444816 Z48633 Hs.283742 Hs.apiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.80 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	60	)	431393 AW971493 Hs.134269 ESTs, Highly similar to cytokine recepto 432125 AW972667 Hs.287510 Homo sepiens CONA EL 142300 for close MA	
446682 AW205632 Hs.211198 ESTs 3.95 441328 Al982794 Hs.159473 ESTs 3.92 455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti 3.85 444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76			435468 AW362803 Hs.166271 ESTs	
441328 Al982794 Hs.159473 ESTs gb:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti 3.85 444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164168 ESTs 3.83 435318 T97301 Hs.18026 ESTs 3.83 435318 T97301 Hs.18026 ESTs 3.82 449941 AW450536 Hs.209260 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76				
9b:CM2-BT0693-210300-123-d09 BT0693 Homo 3.90 438996 AW748336 Hs.168052 KIAA0421 protein 3.86 418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti 3.85 444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76		-	444000 41000004 41 400400	
418303 AA215701 Hs.186541 ESTs, Weakly similar to 138022 hypotheti 3.85 444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 4249941 AW450536 Hs.209260 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	63	•	455778 BE088746 gb:CM2-BT0693-210300-123-d09 BT0693 Homo	3.90
444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon 3.84 429355 AW973253 Hs.292689 ESTs 3.83 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.80 449941 AW450536 Hs.209260 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76			418303 AA215701 Hs.186541 ESTs, Weakly similar to I38022 hypotheti	
70 438578 AA811244 Hs.164168 ESTs 3.83 432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.82 449941 AW450536 Hs.209260 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76 449987 AW079749 Hs.184719 ESTs. Weakly similar to ALU1_HUMAN ALU S 3.76			444816 Z48633 Hs.283742 H.sapiens mRNA for retrotransposon	3.84
432945 AL043683 Hs.8173 hypothetical protein FLJ10803 3.83 435318 T97301 Hs.18026 ESTs 3.82 449941 AW450536 Hs.209260 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76 449987 AW079749 Hs.184719 ESTs. Weakly similar to ALU1_HUMAN ALU S 3.76	70	)	438578 AA811244 Hs.164168 ESTs	
449941 AW450536 Hs.209260 ESTs 3.80 424915 R42755 Hs.23096 ESTs 3.76 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76			432945 AL043683 Hs.8173 hypothetical protein FLJ10803	
424915 R42755 Hs.23096 ESTs 3.76 449987 AW079749 Hs.184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76			AADDAA AMAFOFOO II. DOODOO TOT	
/ 3 449987 AW079749 Hs. 184719 ESTs, Weakly similar to ALU1_HUMAN ALU S 3.76	7.	_	424915 R42755 Hs.23096 ESTs	
3.75	/3		449987 AW079749 Hs. 184719 ESTs, Weakly similar to ALU1_HUMAN ALU S	3.76
				o./ O

			7 BE17766	61 01 Hs.14947	gb:RC1-HT0598-020300-011-h02 HT0598 Hor	
			2 R08950			3.74
				TIS.2/209	4 ESTs, Weakly similar to ALU1_HUMAN ALU S	
	5	43131	3 ANUUU//	7 HS.27219 5 Hs.15282	7 Homo sapiens cDNA FLJ20770 fis, clone CO	3.68
	9	43444	2 MM/3/41	0 HS.10282	to ESIS	3.63
		4277N	A AMO7404	3 Hs.29288	ESTs, Weakly similar to I38022 hypotheti	3.63
		42770	4 AVV9/100	D	Z ESIS	3.62
		43571	4 AA60022	5 Hs.26988	7 BANP homolog, SMAR1 homolog	3.60
	10	43250	8 Al341227	3 MS.20300	0 ESIS	3.60
	••	43854	3 AAR101A	' Hs.15710 1 Hs.19218	0 E318	3.57
		42206	8 Al807519	1 175.19210	A Home continue alleita El 140004 5	3.55
		41825	9 AA2154A	4 Hs.13728	0 Homo sapiens cDNA FLJ13694 fis, clone PL	3.54
		428290	Al932995	He 183/7	5 Homo caniona dena 25004 mDNA	3.54
	15	419457	7 AA24314	6 He 20033	5 Homo sapiens done 25061 mRNA sequence 4 ESTs, Moderately similar to S23A_HUMAN P	3.49
		439312	AAR3390	2 Hs.27074	F ECT.	3.47
		408784	AW97135	0 Hs.63386	ESTS	3.47
		456332	AA228357	7	gb:nc39d05.r1 NCI_CGAP_Pr2 Homo sapiens	3.45
					4 eukaryotic translation initiation factor	3.45
	20	442884	AI076570	Hs.134053	R FSTe	3.44
	-				Homo sapiens cDNA FLJ12727 fis, clone NT	3.44
		434575	AI133446	Hs 299964	Homo sapiens clone FLB7723 PRO2055 mRNA	3.43
		430433	AA478883	Hs.273766	FSTs	3.39
		419317	AA236282	Hs.172318	B ESTs	3.38
	25		T62926			3.37
			H72245			3.37
1		430332	R51790	Hs.239483	Human clone 23933 mRNA sequence	3.35
-		411755	BE327036	Hs.117494	ESTs	3.33
	• •	427882	AA640987	Hs.193767	ESTs	3.28
	30	438899	AF085833	Hs.135624	ESTs	3.28
77		436535	AW295687	Hs.254420	ESTs	3.25
12 m			AI285970		ESTs	3.22
-			AF095687			3.18
	2.5		AI809314	Hs.208501	ESTs, Weakly similar to B34087 hypotheti	3.18
	35		BE156536		gb:QV0-HT0368-310100-091-h10 HT0368 Homo	3.16
-			AA664078		gb:ac04a05.s1 Stratagene lung (937210) H	3.13
			AI766732		ESTs	3.13
3		419341	N71463	Hs.118888	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.13
7	40	434495	AW352170	Hs.129086	Homo sapiens cDNA FLJ12007 fis, done HE	3.12
	40	408113	182427	Hs.194101	Homo sapiens cDNA: FLJ20869 fis. clone A	3.12
ĨŲ.			AI924228		ESTs, Moderately similar to PC4259 ferri	3.12
Ш			AI922821			3.12
		436090	AI640635	Hs.116468	EST	3.11
7-2	45	450230	AW016607	Hs.201582	ESTs	3.11
	43	438011	BE4661/3	Hs.145696	splicing factor (CC1.3)	3.09
N			AI381687	Hs.39526	ESTs	3.09
* <del>***</del>		433102	AI343966	Hs.158528	FAT	3.08
				Hs.125243	ESIS	3.05
	50	440110	AI798851	MS.283108		3.04
	50	435027	A 4 0 2 0 0 0 2	Hs.248678		3.04
		40090/ A2A2A2	AA630693 AI263231	Hs.119769	FOT	3.02
		424040 435354	MIZOJZJ I AAG702G7	Hs.327090		3.02
		400004 .	~~0/0Z0/	Hs.117115	E918	3.00

#### TABLE 23A

Table 23A show the accession numbers for those pkeys lacking unigeneID's for tables 1-20A, 21A, 22A, and 23A. For each probeset we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: CAT numb Unique Eos probeset identifier number

CAT number. Accession: Gene cluster number Genbank accession numbers

15

20

25

#### Pkey CAT Number Accession

BE177661 H06215 BE144709 BE144829 413497 1373771\_1 BE156536 BE156439 BE156700 BE156449 BE156653 BE156533 BE156524 BE156670 BE156721 BE156723 413672 1382512\_1 417670 1692163\_1 R07785 T85948 T86972 AA740616 AA654854 AA229923 418876 179960\_1 N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815 419145 182217\_1 AL118754 AA333202 H38001 423974 233842\_1 AA534222 AA632632 T81234 432340 345248\_1 AA657494 AI582663 AI581639 434966 396504\_1 AA664078 AW363313 AA805009 435073 399701\_1 BE046594 BE046667 AA828585 AI207343 438962 467390\_1 BE088746 BE088802 BE088755 BE088876 BE088947 BE088881 BE088952 455778 1364506\_1 AA228357 AW841786 AW841716 456332 179104\_1

#### TABLE 24: 34 GENES DOWN-REGULATED IN COLON CANCER DERIVED LIVER METASTASES COMPARED TO COLON CANCER PRIMARY TUMOR SAMPLES CLASSIFIED AS DUKE'S B SURVIVOR

Table 24 shows 34 genes down-regulated in colon cancer derived liver metastases compared to colon cancer primary tumor samples classified as Duke's B stage with a positive survival outcome (Duke's B survivor). These were selected from 59680 probesets on the Affymetrix/Eos Hu03 GeneChip array such that the ratio of "average" colon cancer derived liver metastases to "average" Duke's B survivor was greater than or equal to 0.25. The "average" colon cancer derived liver metastases level was set to the 50th percentile. The "average" Duke's B survivor level was set to the 50th percentile.

		_
Pkey: Unique	Eos probeset identifier number	
ExAcon: Exemple	ar Accession number, Genbank accession number	
UnigenelD: Unigene	number	
Unigene Title:	Unigene gene title	

L	20			KI:	Genes down liver metastases vs Duke's B	survivors
		Pkey	ExAccn	UnigenelD	Unigene Title	R1
لِيا	25	414522 416768	AA363733		step II splicing factor SLU7 regenerating islet-derived 1 alpha (panc	0.05 0.07

5

10

15

		rkey	EXACCII	ungeneil	O Unigene i rue	R1
		414522	AW51894	4 Hs.76325	step II splicing factor SLU7	0.05
Щ	25	416768	AA363733	Hs.1032	regenerating islet-derived 1 alpha (panc	0.05
÷.			W03754	Hs.50813	hypothetical protein FLJ20022	0.07
			N98569		phospholipase A2, group IIA (platelets,	0.07
			M13509	Hs.83169	matrix metalloproteinase 1 (interstitial	0.11
Ü				79Hs.145296	disintegrin protease	0.11
5	30	428934	AF039401	Hs.194659	chloride channel, calcium activated, fam	0.11
		417233	W25005	Hs.24395	small inducible cytokine subfamily B (Cy	0.12
Ξ				Hs.105484	regenerating gene type IV	0.12
		425196	AL037915	Hs.155097	carbonic anhydrase II	0.12
77.1		433336	AF017986	Hs.31386		0.13
ũ	35		L15533	Hs.423	pancreatitis-associated protein	0.13
ΠJ				Hs.40098	cysteine knot superfamily 1, BMP antagon	0.15
2,					hypothetical protein MGC12335	0.16
		452852	AK001972	Hs.30822	hypothetical protein FLJ11110	0.17
	4.0	447513	AW955776	Hs.313500	ESTs. Moderately similar to ALU7 HUMAN A	0.17
N	40	423541	AA296922	Hs.129778	gastrointestinal peptide	0.17
		425071	NM_01398	9Hs.154424	deiodinase, iodothyronine, type II	0.18
		406636	L12064		gb:Homo sapiens (clone WR4.12VL) anti-th	0.18
		421515	Y11339	Hs.105352	GalNAc alpha-2, 6-sialyltransferase I, I	0.18
	4.5			Hs.83326	matrix metalloproteinase 3 (stromelysin	0.19
	45		X72755	Hs.77367	monokine induced by gamma interferon	0.20
			AU076405		solute carrier family 26 (sulfate transp	0.20
			AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	0.21
			M73720	Hs.646	carboxypeptidase A3 (mast cell)	0.21
	50	453064		Hs.89463	potassium large conductance calcium-acti	0.21
	50	431727	AW293464	Hs.162031	ESTs	0.22
		433658		Hs.156110	immunoglobulin kappa constant	0.22
			AI422867	Hs.88594	ESTs	0.22
		417880	BE241595	Hs.82848	selectin L (lymphocyte adhesion molecule	0.22
	55	430280	AA361258	Hs.237868	interleukin 7 receptor	0.23
	55	452877	AI250789	Hs.32478	ESTs	0.23
		410310	J02931	Hs.62192	coagulation factor III (thromboplastin,	0.24
		402408				0.24

0.24

#### **TABLE 24B**

Pkey: Ref:

Unique number corresponding to an Eos probeset
Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
Indicates DNA strand from which exons were predicted.
Indicates nucleotide positions of predicted exons.

Strand:

Nt\_position:

10

Pkey	Ref	Strand	Nt_position
402408	9796239	Minus	110326-110491

5

#### **TABLE 25:**

Table 25 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, and ExAccn for all of the sequences in Table 26. Seq ID No links the nucleic acid and protein sequence information in Table 26 to Table 25.

	Pkey: ExAcon: Unigene Unigene Seq.ID.I	: E eID: L e Title: L	xemplar Acc Inigene numb Inigene gene			
	Pkey	ExAccn	UnigenelD	Unigene Title	Seq ID No.	
	426101	AL049987		Homo sapiens mRNA; cDNA DKFZp564F112 (fr	1-4	
	419145	N99638		gb	5&6	
	426818	AA554827	Hs.340046	DKFZp434A0131 protein	7 & 8	
		T58283		Homo sapiens cDNA	9	
	446619	AU076643	Hs.313	secreted phosphoprotein 1 (osteopontin,	10 & 11	
	431958	X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	12 & 13	
		AB033025		Hypothetical protein, XP_051860 (KIAA119	14 &15	
		T49951		DKFZP434G032 protein	16 &17	
			Hs.144097	ESTs	18-20	
		Al357412			21 & 22	
				hypothetical protein MGC5306	23-27	
		AA045573			28 & 29	
		AA292998			30 & 31	
•	429970	AK000072			32 & 33	
		M16801			34 & 35	
			Hs.345911		36	
		Z29572			37 & 38	
4	417332	AW972717	Hs.288462	hypothetical protein FLJ21511	39 & 40	

#### **TABLE 25A**

5

Unique Eos probeset identifier number Gene cluster number Genbank accession numbers

Pkey: CAT number: Accession:

		Pkey	CAT Number	Accession
	10	409041		10962_2 AB033025 AL359061 AL045836 AI751521 AI752804 AI752650 AA853580 AI752290 AA853460 AI752769 AA852309 AA853785 AA853219 AW068503 AI752069 AL049389 AW068368 BE439518 W52813 BE141833 AI940574 AI750606 AL109718 AA242845 AA315795 AA307741 AW954603 AI752070 AA350794 AI752649 AA307755 AW951677 AA298896 BE439692
	15			AA852453 AW068826 AW853984 AA418236 AA639417 AW290917 AI750592 AI752768 AL045837 AI926513 AW262903 BE439819 AI459360 AW339074 AW295181 AW029483 AI750945 AI750659 AI752525 AI147688 BE440122 AI751522 AI473816 AI752291 AI694639 AI925816 AA599476 AA242752 AW021892 AI755098 AW469299 AW769363 AA853579 AI784082 AA852454 AI925501 AA976657 AW150473 AW166734
		417332	166755_1	AW972717 AA523805 AI962905 AI373245 AW235545 AI812045 AW589434 AI826824 AW572339 AI377551 AA195718 AI868470
	20		182217_1 198849_1	N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815 T58283 AA765038 AA283052 H99396 AA814751 Al032674 N81016 N81017 BE222349 AA830545
	20		2408_1	M16801 NM_000901 D57171 AL041328 AF068623 AI201179 AA151766 AA568349 AI698649 AI692765 BE327401 AA744953 AA744951 AW361986 AV651840 T29894 AW945146 AW945145 W24096 AI183952 AI458972 AW190993 AI765359 AI634663 AI741201 AW418944 AI767551 AA679687 AW772342 AW629508 BE504300 AI251790 AI522294 AA724341 AW615402 AI537570 AA470665 AI458375 AW768901 AA447079 T23537 AI783744 R44301 D56621 N91919 AA149749
H	25	426101	26088_1	AL049987 AW362842 T78981 AA247541 Al217018 AW961515 AA632986 AA663108 BE326465 AW872412 Al024689 AA453725 BE150456 AA229448 AA442638 AA442648 Al916737 AA460220 AA868553 Al827987 Al005467 R31132 Al742087 AA442379 N56349 AW769479 Al860142 Al917507 AA813604 Al860141 Al459289 AA522837 Al354470 Al921333 BE466760 AW971193 AW103830 AW277065 AW020895 Al187977 N28268 Al084517 R95914 AA833517 AA563934 AA437299 AA436880 AA447794 AA812876 AA663178 R31089 Al472712 R64648 AA600372 AA229164 AA703066 AW270324 Al191725 AA551512 AA493776
	30		272427_1 31134_1	AA554827 AA701001 AW972954 AL039129 AA385540 AA911663 AK000072 AW840683 AW843764 AW844444 AW844515 AW603469 AW862395 AI860838 AW511708 AF127035 NM_012128 AK000138
	35		3170_1 3394_1	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
	40		418907_1 47438_3	C00249 W40333 BE143121 BE551618 Al207338 BE220568 Al261568 AW841737 AA714722 AA946891 Al033239 AW864696 AW338889 Al342866 AA084522 Al244150 Al610339 AA425635 AA764930 AA976965 AW805766 AA057765 AW805845 AW802595 AA262971 Al969620 N75323 BE549060 AW805725 AA025809 N80776 N64595 AW073372 AA025493 AI819475 AW028879 AW189496 AA442907 AW410368 Al911629 N71276 AW316922 AW805838 AA043880 AW189184 AA449756 AA748153 AA705608 Al910643 AA279492 BE160119 AW805761 AA026262 AA782207 AW057652 AW805768
	45	442577	54549_1	H21998 AW194254 AW275178 AA449040 AA279582 N76314 N54348  AA292998 AW238350 AI676059 AW074092 BE566458 AW078677 AW514801 AW073701 AW170620 AI523736 AI580870  AI923975 AI393326 AI700229 AW450814 AW628452 AI671457 AA937534 AI889694 AW339423 AW291875 AA551874
	<b>50</b>	443162	5613_1	AI682314 AI926227 AA397375 T49951 AA025326 H04839 AA393303 R63101 W57657 W25628 AI961431 R71165 N39940 H01548 H01759 AA641624 AI634930 AA595296 AW994770 AW994747 BE047247 W38159 AA658133 AI701944 AW386273 AA676625 R24676 R79410 AA922863 AI151319 H01013 AA024482 W02674 H01456 AI150858 AW135972 AW631167 AI270332 H04750 T49622 AA004543 R63061 AI093066 AI247539 H01225 H03388 AW472933 AA382448 AI219287 N27194 AW389613 AA649738 AW994764 AW389614 R25176 AA897262 R71626 AA909471 R71240 AW811917 R76109 AI202312 AI866010 R76162 AL117538 R79411
	55	446619	685_1	T58656 AW994674 AU076643 AA594604 AA346866 R18197 AA345192 AA337773 AA089791 R84435 AA337838 AW392167 AA075190 D55416 AW150360 AW366257 AA579816 H93048 AW385689 AW385697 Al186216 AW581197 AL037509 AB019562 AA232626 R97905 AW368019 AA242891 AW888502 AI798331 AW385635 AW581221 T96947 H87989 AA369511 AA075191 R80742 AA366406 W92752 H45586 AI864016 AW888497 BE004992 AI384110 AI624256 AI627593 W92728 AI682719 AA948208 AA171734
	60			N40517 J04765 AA379957 AA362403 NM_000582 AF052124 AA300290 AA333447 AA343721 AW889543 BE566767 R76601 R18015 AA100531 AA489963 AA101296 AA363513 AA344088 AA336750 T77505 D56440 AL110351 AL110331 F12195 R20175 AA336664 H17766 AA363538 AA363590 D28760 AW578517 AA363531 AI814667 AA846899 AA366253 AW951285 AA297992 AA327756 AW361609 AW815455 AW815427 AW815428 D54182 AW852200 AA171630 W27018 AW815864 AW379995 AW378222 AW362610 BE566022 AW021023 C17352 D58435 AA345409 AI623991 AW020967 AI924770 AI799443 AW946393
	65			AA991239 Al571617 Al935181 Al923999 Al826895 Al860319 AW189873 AW270353 AW023584 Al813811 R99929 AW339056 AA913152 Al636352 Al829394 AW151077 AW192580 Al570119 Al086391 AW021764 AW519154 Al375193 AW268678 BE465690 AW019983 AW268654 Al573138 Al141809 Al954553 Al559242 AA568945 AA886417 AW338527 Al635881 BE465666 Al921239 AA968537 Al956027 AA911981 Al827661 AW511046 BE619780 Al922227 Al811870 AW190131 AW129220 AW512906 Al290757 Al819088 Al623771 AA775616 BE349419 Al126375 H88773 Al241758 AW275157 Al337848
	70			Al613425 Al631387 AA922631 Al273483 Al982898 AW168957 Al446481 BE501588 BE048264 Al499922 AW023812 BE220523 AW973846 BE349276 Al141091 AA976060 AW973845 AA101270 Al582472 AW613675 Al139360 Al282627 Al276044 N22345 Al261875 AA634136 Al824468 AW887693 N27107 R21504 Al042223 N22067 AW196871 Al581019 BE004973 AA252035 N22087 AA570717 H11250 Al804026 AA368098 AA021512 H08842 N26275 AA176368 Al758758 AA570371 AA232574 BE221177 AW190221 AW471386 M78225 Al422140 Al624521 AA719775 AA300291 AA568657 Al871430 BE465630 N71862
	75			T72587 W92721 H88774 D54383 AW103693 AW089986 AI382689 R42363 R44962 T98770 AA357374 AW022074 AI356207 T29241 AW089431 AI933875 N66267 N67352 AA121786 AA363910 F09824 T95618 N66888 R80550 AI280667 AW196719

	R59299 AW021049 H73469 AI954311 BE439454 AW079450 AW973850 AA348338 AW896006 AW268145 AA853631 H17650 R39537 N66873 N67240 H06298 AI784199 R44260 AA904118 AA911756 F04544 AA807809 AA665210 AI696448 T29719 AA837240 T64844 H08926
704603_1	Al357412 Al870708 Al590539 W07459
? 7945_1	AA045573 AA279920 R20139 AA372783 AW963629 H21473 R78318 W74359 AA022505 AA369091 AW084075 AA503638

AV660815 Al216262 AA779843 BE219825 AF125534 AW972129 Al91999 Al621283 Al300590 Al953701 AA331415 AW610546 AW793050 Al953679 AW793047 AW610543 Al671103 AW292105 AW024112 R77947 W76339 AA305111 AA132523 AA227467 H21401 AW366572 AW024129 Al701886 Al654744 BE042803 Al347173 AW866053 AW662710 R36639 Al469777 AA962733 Al865366 AA501998 AW866054 BE178974 AA505035 AW235098 Al634028

333252\_1

449032

## Table 26

_	Seq ID NO: 1 <u>DNA sequence</u> Nucleic Acid Accession #: see Table 25 & 25A for complete list
5	see Lable 25 to 25% for complete list
	1 11 21 31 41 51 
10	CAATATAGTA CAATAACTAT TTGCATGACA TTTACATCGG ATATTATGAG TGATCTAGAC
10	TIGATATGAA GTATATGGGA GGATGTGCAA AGGTGATGTG CAAATACTAT GTCATTTTAT 120 AGGGGGGACT TGAGTATCCT TTGTTACCCT CAGGAGATCC TGAAACCAGT CCCCCATGGA 180
	TGACTATAAA CAAAATATAT GTAATAGGTG GTGGTAAGTA CCGTGGAGAA GTAAGAAATAT
15	OUCAAAUIG AGIIAIACAG CTCCATTCTT AGAAACCTTG GAGTACTTTT CTTAGTTTAT 260
	ACTCGTGGTG GTTTCCTTTT GTCTCCTTTA TTACATGGGA CTCTGACATG TGCCCATAGC 420 TAGGGTGACA GTAGGATCTA CCCGATAGTA GGGTGGCAGT AGGATCTACC CAAAAAGCGT 480
	GTTGCTTCTC TTAACTGTGG CCTCCTACAC TGTGTTTTGG ATGATTGGTG ATGTCTTCGA CO
20	TATTCTGTTT CTTTGGAACT TTGAATATAC AACACTTTAC TAGGGAATTA GCAATGGAAG 660 CAGAGCAAAG ATGTACAGAG GAAACAATGC GTAACTCTGA TGGAATTGAA GTCATGAGGC 720
	AGCAGAGAG TTAAATTACA GCTTTAAAAA TTTTTATTTT TTAGAGGGAA TTTACTTGGG 780 AGTAACAGCA GTAATAGTTA ACGGAGCCAG AATGCTTGAG TCATATAATT GCAAAGCAGA 840
	OF TOUCHULA ACADA IUCTA AAGAGTAGTT GCTGTAGTTC CTCTTTGGGT CGTAGGAGGA
25	GTTGTCATAT TACTATATAG CTACTGCATG AAGAAGAGTT CTTAGTGAGG CCTGGGTGAA 960 CAGCTCTTCT TAGTATTCTG TGTGACCCCA TTTGACCTTT TAACAAATCC CTAAGTAAAT 1020
	ACTGTAATAG ACTTATATTT CTGAACATTT TAGTGCTTGC CAATATTTGG TAATATTTAT 1140
•	GITTCCTATA TITGTAATGA ACATTCTTCT TCCGGTACAT TTTTTGTTAA ATTATTGTTT 1200 GATGGATAAA AGTTCACCTT TTATTGTATA AAATTGACTG AGATTAATTT ATACACATTG 1260
느 30	ACAATGGGTA AATAGAATTT TTCAGATTAT TAAAAGCTGA AGGATGACCA CGTAAGCAAA 1320 AAAAAAAAA AAAAAACCAA CAAAAATAAA CCCAAACCCC TCAAACAATT TCGAACACGA 1380
	AACATICTIC IGATGCCGGC ATCCCTGCTT GCAGGTGTGA AGGGGGCAGG AATCAGCGAG 1440
□	GTGTCCTGGG CTGAGTCCCC GGGGAAGAAT ATGAT
	Seq ID NO: 2 <u>DNA sequence</u> Nucleic Acid Accession #: X83301.1
	1 11 21 31 41 51
<u> 40</u>	GCAAAGCCAG CTGGGCTCCT GACTCCCCTG CCTA CTTGGA GAAAGCCAG
	UAGUATIGIA AATGCACCAA TCAGCATGCT GTGTCTAGCT CAAGATTTTC TCCATCCCCT 120
<b>5</b>	TATTITIGGGC CAGTGGCTGT CATTACATAT GAGATGAGTC TCTTGAAGAC TACAGATGAA 180 CTCAAGCTCC ATGAGGAGAT GTTTCATTGT CGAGAGCAGT CATGATGGCC TGCACTCCAC 240
☐ 45 П	ACAATGCAAC AGAGTGAAAG AGCAGGTTCT GCTTCTTTGG TGTAGTCCTG AAGCTTCCTA 300 AGAAACTTCA CATCAGGTGA TGGATAGGAG CAACCCTGTA AAACCAGCCT TAGACTATTT 360
IL Fi	TTCAAACAGG CTGGTGAATT ACCAGATCTC CGTCAAGTGC AGTAACCAGT TCAAGTTGGA 420 AGTGTGTCTT TTGAATGCAG AGAACAAAGT CGTGGACAAC CAGGCTGGGA CCCAGGGCCA 480
TU Li	GCTGAAGGTG CTGGGTGCCA ACCTCTGGTG GCCGTACCTG ATGCACGAAC ACCCCGCCTA 540 CCTGTACTCC TGGGAGGATG GTGATTGCTC ACACCAAAGC CTTGGACCCC TCCCAGCCTG 600
<b>≒</b> 50	IUACUI I IGG GACCAACTCC ACCTACGCAG CAGACAAGGG GGCTCTGTAT GTGGATGTGA
N	TCCGTGTGAA CAGCTACTAC TCTTGGTATC GCAACTACGG GCACCTGGAG TTGATTCGGC 720 TGCAGCTGGC CGCCCAGTTT GAGAATTGGT GTGAGACATC ACAATCCCAT TATTCAGAGC 780
55	TCAAGTGCAG TAACCAGTTC AAGTTGGAAG TATGTCTTTT GAATGCAGAA AAGAAGTGG
33	GTACCTGATG CACGAACACC CCGCCTACCT GTACTCGTGG GAGGATGGTG ATTGCTCACA 1020
	ACAAGGGGGC TCTGTATGTG GATGTGATCC GTGTGAACAG CTACTCACTCT TGGTATCGCA 1140
60	ACTACGGGCA CCTGGAGTTG ATTCGGCTGC AGGCCCTGCA GCTGGCCGCC CAGTTTGTGA 1200 ATTGGTGTAA GACATCACAA TCCCATTATT CAGAGCGCGT ATGGAGTGGA AACGCTTGTA 1260
	GUGITICACC AGICTITCCC AGGGAACTCC GATGAAGTGT TCCAACAAAA TGAGCGAGTG 1220
	AACCAAGAAG AGGATGACAT TAGATCCAGG AGATACAACA GAGGAGATAA TCTCCAGGAT 1380 GCCTGTGAAG AAAGATCCCT GGATCCCAGG ATGATTATAG GACAAGTTGT TCATAATCCA 1440
65	CTCACGCCTG TAATACCAGC ACTTTGGGAG GCTGAGGCGG GCGGATCACT TGAGGTGA AG 1560
	AGCCAGGCAT AGTGGTGCAT GCCTGTAGTC CCAGCTACTT GGGATGCTGA GGCAGGAAGA 1620
	ATTGCTTGAA CCTGGGAGGC AGAGTCTGCG GTGACCGAGA TCATGCCACT GCACTCCAGC 1740 CTGGGTGACA GAGCCAGACT CCGTCTCTAC TAAAAAAAAA AAAAAAAAAA
70	Seq ID NO: 3 Protein sequence:
	Protein Accession #: CAA58280.1
75	1 11 21 31 41 51
75	MDRSNPVKA LDYFSNRLVN YQISVKCSNQ FKLEVCLLNA ENKVVDNQAG TQGQLKVLGA 60
	NLWWPYLMHE HPAYLYSWED GDCSHQSLGP LPACDLWDQL HLRSRQGGSV CGCDPCEQLL 120 LLVSQLRAPG VDSAAAGRPV
80	Seq ID NO: 4 DNA sequence
	Nucleic Acid Accession #: BC002622.1
	1 11 21 31 41 51
85	GGCACGAGGC TCCGCCCGCG GCCGGGATGC ACTAGGCAAA GCCAGCTGGG CTCCTGAGTC 60

5	CGGTGGGTAC TTGGAGAACT TACTACGTCT AGCTGGAGGA TIGTAAATGC ACCAATCAGC 120 ATGCTGTGTC TAGCTCAAGA TTTTCTCCAT CCCCTTATTT TGGGCCAGTG GCTGTCATTA 180 CATATGAGAA CTCAAGCTCC ATGAGGAGAT GTTTCATTGT CGAGAGCAGT CATGATGGCC 240 TGCACTCCAC ACAATGCAAC AGAGTGAAAG AGCAGGTTCT GCTTCTTTGG TGTAGTCCTG 300 AAGCTTCCTA AGAAACTTCA CATCAGGTGA TGGATAGGAG CAACCCTGTA AAACCAGCCT 360 TAGACTATTT TTCAAACAGG CTGGTGAAATT ACCAGATCTC CGTCAAGTGC AGTAACCAGT 420 TCAAGTTGGA AGTGTGCTT TTGAATGCAG AAAACAAAGT CGTGGACAAC CAGGCTGGGA 480
10	ACCCCGCCTA CCTGAAGGTG CTGGGTGCCA ACCTCTGGTG GCCGTACCTG ATGCACGAAC 540 ACCCCGCCTA CCTGTACTCG TGGGAGGATG GTGATTGCTC ACACCAAAGC CTTGGACCCC 600 TCCCAGCCTG TGACCTTTGT GACCAACTCC ACCTACGCAG CAGACAAGGG GGCTCTGTAT 660 GTGGATGTGA TCCGTGTGAA CAGCTACTAC TCTTGGTATC GCAACTACGG GCACCTGGAG 720 TTGATTCAGC TGCAGCTGGC CGCCCAGTTT GAGAATTGGT GTAAGACTACAG ACACCCCAT 770
15	CAGGATGATT ATAGGACAGTTGTACAGTTTTCCAGGGAA 840 CTCCGATGAA GTGTTCCAAC AAAATGAGCG AGTGAACCAA GAAGAGGATG ACATTAGATC 900 CAGGAGATAC AACAGAGGAG ATAATCTCCA GGATGCCTGT GAAGAAAGAT CCCTGGATCC 960 CAGGATGATT ATAGGACAAG TTGTTCATAA TCCAGCAGGC CAGAGAACTT CCAGGGAAAC 1020 TCATTCAAGG AGGTGAAAAT GATGGATGAC TCCTCCAAGA TGAAAATGGA CCAGCCGCAA 1000
20	TGGCTCACGC CTGTAATACC AGCACTTTGG GAGGCTGAGG CAGGCGGATC ACTTGAGGTC 1140 AGGAGTTTGA AACTAGCCTG GCCAACGTGG CAAAACTCCA TCTCTATTAA AAATACAAAA 1200 ATTAGCCAAG CATAGTGGTG CATGCCTGTA GTCCCAGCTA CTTGGGGATGC TGAGGCAGGA 1260 AGAATTGCTT GAACCTGGGA GGCAGAGTCT ACAGTGAGCC GAGATCATGC CACTGCACTC 1320 CAGCCTGGGC AACACAGTGA GACTCCATCT CAAAAAAAAA AAAAAAAAAA
25	Seq ID NO: 5 <u>Protein sequence:</u> Protein Accession #: AAH02622.1
	1 11 21 31 41 51
	MDBSNBW BA I DVECKIEL VOLKER GOVE THE THE
30 <u>⊢</u>	MDRSNPVKPA LDYFSNRLVN YQISVKCSNQ FKLEVCLLNA ENKVVDNQAG TQGQLKVLGA 60 NLWWPYLMHE HPAYLYSWED GDCSHQSLGP LPACDLCDQL HLRSRQGGSV CGCDPCEQLL 120 LLVSQLRAPG VDSAAAGRPV
□ □ 35	Seq ID NO: 6 <u>DNA sequence</u> Nucleic Acid Accession #: see Table 25 & 25A for complete list
<b>10</b>	1 11 21 31 41 51 .
<b>40</b>	ACCTGAGATC AGGAGTTCGA GATCAGCCTG ACCAATAGGG TGAAACCCCG TCTCTACTAA 60 AAATACAAAA AATTAGCTGG ACACGATGGT GGGTGCCTGT GGTCCCGGCT ACTCGGGAGG 120
Ŋ	CIUAUACAGU AGAATCAGTT GACCTGGGAG TTGGTGGTTG CAGTGAGCTG AGATCACACC 180
_	ATTUCATICC AAGCCTGGGC AACAAGAGTG AAACTCCATC GCAAAAAAAAAA
	GATGGTGTGA TTGCCTGGCT AGAAGAACAA TTCCCCGGTGA AGAACAA TTCCCGGCTACA 300
<u></u> 45	CAAUTUTAA AGAGATAA ATCTGTGAAG ATTATAGGGA CTACAGGAAA CTTAATCTTT 420
<b>≓</b>	IIUIIIUAAA AAGUAATTGT AGCAAAAAA AAGAAAATTT CTTACTGTCA TCTAAAAATTC 400
l	ACATGGACAT CTTAGTGGAC TAGAAGTTAA GGGCATAAAT TCTCCCAGTG ATTTTAATT 540 TTAGCATTGT GATTAACACC TTCTAAAATT GCCAGAACTT AATAAATAAT TGCTTTTCAT 600
፲ ፲ 50	IALIAUIAIU CCAICAAATT TAGTAGCTGT TTCAGGCTTT AATGTGTCAA GCCTAAAATC 440
√ 10	CAGATTTITG AGGATCTTCT CCCTCTTAAA AGAGTATTCA GTTAACTGCC GTAGAAATAC 720 ACATGTATAC AAGGGCACTG TATACATCAG TCTAAAAAAAT AAAAATATGT ATACGTTCTG 780
]	UIUAUIUIAU CACAGCATTU CCCAATAGAA ATACCAATGG AGGTCACAAA TGTGGCCCAT ***
ij	ATAGGTTAAT TGGTAAATTT TCTNATAGNC ACC
55	Seq ID NO: 7 DNA sequence
	Nucleic Acid Accession #: AK000942
	Coding sequence: 1204-1503
60	
00	1 11 21 31 41 51
	GTAAAGGAAT GTCTTTTTAA TTCAGCTTTT CTTTTCTCCA TGCTAGTGTT ATCAGGTTTT
	GGTATTTATT TACTTACAGC ATATGTTATG AAGCTGGTTT GAAAATTGGT TTTAGATATA 120 TCTGCAAGTT TACTACTTTG ACTGTAAAAA AAAAAAATGA AAAAGTAGTT GACATCTGC 180
65	CICADAADAA GIIIGCAGGI TGCATATTTG TGTGTAAATA CACAGGCTAA AAGGTAATTT 340
	AIUIICCIIU UUAAIIGAAA TGGTCAGTGG CCCGTTACAG AAACTTATCA CTCATATATO AAA
	AGCACCAGIT CATTCTTTIG CACCTTAGGG ACCATCTGTC CCCTGAGGTG ACCTGAGAAA 360 CAACCAGITG CCCACAGACT GTTATTTCTT CAAGTGAGCC AGGATTTGAT TTCACTGCCT 420
70	IAIAIICIAI IIIIAGIGIA CAGTGCTTTG ATTTTTTGGA AAAACTAAATTTTAAACATA 400
, ,	TTTGAAAAAT GTTATAAGAC TTGGACATTA AGTCTGTTGA TAGCCAAAGT CAGTTTACCA 540 AAGTAAAACA AATAAATTCT ATGCTTCTTC ATTGTCAAAG AGCAGTCTGC CATCATGTGG 600
	ATATAAATGG ACTATGTAAA GTGACATGGT GCTTACTCTC TACCTAATAA TAGCCTCCCT 460
	CCTGTTCCAA CAAGATAACC AACAGGTATA TITAATITTAC CAGTTAATAT GTTTTGGATA 720 ATTGGCTGCC TTGAAATGCT ATATGTTTTA TAGTACATCA TAGCTTTAGT TTTCTTCATA 780
75	AUGAAATIAC AGTTACATCC TGGCTAACAT GGTGAAACTC CATCTCTACT AAAAATACAA BAB
	GGAGAATGGC GTGAACCCAG GAGGCGGAGG TTGCAGTGAG CCGAGATCGT GCAGTGTAG ACC
•	ICIOUCCIOU GAGACAGAGC GAGACTCCAT CTCAAAAAAAAAAAAAA
80	GAGAGAGAG CCTGGAGTAG AGATTCTGTC AAAGAACTTT TTCTTTCTTG AGAAGCATCT 1080 GAAATGGAAT CTGTTGTCTC TTCGAAATAT GTACTGCTGT AACAGTGAAA CAACCCTCAG 1140
	AUTAIGCCTT CGTGTGGGCT ACTCGTTGTG GTTTTGAACT TGGGGGAACT GTCTCTGTTT 1200
	UUU I CAAUAA TATUCAACTO GCTGGCACA TTGGCTCACG CCTGTAATCC CACCAATTTC 12/0
	GGAGGCTGAG GCAGGCGGAT CACCTGAGGT CAGGGCTTCA AGACCAGACT GGCCAACATG 1320 GTGAAACCCC GTCTCTACTG AAAATACAAA AATTAGCTGG GCATGGTGGC AGGTGCCTGT 1380
85	AAICCCAUCI ACICGGGAGG CTGACGTGAG AGAATCGCTT GAACCCGGGA GTTGGAGGTT 1440
	GCAGTGAGCC GAGATTGCAC CATTGCACTC CAGCTTGGGC AACAAGAGTG AAACTCTTGT 1500

10087080 DEE702

**CTCAG** 

85

Seq ID NO: 8 DNA sequence Nucleic Acid Accession #: see Table 25 & 25A for complete list 5 21 31 41 GACTAGGCTG GGCAACATAG TGAGACCTCA TCTCTAAAAT TAAAAAAATA AAAGCCACCA 10 GAAAAAACC TAAAAACATG CCAAGTGACA TCAGTCTTTG ATGAAAATGG CAGCAGAAGA 120 GTGATGCCAT GGGTGGGGGT GGGAAATGCT ATTTCAGCAG AGAGGGAGCT GTCATGGAAG 180 ACACCATGTG GCTGGGCACG GTGGCTCACA CCTGTAATCC CAGCACTTTG GGAGATAGAG 240
GCAGGTGGAT CCCTTGAGCT TAGGAATTTG AGACTAGCCT GGGCAATAAG AGTGAAACTC 300 CATCTCAAAA AAAAAAAAA AAAAAGGTGC ATGAAACATA TGAAGCAAAA AGTGAAAGTC 360 15 CCCATTCTTT TCCTTTTTCC AGAGGTGATT TTTGTGGCCA ATCTGGTTTC ATTCCCTCCC 420 AGACACTTTT CTAGGCATCT ATGCGCCTCT ATTCACATAT AAACAAAATA GGAGTTTTCC 480 TGTGCTTCCC TTAAATGGCA TATGTATCTT TCACTCTTTT TTTTCACCTA GTGGATCTTT 540
AATACCTTAA AAGCTCAACC TGGGCTTGGT GCGGTGGCTC ATACGTGTAA TCCCAGGCCT 600 TTGGGAGGCC AAGGTGGGAG GATCACTTGA GCTCAGGAGT TCCAGACCAT TCCAAAGCAA 660 20 AAACAAAAGG ATTTTGAGAT CAGTGTGGGC AACTTAGCAA AACACCATCT CTTAAAAAAA 720 AAAAAAAA Seq ID NO: 9 DNA sequence BC010433.1 Nucleic Acid Accession #: 25 Coding sequence: 3-335 41 GGTCGCCCTC CGTCGTGGTC TGGCGTGTAT TCCGAGCCTT GGTGTCTGGC GGTTTCCGAG 60 30 CGTTGGTGTC TGGCGGTTTC CGAGCGTTGG TGTCTGGCGG TTTCCGACCG TTGGTGTCTG 120 loosyoso .cepac GCGGTTTCCG ACCGTTGGTG TCTGGCACGC GCCACCCTCT CTTGCTTTGG TTGCGCCATG 180 CCGATGTACC AGACAAGAAG ACAAGAAAAT GATTTGAGGA CAGCTTCAAT CGCGGTGTGA 240 AGAAGAAAGC AGCAAAAGAA ACAAGAAAAA GATTIGAGGA CAGCTICAAT CGCGGTGTGA 240
AGAAGAAAGC AGCAAAACGA CCACTGAAAA CAACGCCGGT GGCAAAATAT CCAAAGAAAG 300
GGTCCCAAGC GGTACATCGT CATAGCCGGA AACAGTCAGA GCCACCAGCC AATGATCTTT 360
TCAATGCTGC GAAAGCTGCC AAAAGTGACA TGCAGCACCG AGAAGTCCGC GTGAAGTGCG 420
TGAAGGCTCT GAAAGGGCTG TACGGTAACC GGGACCTGAC CGCACGCCTG GAGCTCTTCA 480
CTGGCCGCTT CAAGGACTGG ATGGTTTCCA TGATCATGGA CAGAGGTGC AGTGTGGCAG 540
TGGAAGGCCTC AGATTACTG ATACTTTATCC TTAAGGACAT GGAAGGGTG CTGATGGACG 600 35 TGGACTGTGA GAGCGTCTAC CCCATTGTGT AGGCCTCTAA TTGAGGCCTG GCCTCTGCTG 660 40 TGGGTGAATT TCTGTACTGG AAACTTTTCT ACCCTGAGTG CGAGATAAGA ACGATGGGTG 720 GAAGAGAGCA ACGCCAGAGC CCAGGTGCCC AGAGGACTTT CTTCCAGCTT CTGCTGTCCT TCTTTGTGGA GAGCAAGCTC CACGACCACG CTGCTTACTT AGTAGACAAC CTGTGGGACT 840 GTGCAGGGAC TCAGCTGAAG GACTGGGAGG GTCTGACAAG CCTGCTGCTG GAGAAGGACC 900
AGAGCACGTG CCACATGGAG CCAGGGCCAG GGACCTTCCA CCTCCTAGGG TGAAACCAGG 960
AGAGATTGCT TGCTTCACTT GTACAAGGCA GGAACCGTGG CATGGGGTGG GGGAAACTTG 1020 45 GAGTTGGAAG GTGGCTAATC TTTGATTCTA TGTTTTTGAT CCTCCTGGCA CTCCAGACCT 1080 GGGTGATGTG CAGGAGAGCA CACTGATAGA AATCCTTGTG TCCAGTGCCC AGCAACTCCT 1140 GCCTCAGCCT CCCGAGCAGC TGGGACTACA GGCGCCCGCC ACCACGCCTG GCTAACTTTT 1200 TTGTGTTTTT AGTAGAGACG GGTTTTCACC GTGTTGGCCA GGATGGTCTT GATCTCTTGA 1260 50 CCTTGTGATC CACCTGCCTC ATCATCCCAA AGTGCTGGGA TTACAGGCGT GAGCCACTGC 1320 GCCCAGCATG TTAGACAATT TTTAATTCAT CCTCTCTGTG CTGTTGTTTT CTCAGCTGTG 1380
AAAGGAATAT TCTGGTGGGG ACAAGGTTAC AGAGTTGCTG AGAGGGTCTC ATGACATGAA 1440
GGTACTGGCC TTGGCACAGT GCCTGGGGGG GCGGGGACTC CGCACATGCC TGTGATGTCA 1500 CAGITACTGT CAGITCACAG CGAACCTTCC CTCCTTTTCC TGTTGACTTT CCCACACTCC 1560 55 CACACACAC CACACACAC CACACACTCC ATTCACTGTC TCCATGACTC TGGAGTAAAC 1680 TAACGTCTCG AGTTGCCATT GGAAGCCCCG TTGTCCTCAT TTAGACTTTC ATGGGTTATA 1740 GGCACTTTTG ACTTCCTGGG GTCCTTCTTC AGTTAAAAAA AAAAATTAGA AAATTAGGCC 1800 GGGCGTGGTG GCACATGCCT GTAATCCCAG CACCTTGGCC TCCCAAAGTG CTGGGATTAC 1860 AGGAGTGAGC CACCATGCCC AGCCTCCGTT GTCCTCATTT AGACTTTCAT GGGTTATAGG 1920 60 Seq ID NO: 10 DNA sequence 65 Nucleic Acid Accession #: see Table 25 & 25A for complete list 31 41 70 AGTGGNTCCC CCGGNCTGCA GGAATTCGGC ACGAGATCAT GATGGCTAAT ATTTCCTGAG 60 CACCTITICAT TCAGGCATGA TGCCAGGTGC ACCAACTTAC TTAATCCTCA TAGCCACCAC 120 CTGAGCAAGC TCCTGTTTTA TAAATGGACC AGTTCTTGTT GCTGTTGTAC AAGTTATTTT 180 CTTTCTATAA CGTCCTCCTT GTCCTCCTTC CACATTCTTA AAGAAACTTT CCCTTCCTTT 240 AAAGTACTCA GGGAGCCCTG CATTGCTTCT TGAAGCCTTC TCCAGCTTCA TCATCTCACA 300 75 GTGGTCTCT TTTTCACTAA ATGTCCAATA TGCTGCACAT AAGTACCCCA AAGTTAGCAC 360
AGGAATTGTT CCATGGCTGT CATATATGTT AAAAATCATT AAAAGTTCAT TTTTTCTCT 420
ATTATGGGAA GGATACATGC TCCTACTAGT AAATTTAGTA GGTAGAAAAA AATTATCACT 480 ATCTAGACTG CTTTCCATTT AGTCTTTATG CATAGCTTTC GTGTCTGCCT ATTTTTACCT 540 TGTGTTTGTA ACTTACTATT ATAAAATATG CGTCTCTATG TTCATTGTCA ACGATTATTT 600 80 ACAATAACAT GGAGTGGATT TACATGTATT CTCTATATTT GGATTAAAGG AGATAGAGTA 660 TGTGAAATTA AATGGGAGAA GTATCTGATA CATAACAGGC AATACAAATA TTATCACATA 720 GCGTCAATTT ATTTGTGAAT ATTGAAAGCT CCAAAAAAGA AAAAAGTTT TTTTTTAATT 780 CCCGTAATTA CTTATTGCAG TATTGTGTTC ATACAAACTG CTCAGTCATT TTGGAGAAAT 840 AACAATTTT TTCCTCATCA TGAAGTAAGG TATGCTCACT GCAAAAAAA TCTAGAAAAT 900 AAAGAGGAAC ATGCTAAAGA AAAGAATACT CCCATATAAT CTCTGTCTTC ATAAATAATC 960

TTTTGTAACG CTTATACACT GCTGGTGGGA ATGTAAATTA GTTCAGCCAT TGTGAAAAGT 1020

AGCGTAGCAA TTCCTTGAAA AACTTAAAAT AGATTTACCG TTCAACCCAG CAATCCCATT 1080 ATTGGGCATA TACCCAGTGG AATGTAAATC ATCCTGCCAT AAAAACACAT GCACATGTAT 1140 GTTCATTGCA GCACTATTCA CAATAGCAAA GACATGGAAT CAACCTATAT GCCCATCAAT 1200 AGTAGACTGA ATAAAGAAAA TATGGTACAT ATTCACCACA GAATACTAAG CAGCCATAAA 1260 AAAAAA

10	Seq ID NO: 11 <u>DNA sequence</u> Nucleic Acid Accession #: NM_000582.1 Coding sequence: 88-990
	1 11 21 31 41 51
15	GCAGAGCACA GCATCGTCGG GACCAGACTC GTCTCAGGCC AGTTGCAGCC TTCTCAGCCA 60 AACGCCGACC AAGGAAAACT CACTACCATG AGAATTGCAG TGATTTGCTT TTGCCTCCTA 120 GGCATCACCT GTGCCATACC AGTTAAACAG GCTGATTCTG GAAGTTCTGA GGAAAAGCAG 180 CTTTACAACA AATACCCAGA TGCTGTGGCC ACATGGCTAA ACCCTGACCC ATCTCAGAAG 240 CAGAATCTCC TAGCCCCACA GACCCTTCCA AGTAAGTCCA ACGAAAGCCA TGACCACTG 360
20	GATGATATGG ATGATGAAGA TGATGATGAC CATGTGGACA GCCAGGACTC CATGACTCC 300 AACGACTCTG ATGATGTAGA TGACACTGAT GATTCTCACC AGTCTGATGAAG ATCTCACCCAT 420 TCTGATGAAT CTGATGAACT GGTCACTGAT TTTCCCACGG ACCTGCCAGC AACCGAAGTT 480 TTCACTCCAG TTGTCCCCAC AGTAGACACA TATGATGGCC GAGGTGATAG TGTGGTTTAT 540 GCACTCCAG TGACACATCTAA GAAGTTTCGC AGACCTGACA TCCAGTACCC TGATGCTACA 600
25	GACGAGGACA TCACCTCACA CATGGAAAGC GAGGAGTTGA ATGGTGCATA CAAGCCATC 600 CCCGTTGCCC AGGACCTGAA CGCGCCTTCT GATTGGGACA GCCGTGGGAA GGACAGTTAT 720 GAAACGAGTC AGCTGGATGA CCAGAGTGCT GAAACCCACA GCCACAAGCA GTCCAGATTA 780 TATAAGCGGA AAGCCAATGA TGAGAGCAAT GAGCAATTCC ATGTGATTGA TAGTCAGGAA 840 CCCACGA AAGCCATGA ATGCCACAGC CATGAATTTC ACAGCCATGA AGATATGCTG 900
30 ₩	GTTGTAGACC CCAAAAGTAA GGAAGAAGAT AAACACCTGA AATTTCGTAT TTCTCATGAA 960 TTAGATAGTG CATCTTCTGA GGTCAATTAA AAGGAGAAAA AATACAATTT CTCACTTTGC 1020 ATTTAGTCAA AAGAAAAAAT GCTTTATAGC AAAATGAAAG AGAACATGAA ATGCTTCTTT 1080 CTCAGTTTAT TGGTTGAATG TGTATCTATT TGAGTCTGGA AATAACTAAT GTGTTTGATA 1140 ATTAGTTTAG TTTGTGGCTT CATGGAAACT CCCTGTAAAC TAAAAGCTTC AGGGTTATGT 1200 CTATGTTCAT TCTATAGAAG AAATGCAAAC TATCACTGTA TTTTAATATT TGTTATTCTC 1260
	TCATGAATAG AAATTTATGT AGAAGCAAAC AAAATACTTT TACCCATTA AAAAAAAAT 1320 ATAACATTT ATGTCACTAT AATCTTTTGT TTTTTAAGTT AGTGAATAT TTGTTGTGAT 1380 TATCTTTTTG TGGTGGAAT AAATCTTTTA TCTTGAATGT AATAAGAATT TGGTGGTGTC 1440 AATTGCTTAT TTGTTTTCCC ACGGTTGTCC AGCAATTAAT AAAACATAAC CTTTTTTACT 1500
₽ 40	GCCTAAAAAA AAAAAAAAAA AAAA
0 0	Seq ID NO: 12 <u>Protein sequence:</u> Protein Accession #: NP_000573.1
<u> </u>	11 21 31 41 51 
1 45 N 50 N 50	PSKSNESHDH MDDMDDEDDD DHVDSQDSID SNDSDDVDDT DDSHQSDESH HSDESDELVT 120 DFPTDLPATE VFTPVVPTVD TYDGRGDSVV YGLRSKSKKF RRPDIQYPDA TDEDITSHME 180 SEELNGAYKA IPVAQDLNAP SDWDSRGKDS YETSQLDDQS AETHSHKQSR LYKRKANDES 240 NEHSDVIDSQ ELSKVSREFH SHEFHSHEDM LVVDPKSKEE DKHLKFRISH ELDSASSEVN
T TU 55	Seq ID NO: 13 <u>DNA sequence</u> Nucleic Acid Accession #: NM_001793 Coding sequence: 71-2560
60	1 11 21 31 41 51
65	CTIGGAGCG GAGGCGCGG AGCAGGAGCC CGGCCAGGCG CTGGGGAAAG TATTCATGGG 240 CTGCCCTGGG CAAGAGCCAG CTCTGTTTAG CACTGATAAT GATGACTTCA CTGTGCGGAA 300 TGGCGAGACA GTCCAGGAAA GAAGGTCACT GAAGGAAAGG AATCCATTGA AGATCTTCCC 360 ATCCAAACGT ATCTTACGAA GACACAAGAG AGATTGGGTG GTTGCTCCAA TATCTGTCCC 420 TGAAAATGGC AAGGGTCCCT TCCCCCAGAG ACTGAATCAG CTCAAGTCTA ATAAAGATAG 480 AGACACCAAG ATTTTCTACA GCATCACGGG GCCGGGGGCA GACAGCCCCC CTGAGGGTGT 540 CTTCGCTGTA GAGAAGGAGA CAGGCTGGTT GTTGTTGAAT AAGCCACTGG ACCGGGAGGA 600
70	GATTGCCAAG TATGAGCTCT TTGGCCACGC TGTGTCAGAG AATGGTGCCT CAGTGGAGAA 600 CCCCATGAAC ATCTCCATCA TCGTGACCGA CCAGAATGAC CACAAGCCCA AGTTTACCCA 720 GGACACCTTC CGAGGGAGTG TCTTAGAGGG AGTCCTACCA GGTACTTCTG TGATGCAGGT 780 GACAGCCACG GATGAGGATG ATGCCATCTA CACCTACAAT GGGGTGGTTG CTTACTCCAT 840 CCATCACGCACACGA CCTCATGTTC ACCATTCACC GGAGCACAGG 900
75	CACCATCAGC GTCATCTCCA GTGGCCTGGA CCGGGAAAAA GTCCCTGAGT ACACACTGAC CACCACCAGC GACCACCAGC ACGGCAGTGG CAGTAGTGGA 1020 GATCCTTGAT GCCAATGACA ATGCTCCCAT GTTTGACCCC CAGAAGTACG AGGCCCATGT 1080 GCCTGAGAAT GCAGTGGGC ATGAGGTGCA GAGGCTGACG GTCACTGATC TGGACGCCCC 1140 GCCTGACA CCGCTGACGTGCCACCTACCT TATCATGGGC GGTGACGACG GGGACCATTT 1200
80	TACCATCACC ACCCACCCTG AGAGCAACCA GGGCATCCTG ACAACCAOGA AOGGTTTOGA 1280 TTTTGAGGCC AAAAACCAGC ACACCCTGTA CGTTGAAGTG ACCAACGAGG CCCCTTTTGT 1320 GCTGAAGCTC CCAACCTCCACCACCACAT AGTGGTCCAC GTGGAGGATG TGAATGAGGC 1380 ACCTGTGTTT GTCCCACCCT CCAAAGTCGT TGAGGTCCAG GAGGGCATCC CCACTGGGGA 1440 CCTCTTGTG GTCTACACTG CAGAAGACCC TGACAAGGAG AATCAAAAGA TCAGCTACCG 1500
85	CATCCTGAGA GACCCAGCAG GGTGGCTAGC CATGGACCCA GACAGTGGGC AGGTCACAGC 1560 TGTGGGCACC CTCGACCGTG AGGATGAGCA GTTTGTGAGG AACAACATCT ATGAAGTCAT 1620 GGTCTTGGCC ATGGACAATG GAAGCCCTCC CACCACTGGC ACGGGAACCC TTCTGCTAAC 1680

ACTGATTGAT GTCAATGACC ATGGCCCAGT CCCTGAGCCC CGTCAGATCA CCATCTGCAA 1740 CCAAAGCCCT GTGCGCCAGG TGCTGAACAT CACGGACAAG GACCTGTCTC CCCACACCTC 1800
CCCTTTCCAG GCCCAGCTCA CAGATGACTC AGACATCTAC TGGACGGCAG AGGTCAACGA 1860
GGAAGGTGAC ACAGTGGTCT TGTCCCTGAA GAAGTTCCTG AAGCAGGATA CATATGACGT 1920 GCACCTITCT CTGTCTGACC ATGGCAACAA AGAGCAGCTG ACGGTGATCA GGGCCACTGT 1980
GTGCGACTGC CATGGCCATG TCGAAACCTG CCCTGGACCC TGGAAGGGAG GTTTCATCCT 2040
CCCTGTGCTG GGGCCTGTCC TGGCTCTGCT GTTCCTCCTG CTGGTGCTGC TTTTGTTGGT 2100 5 GAGAAAGAAG CGGAAGATCA AGGAGCCCCT CCTACTCCCA GAAGATGACA CCCGTGACAA 2160 CGTCTTCTAC TATGGCGAAG AGGGGGTGG CGAAGAGGAC CAGGACTATG ACATCACCCA 2220
GCTCCACCGA GGTCTGGAGG CCAGGCCGGA GGTGGTTCTC CGCAATGACG TGGCACCAAC 2280 10 CATCATCCG ACACCCATGT ACCGTCCTCG GCCAGCCAAC CCAGATGAAA TCGGCAACTT 2340
TATAATTGAG AACCTGAAGG CGGCTAACAC AGACCCCACA GCCCCGCCCT ACGACACCCT 2400 CTTGGTGTTC GACTATGAGG GCAGCGGCTC CGACGCCGCG TCCCTGAGCT CCCTCACCTC 2460 CTICCGCCTCC GACCAAGACC AAGATTACGA TTATCTGAAC GAGTGGGGCA GCCGCTTCAA 2520 GAAGCTGGCA GACATGTACG GTGGCGGGGA GGACGACTAG GCGGCCTGCC TGCAGGGCTG 2580 15 GGGACCAAAC GTCAGGCCAC AGAGCATCTC CAAGGGGTCT CAGTTCCCCC TTCAGCTGAG 2640 GACTTCGGAG CTTGTCAGGA AGTGGCCGTA GCAACTTGGC GGAGACAGGC TATGAGTCTG 2700 ACGITAGAGT GGTTGCTTCC TTAGCCTTTC AGGATGGAGG AATGTGGGCA GTTTGACTTC 2760
ACGCTGAAA ACCTCTCCAC CTGGGCCAG GTTGCCTCAG AGGCCAAGTT TCCAGAAGCC 2820
TCTTACCTGC CGTAAAATGC TCAACCCTGT GTCCTGGGCC TGGGCCTGCT GTGACTGACC 2880 20 TACAGTGGAC TITCTCTCTG GAATGGAACC TTCTTAGGCC TCCTGGTGCA ACTTAATTIT 2940
TTTTTTTAAT GCTATCTTCA AAACGTTAGA GAAAGTTCTT CAAAAGTGCA GCCCAGAGCT 3000 GCTGGGCCCA CTGGCCGTCC TGCATTTCTG GTTTCCAGAC CCCAATGCCT CCCATTCGGA 3060 TGGATCTCTG CGTTTTTATA CTGAGTGTGC CTAGGTTGCC CCTTATTTTT TATTTTCCCT 3120 25 GTTGCGTTGC TATAGATGAA GGGTGAGGAC AATCGTGTAT ATGTACTAGA ACTTTTTTAT 3180 TAAAGAAACT TTTCCCAGAA AAAAA Seq ID NO: 14 Protein sequence: Protein Accession #: NP\_001784.2 30 11 21 31 41 51 MGLPRGPLAS LLLLQVCWLQ CAASEPCRAV FREAEVTLEA GGAEQEPGQA LGKVFMGCPG 60 35 QEPALFSTDN DDFTVRNGET VQERRSLKER NPLKIFPSKR ILRRHKRDWV VAPISVPENG 120 KGPFPQRLNQ LKSNKDRDTK IFYSITGPGA DSPPEGVFAV EKETGWLLLN KPLDREEIAK 180 YELFGHAVSE NGASVEDPMN ISIIVTDQND HKPKFTQDTF RGSVLEGVLP GTSVMQVTAT 240
DEDDAIYTYN GVVAYSIHSQ EPKDPHDLMF TIHRSTGTIS VISSGLDREK VPEYTLTIQA 300
TDMDGDGSTT TAVAVVEILD ANDNAPMFDP QKYEAHVPEN AVGHEVQRLT VTDLDAPMSP 360 40 AWRATYLIMG GDDGDHFTIT THPESNQGIL TTRKGLDFEA KNQHTLYVEV TNEAPFVLKL 420 PTSTATIVVH VEDVNEAPVF VPPSKVVEVQ EGIPTGEPVC VYTAEDPDKE NQKISYRILR 480 PTSTATIVVH VEDVNEAPVF VPPSK VVEVQ EGIPTGEPVC VYTAEDPDKE NQKISYRILK 480
DPAGWLAMDP DSGQVTAVGT LDREDEQFVR NNIYEVMVLA MDNGSPPTTG TGTLLLTLID 540
VNDHGPVPEP RQITICNQSP VRQVLNITDK DLSPHTSPFQ AQLTDDSDIY WTAEVNEEGD 600
TVVLSLKKFL KQDTYDVHLS LSDHGNKEQL TVIRATVCDC HGHVETCPGP WKGGFILPVL 660
GAVLALLFLL LVLLLLVRKK RKIKEPLLLP EDDTRDNVFY YGEEGGGEED QDYDITQLHR 720 45 GLEARPEVVL RNDVAPTIIP TPMYRPRAN PDEIGNFIIE NLKAANTDPT APPYDTLLVF DYEGSGSDAA SLSSLTSSAS DQDQDYDYLN EWGSRFKKLA DMYGGGEDD Seq ID NO: 15 DNA sequence 50 Nucleic Acid Accession #: XM\_051860.2 Coding sequence: 261-4346 11 21 31 41 55 GAGCTAGCGC TCAAGCAGAG CCCAGCGCGG TGCTATCGGA CAGAGCCTGG CGAGCGCAAG 60 CGGCGCGGGG AGCCAGCGGG GCTGAGCGCG GCCAGGGTCT GAACCCAGAT TTCCCAGACT 120
AGCTACCACT CCGCTTGCCC ACGCCCCGGG AGCTCGCGGC GCCTGGCGGT CAGCGACCAG 180 ACCTACCACT CLOCATION ACCURAGE ACCORDANG ACCIDENCE ACCIDENCE ACCIDENCE ACCORDANG ACCIDENCE ACCIDE 60 CTGGGTGCCC TGACCAGAGC CCTGAGTTGC AACCTGGAA CCCTGGCCAT GACCAAGACC 420
ACCATGTGCA TATCGGCCAG GGCAAGACAC TGCTGCTCAC CTCTTCTGCC ACGGTCTATT 480
CCATCCACAT CTCAGAGGGA GGCAAGACTGG TCATTAAAGA CCACGACGAG CCGATTGTTT 540
TGCGAACCCG GCACATCCTG ATTGACAACG GAGGAGGCT GCATGCTGAA CCCTCTTCAGA GAGTGCCTCT 600 65 GCCCTTTCCA GGGCAATTTC ACCATCATTT TGTATGGAAG GGCTGATGAA GGTATTCAGC 660 CGGATCCTTA CTATGGTCTG AAGTACATTG GGGTTGGTAA AGGAGGCGCT CTTGAGTTGC 720
ATGGACAGAA AAAGCTCTCC TGGACATTTC TGAACAAGAC CCTTCACCCA GGTGGCATGG 780 CAGAAGGAGG CTATTTTTT GAAAGGAGCT GGGGCCACCG TGGAGTTATT GTTCATGTCA 840
TCGACCCCAA ATCAGGCACA GTCATCCATT CTGACCGGTT TGACCACCTAT AGATCCAAGA 900 70 AAGAGAGTGA ACGTCTGGTC CAGTATTTGA ACGCGGTGCC CGATGGCAGG ATCCTTTCTG 960 AAGAGAGTGA ACGTCTGGTC CAGTATTTGA ACGCGGTGCC CGATGGCAGG ATCCTTTCTG 960
TTGCAGTGAA TGATGAAGGT TCTCGAAATC TGGATGACAT GGCCAGGAAG GCGATGACCA 1020
AATTGGGAAG CAAACACTTC CTGCACCTTG GATTTAGACA CCCTTGGAGT TTTCTAACTG 1080
TGAAAGGAAA TCCATCATCT TCAGTGGAAGA ACCATATTGA ATATCATGGA CATCGAGGCT 1140
CTGCTGCTGC CCGGGTATTC AAATTGTTCC AGACAGAGCA TGGCGAATAT TTCAATGTTT 1200
CTTTGTCCAG TGAGTGGGTT CAAGACGTGG AGTGGACAGGA GTGGTTCGAT CATGATAAAG 1260
TATCTCAGAC TAAAGGTGGG GAGAAAATTT CAGACCTCTG GAAAGCTCAC CCAGGAAAAA 1320
TATGCAATCG TCCCATTGAT ATACAGGCCA CTACAATGGA TGGAGTTAAC CTCAGCACCG 1380
AGGTTGTCTA CAAAAAAAGGC CAGGATTATA GGTTTGCTTG CTACCACCG GGCAGAGCCT 1440
GCCGGAGCTA CCGTGTACGG TTCCTCTGTG GGAAGCCTGT GAGGCCCAAA CTCACAGTCA 1500
CCATTGACAC CAATGTGAAC AGCACCATTC TGAACTTGGA GAGTAATGTA CAGTCATGGA 1560 75 CCATTGACAC CAATGTGAAC AGCACCATTC TGAACTTGGA GGATAATGTA CAGTCATGGA 1560


AACCTGGAGA TACCCTGGTC ATTGCCAGTA CTGATTACTC CATGTACCAG GCAGAAGAGT 1620 TCCAGGTGCT TCCCTGCAGA TCCTGCGCCC CCAACCAGGT CAAAGTGGCA GGGAAACCAA 1680 TGTACCTGCA CATCGGGGAG GAGATAGACG GCGTGGACAT GCGGGCGGAG GTTGGGCTTC 1740 TGAGCCGGAA CATCATAGTG ATGGGGGAGA TGGAGGACAA ATGCTACCCC TACAGAAACC 1800

ACATCTGCAA TTTCTTTGAC TTCGATACCT TTGGGGGCCA CATCAAGTTT GCTCTGGGAT 1860

80

TTAAGGCAGC ACACTTGGAG GGCACGGAGC TGAAGCATAT GGGACAGCAG CTGGTGGGTC 1920 AGTACCCGAT TCACTTCCAC CTGGCCGGTG ATGTAGACGA AAGGGGAGGT TATGACCCAC 1980 CCACATACAT CAGGGACCTC TCCATCCATC ATACATTCTC TCGCTGCGTC ACAGTCCATG 2040 GCTCCAATGG CTTGTTGATC AAGGACGTTG TGGGCTATAA CTCTTTGGGC CACTGCTTCT 2100 5 TCACGGAAGA TGGGCCGGAG GAACGCAACA CTTTTGACCA CTGTCTTGGC CTCCTTGTCA 2160 AGTCTGGAAC CCTCCCCC TCGGACCGTG ACAGCAAGAT GTGCAAGATG ATCACAGAGG 2220 ACTCCTACCC GGGGTACATC CCCAAGCCCA GGCAAGACTG CAATGCTGTG TCCACCTTCT 2280 GGATGGCCAA TCCCAACAAC AACCTCATCA ACTGTGCCGC TGCAGGATCT GAGGAAACTG 2340 GATTITGGTT TATTTTTCAC CACGTACCAA CGGGCCCCTC CGTGGGAATG TACTCCCCAG 2400 10 GTTATTCAGA GCACATTCCA CTGGGAAAAT TCTATAACAA CCGAGCACAT TCCAACTACC 2460 GGGCTGGCAT GATCATAGAC AACGGAGTCA AAACCACCGA GGCCTCTGCC AAGGACAAGC 2520 GGCCGTTCCT CTCAATCATC TCTGCCAGAT ACAGCCCTCA CCAGGACGCC GACCCGCTGA 2580 AGCCCCGGGA GCCGGCCATC ATCAGACACT TCATTGCCTA CAAGAACCAG GACCACGGGG 2640 CCTGGCTGCG CGGCGGGGAT GTGTGGCTGG ACAGCTGCCG GTTTGCTGAC AATGGCATTG 2700 15 GCCTGACCCT GGCCAGTGGT GGAACCTTCC CGTATGACGA CGGCTCCAAG CAAGAGATAA 2760 AGAACAGCTT GTTTGTTGGC GAGAGTGGCA ACGTGGGGAC GGAAATGATG GACAATAGGA 2820 TCTGGGGCCC TGGCGGCTTG GACCATAGCG GAAGGACCCT CCCTATAGGC CAGAATTTTC 2880 CAATTAGAGG AATTCAGTTA TATGATGGCC CCATCAACAT CCAAAACTGC ACTTTCCGAA 2940 AGTTTGTGGC CCTGGAGGGC CGGCACACCA GCGCCCTGGC CTTCCGCCTG AATAATGCCT 3000 20 GGCAGAGCTG CCCCCATAAC AACGTGACCG GCATTGCCTT TGAGGACGTT CCGATTACTT 3060 CCAGAGTGTT CTTCGGAGAG CCTGGGCCCT GGTTCAACCA GCTGGACATG GATGGGGATA 3120 AGACATCTGT GTTCCATGAC GTCGACGGCT CCGTGTCCGA GTACCCTGGC TCCTACCTCA 3180 CGAAGAATGA CAACTGGCTG GTCCGGCACC CAGACTGCAT CAATGTTCCC GACTGGAGAG 3240 GGGCCATTTG CAGTGGGTGC TATGCACAGA TGTACATTCA AGCCTACAAG ACCAGTAACC 3300 25 TGCGAATGAA GATCATCAAG AATGACTTCC CCAGCCACCC TCTTTACCTG GAGGGGGCGC 3360 TCACCAGGAG CACCCATTAC CAGCAATACC AACCGGTTGT CACCCTGCAG AAGGGCTACA 3420 CCATCCACTG GGACCAGACG GCCCCGCCG AACTCGCCAT CTGGCTCATC AACTTCAACA 3480 AGGGCGACTG GATCCGAGTG GGGCTCTGCT ACCCGCGAGG CACCACATTC TCCATCCTCT 3540 CGGATGTTCA CAATCGCCTG CTGAAGCAAA CGTCCAAGAC GGGCGTCTTC GTGAGGACCT 3600
TGCAGATGGA CAAAGTGGAG CAGAGCTACC CTGGCAGGAG CCACTACTAC TGGGACGAGG 3660 30 ACTCAGGGCT GTTGTTCCTG AAGCTGAAAG CTCAGAACGA GAGAGAGAAG TTTGCTTTCT 3720 GCTCCATGAA AGGCTGTGAG AGGATAAAGA TTAAAGCTCT GATTCCAAAG AACGCAGGCG 3780 35 40 45 50 TCAGTGACTG CACAGCCACA GCTTACCCCA AGTTCACCGA GAGGGCTGTC GTAGACGTGC 3840 CGATGCCCAA GAAGCTCTTT GGTTCTCAGC TGAAAACAAA GGACCATTTC TTGGAGGTGA 3900 AGATGGAGAG TTCCAAGCAG CACTTCTTCC ACCTCTGGAA CGACTTCGCT TACATTGAAG 3960 TGGATGGGAA GAAGTACCCC AGTTCGGAGG ATGGCATCCA GGTGGTGGTG ATTGACGGGA 4020 ACCAAGGGCG CGTGGTGAGC CACACGAGCT TCAGGAACTC CATTCTGCAA GGCATACCAT 4080 GGCAGCTTT CAACTATGTG GCGACCATCC CTGACAACTC CATTCTGCAA GGCATACCAT 4080 AGGGAAGATA CGTCTCCAGA GGCCCATGGA CCAGAGTGCT GGAAAAGCTT GGGGCAGACA 4200 GGGGTCTCAA GTTGAAAGAG CAAATGGCAT TCGTTGGCTT CAAAGGCAGC TTCCGGCCCA 4260 TCTGGGTGAC ACTGGACACT GAGGATCACA AAGCCAAAAT CTTCCAAGTT GTGCCCATCC 4320 CTGTGGTGAA GAAGAAGATTGTGAGGAC AGCTGCCGCC CGGTGCCACC TCGTGGTAGA 4380 CTATGACGGT GACTCTTGGC AGCAGACCAG TGGGGGATGG CTGGGTCCCC CAGCCCCTGC 4440 CAGCAGCTGC CTGGGAAGGC CGTGTTTCAG CCCTGATGGG CCAAGGGAAG GCTATCAGAG 4500 ACCCTGGTGC TGCCACCTGC CCCTACTCAA GTGTCTACCT GGAGCCCCTG GGGCGGTGCT 4560 GGCCAATGCT GGAAACATTC ACTTTCCTGC AGCCTCTTGG GTGCTCTCTCT CTTATCTTGT 4620
CCTCTTCAGT GGGGGTTTTGG GGACCATATC AGGAGACCTG GGTTTTGTGTGTG ACAGCAAAGA 4680
TCCACTTTGG CAGGAGCCCT GACCCAGCTA GGAGGTAGTC TGGAGGGCTG GTCATTCACA 4740
GATCCCCATG GTCTTCAGCA GACAAGTGAG GGTGGTAAAT GTAGGAGAAA GAGCCTTGGC 4800 CTTAAGGAAA TCTTTACTCC TGTAAGCAAG AGCCAACCTC ACAGGATTAG GAGCTGGGGT 4860 AGAACTGGCT ATCCTTGGGG AAGAGGCAAG CCCTGCCTCT GGCCGTGTCC ACCTTTCAGG 4920 AGACTTTGAG TGGCAGGTTT GGACTTGGAC TAGATGACTC TCAAAGGCCC TTTTAGTTCT 4980 GAGATTCCAG AAATCTGCTG CATTTCACAT GGTACCTGGA ACCCAACAGT TCATGGATAT 5040 CCACTGATAT CCATGATGCT GGGTGCCCCA GCGCACACGG GATGGAGAGG TGAGAACTAA 5100 TGCCTAGCTT GAGGGGTCTG CAGTCCAGTA GGGCAGGCAG TCAGGTCCAT GTGCACTGCA 5160 ATGCCAGGT GAGAAATCAC AGAGAGGTAA AATGGAGGCC AGTGCCATTT CAGAGGGGAG 5220 55 GCTCAGGAAG GCTTCTTGCT TACAGGAATG AAGGCTGGGG GCATTTTGCT GGGGGGAGAT 5280 GAGGCAGCCT CTGGAATGGC TCAGGGATTC AGCCCTCCCT GCCGCTGCCT GCTGAAGCTG 5340 GTGACTACGG GGTCGCCCTT TGCTCACGTC TCTCTGGCCC ACTCATGATG GAGAAGTGTG 5400 60 GTCAGAGGGG AGCAATGGGC TTTGCTGCTT ATGAGCACAG AGGAATTCAG TCCCCAGGCA 5460
GCCCTGCCTC TGACTCCAAG AGGGTGAAGT CCACAGAAGT GAGCTCCTGC CTTAGGGCCT 5520
CATTTGCTCT TCATCCAGGG AACTGAGCAC AGGGGGCCTC CAGGAGACCC TAGATGTGCT 5580
CGTACTCCCT CGGCCTGGGA TTTCAGAGCT GGAAATATAG AAAATATCTA GCCCAAAGCC 5640 TTCATTTTAA CAGATGGGGA AAGTGAGCCC CCAAGATGGG AAAGAACCAC ACAGCTAAGG 5700 65 GAGGGCCTGG GGAGCCCCAC CCTAGCCCTT GCTGCCACAC CACATTGCCT CAACAACCGG 5760 CCCCAGAGTG CCCAGGCACT CCTGAGGTAG CTTCTGGAAA TGGGGACAAG TCCCCTCGAA 5820 GGAAAGGAAA TGACTAGAGT AGAATGACAG CTAGCAGATC TCTTCCCTCC TGCTCCCAGC 5880 GCACACAAAC CCGCCCTCCC CTTGGTGTTG GCGGTCCCTG TGGCCTTCAC TTTGTTCACT 5940 ACCTGTCAGC CCAGCCTGGG TGCACAGTAG CTGCAACTCC CCATTGGTGC TACCTGGCTC 6000 TCCTGTCTCT GCAGCTCTAC AGGTGAGGCC CAGCAGAGGG AGTAGGGCTC GCCATGTTTC 6060 70 TGGTGAGCCA ATTTGGCTGA TCTTGGGTGT CTGAACAGCT ATTGGGTCCA CCCCAGTCCC 6120
TTTCAGCTGC TGCTTAATGC CCTGCTCTCT CCCTGGCCCA CCTTATAGAG AGCCCAAAGA 6180
GCTCCTGTAA GAGGGAGAAC TCTATCTGTG GTTTATAATC TTGCACGAGG CACCAGAGTC 6240 TCCCTGGGTC TTGTGATGAA CTACATTTAT CCCCTTTCCT GCCCCAACCA CAAACTCTTT 6300 75 CCTTCAAAGA GGGCCTGCCT GGCTCCCTCC ACCCAACTGC ACCCATGAGA CTCGGTCCAA 6360 GAGTCCATTC CCCAGGTGGG AGCCAACTGT CAGGGAGGTC TTTCCCACCA AACATCTTTC 6420 80 GGCTCAGTTC ATTTAAAAAA GATATCTATT TGAAAGTTCT CAGAGTTGTA CATATGTTTC 6720 ACAGTACAGG ATCTGTACAT AAAAGTTTCT TTCCTAAACC ATTCACCAAG AGCCAATATC 6780 TAGGCATTTT CTTGGTAGCA CAAATTTTCT TATTGCTTAG AAAATTGTCC TCCTTGTTAT 6840 TTCTGTTTGT AAGACTTAAG TGAGTTAGGT CTTTAAGGAA AGCAACGCTC CTCTGAAATG 6900 85 CTTGTCTTTT TTCTGTTGCC GAAATAGCTG GTCCTTTTTC GGGAGTTAGA TGTATAGAGT 6960 GTTTGTATGT AAACATTTCT TGTAGGCATC ACCATGAACA AAGATATATT TTCTATTTAT 7020

### TTATTATATG TGCACTTCAA GAAGTCACTG TCAGAGAAAT AAAGAATTGT CTTAAATGTC



5	TITTITITI TIAAAAAAA GAGGCTTGGT AAGTTTTTGA TACTTAGTTG ACTITTAGCA 60 TTATCCAGCA TTTGTATTAT GAACCAGTGA GTACTGTAAT TITTCTTTCC CTTTCAGAAA 120 GACTCAAAGG GAACATATAA ATGTTTCCTA TITTITNNNNN NNNNNNNNN NNNNNNNNNN 180 NNNNACCCAT CGTGCGATGA TCNNNNNNN NNNNNNNNN NNNNNTTGGG ATCCAGTTTC 240 AAATAAGGTA TGGGAAAAAC AGATGTTTTC ATTATCGCCA CTTAATCCTT ACTTCCGATT 300 ATAATTATAC ATGTTTGGCT GTAATAACTA TACTAAAGCA TGCTTGTGAA AGTAGACTTC 360 TACAAGGACA GAAAACCCAC AACAACAAAG ATCGATCACG AAAGACAAGG CATAATTCATT 420 CATTAATTTA CTTCTTAG ACCCGGGACA TGTGGGACAA ATACTTTTGT CCTCATGGAT 480 GGCTTGATAA TTTATTTATA TGTTCTAGAG TCTGAGGATT TTCTTTCAGT GGCAGACAAC 540
10	AAAGGATGIT ACAATTTACT TCAAAATAAT ACAATCATGG TTTAATTTAC AGTGTAAATC 600 CATAACTATT TTATAGAGAT GGATTATCAT ACATGGGATT ATAAAAATAA CTTACCCATA 660 TGCTTGCAAA ATAGACTTIT CCTATTGGGA GGAACATCTT TTAACCTAAA ACGGATTTAT 720 TTCAGATGAA TTAGACAGTA CATTTTTCAG GAGAACCAGC CTTACTGGAT GATCTTTTGT 780 CAGGTTTGGA GGCCTCTTCT TTGTCTTTGC AACCATAACC CCTTTTCAGC TGAAGACCAC 840
15	TGGCCTTCAA CCCAAGCCAG GAGTTTGGCT CAAATGA  Seq ID NO: 20 DNA sequence
20	Nucleic Acid Accession #: D32051.1 Coding sequence: 72-1373
	1 11 21 31 41 51
25	GAATTCGAAC CAGGTGGCCA CCCGGTGTCG GTTTCATTTT CCTTTGGAAT TTCTGCTTTA 60 CAGACAGAAC AATGGCAGCC CGAGTACTTA TAATTGGCAG TGGAGGAAGG GAACATACGC 120 TGGCCTGGAA ACTTGCACAG TCTCATCATG TCAAACAAGT GTTGGTTGCC CCAGGAAACG 180 CAGGCACTGC CTGGTCTGAA AAGATTTCAA ATACCGCCAT CTCAATCAGT GACCACACTG 240 CCCTTGCTCA ATTCTGCAAA GAGAAGAAAA TTGAATTTGT AGTTGTTGGA CCAGAAGCAC 300
30 —	CTCTGGCTGC TGGGATTGTT GGGAACCTGA GGTCTGCAGG AGTGCAATGC TTTGGCCCAA 360 CAGCAGAAGC GGCTCAGTTA GAGTCCAGCA AAAGGTTTGC CAAAGAGTTT ATGGACAGAC 420 ATGGAATCCC AACCGCACAA TGGAAGGCTT TCACCAAACC TGAAGAAGCC TGCAGCTTCA 480 TTTTGAGTGC AGACTTCCCT GCTTTGGTTG TGAAGGCCAG TGGTCTTGCA GCTGGAAAAG 540
	GGGTGATTGT TGCAAAGAGC AAAGAAGAGG CCTGCAAAAGC TGTACAAGAG ATCATGCAGG 600 AGAAAGCCTT TGGGGCAGCT GGAGAACAA TTGTCATTGA AGAACTTCTT GACGGAGAAG 660 AGGTGTCGTG TCTGTGTTTC ACTGATGGCA AGACTGTGGC CCCCATGCCC CCAGCACAGG 720 ACCATAAGCG ATTACTGGAG GGAGATGGTG GCCCTAACAC AGGGGGAATG GGAGCCTATT 780 GTCCAGCCCC TCAGGGTTTCT AATGATCTAT TACTAAAAAAT TAAAGATACT GTTCTTCAGA 840
☐ 40 ☐	GGACAGTGGA TGGCATGCAG CAAGAGGGTA CTCCATATAC AGGTATTCTC TATGCTGGAA 900 TAATGCTGAC CAAGAATGGC CCAAAAGTTC TAGAGTTTAA TTGCCGTTTT GGTGATCCAG 960 AGTGCCAAGT AATCCTCCCA CTTCTTAAAA GTGATCTTTA TGAAGTGATT CAGTCCACCT 1020 TAGATGGACT GCTCTGCACA TCTCTGCCTG TTTGGCTAGA AAACCACC GCCCTAACTG 1080 TTGTCATGGC AAGTAAAGGT TATCCTGGAG ACTACACCAA GGGTGTAGAG ATAACAGGGT 1140 TTCCTGAGGC TCAAGCTCTA GGACTGGAGG TGTCCCATGC AGGCACTGCC CTCAAAAATG 1200
ិ 45 ប	GCAAAGTAGT AACTCATGGG GGTAGAGTTC TTGCAGTCAC AGCCATCCGG GAAAATCTCA 1260 TATCAGCCCT TGAGGAAGCC AAGAAAGGAC TAGCTGCTAT AAAGTTTGAG GGAGCAATTT 1320 ATAGGAAAGA CATCGGCTTT CGTGCCATAG CTTTCCTCCA GCAGCCCAGG TAAAACTCTA 1380 AGCAAGTTAG CTGTAGTGCC ATTTCAGAAA CTGGCCTAAA TGGCTATGTA GAACATTCCA 1440
" (15) (15) (15) (15) (15) (15) (15) (15)	TTAACCCTAT AAGTCATTCA GTATTCTTTT CTCTCTGTGG GAGTGATACA GTCTTGGTTT 1500 GTATTTGTT TGAATCAAAA CTGGTTATAG CAATACTCAA ATGGAAAAAA CTTCATGATA 1560 GCGTAAGTTT GGAAAGTTTA GCAAAATCAC AGTGGTACTG ATTTTTATTT GTTTTCTATT 1620 TTTTTATTT TATATTTTTA ATTTTTTAA CAGGGTCTTC CTCTCCGCC CAAGTTCTCA 1680 TGCCTCAGCC TCCCAAATAG CTGGGACTAC AGGCACAGGC CACCACCT GGCTAATTTT 1740
TJ 55	TTIGTATTIT TIGTGGAGAT GGGGTTCACC ATGTTGCCAA GGCCAGTCTG AAAGCCTGGG 1800 CTCAAGTGAT CCTCCTGCTT TGGCCTCCA AAATGCTGGG ACTATAGGCA TGAGGCGCTG 1860 CACTIGGCCT GATACTGATT TTTATTCCTT GCGTTATCAC ATAGTGTTGT ATTTGAAACA 1920 TAGTTCATGG TTTATCAAA GAACTGAAGA TGAGAATACT GGTCATCTAA CTTTGTAATT 1980 TGATTTGATT ATACTGTAAA GTTTGACAGT CCCATTTTAA CCTGCGTTTTG TATCTATTAC 2040 TAAAAATGTAT TTTTTGACCT CTTACTGATT CATGGTTGGT ATGTACAAAC TGTTGACTTG 2100
60	TAAAATCAAT AAAGTCTTAG TTGG  Seq ID NO: 21 <u>Protein sequence:</u> Protein Accession #: BAA06809.1
	Protein Accession #: BAA00009.1
65	1 11 21 31 41 51 
70	FCKEKKIEFV VVGPEAPLAA GIVGNLRSAG VQCFGPTAEA AQLESSKRFA KEFMDRHGIP 120 TAQWKAFTKP EEACSFILSA DFPALVVKAS GLAAGKGVIV AKSKEEACKA VQEIMQEKAF 180 GAAGETIVIE ELLDGEEVSC LCFTDGKTVA PMPPAQDHKR LLEGDGGPNT GGMGAYCPAP 240 QVSNDLLLKI KDTVLQRTVD GMQQEGTPYT GILYAGIMLT KNGPKVLEFN CRFGDPECQV 300 ILPLLKSDLY EVIQSTLDGL LCTSLPVWLE NHTALTVVMA SKGYPGDYTK GVEITGFPEA 360 QALGLEVSHA GTALKNGKVV THGGRVLAVT AIRENLISAL EEAKKGLAAI KFEGAIYRKD 420
75	IGFRAIAFLQ QPR
80	Seq ID NO: 22 <u>DNA sequence</u> Nucleic Acid Accession #: EOS cloned Coding sequence: 1-2424
	1 11 21 31 41 51
85	ATGCCCCCTT TCCTGTTGCT GGAGGCCGTC TGTGTTTTCC TGTTTTTCCAG AGTGCCCCCA 60 TCTCTCCCTC TCCAGGAAGT CCATGTAAGC AAAGAAACCA TCGGGAAGAT TTCAGCTGCC 120 AGCAAAATGA TGTGGTGCTC GGCTGCAGTG GACATCATGT TTCTGTTAGA TGGGTCTAAC 180

AGCGTCGGGA AAGGGAGCTT TGAAAGGTCC AAGCACTTTG CCATCACAGT CTGTGACGGT 240 CTGGAATTCC CCTTGGATTC ATTITCAACC CAACAGGAAG TGAAGGCAAG AATCAAGAGG 360 ATGGTTTTCA AAGGAGGCG CACGGAGACG GAACTTGCTC TGAAATACCT TCTGCACAGA 420
GGGTTGCCTG GAGGCAGAAA TGCTTCTGTG CCCCAGATCC TCATCATCGT CACTGATGGG 480 5 AAGTCCCAGG GGGATGTGGC ACTGCCATCC AAGCAGCTGA AGGAAAGGGG TGTCACTGTG 540 TTTGCTGTGG GGGTCAGGTT TCCCAGGTGG GAGGAGCTGC ATGCACTGGC CAGCGAGCCT 600 AGAGGGCAGC ACGTGCTGTT GGCTGAGCAG GTGGAGGATG CCACCAACGG CCTCTTCAGC ACCCTCAGCA GCTCGGCCAT CTGCTCCAGC GCCACGCCAG ACTGCAGGGT CGAGGCTCAC 720 10 CCCTGTGAGC ACAGGACGCT GGAGATGGTC CGGGAGTTCG CTGGCAATGC CCCATGCTGG 780 AGAGGATCGC GGCGGACCCT TGCGGTGCTG GCTGCACACT GTCCCTTCTA CAGCTGGAAG 840 AGAGTGTTCC TAACCCACCC TGCCACCTGC TACAGGACCA CCTGCCCAGG CCCCTGTGAC 900 TCGCAGCCCT GCCAGAATGG AGGCACATGT GTTCCAGAAG GACTGGACGG CTACCAGTGC 960 CTCTGCCCGC TGGCCTTTGG AGGGGAGGCT AACTGTGCCC TGAAGCTGAG CCTGGAATGC 1020 AGGGTCGACC TCCTCTTCCT GCTGGACAGC TCTGCGGGCA CCACTCTGGA CGGCTTCCTG 1080 CGGGCCAAAG TCTTCGTGAA GCGGTTTGTG CGGGCCGTGC TGAGCGAGGA CTCTCGGGCC 1140 15 CGAGTGGGTG TGGCCACATA CAGCAGGGAG CTGCTGGTGG CGGTGCCTGT GGGGGAGTAC 1200 CAGGATGTGC CTGACCTGGT CTGGAGCCTC GATGGCATTC CCTTCCGTGG TGGCCCCACC 1260
CTGACGGGCA GTGCCTTGCG GCAGGCGGCA GAGCGTGGCT TCGGGAGCGC CACCAGGACA 1320 20 GGCCAGGACC GGCCACGTAG AGTGGTGGTT TTGCTCACTG AGTCACACTC CGAGGATGAG 1380 GTTGCGGGCC CAGCGCGTCA CGCAAGGGCG CGAGAGCTGC TCCTGCTGGG TGTAGGCAGT 1440 GAGGCCGTGC GGGCAGAGCT GGAGGAGATC ACAGGCAGCC CAAAGCATGT GATGGTCTAC 1500 TCGGATCCTC AGGATCTGTT CAACCAAATC CCTGAGCTGC AGGGGAAGCT GTGCAGCCGG 1560 CAGCGGCCAG GGTGCCGGAC ACAAGCCCTG GACCTCGTCT TCATGTTGGA CACCTCTGCC 1620 25 TCAGTAGGGC CCGAGAATTT TGCTCAGATG CAGAGCTTTG TGAGAAGCTG TGCCCTCCAG 1680 TTTGAGGTGA ACCCTGACGT GACACAGGTC GGCCTGGTGG TGTATGGCAG CCAGGTGCAG 1740 ACTGCCTTCG GGCTGGACAC CAAACCCACC CGGGCTGCGA TGCTGCGGGC CATTAGCCAG 1800 GCCCCCTACC TAGGTGGGGT GGGCTCAGCC GGCACCGCCC TGCTGCACAT CTATGACAAA 1860 GTGATGACCG TCCAGAGGGG TGCCCGGCCT GGTGTCCCCA AAGCTGTGGT GGTGCTCACA 1920 30 GGCGGGAGAG GCGCAGAGGA TGCAGCCGTT CCTGCCCAGA AGCTGAGGAA CAATGGCATC 1980 TCTGTCTTGG TCGTGGCGGT GGGGCCTGTC CTAAGTGAGG GTCTGCGGAG GCTTGCAGGT 2040
CCCCGGGATT CCCTGATCCA CGTGGCAGCT TACGCCGACC TGCCGGTACCA CCAGGACGTG 2100
CTCATTGAGT GGCTGTGTGG AGAAGCCAAG CAGCCAGTCA ACCTCTGCAA ACCCAGCCCG 2160
TGCATGAATG AGGGCAGCTG CGTCCTGCAG AATGGGAGCT ACCGCTGCAA GTGTCGGGAT 2220 DOSZOSO "OSZZOS 35 GGCTGGGAGG GCCCCCACTG CGAGAACCGT GAGTGGAGCT CTTGCTCTGT ATGTGTGAGC 2280 CAGGGATGGA TTCTTGAGAC GCCCCTGAGG CACATGGCTC CCGTGCAGGA GGGCAGCAGC 2340 CGTACCCCTC CCAGCAACTA CAGAGAAGGC CTGGGCACTG AAATGGTGCC TACCTTCTGG 2400 AATGTCTGTG CCCCAGGTCC TTAG 40 Seq ID NO: 23 Protein sequence: Protein Accession #: EOS cloned 21 31 41 51 45 MPPFLLLEAV CVFLFSRVPP SLPLQEVHVS KETIGKISAA SKMMWCSAAV DIMFLLDGSN 60 SVGKGSFERS KHFAITVCDG LDISPERVRV GAFQFSSTPH LEFPLDSFST QQEVKARIKR 120 MVFKGGRTET ELALKYLLHR GLPGGRNASV PQILIIVTDG KSQGDVALPS KQLKERGVTV 180 FAVGVRFPRW EELHALASEP RGQHVLIAEQ VEDATNGLFS TLSSSAICSS ATPDCRVEAH 240
PCEHRTLEMV REFAGNAPCW RGSRRTLAVL AAHCPFYSWK RVFLITHPATC YRTTCPGPCD 300
SQPCQNGGTC VPEGLDGYQC LCPLAFGGEA NCALKLSLEC RVDLLFLLDS SAGTTLDGFL 360 50 RAKVFVKRFV RAVLSEDSRA RVGVATYSRE LLVAVPVGEY QDVPDLVWSL DGIPFRGGPT 420 LTGSALRQAA ERGFGSATRT GQDRPRRVVV LLTESHSEDE VAGPARHARA RELLLLGVGS 480 EAVRAELEEI TGSPKHVMVY SDPQDLFNQI PELQGKLCSR QRPGCRTQAL DLVFMLDTSA 540 55 SVGPENFAQM QSFVRSCALQ FEVNPDVTQV GLVVYGSQVQ TAFGLDTKPT RAAMLRAISQ 600
APYLGGVGSA GTALLHIYDK VMTVQRGARP GVPKAVVVLT GGRGAEDAAV PAQKLRNNGI 660
SVLVVGVGPV LSEGLRRLAG PRDSLIHVAA YADLRYHQDV LIEWLCGEAK QPVNLCKPSP 720 CMNEGSCVLQ NGSYRCKCRD GWEGPHCENR EWSSCSVCVS QGWILETPLR HMAPVQEGSS 780 RTPPSNYREG LGTEMVPTFW NVCAPGP 60 Seq ID NO: 24 <u>DNA sequence</u> Nucleic Acid Accession #: see Table 25 & 25A for complete list 65 AGGTCGGCTG GTTATCGGGA GTTGGAGGGC TGAGGTCGGG AGGGTGGTGT GTACAGAGCT CTAGGACTCA CGCACCAGGC CAGTCGCGGG TTTTGGGCCG AGGCCTGGGT TACAAGCAGC 120 AAGTGCGCGG TTGGGGCCAC TGCGAGGCCG TTTTAGAAAA CTGTTTAAAA CAAAGAGCAA 180 TTGATGGATA AATCAGGAAT AGATTCTCTT GACCATGTGA CATCTGATGC TGTGGAACTT 240 GCAAATCGAA GTGATAACTC TTCTGATAGC AGCTTATTTA AAACTCAGTG TATCCCTTAC 300 70 TCACCTAAAG GGGAGAAAAG AAACCCCATT CGAAAATTTG TTCGTACACC TGAAAGTGTT 360 CACGCAAGTA TTCATCAAGT GACTCATCTT TTGAACCAGT ACCATTGACT ATAAAAGCTA 420
TTTTTGAAAG ATTCAAGAAC AGGAAAAAGA GATATAAAAA AAAGAAAAAG AGGAGGTACC 480 75 ATGAAAAAA CGCACCTTGG AGAAAAATTT TAACGTTTGA GCAAGCTGTT GCAAGAGGAT 660 TTTTTAACTA TATTGAAAAA CTGAAGTATG AACACCACCT GAAAGAATCA TTGAAGCAAA 720 TGAATGTTGG TGAAGATTTA GAAAATGAAG ATTTTGACAG TCGTAGATAC AAATTTTTGG 780 ATGATGATGG ATCCATTICT CCTAITGAGG AGTCAACGCT TITACTTGA GGACATGGTG 840
TCTGGAGTTA AAGGTATTGG CATACTCCAC ACATCTGTAC CATTCTTGAG TGATCGCTTA 900
GGAATGAATG TGATTTGGAC TCATTCATGT ATGAGAGTAA GCAATGCTTT TITTTCCAGG 960
GTGTCAAATT GAGAACCAGG TAGATCCCCA CCACCTACAG TAAAAAGGAC CCTAAAGTAA 1020 80 ATTGGTTGAA GAAATTAGAT CCCAAAGATT CTTGGTGAAT TTTGAAGTCT TCATCAGTAT 1080 ATCCATATTA AAACGAGATG ACAGAAGCCA AAGTAATTAT GGGCTGACAG GACAACTGGA 1140 85 TCAGTTTCAT TAAAAAGGGC AAACTTGAAG ATAAATCTTT TGACTCCAGC TCTTTAGAGG 1200 ATCTAAAGTG ACCTTGATGG ACAGTGGAAG AAATCACAAC ATGGAATTCC TCGAATAACA 1260

ATTTATTGAC TTTAAATAAT TTTGTCTAAT GCTACATATA CACAATTAAA AAACCTTTAC 1320 ACTATTTCTA GAAAGTCAGC ATGTATTTTT GGCTCGAAGT TTCTCTAGTG TTTTCTGTGG 1380 ACAATCTGTT GTGCGGCGCC CCTGGGCCCC TTGAGAGAAA ACTITTTAGA ACCCCTTTTG 1500 CGTTGTGGCG GCCCGGGGGC CCCACAGTTG GGTTTAGGTG GGCACCCTTG TGTCTACAAG 1560 5 TGGTGTCTCC CCAAGAGAGA GAACACCTCC GGGGTCAAGC GGACAACAAG AGTGCGTCGT 1620 GAGGACTCTT CACCCAAAGT ATATAAAACC CGCCCCGCGG GGGAACCACC GGCCGCTTTT 1680 CTGTAGACAC AACCCCCACA GTGGGAACCT CTGAGGGCGC ACACACAGGG CGAGCCTTAT 1740 CAACAAGGGG TGCCCAACAG AAACCCCGAG TTAAAAATCG 10 Seq ID NO: 25 DNA sequence BC001972.1 Nucleic Acid Accession #: Coding sequence: 183-1019 15 41 31 11 21 GGTCGGCTGG TTATCGGGAG TTGGAGGGCT GAGGTCGGGA GGGTGGTGTG TACAGAGCTC 60 TAGGACTCAC GCACCAGGCC AGTCGCGGGT TTTGGGCCGA GGCCTGGGTT ACAAGCAGCA AGTGCGCGGT TGGGGCCACT GCGAGGCCGT TTTAGAAAAC TGTTTAAAAC AAAGAGCAAT 180 20 TGATGGATAA ATCAGGAATA GATTCTCTTG ACCATGTGAC ATCTGATGCT GTGGAACTTG 240 CAAATCGAAG TGATAACTCT TCTGATAGCA GCTTATTTAA AACTCAGTGT ATCCCTTACT 300
CACCTAAAGG GGAGAAAAGA AACCCCATTC GAAAATTTGT TCGTACACCT GAAAGTGTTC 360 ACGCAAGTGA TTCATCAAGT GACTCATCTT TTGAACCAAT ACCATTGACT ATAAAAGCTA 420 TTTTTGAAAG ATTCAAGAAC AGGAAAAAGA GATATAAAAA AAAGAAAAAG AGGAGGTACC 480 25 TAGATAAGAA GAAACAATTT AGAAGCAGAG GATCTGGCTT CCCATTTTTTA GAATCAGAGA 600 ATGAAAAAAA CGCACCTTGG AGAAAAATTT TAACGTTTGA GCAAGCTGTT GCAAGAGGAT 660 TITITAACTA TATTIGAAAAA CTGAAGTATG AACACCACCT GAAAGAATCA TTGAAGCAA 720
TGAATGTTGG TGAAGATTTA GAAAATGAAG ATTTTIGACAG TCGTAGATAC AAATTTTTGG 780
ATGATGATGG ATCCATTTCT CCTATTGAGG AGTCAACAGC AGAGGATGAG GATGCAACAC 840 30 ATCTTGAAGA TAACGAATGT GATATCAAAT TGGCAGGGGA TAGTTTCATA GTAAGTTCTG 900 AATTCCCTGT AAGACTGAGT GTATACTTAG AAGAAGAGGA TATTACTGAA GAAGCTGCTT 960 TGTCTAAAAA GAGAGCTACA AAAGCCAAAA ATACTGGACA GAGAGGCCTG AAAATGTGAC 1020 AGGATCATGA ATGTCAAAGG CTTTTATCTT GAGAACATGG TGTCTGGAGT TAAAGGACTA 1080 35 TTGTTAGATC TGTGGGAAGG AATTACAAGA CAGTTGCTAA AAGTTTGAAA AAGACGGTTG 1140 CTAAACGTTA TGAAAAACCA GATAATCTAC TTTTTTACCT TAGGTATTGG CATACTCCAC 1200 ACATCTGTAC CATTCTTGAG TGATCGCTTA GGAATGAATG TGATTTGAAC TCATTCATGT 1260 TGAGAGGGTG TCAAATTGAG AACCAGGTAG ATCCCCACCA CCTACAGTAA AAAGGACCCT 1320 AAAGTAAATT GGTTGAAGAA ATTAGATCCC AAAGATTCTT GGTGAATTTT GAAGTCTTCA 1380 40 TCAGTATATC CATATTAAAA CGAGATGACA GAAGCCAAAG TAATTATGGG CTGACAGGAC 1440 AACTGGATCA GTTTCATTAA AAAGGGCAAA CTTGAAGATA AATCTTTTGA CTCCAGCTCT 1500 TTAGAGGATC TAAAGTGACC TTGATGGACA GTGGAAGAAA TCACAACATG GAATTCCTCG 1560 AATAACAATT TATTGACTTT AAATAATTTT GTCTAATGCT ACATATACAC AATTAAAAAA 1620 45 CCTTTACACT AAAAAAAAAA AAAAAA Seq ID NO: 26 Protein sequence: Protein Accession #: AAH01972.1 50 41 51 31 MDKSGIDSLD HVTSDAVELA NRSDNSSDSS LFKTQCIPYS PKGEKRNPIR KFVRTPESVH 60 ASDSSSDSSF EPIPLTIKAI FERFKNRKKR YKKKKKRRYQ PTGRPRGRPE GRRNPIYSLI 120 DKKKQFRSRG SGFPFLESEN EKNAPWRKIL TFEQAVARGF FNYIEKLKYE HHLKESLKQM 180 NVGEDLENED FDSRRYKFLD DDGSISPIEE STAEDEDATH LEDNECDIKL AGDSFIVSSE 240 55 FPVRLSVYLE EEDITEEAAL SKKRATKAKN TGQRGLKM Seq ID NO: 27 DNA sequence 60 AK027016 Nucleic Acid Accession # Coding sequence: 207-1043 41 51 CTITTCTTCC GCACGGTTGG AGGAGGTCGG CTGGTTATCG GGAGTTGGAG GGCTGAGGTC 60 65 GGGAGGGTGG TGTGTACAGA GCTCTAGGAC TCACGCACCA GGCCAGTCGC GGATTTTGGG 120 CCGAGGCCTG GGTTACAAGC AGCAAGTGCG CGGTTGGGGC CACTGCGAGG CCGTTTTAGA 180 AAACTGTTTA AAACAAAGAG CAATTGATGG ATAAATCAGG AATAGATTCT CTTGACCATG 240 TGACATCTGA TGCTGTGGAA CTTGCAAATC GAAGTGATAA CTCTTCTGAT AGCAGCTTAT 300 TTAAAACTCA GTGTATCCCT TACTCACCTA AAGGGGAGAA AAGAAACCCC ATTCGAAAAT 360 70 GGAGAAATCC TATATACTCA CTAATAGATA AGAAGAAACA ATTTAGAAGC AGAGGATCTG 600 GCTTCCCATT TTTAGAATCA GAGAATGAAA AAAACGCACC TTGGAGAAAA ATTTTAACGT 660 75 TTGAGCAAGC TGTTGCAAGA GGATTTTTTA ACTATATTGA AAAGCTGAAG TATGAACACC ACCTGAAAGA ATCATTGAAG CAAATGAATG TTGGTGAAGA TTTAGAAAAT GAAGATTTTG 780
ACAGTCGTAG ATACAAATTT TTGGATGATG ATGGATCCAT TTCTCCTATT GAGGAGTCAA 840 CAGCAGAGGA TGAGGATGCA ACACATCTTG AAGATAACGA ATGTGATATC AAATTGGCAG 900
GGGATAGTTT CATAGTAAGT TCTGAATTCC CTGTAAGACT GAGTGTATAC TTAGAAGAAG 960
AGGATATTAC TGAAGAAGCT GCTTTGTCTA AAAAGAGAGC TACAAAAGCC AAAAATACTG 1020 80 GACAGAGAGG CCTGAAAATG TGACAGGATC ATGAATGTCA AAGGCTTTTA TCTTGAGAAC 1080 ATGGTGTCTG GAGTTAAAGG TATTGGCATA CTCCACACAT CTGTACCATT CTTGAGTGAT 1140 CGCTTAGGAA TGAATGTGAT TTGAACTCAT TCATGTTGAG AGGGTGTCAA ATTGAGAACC 1200 AGGTAGATCC CCACCACCTA CAGTAAAAAG GACCCTAAAG TAAATTGGTT GAAGAAATTA 1260

Ш

Ö

85

GATCCCAAAG ATTCTTGGTG AATTTTGAAG TCTTCATCAG TATATCCATA TTAAAACGAG 1320

	ATGACAGAAG CCAAAGTAAT TATGGCAAGT AATGGTTTTT ATCTTAACTA TAAGTTATTT 1380 GCTCAAGGGT GTAATGGTCA TTACCAAGGC TTTTAGAATG CAGTTTCTCA TTTGCTGTGG 1440 ACATGACCAT AAAAAAAAAT TTCCCAGTAG GTTTTCTATC TGCTACGTTG CTAGCAATCA 1500 GCTTATTGGG AACAGTTGAT TAACTGTAAT AGAAATGCAA TACAAAATAAA ATGTGAACCA 1560 CATGTGATTT TTCTTTAAAA TCAGTGAGAT TTGAAAATTC TCCTAGATCT CTTGAATCAT 1620 GCAAATTTGC TTTGCCTTTA TATTGTAACC CTTGTGGGTT GCTAATAACC AAGCAGTTTG 1680 TAGTAGAGTT AACTCAGGCT CGTTCTAGGG ACTCATTCAT GTTCACTCAC TGTACACTCA 1740 TCTCTGGAAA TGTAAAAATTT ACTTTTTATAC TATTGTTATG TAGGGCTGAC AGGACAACTG 1800
1	TCTCTATAGG AAGCCATAGC ACTCCTAATG TTTGGTGCTA TGTTTTCCTG AGGAGATATA 1980 AAACGTAATA ATCCATGATT GTTGCCATGT GAGAGTTTTA AAGGTTAATC AAAATTTCTC 2040 TTCTTCAGGG CAAACTTGAA GATAAATCTT TTGACTCCAG CTCTTTAGAG GATCTAAAGT 2100
1.	GACCTTGATG GACAGTGGAA GAAATCACAA CATGGAATTC CTCGAATAAC AATTTATTGA 2160 CTTTAAATAA TTTTGTCTAA TGCTACATAT ACACAATTAA AAAACCTTTA CACTATTTCT 2220 AGAAAGTCAG CATGTATTT TGGCTCGAAG TTTCTCTAGT GTTTTCTGTG GAAGGAATAA 2280 AAATTTGAGT TTCAAAAAAAA AAAAAAAAAAAAAAAA
20	Seq ID NO: 28 <u>Protein sequence</u> : Protein Accession #: BAB15628.1
	1 11 21 31 41 51 
2:	MDK SGIDSI D HVTSDAVEL A NIBSDASSONS I EVTOCIDVE DV CEV DAIDID VEV DTDESIVE CO
30	
L	Seq ID NO: 29 <u>DNA sequence</u> Nucleic Acid Accession #: NM_004289.3 Coding sequence: 493-1695
: I	
<del>-</del>	CAGGGGGGCG GCGGGAACC CCGAGCGGCT CGGAGTGGCC CCTTGGACGC CGGGGAAGAG 120
₩ 40	GAGAATGGGG TACTAAGAGA AAAGCACGAA GCTGTGGATC ATAGTTCCCA GCATGAGGAA 240
	AATGAAGAAA GGGTGTCAGC CCAGAAGGAG AACTCACTTC AGCAGAATGA TGATGATGAA 300 AACAAAATAG CAGAGAAACC TGACTGGGAG GCAGAAAAGA CCACTGAATC TAGAAATGAG 360
	AGACATCTGA ATGGGACAGA TACTTCTTTC TCTCTGGAAG ACTTATTCCA GTTGCTTTCA 420
<b>45</b>	TCACAGCCTG AAAATTCACT GGAGGGCATC TCATTGGGAG ATATTCCTCT TCCAGGCAGT 480
	ATCAGTGATG GCATGAATTC TTCAGCACAT TATCATGTAA ACTTCAGCCA GGCTATAAGT 540 CAGGATGTGA ATCTTCATGA GGCCATCTTG CTTTGTCCCA ACAATACATT TAGAAGAGAT 600
TU	CCAACAGCAA GGACTTCACA GTCACAAGAA CCATTTCTGC AGTTAAATTC TCATACCACC 660
145 111 112 124 50	AATCCTGAGC AAACCCTTCC TGGAACTAAT TTGACAGGAT TTCTTTCACC GGTTGACAAT 720 CATATGAGGA ATCTAACAAG CCAAGACCTA CTGTATGACC TTGACATAAA TATATTTGAT 780
<b>≒</b> 50	GAGATAAACT TAATGTCATT GGCCACAGAA GACAACTTTG ATCCAATCGA TGTTTCTCAG 840
Ō	CITITIGATG AACCAGATTC TGATTCTGGC CTTTCTTTAG ATTCAAGTCA CAATAATACC 900
Ti.	TCTGTCATCA AGTCTAATTC CTCTCACTCT GTGTGTGATG AAGGTGCTAT AGGTTATTGC 960 ACTGACCATG AATCTAGTTC CCATCATGAC TTAGAAGGTG CTGTAGGTGG CTACTACCCA 1020
55	GAACCCAGTA AGCTTTGTCA CTTGGATCAA AGTGATTCTG ATTTCCATGG AGATCTTACA 1080
33	TTTCAACACG TATTTCATAA CCACACTTAC CACTTACAGC CAACTGCACC AGAATCTACT 1140 TCTGAACCTT TTCCGTGGCC TGGGAAGTCA CAGAAGATAA GGAGTAGATA CCTTGAAGAC 1200
	ACAGATAGAA ACTTGAGCCG TGATGAACAG CGTGCTAAAG CTTTGCATAT CCCTTTTTCT 1260
	GTAGATGAAA TTGTCGGCAT GCCTGTTGAT TCTTTCAATA GCATGTTAAG TAGATATTAT 1320 CTGACAGACC TACAAGTCTC ACTTATCCGT GACATCAGAC GAAGAGGGAA AAATAAAGTT 1380
60	GCTGCGCAGA ACTGTCGTAA ACGCAAATTG GACATAATTT TGAATTTAGA AGATGATGTA 1440
	TGTAACTTGC AAGCAAAGAA GGAAACTCTT AAGAGAGAG AAGCACAATG TAACAAAGCT 1500
	ATTAACATAA TGAAACAGAA ACTGCATGAC CTTTATCATG ATATTTTTAG TAGATTAAGA 1560 GATGACCAAG GTAGGCCAGT CAATCCCAAC CACTATGCTC TCCAGTGTAC CCATGATGGA 1620
65	AGTATCITGA TAGTACCCAA AGAACTGGTG GCCTCAGGCC ACAAAAAGGA AACCCAAAAG 1680
05	GGAAAGAGAA AGTGAGAAGA AACTGAAGAT GGACTCTATT ATGTGAAGTA GTAATGTTCA 1740 GAAACTGATT ATTTGGATCA GAAACCATTG AAACTGCTTC AAGAATTGTA TCTTTAAGTA 1800
	CTGCTACTTG AATAACTCAG TTAACGCTGT TTTGAAGCTT ACATGGACAA ATGTTTAGGA 1860
	CTTCAAGATC ACACTTGTGG GCAATCTGGG GGAGCCACAA CTTTTCATGA AGTGCATTGT 1920 ATACAAAATT CATAGTTATG TCCAAAGAAT AGGTTAACAT GAAAACCCAG TAAGACTTTC 1980
70	CATCITGGCA GCCATCCTTT TTAAGAGTAA GTTGGTTACT TCAAAAAGAG CAAACACTGG 2040
	GUATCAAATT ATTITAAGAG GTATTTCAGT TTTAAATGCA AAATAGCCTT ATTTTCATTT 2100
	AGTTTGTTAG CACTATAGTG AGCTTTTCAA ACACTATTTT AATCTTTATA TTTAACTTAT 2160 AAATTTTGCT TTCT
75	
13	Seq ID NO: 30 Protein sequence:
	Protein Accession #: NP_004280
	1 11 21 31 41 51
80	
	MNSSAHYHVN FSQAISQDVN LHEAILLCPN NTFRRDPTAR TSQSQEPFLQ LNSHTTNPEQ 60
	TLPGTNLTGF LSPVDNHMRN LTSQDLLYDL DINIFDEINL MSLATEDNFD PIDVSQLFDE 120 PDSDSGLSLD SSHNNTSVIK SNSSHSVCDE GAIGYCTDHE SSSHHDLEGA VGGYYPEPSK 180
85	LCHLDQSDSD FHGDLTFOHV FHNHTYHLOP TAPESTSEPF PWPGKSOKIR SRVI FDTDRN 240
63	LSRDEQRAKA LHIPFSVDEI VGMPVDSFNS MLSRYYLTDL QVSLIRDIRR RGKNKVAAQN 300 CRKRKLDIIL NLEDDVCNLQ AKKETLKREQ AQCNKAINIM KQKLHDLYHD IFSRLRDDQG 360
	ייין ארבויים אייין ארבויים אייין ארבויים אייין ארבויים אייין איייים אייים איייים אייים איייים אייים אייים איייים אייים איייים אייייים איייים א

#### RPVNPNHYAL QCTHDGSILI VPKELVASGH KKETQKGKRK

	5	Seq ID NO: 31 <u>DNA sequence</u> Nucleic Acid Accession #: NM_033260.1 Coding sequence: I-1208
		1 11 21 31 41 51
	10	ATGAAGTTGG AGGTGTTCGT CCCTCGCGCG GCCCACGGGG ACAAGCAGGG CAGTGACCTG 60 GAGGGCGGG GCGGCAGCGA CGCGCCGTCC CCGCTGTCGG CGGCGGAGA CGACTCCCTG 120 GGCTCAGATG GGGACTGCGC GGCCAAGCCG TCCGCGGGGG AGGACGCCAG AGATACGCAG 180 GGCGACGGCG AACAGAGTGC GGGAGGCGGG CCGGGCGCGG AGGAGGCGAT CCCGGCAGCA 24
	15	GCTGCTGCAG CGGTGGTGC GGAGGGCGG GAGGCCGGG CGGCGGGGC AGCCGGGC 360 GGCGCGGGGA GCGGCGAGGG TGCACGCAGC AAGCCATATA CGCGGCGGCC CAAGCCCCCC 360 TACTCGTACA TCGCGCTCAT CGCCATGGC ATCCGCGACT CGGCGGGCG GCGCTTGACG 420 CTGGCGGAGA TCAACGAGTA CCTCATGGC AAGTTCCCCT TTTTCCGCGG CAGCTACACG 480
	20	GGCTGGCGCA ACTCCGTGCG CCACAACCTT TCGCTCAACG ACTGCTTCGT CAAGGTGCTG 540 CGCGACCCCT CGCGGCCCTG GGGCAAGGAC AACTACTGGA TGCTCAACCC CAACAGCGAG 600 TACACCTTCG CCGACGGGT CTTCCGCCGC CGCCGCAAGC GCCCTCAAGCCA CCGCGCGCG 660 GTCCCCGCGC CCGGGCTGCG GCCCGAAGGAG GCCCGGGCC TCCCCGCCGC CCCGCCGCCC 720 GCGCCCGCCC CCCCGCCGC CCCCGCAGAAGAGCGCCC 780
	25	AGCCCGCGG GCAAGTTCTC CAGCTCCTTC GCCATCGACA GCATCCTGCG CAAGCCCTTC 840 CGCAGCCGTC GCCTCAGGGA CACGGCCCC GGGACGACGC TTCAGTGGGG CGCCGCCC 900 TGCCCGCCGC TGCCCGCGTT CCCCGCGCTC CTCCCCGCGG CGCCCTGCAG GCCCTGCTG 960 CCGCTCTGCG CGTACGGCGC GGGCGGCCG GGCGGCTGG GCGCCGCGAGCCGAGC
ļub.	30	CTGCAGGCGG CCTTAGTCCG NCGTCCTGGC CCGCACCTGT CGTACCCGGT GGAGACGCTC 1200 CTAGCTTGA
	o #	Seq ID NO: 32 Protein sequence: Protein Accession #: NP_150285.1
M	35	1 11 21 31 41 51
	40	MKLEVFVPRA AHGDKQGSDL EGAGGSDAPS PLSAAGDDSL GSDGDCAAKP SAGGGARDTQ 60 GDGEQSAGGG PGAEEAIPAA AAAAVVAEGA EAGAAGPGAG GAGSGEGARS KPYTRRPKPP 120 YSYIALIAMA IRDSAGGRLT LAEINEYLMG KFPFFRGSYT GWRNSVRHNL SLNDCFVKVL 180 RDPSRPWGKD NYWMLNPNSE YTFADGVFRR RKKLSHRAP VPAPGLPEE APGLPAAPPP 240 APAAPASPRM RSPARQEERA SPAGKFSSSF AIDSILRKPF RSRKLRDTAP GTTLQWGAAP 300 CPPLPAFPAL LPAAPCRALL PLCAYGAGEP ARLGAREAEV PPTAPPLLLA PLPAAAPAKP 360
		LRGPAAGGAH LYCPLRLPAA LQAALVRRPG PHLSYPVETL LA
	45	Seq ID NO: 33 <u>DNA sequence</u> Nucleic Acid Accession #: NM_012128.2 Coding sequence: 43-2796
	50	1 11 21 31 41 51                   GAACAAACCA ACATTTGAGC CAGGAATAAC TAGAGAGGAA CAATGGGGTT ATTCAGAGGT 60 TITGTTTTCC TCTTAGTTCT GTGCCTGCTG CACCAGTCAA ATACTTCCTT CATTAAGCTG 120
P.L	55	AATAATAATG GCTTTGAAGA TATTGTCATT GTTATAGATC CTAGTGTGCC AGAAGATGAA 180 AAAATAATTG AACAAATAGA GGATATGGTG ACTACAGCTT CTACGTACCT GTTTGAAGCC 240 ACAGAAAAAA GATTTTTTTT CAAAAATGTA TCTATATTAA TTCCTGAGGAA TTGGAAGGAA 300 AATCCTCAGT ACAAAAGGCC AAAACATGAA AACCATAAAC ATGCTGATGT TATAGTTGCA 360 CCACCTACAC TCCCAGGTAG AGATGAACCA TACACCAAGC AGTTCACAGA ATGTGGAGAG 420 AAAGGCGAAT ACATTCACTT CACCCTGAC CTTCTACTTG GAAAAAAAACA AAATGAATAT 480
	60	GGACCACCAG GCAAACTGTT TGTCCATGAG TGGGCTCACC TCCGGTGGGG AGTGTTTGAT 540 GAGTACAATG AAGATCAGCC TTTCTACCGT GCTAAGTCAA AAAAAATCGA AGCAACAAGG 600 TGTTCCGCAG GTATCTCTGG TAGAAATAGA GTTTATAAGT GTCAAGGAGG CAGCTGTCTT 660 AGTAGAGCAT GCAGAATTGA TTCTACAACA AAACTGTATG GAAAAGATTG TCAATTCTTT 720 CCTGATAAAG TACAAACAGA AAAAGCATCC ATAATGTTTA TGCAAAAGTAT TGATTCTGTT 780
	65	GTTGAATTTT GTAACGAAAA AACCCATAAT CAAGAAGCTC CAAGCCTACA AAACATAAAG 840 TGCAATTTTA GAAGTACATG GGAGGTGATT AGCAATTCTG AGGATTTTAA AAACACCATA 900 CCCATGGTGA CACCACCTCC TCCACCTGTC TTCTCATTGC TGAAGATCCG TCAAAGAATT 960 GTGTGCTTAG TTCTTGATAA GTCTGGAAGC ATGGGGGGTA AGGACCGCCT AAATCGAATG 1020 AATCAAGCAG CAAAACATTT CCTGCTGCAG ACTGTTGAAA ATGGATCCTG GGTGGGGATG 1080
	70	GTTCACTITIG ATAGTACTIGC CACTATTIGTA AATAAGCTAA TCCAAAATAAA AAGCAGTGAT 1140 GAAAGAAACA CACTCATGGC AGGATTACCT ACATATCCTC TGGGAGGAAC TTCCATCTGC 1200 TCTGGAATTA AATATGCATT TCAGGTGATT GGAGGAGCTAC ATTCCCAACT CGATGGATCC 1260 GAAGTACTGC TGCTGACTGA TGGGGAGGAT AACACTGCAA GTTCCTTAT TGATGAAGTG 1320 AAACAAAGTG GGGCCATTGT TCATTTTATT GCTTTGGGAA GAGCTGCTGA TGAAGCAGTA 1380
	75	ATAGAGATGA GCAAGATAAC AGGAGGAAGT CATTTTTATG TITTCAGATGA AGCTCAGAAC 1440 AATGGCCTCA TTGATGCTTT TGGGGCTCTT ACATCAGGAA ATACTGATCT CTCCCAGAAG 1500 TCCCTTCAGC TCGAAAGTAA GGGATTAACA CTGAATAGTA ATGCCTGGAT GAACGACACT 1560 GTCATAATTG ATAGTACAGT GGGAAAGGAC ACGTTCTTTC TCATCACATG GAACAGTCTG 1620 CCTCCCAGTA TTTCTCTCTG GGATCCCAGT GGAACAATAA TGGAAAATTT CACAGTGGAT 1680
	80	GCAACTTCCA AAATGGCCTA TCTCAGTATT CCAGGAACTG CAAAGGTGGG CACTTGGGCA 1740 TACAATCTTC AAGCCAAAGC GAACCCAGAA ACATTAACTA TTACAGTAAC TTCTCGAGCA 1800 GCAAATTCTT CTGTGCCTCC AATCACAGTG AATGCTAAAA TGAATAAGGA CGTAAACAGT 1860 TTCCCCAGCC CAATGATTGT TTACGCAGAA ATTCTACAAG GATATGTACC TGTTCTTGGA 1920
	85	GCCAATGTGA CTGCTTTCAT TGAATCACAG AATGGACATA CAGAAGTTTT GGAACTTTTG 1980 GATAATGGTG CAGGCGCTGA TTCTTTCAAG AATGATGGAG TCTACTCCAG GTATTTTACA 2040 GCATATACAG AAAATGGCAG ATATAGCTTA AAAGTTCGGG CTCATGGAGG AGCAAACACT 2100 GCCAGGCTAA AATTACGGCC TCCACTGAAT AGAGCCGCGT ACATACCAGG CTGGGTAGTG 2160

ΠJ

85

AGAGCAGTGG AAGGGCAACA CAACTATTTA TGTGCTGGAA GAAATGATTG CATCATTGAT 2160 AAGATTCGAC GAAAGAATTG TCCTGCTTGC AGACTTCAGA AATGTCTTCA AGCTGGAATG 2220

AATTTAGGAG CACGAAAGTC AAAGAAGTTG GGAAAGTTAA AAGGGATTCA CGAGGAGCAG 2280 CCACAGCAGC AGCAGCCCC ACCCCCACCC CCACCCCCGC AAAGCCCAGA GGAAGGGACA 2340

ACGTACATCG CTCCTGCAAA AGAACCCTCG GTCAACACAG CACTGGTTCC TCAGCTCTCC 2400 ACAATCTCAC GAGCGCTCAC ACCTTCCCCC GTTATGGTCC TTGAAAACAT TGAACCTGAA 2460 ATTGTATATG CAGGCTATGA CAGCTCAAAA CCAGATACAG CCGAAAATCT GCTCTCCACG 2520 CTCAACCGCT TAGCAGGCAA ACAGATGATC CAAGTCGTGA AGTGGGCAAA GGTACTTCCA 2580 GGATTTAAAA ACTTGCCTCT TGAGGACCAA ATTACCCTAA TCCAGTATTC TTGGATGTGT 2640 5 CTATCATCAT TTGCCTTGAG CTGGAGATCG TACAAACATA CGAACAGCCA ATTTCTCTAT 2700 TTTGCACCAG ACCTAGTCTT TAATGAAGAG AAGATGCATC AGTCTGCCAT GTATGAACTA 2760
TGCCAGGGGA TGCACCAAAT CAGCCTTCAG TTCGTTCGAC TGCAGCTCAC CTTTGAAGAA 2820
TACACCATCA TGAAAGTTTT GCTGCTACTA AGCACAATTC CAAAGGATGG CCTCAAAAGC 2880 10 CAGGCTGCAT TTGAAGAAAT GAGGACAAAT TACATCAAAG AACTGAGGAA GATGGTAACT 2940 AAGTGTCCCA ACAATTCTGG GCAGAGCTGG CAGAGGTTCT ACCAACTGAC CAAGCTGCTG 3000
GACTCCATGC ATGACCTGGT GAGCGACCTG CTGGAATTCT GCTTCTACAC CTTCCGAGAG 3060 TCCCATGCGC TGAAGGTAGA GTTCCCCGCA ATGCTGGTGG AGATCATCAG CGACCAGCTG 3120 CCCAAGGTGG AGTCGGGGAA CGCCAAGCCG CTCTACTTCC ACCGGAAGTG ACTGCCCGCT 3180 GCCCAGAAGA ACTTTGCCTT AAGTTTCCCT GTGTTGTTCC ACACCCAGAA GGACCCAAGA 3240
AAACCTGTTT TTAACATGTG ATGGTTGATT CACACTTGTT CAACAGTTTC TCAAGTTTTAA 3300 15 AGTCATGTCA GAGGTTTGGA GCCGGGAAAG CTGTTTTTCC GTGGATTTGG CGAGACCAGA 3360 GCAGTCTGAA GGATTCCCCA CCTCCAATCC CCCAGCGCTT AGAAACATGT TCCTGTTCCT 3420 CGGGATGAAA AGCCATATCT AGTCAATAAC TCTGATTTTG ATATTTTCAC AGATGGAAGA 3480 20 AGTTTTAACT ATGCCGTGTA GTTTCTGGTA TCGTTCGCTT GTTTTAAAAG GGTTCAAGGA 3540 CTAACGAACG TTTTAAAGCT TACCCTTGGT TTGCACATAA AACGTATAGT CAATATGGGG 3600 CATTAATATT CTTTGTTAT TAAAAAAACA CAAAAAAATA ATAAAAAAAT ATATACAGAT 3660 TCCTGTTGTG TAATAACAGA ACTCGTGGCG TGGGGCAGCA GCTGCCTCTG AGCCCTCGCT 3720 CGTCCACGGT CTTCTGCATC ACTGGTATAC ACACTCGTTA GCGTCCATTT CTTATTTAAT 3780 25 TAGAATGGAT AAGATGATGT TAAATGCCTT GGTTTGATTT CTAGTATCTA TTGTGTTGGC 3840
TTTACAAATA ATTTTTTGCA GTCTTTTGCT GTGCTGTACA TTACTGTATG TATAAATTAT 3900 GAAGGACCTG AAATAAGGTA TAAGGATCTT TTGTAAATGA GACACATACA AAAAAAATCT 3960 TTAATGGTTA ATAGGATGAA TGGGAAAGTA TTTTTGAAAG AATTCTATTT TGCTGGAGAC 4020 TATTTAAGTA CTATCTTTGT CTAAACAAGG TAATTTTTTT TTGTAAAGTG CAATGTCCTG 4080 30 CATGCATAAT GAACCGTTTA CAGTGTATTT AAGAAAGGGA AAGCTGTGCC TTTTTTAGCT 4140 TCATATCTAA TTTACCATTA TTTTACAGTC TCTGTTGTAA ATAACCACAC TGAAACCTCT 4200 TCGGTTGTCT TGAAACCTTT CTACTTTTTC TGTACTTTTT GTTTTGTTCT TGGTCTCCCG 4260
CTTGGGGCAT TTGTGGGACT CCAGCACGTT TTCTGGCTTC TGCTTCATCC TGCTCCATCG 4320 GGGAATGACA CACTGCGGTG TCTGCAGCTC CTGGAAGGTG TCATTTGACA ACACATGTGG 4380
GAGAGGAGGT CCTTGGAGTG CTGCAGCTTT GGGAAAGCCT GCCTCGTTTC CCTTTTCCTC 4440 35 TAGAAGCAGA ACCAGCTCTA CGAGAGTGAG ACTGGGAACT TGATGGCTCA GAGAGCATCT 4500 TITICETCECA TITITAGAAAA TCAGATTITIC TCCTGTGGGA AAAAAAAATT CCATGCACTC 4560
TCTCTCTGTT AAAGATCAGC TATTCCCTTC TGATCTTGGA AAGAGGTTCT GCACCTCCTGG 4620
AACCGGTCAC AGGAACGCAC AGATCATGCC AGGATGCGCT GGGACGGGCCC ATCTTGGCAA 4600 40 GGTTCAGTCT GAATGGCAG AGAICAIGGC AGGAIGCGCT GGGACGGCCC ATCTTGGCAA 4680
GGTTCAGTCT GAATGGCATG GAGACCGGGA GATAGAGGGG TTTTAGATTT TTAAAAGGTA 4740
GGTTTTAAAA ATAAGTTTTA TACATAAACA GTTTTTGGAGA AAAATTACAG ATCATATAAG 4860
CAAGACAGTG GCACTAAAAT GTTTAATTCA TTAATCTGTT TGTTTGGCAC TGATGCAATG 4860
TATGGCTTTT CTCTTGCCCC AAATCACAAA CATATGTATC TTTTGGGGAAA CTAACAATAT 4920 GATTGCACTA AATAAACTAC TTTGAATAGA GGCCAAATTA ATCTTTTAAA AATGATGATA 4980 45 ATCATCAGGT TTACTCAGTG AAATCATATT AATTATTTTC CAAAATCTAA AAGCTGTAGC 5040 TGGAGAAGCC CATGGCCACG AGGAAGCAGC AATTAATTAG ATCAACACTT TTCTCCAGGG 5100 TICACCATGC AGGCAACATT ACCTTGCTT TCAAAAGACA CCTGCCTTAG TGCAAGGGGA 5160
AACCTGTGAA AGCTGCACTC AGAGGGAGGA GTCTTTCTTA CATAATTTGC AATTTCAGGA 5220
ATTTAATTTA TAGGCAGATC TTTAAATACA GTCAACTTAC GGTGCACAGT AATATGAAAG 5280
CCACACTTTG AAGGTAATAA ATACACAGCA TGCAGACTTGC GGAGTTGCTAG CAAACAAATG 5340 50 GCTTACTTAC AAAAGCAGCT TTTAGTTCAG ACTTAGTTTT TATAAAATGA GAATTCTGAC 5400 TTACTTAACC AGGTTTGGGA TGGAGATGGT CTGCATCAGC TTTTTGTATT AACAAAGTTA 5460 CTGGCTCTTT GTGTGTCTCC AGGTAACTTT GCTTGATTAA ACAGCAAAGC CATATTCTAA 5520 ATTCACTGTT GAATGCCTGT CCCAGTCCAA ATTGTCTGTC TGCTCTTATT TTTGTACCAT 5580 55 ATTGCTCTTA AAAATCTTGG TTTGGTACAG TTCATAATTC ACCAAAAAGT TCATATAATT 5640
TAAAGAAACA CTAAATTAGT TTAAAATGAA GCAATTAATA TCTTTATGCA AAAACATATG 5700
TCTGTCTTTG CAAAGGACTG TAAGCAGATT ACAATAAATC CTTTACTTT

Seq ID NO: 36 Protein sequence: Protein Accession #: NP\_000892.1

oosyoso.cepyoe

85

51 65 METKGYHSLP EGLDMERRWG QVSQAVERSS LGPTERTDEN NYMEIVNVSC VSGAIPNNST 60 QGSSKEKQEL LPCLQQDNNR PGILTSDIKT ELESKELSAT VAESMGLYMD SVRDADYSYE 120 QQNQQGSMSP AKIYQNVEQL VKFYKGNGHR PSTLSCVNTP LRSFMSDSGS SVNGGVMRAI 180 VKSPIMCHEK SPSVCSPLNM TSSVCSPAGI NSVSSTTASF GSFPVHSPIT QGTPLTCSPN 240 AENRGSRSHS PAHASNVGSP LSSPLSSMKS SISSPPSHCS VKSPVSSPNN VTLRSSVSSP 300 70 ANINNSRCSV SSPSNTNNRS TLSSPAASTV GSICSPVNNA FSYTASGTSA GSSTLRDVVP 360 SPDTQEKGAQ EVPFPKTEEV ESAISNGVTG QLNIVQYIKP EPDGAFSSSC LGGNSKINSD 420 SSFSVPIKQE STKHSCSGTS FKGNPTVNPF PFMDGSYFSF MDDKDYYSLS GILGPPVPGF 480
DGNCEGSGFP VGIKQEPDDG SYYPEASIPS SAIVGVNSGG QSFHYRIGAQ GTISLSRSAR 540
DQSFQHLSSF PPVNTLVESW KSHGDLSSRR SDGYPVLEYI PENVSSSTLR SVSTGSSRPS 600 75 KICLVCGDEA SGCHYGVVTC GSCKVFFKRA VEGQHNYLCA GRNDCIIDKI RRKNCPACRL 660 QKCLQAGMNL GARKSKKLGK LKGIHEEQPQ QQQPPPPPPP PQSPEEGTTY IAPAKEPSVN 720
TALVPQLSTI SRALTPSPVM VLENIEPEIV YAGYDSSKPD TAENLLSTLN RLAGKQMIQV 780 VKWAKVLPGF KNLPLEDQIT LIQYSWMCLS SFALSWRSYK HTNSQFLYFA PDLVFNEEKM 840 HQSAMYELCQ GMHQISLQFV RLQLTFEEYT IMKVLLLLST IPKDGLKSQA AFEEMRTNYI 900 80 KELRKMVTKC PNNSGQSWQR FYQLTKLLDS MHDLVSDLLE FCFYTFRESH ALKVEFPAML 960 VEIISDQLPK VESGNAKPLY FHRK

Seq ID NO: 37 <u>DNA sequence</u> Nucleic Acid Accession #: see Table 25 & 25A for complete list

21 31 41 51 CCTACCAGGT TCAAGCAACT CTGCTGCCTC AGCTCCCAAG TAGCTGGGAT TACAGGTGCA 60 TGCCACTACA CCTGGCTTTT TGTATTTTTA GTAGAGATGG TTTTCACTAT GTTGGCCAGG 120
CTGATCTTGA ATTCCTGGCC TGAAGTAATC TGCCTGCCTC AGCCTCCCAA AGTGCTGGGA 180
TTATAGGAGC CACCACACCT GGCATAACTG GTATTTTTTA TATGCTTCCT GGGCAACTTA 240 5 AAAAATTGAT TACTCTGTTG TTTCTTCCTT TTTTTTTTT TTTTGGCTTT GACCAATTTG 300 TGAGACCCAA GTATCTCCTA CCTAGAAAAA AAACACACTA AACAGTAAAT GATTACCAAC CTATTTGGAA CAAATCTCAA TTAATTAACA TATACTTCAA GGAGAAGACT TAACAAAATC 420 10 TTACTTTTCA TTCTTAATAG CTCTTTCCAT AAAAATGTTC CACAAGTGTA TCAAATTAGT 480 CCTAACAACT ACTGTTAAGT GATTAATGAA ACAGGAGTGA CAGGAGTGAA TTTAATAATA 540
GCAATAAATA CAGATGGGAC TACATAAATT GTGGAGGTCC TGATGCAAAA CTCTCTCTT 600
ATTCGATGGC ATCTCAGCTT TCTCATAGAG CTGTTTCACT GTGAGGGGTCT TTATCCTTCA 660
TGCAGACCTT CATTATTTTCTTCTTACC CAATCAGTCC ATAACAGAG CTGTTTCAC 670 TGCAGAGCTT CATTATTTTC TTTCTTCTAG CAATCAGTCC AAAGCACAAT GTCAGAAAGA 720 15 TCACAACACA TGCAGCAATA ATGGGCTCTA TTGGTACACC CACAGTTTTA TCTTTAACAA 780 Seq ID NO: 38 <u>DNA sequence</u> Nucleic Acid Accession #: NM 001192.1 20 Coding sequence: 219-773 AAGACTCAAA CTTAGAAACT TGAATTAGAT GTGGTATTCA AATCCTTACG TGCCGCGAAG 60 25 ACACAGACAG CCCCCGTAAG AACCCACGAA GCAGGCGAAG TTCATTGTTC TCAACATTCT 120 AGCTGCTCTT GCTGCATTTG CTCTGGAATT CTTGTAGAGA TATTACTTGT CCTTCCAGGC 180 TGTTCTTTCT GTAGCTCCCT TGTTTTCTTT TTGTGATCAT GTTGCAGATG GCTGGGCAGT 240 GCTCCCAAAA TGAATATTTT GACAGTTTGT TGCATGCTTG CATACCTTGT CAACTTCGAT 300 GCTCCCAAAA TGAATATTTT GACAGTTTGT TGCATGCTTG CATACCTTGT CAACTTCGAT 300
GTTCTTCTAA TACTCCTCCT CTAACATGTC AGCGTTATTG TAATGCAAGT GTGACCAATT 360
CAGTGAAAGG AACGAATGCG ATTCTCTGGA CCTGTTTGGG ACTGAGCCTTA ATAATTTCTT 420
TGGCAGTTTT CGTGCTAATG TTTTTGCTAA GGAAGATAAG CTCTGAACCA TTAAAAGGACG 480
AGTTTAAAAA CACAGGATCA GGTCTCCTGG GCATGGCTAA CACTTGACCTG GAAAAGAGCA 540
GGACTGGTGA TGAAATTATT CTTCCGAGAG GCCTCCTGAA CACTTGCCTTT CAACTGCCAG 660
GTGAAGACTG CATCAAGAGC AAACCGAAGG TCGACTCCTGA CACTTGCTTT CAACTGCCAG 660 30 ioderoeo .ceeroe GTGAAGACTG CATCAAGAGC AAACCGAAGG TCGACTCTGA CCATTGCTTT CCACTCCCAG 660
CTATGGAGGA AGGCGCAACC ATTCTTGTCA CCACGAAAAC GAATGACTAT TGCAAGAGCC 720 35 TGCCAGCTGC TTTGAGTGCC ACTTAAAAAT CTATTGTCAG AATAGATGAT TGCAAAACC 780
TTTCGACTCG AGCAGTGCCA CTTTAAAAAT CTTTTGTCAG AATAGATGAT GTGTCAGATC 840
TCTTTAGGAT GACTGTATTT TTCAGTTGCC GATACAGCTT TTTGTCCTT AACTGTGGAA 900 ACTICTITATG TTAGATATAT TTCTCTAGGT TACTGTTGGG AGCTTAATGG TAGAAACTTC 960 40 CTTGGTTTCA TGATTAAAGT CTTTTTTTTT CCTGA Seq ID NO: 39 <u>Protein sequence:</u> Protein Accession #: NP\_001183.1 45 41 51 MLQMAGQCSQ NEYFDSLLHA CIPCQLRCSS NTPPLTCQRY CNASVTNSVK GTNAILWTCL 60 GLSLIISLAV FVLMFLLRKI SSEPLKDEFK NTGSGLLGMA NIDLEKSRTG DEIILPRGLE 120 50 YTVEECTCED CIKSKPKVDS DHCFPLPAME EGATILVTTK TNDYCKSLPA ALSATEIEKS 180 Seq ID NO: 40 DNA sequence 55 Nucleic Acid Accession #: NM 025087.1 Coding sequence: 183-2282 21 31 41 60 ACACTGCCTC GGTTCGGCAA GTGGGTCAGT TGGCTGGGGC TCACTTGGCA ACGGGACGCG 60 GGAACGAGGG GCGCGGACGC AGGCCCGGGA GGACGCCGCG GCGGGAACCT GGGGGCGCAG 120
GGCTAGGGCA GCCGCACGGC TTTCCTGGAA AGGCCTGCC CTCGCCGCGG 180
CGATGACCT GCTGTGGAGA GAAATCCTCT TGGAGTCGCT GCTGGGATG TTTTCTTGGT 240
CTCTCTACCA TGACCTGGGA CCGATGATCT ATTACTTTCC TTTGCAAACA CTAGAACTCA 300
CTGGGCTTGA AGGTTTTAGT ATAGCATTTC TTTCTCCAAT ATTCCTCAACA ATTACTCCTT 360
TCTGGAAATT GGTTAACAAG AAGTGGATGC TAACCCTGCT GAGGATAATC ACTATTGGCA 420 65 TCTGGAAATT GGTTAACAAG AAGTGGATGC TAACCCTGCT GAGGATAATC ACTATTGGCA 420 GCATAGCCTC CTTCCAGGCT CCAAATGCCA AACTTCGACT GATGGTTCTT GCGCTTGGGG 480 GEATAGECTE CITECAGGET CEAAATGCEA AACTICGACT GATGGTTCTT GCGCTIGGGG 480
TGTCTTCCTC ACTGATAGTG CAAGCTGTGA CTTGGTGGTC AGGAAGTCAT TTGCAAAAGGT 540
ACCTCAGAAT TTGGGGATTC ATTTTAGGAC AGATTGTTCT TGTTGTTCTA CGCATATGGT 600
ATACTTCACT AAACCCAATC TGGAGTTATC AGATGTCCAA CAAAGTGATA CTGACATTAA 660
GTGCCATAGC CACACTTGAT CGTATTGGCA CAGATGGTGA CTGCAGTAAA CCTGAAGAAA 720
AGAAGACTGG TAGGCTAGCC ACGGGGATGG CCTCTAGACC CAACTGGCTG CTGGCAGGGG 780
CTGCTTTTGG TAGCCTTGTT 140
CCACATGGCC AGTGCACTCCACATC CAGGGCCAGA TCCTAACCCA TTTGGAGGTG. 900 70 CCAGATGGGC AGTGAGTGGG CATCCACATC CAGGGCCAGA TCCTAACCCA TTTGGAGGTG 900 CAGTACTGCT GTGCTTGGCA AGTGGATTGA TGCTTCCATC TTGTTTGTGG TTTCGTGGTA 960 75 CTGGTTTGAT CTGGTGGGTT ACAGGAACAG CTTCAGCTGC GGGGCTCCTT TACCTGCACA 1020 CATGGGCAGC TGCTGTGTCT GGCTGTGTCT TCGCCATCTT TACTGCATCC ATGTGGCCCC 1080 AAACACTTGG ACACCTTATT AACTCAGGGA CAAACCCTGG GAAAACCATG ACCATTGCCA 1140 80 ACAGITCTAA AGTGCTTTTC AGAAAGAGTG AAAAATACAT GAAACTTTTT CTGTGGCTGC 1380 TTGTTGGTGT GGGATTGTTG GGATTAGGAC TACGGCATAA AGCCTATGAG AGAAAACTGG 1440 GCAAAGTGGC ACCAACCAAA GAGGTCTCTG CTGCCATCTG GCCTTTCAGG TTTGGATATG 1500 85 ACAATGAAGG GTGGTCTAGT CTAGAAAGAT CAGCTCACCT GCTCAATGAA ACAGGTGCAG 1560 ATTTCATAAC AATTTTGGAG AGTGATGCTT CTAAGCCCTA TATGGGGAAC AATGACTTAA 1620

Seq ID NO: 41 <u>Protein sequence:</u> Protein Accession #: NP\_079363.1

DHREVSEKIH FNPRFGSYKE GHNYENNHNF HMNTPKYFL

20

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.